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Liver biopsy is recommended as the gold standard method to determine diagnosis, 
fibrosis staging, prognosis and therapeutic indications in patients with chronic liver 
disease. However, liver biopsy is an invasive procedure with a risk of complications 
which can be serious. This book provides the management of the complications in liver 
biopsy. Additionally, this book provides also the references for the new technology 
of liver biopsy including the non-invasive elastography, imaging methods and blood 
panels which could be the alternatives to liver biopsy. The non-invasive methods, 
especially the elastography, which is the new procedure in hot topics, which were 
frequently reported in these years. In this book, the professionals of elastography 
show the mechanism, availability and how to use this technology in a clinical field 
of elastography. The comprehension of elastography could be a great help for better 
dealing and for understanding of liver biopsy.
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Preface 
Liver biopsy is recommended as the gold standard method to determine diagnosis,
fibrosis staging, prognosis and therapeutic indications in patients with chronic liver
disease. This book covers the whole clinical field of liver biopsy including the basic 
principles of the procedure, protocol, indications, pathohistological evaluation, and 
complications. The book covers special evaluation procedures such as electron 
microscopy, immunostochimistry and flow cytometry. Non-invasive methods, 
especially the elastography, which is the new procedure in hot topics, are all here
frequently reported. One of the reasons for the progress of non-invasive 
technologies is that liver biopsy is an invasive procedure with a risk of 
complications- which can be very serious. This book provides the references for the 
non-invasive procedures including elastography, imaging methods and blood 
panels which could present the alternatives to liver biopsy. In this book, the
professionals of elastography show the mechanism, availability and how to use it in
a clinical field. The comprehension of elastography could be a great help for dealing 
and for understanding for liver biopsy. 
Hirokazu Takahashi, M.D, PhD
Department of Internal Medicine, 
   Saga Medical School,
   Nabeshima, Saga,
Japan 
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The Role of Liver Biopsy in the  
Non-Invasive Methods Era and Liver Stiffness 
Measurement Using Transient Elastography 
C. Rinaldi A. Lesmana and Laurentius A. Lesmana 
Division of Hepatology, Department of Internal Medicine,  
Cipto Mangunkusumo Hospital, University of Indonesia 
Digestive Disease Centre, Medistra Hospital, Jakarta 
Indonesia 
1. Introduction 
Liver biopsy is still the most accurate tool to assess liver histopathology in chronic liver disease 
(CLD), especially in patients with chronic active hepatitis who need a treatment decision. 
Nowadays, there are many non-invasive methods are being used to assess liver fibrosis and 
might replace liver biopsy. One of the new methods is transient elastography (TE/Fibroscan) 
which has been widely used to predict liver fibrosis in chronic active hepatitis B and C. 
However, whether TE is ready to replace the liver biopsy is still controversial.  
In cases like chronic hepatitis B infection (CHB), autoimmune hepatitis (AIH), non-alcoholic 
steatohepatitis (NASH), drug induced liver injury (DILI), and cholestatic liver diseases, the 
role of liver biopsy is very important to make the whole information of liver histopathology 
(not only about liver fibrosis). On the other hand, to make a diagnosis of liver cirrhosis, we 
have some parameters that can be used, such as clinical stigmata of advanced chronic liver 
disease (jaundice, hyper pigmentation, spider nevi, palmar erythema, ascites, edema, and 
others), low level of platelet count, and low level of albumin, prolonged protombin time, 
and picture of liver cirrhosis based on ultrasound examination.  
In chronic active hepatitis B infection, the treatment decision is usually based on the increase 
level of alanine aminotransferase (ALT), high HBV-DNA serum level, and the presence of 
HBeAg status. In patients with normal ALT level or less than 2x ULN, the liver biopsy is 
needed to decide whether the antiviral therapy should be started or not. In this group, not 
only liver fibrosis assessment is important, but also the degree of necroinflammation will 
influence the decision of antiviral therapy. From the point of view of liver fibrosis itself 
when using TE, it is not always accurate to differentiate between fibrosis 1 or 2, since this 
differentiation is also important to start antiviral therapy.  
Despite the etiology of liver injury, TE itself has problem with overweight and obese patients, 
and patients with narrowed intercostals space. TE also cannot be performed in ascitic patient 
because the interposed fluid blocks the shear wave. The increase of liver stiffness cut off is also 
can be influenced by metabolic syndrome, age, BMI, and the increase of ALT level. 
The liver biopsy still has the most important role in assessing liver histopathology but we 
might reduce the need of liver biopsy examination in some patients. At this moment, TE can 
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4 
be used as a predictor tool in assessing liver fibrosis in chronic active hepatitis with regard 
to clinical and laboratory parameters.  
A lot of study is still needed to validate the usefulness of TE in assessing liver fibrosis in 
chronic active hepatitis.  
2. Liver biopsy 
2.1 History and definition 
In 1883, the first liver biopsy was performed by Ehrlich to assess hepatic glycogen content in 
a diabetic patient, followed by Lucatello who performed liver biopsy to analyze a tropical 
abscess of the liver 12 years later. In 1907, Schuper is the one who published a series number 
of liver biopsy which are performed in humans and rats. The liver biopsy technique has 
been evolved for many years, and in 1958 Menghini technique of liver biopsy has been 
introduced and widely used in the clinical practice. This technique can be easily performed 
by experienced and well-trained clinicians and especially hepatologists. Liver biopsy is a 
technique to obtain, view, and assess the liver histology, either by cutting or aspiration. This 
technique can be done via transcutaneous route, or transjugular. (1) 
 
 
Copyright 2006 by Elsevier Inc. 
Fig. 1. Typical set-up of materials required for an aspiration transcutaneous liver biopsy. 
The syringe is already connected to an aspiration needle (Menghini) biopsy set.  
The other syringe is used for local anesthesia. Adapted from Zakim and Boyer’s 
Hepatology 2006. 
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Fig. 2. The approach to transcutaneous liver biopsy. A transcutaneous biopsy of the liver is 
performed in complete expiration to limit accidental pulmonary injury. As the liver is 
frequently cirrhotic and therefore small, an intercostal approach is necessary. However, in large 
livers a subcostal route is preferred as a safer route. The schematic illustrates the two principal 
types of needle used: cutting needles and aspiration needles, for which several models are 
commercially available and which should be chosen according to the patient's risk profile and 
the clinical indication for the biopsy. Adapted from Zakim and Boyer’s Hepatology 2006. 
2.2 The clinical importance of liver biopsy: Its use, risk and assessment 
Liver biopsy is an important examination in assessing the progression of liver disease, 
establish the diagnosis when there is no clear etiology, and to make a decision of therapy. 
We know that the risks of liver disease progression are liver cirrhosis (LC) and liver 
cancer/hepatocellular carcinoma (HCC). These could be due to chronic active hepatitis virus 
infection (such as hepatitis B (HBV) and C (HCV) virus), drug induced liver injury (DILI), 
alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis 
(AIH), etc. In chronic active hepatitis virus infection, of course we need to do liver biopsy in 
special circumstances (based on the guidelines). However, the disease such as AIH, DILI, 
and NASH, liver biopsy examination could be a mandatory since we need to see clearly the 
histology picture to establish the diagnosis. Even sometimes, patient with unknown etiology 
of hepatomegaly with abnormality liver biochemistry test, we do need a liver biopsy. Liver 
biopsy in Non-Alcoholic Fatty Liver Disease (NAFLD) can become a dilemma since we 
know that not all patients with fatty liver will develop NASH. There were some contrarily 
about doing liver biopsy since there are side effects that could happen, such as 
bleeding/hemorrhage and pain. The frequency of complications was 3.2% in physicians 
with a history of less than 20 biopsies, compared to 1.1% when over 100 had been 
performed. Recently, the use of ultrasound as a guide to liver biopsy has been used widely 
among the hepatologists. Many recommendations has also been made regarding to liver 
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biopsy preparation but there is still lack of evidence. The only thing is that really matters are 
anticoagulant use and hemostase examination.   Sampling error is that something that could 
happened because we only use small needle and probably we could only assess small area 
of the liver tissue even though we have the preconditions for liver tissue sampling so it can 
be assessed very well by the pathologist. However, until now liver biopsy is still a gold 
standard to obtain information about what happened in the progression of liver diseases 
and of course to see the improvement of liver histology after the patients received treatment. 
In Advanced liver disease, we have clinical (chronic liver disease stigmata such as icteric, 
spider nevi, hyper pigmentation, palmar erythema, splenomegaly, ascites, caput Medusa, 
and leg edema), biochemical parameters (low platelet count, albumin globulin ratio, 
hyperbilirubinemia, abnormal hemostase, etc), and imaging studies (ultrasound, CT-scan, 
MRI) to confirm the diagnosis so we don’t have to perform any liver biopsy. (2,3,4,5) 
 
  
Fig. 3. Liver Cirrhosis and Hepatocellular Carcinoma Illustrations. 
2.3 Non invasive methods in assessing liver fibrosis 
The ideal non invasive methods in assessing liver fibrosis should be highly sensitive and 
specific, technically easy to measure, inexpensive, minimal or no side effect, and can be 
used easily to monitor the progression or regression of liver disease during the treatment. 
There are several direct and indirect serum markers that have been studied for long time 
to assess liver fibrosis. The direct markers such as collagens (procollagen I C 
peptide/PICP, procollagen III N peptide/PIIINP, type IV collagen and its fragments (NC1 
and PIVNP), glycoproteins and polysaccharides (hyaluronic acid/HA, laminin, tenascin, 
YKL-40/chondrex), collagenase and their inhibitors (metalloproteinases/MMPs, tissue 
inhibitors of metalloproteinases/TIMPs), and cytokines (TGF-β1 and PDGF) are related to 
matrix deposition since we know that the activation process of stellate cell which is the 
key event of liver fibrosis is related to the increase production of MMP-1, MMP-2, and 
TIMPs, and leading to replacement by interstitial collagen. However, most of the studies 
showed the significant difference between no or mild fibrosis group (F0-F1) and 
moderate-severe liver fibrosis group (F2-F4) or between F0-F2 vs. F3-F4 group. (6,7,8,9,10) 
When it comes to differentiate between F1 and F2, most of the studies showed unsatisfied 
result. Mostly have not very high sensitivity when it is used to differentiate between F1 
and F2. In a large cohort study, nine different markers have been evaluated in HCV, ALD, 
and NAFLD patients, and it is found that HA, TIMP-1, and PIIINP were selected as 
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having the best accuracy in diagnosing F2-F4 with the AUROC were 0.77, 0.94, and 0.87. 
Another large study in 696 HCV patients has shown that HA, TIMP-1 and α-2-
macroglobulin were having 75% accuracy in diagnosing F2-F4 with AUROC 0.82-0.83. 
Zhang BB et al also showed very good results of the direct serum markers such as PDGF-
BB, TIMP-1, TIMP-1/MMP-1, and TIMP-1mRNA when diagnosing hepatic inflammation 
and fibrosis in CHB patients compared to normal control. It showed good correlations  
(r=0.239-0.565; p=0.000-0.0033), but in this study didn’t show any differences between 
fibrosis stages. Study by Oberti et al, showed that the best diagnostic accuracy was found 
for HA, laminin, PIIINP, and TGF-β1, but it didn’t show any diagnostic advantage when 
those markers were taken together. All of these markers are not liver specific as it might 
be influenced by some other conditions, such as inflammation at any other organs. The 
value of these markers in diagnosing the liver condition also can be questionable whether 
due to the progression of matrix deposition or recovery process after inflammation 
process. (6,11,12) The cost-effectiveness of the non-invasive markers is still debatable since 
in most countries in Asia, the price of non-invasive markers can become a problem when 
it comes to the market.  
The indirect markers such as serum ALT levels, AST/ALT ratio, platelet count (PT), 
prothrombin index, and multi-combination indirect fibrosis test (Forns index, Fibro Test, 
APRI, PGA, PGAA, FIB-4, Hepascore and Acti Test) also have been studied for many years 
whether it could be used to replace liver biopsy or not. The simple indirect marker test such 
as ALT level seemed that is not really a good marker in hepatic fibrosis prediction since 
there have been many studies showed that even though patients with normal ALT could 
possibly have advance liver fibrosis. (8,13,14,15,16) The AST/ALT ratio showed a good 
predictive value in advanced liver disease, especially when combined with platelet count 
which has been reported mostly in CHC patients. A retrospective study by Yilmaz et al 
showed statistically significance for the correlation between APRI score and hepatic 
fibrosis in CHC (r=0.2634, p=0.0059) and NAFLD (r=0.2273, p=0.0069) patients but not in 
CHB (r=0.1005, p=0.1495) patients even though the r values showed not very strong 
correlation. This study also found that APRI has sensitivity 55.0% and specificity 75.4% 
for CHC, 60.0% and 73.3% for NAFLD, and 55% and 75.4% for CHB. (17) Another 
retrospective study comparing 6 non-invasive liver fibrosis markers (APRI, Fibrometer, 
FIB-4, Hepascore, Forns index, and Shanghai Liver Fibrosis Group/SLFG’s index) showed 
that better correlation were found in Fibrometer (r=0.69), Hepascore (r=0.62), and SLFG 
(r=0.68) with METAVIR score (p< 0.001) of liver histopathology compared with others. 
Fibrometer, Hepascore, and SLFG are more representing direct markers while APRI, FIB-
4, and Forns index are indirect markers. However, in this study only showed the AUROCs 
were better when these markers are used to differentiate between F0-F2 and F3-4 
compared to F0-1 and F2-4 group. (18) 
2.4 Imaging studies in assessing liver fibrosis 
There are some imaging studies that can be used to assess the liver morphology such as 
ultrasound, CT-scan, and Magnetic Resonance Imaging (MRI). However, none of these 
modalities can be used when the differentiation between mild and early significant liver 
fibrosis is needed. In chronic active hepatitis, the only finding that can be found with these 
imaging modalities is the cirrhotic liver. (7,19) On the other side the imaging studies like CT-
scan and MRI will cost a lot of money. A retrospective cross sectional study looking at 
comparative MR imaging studies with superparamagnetic iron oxide (SPIO)-enhanced and 
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double-enhanced spoiled gradient echo (SPGR) sequences in 101 patients (HCV, HBV, AIH, 
NASH, PBC, PSC, alcoholic hepatitis, and cryptogenic) showed that qualitative and 
quantitative image scores were significantly higher for patients with METAVIR fibrosis 
scores of 3 or higher than for those with scores of 2 or lower (p < .001). Diagnostic 
performance for detection of grade 3 or more severe fibrosis was better with the doubled-
enhanced sequence than with the SPIO-enhanced sequences. This study showed a good 
performance only when it comes to assess advanced liver fibrosis. The limitations of this 
study were retrospective study and only have a small number patient with mild fibrosis.(20) 
During the development of imaging studies, a modified phase contrast magnetic resonance 
(MR) imaging sequence to assess liver tissue shear waves, which is called MR elastography, 
also has been studied. In twelve patients with chronic liver disease (HCV, AIH, NASH, liver 
cirrhosis due to sarcoidosis) who underwent MR elastography, there were 11 patients with 
liver fibrosis (stage 1 in four patients, stage 2 in three patients, stage 3 in three patients, and 
stage 4 in one patient) based on histopathology results and from the imaging result showed 
that the mean liver stiffness was significantly higher than was found in healthy control 
group (p < .001). This preliminary study has shown that MR elastography can be used to 
differentiate between normal and fibrotic liver but still it needs a lot of sample to confirm 
these findings especially when it will be used to differentiate between mild and advance 
liver fibrosis. (21) 
2.5 Transient elastography (Fibroscan) in assessing liver fibrosis 
Transient Elastography (TE/Fibroscan, Echosens, Paris, France) has been introduced recently 
as a new tool for liver fibrosis assessment. It is an easy and user friendly technique for 
clinicians and very comfortable examination for the patients. The non-fasting patients lying 
flat on their back, with the right arm tucked behind the head to facilitate access to the right 
upper quadrant. The ultrasound transducer probe is mounted on the axis of a vibrator and the 
elastic shear wave induced by the vibrations will propagates through the liver tissue. The 
examination will takes only less than 5 minutes in experienced and well trained clinicians or 
nurses (after 100 examinations).  Liver stiffness values range from 2.5 to 7.5 kPa. The validity of 
this examination depends on the interquartile range (IQR), which reflects the variability of the 
validated measures, and should not exceed 30% of the median value. The success rate should 
be at least 60%. The limitations of this examination are when dealing with obese patients, 
patients with ascites, and high ALT level. Failure rates to perform this examination in high 
BMI patients have been showed in several studies and the range was showed between 2.4% 
and 9.4%. (22,23) The level of ALT has become a major issue since many studies have shown 
that higher ALT will make the higher liver stiffness value. (24,25,26) Most of the TE studies in 
Western countries were done in CHC patients since we know that CHC is more prevalent. On 
the other side, most Asian countries tried to look this new tool for liver fibrosis assessment in 
CHB patients. There are several major issues when we look two sides of the world’s 
perspective about this examination. First, the different etiology of the liver disease could make 
the difference of liver stiffness value even though there were some studies in CHB patients 
done in Western countries and showed the similar proposed cut off with CHC for F2. In Asian 
countries, many factors have been known can influence the progression of liver disease such as 
metabolic factors, medicines, genetic polymorphism, and viral genotype. These factors could 
contribute differently when compare to Western countries. Second, the liver stiffness value 
impact between CHC and CHB is still debatable in liver fibrosis measurement. When 
diagnosing the liver fibrosis progression to consider for antiviral therapy, in CHC patients 
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probably is simpler than in CHB patients because in CHB not only the fibrosis is important but 
also the necroinflammation of the liver. Third, the AUROCs for F2 prediction in CHB which 
were reported in Asian studies found lower value than it found in Western studies. Beyond 
this point, study by Chan et al has showed there was a grey area  in CHB patients with normal 
ALT between LSM 6.0-9.0 kPa, where a LSM 5.0-6.0 kPa would indicate insignificant fibrosis, a 
LSM >9.0 kPa had a high chance of bridging fibrosis, and that >12.0 kPa had a high chance of 
cirrhosis. It means in this grey zone the liver biopsy might be needed. (24,27,28) The use of TE 
in liver cirrhosis (LC) patients is still controversies since we have a lot of non-invasive 
parameters that can be used to diagnose LC. In some special conditions such as hemophilia, 
aplastic anemia, thrombocytopenia not related to liver disease, etc, TE might be a good 
consideration when those patients suffered from chronic active hepatitis virus infection  
(B & C).  
 
 
Fig. 4. Fibroscan. 
2.6 Liver biopsy or non invasive method in clinical practice 
In clinical practice, it is not about which one is better to another method in liver fibrosis 
assessment but it is more important to see patient to patient’s problem based. The final 
purpose of all these is to make a better clinical decision for the patient but not for the 
doctor because most patients would like to know whether they have advanced fibrosis or 
not. Overall, we need to give more concern in patient’s safety, cost-effectiveness, and of 
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course what advantage that the patient will have from each examination for disease 
management. 
3. Conclusions 
Liver biopsy still has an important role in the non-invasive methods era even though the 
need of liver biopsy could be reduced with many kinds of non-invasive methods in liver 
fibrosis prediction. Further development of non-invasive methods is still needed since we 
haven’t found the perfect non-invasive method that can entirely replace liver biopsy 
examination.   
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need of liver biopsy could be reduced with many kinds of non-invasive methods in liver 
fibrosis prediction. Further development of non-invasive methods is still needed since we 
haven’t found the perfect non-invasive method that can entirely replace liver biopsy 
examination.   
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1. Introduction   
The most common histopathological classification of chronic hepatitis was determined by 
descriptive terms, which included a subjective factor of histopathological description. It 
might have caused a lot of interpretative discrepancies among diagnosticians dealing with 
chronic liver inflammation. These difficulties led sometimes to inappropriate treatment 
protocol, such as the use of interferon, or caused discrepancies in the morphological rating 
of treatment efficiency. The first attempt of rating liver specimens in an objective way was 
Histological Activity Index (HAI), reported in 1981 by Knodell et al. Subsequently, many 
locally used modifications have been created (Lindh, Scheuer, Batts&Ludwig, Ishak, 
Gabriel, METAVIR). It made chronic hepatitis classification much more objective and helped 
in statistical analysis of research results. New diagnostic criteria of chronic liver diseases 
prepared in 1984 by the World Congress of Gastroenterology and International Association 
for the Study of the Liver (IASL) prompted authors to update previously used classifications 
(International Working Party, 1994). The purpose of this study is to optimize the clinical 
data necessary in proper diagnosis, taking into account the new criteria of inflammatory 
activity, process of fibrosis and steatosis.   
2.1 Clinical part of the protocol 
The points of the protocol relating to the anamnesis are to determine the nature of the 
disease – acute or chronic – in accordance with definition based on time criterion 
proposed by Leevy in 1976 (Leevy et al., 1976). Additionally, anamnesis should lead to the 
detection of two or more coexisting etiologic factors, for example infection with two 
hepatitis viruses. The protocol also considers the source of infection, as this factor may be 
important in determining prognostic significance, such as perinatal HBV/HCV infection, 
which leads to chronic state and increases the probability of developing primary liver 
cancer in adulthood. 
The authors propose to include five hepatotrophic viruses into the protocol. Knowledge and 
description of the viruses will help in development of serological and immunological tests. 
Viral factors can be detected using: 
 Indication of viral markers by immunoassay and radioimmunoassay methods (EIA and 
RIA), 
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 Polymerase Chain Reaction (PCR) in the serum, 
 Fluorescence in situ hybridisation (FISH) or chromogenic in situ hybridization (CISH) 
 Measurement of viral genetic material (RNA, DNA) in the serum (RT-PCR). 
A large number of liver lesions are caused by toxic agents such as alcohol and long-term 
drug use. This aspect requires special attention in anamnesis. Less common etiologic factors 
in adults, but more common in children are congenital metabolic disorders such as:   
α1-antiprotease (α1-antitrypsin) deficiency, storage diseases, galactose intolerance or 
abnormal metabolism of copper and iron. 
Laboratory test are divided into three groups: 
 non-specific tests of liver parenchymal necrosis, 
 tests to assess liver viability, 
 general tests of the inflammatory process. 
Radiological procedures, such us abdominal ultrasonography, bile ducts X-ray 
(cholecystography, cholangiography), magnetic resonance imaging (MRI) and computed 
tomography (CT) are the main sources of knowledge relating to the size of the liver, 
presence of focal lesions and some of the extrahepatic bile ducts malfunctions. If liver biopsy 
is performed earlier, its results should be attached. This knowledge simplifies proper 
diagnosis and enables assessment of the dynamics of the inflammatory and fibrotic process. 
The summary of the clinical part of the protocol is to establish preliminary diagnosis causing 
liver dysfunction. If the diagnostician is unable to establish the etiology of the disease it is 
possible to conduct research with additional selective histopathological techniques, such as 
immunohistochemical analysis of liver tissue performed using sera containing monoclonal 
antibodies to detect viral antigens. It is possible to use other specific techniques, PCR or 
hybridization in situ, to detect viral nucleic acids. If the clinical data is not complete and 
morphological picture is not characteristic, descriptive morphological diagnosis should be 
used. When there is the suspicion of morphological abnormalities the test for the presence of 
iron or copper can be performed. 
2.2 Morphological part of the protocol 
Morphological protocol describes necro-inflammatory activity, fibrosis and degenerative 
alteration of hepatocytes. 
Grading for necro-inflammatory activity is based on a 4-point scale assessing the intensity of 
inflammatory and necrotic process – piecemeal necrosis including bridging necrosis, focal 
lobular necrosis and portal inflammation. The primary grading scoring system for necro-
inflammatory activity proposed by Batts (Table 1) was modified by a group of Polish 
hepatologists and introduced to the protocol (Batts&Ludwig 1995, Gabriel et al., 1999). 
Piecemeal necrosis is a specific morphological change produced by a cytotoxic reaction of 
lymphocytes to hepatocytes. It is the death of hepatocytes at the margin of the lobule which 
is associated with the destruction of the limiting plate. The process extends piecemeal 
towards the centre of the lobule. Lymphocytes are seen adjacent to the damaged 
hepatocytes. The severity of lobular necrosis may encompass changes from a single foci of 
lymphocytic or lymphocytic-granulocytic infiltration (without hepatocyte death), through 
inflammatory-cell infiltration with single hepatocyte destruction to advanced confluent 
bridging necrosis  involving a considerable portion of lobular surface with the associated 
collapse of the lobular stroma or perivenular confluent necrosis. The assessment of the 
intensity of inflammatory infiltration in portal spaces was not taken into consideration due 
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to less prognostic significance and difficulties in objective assessment. This category of 
portal inflammation, according to Theise, is inappropriate for clinical evaluation as it is a 
defining lesion for chronic hepatitis. Furthermore, prominent lymohoid aggregates or 
follicles of hepatitis C might falsely inflate the severity of necroinflammatory activity 
compared to conditions where such lymphoid follicles are much less typical (chronic 
hepatitis B, autoimmune cholangitis, primary biliary cirrhosis) (Theise 2007). The presence 
of degenerative and regenerative changes in hepatocytes is an additional element 
accompanying inflammatory infiltrations and/or necrosis. It seems that these changes are of 
minor importance in determining the inflammatory activity and are secondary to necrosis 
and inflammation. 
 
Grading Terminology Criteria 
Semiquantitative Descriptive Lymphocytic piecemeal necrosis 
Lobular inflammation 
and necrosis 
0 
Portal 
inflammatory 
only, no activity 
None None 
1 Minimal Minimal, patchy Minimal; occasional spotty necrosis 
2 Mild 
Mild; involving  
some or all  
portal tracts 
Mild; little 
hepatocellular damage 
3 Moderate Moderate; involving all portal tracts 
Moderate; noticeable 
hepatocellular damage 
4 Severe Severe; may here bridging necrosis 
Severe; prominent 
diffuse hepatocellular 
damage 
Table 1. Grading of disease activity in chronic hepatitis (Batts&Ludwig) 
Another part of the protocol is the assessment of the intensity of fibrotic process - staging. 
The evaluation of fibrosis staging is based on a 4-point scale proposed by Batts&Ludwig. 
There are also other semi-quantitative scoring systems by METAVIR, Knodel, Desmet or 
Scheuer used to assess hepatitis activity but of local significance and usage. The comparison 
of scoring systems used by different authors for staging of chronic hepatitis is presented in 
Table 2. This parameter can be accurately assessed in histopathological sections after 
additional histochemical staining techniques for the detection of collagen fibers, such as 
Azan and Masson’s trichrome. When pathological fibrosis is present in the liver tissue, both 
the number of actively formed collagen fibres and their location should be determined to 
assess its severity. The term ‘portal fibrosis’ refers to the involvement in the process of 
collagen fibroplasia of portal tracts alone. Periportal fibrosis means the presence of collagen 
fibres in portal tracts and their extension into the lobules or formation of single fibrous 
bridges which connect the adjacent portal tracts (portal-portal fibrosis). Bridging fibrosis is 
the presence of fibrous bridges which connect the adjacent portal tracts or portal tracts and 
the central venule, which leads to architectural distortion. Bridging fibrosis and nodular 
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regeneration correspond to stage 4 of histopathological severity. Proposed protocol does not 
include the scoring system proposed by Desmet, which differentiated the occurrence of 
porto-portal and porto-central septa as separate stages. The latter was attributed as playing 
a greater importance in the development of cirrhosis (Desmet 1994). The authors have 
added the description of advanced vascular changes to this point after consideration of the 
submitted proposals. It is of great importance in describing specimens of transplanted liver, 
especially during chronic graft rejection process. It is also useful in the evaluation of portal 
hypertension. 
 
 
Score Description Knodell et al. (1981) 
Desmet et al. 
(1994) Scheuer (1991) 
0 No fibrosis No fibrosis None None 
1 Mild fibrosis Fibrosis portal expansion 
Periportal fibrous 
expansion 
Enlarged, fibrotic 
portal tracts 
2 Moderate fibrosis  
Porto-portal septa   
( ≥ 1 septum) 
Periportal or portal-
portal septa, but 
intact architecture 
3 Severe fibrosis 
Bridging fibrosis 
(portal-portal or 
portal-central 
linkage) 
Porto-central 
septa     
 ( ≥ 1 septum) 
Fibrosis with 
architectural 
distortion, but no 
obvious cirrhosis 
4 Cirrhosis Cirrhosis Cirrhosis Probable or definite cirrhosis 
Table 2. Scoring systems for staging of chronic hepatitis. 
Additional morphological features of lesser importance are ballooning degeneration, 
steatosis, cholestasis, bilirubinostasis, state of bile in ducts and ductules. The presence of 
ballooning degeneration and steatosis may indicate toxic damage or metabolic disorders 
such as non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH). 
Determining the degree of steatosis is important in liver transplant eligibility. 70% of cases 
of infections with HCV (mostly genotype 3a HCV) is associated with the presence of 
steatosis. Hepatic steatosis in the course of chronic hepatitis C is one of the risk factors for 
Proposed Protocol for Histopathological  
Examination of Liver Specimen in Diagnosing Chronic Hepatitis 
 
17 
fibrosis progression. Moreover, steatosis decreases the rate of sustained response for 
antiviral therapy.   
Estimation of steatosis extent with numerical semi-quantitative assessment is commonly 
used in NAFLD. Many scoring scales were proposed. Currently the most widely used are 
the scales proposed by Brunt, Kleiner, Mendler and Dixon. The scoring system proposed by 
Kleiner et al. estimating NAFLD activity score (NAS) seems to be most suitable due to its 
simple and clear grading of steatosis and ballooning degeneration. The scoring scale 
proposed by Kleiner et al. is presented in Table 3. 
 
NAFLD Activity Score (NAS) (0-8) 
Sum of scores for steatosis, lobular inflammation and hepatocellular ballooning. 
Steatosis (0-3) 
0 - 5% hepatocytes involved 
1 – 5-33% of hepatocytes 
involved 
2 - 33-66% hepatocytes involved
3 - >66% hepatocytes involved 
Hepatocyte ballooning (0-2)
0 – none 
1 – few ballooned cells 
2 – many cells / prominent 
ballooning 
Lobular inflammation (0-3) 
0 – none 
1 - <2 foci per x 200 field 
2 – 2-4 foci per x 200 field 
3 - >4 foci per x 200 field 
Correlation between total NAFLD activity scores and an overall histological diagnosis  
of steatohepatitis 
NAFLD activity score Histological diagnosis of steatohepatitis 
≥5   Probable or define NASH 
3-4   Uncertain NASH 
≤2   Not NASH 
Table 3. Scoring system according to Kleiner et al.  
Cholestasis is usually observed in chronic biliary diseases such as primary liver cirrhosis, 
primary sclerosing cholangitis and autoimmune cholangitis. Cholestasis in acute phase of 
infection is typical for viral infections, but it occurs rarely during chronic and autoimmune 
hepatitis. Accurate assessment of biliary tracts within portal spaces is important for 
determining the stage of primary biliary cirrhosis, primary sclerosing cholangitis and 
autoimmune processes of destruction of the bile ducts during chronic graft rejection. 
Regenerative proliferation of bile ductules is accompanied by advanced changes in organ 
architecture in cases of chronic inflammations with high activity and in the course of cirrhosis. 
The last point of the morphological protocol is biopsy-point rating, which seems to be useful 
for statistical evaluation of process activity. A justified criticism of the approach proposed 
by Knodell et al. is that it incorporates necro-inflammatory activity and fibrosis into an 
overall grade (Knodell et al., 1981). This implies that these two histological features increase 
in parallel to each other. The morphological component of the protocol involves a detailed 
description of the specimen, which helps for proper interpretation by the clinician. The last 
point of the protocol is to establish a final diagnosis with the use of descriptive terminology 
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Cholestasis is usually observed in chronic biliary diseases such as primary liver cirrhosis, 
primary sclerosing cholangitis and autoimmune cholangitis. Cholestasis in acute phase of 
infection is typical for viral infections, but it occurs rarely during chronic and autoimmune 
hepatitis. Accurate assessment of biliary tracts within portal spaces is important for 
determining the stage of primary biliary cirrhosis, primary sclerosing cholangitis and 
autoimmune processes of destruction of the bile ducts during chronic graft rejection. 
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for statistical evaluation of process activity. A justified criticism of the approach proposed 
by Knodell et al. is that it incorporates necro-inflammatory activity and fibrosis into an 
overall grade (Knodell et al., 1981). This implies that these two histological features increase 
in parallel to each other. The morphological component of the protocol involves a detailed 
description of the specimen, which helps for proper interpretation by the clinician. The last 
point of the protocol is to establish a final diagnosis with the use of descriptive terminology 
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(hepatitis with minimal, mild, moderate, severe inflammatory activity [grade], portal, 
periportal, septal fibrosis, cirrhosis [stage]).  
There are several possibilities as to how to compose the final conclusion: 
a. The unequivocal histopathological picture is indictive for… 
b. The histopathological picture, aside from the clinical data, can lead to diagnosis.  
c. The unequivocal diagnosis is not possible due to i.e. disintegrated material, improper  
fixing of material, non-representative material.  
If the etiology is unknown, the pathologist may propose additional tests. When the clinical 
data is not complete, the morphological picture is not characteristic or specimen is 
insufficient for certain diagnosis – the biopsy specimen is shorter than 25 mm or includes 
less than 11 portal tracts – delineation of morphological features and alterations should be 
carried out. Staging and grading is allowed only for the assessment of biopsy specimens 
which fulfill all of the above mentioned criteria. 
Additional tests can be performed in the case of morphological abnormalities - the Prussian 
blue reaction in Perl's test for iron presence, rhodamine according to Lindqvist for copper 
deposits, PAS following digestion with diastase for α1-antiprotease. 
Results of prior biopsy should be attached. This allows for the assessment of the dynamics 
of the inflammatory or fibrotic process. 
The summary of the clinical part of the protocol is to establish preliminary diagnosis of liver 
dysfunction.  
If the diagnostician is unable to establish the etiology of the disease, it is possible to conduct 
research with additional selective histopathological techniques, such as immunohistochemical 
analysis of liver tissue performed using sera containing monoclonal antibodies to detect viral 
antigens. It is possible to use other specific techniques, PCR or hybridization in situ, FISH and 
CISH to detect viral nucleic acids.  
2.3 Difficulties in the differential diagnosis of chronic hepatitis 
So far, pathologists have generally determined the degree and extent of hepatitis activity or 
progression of disease. Lobular inflammatory cell infiltration tends to predominate in acute 
phases of hepatitis, while portal and periportal inflammation is characteristic of chronic 
state. Portal hepatitis is a frequent form of chronic inflammation, consisting of infiltrations 
which comprise lymphocytes, plasma cells and macrophages. Plasma cells are predominant 
in autoimmune hepatitis alongside destruction of bile ducts with lymphocytic infiltration. 
Aggregates of lymphocytes or lymph follicles are observed in approximately 50% of chronic 
hepatitis C patients. When portal hepatitis is not accompanied by periportal or lobular 
infiltrations, the process is described as non-active. When periportal hepatitis is associated 
with focal hepatocyte destruction, the process is termed piecemeal necrosis. Mild 
inflammation, involving portal tracts is known as portal hepatitis. It is difficult to 
differentiate between true chronic hepatitis and non-specific hepatitis, or reactive chronic 
hepatitis, which accompanies a number of systemic diseases. When piecemeal necrosis or 
marked lobular necrosis coexists with inflammatory cells infiltrations, chronic hepatitis 
should be suspected. Marked fibrosis (septal fibrosis/cirrhosis) suggests chronic hepatitis or 
chronic biliary disease. If mild inflammatory infiltration in portal tracts exists as separate 
alteration, the condition is described as chronic reactive hepatitis.  The diagnosis of chronic 
liver disease cannot be stated only on the basis of histopathological assessment and must be 
supported by clinical data (disease duration at least 6 months). 
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2.4 Proposed protocol for  histopathological examination of liver biopsy specimen  
 
ID History   
First Name  
Address: Last name  
Date of birth  
(Preliminary) Clinical diagnosis  
Since when has he/she been ill? 
(month, year)  
Has he/she ever suffered from 
hepatitis? (year)   
What type? (if documented)   
The way of infection   
Completed hepatitis vaccination   
Other diseases 
metabolic diseases   
other   
BMI kg/m2 Height cm 
Body weight kg Waist circumference cm 
  Hip circumference cm 
Drugs used: 
Actually   
Formerly   
Alcohol 
 (average amount per week)    
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2.4 Proposed protocol for  histopathological examination of liver biopsy specimen  
 
ID History   
First Name  
Address: Last name  
Date of birth  
(Preliminary) Clinical diagnosis  
Since when has he/she been ill? 
(month, year)  
Has he/she ever suffered from 
hepatitis? (year)   
What type? (if documented)   
The way of infection   
Completed hepatitis vaccination   
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Etiological factors examined 
(serological methods and molecular biology) 
HBV HCV HDV Others 
HBsAG  … 
Anty HBs … 
HBeAg … 
Anty HBe … 
Anty HBc … 
DNA-HBV (PCR) … 
HBV-DNA (pg/ml) … 
Anty HCV … 
RNA HCV(PCR) … 
Viral genotype    … 
Viral load (IU/ml) … 
Anty HDV … 
 
RNA-HDV(pg/ml)          ….
HAV … 
HGV … 
 
HIV … 
CMV … 
HSV … 
 
 
 
Radiology  (USG, CT, MRI, bile ducts X-ray)  
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Laboratory tests 
 
pANCA 
 
ANA   …………… 
SMA   …………… 
LKM-1  …………… 
AMA  …………… 
IgG  …………… 
α1 AT level …………… 
 
 
Total protein ……………………… 
Albumin: ……………………… 
Globulin: 
 α1 ……………………… 
 α2 ……………………… 
 β ……………………… 
 γ ……………………… 
a) parenchymal necrosis tests:  
 ALT ……………… AST   ……………… 
b)  
alkaline phosphatase  ………… GGTP ………… bilirubin …………… 
TIBC  ………… Fe ………… ferritin  …………… 
cholesterol  ………… HDL ………… LDL  ……………. 
triglycerides  ………… ceruloplasmin   ………… glucose   ……………. 
c) blood morphology  
RBC ………… WBC ………… Neutrophils …………… 
HGB  …………  Lymphocytes  …………… 
HCT  …………  Monocytes  …………… 
MCV  ………… PLT ………… Eosynophils  …………… 
d) inflammatory process test  
 CRP ……………… Erythrocyte  sedimentation rate        ………………  
e) coagulation  
INR ……………… prothrombin  index  ……………… fibrinogen     ……………… 
 
Short course of the disease: results of the former liver biopsy (Nr…  Date…) 
 
date and signature of physician 
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Short course of the disease: results of the former liver biopsy (Nr…  Date…) 
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Histopathology 
 
Immunohistochemical and in situ hybridisation tissue tests: 
Etiologic factors………………………………………………………………….. 
HBsAg……  HCVAg………………  HBV DNA (PCR/CISH or FISH) 
HBcAg………  HDVAg………………  HCV RNA (PCR/CISH or FISH) 
HBeAg……… 
Staining for the presence of:  Fe………… Cu…………… α1- antiprotease……………… 
 
 
Inflammatory activity grade 
Criteria
Score * piecemeal necrosis-range lobular inflammation and necrosis 
0  none none 
1 minimal single minimal grade inflammation, single focal necrosis 
2 mild occupying single portal areas low grade inflammation, slight destruction of hepatocytes 
3 moderate occupying all portal areas 
moderate grade inflammation, 
noticeable destruction of    
hepatocytes 
4 severe occupying all portal areas  
high grade inflammation, prominent 
diffuse hepatocellular 
damage, the presence of bridging or 
perivenular necrosis 
 
Regressive changes in hepatocytes 
Ballooning degeneration grade…………… 
Score** 
Steatosis grade…………… 
Score** 
0 –  none 0 –  <5%  hepatocytes involved 
1 –  few ballooned cells 1 –  5-33%  hepatocytes involved 
2 –  many cells or prominent 
 ballooning 2 –  33-66%  hepatocytes involved 
 
 3 –  >66%  hepatocytes involved 
 
Regenerative changes in hepatocytes (dysplasia)…………………………………… 
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Stage of fibrosis 
Score * Fibrosis Criteria 
0 no fibrosis normal amount of connective tissue 
1 fibrosis of portal  area occupation of portal areas by fibrosis 
2 periportal fibrosis periportal fibrosis or single bridges portal-portal 
3 bridging fibrosis many fibrous bridges with distortion of hepatic architecture 
4 cirrhosis cirrhosis 
 
Cholestasis and bilirubinostasis……………………………………… 
Changes in vessels……………………………. 
 
Scoring 
     
inflammation …    steatosis …        ballooning … fibrosis … 
 
Histopathological description: 
 
 
     
Additional studies proposed ……………………………………………………….  
 
Final diagnosis ………………………………………………………. 
 
In descriptive terminology ………………………………………………………. 
 
Proposed differentiation  ………………………………………………………. 
 
  
date and signature of physician 
*According to modified Batts & Ludwig scoring system 
** According to Kleiner scoring system 
3. Conclusion 
A standardized universal protocol of liver biopsy such as the proposed scheme will facilitate 
the diagnosis of patients with suspected chronic liver disease. Obtaining complete and 
accurate clinical data by pathologists will allow more precise interpretation of observed 
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histological findings and will point to the necessity of additional tests. The histopathological 
picture should be assessed independently by two experienced pathologists in the case of 
research. In normal practice assessment by one experienced hepato-pathologist is accurate. 
In the future, in the final version of the protocol, histopathological data should be stored in a 
database especially prepared for pathologists. 
The prevalence of this protocol will unify the terminology used so far and will reduce 
differences in interpretation between the various centers. Modern treatment of chronic liver 
diseases is very expensive, especially in the case of viral infections. It requires a strict 
eligibility of patients for therapy. We hope that application of this protocol will assist in the 
proper use of financial resources thus leading to an increase in the number of complete 
recoveries. 
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Principles of the Biopsy Procedure 
Anna Piekarska  
Medical University of Łódź 
Poland 
1. Introduction 
A liver biopsy is a procedure where a small piece of liver tissue or liver cells are removed for 
microscopic examination. Taking a liver biopsy specimen for a microscopic examination can 
be performed in two ways: blind and guided liver biopsy. 
2.1 Blind biopsy 
The first, most common type of biopsy is a core-needle, blind biopsy.  
In this procedure a small piece of liver tissue is taken from the organ with the use of needle 
which diameter is 1.2 - 1.6 mm. The principle of this procedure is that the morphology of the 
liver specimen is the same as the morphology of whole organ. The size of the tissue sample 
taken from the liver enables the pathologist to evaluate the cell composition and to describe 
the location of particular cells in relation to other cells.  
Indications for a core-needle liver biopsy are presented in Table1.  
A core-biopsy can be performed as: a percutaneous core -needle biopsy, a transvenous 
(transjugular) core-needle biopsy, laparoscopic liver biopsy,  open wedge (surgical) biopsy.  
2.1.1 A percutaneous core -needle biopsy 
This type of biopsy is the most frequent. Indications are presented in Table 1. Percutaneous 
core-needle biopsy can be performed relatively easy. It can be performed in local anesthesia 
with the use of basic equipment.  
2.1.2 A transvenous (transjugular) core-needle biopsy 
This technique of performing a liver biopsy is indicated in patients with the increased risk of 
bleeding (e.g. thrombocytopenia), since in case of bleeding from biopsy site, liver blood 
directly flows to the lumen of hepatic vein and therefore it does not cause a subcapsular 
hematoma or bleeding into body cavities. However, the transvenous biopsy is a more 
invasive technique than the percutaneous biopsy.  It requires technical resources (imaging 
equipment) and is more expensive. 
2.1.3 Laparoscopic liver biopsy 
The laparoscopic surgery in the upper abdomen enables to take a liver tissue for 
pathological examination. However, the necessity to make a liver biopsy is hardly ever an 
indication for performing a laparoscopic surgery. Liver biopsy made with the use of this 
technique most frequently accompanies other medical procedures (e.g. cholecystectomy). 
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1. Introduction 
A liver biopsy is a procedure where a small piece of liver tissue or liver cells are removed for 
microscopic examination. Taking a liver biopsy specimen for a microscopic examination can 
be performed in two ways: blind and guided liver biopsy. 
2.1 Blind biopsy 
The first, most common type of biopsy is a core-needle, blind biopsy.  
In this procedure a small piece of liver tissue is taken from the organ with the use of needle 
which diameter is 1.2 - 1.6 mm. The principle of this procedure is that the morphology of the 
liver specimen is the same as the morphology of whole organ. The size of the tissue sample 
taken from the liver enables the pathologist to evaluate the cell composition and to describe 
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A core-biopsy can be performed as: a percutaneous core -needle biopsy, a transvenous 
(transjugular) core-needle biopsy, laparoscopic liver biopsy,  open wedge (surgical) biopsy.  
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bleeding (e.g. thrombocytopenia), since in case of bleeding from biopsy site, liver blood 
directly flows to the lumen of hepatic vein and therefore it does not cause a subcapsular 
hematoma or bleeding into body cavities. However, the transvenous biopsy is a more 
invasive technique than the percutaneous biopsy.  It requires technical resources (imaging 
equipment) and is more expensive. 
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The laparoscopic surgery in the upper abdomen enables to take a liver tissue for 
pathological examination. However, the necessity to make a liver biopsy is hardly ever an 
indication for performing a laparoscopic surgery. Liver biopsy made with the use of this 
technique most frequently accompanies other medical procedures (e.g. cholecystectomy). 
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Disease entity Reason for performing biopsy Comments 
Chronic viral hepatitis B 
and C 
1. Confirmation of clinical diagnosis 
2. Assessment of grading of 
inflammation and staging of fibrosis 
In many cases – 
necessary to qualify a 
patient for antiviral 
treatment 
Alcoholic hepatitis 
Non-alcoholic fatty liver 
disease 
Autoimmune hepatitis 
1. Confirmation of clinical diagnosis 
2. Assessment of progression of 
disease 
Most often it serves as a 
tool for differential 
diagnosis 
Hemochromatosis 1.Setting a diagnosis 
2. Quantitative evaluation of liver iron 
level 
 
Wilson’s disease 
Primary biliary cirrhosis 
1. Confirmation of clinical diagnosis 
2. Assessment of progression of 
disease 
 
Primary sclerosing 
cholangitis 
1.Setting a diagnosis 
2. Differential diagnosis of cholestasis
Liver biopsy is 
indicated when 
diagnosis is not 
possible on the basis of 
imaging 
Drug-induced  liver disease
1. Confirmation of clinical diagnosis 
2. Assessment of progression of 
disease 
 
Evaluation of transplanted 
liver in a recipient 
1. Diagnosis of  acute or chronic 
transplant rejection 
2. Post – transplant viral hepatitis 
 
Fever of unknown origin 1.Setting a diagnosis  
Anomalous levels of liver 
enzymes of unknown 
origin 
1.Setting a diagnosis  
Table 1. Indications for a core-needle blind liver biopsy  
2.1.4 Open wedge (surgical) liver biopsy 
A small piece of subcapsular liver tissue can be obtained during laparotomy.  
The piece of tissue taken during open surgery is usually bigger than the specimen taken 
percutaneously. However, the tissue is often damaged due to the technique of excision and 
handling of specimen during surgery. Moreover the subcapsular specimen may not be fully 
representative for morphology of liver diease. 
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2.2 Guided liver biopsy 
The second type of biopsy is a core-needle or fine-needle-aspiration biopsy. 
Guided biopsy is aimed at diagnostics of focal lesions in liver and must be performed under 
visual control. In most cases ultrasonography is used for this purpose. Computed 
tomography is used less frequently.   
The use of a fine needle allows for aspiration of liver cells only. The obtained biological 
material consists of liver cell which are not bound to each other and immersed in liquid 
material. This type of biopsy is used for diagnostics of  focal changes in liver – filled with 
liquid or hypoechogenic (e.g. cysts). 
However, for diagnostics of solid focal changes in liver (tumour metastasis, hepato-cellular 
carcinoma) core needle biopsy is recommended. This technique allows for obtaining a 
tumour tissue, which considerably facilitates setting a diagnosis. 
3. A place of liver biopsy in diagnostic workup in liver disease 
It should be underlined that a decision to make a biopsy is one of the last steps taken in 
diagnostics of liver diseases.  In view of the fact that the method is invasive and has its 
limitations, it should be performed only when it is supposed to provide information 
necessary for treatment of the patient. Below there is a list of information about the patient 
and additional examinations which should be  made before taking a decision of performing 
a biopsy. 
3.1 Hepatological diagnostics before taking a liver biopsy 
Before performing a biopsy one should try to establish the cause of the liver disease on the 
basis of non-invasive examinations so as to gather as much information as possible for the 
pathologist examining the specimen referring to etiology, progression of the liver disease.  
Following tests should be made in each patient: 
 blood cell count (pancytopenia might imply portal hypertension) 
 biochemical (ALT, AST, ALP, GTP, bilirubin), indicating the presence of hepatocyte 
necrosis and cholestasis 
 viral markers (anti-HAV IgM, HBsAg, HBeAg, anti-HBc-total, anti-HCV, anti-delta) 
 molecular examinations – depending on the results received above. (HBV-DNA 
quantitatively, HCV-RNA quantitatively) 
 antibody analysis (ANA, AMA, ASMA, anti-LKM, anti-SLA) 
 proteinogram 
 in justified cases – examination for presence of Wilson’s disease (plasma ceruloplasmin 
level, plasma copper level, copper excretion via urine), hemochromatosis (plasma 
ferritin level, plasma iron level, possibly analysis of mutation of C282Y and H63D 
genes) 
 ultrasonography examination of a liver and evaluation with the use of Doppler analysis 
of potential presence of portal hypertension 
The age of the patient is often a determining factor as for the decision about performing a 
liver biopsy and the way in which it should be performed. In case of children and young 
adults (younger than 16 years old) parents often do not give consent to a liver biopsy and 
they demand less invasive diagnostic methods. Moreover, children who are subjected to a 
percutaneous biopsy, should undergo a short-term general anesthesia.  In the case of elderly 
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Disease entity Reason for performing biopsy Comments 
Chronic viral hepatitis B 
and C 
1. Confirmation of clinical diagnosis 
2. Assessment of grading of 
inflammation and staging of fibrosis 
In many cases – 
necessary to qualify a 
patient for antiviral 
treatment 
Alcoholic hepatitis 
Non-alcoholic fatty liver 
disease 
Autoimmune hepatitis 
1. Confirmation of clinical diagnosis 
2. Assessment of progression of 
disease 
Most often it serves as a 
tool for differential 
diagnosis 
Hemochromatosis 1.Setting a diagnosis 
2. Quantitative evaluation of liver iron 
level 
 
Wilson’s disease 
Primary biliary cirrhosis 
1. Confirmation of clinical diagnosis 
2. Assessment of progression of 
disease 
 
Primary sclerosing 
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1.Setting a diagnosis 
2. Differential diagnosis of cholestasis
Liver biopsy is 
indicated when 
diagnosis is not 
possible on the basis of 
imaging 
Drug-induced  liver disease
1. Confirmation of clinical diagnosis 
2. Assessment of progression of 
disease 
 
Evaluation of transplanted 
liver in a recipient 
1. Diagnosis of  acute or chronic 
transplant rejection 
2. Post – transplant viral hepatitis 
 
Fever of unknown origin 1.Setting a diagnosis  
Anomalous levels of liver 
enzymes of unknown 
origin 
1.Setting a diagnosis  
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2.2 Guided liver biopsy 
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patients the doctor should decide whether the information gathered after taking a liver 
biopsy specimen will considerably influence further treatment.  For example: elderly 
patients suffering from chronic hepatitis C very often have numerous contraindications for 
interferon and ribavirin therapy. Therefore, a liver biopsy as a tool for qualification to 
antiviral treatment is useless in this setting.   
A free consent to liver biopsy. 
In every case the written consent for the procedure should be obtained from the patient or 
his committee. The patient should achieve complete information about indications for the 
procedure, diagnostic benefits and potential complications.   
Cooperation of the patient is a crucial element qualifying him for liver biopsy. 
The procedure performed in local anesthesia involves inserting a needle when the patient 
has exhaled the air. Inhaling or moving the body when the doctor inserts a needle might 
lead to liver rupture and massive hemorrhage. The patient must be informed about such 
possibility and should be taught to control his breathing. If, in the doctor’s opinion, it is not 
possible (small children, patients with mental or behavioral disorders), the patient should be 
given short-term general anesthesia. Otherwise the procedure should be abandoned. 
Moreover, the patient is then asked to stay in bed for 3 hours following the procedure.   
Body mass (BMI). In obese patients (>30 BMI) it might be difficult to take a liver biopsy 
specimen percutaneously because of thick subcutaneous fatty tissue.  
Concomitant diseases (e.g. circulatory insufficiency, scoliosis) might hamper performing  
a liver biopsy as it might be difficult to put the patient in the appropriate position and  
make him stay in that position for more than 10 minutes. Those suffering from hemophilia 
are usually disqualified from this kind of procedure because of the increased risk of 
bleeding. 
Allergy to medicaments used for local anesthesia (e.g. lidocaine) might  make the 
percutaneous biopsy impossible to perform. 
The information on medicaments taken by the patient for a longer period, especially 
anticoagulant medications (salicylic acid, acenocumarol) is crucial when the liver biopsy is 
planned. Patient should stop taking salicylic acid for one week before the liver biopsy. 
Administering of acenocumarol should be stopped two days before the liver biopsy. If it is 
not possible the doctor should perform transvenous biopsy or should not perform the 
biopsy at all. 
Menstrual cycle phase should be considered in female patients. Biopsy should not be made 
during menstruation (1 – 5 day) because of the increased risk of liver bleeding. 
4. Answers a liver biopsy can give 
 In majority cases of acute viral hepatitis liver biopsy is not performed. The diagnosis 
can be set on the base of biochemical and serologic examinations. The exceptions are the 
patients in whom on the base of other examinations and anamnesis it is not possible to 
determine whether they suffer from chronic or acute hepatitis. Since 
pathomorphological findings in these two kinds of hepatitis are different, liver biopsy 
might be helpful in setting the right  diagnosis and qualifying for treatment. It is 
important as the treatment of these diseases differ a lot.  
 In case of chronic viral hepatitis B and C morphological evaluation of a liver biopsy 
specimen helps to assess the grade and stage of the diasease (according to one of 
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assessment scales). In routine diagnostics the pathological examination of specimen 
does not help to discover etiology. The results of assessment of grade of inflammation 
and stage of fibrosis serve as a tool for qualification for treatment. Besides, 
morphological analysis facilitates diagnosing other liver diseases which accompany 
viral hepatitis (fatty liver disease, alcoholic liver disease, autoimmune hepatitis).  
Morphological analysis also helps to evaluate remission of changes after antiviral 
treatment.  
 Alcoholic liver disease (ALD) can be diagnosed without an analysis of the specimen in 
most cases. In any doubts, biopsy helps to set the right diagnosis, evaluate the fibrosis 
and presence of other inflammatory processes (e.g. AIH). 
 Biopsy specimen analysis is crucial in the case of non-alcoholic fatty liver disease 
(NAFLD) since additional analysis (biochemical and serologic) allow to exclude 
existence of other liver diseases. Morphological analysis helps to differentiate NAFLD 
and non-alcoholic steatohepatitis (NASH), evaluate accumulation of fat in hepatocytes  
in Dixon’s scale as well as consequences of the disease manifested by progression of 
fibrosis.  
 Suspicion of the presence of autoimmune hepatitis (AIH) is an indication for liver 
biopsy.  Morphological analysis helps to set a diagnosis in the case of unclear results of 
autoantibodies, differentiate e.g. AIH and ALD and evaluate the progression of the 
disease and its consequences – fibrosis and cirrhosis. Morphological analysis also 
proves how effective the applied treatment is.  
 Diagnosing liver metabolic diseases  (Wilson’s disease, hemochromatosis) without 
morphological analysis might be impossible to do. Morphological analysis not only 
enables to set the right diagnosis and differentiate with other liver diseases but also 
helps to make a quantitative evaluation of iron in the liver biopsy specimen, which is 
significant for further therapy. 
5. Answers a liver biopsy cannot give 
Liver biopsy should not be made: 
 if the diagnosis can be established with the use of non-invasive methods, 
 if the information gathered does not change decisions as for the therapy, 
 if biopsy might be a health hazard. 
Therefore, the biopsy should not be performed in patients with decompensated liver 
cirrhosis. When the clinical diagnosis is obvious (ascites, oedema, jaundice, symptoms of 
portal hypertension) the liver biopsy will not give more diagnostic information and will 
not influence on the choice of treatment method. Besides, in the case of hemorrhagic 
diathesis which accompanies cirrhosis, the liver biopsy may lead to hemorrhage. As 
medical practice shows, in patients suffering from cirrhosis, it is difficult or even 
impossible to obtain a representative liver biopsy specimen. Moreover, the specimen is 
often small and dismembered, which makes the pathologic examination almost 
impossible. 
6. Diagnostic workup before commencing a liver biopsy 
Set of tests which should be performed during last 24 hours before core biopsy is presented 
in Table 2.  
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(NAFLD) since additional analysis (biochemical and serologic) allow to exclude 
existence of other liver diseases. Morphological analysis helps to differentiate NAFLD 
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 Diagnosing liver metabolic diseases  (Wilson’s disease, hemochromatosis) without 
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significant for further therapy. 
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Liver biopsy should not be made: 
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Therefore, the biopsy should not be performed in patients with decompensated liver 
cirrhosis. When the clinical diagnosis is obvious (ascites, oedema, jaundice, symptoms of 
portal hypertension) the liver biopsy will not give more diagnostic information and will 
not influence on the choice of treatment method. Besides, in the case of hemorrhagic 
diathesis which accompanies cirrhosis, the liver biopsy may lead to hemorrhage. As 
medical practice shows, in patients suffering from cirrhosis, it is difficult or even 
impossible to obtain a representative liver biopsy specimen. Moreover, the specimen is 
often small and dismembered, which makes the pathologic examination almost 
impossible. 
6. Diagnostic workup before commencing a liver biopsy 
Set of tests which should be performed during last 24 hours before core biopsy is presented 
in Table 2.  
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Analysis Comments
Blood cell count The number of platelets should exceed 60,000/µl, to avoid bleeding 
Blood group 
Identifying blood group before the biopsy 
allows for faster blood transfusion in the 
event of possible hemorrhage 
Coagulogical analysis 
Prothrombin time should not exceed the 
reference value by more than 4 seconds 
(INR>1.4) 
Activated partial thromboplastic time 
(APTT) should not exceed the reference 
value by 1.5 times 
Image examination (e.g. USG, CT) Excluding focal lesions in the liver 
Table 2. Set of tests which should be made directly before blind liver biopsy. 
7. The choice of type of liver biopsy 
Focal changes discovered in ultrasound examination or computed tomography are 
indications for an image-controlled biopsy. 
In patient with chronic hepatitis in whom a solid focal change is diagnosed two USG-guided 
core biopsies should be made. The first specimen should be obtain from the solid lesion.  
The other should be obtained from other part of liver (with the avoidance of lesion  
volume).   
8. How to prepare a patient to liver biopsy 
On the day of biopsy the patients is advised to remain fast. He should be examined by the 
physician performing the procedure. Fever, cough, bleeding or circulatory insufficiency 
diagnosed prior to the biopsy should be temporary contraindications for it. Thirty minutes 
before the surgery the patient is sedated with 5 mg of diazepam administered 
intramuscularly. 
9. Anesthesia 
In adults and children who can cooperate during the procedure (usually above 15 years  
of age) liver biopsy is made in local anesthesia. To do it one should use 8-10 ml of 1% 
lidocaine solution. The technique of anesthesia is described below (Point 10). When the 
patient is not willing to cooperate, the procedure should be performed in short-term general 
anesthesia.  
10. Technique of core biopsy 
10.1 The position of the patient 
The patient should be in supine position, with his right upper limb placed behind the head, 
the left one – along the body. Intercostals spaces should be as wide as possible (middle 
armpit line should be in the shape of arch). 
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10.2 Determining the area of biopsy 
Upper and lower limits of liver dullness should be established with the use of percussion. 
Next, the physician should mark the area of biopsy in the intercostals space, in the middle of 
liver dullness, on the middle armpit line or anterior armpit line. 
10.3 Antiseptics 
After putting on sterile gloves the area of biopsy should be cleansed twice with antiseptic 
substance and the skin should be left to dry. 
10.4 Local anesthesia 
The anesthesia should be done in the place selected beforehand. Lidocaine solution should 
be injected subcutaneously and later on, the needle must be inserted deeper, inside the 
intercostals space, continuously injecting a solution. Once the needle touches the capsule the 
needle should be slowly withdrawn and the solution – administered.  
10.5 Liver biopsy 
After application of anesthetic, the assisting nurse opens a set for liver biopsy. It consists of a 
blockage controlled syringe, a biopsy needle, a hypodermic needle and a blade.  
The first activity involves putting a hypodermic needle for on the blockage controlled 
syringe and then aspiration of 4 ml of aseptic solution of isotonic salt in such a way that the 
“brake” in the syringe remains in the unblocked position. Next, the hypodermic needle 
should be taken off and replaced with the biopsy needle. The syringe with the biopsy needle 
should be put aside in a sterile place and with the use of scalpel the doctor should make an 
incision – 2 to 3 mm long - in the intercostals space skin. Then the needle biopsy should be 
placed inside the incision as deep as to the liver capsule. At this moment the needle should 
be moved a few milimetres backwards. The patient should inhale air, exhale it to the end 
and then hold his breath. At the moment the patients does not breathe the doctor should 
inject about 2 ml of isotonic salt and then, pull the piston to block the “brake” and quickly 
move the needle in the direction of liver to the depth of about 3 cm and take it out 
immediately. After removing the needle from the intercostals space the patient should be 
allowed to breathe freely. With a sterile gauze pad one should press the area where the liver 
specimen has been taken since the skin might start bleeding a little. After putting a sterile 
dressing on the biopsy area the biopsy needle should be emptied , which should be done by 
unblocking the “brake” of the syringe. The content of the needle should be put in a prepared 
container with formalin solution. Then the doctor performing the biopsy should 
macroscopically evaluate the size of the taken specimen. If it is too small or dismembered 
too much, the procedure should be repeated.  
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10.2 Determining the area of biopsy 
Upper and lower limits of liver dullness should be established with the use of percussion. 
Next, the physician should mark the area of biopsy in the intercostals space, in the middle of 
liver dullness, on the middle armpit line or anterior armpit line. 
10.3 Antiseptics 
After putting on sterile gloves the area of biopsy should be cleansed twice with antiseptic 
substance and the skin should be left to dry. 
10.4 Local anesthesia 
The anesthesia should be done in the place selected beforehand. Lidocaine solution should 
be injected subcutaneously and later on, the needle must be inserted deeper, inside the 
intercostals space, continuously injecting a solution. Once the needle touches the capsule the 
needle should be slowly withdrawn and the solution – administered.  
10.5 Liver biopsy 
After application of anesthetic, the assisting nurse opens a set for liver biopsy. It consists of a 
blockage controlled syringe, a biopsy needle, a hypodermic needle and a blade.  
The first activity involves putting a hypodermic needle for on the blockage controlled 
syringe and then aspiration of 4 ml of aseptic solution of isotonic salt in such a way that the 
“brake” in the syringe remains in the unblocked position. Next, the hypodermic needle 
should be taken off and replaced with the biopsy needle. The syringe with the biopsy needle 
should be put aside in a sterile place and with the use of scalpel the doctor should make an 
incision – 2 to 3 mm long - in the intercostals space skin. Then the needle biopsy should be 
placed inside the incision as deep as to the liver capsule. At this moment the needle should 
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dressing on the biopsy area the biopsy needle should be emptied , which should be done by 
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1. Introduction 
Most liver diseases are caused by host immune responses, and there have been many 
studies on the analysis of circulating lymphocyte subsets and their production of cytokines 
in patients with liver diseases. Although circulating lymphocytes are relatively easy to 
obtain and analyze, analysis of intrahepatic lymphocytes would be more important for 
understanding the immunopathogenesis of liver diseases, especially, viral hepatitis and 
autoimmune liver diseases.  
Two approaches are currently available to analyze intrahepatic lymphocytes in liver biopsy 
specimens, an immunohistochemical approach and a flow cytomeric analysis of isolated 
lymphocytes from liver tissues. Although use of an immunohistochemical approach would 
allow the distribution of particular lymphocyte subsets to be determined, quantitative 
estimation of infiltrating lymphocyte populations may be incorrect. In contrast, flow 
cytometry can determine the precise percentages of each lymphocyte population, but it does 
not provide any information on their intrahepatic distribution. The use of multiple 
antibodies to identify lymphocyte subsets can enable multi-color flow cytometric analysis, 
revealing the precise percentages of each subset, even those constituting an extremely minor 
subset of lymphocytes. Moreover, molecular biological approaches have been used to 
analyze the immunopathogenesis of liver diseases. 
This chapter summarizes findings obtained from the immunological analyses of biopsied 
liver tissues and how immunological analyses of liver biopsy specimens have contributed to 
the understanding of the immunopathogenesis of liver diseases. We also describe recent 
technical advances in the immunological analyses of liver biopsy specimens that can further 
enhance our understanding of the pathogenesis of liver diseases. 
2. Methods for analyzing immunological responses in the liver  
2.1 Immunohistochemical approach (Luttmann et al., 2006) 
Immunohistochemical methods can be used to characterize and localize liver-infiltrating cells 
and proteins such as cytokines, as well as quantitate their degree of infiltration, information 
essential for the analysis of local immune responses. Paraffin-fixed and frozen liver biopsy 
specimens, as well as specimens fixed by other methods, can be analyzed, although the 
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This chapter summarizes findings obtained from the immunological analyses of biopsied 
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the understanding of the immunopathogenesis of liver diseases. We also describe recent 
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enhance our understanding of the pathogenesis of liver diseases. 
2. Methods for analyzing immunological responses in the liver  
2.1 Immunohistochemical approach (Luttmann et al., 2006) 
Immunohistochemical methods can be used to characterize and localize liver-infiltrating cells 
and proteins such as cytokines, as well as quantitate their degree of infiltration, information 
essential for the analysis of local immune responses. Paraffin-fixed and frozen liver biopsy 
specimens, as well as specimens fixed by other methods, can be analyzed, although the 
immunogenicity of some antigens can be usually better preserved by cryofixation than by 
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chemical fixation. The underlying principle of the immunohistochemical approach is the 
binding of an antigen by a specific antibody (the first antibody). The first antibody is usually 
labeled with a fluorochrome, enzyme, or particle. If an unlabeled antibody is used, the 
secondary antibody must be labeled. Staining with labeled primary antibodies results in better 
detection of antigens, with less nonspecific background staining. Although high 
concentrations of antibodies can detect small amounts of antigens, higher antibody 
concentrations are associated with increased nonspecific binding. Therefore, the specific 
detection of each antigen requires the optimal dilution of each antibody as well as an optimal 
incubation period and temperature. As an example, we describe the immunohistochemical 
detection of antigen, using both a primary and a secondary antibody, in paraffin-fixed tissue 
samples.  
Paraffin-fixed tissue samples must firstly be deparaffinized and rehydrated. Sections are 
then immersed in 10 mM citrate buffer, pH 6.0, and heated in a microwave oven for 
antigen retrieval. Alternatively, sections can be heated in a water bath, autoclave, or steam 
pot, or incubated with proteolytic enzymes, for antigen retrieval. After quenching 
endogenous peroxidase activity with 0.3% H2O2 in methanol, the sections are incubated 
with non-specific proteins, such as normal horse serum or bovine serum albumin, to 
inhibit non-specific finding. The sections are subsequently incubated with primary 
antibodies, either for 30 min at room temperature or overnight at 4C, with shorter 
incubation periods usually effective for the detection of specific antigen-antibody binding. 
After rinsing in PBS three times, the sections are incubated with biotinylated secondary 
antibody for 60 min at room temperature, followed by treatment with peroxidase-labeled 
streptavidin for 20 min. Peroxidase activity is developed with 0.25 mg/ml 3,3’-
diaminobenzidine tetrahydrochloride in the presence of 0.003% hydrogen peroxide in 0.05 
M Tris-buffered saline, pH 7.4, and the sections are counterstained for nuclei in 
hematoxylin.  
2.2 Gene expression associated with immune responses in liver biopsy specimen 
In situ hybridization can be used to analyze the expression of specific genes in liver 
biopsy specimens. In addition, the distribution of expression of specific genes in these 
samples can be analyzed by in situ hybridization followed by counter staining for cells 
and organelles.  
In situ hybridization can be performed using both isotope-labeled and non-isotope-labeled 
probes. We briefly describe a non-isotope-labeled method. Tissue samples are digested with 
proteinase and incubated overnight with digoxigenin-labeled riboprobes at 55ºC. The slides 
are then washed in sodium dodecyl sulphate in saline sodium citrate and finally in Tris 
buffered saline containing 0.1% Tween 20 and 1% fetal calf serum (FCS). The tissue samples 
are subsequently incubated with an alkaline phosphatase conjugated antibody against 
digoxigenin. Signal is detected using 5-bromo-4-chloro-3-indoyl phosphatase as a substrate 
and nitro blue tetrazolium as a coupler.  
2.3 Characterization of the phenotypes of isolated intrahepatic lymphocytes (IHLs) 
IHLs can be isolated from liver biopsy specimens by enzymatic digestion and density 
gradient centrifugation (Hata et al., 1990, Doherty et al., 1999). Briefly, tissue samples are 
minced into 1 mm2 pieces and incubated while rotating for 20 min at 37°C in Hank’s 
Balanced Salt Solution (HBSS) containing 0.5 mg/ml collagenase, 0.02 mg/ml DNase, 2% 
FCS and 0.6% bovine serum albumin (BSA). Undigested tissue is removed by filtration 
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through a 100 μm diameter mesh and the cells are washed twice with HBSS. Hepatocytes 
are removed by centrifugation at 30 × g for 1 min and the remaining cells are collected and 
resuspended in RPMI medium containing 10% FCS. Cell yields and viabilities are 
determined by microscopic examination of ethidium bromide/acridine orange stained 
preparations. Yields are usually about 1–2 × 106 mononuclear cells per 200 mg tissue sample, 
a sufficient number of cells for further analyses. 
The phenotype, cytotoxicity (Hata et al., 1990) and cytokine production (Doherty et al., 1999) 
of isolated IHLs can be analyzed by flow cytometry. Moreover, multi-color flow cytometric 
analyses can identify minor populations of lymphocytes and intracytoplasmic cytokines. 
The function of IHLs present in liver biopsy specimens can therefore be analyzed in detail, 
resulting in a comprehensive understanding of intrahepatic immune responses in liver 
diseases. 
2.4 Further application of immunological analysis  
RNA and DNA in liver biopsy specimens can be isolated using commercial kits, followed by 
PCR or RT-PCR for the quantitative evaluation of DNA or RNA encoding proteins 
associated with the immune system.  
Recent advances in microarray technology can be also applied to liver biopsy samples. 
Tissue microarrays are constructed by transferring cores of paraffin-embedded tissue to 
precored holes in a recipient paraffin block (Kononen et al., 1998). Microarray analysis 
enables the evaluation of the expression of multiple genes in liver biopsy specimens in a 
high throughput manner.  
3. Immunological analysis in liver diseases 
Intrahepatic immune responses have been analyzed in liver biopsy specimens, enhancing 
our understanding of the immunopathogenesis of liver diseases.  
3.1 Acute viral hepatitis 
Immunological analysis has been extensively performed in transgenic mouse and 
chimpanzee models of acute infection. In one model, transgenic mice, in which infectious 
HBV virions replicate in the livers with all HBV-related antigens expressed, were injected 
with HBsAg-specific cytotoxic T lymphocytes (CTLs) that had been induced in 
nontransgenic mice. The transgenic mice produced interferon (IFN)- and tumor necrosis 
factor (TNF)- which purged viral RNA and DNA without destroying infected hepatocytes 
(Guidotti et al., 1996, Chisari, 1997, Guidotti et al., 2001). Importantly, this noncytolytic 
clearance of intracellular HBV is more efficient at controlling HBV replication than the 
killing of infected hepatocytes. In this sense, hepatitis is not only a harmful event but also 
represents an effective mechanism by which CTLs suppress HBV. Noncytolytic viral 
eradication can account for recovery from acute HBV infection, in that most HBV is cleared 
from hepatocytes with only a fraction of the hepatocytes being destroyed. This phenomenon 
was confirmed using a chimpanzee infection model. HBV-DNA was profoundly decreased 
in the liver and blood of acutely infected chimpanzees before peak serum alanine 
aminotransferase (ALT) concentrations were reached (Guidotti et al., 1999), suggesting that 
this noncytopathic T cell effector mechanism results in early viral inhibition or eradication, 
whereas a cytopathic T cell effector mechanism would be required to eliminate the 
remaining virus by destroying infected hepatocytes. 
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a sufficient number of cells for further analyses. 
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of isolated IHLs can be analyzed by flow cytometry. Moreover, multi-color flow cytometric 
analyses can identify minor populations of lymphocytes and intracytoplasmic cytokines. 
The function of IHLs present in liver biopsy specimens can therefore be analyzed in detail, 
resulting in a comprehensive understanding of intrahepatic immune responses in liver 
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2.4 Further application of immunological analysis  
RNA and DNA in liver biopsy specimens can be isolated using commercial kits, followed by 
PCR or RT-PCR for the quantitative evaluation of DNA or RNA encoding proteins 
associated with the immune system.  
Recent advances in microarray technology can be also applied to liver biopsy samples. 
Tissue microarrays are constructed by transferring cores of paraffin-embedded tissue to 
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enables the evaluation of the expression of multiple genes in liver biopsy specimens in a 
high throughput manner.  
3. Immunological analysis in liver diseases 
Intrahepatic immune responses have been analyzed in liver biopsy specimens, enhancing 
our understanding of the immunopathogenesis of liver diseases.  
3.1 Acute viral hepatitis 
Immunological analysis has been extensively performed in transgenic mouse and 
chimpanzee models of acute infection. In one model, transgenic mice, in which infectious 
HBV virions replicate in the livers with all HBV-related antigens expressed, were injected 
with HBsAg-specific cytotoxic T lymphocytes (CTLs) that had been induced in 
nontransgenic mice. The transgenic mice produced interferon (IFN)- and tumor necrosis 
factor (TNF)- which purged viral RNA and DNA without destroying infected hepatocytes 
(Guidotti et al., 1996, Chisari, 1997, Guidotti et al., 2001). Importantly, this noncytolytic 
clearance of intracellular HBV is more efficient at controlling HBV replication than the 
killing of infected hepatocytes. In this sense, hepatitis is not only a harmful event but also 
represents an effective mechanism by which CTLs suppress HBV. Noncytolytic viral 
eradication can account for recovery from acute HBV infection, in that most HBV is cleared 
from hepatocytes with only a fraction of the hepatocytes being destroyed. This phenomenon 
was confirmed using a chimpanzee infection model. HBV-DNA was profoundly decreased 
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aminotransferase (ALT) concentrations were reached (Guidotti et al., 1999), suggesting that 
this noncytopathic T cell effector mechanism results in early viral inhibition or eradication, 
whereas a cytopathic T cell effector mechanism would be required to eliminate the 
remaining virus by destroying infected hepatocytes. 
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There have been a limited number of immunological analyses of local immune responses in 
the liver of patients with acute viral hepatitis, due primarily to relative contraindications for 
liver biopsy in these patients. Moreover, the kinetics of local immune response cannot be 
analyzed in humans, because repeated liver biopsies are not usually required and are 
ethically not allowed during the course of acute hepatitis. 
The CD4/CD8 ratio of liver-derived T cell clones was found to be 0.3-0.5 during the acute 
phase of HAV infection, indicating a CD8+ T cell predominance, but 1.2 during the recovery 
phase, indicating a CD4+ T cell predominance (Fleischer et al., 1990). Half of the T cell 
clones showed cytotoxicity against HAV-infected autologous fibroblasts, further suggesting 
that the intrahepatic HAV-specific T cell response has an important role in the pathogenesis 
of acute hepatitis A and in viral eradication.  
Immunohistochemical analysis of intrahepatic lymphocyte populations in patients with 
acute hepatitis A, B and C showed that CD45RO+ memory T cells were the most 
prominent cell population in all 3 types of acute hepatitis, and that the numbers of these 
cells were significantly higher in portal areas of patients with acute hepatitis C than in 
those with acute hepatitis B (Hashimoto et al., 1996). In addition, the ratio of CD20+ B 
cells to CD45RO+ memory T cells was significantly lower in acute hepatitis B than in the 
two other types of acute hepatitis (Hashimoto et al., 1996). These data indicate that 
memory T cells are involved in the immunopathogenesis of all types of acute viral 
hepatitis. However, the clinical significance of the differences among acute hepatitis A, B 
and C remains unclear. 
Recently, the signal delivered by a CD28 superfamily, programmed death-1 (PD-1) protein, 
was shown to impair virus-specific CD8+ T-cell responses during chronic viral infection 
(Watanabe et al., 2010), suggesting that this protein plays an important role in insufficient T 
cell responses against hepatitis viral antigen, leading to persistent viral infection. In patients 
with acute hepatitis C, PD-1 expression was higher on CD4+ than on CD8+ T cells in the 
liver, with expression more prominent on intrahepatic than on peripheral blood 
lymphocytes. However, no correlation was observed between PD-1 expression on T cells 
and clinical outcomes in patients with acute viral hepatitis (Kasprowicz et al., 2008).  
PD-1 expression is thought to be regulated during acute hepatitis, with PD-1 up-regulated 
on CD8+ T cells during the early phase of acute hepatitis B (Zhang et al., 2008). Successful 
viral clearance correlated with a subsequent decrease in PD-1 expression, and the delayed 
PD-1 expression on HBV-specific CD8+ T cells was associated with acute liver failure 
(Zhang et al., 2008), suggesting that impaired regulation of PD-1 expression may lead to 
enhanced immune response and severe hepatitis.  
In summary, intrahepatic viral-specific memory T cells are directly involved in the 
immunopathogenesis of acute viral hepatitis, and the kinetics of PD-1 expression in the liver 
may determine patient outcomes. However, there is limited information on the 
characterization of intrahepatic lymphocytes and on local immune responses in the liver in 
patients with acute viral hepatitis.  
3.2 Chronic hepatitis 
There are few animal models of chronic hepatitis, and most of our knowledge regarding its 
immunopathogenesis is derived from analyses of human liver tissues. Because local 
immune responses cannot be analyzed over time in patients, however, findings obtained 
from animal models may help enhance our understanding of the kinetics of immune 
responses in the liver.  
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Many studies have analyzed intrahepatic lymphocytes in patients with chronic hepatitis, 
both immunohistochemically and by flow cytometry. Most of these studies analyzed the 
makeup of infiltrating cells, the expression of costimulatory molecules in the liver and the 
antigen specificity of infiltrating T cells. These results have greatly contributed to 
understanding the immunopathogenesis of various chronic liver diseases.  
3.2.1 Composition of infiltrating cells 
Chronic hepatitis is characterized by lymphoid cell infiltration mainly in portal tracts. Most 
infiltrating cells are CD3+ T cells, with most of the latter being CD45RO+ memory cells. The 
CD4/CD8 ratio is similar in patients with hepatitis B and C; 50-60% of infiltrating cells are 
CD4+ helper T lymphocytes, around 25% are CD8+ CTLs and 15% are B lymphocytes. CD8+ 
T lymphocytes are located in the peripheral part of portal tracts and intralobular necrotic 
foci (Walewska-Zielecka et al., 2008). Natural killer cells are also involved in the 
immunopathogenesis of chronic hepatitis, with CD3-CD56brightNKG2A+ cells associated 
with necroinflammation of the liver and CD3-CD56dimNKG2A+ cells associated with low 
viral load (Bonorino et al., 2009).  
The percentages of virus-specific T lymphocytes in the liver have been clarified by 
immunohistochemical staining with peptide-MHC tetramer. The proportion of CD8+T 
lymphocytes in the livers of patients with chronic HBV specific for HBc18-27, a major HBV 
epitope, has been found to range from 0.18% to 1.28% (Shimada et al., 2003). In patients with 
chronic hepatitis C, 1-2% of CTLs in the liver were found to be HCV NS3-specific, compared 
with 0.01% to 1.2% of PBLs (He et al., 1999). Due to the low percentages of lymphocyte 
populations specific for viral epitopes, most intrahepatic lymphocytes are thought to be 
antigen-nonspecific. The contribution of virus-specific and -nonspecific cells to hepatocyte 
damage and viral control in chronic viral hepatitis in humans remains unclear. However, in 
the HBV transgenic mouse model of acute hepatitis, administration of antibodies against the 
chemokines, IFN-gamma inducible protein (IP-10) and monokine induced by interferon-
gamma (Mig) reduced the recruitment of mostly Ag-nonspecific mononuclear cells into the 
liver that had been induced by cytokines and chemokines produced by injected CTLs, 
leading to a reduction in the severity of hepatitis without affecting the antiviral activity of 
the CTLs (Kakimi et al., 2001). The findings indicate that CTLs can suppress virus without 
damaging hepatocytes, whereas secondarily recruited mononuclear cells, with little antiviral 
activity, destroy hepatocytes in an Ag-nonspecific manner.  
In humans, several cytokines and chemokines are thought to be involved in the recruitment 
of T lymphocytes into the liver. For example, intrahepatic levels of IP-10/CXCL10 and 
Mig/CXCL19 have been reported to correlate with liver inflammation and fibrosis in the 
livers of patients with chronic hepatitis C (Zeremski et al., 2008). Moreover, their receptor, 
CXCR3, is expressed on most intrahepatic T lymphocytes, indicating that 
chemokine/receptor systems have an important role in T cell recruitment into inflamed 
livers. We have reported that Mip3 produced by DCs after phagocytosis of apoptotic cells 
is chemotactic for CCR6-expressing CD4+ T lymphocytes, but not for CD8+ T lymphocytes 
(Shimizu et al., 2001). A complex chemokine/chemokine receptor network is therefore 
present in the livers of patients with chronic hepatitis, and manipulation of this network 
may control the magnitude of liver inflammation. 
3.2.2 Chronic hepatitis B 
Several studies have characterized CD4+ T lymphocytes in patients with chronic hepatitis B. 
For example, these livers have been found to contain Th0 cells, which produce not only IFN-
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, but also IL-4 and IL-5, thus differing from cells in the livers of patients with chronic 
hepatitis C, which are mostly Th1 cells (Bertoletti et al., 1997).  CD4+ T lymphocytes that 
produce TNF- and IL-17 infiltrate into the livers of patients with chronic hepatitis B and 
are involved in liver inflammation (Zhang et al., 2010). IL-17 producing CD4+ T 
lymphocytes, called Th17 cells, are a third distinct subset of T helper cells and play an 
important role in innate and adoptive immunity and in autoimmunity. In a transgenic 
mouse model, CD4+ T lymphocytes, as well as CD8+ T lymphocytes, have been shown 
effective for noncytolytic viral purge by secreting TNF- and IFN-(Franco et al., 1997). 
Although noncytolytic antiviral mechanism mediated by T lymphocytes was first described 
in a transgenic mouse model (Guidotti et al., 1996), a similar phenomenon was recently 
observed in the livers of patients with chronic hepatitis B.  
The natural history of chronic HBV infection is somewhat complex. Most people infected at 
birth are asymptomatic during their first 20-30 years, called the immune tolerant phase. This 
tolerant phase later breaks down, resulting in ALT flare-ups due to activation of the 
immune response against HBV. After an ALT flare, 80-90% of chronically infected patients 
experience a great reduction, but not a diminishing, of HBV replication, these patients 
seroconvert, from HBeAg to anti-HBe antibody, and become inactive carriers. In the other 
10-20% of chronically infected patients, ALT remains elevated and active HBV replication 
persists, resulting in disease progression to chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma. Although the precise pathogenetic mechanisms differentiating 
inactive carriers from chronic hepatitis patients are unclear, recent immunological analyses 
have provided new insights into the understanding of these mechanisms. 
Livers of patients with low HBV replication contain intralobular CD8+ T lymphocytes (Tang 
et al., 2003), suggesting that the host immune system recognizes viral antigens and may 
carry out immune surveillance in the livers of inactive carriers. Moreover, the same numbers 
of HBcAg-specific CD8+ T lymphocytes are present in the livers of individuals with high 
viral replication/elevated serum ALT and low viral load/normal ALT (Maini et al., 2000), 
suggesting that HBV-specific CD8+ T cells effectively control viral replication without 
damaging infected hepatocytes in inactive carriers, but fails to do so in patients with chronic 
hepatitis. Although the mechanism underlying this failure of viral control remains unclear, 
two possible mechanisms have been hypothesized, one involving regulatory T cells and the 
other involving the costimulatory molecule, PD-1. Regulatory T cells (Tregs) expressing the 
transcription factor Foxp3 are specialized cells that exert negative control on a variety of 
physiological and pathological immune responses, resulting in maintenance of 
immunological self-tolerance (Miyara et al., 2011). Circulating and intrahepatic Tregs are 
involved in persistent infection by hepatitis virus. CD4+CD25+ cells and Foxp3+ cells are 
increased in the livers of patients with chronic hepatitis B (Xu et al., 2006), and patients with 
high viral load have a higher proportion of Tregs in the liver (Stoop et al., 2008), suggesting 
that intrahepatic Tregs suppress antiviral immune responses in the liver.  
PD-1 is a surface receptor critical for the regulation of T cell function (Francisco et al., 2010, 
Fife BT et al., 2011). The binding to PD-1 by its ligands PD-L1 and PD-L2 results in the 
antigen-specific inhibition of T-cell proliferation, cytokine production, and cytolytic 
function. In the liver, PD-1 is expressed on lymphocytes; PD-L1 is expressed on 
lymphocytes, hepatocytes and sinusoidal endothelial cell; and PD-L2 is expressed on 
Kupffer cells and DCs (Chen et al., 2010). Intrahepatic HBV-specific CD8+ T cells express 
higher levels of PD-1, and upregulation of intrahepatic PD-1/PD-L1 is associated with liver 
inflammation and ALT elevation (Fisicaro et al., 2010, Xie et al., 2009). Although the 
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mechanism underlying the upregulation of PD-1 on CD8+ T cells in inflamed livers is 
unknown, signals from PD-1 inhibit HBV-specific T cells, resulting in insufficient antiviral 
responses and liver inflammation. Importantly, PD-1/PD-L1 blockade increased CD8+ T cell 
proliferation and enhanced IFN-and IL-2 production by intrahepatic lymphocytes (Fisicaro 
et al., 2010). These findings suggest that inhibiting PD-1/PD-L1 may have therapeutic 
potential for the control of hepatitis B. 
Local immune response is also regarded as important during the treatment of hepatitis B. 
The numbers of pretreatment intrahepatic CD8+ T cells has been shown to predict better 
responses to IFN- and lamivudine (Tang et al., 2004, 2005). 
3.2.3 Chronic hepatitis C 
The local immune response occurring in the livers of patients with chronic hepatitis C is 
similar to that in chronic hepatitis B. Intrahepatic CD4+ T cells, most of which are Th1 cells 
producing IFN- but not IL-4 and IL-5 (Bertoletti et al., 1997), are located in portal and 
periportal areas, with the proportions of these cells correlating with histological activity 
index (Fiore et al., 1997). However, no correlation has been found between the proportion of 
intrahepatic CD4+ T cells and viremia or serum ALT levels (Tran et al., 1997). Most 
intrahepatic CD4+ T cells in the livers of patients with chronic hepatitis C are CD45RO+, but 
the percentages of CD4+CD27+ and CD4+CD28+ T cells are lower (Wang et al., 2006), 
suggesting that memory T cells at relatively early stages of differentiation are involved in 
liver inflammation. 
In patients with chronic hepatitis C, CD8+ T cells are located in the lobules within areas of 
inflammation and spotty necrosis, with the proportion correlating with histological 
activity index (Fiore et al., 1997). Intrahepatic CD8+ T cells show higher percentages of 
CCR7+L-selectin- cells, which are distinct from central memory and effector memory cells 
(Heydtmann et al., 2006). The CCR7 ligands CCL19 and CCL21 are expressed on 
sinusoidal endothelial cells, suggesting a mechanism of CD8+ T cell recruitment to the 
inflamed liver. Other chemokine receptors that mediate T cell recruitment are CCR5 and 
CXCR3 (Larrubia et al., 2007). Although the numbers of intrahepatic CD8+ T cells were 
reported to correlate with serum enzyme concentrations, and intralobular CD8+ T cells 
showed weak correlation with serum ALT concentrations (Freeman et al., 2003), 
intrahepatic HCV-specific CD8+ T cells do not secrete IFN- but secrete IL-10, an 
immunosuppressive cytokine (Spangenberg et al., 2005). The presence of these IL-10 
secreting T cells is associated with low levels of hepatocyte apoptosis, ALT and fibrosis 
(Abel et al., 2006). Increased production of IL-10, but not IFN- may result in an 
insufficient anti-HCV response in the liver. 
Similar to intrahepatic T cells in patients with chronic hepatitis B, intrahepatic HCV-specific 
cells were found to express high levels of PD-1 (Radziewicz et al. 2007), which may be 
responsible for the absence of IFN- production, as well as poor proliferation and low 
cytolytic activity. Moreover, large numbers of Foxp3+ cells, mostly CD4+ T cells, are present 
in the portal tracts of the livers of patients with chronic hepatitis C (Ward et al., 2007, 
Claassen et al., 2010, Sturm et al., 2010). These cells are also in contact with CD8+ T cells in 
necro-inflammatory areas, suggesting that CD8+ T cells are inhibited by cell-cell contact 
with Tregs (Sturm et al., 2010). These immunosuppressive mechanisms present in the livers 
of patients with chronic hepatitis C may be responsible for persistent HCV infection despite 
the presence of HCV-specific T cells in the liver. 
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, but also IL-4 and IL-5, thus differing from cells in the livers of patients with chronic 
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with Tregs (Sturm et al., 2010). These immunosuppressive mechanisms present in the livers 
of patients with chronic hepatitis C may be responsible for persistent HCV infection despite 
the presence of HCV-specific T cells in the liver. 
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In addition to T cells, livers of patients with chronic hepatitis C often contain lymphoid 
follicles in portal tracts, a characteristic of HCV-infected livers. We previously reported that 
functional and clonal expansion of B cells occurs in lymphoid follicles with germinal centers 
in HCV-infected livers (Murakami et al., 1999), although the antigen specificity of these B 
cells is unclear. 
Local immune responses may be involved in viral eradication during patient treatment with 
IFN. The numbers of pretreatment CD8+ T cells in portal tracts and intrahepatic HCV-
specific CD8+ CTLs have been reported associated with a better response to IFN- or a 
sustained virological response (Nelson et al., 1998, Vrolijk et al., 2003). Therefore, 
upregulation of intrahepatic T cell response may enhance the effectiveness of antiviral 
treatment. 
3.3 Autoimmune liver disease 
The dominant population of intrahepatic T cells in patients with primary biliary cirrhosis 
has been reported to be CD4+TCR+ T cells, whereas the dominant population in patients 
with chronic hepatitis B and C has been reported to be CD8+TCR+ T cells (Löhr et al., 
1994). This finding, however, remains controversial and it does not help distinguish 
autoimmune liver disease from viral hepatitis. 
3.3.1 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) 
The liver histology of patients with PBC has been extensively analyzed. A characteristic 
early stage histologic feature in these patients is nonsuppurative destructive cholangitis. 
Although the biliary epithelium is thought to be the target for host immune responses, the 
mechanism underlying epithelial destruction is unclear. CD8+ T cells are present within 
the bile duct epithelial layer of patients with chronic nonsuppurative destructive 
cholangitis, suggesting that CTLs destroy the bile duct epithelium. B7-2 (CD86), but not 
B7-1 (CD80), expression has been observed in bile duct epithelium during early stages of 
PBC and PSC (Tsuneyama et al., 1998), suggesting that bile duct epithelium may act as 
antigen-presenting cells. Immunopathologically important target antigens have not been 
determined. Although the generation of anti-mitochondrial antibodies is important for the 
diagnosis of PBC, mitochondrial antigens are not thought to be the pathogenetic target for 
immune cells. Livers of patients with PBC have been reported to contain more Tregs than 
livers of patients with autoimmune hepatitis (Sasaki et al., 2008), with Tregs infiltrating 
into the biliary epithelial layer during chronic nonsuppurative destructive cholangitis 
(Sasaki et al., 2007). Moreover, the numbers of Foxp3+ Tregs were found to parallel the 
degree of portal inflammation. These results, showing the presence of Tregs in the livers 
of patients with PBC and that their regulatory functions are not reduced in the livers of 
patients with PBC and PSC, suggest that autoimmunity in PBC is not due to a reduction in 
Treg function.  
PD-1 expression has also been assayed in livers of patients with PBC. PD-1 is expressed on 
more than 50% of intrahepatic T lymphocytes in the portal tracts, but their levels of 
expression are lower than in patients with autoimmune hepatitis (Oikawa et al., 2007).  
3.3.2 Autoimmune hepatitis (AIH) 
CD4+ T cells and CD20+ B cells have been reported to be located in the center of portal 
areas, with CD8+ T cells at the periphery of the portal area (De Biasio et al., 2006). Although 
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CD4+ T cells constitute the major population of intrahepatic lymphocytes, many CD80+, 
CD86+ and CD152+ cells are present in the livers of patients with autoimmune hepatitis 
(Kurokochi et al., 2006). Moreover, patients with high levels of intrahepatic CD86+ cells 
showed good responses to corticosteroids (Kurokochi et al., 2006).  
One of the putative target antigens in the immunopathogenesis of autoimmune hepatitis is 
asialoglycoprotein receptor, and antibodies against this receptor are often present in patients 
with autoimmune hepatitis. Although the mechanism of antibody production is unknown, 
intrahepatic T helper cells in patients with autoimmune hepatitis can stimulate the 
production of the autoantibody. Few Tregs are observed in these livers, with those present 
having impaired function (Longhi et al., 2010), suggesting that decreased functional activity 
of Tregs may predispose to enhanced autoimmune reactions. 
3.4 Nonalcoholic fatty liver disease 
Nonalcoholic fatty liver disease (NAFLD) is a frequently occurring chronic liver disease and 
can range in intensity from simple steatosis to nonalcoholic steatohepatitis (NASH). Due to 
chronic necro-inflammatory changes, patients with NASH may develop cirrhosis or 
hepatocellular carcinoma, although these are rare in patients with simple steatosis. 
Histologically, steatosis (usually >5% per liver tissue section), cellular injury such as 
ballooned hepatocytes or Mallory-Denk bodies, and accompanying lobular inflammation 
are observed in the livers of patients with NAFLD. Inflammatory infiltrates in these livers 
consist predominantly of lymphocytes, as well as plasma cells and polymorphonuclear 
leucocytes in portal tracts of the liver (Brunt et al., 2010). The ‘two-hit theory’ is widely 
accepted in the pathogenesis of NAFLD, and patients with simple steatosis are regarded as 
not showing disease progression because of the absence of the second hit (Day et al., 1998). 
Adipocytokines from adipose tissue and gut-derived factors (i.e. endotoxin) are regarded as 
the principal pathogenetic factors, the second hits, in the disease progression of NAFLD 
(Tilg et al., 2010), but recent reports have revealed that immunological mechanisms are 
directly involved in its pathogenesis. An immunohistochemical analysis of liver biopsy 
specimens showed that cells of the innate immune system, including neutrophils, 
macrophages (Kupffer cells) and NKT cells, are involved in the pathogenesis of NAFLD. 
Livers of patients with NASH showed increased hepatic neutrophil infiltration and 
increased hepatic expression of mRNAs coding for proinflammatory cytokines, as 
determined by quantitative RT-PCR. Furthermore, activation of the complement system in 
the liver is associated with the severity of NAFLD (Rensen et al., 2009). In rodent models of 
NAFLD, activation of Kupffer cells and proinflammatory cytokines are involved in disease 
progression (Maher et al., 2008, Syn et al., 2009). Kupffer cells are thought to be activated by 
gut-derived factors, adipocytokines and apoptotic cells, and to produce proinflammatory 
cytokines and reactive oxygen species (ROS). Proinflammatory cytokines and ROS may 
induce insulin resistance, which is regarded as important in the development of NAFLD. In 
addition, recent studies by our group and others have found that accumulation of NKT cells 
in the liver is associated with disease progression to NASH (Fig. 1), suggesting that NKT 
cells may contribute to disease progression in NAFLD (Tajiri et al., 2009, Syn et al., 2010). 
CD1d, a molecule essential for the activation and maintenance of NKT cells (Godfrey et al., 
2004), is highly expressed on activated macrophages in the livers of NASH patients (Tajiri et 
al., 2009), suggesting that NKT and Kupffer cells may interact during the pathogenesis of 
NAFLD (Fig. 2).  
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Fig. 1. Immunological analysis of liver biopsy specimens in patients with NAFLD. 
(A) Samples were stained with monoclonal antibody against CD56 in patients with (left 
panel) simple steatosis and (right panel) NASH. (B) Flow cytometric analysis of 
mononuclear cells isolated from livers of patients with (left panel) simple steatosis and 
(right panel) NASH. The numbers in each quadrant represent the percentages of 
mononuclear cells. Right-upper quadrant represents NKT (CD3+CD56+) cells. 
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Fig. 2. Hypothesis of the pathogenesis of NAFLD.  
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4. Conclusion 
Although analysis of intrahepatic immune response is difficult to be performed, valuable 
information on the immunopathogenesis of liver diseases could be obtained. Accumulation 
of the findings would finally lead to a novel immunotherapeutic approach for the 
management of various liver diseases. 
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Fig. 1. Immunological analysis of liver biopsy specimens in patients with NAFLD. 
(A) Samples were stained with monoclonal antibody against CD56 in patients with (left 
panel) simple steatosis and (right panel) NASH. (B) Flow cytometric analysis of 
mononuclear cells isolated from livers of patients with (left panel) simple steatosis and 
(right panel) NASH. The numbers in each quadrant represent the percentages of 
mononuclear cells. Right-upper quadrant represents NKT (CD3+CD56+) cells. 
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Fig. 2. Hypothesis of the pathogenesis of NAFLD.  
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4. Conclusion 
Although analysis of intrahepatic immune response is difficult to be performed, valuable 
information on the immunopathogenesis of liver diseases could be obtained. Accumulation 
of the findings would finally lead to a novel immunotherapeutic approach for the 
management of various liver diseases. 
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1. Introduction 
Detection and localization of hepatitis viruses in liver tissue are vital for diagnostic purposes 
and clinical management of infected patients, as well as for the elucidation of 
viropathological mechanisms. The fragility of RNA and/or the low levels of viral expression 
in infected tissues are a constant limitation in molecular assays for viral characterization. 
Viral antigen detection, by immunochemistry, in liver biopsies is an attractive option for 
precise localization and quantification of viral proteins with direct access to histological 
patterns. We will describe studies using immunohistochemical methods effective on fixed, 
archived specimens, including liver biopsies and surgical resection samples.  
1.1 Chronic hepatitis B 
Natural course of type B hepatitis is now well established and the different phases of the 
disease are clearly defined. Briefly, after contamination early in life, there is a first phase 
of immune tolerance. During this phase, the virus is highly replicative, HBV DNA, HBs and 
HBe antigen are at high level in the serum, but clinical, biological, and histological signs 
are more or less normal. These patients are highly contagious, and most of them are going 
to be HBV carriers for the rest of their life. This model if frequent in highly endemic 
countries where a high rate of mother-to-baby transmission exists (especially in Asia); 
This phase is absent when people are infected as adults, their immune system being 
mature. They present an acute hepatitis and only a few of them (10%) will remain carrier 
with chronic hepatitis B. The phase of tolerance lasts for about 15 to 20 years. Nowadays 
very few people are having liver biopsy during that period. When it was done in the 
70’s/80’s HBV antigens immunostaining were quite impressive: HBs antigen was present 
in a diffuse aspect grade associated with a strong expression for HBc antigen on more 
than 50% of nuclei (Table 1).  
During the second phase of the immune clearance phase, hepatitis activity increase with 
fluctuating high level of ALT, necrosis, inflammatory cells infiltrates, fibrosis and decrease 
HBV viraemia. This period of high activity is associated sometimes with severe hepatic failure. 
At the end of this phase occurs HBe seroconversion which is often associated with clinical 
remission. The expression of HBV antigens detected by immunostaining is varying according 
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HBV viraemia. This period of high activity is associated sometimes with severe hepatic failure. 
At the end of this phase occurs HBe seroconversion which is often associated with clinical 
remission. The expression of HBV antigens detected by immunostaining is varying according 
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to the time from infection when the biopsy was performed. The large number of HBs diffuse 
positive hepatocytes is decreasing with time. Many small clusters of cytoplasmic or sub 
membranous cells are gathering in the liver tissue the nuclear expression of HBc antigen is 
progressively changed in cytoplasmic expression and finally HBc antigen is undetectable. This 
stage corresponds to a very low viral replication (HBV DNA from 1000 UI/ml to null.). 
 
Phases of 
natural history HBs diffuse HBs cluster 
HBc 
nuclear 
HBc 
cytoplasmic 
  membranous Sub membranous cytoplasmic   
Immune 
tolerance ++ to +++ unusual unusual unusual 
very 
frequent unusual 
Immune 
clearance 0 to +++ frequent emerging rare frequent emerging 
Inactive phase 
early period 0 to + rare frequent frequent unusual frequent 
Inactive phase 
late period 0 to + absent frequent 
Very 
frequent absent 
rare or 
absent 
Reactivation + to +++ frequent frequent frequent frequent frequent 
Table 1. Summary of the aspects and patterns of HBV antigen along the natural course of 
chronic type B hepatitis. 
During the third phase called the inactive carrier phase, clinical remission may occur earlier in 
life if infection had occurred in adulthood ; Usually liver biopsy is done at that period to 
graduate residual inflammatory activity and over all staging the fibrosis. HBs Ag can be 
detected by immunostaining : 
- on very few hepatocytes; this can be seen after a very long carriage of HBV; it is 
correlated with a low level of HBs antigen in the serum. 
- on very large clusters of cytoplasmic pattern including almost all the hepatocytes. These 
patients have a very high level of HBs antigen in serum, exclusively made of spherical 
and tubular empty particles. 
HBc antigen is usually undetectable. In very low replicative patients some cytoplamic 
expression can be detected in rare hepatocytes. 
During this inactive phase, reactivations may occur. If liver biopsy is done during this period, 
expression of viral antigens is similar to the clearance period, associated in many cases with 
intense expression of HBs antigen in the diffuse or cluster like pattern. If the patient is not 
treated for this reactivation, HBs antigen will decrease and HBc antigen will appear in some 
nuclei.  
1.2 Liver transplantation 
In the vast majority of the cases, histological examination is able to explain if a flare of 
activity (cytolysis) is associated with graft rejection or re-infection of the graft by HBV. In 
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case of re-infection, diffuse HBs antigen is weakly present in its cytoplasmic pattern and 
nuclear HBc is detected. 
1.3 Occult HBV hepatitis 
In some cases of occult hepatitis infection (HBV DNA detectable in the liver and possibly in 
the serum in the absence of the landmark of HBV infection, the HBsAg in the serum).  
In those cases, few hepatocytes may be weakly positive for either HBs or HBc antigen. It can 
be helpful for the diagnosis of these very peculiar forms of HBV infections. 
1.4 Hepatitis C hepatitis 
The Hepatitis C virus (HCV) genome is a single stranded RNA molecule of about 9500 bp. 
This RNA encodes for a large poly-protein that is processed by host and virus proteases into 
several structural and non structural viral proteins (Envelope, Capsid and NS2a/b NS3a/b 
NS4a/b NS5a/b respectively). The detection of HCV replicative intermediates or virus antigen 
may be helpful for diagnosis or clinical management of patients with HCV infection and it is of 
crucial importance for monitoring patients prior and post- HCV-related liver transplantation. 
In a general point of view, HCV replication level seems to be relatively low in infected liver, 
hampering the detection of HCV particles directly in the liver (Shimizu et al., 1996, Negro, 
1998). Detection methods based on HCV RNA amplification as in situ PCR or in situ 
hybridization are not completely efficient for HCV detection and can lead to conflicting results 
concerning viral particles localization (Lau et al., 1996). However they remain an interesting 
tool when used in complement of classical method (Biagini et al., 2001, Comar et al., 2006). 
Limitation of these methods is probably due to RNA rapid degradation in tissues and 
difficulty to design efficient probes to overcome high variability of HCV genomes.  
Detection of HCV antigens by immunochemistry in liver biopsies constitutes therefore an 
interesting option that allows both localization and quantification of viral proteins (Galy et 
al, 2006).  
2. Methods  
2.1 Hepatitis B antigens 
Slides are deparaffinized in methylcyclohexane (two baths for 10 minutes) then re-hydrated 
through 4 baths of ethanol and soaked for half an hour in PBS pH 7.2; and endogenous 
peroxidase blocked by H2O2. 
Slides are then incubated in a humid chamber for 30 minutes at room temperature with 
diluted anti-HBs antibody, and then rinsed 4 times in PBS pH 7.2. A second incubation in 
same conditions is made with the secondary antibody (anti rabbit or mouse 
immunoglobulin, according to the primary antibody) labelled with peroxydase. Commercial 
kit with DAB substrate (Dako USA) are used to develop the final reaction. 
Counterstaining with Harris haematoxylin is added on slides for HBs antigen search. 
Usually no counterstaining is performed on slides tested for HBc antigen as it might interact 
with the nuclear expression of this viral antigen. 
Reagents: 
- Anti-Hbs monoclonal mouse antibody Dako USA (clone 3E7) or Argene F( ref:11-086) 
- Polyclonal rabbit Anti –Hbc ready to use Dako USA 
- Antibody diluent Dako USA 
- Envision dual link kit Dako USA 
- Hematoxylin Biomedia USA 
 
Liver Biopsy 
 
50
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correlated with a low level of HBs antigen in the serum. 
- on very large clusters of cytoplasmic pattern including almost all the hepatocytes. These 
patients have a very high level of HBs antigen in serum, exclusively made of spherical 
and tubular empty particles. 
HBc antigen is usually undetectable. In very low replicative patients some cytoplamic 
expression can be detected in rare hepatocytes. 
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activity (cytolysis) is associated with graft rejection or re-infection of the graft by HBV. In 
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case of re-infection, diffuse HBs antigen is weakly present in its cytoplasmic pattern and 
nuclear HBc is detected. 
1.3 Occult HBV hepatitis 
In some cases of occult hepatitis infection (HBV DNA detectable in the liver and possibly in 
the serum in the absence of the landmark of HBV infection, the HBsAg in the serum).  
In those cases, few hepatocytes may be weakly positive for either HBs or HBc antigen. It can 
be helpful for the diagnosis of these very peculiar forms of HBV infections. 
1.4 Hepatitis C hepatitis 
The Hepatitis C virus (HCV) genome is a single stranded RNA molecule of about 9500 bp. 
This RNA encodes for a large poly-protein that is processed by host and virus proteases into 
several structural and non structural viral proteins (Envelope, Capsid and NS2a/b NS3a/b 
NS4a/b NS5a/b respectively). The detection of HCV replicative intermediates or virus antigen 
may be helpful for diagnosis or clinical management of patients with HCV infection and it is of 
crucial importance for monitoring patients prior and post- HCV-related liver transplantation. 
In a general point of view, HCV replication level seems to be relatively low in infected liver, 
hampering the detection of HCV particles directly in the liver (Shimizu et al., 1996, Negro, 
1998). Detection methods based on HCV RNA amplification as in situ PCR or in situ 
hybridization are not completely efficient for HCV detection and can lead to conflicting results 
concerning viral particles localization (Lau et al., 1996). However they remain an interesting 
tool when used in complement of classical method (Biagini et al., 2001, Comar et al., 2006). 
Limitation of these methods is probably due to RNA rapid degradation in tissues and 
difficulty to design efficient probes to overcome high variability of HCV genomes.  
Detection of HCV antigens by immunochemistry in liver biopsies constitutes therefore an 
interesting option that allows both localization and quantification of viral proteins (Galy et 
al, 2006).  
2. Methods  
2.1 Hepatitis B antigens 
Slides are deparaffinized in methylcyclohexane (two baths for 10 minutes) then re-hydrated 
through 4 baths of ethanol and soaked for half an hour in PBS pH 7.2; and endogenous 
peroxidase blocked by H2O2. 
Slides are then incubated in a humid chamber for 30 minutes at room temperature with 
diluted anti-HBs antibody, and then rinsed 4 times in PBS pH 7.2. A second incubation in 
same conditions is made with the secondary antibody (anti rabbit or mouse 
immunoglobulin, according to the primary antibody) labelled with peroxydase. Commercial 
kit with DAB substrate (Dako USA) are used to develop the final reaction. 
Counterstaining with Harris haematoxylin is added on slides for HBs antigen search. 
Usually no counterstaining is performed on slides tested for HBc antigen as it might interact 
with the nuclear expression of this viral antigen. 
Reagents: 
- Anti-Hbs monoclonal mouse antibody Dako USA (clone 3E7) or Argene F( ref:11-086) 
- Polyclonal rabbit Anti –Hbc ready to use Dako USA 
- Antibody diluent Dako USA 
- Envision dual link kit Dako USA 
- Hematoxylin Biomedia USA 
 
Liver Biopsy 
 
52
2.2 Hepatitis C antigen 
First tissue sections are deparaffinized in xylene for 10 minutes (twice). Then Rehydrate in 
graded ethanol concentrations (100% and 95% for 5 min each) and proceed immediately to 
Block endogenous peroxidase activities with incubation in methanol (0.3% hydrogen peroxide) 
for 30 minutes at room temperature. The unmasking procedure includes a microwave 
treatment. The slides are placed in microwave for 15min in antigen unmasking solution 
(Vector H3300 - Vector Laboratories, Burlingame, CA, USA). Keep slides to cool down for 30 
min in the same unmasking solution. Incubate with PBS solution (5% skimmed milk and 0,1% 
BSA) for 1 hour at room temperature. Sections are incubated overnight with the primary mAb 
(For D4.12.9: concentration 0.2µg/ml) at 4°C. Sections without primary antibody can be used as 
controls. Wash in PBS (3x5 min). Incubate 30 min with Secondary antibody at 5µl/ml (Elite 
Kit- Vector Laboratories, Burlingame, CA, USA) in PBS solution (0,1% BSA). Wash again in 
PBS (3x5 min). Amplify signal at 37°C for 45min with VECTASTAIN ABC Kit (Vector 
Laboratories, Burlingame, CA, USA) – Use 0,1%BSA PBS solution. Wash in PBS (3x5 
min).Incubate tissue sections with the DAB substrate (Vector kit SK 4100, Vector Laboratories, 
Burlingame, CA, USA) at room temperature for 5 minutes.Wash in PBS (3x5 min). 
Counterstain the sections with Mayer’s haematoxylin. Dehydrate through a successive ethanol 
baths (95% Ethanol, absolute ethanol and xylene -5 min in each solution). Mount slides using 
standard microscope cover glass and mounting medium. 
2.3 Hepatitis delta antigen 
Direct immunostaining in fluorescence may be used for delta antigen. Once deparaffinized 
as above, slides are at first incubated for 30 minutes with a solution of proteinase  
K(21 mg/ml in Tris EDTA buffer) then rinsed in PBS for 15 minutes . Incubation with the 
FITC labelled anti-delta antibody is performed in humid chamber for half an hour. Slides 
are rinsed in two baths of PBS for 15 minutes and mounted. 
Reagents: 
- Proteinase K recombinant Roche USA  
- Tris EDTA buffer Sigma Aldrich USA 
- Polyclonal rabbit anti delta antibody labelled with FITC is kindly provided by Dr Alan 
Kay INSERM unit 1052, Lyon, France. 
3. Examples of viral hepatitis antigens detection  
3.1 Hepatitis B  
3.1.1 Cytological patterns of HBs antigen 
Three different patterns are seen on liver biopsies: 
i. Cytoplasmic : this is the most common pattern , consisting in a large vacuole made of the 
Golgi reticulum full of viral envelopes. In light microscopy it is usually called “ground 
glass” hepatocytes. The intensity of the staining is closely correlated with the amount of 
viral envelope in the cell (Figure 1). 
ii. Submembranous : This pattern is not frequent ; it is associated with a strong production 
of viral envelope and might be a former stage of the cytoplasmic pattern (Figure 2). 
iii. Membranous: This is a less common pattern. It is often seen on a few hepatocytes; it is 
mostly associated with strong viral expression and is rather present in active 
periportal zone. Staining underlines the cell membrane in a perfect straight line. 
(Figure 3) 
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Fig. 1. Two typical ground glass hepatocytes stained with immunoperoxydase for HBs 
antigen.( magnification x 600) 
 
 
Fig. 2. Submembranous expression of HBs antigen in hepatocytes ( immunoproxydase 
magnification x 600). 
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Fig. 1. Two typical ground glass hepatocytes stained with immunoperoxydase for HBs 
antigen.( magnification x 600) 
 
 
Fig. 2. Submembranous expression of HBs antigen in hepatocytes ( immunoproxydase 
magnification x 600). 
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Fig. 3. Membranous expression of HBs antigen: arrow shows the perfectly straight pattern of 
the cell membrane (immunoperoxydase magnification x 600). 
3.1.2 Cytological patterns of HBc antigen 
i. Nuclear: This is the most common expression pattern of this antigen in liver cells  
(Figure 4). 
ii. Cytoplasmic : The design is different from the HBs Antigen one as it is not gathered in a 
part of the cell but more or less diffuse in the whole cytoplasmic area (Figure 5). 
iii. In many cases, cells can express both of these patterns (Figure 6). 
 
 
Fig. 4. Nuclear expression of HBc antigen. Note the large scale of intensity of the staining 
(immunoproxydase, magnification x 600). 
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Fig. 5. Cytoplasmic expression of HBc antigen (immunoperoxydase, magnification x 600). 
 
 
Fig. 6. Double expression of HBc antigen: cytoplasmic and nuclear, sometimes in the same 
hepatocyte (immunoperoxydase magnification x 600). 
3.1.3 Antigen expression in liver tissue 
The antigen expression in liver tissue is important to observe as it correlates to the stage of 
replication and natural history of the disease. 
HBs antigen 
Two main patterns can be observed: 
i. Diffuse or dotted: Positive liver cells are non confluent, diffuse in the lobule. It can be 
useful to estimate the number of positive cells in the biopsy. This can be done semi 
quantitatively as an amount grade +, ++, +++ (Figures 7, 8, 9). 
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Fig. 5. Cytoplasmic expression of HBc antigen (immunoperoxydase, magnification x 600). 
 
 
Fig. 6. Double expression of HBc antigen: cytoplasmic and nuclear, sometimes in the same 
hepatocyte (immunoperoxydase magnification x 600). 
3.1.3 Antigen expression in liver tissue 
The antigen expression in liver tissue is important to observe as it correlates to the stage of 
replication and natural history of the disease. 
HBs antigen 
Two main patterns can be observed: 
i. Diffuse or dotted: Positive liver cells are non confluent, diffuse in the lobule. It can be 
useful to estimate the number of positive cells in the biopsy. This can be done semi 
quantitatively as an amount grade +, ++, +++ (Figures 7, 8, 9). 
 
Liver Biopsy 
 
56
 
 
Fig. 7. Diffuse expression of cytoplasmic HBs antigen: amount grade: + , the only strong 
positive cell out of a 15 mm length needle biopsy (immunoperoxydase magnification x 100). 
 
 
Fig. 8. Diffuse expression of cytoplasmic HBs antigen in strongly stained hepatocytes, 
amount grade: ++ (immunoperoxydase magnification x 100) 
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Fig. 9. Diffuse expression of cytoplasmic HBs antigen, light staining, amount grade +++ 
(immunoperoxydase, magnification x 100) 
 
 
Fig. 10. Diffuse expression of cytoplasmic  HBs antigen, strong staining, amount grade +++ 
(immunoproxydase, magnification x 75). 
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Fig. 7. Diffuse expression of cytoplasmic HBs antigen: amount grade: + , the only strong 
positive cell out of a 15 mm length needle biopsy (immunoperoxydase magnification x 100). 
 
 
Fig. 8. Diffuse expression of cytoplasmic HBs antigen in strongly stained hepatocytes, 
amount grade: ++ (immunoperoxydase magnification x 100) 
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Fig. 9. Diffuse expression of cytoplasmic HBs antigen, light staining, amount grade +++ 
(immunoperoxydase, magnification x 100) 
 
 
Fig. 10. Diffuse expression of cytoplasmic  HBs antigen, strong staining, amount grade +++ 
(immunoproxydase, magnification x 75). 
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ii. Confluent or cluster-like pattern: Positive cells are closely gathered inside the lobule can 
be detected on contiguous lobules (Figures 11, 12, 13). Sometimes, this pattern can be 
associated with the diffuse pattern on the external zone of the cluster (around the 
cluster). The distribution of these clusters of positive cells is not homogenous in the 
whole liver. False negative of the immunochemistry staining is possible if the needle 
doesn’t reach a positive zone (See Figure 12) with a strong contrast between positive 
and negative area on a surgical biopsy); 
 
 
Fig. 11. Large cluster of sub membranous HBs antigen positive hepatocytes 
(immunoperoxydase, magnification x 40). 
 
 
Fig. 12. Cluster of HBs antigen positive cells crossing a lobule from portal tract to Centro 
lobular vein. ( immunoperoxydase, magnification x 75 
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Fig. 13. Large cluster of HBs antigen positive hepatocytes with a cytoplasmic pattern. Note 
the strong contrast between positive and a very weak positive area (immunoproxydase, 
magnification x 40). 
Sub membranous and membranous pattern are always expressed in the liver tissue as a 
cluster like pattern (Figure 14) 
 
 
Fig. 14. Presence of three patterns of HBs antigen: 
top : sub membranous, centre: membranous and left: cytoplasmic. (immunoperoxydase, 
magnification x 40) 
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Fig. 15. Very weak expression of HBs antigen in a liver biopsy of an occult carrier of HBV 
(immunoperoxydase, magnification x 400). 
HBc antigen 
As the presence of HBc antigen in the liver is correlated with the amount of invective whole 
Dane particles, quantification is possible. For the nuclear pattern it is usual to calculate the 
percentage of positive cells in the biopsy. 
Five classes of percentage are described: less than 1%, from 1 to 5%, from 5 to 20%, from 20% 
to 50% and over 50%.  
The cyoplasmic pattern is more difficult to quantify as it might be very weakly expressed in 
some cells. We usually describe 4 classes: rare positive cells, positive +, positive ++, positive 
+++. 
3.2 Hepatitis C  
In our personal experience (Galy et al., 2006), the staining location for Anti-E2 
immunostaining is mainly cytoplasmic with occasional perimembranous staining 
(including cytoplasmic and nuclear membrane). Staining pattern is mainly coarse 
granular with microvesicular pattern (Figure 16 ). HCV staining patterns appears to differ 
slightly according to the pathological status of the liver tissue. We observed a very strong 
staining of hepatocyte membrane, cytoplasm and perinuclear regions in liver from patient 
with active HCV-related cirrhosis (Intense plasma and nuclear membrane staining was 
observed in cases with high inflammatory activity). In non-cirrhotic and non-tumoral 
tissues Anti-E2 staining intensity increases with hepatitis fibrosis state. In HCV-related 
tumors, staining was exclusively detected within regeneration nodules and confined to 
hepatocytes whose morphology remains unchanged. Staining pattern appeared with two 
distinct patterns: trabecular throughout the hepatic parenchyma or concerning isolated 
cells. 
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Fig. 16. Expression of HCV E2 antigen in a  liver biopsy of cirrhotic liver of an HCV chronic 
carriers. Arrows: Few remaining hepatocytes strongly positive with anti-E2 antibody. 
Immunoperoxydase magnification X 200 
3.3 Hepatitis delta 
Antigen delta is expressed mainly in the nucleus of the hepatocyte and in rare cases can also 
be expressed in the cytoplasm; it depends on the stage of the replication and the production 
of antigen. The nuclear expression seems to be more correlated with a period of stoking of 
viral core. The result of the test is qualitative: negative or positive (Figure 17). 
 
 
Fig. 17. Intranuclear expression of Delta (HDV) antigen. FITC labelling, magnification x 100 
4. Conclusion 
Concerning Hepatitis B virus (HBV) detection of HBs and HBc antigens are informative and 
provide different patterns providing elements in correlation with the natural history of HBV 
infection including viral load. In the specific case of occult HBV infection (HBV DNA 
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detected in the absence of HBsAg in the serum) it may help to confirm the diagnosis. For 
Hepatitis C virus (HCV) antigen detection it exists antibodies that are able to successfully 
detected HCV on paraffin-embedded sections from fresh as well as archived-frozen, 
material. It should be noted that HCV detection in archived serum may be problematic due 
to delicate extraction and stability of RNA and this is the same for hepatitis delta virus 
diagnosis (HDV). Thus, IHC represents a very stable diagnostic tool as compared to RNA-
based approaches. We found important differences in the localization of HCV between 
tumor and non-involved, adjacent tissue in HCC cases.  
These protocols offer easy, precise and strong staining resolution with distinct patterns 
consistent with the liver pathology, irrespective of the hepatitis viruses examined. This 
approach provides applications for diagnosis as well as for exploratory pathological studies. 
Thus, IHC to detect viral hepatitis antigens may have a number of important applications 
for clinical diagnostic, research on the mechanisms of pathogenesis of viral hepatitis-
containing lesions, and retrospective evaluation of the contribution of hepatitis viruses to 
liver diseases using archives of paraffin-embedded material not suitable for molecular 
analysis. 
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1. Introduction 
Liver biopsy remained the gold standard in the  diagnostics of chronic diffuse liver diseases 
despite the effectivity of some recent noninvasive diagnostic tools for the detection of fatty 
liver (Amacher, 2011; Copel, 2003; Germani et al, 2011; Karamashi, 2008; Lewindon, 2011; 
Sporea, et al., 2008; Strauss, 2010; Talwalkar, 2002).This means, that liver biopsy is applied in 
the diagnostic procedure of almost every patient with suggested chronic diffuse liver 
disease. Beside establishment of the diagnosis, liver biopsy specimens  can be used also for 
research projects, aiming to obtain knowledge from the pathophysiological background of 
these conditions. 
Trace element contamination is growing with the great progress of industry. Consequently, 
the trace element load of living organisms is also increasing.  Some elements can play a role 
in the formation of malignant tumors. (Boffetta, 1993; Hayes, 1997; Navarro Silvera, 2007; 
Sky-Peck, 1986; Wingren & Axelson, 1993). It is well known that the liver is involved in the 
metabolism of compounds containing also certain trace elements. Thus, determination of 
these elements in biopsy samples and searching for correlations between element content 
and some liver diseases seems to be promising. 
Ultrasonography  is widely used in the diagnostic procedure of patients with liver diseases. 
Chronic diffuse liver diseases produce the  characteristic ultrasound image of bright liver 
(Lonardo et al., 1997; Joseph et al., 1979). On the basis of in vivo measurements of liver 
ultrasound attenuation (), two major appearances of bright liver were differentiated, the 
low (DI type) and the high (DII type) attenuation types. It was proved previously that low 
(DI type) bright liver shows increase of connective tissue content, while high (DII) 
attenuation type bright liver is associated with fatty liver, correlating with  subcutaneous fat 
thickness (SCF) and body mass index (BMI). (Szebeni et al., 1999; Szebeni et al., 2006). 
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1. Introduction 
Liver biopsy remained the gold standard in the  diagnostics of chronic diffuse liver diseases 
despite the effectivity of some recent noninvasive diagnostic tools for the detection of fatty 
liver (Amacher, 2011; Copel, 2003; Germani et al, 2011; Karamashi, 2008; Lewindon, 2011; 
Sporea, et al., 2008; Strauss, 2010; Talwalkar, 2002).This means, that liver biopsy is applied in 
the diagnostic procedure of almost every patient with suggested chronic diffuse liver 
disease. Beside establishment of the diagnosis, liver biopsy specimens  can be used also for 
research projects, aiming to obtain knowledge from the pathophysiological background of 
these conditions. 
Trace element contamination is growing with the great progress of industry. Consequently, 
the trace element load of living organisms is also increasing.  Some elements can play a role 
in the formation of malignant tumors. (Boffetta, 1993; Hayes, 1997; Navarro Silvera, 2007; 
Sky-Peck, 1986; Wingren & Axelson, 1993). It is well known that the liver is involved in the 
metabolism of compounds containing also certain trace elements. Thus, determination of 
these elements in biopsy samples and searching for correlations between element content 
and some liver diseases seems to be promising. 
Ultrasonography  is widely used in the diagnostic procedure of patients with liver diseases. 
Chronic diffuse liver diseases produce the  characteristic ultrasound image of bright liver 
(Lonardo et al., 1997; Joseph et al., 1979). On the basis of in vivo measurements of liver 
ultrasound attenuation (), two major appearances of bright liver were differentiated, the 
low (DI type) and the high (DII type) attenuation types. It was proved previously that low 
(DI type) bright liver shows increase of connective tissue content, while high (DII) 
attenuation type bright liver is associated with fatty liver, correlating with  subcutaneous fat 
thickness (SCF) and body mass index (BMI). (Szebeni et al., 1999; Szebeni et al., 2006). 
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2. Objectives  
The main objective was to determine the trace element content of the liver from biopsy 
samples.  It was also studied that the trace element content  is similar or differing from each 
other  in patients with normal ultrasound liver pattern as well as in patients with chronic 
diffuse liver diseases showing low attenuation (DI) type or high attenuation (DII) type 
bright liver. Another objective of the present study was the determination of possible 
contamination of biopsy samples by steel-metals during sample collection using a porcine 
liver model. Additional objective was the determination and comparison of intra-individual 
variability of element concentrations in a porcine liver as well as in a human liver obtained 
from cadaveric donor with liver steatosis.  The choice of analytical methods was a key 
question. An appropriate method should be capable of measuring very low concentrations 
simultaneously and sample consumption should be restricted to the possible minimum. The 
suitability of histochemical staining methods and two microanalytical methods were 
studied.  Inductively coupled plasma mass spectrometry (ICP-MS) has favourable detection 
limits and was selected for simultaneous determination of micro and trace elements (Labat, 
et al., 2003; Millos, et al., 2008). Total reflection X-ray fluorescence spectrometry (TXRF) is 
also a suitable and powerful technique for analysis of small-mass biopsy samples, because it 
requires small amount of substance (Marco, et al., 2004).  
3. Material and methods 
3.1 Material 
183 patients (110 males, age 26-80; and 73 females, age 23-70) were examined because of the 
suggestion of chronic diffuse liver disease. After clinical (history, physical examination, 
BMI, abdominal circumference, waist/hip ratio), laboratory (liver function tests, total se 
cholesterol, low density and high density cholesterol, trigliceride, INR, platelet count, etc…) 
and ultrasound examinations, liver biopsy was performed for establishing the correct 
diagnosis. Semiquantitative histopathological analysis was also done in these patients. 
Biopsy materials were used retrospectively for research purposes, namely for analysis of the 
concentration of the  following trace elements: Cr, Mn, Fe, Ni, Cu, Zn, Rb, Mo and Pb. 
3.2 Methods 
3.2.1 Ultrasound examinations 
Ultrasound scanning of the liver – as part of a general abdominal ultrasound examination  - 
and  subcutaneous fat thickness determinations were made by a B-K Medical Hawk 2102 EXL 
scanner.  For liver scanning  5 MHz curved transducer, for subcutaneous fat thickness 
measurements  12 MHz linear transcducer was used. Attenuation of the liver was measured 
with the aid of a homogeneous tissue equivalent reference phantom with known attenuation. 
After scanning of the phantom and the patient’s liver with the same equipment setting, a 
special software was applied, capable to digitizing the image, as well as obtain and compare 
their brightness diagrams and evaluate attenuation  of the patient’s liver  (Szebeni et al., 2006).  
3.2.2 Percutaneous liver biopsy 
Before the intervention, detailed information was given to the patient about the procedure 
and importance of percutaneous liver biopsy. Thereafter a statement of permission was 
subscribed by the patient. 30 minutes before the biopsy slight sedation was applied  
(0,07 mg/kg midazolam was given intramuscularly). 15 minutes before the intervention  
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0,5 mg atropin was injected subcutaneously. The biopsy was made in the left decubitus 
position using generally applied disposable Braun Hepafix needle. The site of the biopsy 
was determined by percussion between the anterior and median axillary line according to 
the hepatic dullness. 1% Lidocain injection was used for local anaesthesia. The puncture was 
made in deep outbreath in most cases blindly, but sometimes under ultrasonic guidance. 
The obtained biopsy specimen was fixed in 4% neutral formalin solution for histological 
examination. For trace element determination a small part of the material was deep-freezed 
and stored on -20º C till the analytical process. 
3.2.3 Semiquantitative histopathologic evaluation 
Histopathological studies have been performed in formalin-fixed, paraffin-embedded 
biopsy materials. In addition to the routine hematoxylin-eosin (H&E), periodic acid-Schiff 
(PAS) stains, the specimens were also stained by picrosirius red (Szendrői et al., 1984), a 1% 
alcoholic solution of rubeanic acid (dithiooxamide) counterstained with Nuclear Fast Red 
(Vacca, 1985). The amount and distribution of connective tissue was visualized by the 
picrosirius red stain. Fibrosis was diagnosed when the retained lobular architecture was 
surrounded by the collagen fibers, and it was semiquantitatively graded as mild, 
intermediate and severe. In cirrhotic livers the lobular architecture has been distorted. 
Rubeanic acid method is principally used for identification of copper in histological 
preparates, but other metals are also identifiable: while the copper granules are 
characteristically greenish-black, the nickel is bluish-violet, and the cobalt is yellowish-
brown (Quicke,1979, Vacca, 1985).  
The severity of the fatty change was semiquantitatively scored in H&E stained samples. 
Mild form was diagnosed when the lipid droplets occupied up to 25% of the liver, 
intermediate between 25-65%, and severe when they exceeded 65%. The necroinflammatory 
reaction was evaluated in at least 20 portal of intralobular areas, and graded as mild (1-5 
portal tracts involved), intermediate (6-10 portal tracts) or severe (over 10 portal tracts 
affected).  
3.2.4 Trace element analysis 
3.2.4.1 Sample collection and preparation 
For reference measurement twelve porcine liver portions (different size, in the range from 7 
mg to 545 mg wet weight) were cut by a quartz blade, immediately weighed on a 
microbalance and freeze-dried. Time relationship of element release from biopsy needles 
was investigated applying 0.1, 1 and 24h contact time. Disposable Braun-Hepafix liver 
biopsy needles were used for sampling porcine and human cadaver liver and the same 
sample preparation was applied. The sample preparation was performed in a clean bench 
and the porcine liver was stored at 4ºC during the exposure intervals. Suprapure nitric acid 
(Merck, Darmstadt, Germany) and high-purity water from a Milli-Q system were used 
throughout the work. Polypropylene microvials (used for sample storage) were cleaned 
with 0.5 mol/l nitric acid for 1h then rinsed with high-purity water and dried in a clean 
bench. The samples were digested in a laboratory microwave system according to the 
method described in our previous work (Varga et al., 2005). Distribution of the elements 
within the liver was investigated taking  biopsy samples from  different localizations of a 
cadaveric liver with steatosis with the same technique described before.  
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3.2.4.2 Instrumentation and technique 
Total reflection X-ray fluorescence (TXRF) analysis was performed using an Atomika EXTRA 
IIA spectrometer equipped with line focused X-ray tubes and an energy dispersive Si(Li) 
detector. Mo K 17.4 keV, W continuum (Bremsstrahlung) 35 keV excitation and 1000 s data 
acquisition live time were applied. K lines were used for Cr, Mn, Fe, Ni, Cu, Zn, Rb and Mo, L 
line was used for Pb determination. 100 l of sample solution was used to prepare specimens 
for the TXRF analysis in the following manner. 25 l of sample solution was pipetted onto a 
previously siliconized quartz glass carrier and allowed to dry in a clean bench at 40°C. This 
procedure was repeated until 100 l total volume of sample solution was reached. Finally,  
10 l yttrium chloride solution containing 0.1 mg/dm3 yttrium was added as an internal 
standard for the quantification of TXRF measurements. Biopsy samples were analyzed by 
TXRF spectrometry after nitric acid digestion. Small volume microwave digestion was 
developed especially for biopsy samples and proved to be applicable for liver biopsies having 
sample size as small as only 1 mg or less. An efficient XRF method was developed for autopsy 
samples having sample mass of about 500 mg without digestion. Samples were analyzed by a 
benchtop XRF spectrometer -PANalytical MiniPal2 (Almelo, the Netherlands)- equipped with 
low power, Rh anode X-ray tube and a Si-PIN semiconductor detector (Fig. 1).  
 
 
 
Fig. 1. Atomika Extra IIA TXRF Spectometer and PANalytical MiniPal2 benchtop XRF 
Spectrometer 
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TXRF analytical method was validated applying NIST 1577a Bovine Liver  Certified 
Reference Material (Table 1.) 
 
 Certified values(g/g)
Measured values
(g/g) SD 
Recovery 
(%) 
P  11100       400 11780 880 106.1 
S  7800        100 7290 550 93.5 
K  9260       70 11300 830 113.5 
Mn  9.9     0.8 11.8 0.9 119.2 
Fe  194       20 193 14 99.5 
Pb  0.135  0.015 n.d. - - 
Cu  158       7. 156 11 98.5 
Se  0.71   0.07 0.56 0.21 78.9 
Zn  123        8 127 9 103.3 
Rb  12.5     0.1 11.9 0.8 94.8 
Sr  0.138  0.003 n.d. - - 
Mo  3.5     0.5 3.7 0.4 105.7 
(4 independent replicate, concentrations in g/g corresponding to dry weight)  
n.d.  signifies concentration under the limit of detection (LOD) 
Table 1. TXRF analysis results of NIST 1577a Bovine Liver CRM. 
An inductively coupled plasma mass spectrometer (ICP-MS) is capable for analysis of 70-80 
elements in multielemental mode, from 1-5 cm3 volume of a sample, moreover the detection 
limits of elements are in µg/kg-ng/kg (ppb-ppt) concentration range. Nowadays there is 
very important to analyze growingly smaller concentrations of elements. An ICP-MS has 
different physical and chemical interfering effects analyzing various samples. The smaller 
the concentration of an analyte and the larger the concentration of the matrix the larger the 
interfering effects (Kovács et al., 2006). From the spectroscopic analytical instruments 
generally the inductively coupled plasma mass spectrometer is capable of analyzing the 
smallest concentration of elements. 
 
 
Fig. 2. The applied inductively coupled plasma mass spectrometer 
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As the human origin samples (e.g. human liver) contain small enough concentration of 
elements so an inductively coupled plasma mass spectrometer (Fig. 2.) was applied to 
analyze the various elements. 
An X7 type (Thermo Elemental, Winsford, UK) inductively coupled plasma quadrupole 
mass spectrometer was used to detect the elements. 
The instrument was operated with a Peltier cooled impact bead spray chamber, single piece 
quartz torch (1.5 mm i.d. injector) and a conventional glass concentric nebulizer. 
The following isotopes were measured during the research work: 25Mg, 52Cr, 53Cr, 55Mn, 
54Fe, 56Fe, 58Ni, 59Co, 60Ni, 65Cu, 64Zn, 66Zn, 75As, 78Se, 80Se, 82Se, 111Cd, 114Cd and 208Pb.Table 2.  
shows the applied operating instrumental parameters. 
 
ICP-MS system: X7 type (Thermo Elemental, Winsford, UK) 
RF power: 1400 W
Nebulizer gas flow: 0.80 L/min
Auxiliary gas flow: 0.95 L/min
Cool gas flow: 15.0 L/min
Sample uptake rate: 0.88 mL/min
Interface: Xi interface cones (Ni)
Data acquisition:
Dwell time per isotope: 20 ms 
Number of sweeps: 21
Number of replicates: 3
Sample uptake and wash time: 35 s
Calibration mode: Peak jump
Number of integration: 3/sample5/blank
Table 2. ICP-MS operating and data acquisition parameters 
3.2.4.3 Intra-individual variability of element concentrations in human liver 
A small liver biopsy specimen does not represent the liver as a whole. In order to be able to 
draw conclusions regarding differences of trace element contents of liver samples, we have 
to assume uniform trace element distributions throughout the whole organ. This 
assumption should be checked by comparison of samples taken from different lobes of the 
same liver. The latter study can be performed only on autopsy samples.  
Intra-individual variability of elemental concentrations was investigated by the analysis of 
multiple human liver biopsy samples obtained from cadaveric donor with liver steatosis. 
The purpose of these investigations was the high hepatic Ni concentration observed in the 
human liver and its uneven distribution. Similar sampling was made on porcine liver for 
comparison. Concentrations of Fe, Ni, Cu, Zn, Rb, and Mo determined by total reflection X-
ray fluorescence spectrometry are listed in Table 3. Cr, Mn, Co and Pb were measured only 
by inductively coupled plasma-atomic emission spectrometry. Element concentrations 
determined by both techniques were in good agreement and not presented in Table 3. as a 
repetition. The variability of element concentrations was between 8.7 and 17.6 % RSD. 
Exceptions were Pb, Ni and Cr having variability of 27.8, 73.0 and 68.6 % RSD, respectively. 
In case of porcine liver the intra-individual variability was less than 13.5 % RSD for each 
element. It can be also emphasized, that nickel distribution was quite even in porcine liver 
and average Ni concentration (0.16 μg/g dry weight) was two orders of magnitude lower 
compared to the value measured in the investigated human liver.   
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 Crb Mnb Fea Cob Nia Cua Zna Rba Moa Pbb 
1 1.80 ±0.09 
6.2 
±0.4 
789 
±106 
0.20 
±0.03 
45.2 
±1.7 
21.0 
±1.5 
402 
±44 
9.7 
±0.7 
3.50 
±0.12 
2.53 
±0.14 
2 1.15 ±0.16 
7.3 
±0.5 
910 
±81 
0.17 
±0.02 
26.3 
±1.4 
15.3 
±1.6 
401 
±32 
9.3 
±1.1 
3.66 
±0.17 
1.54 
±0.11 
3 0.82 ±0.08 
6.5 
±0.5 
843 
±77 
0.13 
±0.02 
12.9 
±1.7 
14.5 
±1.2 
395 
±40 
6.8 
±1.0 
6.16 
±0.18 
1.23 
±0.12 
4 2.28 ±0.15 
6.8 
±0.4 
865 
±99 
0.23 
±0.02 
20.8 
±1.1 
17.2 
±1.4 
397 
±36 
9.4 
±0.9 
2.98 
±0.21 
1.81 
±0.09 
5 1.42 ±0.15 
6.8 
±0.6 
790 
±92 
0.20 
±0.01 
37.9 
±2.1 
19.5 
±1.4 
349 
±38 
7.2 
±0.6 
3.18 
±0.13 
2.52 
±0.10 
6 3.66 ±0.18 
7.7 
±0.7 
980 
±68 
0.15 
±0.03 
34.7 
±1.5 
19.5 
±1.8 
425 
±28 
8.9 
±0.6 
3.23 
±0.14 
1.51 
±0.11 
7 0.65 ±0.10 
7.0 
±0.5 
1205 
±88 
0.13 
±0.02 
15.5 
±0.9 
18.0 
±1.4 
523 
±44 
10.9 
±0.7 
3.00 
±0.18 
1.22 
±0.10 
8 4.08 ±0.22 
7.4 
±0.5 
944 
±76 
0.19 
±0.02 
30.8 
±1.5 
17.6 
±1.5 
480 
±39 
9.2 
±0.8 
3.15 
±0.11 
1.89 
±0.12 
9 0.76 ±0.11 
5.6 
±0.5 
842 
±53 
0.19 
±0.03 
99.1 
±2.4 
15.0 
±1.2 
384 
±30 
9.9 
±0.7 
2.73 
±0.16 
2.27 
±0.10 
           
mean 1.85 6.8 906 0.18 35.6 17.5 417 9.0 3.18 1.84 
RSD% 68.6 9.5 14.4 17.6 73.0 12.9 12.7 14.3 8.7 27.8 
Table 3. Intra-individual variation of element concentrations in a human liver obtained from 
cadaveric donor. (concentrations in g/g dry weight, a: measured by TXRF, b: measured by 
ICP-MS) 
4. Results  
4.1 Investigation of possible contamination from biopsy needles 
Percutaneous human liver biopsies taken from living patients could not be repeated 
frequently; therefore considerable contamination was indirectly disproved. In the present 
study, the possible contamination of biopsy samples during sample collection was 
determined using a porcine liver model. Availability in large amount was the purpose of 
using porcine liver for the method development. Twelve portions from a porcine liver were 
freeze-dried. Portions of porcine liver were cut by a quartz blade and treated as same as the 
steel needle biopsy samples. Concentrations determined in samples taken by a quartz device 
represented the non-contaminated values and were used to determine reproducibility of 
measurement and intra-individual variations. The precision of the drying process, the 
sample preparation and the analytical measurements was tested by the analysis of porcine 
liver. Calculated mean dry/wet mass ratio was 0.347 with an acceptable low relative 
standard deviation (RSD) of 2.2 %. Freeze-dried samples were subjected to microwave 
digestion in concentrated nitric acid (Suprapure, Merck). The precision of the concentration 
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As the human origin samples (e.g. human liver) contain small enough concentration of 
elements so an inductively coupled plasma mass spectrometer (Fig. 2.) was applied to 
analyze the various elements. 
An X7 type (Thermo Elemental, Winsford, UK) inductively coupled plasma quadrupole 
mass spectrometer was used to detect the elements. 
The instrument was operated with a Peltier cooled impact bead spray chamber, single piece 
quartz torch (1.5 mm i.d. injector) and a conventional glass concentric nebulizer. 
The following isotopes were measured during the research work: 25Mg, 52Cr, 53Cr, 55Mn, 
54Fe, 56Fe, 58Ni, 59Co, 60Ni, 65Cu, 64Zn, 66Zn, 75As, 78Se, 80Se, 82Se, 111Cd, 114Cd and 208Pb.Table 2.  
shows the applied operating instrumental parameters. 
 
ICP-MS system: X7 type (Thermo Elemental, Winsford, UK) 
RF power: 1400 W
Nebulizer gas flow: 0.80 L/min
Auxiliary gas flow: 0.95 L/min
Cool gas flow: 15.0 L/min
Sample uptake rate: 0.88 mL/min
Interface: Xi interface cones (Ni)
Data acquisition:
Dwell time per isotope: 20 ms 
Number of sweeps: 21
Number of replicates: 3
Sample uptake and wash time: 35 s
Calibration mode: Peak jump
Number of integration: 3/sample5/blank
Table 2. ICP-MS operating and data acquisition parameters 
3.2.4.3 Intra-individual variability of element concentrations in human liver 
A small liver biopsy specimen does not represent the liver as a whole. In order to be able to 
draw conclusions regarding differences of trace element contents of liver samples, we have 
to assume uniform trace element distributions throughout the whole organ. This 
assumption should be checked by comparison of samples taken from different lobes of the 
same liver. The latter study can be performed only on autopsy samples.  
Intra-individual variability of elemental concentrations was investigated by the analysis of 
multiple human liver biopsy samples obtained from cadaveric donor with liver steatosis. 
The purpose of these investigations was the high hepatic Ni concentration observed in the 
human liver and its uneven distribution. Similar sampling was made on porcine liver for 
comparison. Concentrations of Fe, Ni, Cu, Zn, Rb, and Mo determined by total reflection X-
ray fluorescence spectrometry are listed in Table 3. Cr, Mn, Co and Pb were measured only 
by inductively coupled plasma-atomic emission spectrometry. Element concentrations 
determined by both techniques were in good agreement and not presented in Table 3. as a 
repetition. The variability of element concentrations was between 8.7 and 17.6 % RSD. 
Exceptions were Pb, Ni and Cr having variability of 27.8, 73.0 and 68.6 % RSD, respectively. 
In case of porcine liver the intra-individual variability was less than 13.5 % RSD for each 
element. It can be also emphasized, that nickel distribution was quite even in porcine liver 
and average Ni concentration (0.16 μg/g dry weight) was two orders of magnitude lower 
compared to the value measured in the investigated human liver.   
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 Crb Mnb Fea Cob Nia Cua Zna Rba Moa Pbb 
1 1.80 ±0.09 
6.2 
±0.4 
789 
±106 
0.20 
±0.03 
45.2 
±1.7 
21.0 
±1.5 
402 
±44 
9.7 
±0.7 
3.50 
±0.12 
2.53 
±0.14 
2 1.15 ±0.16 
7.3 
±0.5 
910 
±81 
0.17 
±0.02 
26.3 
±1.4 
15.3 
±1.6 
401 
±32 
9.3 
±1.1 
3.66 
±0.17 
1.54 
±0.11 
3 0.82 ±0.08 
6.5 
±0.5 
843 
±77 
0.13 
±0.02 
12.9 
±1.7 
14.5 
±1.2 
395 
±40 
6.8 
±1.0 
6.16 
±0.18 
1.23 
±0.12 
4 2.28 ±0.15 
6.8 
±0.4 
865 
±99 
0.23 
±0.02 
20.8 
±1.1 
17.2 
±1.4 
397 
±36 
9.4 
±0.9 
2.98 
±0.21 
1.81 
±0.09 
5 1.42 ±0.15 
6.8 
±0.6 
790 
±92 
0.20 
±0.01 
37.9 
±2.1 
19.5 
±1.4 
349 
±38 
7.2 
±0.6 
3.18 
±0.13 
2.52 
±0.10 
6 3.66 ±0.18 
7.7 
±0.7 
980 
±68 
0.15 
±0.03 
34.7 
±1.5 
19.5 
±1.8 
425 
±28 
8.9 
±0.6 
3.23 
±0.14 
1.51 
±0.11 
7 0.65 ±0.10 
7.0 
±0.5 
1205 
±88 
0.13 
±0.02 
15.5 
±0.9 
18.0 
±1.4 
523 
±44 
10.9 
±0.7 
3.00 
±0.18 
1.22 
±0.10 
8 4.08 ±0.22 
7.4 
±0.5 
944 
±76 
0.19 
±0.02 
30.8 
±1.5 
17.6 
±1.5 
480 
±39 
9.2 
±0.8 
3.15 
±0.11 
1.89 
±0.12 
9 0.76 ±0.11 
5.6 
±0.5 
842 
±53 
0.19 
±0.03 
99.1 
±2.4 
15.0 
±1.2 
384 
±30 
9.9 
±0.7 
2.73 
±0.16 
2.27 
±0.10 
           
mean 1.85 6.8 906 0.18 35.6 17.5 417 9.0 3.18 1.84 
RSD% 68.6 9.5 14.4 17.6 73.0 12.9 12.7 14.3 8.7 27.8 
Table 3. Intra-individual variation of element concentrations in a human liver obtained from 
cadaveric donor. (concentrations in g/g dry weight, a: measured by TXRF, b: measured by 
ICP-MS) 
4. Results  
4.1 Investigation of possible contamination from biopsy needles 
Percutaneous human liver biopsies taken from living patients could not be repeated 
frequently; therefore considerable contamination was indirectly disproved. In the present 
study, the possible contamination of biopsy samples during sample collection was 
determined using a porcine liver model. Availability in large amount was the purpose of 
using porcine liver for the method development. Twelve portions from a porcine liver were 
freeze-dried. Portions of porcine liver were cut by a quartz blade and treated as same as the 
steel needle biopsy samples. Concentrations determined in samples taken by a quartz device 
represented the non-contaminated values and were used to determine reproducibility of 
measurement and intra-individual variations. The precision of the drying process, the 
sample preparation and the analytical measurements was tested by the analysis of porcine 
liver. Calculated mean dry/wet mass ratio was 0.347 with an acceptable low relative 
standard deviation (RSD) of 2.2 %. Freeze-dried samples were subjected to microwave 
digestion in concentrated nitric acid (Suprapure, Merck). The precision of the concentration 
determination was found to be better than 14.2 % RSD by TXRF and 13.9 %RSD by ICP-MS 
for Mn, Fe, Cu, Zn, Rb and Mo (Cr, Co and Ni in the porcine liver was below the detection 
limit of TXRF in the given conditions: LODs of TXRF measurement were 0.92, 0.89 and 0.85 
μg /g d.w. for Cr, Co and Ni).  
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All materials, solutions and tools used during the sample collection and preparation were 
tested for possible contamination: Analysis of repeated procedural blank samples showed that 
no measurable contamination of steel-metals originates from labware or reagents. Biopsy 
needles and scalpels were digested and analyzed previously. The material of biopsy needles 
was found to be a standard stainless steel with a main composition of Cr:Fe:Ni / 18:72:9 and 
Mn content of 0.1 % w/w. These four metals would be expected as possible contaminants. To 
investigate the possible release of elements from the steel needle biopsies the samples were 
allowed to contact with the needle for different time in a refrigerator at 4ºC. According to the 
present data no observable contamination could be determined after  6 minutes contact of the 
porcine liver tissue and the biopsy needle. After 1 hour contact the tissue concentration of Cr 
and Ni was significantly higher than those measured in the samples taken by a quartz blade 
(0.41 and 0.29 g/g instead of 0.06 and 0.15 g/g d.w., respectively). The change of Mn and Fe 
concentration was in the range of measurement uncertainty.  
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Fig. 3. Concentration of different elements in porcine liver samples after increasing contact 
time with biopsy needle. 
The analysis of biopsy samples having 24h contact with the needle showed considerable 
increase of chromium, manganese, iron and nickel concentration: the increments were 54.9 
for Cr, 269 for Fe 15.6 for Ni and 2.1 for Mn in g/g d.w. The results are demonstrated in 
Fig. 3.  In contrast of steel metals, concentration of essential elements, such as copper and 
zinc remained constant as expected. Although the steel needles in the present study could 
not be substituted by polypropylene or Teflon utensils, it was demonstrated that the 
application of needle biopsy sampling in the reported analysis does not involve measurable 
contamination if contact time is kept to several minutes as usual in the clinical practice. 
4.2 Intra-individual variability of element concentrations in human liver 
A small specimen from liver biopsy does not represent the liver as a whole. In order to able 
to draw conclusions regarding differences of trace element contents of liver samples, we 
have to assume uniform trace element distributions throughout the whole organ. This 
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assumption should be checked by comparison of samples taken from different lobes of the 
same liver. The latter study can be performed only on autopsy samples.  
Intra-individual variability of elemental concentrations was investigated by the analysis of 
multiple human liver biopsy samples obtained from cadaveric donor with liver steatosis. 
The purpose of these investigations was the high hepatic Ni concentration observed in the 
human liver and its uneven distribution. Similar sampling was made on porcine liver for 
comparison. Concentrations of Fe, Ni, Cu, Zn, Rb, and Mo determined by total reflection X-
ray fluorescence spectrometry are listed in Table 3. Cr, Mn, Co and Pb were measured only 
by inductively coupled plasma-atomic emission spectrometry. Element concentrations 
determined by both techniques were in good agreement and not presented in Table 3. as a 
repetition. The variability of element concentrations was between 8.7 and 17.6 % relative 
standard deviation (RSD). Exceptions were Pb, Ni and Cr having variability of 27.8, 73.0 and 
68.6 % RSD, respectively. In case of porcine liver the intra-individual variability was less 
than 13.5 % RSD for each element. It can be also emphasized, that nickel distribution was 
quite even in porcine liver and average Ni concentration (0.16 μg/g d.w.) was two orders of 
magnitude lower compared to the value measured in the investigated human liver.   
4.3 Correlation between ultrasound data and trace element concentration 
From the 183 examined patients 54 normal liver pattern  was found (Fig. 4.),  53 showed low 
attenuation type (DI) (Fig. 5.) and 76 had high attenuation type (DII) bright liver (Fig. 6.). 
Average attenuation in the normal group was 0,64 ± 0,07 dB/cm/MHz, in the DI group 0,75 
± 0,12 dB/cm/MHz and in the DII group 1,34 ± 0,28 dB/cm/MHz. SCF values proved to be  
6,8 ± 3,8 mm in the normal group, 8,4 ± 3,9 mm in the DI type, and 14,5 ± 5,5 mm in DII type   
bright liver. 
 
 
Fig. 4. Normal ultrasound liver pattern. Echogenicity and echodensity of the liver and the 
kidney are similar. 
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Fig. 5. Low attenuation (DI) type bright liver pattern. Echogenicity and echodensity of the 
liver and the kidney are different.  The bright liver pattern is seen throughout the whole 
depth of the liver. 
 
 
Fig. 6. High attenuation (DII) type bright liver pattern. Echogenicity and echodensity of the 
liver and the kidney are different.  The bright liver pattern is seen mainly superficially, 
toward the depth of the liver  gradually  decreasing. 
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Mild fatty degeneration did not alter the ultrasonic reflectivity and echodensity, but the 
DII type bright liver pattern was always accompanied by severe fatty change (Fig. 7.). In 
hepatic samples from patients with normal ultrasound pattern, the amount of connective 
tissue was either normal, or just a slight fibrosis was seen (5/54 cases). In DI type bright 
liver pattern the typical histopathological alteration was the moderate or severe 
accumulation of connective tissue (Fig. 8.), accompanied by necroinflammation (Fig. 9.), 
but in DII type bright liver there typical morphological finding was just a slight portal 
fibrosis (37 samples). 
 
 
 
 
 
 
 
 
 
Fig. 7. In the liver multiple, large lipid vacuoles are seen representing a severe fatty 
degeneration (HE 400x). 
Copper was demonstrated in 12, while nickel in 2 cases. None of the copper-positive 
patients suffered from Wilson disease. The amount of the metal granules was mild, and 
showed uneven distribution (Fig.  10.). In all but one specimens there were evidence of 
fatty degeneration, accumulation of connective tissue (septal fibrosis or cirrhosis), and 
inflammatory reaction. Presence of copper was observed in 1 case with normal liver.  
Histologically visible nickel was demonstrated just in 2 cases. One sample had a fatty 
change accompanied by infiltration of chronic inflammatory cells, the other specimen was 
taken from an alcoholic patients displaying fatty change and incomplete cirrhosis. 
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Fig. 8. The picrosirius red stain reveals a micronodular cirrhosis (200x).  
 
 
Fig. 9. The portal tract is loaded with moderate amount of chronic inflammatory cells. 
Moreover, focal, unicellular, intralobular necrosis is shown, surrounded by inflammatory 
cells (HE 300x). 
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Fig. 10. Greenish-black copper-granules in the liver with fatty degeneration of intermediate 
degree. Rubeanic acid, 400x 
Significant correlation was found between trace element determinations and the 
ultrasound and histopathological data in the case of Ni  (Varga et al., 2005).  This finding 
was  confirmed in the present study  with  a larger  sample size (Fig. 11.). In the normal 
and low attenuation (DI) type bright liver groups very low Ni concentrations were found, 
close to the detectability limit (Fig. 11.). On the contrary, in the high attenuation (DII) type 
bright liver  group the Ni concentrations were substantially higher in all cases  
and some of them were extremely high, up to 700 μg/g (Fig. 11.). Decreased Fe 
concentration was also observed in the group of patients with steatosis.  Distribution of 
elements within the liver was investigated taking  biopsy samples from different 
localizations of a cadaveric liver. It is seen on table 3. in 3.2.4.2 , that the essential elements 
are uniformly distributed in the liver except the Cr.  Ni  showed surprisingly uneven 
distribution. The possible contamination with Ni can be excluded on the basis of our 
studies. Therefore the high Ni content of the liver can be taken as concomittant sign of 
fatty degeneration.   
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Fig. 11. Concentration of Ni in the three ultrasound based groups of patients. It is well seen, 
that the Ni  content is much higher in the DII. type bright liver group, representing fatty 
liver, than in the normal, or DI type bright  liver groups.  
Three typical X-ray fluorescence spectra illustrate simultaneous analysis and distibution 
of maior, minor and trace elements obtained from liver biopsy samples. The only 
significant difference between the three ultrasonically determined groups was in the 
concentration of Ni and Fe as demonstrated on figures 12., 13. and 14. It is seen in figure 
12., (normal ultrasonic pattern), that the Ni concentration is low, near to the 
quantification limit of the applied analytical method.  On the 13. figure, originated from 
a liver biopsy sample of a patient with DI type bright liver the Ni concentration is in the 
normal range.  On the contrary, on figure 14. the spectrum of a liver biopsy sample of a 
patient with fatty liver (ultrasonically DII type bright liver), high Ni concentration can be 
observed. Intense peak appearing at 2.7 keV energy is due to scattered radiation of the X-
ray tube (Rh K-lines). As concerning the iron content, in the patient with liver steatosis 
(Fig. 14.), lower Fe concentration was found, than in the patients from the other groups 
(Figs. 12.,13.). 
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Fig. 12. TXRF spectrum of a liver biopsy sample of a patient from the normal group.  
 
 
Fig. 13. TXRF spectrum of a liver biopsy sample of a patient from the DI type bright liver 
group. 
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Fig. 12. TXRF spectrum of a liver biopsy sample of a patient from the normal group.  
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group. 
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Fig. 14. TXRF spectrum of a liver biopsy sample of a patient from the DII type bright liver 
group (high Ni content). 
5. Discussion 
For the investigation of the pathological background of the different types of bright liver, 
quantitative measurement of the liver attenuation is necessary; a simple and reliable method 
was elaborated together with  J.D. Satrapa (Satrapa, & Szebeni, 1996; Szebeni, & Satrapa, 
1996).  Evaluation of trace element analysis in  subjects with normal ultrasound liver pattern 
and in patients with chronic diffuse liver diseases showing bright liver demonstrated, that 
the two types of ultrasound attenuation  had different pathological background and also 
was not uniform from the point of view of trace element content.  On the basis of 
attenuation measurements and semiquantitative histopathological analysis it was proved 
that low attenuation (DI) type bright livers show increase of connective tissue content while 
high attenuation (DII) type bright livers are associated with lipid deposition dominance 
(Szebeni, A. et al., 2006). It was also proved that some parameters, e.g. body mass index 
(BMI), subcutaneous fat thickness (SCF), could well be associated  with the groups of liver 
ultrasound attenuation (Szebeni et al., 1999).  
The different attenuation patterns reflect various histopathological alterations: fibrosis, fatty 
degeneration, chronic inflammation, alone, or in combination. DI pattern was mainly due to 
chronic, fibrotizing inflammation, while the severe fatty change was the major finding in DII 
cases. 
Although trace metals are relatively frequently stored in the liver, the routine histological 
techniques rarely display their presence, therefore, if these metals do not reach the toxic 
levels, they may remain unidentified. Some technical notes also seem important, because it 
was found that reliable histological assessment for copper is only possible in formalin fixed 
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liver tissue (Hoffmann et al., 2009), and not after alcohol fixation. The rubeanic acid stain is a 
very useful method for demonstration of copper in Wilson disease and in various liver 
diseases with cholestasis, but in our positive cases both possibilities could have been 
excluded. It has long been known that accumulation of intrahepatic copper is most 
frequently demonstrable in alcoholic cirrhosis, but it is not related to the concomitant 
cholestasis or to the activity of the process (Berresford et al., 1980). The cirrhotic process by 
itself, however, was not a decisive feature in our material, because in 10, histologically 
proven incomplete or complete cirrhosis no rubeanic acid positivity was observed. It is 
interesting that in most of the copper-containing liver specimens a fatty degeneration was 
seen. The relationship between the two condition is not clear, but it was published that in 
cultured rat hepatocytes Cu induced lipid peroxidation, while similar effect was not seen 
after Ni administration (Furono et al., 1996). 
Nickel was histochemically identified just in 2 cases. In both cases fatty degeneration was 
seen. In the literature very few data are available about the non-toxicological appearance of 
this metal. Rezuke et al. have determined nickel concentrations in various human tissues 
from 10 postmortem specimens by using electrothermal atomic absorption 
spectrophotometry with Zeemann background correction (Rezuke et al., 1987). In their 
reference work they have found a relatively higher Ni-concentration in thyroid and adrenal 
gland as compared with other organs, and it was suggested that biliary excretion may be a 
significant route for the elimination of nickel in humans. It was found that in vitro Ni uptake 
by rat hepatocytes was partly through the Ca channel transport processes (Funakoshi, 1997). 
Exposure of  HepG2 human hepatoma cells to nickel(2+) ions resulted in a stimulation of 
Ser/Thr Akt and this activation is most likely independent of oxidative processes, since no 
oxidation of cellular glutathion was detected (Eckers et al., 2009). The mitochondrium also 
seems to be the place of its effects, because there are data that Ni is a potent competitive 
inhibitor of calcium transport in mitochondria (Bragadin et al., 1997, Ligeti et al., 1981). So 
the hepatic fatty  change and the presence of copper and nickel in these samples are not 
necessary independent findings. 
Nowadays a lot of analytical laboratory use an inductively coupled plasma optical emission 
spectrometer (ICP-OES) or an inductively coupled plasma mass spectrometer (ICP-MS) for 
multielemental analysis of various samples. Generally analyses of various essential elements 
and potential toxic elements with relatively low concentration are required, for which an 
ICP-MS is needed due to much smaller detection limits of the elements. 
To elaborate analytical methods for analysis of the examined elements with an inductively 
coupled plasma mass spectrometer the most important interfering effects (problems) were 
evaluated before analysis: 1) isobaric elemental, 2) isobaric molecular and 3) physical 
interferences (Montaser, 1998; www.epa.gov). EPA 6020A describes the interferences in ICP-
MS techniques (www.epa.gov): 
- Isobaric elemental interferences: 
These types of interferences in ICP-MS are caused by isotopes of different elements 
forming atomic ions with the same nominal mass-to-charge ratio (m/z). An evaluation 
software must be used to correct for these interferences, however these types of 
interferences are not  easily corrected. 
- Isobaric molecular and doubly-charged ion interferences: 
These interferences are caused by ions consisting of more than one atom or charge, 
respectively. Most isobaric interferences that could affect ICP-MS determinations have 
been identified in different literature. 
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Fig. 14. TXRF spectrum of a liver biopsy sample of a patient from the DII type bright liver 
group (high Ni content). 
5. Discussion 
For the investigation of the pathological background of the different types of bright liver, 
quantitative measurement of the liver attenuation is necessary; a simple and reliable method 
was elaborated together with  J.D. Satrapa (Satrapa, & Szebeni, 1996; Szebeni, & Satrapa, 
1996).  Evaluation of trace element analysis in  subjects with normal ultrasound liver pattern 
and in patients with chronic diffuse liver diseases showing bright liver demonstrated, that 
the two types of ultrasound attenuation  had different pathological background and also 
was not uniform from the point of view of trace element content.  On the basis of 
attenuation measurements and semiquantitative histopathological analysis it was proved 
that low attenuation (DI) type bright livers show increase of connective tissue content while 
high attenuation (DII) type bright livers are associated with lipid deposition dominance 
(Szebeni, A. et al., 2006). It was also proved that some parameters, e.g. body mass index 
(BMI), subcutaneous fat thickness (SCF), could well be associated  with the groups of liver 
ultrasound attenuation (Szebeni et al., 1999).  
The different attenuation patterns reflect various histopathological alterations: fibrosis, fatty 
degeneration, chronic inflammation, alone, or in combination. DI pattern was mainly due to 
chronic, fibrotizing inflammation, while the severe fatty change was the major finding in DII 
cases. 
Although trace metals are relatively frequently stored in the liver, the routine histological 
techniques rarely display their presence, therefore, if these metals do not reach the toxic 
levels, they may remain unidentified. Some technical notes also seem important, because it 
was found that reliable histological assessment for copper is only possible in formalin fixed 
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liver tissue (Hoffmann et al., 2009), and not after alcohol fixation. The rubeanic acid stain is a 
very useful method for demonstration of copper in Wilson disease and in various liver 
diseases with cholestasis, but in our positive cases both possibilities could have been 
excluded. It has long been known that accumulation of intrahepatic copper is most 
frequently demonstrable in alcoholic cirrhosis, but it is not related to the concomitant 
cholestasis or to the activity of the process (Berresford et al., 1980). The cirrhotic process by 
itself, however, was not a decisive feature in our material, because in 10, histologically 
proven incomplete or complete cirrhosis no rubeanic acid positivity was observed. It is 
interesting that in most of the copper-containing liver specimens a fatty degeneration was 
seen. The relationship between the two condition is not clear, but it was published that in 
cultured rat hepatocytes Cu induced lipid peroxidation, while similar effect was not seen 
after Ni administration (Furono et al., 1996). 
Nickel was histochemically identified just in 2 cases. In both cases fatty degeneration was 
seen. In the literature very few data are available about the non-toxicological appearance of 
this metal. Rezuke et al. have determined nickel concentrations in various human tissues 
from 10 postmortem specimens by using electrothermal atomic absorption 
spectrophotometry with Zeemann background correction (Rezuke et al., 1987). In their 
reference work they have found a relatively higher Ni-concentration in thyroid and adrenal 
gland as compared with other organs, and it was suggested that biliary excretion may be a 
significant route for the elimination of nickel in humans. It was found that in vitro Ni uptake 
by rat hepatocytes was partly through the Ca channel transport processes (Funakoshi, 1997). 
Exposure of  HepG2 human hepatoma cells to nickel(2+) ions resulted in a stimulation of 
Ser/Thr Akt and this activation is most likely independent of oxidative processes, since no 
oxidation of cellular glutathion was detected (Eckers et al., 2009). The mitochondrium also 
seems to be the place of its effects, because there are data that Ni is a potent competitive 
inhibitor of calcium transport in mitochondria (Bragadin et al., 1997, Ligeti et al., 1981). So 
the hepatic fatty  change and the presence of copper and nickel in these samples are not 
necessary independent findings. 
Nowadays a lot of analytical laboratory use an inductively coupled plasma optical emission 
spectrometer (ICP-OES) or an inductively coupled plasma mass spectrometer (ICP-MS) for 
multielemental analysis of various samples. Generally analyses of various essential elements 
and potential toxic elements with relatively low concentration are required, for which an 
ICP-MS is needed due to much smaller detection limits of the elements. 
To elaborate analytical methods for analysis of the examined elements with an inductively 
coupled plasma mass spectrometer the most important interfering effects (problems) were 
evaluated before analysis: 1) isobaric elemental, 2) isobaric molecular and 3) physical 
interferences (Montaser, 1998; www.epa.gov). EPA 6020A describes the interferences in ICP-
MS techniques (www.epa.gov): 
- Isobaric elemental interferences: 
These types of interferences in ICP-MS are caused by isotopes of different elements 
forming atomic ions with the same nominal mass-to-charge ratio (m/z). An evaluation 
software must be used to correct for these interferences, however these types of 
interferences are not  easily corrected. 
- Isobaric molecular and doubly-charged ion interferences: 
These interferences are caused by ions consisting of more than one atom or charge, 
respectively. Most isobaric interferences that could affect ICP-MS determinations have 
been identified in different literature. 
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- Physical interferences: 
These are associated with the sample nebulization and transport processes as well as 
with ion-transmission efficiencies. Nebulization and transport processes can be 
affected if a matrix component causes a change in  surface tension or viscosity. 
Changes in matrix composition can cause significant signal suppression or 
enhancement (Beauchemin et al., 1987). Dissolved solids can deposit on the nebulizer 
tip of a pneumatic nebulizer and on the interface skimmers (reducing the orifice size 
and the instrument performance). One or more suitable internal standards can be 
used to correct for physical interferences, if it is carefully matched to the analyte so 
that the two elements are similarly affected by matrix changes. 
- Memory interferences: 
Sample deposition on the sampler and skimmer cones, spray chamber design, and the 
type of nebulizer affect the extent of observed memory interferences. The rinse period 
between samples must be long enough to eliminate significant memory interference. 
The isobaric elemental, isobaric molecular and doubly-charged ion interferences caused by 
various ions consisting of one or more than one atom or charge. These types of possibly 
emerging interferences are listed in Table 4., which are described in the Plasmalab software 
(2007) made by Thermo Fisher for analysis of different samples and build an appropriate 
analytical method. Before analysis these interferences were evaluated and were taken into 
consideration for decrease or eliminate these interfering effects. 
To eliminate the doubly-charged ion interferences, before analysis the tuning parameters 
were optimized considering the appropriate plasma temperature which ensures the 
minimum level of doubly-charged ions. 
The interferences (Plasmalab, 2007) caused by various dimer, trimer or tetramer ions 
consisting of two, three or four elements were decreased by gas mixture using 7% hydrogen 
in helium (7% H2 + 93% He) as collision cell technology (CCT) gas. 
Collision/reaction cell technology has proved to be effective methods for decrease/eliminate 
the interferences caused by various dimer, trimer or tetramer ions and thus allow the 
determination of the major isotopes (52Cr, 56Fe and 80Se). This method needs a 
collision/reaction cell, which is composed of a multipole (quadrupole, hexapole or octopole) 
before the quadrupole analyzer. A collision/reaction gas is introduced into the cell where, by a 
number of different ion-molecule collision and reaction mechanisms, most of poly-atomic 
interfering ions were converted to harmless non-interfering species. The analyte ions continue 
the way into the quadrupole analyzer for normal mass separation and detection. Owing to the 
collision/reaction cell technology the most abundant and thus most sensitive isotope can be 
used for the analysis of a given element. Different collision and reaction gases or gas mixtures 
have been selected to apply in an ICP-MS. Generally a mixture of H2 and He gases (7-8% H2 in 
He), NH3 (1% NH3 in He) and CH4 gases are widely applied in ICP-MS. Moreover O2, N2O or 
other gases or mixtures can be used as collision/reaction gases also. 
In the case of the analysis of the most abundant selenium isotope (80Se) by ICP-MS the next 
possible mechanisms can be for reduction/elimination of polyatomic interferences. 
 collisional dissociation: 
e.g. ArAr+ + He = Ar + Ar+ + He 
 chemical reaction: 
e.g. ArAr+ + H2 = ArH + ArH+ 
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 charge transfer: 
e.g. ArAr+ + H = ArAr + H+ 
 collisional retardation/energy filtering: 
e.g. ArAr+* + He = ArAr+ + He* 
 
Symbol Abundance Interferences
25Mg 10.11 
40Ar+15N, 16O+39K, 14N+41K, 1H+54Fe, 1H+54Cr, 15N+40Ca, 36Ar+19F, 
12C+43Ca, 109Ag++, 110Pd++, 110Cd++
52Cr 83.76 
40Ar+12C, 36Ar+16O, 1H+51V, 12C+40Ca, 17OH+35Cl, 13C+39K, 16O+36S, 
103Rh++, 104Ru++, 104Pd++
53Cr 9.55 
40Ar+13C, 17OH+36Ar, 14N+39K, 1H+52Cr, 16O+37Cl, 12C+41K, 13C+40Ca, 
18O+35Cl, 17OH+36S, 106Pd++, 105Pd++, 106Cd++
55Mn 100 
40Ar+15N, 16O+39K, 14N+41K, 1H+54Fe, 1H+54Cr, 15N+40Ca, 36Ar+19F, 
12C+43Ca, 109Ag++, 110Pd++, 110Cd++
54Fe 5.9 
54Cr, 40Ar+14N, 14N+40Ca, 17OH+37Cl, 1H+53Cr, 12C+42Ca, 15N+39K, 
19OH+35Cl, 107Ag++, 108Pd++, 108Cd++
56Fe 91.52 
40Ar+16O, 1H+55Mn, 16O+40Ca, 17OH+39K, 12C+44Ca, 14N+42Ca, 
36Ar+20Ne, 112Cd++, 111Cd++, 112Sn++
58Ni 67.76 
58Fe, 40Ar+18O, 12C+46Ti, 17OH+41K, 1H+57Fe, 14N+44Ca, 13C+45Sc, 
16O+42Ca, 18O+40Ca, 19OH+39K, 115In++, 116Sn++, 116Cd++, 115Sn++ 
59Co 100 
19OH+40Ar, 14N+45Sc, 40Ar+19F, 1H+58Ni, 12C+47Ti, 17OH+42Ca, 
36Ar+23Na, 1H+58Fe, 19OH+40Ca, 16O+43Ca, 118Sn++, 117Sn++ 
60Ni 26.16 
1H+59Co, 40Ar+20Ne, 12C+48Ti, 14N+46Ti, 16O+44Ca, 15N+45Sc, 
36Ar+24Mg, 12C+48Ca, 17OH+43Ca, 120Sn++, 119Sn++
65Cu 30.91 
14N+51V, 17OH+48Ti, 1H+64Zn, 40Ar+25Mg, 12C+53Cr, 16O+49Ti, 
1H+64Ni, 13C+52Cr, 17OH+48Ca, 130Te++, 129Xe++, 130Xe++, 130Ba++ 
64Zn 48.89 
64Ni, 12C+52Cr, 40Ar+24Mg, 16º+48Ti, 1H+63Cu, 17OH+47Ti, 14N+50Ti, 
14N+50Cr, 13C+51V, 36Ar+28Si, 14N+50V, 19OH+45Sc, 16O+48Ca, 127I++, 
128Te++, 128Xe++
66Zn 27.81 
14N+52Cr, 1H+65Cu, 40Ar+26Mg, 12C+54Fe, 17OH+49Ti, 16O+50Ti, 
16O+50Cr, 12C+54Cr, 15N+51V, 16O+50V, 18O+48Ti, 13C+53Cr, 132Xe++, 
131Xe++
75As 100 
40Ar+35Cl, 16O+59Co, 12C+63Cu, 17OH+58Ni, 1H+74Ge, 14N+61Ni, 
1H+74Se, 17OH+58Fe, 36Ar+39K, 19OH+56Fe, 149Sm++, 150Sm++, 150Nd++ 
78Se 23.61 
78Kr, 14N+64Zn, 12C+66Zn, 1H+77Se, 16O+62Ni, 17OH+61Ni, 14N+64Ni, 
13C+65Cu, 15N+63Cu, 19OH+59Co, 156Gd++, 155Gd++
80Se 49.96 
80Kr, 40Ar+40Ar, 40Ar+40Ca, 17OH+63Cu, 1H+79Br, 16O+64Zn, 14N+66Zn, 
12C+68Zn, 16O+64Ni, 15N+65Cu, 159Tb++, 160Gd++, 160Dy++
82Se 8.84 
82Kr, 1H+81Br, 17OH+65Cu, 16O+66Zn, 12C+70Ge, 14N+68Zn, 13C+69Ga, 
40Ar+42Ca, 12C+70Zn, 19OH+63Cu, 164Dy++, 163Dy++, 164Er++ 
111Cd 12.86 
12C+99Tc, 40Ar+71Ga, 17OH+94Zr, 16O+95Mo, 1H+110Pd, 12C+99Ru, 
1H+110Cd, 14N+97Mo, 17OH+94Mo, 36Ar+75As, 13C+98Mo, 18O+93Nb 
114Cd 28.81 
114Sn, 40Ar+74Ge, 12C+102Ru, 16O+98Mo, 14N+100Ru, 1H+113Cd, 
14N+100Mo, 17OH+97Mo, 1H+113In, 16O+98Ru, 40Ar+74Se, 12C+102Pd, 
15N+99Tc, 13C+101Ru
208Pb 52.38 
16O+192Os, 17OH+191Ir, 14N+194Pt, 40Ar+168Er, 12C+196Pt, 1H+207Pb, 
16O+192Pt, 13C+195Pt, 15N+193Ir, 12C+196Hg, 40Ar+168Yb
Table 4. The most important isobaric interference ions (Plasmalab, 2007) 
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- Physical interferences: 
These are associated with the sample nebulization and transport processes as well as 
with ion-transmission efficiencies. Nebulization and transport processes can be 
affected if a matrix component causes a change in  surface tension or viscosity. 
Changes in matrix composition can cause significant signal suppression or 
enhancement (Beauchemin et al., 1987). Dissolved solids can deposit on the nebulizer 
tip of a pneumatic nebulizer and on the interface skimmers (reducing the orifice size 
and the instrument performance). One or more suitable internal standards can be 
used to correct for physical interferences, if it is carefully matched to the analyte so 
that the two elements are similarly affected by matrix changes. 
- Memory interferences: 
Sample deposition on the sampler and skimmer cones, spray chamber design, and the 
type of nebulizer affect the extent of observed memory interferences. The rinse period 
between samples must be long enough to eliminate significant memory interference. 
The isobaric elemental, isobaric molecular and doubly-charged ion interferences caused by 
various ions consisting of one or more than one atom or charge. These types of possibly 
emerging interferences are listed in Table 4., which are described in the Plasmalab software 
(2007) made by Thermo Fisher for analysis of different samples and build an appropriate 
analytical method. Before analysis these interferences were evaluated and were taken into 
consideration for decrease or eliminate these interfering effects. 
To eliminate the doubly-charged ion interferences, before analysis the tuning parameters 
were optimized considering the appropriate plasma temperature which ensures the 
minimum level of doubly-charged ions. 
The interferences (Plasmalab, 2007) caused by various dimer, trimer or tetramer ions 
consisting of two, three or four elements were decreased by gas mixture using 7% hydrogen 
in helium (7% H2 + 93% He) as collision cell technology (CCT) gas. 
Collision/reaction cell technology has proved to be effective methods for decrease/eliminate 
the interferences caused by various dimer, trimer or tetramer ions and thus allow the 
determination of the major isotopes (52Cr, 56Fe and 80Se). This method needs a 
collision/reaction cell, which is composed of a multipole (quadrupole, hexapole or octopole) 
before the quadrupole analyzer. A collision/reaction gas is introduced into the cell where, by a 
number of different ion-molecule collision and reaction mechanisms, most of poly-atomic 
interfering ions were converted to harmless non-interfering species. The analyte ions continue 
the way into the quadrupole analyzer for normal mass separation and detection. Owing to the 
collision/reaction cell technology the most abundant and thus most sensitive isotope can be 
used for the analysis of a given element. Different collision and reaction gases or gas mixtures 
have been selected to apply in an ICP-MS. Generally a mixture of H2 and He gases (7-8% H2 in 
He), NH3 (1% NH3 in He) and CH4 gases are widely applied in ICP-MS. Moreover O2, N2O or 
other gases or mixtures can be used as collision/reaction gases also. 
In the case of the analysis of the most abundant selenium isotope (80Se) by ICP-MS the next 
possible mechanisms can be for reduction/elimination of polyatomic interferences. 
 collisional dissociation: 
e.g. ArAr+ + He = Ar + Ar+ + He 
 chemical reaction: 
e.g. ArAr+ + H2 = ArH + ArH+ 
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 charge transfer: 
e.g. ArAr+ + H = ArAr + H+ 
 collisional retardation/energy filtering: 
e.g. ArAr+* + He = ArAr+ + He* 
 
Symbol Abundance Interferences
25Mg 10.11 
40Ar+15N, 16O+39K, 14N+41K, 1H+54Fe, 1H+54Cr, 15N+40Ca, 36Ar+19F, 
12C+43Ca, 109Ag++, 110Pd++, 110Cd++
52Cr 83.76 
40Ar+12C, 36Ar+16O, 1H+51V, 12C+40Ca, 17OH+35Cl, 13C+39K, 16O+36S, 
103Rh++, 104Ru++, 104Pd++
53Cr 9.55 
40Ar+13C, 17OH+36Ar, 14N+39K, 1H+52Cr, 16O+37Cl, 12C+41K, 13C+40Ca, 
18O+35Cl, 17OH+36S, 106Pd++, 105Pd++, 106Cd++
55Mn 100 
40Ar+15N, 16O+39K, 14N+41K, 1H+54Fe, 1H+54Cr, 15N+40Ca, 36Ar+19F, 
12C+43Ca, 109Ag++, 110Pd++, 110Cd++
54Fe 5.9 
54Cr, 40Ar+14N, 14N+40Ca, 17OH+37Cl, 1H+53Cr, 12C+42Ca, 15N+39K, 
19OH+35Cl, 107Ag++, 108Pd++, 108Cd++
56Fe 91.52 
40Ar+16O, 1H+55Mn, 16O+40Ca, 17OH+39K, 12C+44Ca, 14N+42Ca, 
36Ar+20Ne, 112Cd++, 111Cd++, 112Sn++
58Ni 67.76 
58Fe, 40Ar+18O, 12C+46Ti, 17OH+41K, 1H+57Fe, 14N+44Ca, 13C+45Sc, 
16O+42Ca, 18O+40Ca, 19OH+39K, 115In++, 116Sn++, 116Cd++, 115Sn++ 
59Co 100 
19OH+40Ar, 14N+45Sc, 40Ar+19F, 1H+58Ni, 12C+47Ti, 17OH+42Ca, 
36Ar+23Na, 1H+58Fe, 19OH+40Ca, 16O+43Ca, 118Sn++, 117Sn++ 
60Ni 26.16 
1H+59Co, 40Ar+20Ne, 12C+48Ti, 14N+46Ti, 16O+44Ca, 15N+45Sc, 
36Ar+24Mg, 12C+48Ca, 17OH+43Ca, 120Sn++, 119Sn++
65Cu 30.91 
14N+51V, 17OH+48Ti, 1H+64Zn, 40Ar+25Mg, 12C+53Cr, 16O+49Ti, 
1H+64Ni, 13C+52Cr, 17OH+48Ca, 130Te++, 129Xe++, 130Xe++, 130Ba++ 
64Zn 48.89 
64Ni, 12C+52Cr, 40Ar+24Mg, 16º+48Ti, 1H+63Cu, 17OH+47Ti, 14N+50Ti, 
14N+50Cr, 13C+51V, 36Ar+28Si, 14N+50V, 19OH+45Sc, 16O+48Ca, 127I++, 
128Te++, 128Xe++
66Zn 27.81 
14N+52Cr, 1H+65Cu, 40Ar+26Mg, 12C+54Fe, 17OH+49Ti, 16O+50Ti, 
16O+50Cr, 12C+54Cr, 15N+51V, 16O+50V, 18O+48Ti, 13C+53Cr, 132Xe++, 
131Xe++
75As 100 
40Ar+35Cl, 16O+59Co, 12C+63Cu, 17OH+58Ni, 1H+74Ge, 14N+61Ni, 
1H+74Se, 17OH+58Fe, 36Ar+39K, 19OH+56Fe, 149Sm++, 150Sm++, 150Nd++ 
78Se 23.61 
78Kr, 14N+64Zn, 12C+66Zn, 1H+77Se, 16O+62Ni, 17OH+61Ni, 14N+64Ni, 
13C+65Cu, 15N+63Cu, 19OH+59Co, 156Gd++, 155Gd++
80Se 49.96 
80Kr, 40Ar+40Ar, 40Ar+40Ca, 17OH+63Cu, 1H+79Br, 16O+64Zn, 14N+66Zn, 
12C+68Zn, 16O+64Ni, 15N+65Cu, 159Tb++, 160Gd++, 160Dy++
82Se 8.84 
82Kr, 1H+81Br, 17OH+65Cu, 16O+66Zn, 12C+70Ge, 14N+68Zn, 13C+69Ga, 
40Ar+42Ca, 12C+70Zn, 19OH+63Cu, 164Dy++, 163Dy++, 164Er++ 
111Cd 12.86 
12C+99Tc, 40Ar+71Ga, 17OH+94Zr, 16O+95Mo, 1H+110Pd, 12C+99Ru, 
1H+110Cd, 14N+97Mo, 17OH+94Mo, 36Ar+75As, 13C+98Mo, 18O+93Nb 
114Cd 28.81 
114Sn, 40Ar+74Ge, 12C+102Ru, 16O+98Mo, 14N+100Ru, 1H+113Cd, 
14N+100Mo, 17OH+97Mo, 1H+113In, 16O+98Ru, 40Ar+74Se, 12C+102Pd, 
15N+99Tc, 13C+101Ru
208Pb 52.38 
16O+192Os, 17OH+191Ir, 14N+194Pt, 40Ar+168Er, 12C+196Pt, 1H+207Pb, 
16O+192Pt, 13C+195Pt, 15N+193Ir, 12C+196Hg, 40Ar+168Yb
Table 4. The most important isobaric interference ions (Plasmalab, 2007) 
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Those inductively coupled plasma mass spectrometers which use CCT or reaction gases, 
have the best detection limits, for example the detection limit of selenium approximately 
0.001 µg/l for 80Se isotope. These best detection limits origin from using the collision and/or 
reaction gases to reduce the interfering effects on various element peak. CCT can eliminate 
approximately 99.99% of the 40Ar40Ar+ and 39Ar39Ar+ interferences on 80Se and 78Se, 
respectively. 
On the basis of the above we can conclude that a quadrupole inductively coupled plasma 
mass spectrometer which instrument applying a collision/reaction cell technique is the most 
appropriate to analyze ultra trace elements in routine analysis of human origin samples, 
which can decrease effectively the interference of polyadducts. 
Sample contamination during autopsy was nominated the major source of uncertainty of 
trace element analysis of biological samples. Biopsies taken by the use of stainless steel 
needles were recommended to analyze only for non-steel metals (Versieck et al, 1973; 
Versieck et al, 1982). For urine and blood recommendations were outlined to eliminate 
possible contamination during sample collection (Cornelis et al., 1992). Burguera et al. 
(Burguera et al, 2005) reported that Mn contamination during Atomic Absorption 
Spectrometry (AAS) analysis of urine samples was avoided by using new plastic and 
glassware containers soaked for at least 4h in 2 mol/l nitric acid. Christensen  (Christensen, 
1995) gave a detailed overview on contamination control in trace element analysis. The 
author concluded: Although it is impossible in most instances, the whole analytical 
procedure recommended to be carried out in clean room facilities. Blood samples were 
analyzed by Zeeman-ETAAS taken in a clean room. After puncture steel needle was 
withdrawn, venous blood was collected using a teflon catheter in 6 vials. Vial No. 5 was 
used for analysis in order to avoid contamination by steel-metals (Kristiansen et al., 1997). 
Oral mucosa biopsies were taken by CO2-laser bistoury technique for minimizing the 
contamination during sample collection and 36 elements were determined by radiochemical 
neutron activation analysis (Foglio Bonda et al., 2001).  
Multielement analysis of porcine liver and human cadaveric liver biopsy samples applying 
total reflection X-ray fluorescence spectrometry and inductively coupled plasma mass 
spectrometry are described with a special respect to Ni content. Porcine liver can be 
successfully applied to estimate the reproducibility of biopsy sampling and to investigate 
possible contamination by steel metals originating from the biopsy needles. Evidence of 
tissue contamination by steel-metals during hours of contact with the steel biopsy needle 
was shown. However, contamination was not measurable applying less than 6 min. contact 
as usual in the clinical practice.  
The intra-individual variability of element concentrations was determined by the analysis of 
biopsies taken from a cadaveric human liver. Variability of Mn, Fe, Cu, Zn and Rb 
concentration was in the range of 9-18 %RSD. Pb, Ni and Cr found to be inhomogeneously 
distributed in the liver having variability of 28, 73 and 69 %RSD, respectively. It was beyond 
the scope of the present study to explore the causes of  inhomogeneity. The result presented 
in this paper demonstrated that despite of its uneven distribution, Ni concentration in 
human liver biopsy samples seemed to be suitable for classification of patients. 
Analizing trace elements by microanalitical methods in human liver biopsy samples, 
collected from 52 individuals in a previous work (Varga et al., 2005), a probable correlation 
between high nickel concentration and hepatic steatosis was found: accumulation of nickel 
was exclusively observed in cases of steatosis. Decreased Fe concentration was also 
observed in the group of patients with steatosis.  In the present study this finding could be 
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confirmed on a larger sample size, at 183 patients (Fig. 11.).  Investigations of cadaver liver  
showed that  Ni  was  the only element distributed unevenly within the cadaver liver. 
Nevertheless, absolute values of Ni concentrations were so much higher in every segment  
of fatty livers, than the very low levels in normal one and in other diffuse liver diseases, that 
despite of the inhomogeneous distribution this sign is considered characteristic  to fatty 
liver. The cause of  Ni enrichment is not known so far. 
6. Conclusions  
Histological staining methods were not  enough sensitive for the demonstration of nickel in 
cases with chronic dissuse liver diseases.  
TXRF and ICP-MS methods were successfully applied for element analysis of liver biopsy 
samples. The two methods gave essentially same results; yet, for certain elements ICP-MS 
was more sensitive. 
It was proved that no contamination occurred at the sampling and preparation procedures. 
It was demonstrated, that distribution of the examined trace elements – except Ni - was 
homogeneous, thus microquantities of liver material is informative.  
In fatty degeneration of  the liver, established by ultrasound and histology, the enrichment 
of Ni was found by TXRF and ICPMS methods, in some cases to extremely great extent. The 
Ni concentration was much higher than normal in every fatty liver cases, therefore, despite 
of the inhomogeneous distribution, this phenomenon can be interpreted as characteristic to 
fatty liver. 
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Those inductively coupled plasma mass spectrometers which use CCT or reaction gases, 
have the best detection limits, for example the detection limit of selenium approximately 
0.001 µg/l for 80Se isotope. These best detection limits origin from using the collision and/or 
reaction gases to reduce the interfering effects on various element peak. CCT can eliminate 
approximately 99.99% of the 40Ar40Ar+ and 39Ar39Ar+ interferences on 80Se and 78Se, 
respectively. 
On the basis of the above we can conclude that a quadrupole inductively coupled plasma 
mass spectrometer which instrument applying a collision/reaction cell technique is the most 
appropriate to analyze ultra trace elements in routine analysis of human origin samples, 
which can decrease effectively the interference of polyadducts. 
Sample contamination during autopsy was nominated the major source of uncertainty of 
trace element analysis of biological samples. Biopsies taken by the use of stainless steel 
needles were recommended to analyze only for non-steel metals (Versieck et al, 1973; 
Versieck et al, 1982). For urine and blood recommendations were outlined to eliminate 
possible contamination during sample collection (Cornelis et al., 1992). Burguera et al. 
(Burguera et al, 2005) reported that Mn contamination during Atomic Absorption 
Spectrometry (AAS) analysis of urine samples was avoided by using new plastic and 
glassware containers soaked for at least 4h in 2 mol/l nitric acid. Christensen  (Christensen, 
1995) gave a detailed overview on contamination control in trace element analysis. The 
author concluded: Although it is impossible in most instances, the whole analytical 
procedure recommended to be carried out in clean room facilities. Blood samples were 
analyzed by Zeeman-ETAAS taken in a clean room. After puncture steel needle was 
withdrawn, venous blood was collected using a teflon catheter in 6 vials. Vial No. 5 was 
used for analysis in order to avoid contamination by steel-metals (Kristiansen et al., 1997). 
Oral mucosa biopsies were taken by CO2-laser bistoury technique for minimizing the 
contamination during sample collection and 36 elements were determined by radiochemical 
neutron activation analysis (Foglio Bonda et al., 2001).  
Multielement analysis of porcine liver and human cadaveric liver biopsy samples applying 
total reflection X-ray fluorescence spectrometry and inductively coupled plasma mass 
spectrometry are described with a special respect to Ni content. Porcine liver can be 
successfully applied to estimate the reproducibility of biopsy sampling and to investigate 
possible contamination by steel metals originating from the biopsy needles. Evidence of 
tissue contamination by steel-metals during hours of contact with the steel biopsy needle 
was shown. However, contamination was not measurable applying less than 6 min. contact 
as usual in the clinical practice.  
The intra-individual variability of element concentrations was determined by the analysis of 
biopsies taken from a cadaveric human liver. Variability of Mn, Fe, Cu, Zn and Rb 
concentration was in the range of 9-18 %RSD. Pb, Ni and Cr found to be inhomogeneously 
distributed in the liver having variability of 28, 73 and 69 %RSD, respectively. It was beyond 
the scope of the present study to explore the causes of  inhomogeneity. The result presented 
in this paper demonstrated that despite of its uneven distribution, Ni concentration in 
human liver biopsy samples seemed to be suitable for classification of patients. 
Analizing trace elements by microanalitical methods in human liver biopsy samples, 
collected from 52 individuals in a previous work (Varga et al., 2005), a probable correlation 
between high nickel concentration and hepatic steatosis was found: accumulation of nickel 
was exclusively observed in cases of steatosis. Decreased Fe concentration was also 
observed in the group of patients with steatosis.  In the present study this finding could be 
Microanalytical Determination of Trace Elements from  
Liver Biopsy Materials of Patients with Chronic Diffuse Liver Diseases… 
 
83 
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1. Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common human cancer world-wide but 
the third most common cause of mortality and evidence has been accumulating in various 
countries that HCC is increasing (Andrisani et al., 2011; Parkin et al., 2000; Perkin, 2004). 
Major etiologic agents in HCC pathogenesis are chronic infection with hepatitis B virus or 
hepatitis C virus (Bruix et al., 2004; Poynard et al., 2003). Advanced liver fibrosis and HCC 
have been indicated to develop in about 30% of patients with chronic hepatitis B or C. Other 
causal factors of lower incidence include alcohol abuse, metabolic disorders, and 
environmental agents, e.g., exposure to aflatoxin B1 (Llovet et al., 2003). HCC typically 
develops in the cirrhotic liver in about 80% of cases and develops only in the non-cirrhotic 
liver in less than 20% of cases (Alkofer, 2011). When diagnosed at early stage, HCC remains 
eligible for potential curative options such as surgical resection, orthotopic liver 
transplantation or percutaneous destructions. The absence of advanced fibrosis or cirrhosis 
makes resection feasible more often. However, most of HCCs have widespread 
dissemination within the liver at diagnosis (intermediary stage) or show extrahepatic 
dissemination within the portal tract, lymph nodes or distant visceral metastasis (Llovet et 
al., 2008). As recommended by Llovet and Bruix (2008), new and efficacious therapies are 
needed, along with new diagnostic biomarkers for early detection of liver cancer.  
Liver biopsy, since its initial introduction by Klatskin as a clinical tool 100 years ago, soon 
became the major diagnostic test for liver disease (Afdhal & Manning, 2008). Many studies 
have been performed to evaluate the use of readily available laboratory biomarkers to 
predict significant fibrosis or cirrhosis or HCC to substantially reduce the number of 
performed biopsies (Attallah et al., 2007; 2009a, Ismail, 2010; Pinzani, 2010). However, 
biomarkers alone are not sufficient to allow definitive decisions to be made for a given 
patient (Halfon et al., 2008). Reproducibility studies of noninvasive markers should be 
performed according to professional recommendations and respecting standards previously 
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proposed by experts (Munteanu et al., 2008; Sanai FM, Jeeffe, 2011). However, histological 
examination of liver biopsy specimens is still the gold standard for evaluating the presence 
of liver fibrosis, pathogenesis of liver injury and assessment of anti-viral treatment. Besides 
establishing the diagnosis, the biopsy is often used to assess the severity of the disease in 
terms of both grade and stage (Patton et al., 2010). 
The assessment of cellular kinetics of liver biopsies is of great importance for understanding 
the development of liver disease. Cellular DNA content can be measured by flow cytometry 
(FCM) with the aim of (1) revealing cell distribution within the major phases (G0/G1, S-
phase and G2/M) of the cell cycle, (2) estimating the frequency of apoptotic cells with 
fractional DNA content, and/or (3) disclosing the DNA-ploidy of the measured cell 
population (Darzynkiewicz et al., 2010). On the other hand, Argyrophilic nucleolar 
organizer regions (AgNORs) proteins are a set of argyrophilic nucleolar proteins that 
accumulate in highly proliferating cells, whereas their expression is very low in 
nonproliferating cells (Fariña  et al., 2011). The simple and universally applicable methods 
for staining fixed and non fixed liver cells will be described. Methods for staining of cell 
suspension from liver biopsies, and deconvolution of DNA-content-frequency histograms to 
estimate the percentage of cells in major phases of the cell cycle and frequency of apoptotic 
cells with fractional DNA content will be presented. In addition, the advantage and 
disadvantages of the DNA-FCM and AgNORs count in the assessment of cellular kinetics of 
liver biopsies in liver disease will be investigated.  
2. Principles of flow cytometry 
2.1 Basis of flow cytometry 
Modern flow cytometers are able to analyze several thousand particles every second 
(analyzer flow cytometry) and can actively separate and isolate particles having specified 
properties; cell sorter flow cytometry (Darzynkiewicz  et al., 2011). A flow cytometer is 
similar to a microscope, except that, instead of producing an image of the cell, flow 
cytometry offers "high-throughput" (for a large number of cells) automated quantification of 
set parameters . To analyze tissues, such as liver biopsies, a single-cell suspension must first 
be prepared using mechanical or enzymatic methods. The idea of flow cytoemtry is based 
on a beam of light (usually laser light) of a single wavelength is directed onto a 
hydrodynamically-focused stream of fluid (Cho et al., 2010).  
A number of detectors are aimed at the point where the stream passes through the light 
beam: one in line with the light beam (Forward Scatter or FSC) and several perpendicular to 
it (Side Scatter (SSC) and one or more fluorescent detectors). Each suspended particle from 
0.2 to 150 micrometers passing through the beam scatters the ray, and fluorescent chemicals 
(such as propidium iodide which used for binding to DNA) found in stained cells or 
attached to the particle (as conjugated fluoresce antibodies used for immunophenotyping) 
may be excited into emitting light at a longer wavelength than the light source (de Tute, 
2011).  This combination of scattered and fluorescent light is picked up by the detectors, and, 
by analyzing fluctuations in brightness at each detector. Forward scatter (FSC) correlates 
with the cell size and side scatter (SSC) depends on the inner complexity of the particle (i.e., 
shape of the nucleus, the amount and type of cytoplasmic granules or the membrane 
roughness) (Fig. 1). 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry. It 
provides a method for sorting a heterogeneous mixture of biological cells into two or more 
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containers, one cell at a time, based upon the specific light scattering and fluorescent 
characteristics of each cell. It is a useful scientific instrument, as it provides fast, objective 
and quantitative recording of fluorescent signals from individual cells as well as physical 
separation of cells of particular interest. The cell sorted machines have ability to sort cells 
with highly sterility and purity more than 98%, so these cells can be use for tissue culture 
applications (Cho et al., 2010).  
 
 
Fig. 1. Diagram of general components of flow cytometry. 
2.2 DNA ploidy and cell cycle analysis 
2.2.1 Cell cycle phases 
The cell cycle is commonly divided into “phases” – interphase and mitosis.  Interphase is 
further divided into three sub-phases, G1, S, and G2.  In G1, cells integrate environmental 
and internal signals that are aimed at the “replicate”/“do not replicate” decision 
(Darzynkiewicz et al., 2010). The S phase is defined by the ability to synthesize genomic 
DNA.  G2 was originally defined as the second gap between S and Mitosis, but is now 
known to function as a time of DNA damage repair, and likely, preparation for entering 
Mitosis (M phase). Mitosis has been traditionally sub-divided into stages defined by 
nuclear morphology – prophase, prometaphase, metaphase, anaphase A and B, and 
telophase.  A final phase, division of the cytoplasm that overlaps telophase and is often 
lumped with mitosis, is cytokinesis (CK). The major cell cycle sub-phases, G1, S, G2+M 
can typically be identified by direct quantitative measurement of the DNA by flow 
cytometry based on staining of DNA with fluorescence dye such as propidium iodide 
(Fig. 2).  
  
Liver Biopsy 
 
88
proposed by experts (Munteanu et al., 2008; Sanai FM, Jeeffe, 2011). However, histological 
examination of liver biopsy specimens is still the gold standard for evaluating the presence 
of liver fibrosis, pathogenesis of liver injury and assessment of anti-viral treatment. Besides 
establishing the diagnosis, the biopsy is often used to assess the severity of the disease in 
terms of both grade and stage (Patton et al., 2010). 
The assessment of cellular kinetics of liver biopsies is of great importance for understanding 
the development of liver disease. Cellular DNA content can be measured by flow cytometry 
(FCM) with the aim of (1) revealing cell distribution within the major phases (G0/G1, S-
phase and G2/M) of the cell cycle, (2) estimating the frequency of apoptotic cells with 
fractional DNA content, and/or (3) disclosing the DNA-ploidy of the measured cell 
population (Darzynkiewicz et al., 2010). On the other hand, Argyrophilic nucleolar 
organizer regions (AgNORs) proteins are a set of argyrophilic nucleolar proteins that 
accumulate in highly proliferating cells, whereas their expression is very low in 
nonproliferating cells (Fariña  et al., 2011). The simple and universally applicable methods 
for staining fixed and non fixed liver cells will be described. Methods for staining of cell 
suspension from liver biopsies, and deconvolution of DNA-content-frequency histograms to 
estimate the percentage of cells in major phases of the cell cycle and frequency of apoptotic 
cells with fractional DNA content will be presented. In addition, the advantage and 
disadvantages of the DNA-FCM and AgNORs count in the assessment of cellular kinetics of 
liver biopsies in liver disease will be investigated.  
2. Principles of flow cytometry 
2.1 Basis of flow cytometry 
Modern flow cytometers are able to analyze several thousand particles every second 
(analyzer flow cytometry) and can actively separate and isolate particles having specified 
properties; cell sorter flow cytometry (Darzynkiewicz  et al., 2011). A flow cytometer is 
similar to a microscope, except that, instead of producing an image of the cell, flow 
cytometry offers "high-throughput" (for a large number of cells) automated quantification of 
set parameters . To analyze tissues, such as liver biopsies, a single-cell suspension must first 
be prepared using mechanical or enzymatic methods. The idea of flow cytoemtry is based 
on a beam of light (usually laser light) of a single wavelength is directed onto a 
hydrodynamically-focused stream of fluid (Cho et al., 2010).  
A number of detectors are aimed at the point where the stream passes through the light 
beam: one in line with the light beam (Forward Scatter or FSC) and several perpendicular to 
it (Side Scatter (SSC) and one or more fluorescent detectors). Each suspended particle from 
0.2 to 150 micrometers passing through the beam scatters the ray, and fluorescent chemicals 
(such as propidium iodide which used for binding to DNA) found in stained cells or 
attached to the particle (as conjugated fluoresce antibodies used for immunophenotyping) 
may be excited into emitting light at a longer wavelength than the light source (de Tute, 
2011).  This combination of scattered and fluorescent light is picked up by the detectors, and, 
by analyzing fluctuations in brightness at each detector. Forward scatter (FSC) correlates 
with the cell size and side scatter (SSC) depends on the inner complexity of the particle (i.e., 
shape of the nucleus, the amount and type of cytoplasmic granules or the membrane 
roughness) (Fig. 1). 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry. It 
provides a method for sorting a heterogeneous mixture of biological cells into two or more 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
89 
containers, one cell at a time, based upon the specific light scattering and fluorescent 
characteristics of each cell. It is a useful scientific instrument, as it provides fast, objective 
and quantitative recording of fluorescent signals from individual cells as well as physical 
separation of cells of particular interest. The cell sorted machines have ability to sort cells 
with highly sterility and purity more than 98%, so these cells can be use for tissue culture 
applications (Cho et al., 2010).  
 
 
Fig. 1. Diagram of general components of flow cytometry. 
2.2 DNA ploidy and cell cycle analysis 
2.2.1 Cell cycle phases 
The cell cycle is commonly divided into “phases” – interphase and mitosis.  Interphase is 
further divided into three sub-phases, G1, S, and G2.  In G1, cells integrate environmental 
and internal signals that are aimed at the “replicate”/“do not replicate” decision 
(Darzynkiewicz et al., 2010). The S phase is defined by the ability to synthesize genomic 
DNA.  G2 was originally defined as the second gap between S and Mitosis, but is now 
known to function as a time of DNA damage repair, and likely, preparation for entering 
Mitosis (M phase). Mitosis has been traditionally sub-divided into stages defined by 
nuclear morphology – prophase, prometaphase, metaphase, anaphase A and B, and 
telophase.  A final phase, division of the cytoplasm that overlaps telophase and is often 
lumped with mitosis, is cytokinesis (CK). The major cell cycle sub-phases, G1, S, G2+M 
can typically be identified by direct quantitative measurement of the DNA by flow 
cytometry based on staining of DNA with fluorescence dye such as propidium iodide 
(Fig. 2).  
  
Liver Biopsy 
 
90
 
 
Fig. 2. The cell cycle phases (A) and diploid DNA histogram measured by flow cytometry 
(B). 
2.2.2 DNA ploidy by flow cytometry 
DNA content measurement by cytometry serves to estimate frequency of cells in particular 
phases (G0/1 versus S versus G2M) of the cell cycle as well as to assess DNA ploidy. In most 
situations DNA ploidy is being assessed in hematological or solid tumors; the evidence of 
aneuploidy by itself is a definitive marker of a presence of the tumor (Darzynkiewicz et al., 
2010). Often is also considered to be a prognostic indicator of tumor progression and 
outcome of the treatment. To assess DNA ploidy of the tumor sample one has to compare 
DNA content of the G0/G1 cells population of the presumed tumor cells with that of normal 
(control) cells. Towards this end most frequently the peak value of the integrated 
fluorescence (peak channel) of G0/1 population of normal cells is being considered to be  
DI 1.0 and DNA ploidy of the tumor cells is expressed as a ratio of the peak value 
(channel) of fluorescence intensity of these cells with respect to that of the normal G0/1 cells 
(Darzynkiewicz et al., 2011). It is also common to express DI of the tumor as a ratio of modal 
rather than the peak value of fluorescence intensity representing DNA content of G0/G1 
population tumor cells to modal value of G0/1 population of normal cells. Some authors still 
prefer to use the mean values of fluorescence intensity of G0/1 population rather than the 
peak or modal values to obtain this ratio (Darzynkiewicz et al., 2010). In essence, when DNA 
measurement is done correctly and accurately, either of these approaches is expected to 
yield similar estimate of DI of aneuploid cells. From our experience, we can use normal 
lymphocytes, including lymphocytes from the same patient, as external standard control of 
DI 1.0 (Fig. 3). 
For comparison with the tumor it is necessary to use normal cells both as external and 
internal control standards. When used as external control they have to be subjected to 
identical processing and staining procedure and measured by cytometry under identical  
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Fig. 3. Apoptotic cells (sub G0/G1 region) as measured by flow cytometry. Figure B shows 
high percentage of apoptotic cells (indicated by arrows) in comparison with low percentage 
shown in figure A. 
laser and detector settings as tumor sample (Shankey and Rabinovitch, 2002). The external 
lymphocyte control cells should be measured prior to- and also after- measurement of 
tumor sample. This double- measurement of control cells allows one to detect the possible 
shift in fluorescence readout e.g., due to mis adjustment in instrument settings in the course 
of the sequential measurements. In addition to external control, normal cells should also be 
admixed (e.g., in 1:1 proportion) with the tumor sample cells and used then as internal 
control in another set of measurements (Darzynkiewicz et al., 2010). Often, normal stromal- 
or tumor infiltrating cells are already present in the tumor sample and they can be used as 
an internal control of DNA ploidy. In fact, when DNA ploidy is assessed based on 
measurement of nuclei isolated from paraffin blocks, the internal control provided by the 
presence of stromal and infiltrating normal cells that provide standard for DI 1.0 is the 
only way to assess DNA ploidy of the tumor (Shankey et al.,1993). This is due to the fact that 
DNA stains ability after formaldehyde fixation and paraffin embedding is markedly altered 
making external standards useless (Darzynkiewicz et al., 2010). Two different types of 
reagents are necessary to ensure accuracy of DNA content analysis. Controls are used to 
assure proper instrument performance and to validate the DNA staining technique 
(Robinson et al., 2002). Fresh or fixed cells such as chicken erythrocytes (internal control or 
human lymphocytes (external control) have been used to determine staining consistency 
between samples, variations in DNA binding by different cell population can produce 
ambiguity in the correction definition of the diploid DNA content (Shankey et al., 1993, 
Darzynkiewicz et al., 2010) as shown in Fig. 4 & Fig. 5. 
Fluorescent beads are useful controls to determine instrument performance and linearity 
because their fluorescence is consistent on a day-to day basis (Darzynkiewicz et al., 2010). 
These standards are used to define the amount of DNA related fluorescence that is 
equivalent to the amount that would be obtained from a diploid human cell.   
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Fig. 2. The cell cycle phases (A) and diploid DNA histogram measured by flow cytometry 
(B). 
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Fig. 4. Blood lymphocytes (blue) used as external control for DNA ploidy analysis by flow 
cytometry. DNA ploidy of liver biopsy from HCC patient (red). 
 
 
Fig. 5. Chicken red blood cells can be used as internal control during DNA ploidy analysis 
by flow cytoemtry. 
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2.2.3 Doublet discrimination 
Because cells and especially fixated cells tend to stick together, cell aggregates have to be 
excluded from analysis through a process called doublet discrimination. This is important 
because a doublet of two cells in the G0/G1 phase has the same total amount of DNA and 
thus the same fluorescence intensity as a single cell in the G2/M phase (Wersto et al., 2001). 
G0/G1 doublets would therefore create false positive results for G2/M cells. 
2.2.4 Analysis of cellular DNA content by flow cytometry 
Flow cytometry analysis of ploidy and cell cycle analysis were one of the first applications of 
flow cytometry and this technique remains the only rapid and efficient means of making 
such measurements (López-Otero et al., 2010). As previously described, distribution of cells 
within the major phases of the cell cycle is based on differences in DNA content between the 
cells in pre replicative phase (G0/1) versus the cells that actually replicate DNA (S phase) 
versus the post replicative plus mitotic (G2 + M) phase cells (Darzynkiewicz et al., 2010). It is 
generally accepted that DNA content measured by cytometry (DNA ploidy) is defined as 
DNA index (DI) and for normal (non tumor, euploid) cells in G0/1 phase of the cell cycle DI 
= 1.0. Cells in G2/M phase of the cell cycle have DI = 2.0 and the S-phase normal cells are 
characterized by 1.0 < DI < 2.0. Different histograms DNA ploidy measured using flow 
cytometry based on liver biopsied from HCC and liver cirrhosis with different DNA index 
are shown in Fig. 6. Analysis of DNA content reveals cell ploidy, provides information on 
cell position in the cell cycle and also allows one to estimate frequency of apoptotic cells that 
are characterized by fractional DNA content (Shankey et al., 1993, Darzynkiewicz et al., 
2010). Such apoptotic cells can be identified as the cells with fractional DNA content (DI < 
1.0). It is often being defined as “sub-G1” cell population. 
 
Fig. 6. Different ploidy histograms of liver biopsies from pateints with HCC. Figures A,C 
from tumor part and B,D from residual part (non tumor part) of HCC liver biospes. 
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cytometry. DNA ploidy of liver biopsy from HCC patient (red). 
 
 
Fig. 5. Chicken red blood cells can be used as internal control during DNA ploidy analysis 
by flow cytoemtry. 
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2010). Such apoptotic cells can be identified as the cells with fractional DNA content (DI < 
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3. Simple and universally applicable method for staining fixed and non fixed 
liver cells and analysis by flow cytoemtry 
In cirrhotic patients with early HCC, a pre-operative liver biopsy should be performed 
because it has a low complication rate and it provides clinically useful information for the 
management of these patients (Colecchia et al., 2011). Knowledge of pre-operative tumor 
grade is crucial in the management of HCC because it can influence recurrence and survival 
after surgery. The accuracy of pre-operative needle biopsy in tumor grading has been 
assessed in only a few studies with conflicting results (D’Amico et al., 2009; Pawlik et al., 
2007). Fine needle aspiration biopsy (FNA) is currently the preferred technique for 
diagnosing liver masses because of its safety and rapidity. The cytological diagnosis is 
usually taken as definitive, which makes it critical for patient management (Kocjan G  2010). 
However, in the literature it is reported that FNA of the liver has variable diagnostic 
sensitivity (60–100%), and that difficulties exist in diagnosing well-differentiated HCCs and 
in distinguishing primary from metastatic tumors (Kuo  et al., 2004; Ligato  et al., 2008). For 
this reason, additional studies that can be performed on cytological samples are desirable to 
aid diagnosis.  
DNA analysis has diagnostic and  or prognostic significance in different human neoplasias, 
and can be performed on FNA samples. The following is the simple and universally 
applicable method for staining fixed and non fixed liver cells and analysis by flow 
cytoemtry. Single-cell suspensions can be prepared by mechanical dissociation of the fresh 
biopsy specimen in RPMI-1640 medium (Sigma Chemical Co., St. Louis, MO) or phosphate 
buffer saline (PBS) followed by filtration through a piece of fine nylon mesh (45 m pore-
size) and centrifugation to remove debris and cell clumps. Cells were permeabilized with 
Triton X-100 (Sigma) (0.1 % in di-ionized H2O followed by staining using propidium iodide 
(Sigma) (50 g/ ml in PBS) as a DNA specific fluorochrome. Core liver biopsy or cell 
suspension can be preserved in media (sterile DMEM media or phosphate buffer saline) in 
freezer – 20 0C for more than one month. Also cells can fixed in absolute alcohol then be 
preserved at freezer – 20 0C. Flow cytometric analysis can be performed with a any flow 
cytometer (such as Coulter EPICS profile II Coulter Corp., Hialeah, FL ), configured with a 
488 nm argon ion laser. Peripheral blood lymphocytes were used as an external standard for 
tissue material. A total of 10000 events per sample were acquired. DNA aneuploidy was 
defined as any population with a distinct additional peak (s) or the presence of a tetraploid 
population greater than 15%. The coefficient of variation (CV) was defined as the standard 
deviation as a percentage of the mean DNA value of the diploid peak. Samples were 
excluded when CV exceeded 5%. Histograms showing only one G0/G1 peak was 
considered as diploid cells (normal) and those showing two distinct peaks were considered 
as aneuploid cells (Attallah et al., 2009b). 
4. DNA-FCM in the assessment of cellular kinetics of liver biopsies in liver 
cirrhosis and HCC  
It is scientifically and clinically important to better understand the intermediate events that 
predispose to neoplastic progression. Many neoplasms generate DNA-flow cytometry 
histograms which differ from the normal in having more than one peak with a different 
DNA content, the term aneuploid being used to describe these populations. Aneuploidy is 
believed to correlate with poor prognosis and early recurrence following surgery (Quinn 
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and Wright 1990; Tripathi  et al., 2008). According to the multi-step theory of neoplastic 
progression, cancer development is associated with the evolution of a clone of cells with an 
acquired genomic instability and abnormal proliferation, i.e. progression to malignancy is 
associated with the expansion of cells with altered DNA. In our previous study, (Attallah et 
al., 1999b), the cellular DNA content, known as ploidy state, of cells and expressed as DI 
revealed that normal liver showed a diploid pattern. Abnormal DNA content was observed 
in 78.6% of the tumor sites of HCC, (50% were aneuploid (1:15, DI, 1:8), 28.6% were 
tetraploid), in agreement with Chen et al. (1991). Mise et al. (1998) found that DNA 
aneuploidy was observed in 31 of 80 tumors (38.8%) while Kato et al. (1998) demonstrated 
that, aneuploidy was seen in 45% (9 of 20) of tumors. However, 21.4% of HCC patients were 
in a diploid state. 
Ploidy study estimates quantitative changes in chromosome complement by measuring 
nuclear DNA content. At least two possibilities can be considered. One is that there may be a 
balanced translocations chromosomal rearrangement without change in chromosomal volume, 
point mutations or deletions (Hayashi  et al., 1988; Hiddeman  et al., 1984; Raiker,  et al., 1989) 
which cannot be identified as abnormalities by flow cytometry measurement. The other 
possibility is the degree of quantitative change of chromosomes. It is difficult to identify a 
small change, such as a defect in the short arm of a chromosome (Hayashi et al., 1988) or an 
abnormal or small-sized chromosome (Maletz et al, 1986; Tripathi  et al., 2008). Residual liver 
lesions of HCC had aneuploid cell populations in 43% of cases. Aneuploidy was found in 
44.5% of the liver cirrhosis patients group. The high percentage of aneuploidy in residual liver 
lesions of the HCC group or the cirrhotic liver group did not agree with the data of Rua et al. 
(1996) which demonstrated that aneuploidy is found in only 11% of cirrhotic parts of 
peritumoral HCC. The discrepancy is not completely clear and may be due to the method 
used. In the study of Rua et al., parafin-embedded tissues were used while our samples were 
tested fresh. In addition, dysplasia was found in 66% of cirrhotic cases and this in agreement 
with Anthony et al., (1973) and Roncalliet al., (2010). Aneuploidy was found in 69% of 
dysplastic cases. The proliferative activity (S-phase and G2/M phases), measured by flow 
cytometry, revealed statistically a significant difference between the liver cirrhosis group and 
normal liver (P < 0.05) and this agrees with Rua et al. (1996), who suggested that S phase 
fraction of cirrhotic liver parenchyma may be employed as a new additional parameter in the 
prognostic evaluation of HCC patients. There may be a relationship between the development 
of carcinoma and an increased cell proliferation, presumably due to an increased rate of 
random mutations (Jain  et al., 2010; Tarao et al., 1994a). 
The survival of patients with HCC which developed in a cirrhotic liver with a diploid DNA 
content and a high S-phase fraction was significantly reduced (Rua et al., 1996). Tarao et al. 
(1994a) demonstrated that HCC developed within a 3-year period in 64.3% of the cirrhotic 
patients with high DNA synthesis activity and only in 14.3% of the cirrhotic patients with 
low DNA synthesis activity. Ballardini et al. (1994) found higher reactivity for proliferating 
cell nuclear antigen in the cirrhotic liver of patients who eventually developed HCC, and 
therefore they suggest a differentiated follow-up of these patients. In the present study, 
proliferation activity of diploid tumors and residual liver lesions showed an increase but 
was not statistically significant (P < 0.06, P< 0.08 respectively). Patients with cirrhosis and 
high cell proliferation rates are at increased risk of developing cancer as reported by Baker 
et al. (1995) and But et al., (2008). So, the presence of liver cell dysplasia (66%) and a high 
proliferation rate may explain the high percentage of aneuploidy in the cirrhotic patients 
group and in residual liver tissues of HCC. The increase of aneuploidy in liver cirrhosis 
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patients and residual liver lesions of HCC demonstrated that liver cirrhosis is a 
premalignant lesion for HCC and that high proliferating activity and aneuploid cirrhotic 
patients must be followed up, as reported by Ballardini et al. (1994) and Roncalli  et al., 
(2010). We can conclude that, DNA ploidy analysis of core liver biopsy specimens is useful 
in the investigation of the cell kinetics of liver cirrhosis and HCC. Dysplasia, cell 
proliferation and aneuploidy in liver cirrhosis may be an indication of a risk factor of liver 
cirrhosis for development of HCC. Also quantitative DNA content analysis using small 
needle liver biopsies is simple and technically convenient for flow cytometric ploidy 
analysis. 
5. DNA ploidy and liver cell dysplasia in liver biopsies from patients with liver 
cirrhosis 
There is controversy among pathologist when assessing the presence or absence of liver cell 
dysplasia in liver biopsies taken from cirrhotic patients (El-Sayed et al., 2004). Flow 
cytometry is a rapid cell proliferation (technique and can assess thousands of cells in a few 
minutes. Moreover, FCM can identify cases with high cell proliferation (high S phase and 
G2/M), which are very susceptible to different mutagenic agents or chemicals, which results 
in neoplastic transformation. FCM can therefore be considered as a better ancillary 
technique in the assessment of liver cell dysplasia because it is objective and not able to 
misinterpretation or inter-observer discordance (Attallah et al., 2009b).  In our previous 
study (El-Sayed et al., 2004), liver cell dysplasia was found in 60 % of patients with liver 
cirrhosis, small cell dysplasia in 38 %  and large cell dysplasia in 62 %. Our results are in 
agreement with finding of Roncalli et al (1989) and Lin et al., (1990).  We used FCM to 
determine the DNA ploidy, cellular DNA content and proliferation index (PI). We found 
that 81.5 % of cases that were histopathologically shown to have liver cell dysplasia also had 
aneuploidy. In addition, aneuploidy was found in 11.1% of biopsies without liver cell 
dysplasia. This may be due to the higher sensitivity of FCM.  These results confirm the 
aneuploidy nature of liver cell dysplasia (Anthony et al., 1973; Park and Roncalli et al., 1989; 
Roncalli  et al., 2010). 
The DNA content of liver cells expressed as DI was significantly higher (P<0.0001) in cases 
with liver cell dysplasia than cases without liver cell dysplasia, in accordance with the 
finding of other investigations (Henmi A,  et al., 1985; Lee et al., 1997, Roncalli et al.,1989; 
van Dekken et al., 2005). Libbrecht et al., (2001) indicated that the presence of liver cell 
dysplasia in a needle liver biopsy of patients with the viral induced chronic liver disease is 
an independent risk factor for the development of HCC. At least two possibilities can be 
considered to explain the diploidy in liver cirrhosis biopsies with dysplasia. One is that 
there may be balanced translocations chromosomal rearrangements without change in 
chromosomal volume, point mutations, or deletions that con not be identified by FCM 
measurement (Fukushi et al., 2009; Hayashi et al., 1989; Tomioka, 2003). The other 
possibility may be due to the degree of quantitative change of chromosomes. It is difficult to 
identify a small change, such as a defect in the short arm of a chromosome. It is difficult to 
identify a small change, such as a defect short arm of a chromosome or an abnormal or small 
sized chromosome. Furthermore, the aneuploidy was found more commonly in large cell 
dysplasia (LCD) compared with small cell dysplasia (SCD), but no multiple aneuploid peaks 
(polypoidy) were found in either LCD or SCD. We showed that the cellular DNA contents 
were insignificant relation with activity of cirrhosis (El-Sayed et al., 2004), which is in 
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agreement with Lin et al., (1990). Moreover, active cirrhosis was significantly (P<0.05) 
associated with a higher PI (S + G2M phases) than diploid cases with inactive cirrhosis and 
my due to liver response to cell injury (Pahlavan et al., 2006; Schaffner 1991). The value of 
detecting these cellular DNA changes in liver cirrhosis by FCM is of prognostic value in 
regards to early detection of preneoplastic changes in liver cirrhosis were found to be at 
increased risk of developing HCC (Clemente et al., 2007; Ruà et al., 1996; Tarao et al., 1994b). 
The presence of an aneuploid DNA pattern had been reported by Hoso and Nakanuma  
(1991), to a precancerous change in cases with atypical adenomatous hyperplasia, of the 
liver. Yet, the presence of liver cell dysplasia, although not specific as premalignant 
condition, could be considered as a serious hand mark in cases of liver cirrhosis. In our 
previous study, DNA aneuploidy was indentified in 46.7 % of patients with liver cirrhosis 
(El-Sayed et al., 2004). However, Thomas et al., (1992) reported a lower incidence (25 %) of 
DNA aneuploidy in patients with liver cirrhosis. This difference may be due to the use of 
archival material of paraffin embedded blocks. Also serum albumin levels was significantly 
lower (P<0.008) in patients with liver cell dysplasia than patients without dysplasia. 
Moreover, a significant negative correlation (P<0.05) was found between the serum albumin 
and the percentage of aneuploid cells. This may be a attributed to poor synthesis of albumin 
by these dysplastic hepatic cells as a result of change in the nuclear DNA contents of these 
aneuploid cells. So we can conclude that liver cell dysplasia is associated with aneuploidy, 
as measured by flow cytometry,  may carry the risk for progression to HCC  and liver 
cirrhotic  patients with aneuploidy must be followed up. 
6. Advantage and disadvantages of the DNA-FCM count in the assessment of 
cellular kinetics of liver biopsies in liver disease 
Measurement of DNA content of individual cells by using flow cytometry offers a number 
of advantages over cytogenetic analysis (Nunez et al., 2004; Ritter et al., 1994). Unlike 
cytogenetic analysis, in which 20 to 40 cells are routinely analyzed, cytometric analysis can 
measure ten thousands of cells or nuclei. One of the most advantages of cytometric DNA 
content analysis is that it does not rely on metaphase cells, and cell in all phases of the cell 
cycle are generally included in the analysis. The critical limitation of cytometric analysis is 
the significantly lower resolution compared with karotyping. Flow cytometric DNA content 
analysis con not provide information on chromosome structure and is thus incapable of 
detecting balance chromosomal translocation (Dundar et al., 2010; Shankey et al., 1993). The 
limitation imposed on cytometric  analysis even  using high precision instruments and the 
most stiometric DNA binding fluorescence dye; DAPI (4, 6 diamidino 2-phenylindole), 
prevent cytometric  from detecting  chromosomal gains or losses involving more than about 
5 % of the total  DNA. In practical terms, this implies that the smallest change that can be 
detected theoretically is the gain or loss of equivalent of one large (e.g. A-group) 
chromosome (Shankey et al., 1993). 
7. Nucleolar organizer regions 
Nucleolar organizer regions (NORs) are situated within the nucleolus of a cell that are of 
central importance in the transcription of DNA to ribosomal RNA and hence in the 
ultimate assembly of proteins (Howat et al., 1989; Schwint et al., 1996; Uno et al., 1998). 
NORs are located, one each on the short arms of the five acrocentric chromosomes namely 
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NORs are located, one each on the short arms of the five acrocentric chromosomes namely 
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13, 14, 15, 21, and 22 as secondary constrictions close to the centromere (Howell, 1982; 
Vuhahula et al., 1995). The number of NOR-bearing chromosomes are seen in the 
karyotype (Landini et al., 1990). NORs could be demonstrated in histological sections by 
means of the argyrophilia of their associated proteins using the structures and simple 
silver staining method and thus demonstrated as termed AgNORs (Crocker, 1995; Crocker 
& Skilbeck 1987; Trere`, 2000).  
AgNOR proteins are a set of argyrophilic nucleolar proteins that accumulate in highly 
proliferating cells, whereas their expression is very low in nonproliferating cells. Some of 
these proteins remain associated with the NORs during mitosis. In situ, the expression of 
AgNOR proteins is measured globally by quantification of the level of silver staining using 
morphometry and image analysis (Sirri et al., 2000). The distribution of AgNORs and their 
quantities have been associated with proliferative activity and ploidy in different neoplastic 
and preneoplastic conditions. Several studies investigated the correlation of the number of 
detectable AgNORs with the degree of nucleolar dispersion or disaggregation, which is 
related directly to cell proliferation and the NOR-bearing chromosomes (Arora et al., 2002; 
Giri et al., 1989; Underwood & Giri, 1988).  
7.1 Staining of nucleolar organizer regions 
In our laboratories, liver biopsy samples were taken from the most representative area of the 
diseased tissue. The biopsy specimens were then fixed in 10% buffered formalin and 
subsequently processed to prepare paraffin blocks. Two separate sets of sections of 4 μm 
thickness were obtained from each block. One set stained by the hematoxylin and eosin 
(H&E) technique for routine histological evaluation and confirmation of diagnosis. Another 
set of sections were stained for localization and quantification of AgNORs according to the 
method described by Lindner et al., (1993). The sections were deparaffinized in xylene, and 
hydrated through 100% and 95% ethanol to water. Reduction of sections was done with 1% 
potassium iodide for 60 min. Silver staining solution was prepared by dissolving 2% gelatin 
in 1% formic acid at room temperature and filtered through syringe filter (Sigma Chemical 
Co., St. Louis, MO, USA). One part of the solution was mixed with two parts of 50% silver 
nitrate immediately before use. Staining was done in dark at room temperature for 30 min, 
then sections were immersed in 5% sodium thiosulphate for 5 min. Sections were washed in 
water, dehydrated in 95% and 100% ethanol, and mounted in permanent mounting media 
(Attallah et al., 2009b). 
7.2 Counting of silver stained nucleolar organizer regions (AgNORs)  
AgNORs appear as brown black dots inside the nucleus using silver stain. Counting of 
AgNORs was done without any knowledge of the histological or the clinical data. The slides 
were examined with an oil immersion objective at 1000 magnification. The examined fields 
were selected randomly. AgNORs were counted in 100 nuclei, which were randomly 
selected. The absolute number of AgNORs within each nucleus was counted and the mean 
number of AgNORs per nucleus (mAgNORs) was determined for each case (fig. 7). 
Background should be pale yellow and clear,  the nucleus yellow and/or brown, and 
AgNOR sites intra-nucleolar black dots. 
Most studies have shown that high AgNORs counts can reflect a tumor's degree of 
malignancy, differentiate among reactive, benign, and malignant conditions (Derenzini & 
Ploton 1991; Khan et al., 2006; Kummoona et al., 2008; Raikhlin et al., 2006). Crocher & 
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McGovern (1988) applied the AgNORs method to normal, cirrhotic, and carcinomatous 
livers and recognized a significant difference in their AgNORs scores. Study of Jain et al. 
(1998) indicated that both quantitative and qualitative analysis of AgNORs may be useful as 
an adjunct to routine hematoxylin and eosin stain to distinguish cirrhosis from HCC 
especially when the latter is well differentiated. Also, AgNORs count in the hyperplastic foci 
was significantly higher than that in the controls (Wakasa et al., 1998). Jagan et al. (2008) 
investigated the antiproliferative effect of gallic acid during diethylnitrosamine (DEN)-
induced HCC in male Wistar albino rats. They used levels of AgNORs as a tumor marker, 
which can be an indicator of tumor response to therapy. 
 
 
Fig. 7. The AgNORs staining in liver of patient with HCC. The findings were viewed 
following staining under the light microscope using 100Χ oil immersion lens and cedar 
wood oil. Nucleolar organizer regions appear as brown black dots inside the nucleus using 
silver stain (AgNORs count). 
7.3 AgNOR count reflects DNA ploidy or proliferative activity 
Several attempts have been made to determine whether mean AgNOR count reflects 
ploidy or proliferative activity. However, several studies have correlated the mean 
AgNOR count with Ki-67, bromodeoxyuridine (BrdU)-labeling indexes (Munakataet al., 
1994; Trere et al., 1991), and proliferating cell nuclear antigen (PCNA) in mucosa-
associated lymphoid tissues and gastrointestinal stromal tumors (Yu et al., 1992). Mikow 
et al. (1993) indicated that mean AgNOR reflects the proliferative activity rather than 
ploidy. Another study failed to show a relationship between AgNORs count and Ki-67 
and BrdU-labeling indexes (Nyska, 1995), or between diploid and aneuploid tumors 
(Nagao et al., 1995). This is in a disagreement with a study of mean AgNOR in 
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trophoblastic disease, which indicated that mean AgNOR is a reflection of ploidy and 
proliferative activities (Maier et al., 1990). However, in contrast to immunohistochemical 
methods merely determining the growth fraction of the cells by Ki-67 and proliferating 
cell nuclear antigen (PCNA) analysis AgNORs apparently reflect time-related 
proliferation rates and ploidy. Thus, AgNOR analysis may provide further insights 
concerning the biological behavior of the cell and is simple, inexpensive, and reliable 
method of evaluating the proliferative activity and ploidy of the cell (Meng et al., 1996). 
Celikel (1995) found a correlation between mean AgNOR and ploidy and proliferation 
activity of urinary bladder tumor as measured by DNA flow cytometry. Also, Borzio et al. 
(1998) demonstrated that a high hepatocyte proliferation rate detected by AgNORs is a 
major risk factor for HCC development in the cirrhotic liver. Therefore, they indicated that 
the evaluation of the hepatocyte proliferation rate is very important to identify patients 
requiring stricter follow-up program for early diagnosis of HCC. High AgNOR count in 
cirrhotic liver as a marker of regenerative capacity has been associated with a significantly 
increased incidence in development of HCC in chronic liver disease (Derenzini et al., 1993). 
However, in liver cirrhosis, dysplasia had a significant relationship with ploidy and 
AgNORs. So, the incidence of high AgNORs count, dysplasia, and presence of aneuploidy 
by DNA flow cytometry suggest that liver cirrhosis may be considered as a more serious 
condition in the evolution of HCC.  
Recently, we compared the results of DNA flow cytometry and AgNORs with the 
histopathological data. It was found that the lowest mean AgNOR count per nucleus was 
found in the normal liver (1.3± 0.9) and the highest count was (3.89± 0.827) in tumor lesion 
of HCC (Attallah et al., 2009b). A gradual increase in the AgNOR count per nucleus was 
noted as disease progressed from normal liver through liver cirrhosis to HCC tumor lesions. 
Analysis of AgNOR counts showed a significant difference between tumor and residual 
liver tissues of HCC or normal liver (P < 0.001) and this is in agreement with several studies 
(Shemizu  et al., 1995; Siddiqui  et al., 1999; Politi et al., 2004).  However, Chen et al. (2003) 
revealed that AgNOR area and AgNOR area-count ratio are the most valuable features for 
differential diagnosis of normal, preneoplastic, and cancer cells. Spolidorio et al. (2002) 
found that the morphometric results were statistically different for normal mucosa, 
dysplasia, and microinvasive oral carcinoma and they concluded that an increase of NOR 
activity follows the disease progression and may reflect the degree of cellular proliferation 
and malignancy. Siddiqui et al. (1999) revealed a gradual increase in mean AgNOR counts 
from normal liver through cirrhosis to HCC. The difference in NOR counts was significant 
in these three groups. The hepatocellular carcinomas were graded according to the 
Edmondson-Steiner histological grading system. Grade I hepatocellular carcinomas show 
AgNOR counts ranging between 5 and 6/cell, a score that is much higher than in the normal 
liver, where it ranges between 1.2 and 2.0/cell. This technique can be used to assess the 
lesions where the distinction between normal liver and grade I HCC is difficult with the use 
of routine methods, on the light of the hypothesis of a relationship between the 
development of carcinoma and an increased cell proliferation, presumably by an increase of 
random mutations (Jain et al., 2010; Tarao  et al., 1994a). So, quantification of AgNOR is 
considered to have putative relationship with ploidy in HCC. Our study presents 
complementary methods to histopathology, which are valuable to pathologists, when they 
have difficulty in diagnosis of early stages of HCC on the basis of liver biopsy. Finally, both 
AgNORs count and DNA ploidy analysis are useful and valuable indicators of cellular 
kinetics in HCC. 
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8. Conclusion remarks and future research 
The assessment of cellular kinetics of liver biopsies is of great importance for understanding 
the development and diagnosis of liver disease. Flow cytometric analyses of ploidy and cell 
cycle were one of the first applications of flow cytometry and this technique remains the 
only rapid and efficient means of making such measurement particularly for core liver 
biopsies. AgNOR proteins are a set of argyrophilic nucleolar proteins that accumulate in 
highly proliferating cells, whereas their expression is very low in nonproliferating cells. The 
AgNOR tissue marker can be used as a routine complementary histopathologic study and 
DNA ploidy by flow cytometry, since the variations in its number and distribution indicate 
existence of cell alterations in a given lesion and the use of this technique is easy and 
inexpensive. Diagnosis of HCC using both DNA ploidy and mean AgNORs are useful in the 
detection of cellular and structural abnormalities. However, further research are required to 
confirm the relationship between viral infections such as HCV and cancer,  cell proliferation  
and apoptosis based on liver biopsies from patients cirrhosis and HCC. 
The detection of viral antigens based on specific monoclonal antibodies and/or the detection 
of viral hepatitis nucleic acids such as HCV RNA and HBV DNA in the liver biopsies and its 
relation to cell cycle analyses measured by flow cytometry will be the future research in this 
field.  
9. Acknowledgment 
This work was partially funded through the Science and Technology Development Fund 
(STDF), Egypt "Grant no. 894" to Dr. Ashraf Tabll. 
10. References 
Afdhal NH., & Manning D. (2008). Diagnosis of liver fibrosis in 2008 and beyond. 
Gastroentérol Clin Bio 32: 88-90. 
Alkofer B., Lepennec V., & Chiche L. (2011). Hepatocellular cancer in the non-cirrhotic liver. 
J Visc Sur, 148, 3—11. 
Andrisani OM., Studach L., & Merle L. (2011). Gene signatures in hepatocellular carcinoma 
(HCC). Seminars Canc Biol, 21: 4–9. 
Anthony PP., Vogel CL., & Barker LF. (1973). Liver cell dysplasia: a premalignant condition. 
J Clin Pathol, 26(3), 217-23. PMID: 4700503  
Arora B., Jain R., Kumar S., Rekhi B., Arora H., & Arora DR. (2002). Morphometric analysis 
of AgNORs in the lymph node lesions. Adv Clin Path, 6(2):95-99. 
Attallah AM., Shiha G., Ismail H., Mansy SE., El-Sherbiny RE., & El-Dosoky I. (2009a). 
Expression of p53 protein in liver and sera of patients with liver fibrosis, cirrhosis 
or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem, 
42: 455-461. 
Attallah AM., Tabll AA., El-Nashar E., El-Bakry KA., El-Sadany M., Ibrahim T., & El-Dosoky 
I. (2009b). AgNORs count and DNA ploidy in liver biopsies from patients with 
schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Biochem, 42(16-
17):1616-20. 
Attallah AM., Tabll AA., Salem SF., El-Sadany M., Ibrahim TA., Osman S., & El-Dosoky I. 
(1999). DNA ploidy of liver biopsies from patients with liver cirrhosis and 
  
Liver Biopsy 
 
100 
trophoblastic disease, which indicated that mean AgNOR is a reflection of ploidy and 
proliferative activities (Maier et al., 1990). However, in contrast to immunohistochemical 
methods merely determining the growth fraction of the cells by Ki-67 and proliferating 
cell nuclear antigen (PCNA) analysis AgNORs apparently reflect time-related 
proliferation rates and ploidy. Thus, AgNOR analysis may provide further insights 
concerning the biological behavior of the cell and is simple, inexpensive, and reliable 
method of evaluating the proliferative activity and ploidy of the cell (Meng et al., 1996). 
Celikel (1995) found a correlation between mean AgNOR and ploidy and proliferation 
activity of urinary bladder tumor as measured by DNA flow cytometry. Also, Borzio et al. 
(1998) demonstrated that a high hepatocyte proliferation rate detected by AgNORs is a 
major risk factor for HCC development in the cirrhotic liver. Therefore, they indicated that 
the evaluation of the hepatocyte proliferation rate is very important to identify patients 
requiring stricter follow-up program for early diagnosis of HCC. High AgNOR count in 
cirrhotic liver as a marker of regenerative capacity has been associated with a significantly 
increased incidence in development of HCC in chronic liver disease (Derenzini et al., 1993). 
However, in liver cirrhosis, dysplasia had a significant relationship with ploidy and 
AgNORs. So, the incidence of high AgNORs count, dysplasia, and presence of aneuploidy 
by DNA flow cytometry suggest that liver cirrhosis may be considered as a more serious 
condition in the evolution of HCC.  
Recently, we compared the results of DNA flow cytometry and AgNORs with the 
histopathological data. It was found that the lowest mean AgNOR count per nucleus was 
found in the normal liver (1.3± 0.9) and the highest count was (3.89± 0.827) in tumor lesion 
of HCC (Attallah et al., 2009b). A gradual increase in the AgNOR count per nucleus was 
noted as disease progressed from normal liver through liver cirrhosis to HCC tumor lesions. 
Analysis of AgNOR counts showed a significant difference between tumor and residual 
liver tissues of HCC or normal liver (P < 0.001) and this is in agreement with several studies 
(Shemizu  et al., 1995; Siddiqui  et al., 1999; Politi et al., 2004).  However, Chen et al. (2003) 
revealed that AgNOR area and AgNOR area-count ratio are the most valuable features for 
differential diagnosis of normal, preneoplastic, and cancer cells. Spolidorio et al. (2002) 
found that the morphometric results were statistically different for normal mucosa, 
dysplasia, and microinvasive oral carcinoma and they concluded that an increase of NOR 
activity follows the disease progression and may reflect the degree of cellular proliferation 
and malignancy. Siddiqui et al. (1999) revealed a gradual increase in mean AgNOR counts 
from normal liver through cirrhosis to HCC. The difference in NOR counts was significant 
in these three groups. The hepatocellular carcinomas were graded according to the 
Edmondson-Steiner histological grading system. Grade I hepatocellular carcinomas show 
AgNOR counts ranging between 5 and 6/cell, a score that is much higher than in the normal 
liver, where it ranges between 1.2 and 2.0/cell. This technique can be used to assess the 
lesions where the distinction between normal liver and grade I HCC is difficult with the use 
of routine methods, on the light of the hypothesis of a relationship between the 
development of carcinoma and an increased cell proliferation, presumably by an increase of 
random mutations (Jain et al., 2010; Tarao  et al., 1994a). So, quantification of AgNOR is 
considered to have putative relationship with ploidy in HCC. Our study presents 
complementary methods to histopathology, which are valuable to pathologists, when they 
have difficulty in diagnosis of early stages of HCC on the basis of liver biopsy. Finally, both 
AgNORs count and DNA ploidy analysis are useful and valuable indicators of cellular 
kinetics in HCC. 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
101 
8. Conclusion remarks and future research 
The assessment of cellular kinetics of liver biopsies is of great importance for understanding 
the development and diagnosis of liver disease. Flow cytometric analyses of ploidy and cell 
cycle were one of the first applications of flow cytometry and this technique remains the 
only rapid and efficient means of making such measurement particularly for core liver 
biopsies. AgNOR proteins are a set of argyrophilic nucleolar proteins that accumulate in 
highly proliferating cells, whereas their expression is very low in nonproliferating cells. The 
AgNOR tissue marker can be used as a routine complementary histopathologic study and 
DNA ploidy by flow cytometry, since the variations in its number and distribution indicate 
existence of cell alterations in a given lesion and the use of this technique is easy and 
inexpensive. Diagnosis of HCC using both DNA ploidy and mean AgNORs are useful in the 
detection of cellular and structural abnormalities. However, further research are required to 
confirm the relationship between viral infections such as HCV and cancer,  cell proliferation  
and apoptosis based on liver biopsies from patients cirrhosis and HCC. 
The detection of viral antigens based on specific monoclonal antibodies and/or the detection 
of viral hepatitis nucleic acids such as HCV RNA and HBV DNA in the liver biopsies and its 
relation to cell cycle analyses measured by flow cytometry will be the future research in this 
field.  
9. Acknowledgment 
This work was partially funded through the Science and Technology Development Fund 
(STDF), Egypt "Grant no. 894" to Dr. Ashraf Tabll. 
10. References 
Afdhal NH., & Manning D. (2008). Diagnosis of liver fibrosis in 2008 and beyond. 
Gastroentérol Clin Bio 32: 88-90. 
Alkofer B., Lepennec V., & Chiche L. (2011). Hepatocellular cancer in the non-cirrhotic liver. 
J Visc Sur, 148, 3—11. 
Andrisani OM., Studach L., & Merle L. (2011). Gene signatures in hepatocellular carcinoma 
(HCC). Seminars Canc Biol, 21: 4–9. 
Anthony PP., Vogel CL., & Barker LF. (1973). Liver cell dysplasia: a premalignant condition. 
J Clin Pathol, 26(3), 217-23. PMID: 4700503  
Arora B., Jain R., Kumar S., Rekhi B., Arora H., & Arora DR. (2002). Morphometric analysis 
of AgNORs in the lymph node lesions. Adv Clin Path, 6(2):95-99. 
Attallah AM., Shiha G., Ismail H., Mansy SE., El-Sherbiny RE., & El-Dosoky I. (2009a). 
Expression of p53 protein in liver and sera of patients with liver fibrosis, cirrhosis 
or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem, 
42: 455-461. 
Attallah AM., Tabll AA., El-Nashar E., El-Bakry KA., El-Sadany M., Ibrahim T., & El-Dosoky 
I. (2009b). AgNORs count and DNA ploidy in liver biopsies from patients with 
schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Biochem, 42(16-
17):1616-20. 
Attallah AM., Tabll AA., Salem SF., El-Sadany M., Ibrahim TA., Osman S., & El-Dosoky I. 
(1999). DNA ploidy of liver biopsies from patients with liver cirrhosis and 
  
Liver Biopsy 
 
102 
hepatocellular carcinoma: a flow cytometric analysis. Cancer Lett, 142(1):65-69. 
PMID: 10424782 
Attallah AM., Zahran F., Ismail H., Omran M., El-Dosoky I., & Shiha G. (2007). 
Immunochemical identification and detection of serum fibronectin in liver fibrosis 
patients with chronic hepatitis C.  J Immunoassay Immunochem, 28(4): 331-342. 
Baker ME.,  Pelley R. (1995). Hepatic metastases: basic principles and implications for 
radiologists. Radiology, 197(2):329-37.  PMID: 7480672 
Ballardini G., Groff P., Zoli M., Bianchi G., Giostra F., Francesconi R., Lenzi M., Zauli D., 
Cassani F., & Bianchi F. (1994). Increased risk of hepatocellular carcinoma 
development in patients with cirrhosis and with high hepatocellular proliferation. J 
Hepatol, 20(2):218-22. PMID: 7911817 
Barwick K., Rosai J., (1996). Liver. In: Ackerman's Surgical Pathology, 8th ed. J. Rosai, pp. 857, 
Mosby-Year Book, New York. 
Borzio M., Trere D., Borzio F., Ferrari A., Bruno S., Roncalli M., Colloredo G., Leandro G., 
Oliveri F., & Derenzini M. (1998). Hepatocyte proliferation rate is a powerful 
parameter for predicting hepatocellular carcinoma development in liver cirrhosis. 
Mol Pathol, 51(2):96–101. 
Bruix J., Boix L., Sala M., & Llovet JM. (2004). Focus on hepatocellular carcinoma. Cancer 
Cell, 5:215–9. 
But DY., Lai CL., & Yuen MF. (2008). Natural history of hepatitis-related hepatocellular 
carcinoma. World J Gastroenterol, 14(11):1652-6. PMID:18350595 
Celikel C. (1995). DNA Flow cytometric studies and AgNOR counts in patients with 
transitional cell carcinoma of bladder. Eur Urol, 28:152–157. 
Chen M., Lee JC., Lo S., & Shen J. (2003). Argyrophilic nuclear organizer regions in  
nasopharyngeal carcinoma and paraneoplastic epithelia. Head Neck, 25(5):395–399. 
Chen MF., Hwang TL., Tsao KC., Sun CF., & Chen TJ. (1991). Flow cytometric DNA analysis 
of hepatocellular carcinoma: preliminary report. Surgery, 109(4):455-8. PMID: 
1706892. 
Cho SH., Godin JM., Chen CH., Qiao W., Lee H., & Lo YH. (2010). Review Article: Recent 
advancements in optofluidic flow cytometer. Biomicrofluidics, 4(4):43001. PMID: 
21267434. 
Clemente C., Elba S., Buongiorno G., Guerra V., D'Attoma B., Orlando A., & Russo F. (2007). 
Manganese superoxide dismutase activity and incidence of hepatocellular 
carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up 
study. Liver Int, 27(6):791-797. PMID: 17617122. 
Colecchia A., Scaioli E., Montrone L., Vestito A., Di Biase AR., Pieri M., D'Errico-Grigioni A., 
Bacchi-Reggiani ML., Ravaioli M., Grazi GL., & Festi D. (2011). Pre-operative liver 
biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe 
and accurate diagnostic tool for tumour grading assessment. J Hepatol, 54(2):300–
305. PMID: 21056498. 
Crocker J., McGovern J. (1988). Nucleolar organizer region in normal, cirrhotic, and 
carcinomatous livers. J Clin Pathol 41:1044–1048. 
Crocker J., Skilbeck N. (1987). Nucleolar organizer region associated proteins in cutaneous 
melanocytic lesions: a quantitative study. J Clin Pathol, 40: 885–889. 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
103 
Crocker J. (1992). Nucleolar organizer regions (NORs) in neoplasms. In: Oxford text book of 
pathology vol 1. McGee JD, Issacson PG, et al, eds. pp. 586-590. Oxford university 
press; Oxford. 
D’Amico F., Schwartz ME., Vitale A., Tabrizian P., Roayaie S., Thung S., Guido M., del Rio 
Martin J., Schiano T., & Cillo U. (2009). Predicting recurrence after liver 
transplantation in patients with hepatocellular carcinoma exceeding the up-to 
seven criteria. Liver Transpl, 15(10):1278–1287. 
Darzynkiewicz Z., Halicka HD., & Zhao H. (2010). Analysis of cellular DNA content by flow 
and laser scanning cytometry. Adv Exp Med Biol, 676:137-147. PMID: 20687474. 
Darzynkiewicz Z., Traganos F., Zhao H., Halicka HD., & Li J. (2011). Cytometry of DNA 
replication and RNA synthesis: Historical perspective and recent advances based 
on "click chemistry". Cytometry A, In press.  PMID: 21425239. 
de Tute RM. (2011). Flow cytometry and its use in the diagnosis and management of mature 
lymphoid malignancies. Histopathology 58(1):90-105. PMID: 21261686 
Derenzini M., & Ploton D. (1991). Interphase nucleolar organizer region in cancer cells. Int 
Rev Exp Pathol, 32:149–152. 
Derenzini M., Trerè D., Oliveri F., David E., Colombatto P., Bonino F., & Brunetto MR. 
(1993). Is high AgNOR quantity in hepatocytes associated with increased risk of 
hepatocellular carcinoma in chronic liver disease?. J Clin Pathol 46(8):727–729. 
Dundar M., Kiraz A., Tasdemir S., Akalin H., Kurtoglu S., Hafo F., Cine N., & Savli H. 
(2010). Unbalanced 3;22 translocation with 22q11 and 3p deletion syndrome. Am J 
Med Genet A, 152A(11):2791-5. PMID: 20949503 
El-Sayed SS., El-Sadany M., Tabll AA., Soltan A., El-Dosoky I., & Attallah AM. (2004). DNA 
ploidy and liver cell dysplasia in liver biopsies from patients with liver cirrhosis. 
Can J Gastroenterol, 18(2):87-91. PMID: 14997216. 
Fariña RA., Becar M., Plaza C., Espinoza I., & Franco ME. (2011). Relation between single 
photon emission computed tomography, AgNOR count, and histomorphologic 
features in patients with active mandibular condylar hyperplasia. J Oral Maxillofac 
Surg, 69(2):356-361. PMID: 21122972 
Fukushi D., Watanabe N., Kasai F., Haruta M., Kikuchi A., Kikuta A., Kato K., Nakadate H., 
Tsunematsu Y., & Kaneko Y. (2009). Centrosome amplification is correlated with 
ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors. 
Cancer Genet Cytogenet, 188(1):32-41. 
Giri D., Nottingham J., Lawry J., Dundas S., & Underwood J. (1989). Silver binding nucleolar 
organizer regions (AgNORs) in benign and malignant breast lesions: correlation 
with ploidy and growth phase by DNA flow cytometry. J Pathol, 157:307–313. 
Halfon P., Munteanu M., & Poynard T. (2008). FibroTest-ActiTest as a non-invasive marker 
of liver fibrosis. Gastroentérol Clin Bio, 32:22-39. 
Hayashi Y., Kanda N., Inaba T., Hanada R., Nagahara N., Muchi H., & Yamamoto K. (1989). 
Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker 
chromosome 1. Cancer, 63(1):126-32. PMID: 2910410. 
Henmi A., Uchida T., & Shikata T. (1985). Karyometric analysis of liver cell dysplasia and 
hepatocellular carcinoma. Evidence against precancerous nature of liver cell 
dysplasia. Cancer, 55(11):2594-9. PMID: 2986818 
Hiddemann W., Schumann J., Andreef M., Barlogie B., Herman CJ., Leif RC., Mayall BH., 
Murphy RF., & Sandberg AA. (1984). Convention on nomenclature for DNA 
  
Liver Biopsy 
 
102 
hepatocellular carcinoma: a flow cytometric analysis. Cancer Lett, 142(1):65-69. 
PMID: 10424782 
Attallah AM., Zahran F., Ismail H., Omran M., El-Dosoky I., & Shiha G. (2007). 
Immunochemical identification and detection of serum fibronectin in liver fibrosis 
patients with chronic hepatitis C.  J Immunoassay Immunochem, 28(4): 331-342. 
Baker ME.,  Pelley R. (1995). Hepatic metastases: basic principles and implications for 
radiologists. Radiology, 197(2):329-37.  PMID: 7480672 
Ballardini G., Groff P., Zoli M., Bianchi G., Giostra F., Francesconi R., Lenzi M., Zauli D., 
Cassani F., & Bianchi F. (1994). Increased risk of hepatocellular carcinoma 
development in patients with cirrhosis and with high hepatocellular proliferation. J 
Hepatol, 20(2):218-22. PMID: 7911817 
Barwick K., Rosai J., (1996). Liver. In: Ackerman's Surgical Pathology, 8th ed. J. Rosai, pp. 857, 
Mosby-Year Book, New York. 
Borzio M., Trere D., Borzio F., Ferrari A., Bruno S., Roncalli M., Colloredo G., Leandro G., 
Oliveri F., & Derenzini M. (1998). Hepatocyte proliferation rate is a powerful 
parameter for predicting hepatocellular carcinoma development in liver cirrhosis. 
Mol Pathol, 51(2):96–101. 
Bruix J., Boix L., Sala M., & Llovet JM. (2004). Focus on hepatocellular carcinoma. Cancer 
Cell, 5:215–9. 
But DY., Lai CL., & Yuen MF. (2008). Natural history of hepatitis-related hepatocellular 
carcinoma. World J Gastroenterol, 14(11):1652-6. PMID:18350595 
Celikel C. (1995). DNA Flow cytometric studies and AgNOR counts in patients with 
transitional cell carcinoma of bladder. Eur Urol, 28:152–157. 
Chen M., Lee JC., Lo S., & Shen J. (2003). Argyrophilic nuclear organizer regions in  
nasopharyngeal carcinoma and paraneoplastic epithelia. Head Neck, 25(5):395–399. 
Chen MF., Hwang TL., Tsao KC., Sun CF., & Chen TJ. (1991). Flow cytometric DNA analysis 
of hepatocellular carcinoma: preliminary report. Surgery, 109(4):455-8. PMID: 
1706892. 
Cho SH., Godin JM., Chen CH., Qiao W., Lee H., & Lo YH. (2010). Review Article: Recent 
advancements in optofluidic flow cytometer. Biomicrofluidics, 4(4):43001. PMID: 
21267434. 
Clemente C., Elba S., Buongiorno G., Guerra V., D'Attoma B., Orlando A., & Russo F. (2007). 
Manganese superoxide dismutase activity and incidence of hepatocellular 
carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up 
study. Liver Int, 27(6):791-797. PMID: 17617122. 
Colecchia A., Scaioli E., Montrone L., Vestito A., Di Biase AR., Pieri M., D'Errico-Grigioni A., 
Bacchi-Reggiani ML., Ravaioli M., Grazi GL., & Festi D. (2011). Pre-operative liver 
biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe 
and accurate diagnostic tool for tumour grading assessment. J Hepatol, 54(2):300–
305. PMID: 21056498. 
Crocker J., McGovern J. (1988). Nucleolar organizer region in normal, cirrhotic, and 
carcinomatous livers. J Clin Pathol 41:1044–1048. 
Crocker J., Skilbeck N. (1987). Nucleolar organizer region associated proteins in cutaneous 
melanocytic lesions: a quantitative study. J Clin Pathol, 40: 885–889. 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
103 
Crocker J. (1992). Nucleolar organizer regions (NORs) in neoplasms. In: Oxford text book of 
pathology vol 1. McGee JD, Issacson PG, et al, eds. pp. 586-590. Oxford university 
press; Oxford. 
D’Amico F., Schwartz ME., Vitale A., Tabrizian P., Roayaie S., Thung S., Guido M., del Rio 
Martin J., Schiano T., & Cillo U. (2009). Predicting recurrence after liver 
transplantation in patients with hepatocellular carcinoma exceeding the up-to 
seven criteria. Liver Transpl, 15(10):1278–1287. 
Darzynkiewicz Z., Halicka HD., & Zhao H. (2010). Analysis of cellular DNA content by flow 
and laser scanning cytometry. Adv Exp Med Biol, 676:137-147. PMID: 20687474. 
Darzynkiewicz Z., Traganos F., Zhao H., Halicka HD., & Li J. (2011). Cytometry of DNA 
replication and RNA synthesis: Historical perspective and recent advances based 
on "click chemistry". Cytometry A, In press.  PMID: 21425239. 
de Tute RM. (2011). Flow cytometry and its use in the diagnosis and management of mature 
lymphoid malignancies. Histopathology 58(1):90-105. PMID: 21261686 
Derenzini M., & Ploton D. (1991). Interphase nucleolar organizer region in cancer cells. Int 
Rev Exp Pathol, 32:149–152. 
Derenzini M., Trerè D., Oliveri F., David E., Colombatto P., Bonino F., & Brunetto MR. 
(1993). Is high AgNOR quantity in hepatocytes associated with increased risk of 
hepatocellular carcinoma in chronic liver disease?. J Clin Pathol 46(8):727–729. 
Dundar M., Kiraz A., Tasdemir S., Akalin H., Kurtoglu S., Hafo F., Cine N., & Savli H. 
(2010). Unbalanced 3;22 translocation with 22q11 and 3p deletion syndrome. Am J 
Med Genet A, 152A(11):2791-5. PMID: 20949503 
El-Sayed SS., El-Sadany M., Tabll AA., Soltan A., El-Dosoky I., & Attallah AM. (2004). DNA 
ploidy and liver cell dysplasia in liver biopsies from patients with liver cirrhosis. 
Can J Gastroenterol, 18(2):87-91. PMID: 14997216. 
Fariña RA., Becar M., Plaza C., Espinoza I., & Franco ME. (2011). Relation between single 
photon emission computed tomography, AgNOR count, and histomorphologic 
features in patients with active mandibular condylar hyperplasia. J Oral Maxillofac 
Surg, 69(2):356-361. PMID: 21122972 
Fukushi D., Watanabe N., Kasai F., Haruta M., Kikuchi A., Kikuta A., Kato K., Nakadate H., 
Tsunematsu Y., & Kaneko Y. (2009). Centrosome amplification is correlated with 
ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors. 
Cancer Genet Cytogenet, 188(1):32-41. 
Giri D., Nottingham J., Lawry J., Dundas S., & Underwood J. (1989). Silver binding nucleolar 
organizer regions (AgNORs) in benign and malignant breast lesions: correlation 
with ploidy and growth phase by DNA flow cytometry. J Pathol, 157:307–313. 
Halfon P., Munteanu M., & Poynard T. (2008). FibroTest-ActiTest as a non-invasive marker 
of liver fibrosis. Gastroentérol Clin Bio, 32:22-39. 
Hayashi Y., Kanda N., Inaba T., Hanada R., Nagahara N., Muchi H., & Yamamoto K. (1989). 
Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker 
chromosome 1. Cancer, 63(1):126-32. PMID: 2910410. 
Henmi A., Uchida T., & Shikata T. (1985). Karyometric analysis of liver cell dysplasia and 
hepatocellular carcinoma. Evidence against precancerous nature of liver cell 
dysplasia. Cancer, 55(11):2594-9. PMID: 2986818 
Hiddemann W., Schumann J., Andreef M., Barlogie B., Herman CJ., Leif RC., Mayall BH., 
Murphy RF., & Sandberg AA. (1984). Convention on nomenclature for DNA 
  
Liver Biopsy 
 
104 
cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer 
Genet Cytogenet, 13(2):181-3. PMID: 6478442 
Hoso M., & Nakanuma Y. (1991). Cytophotometric DNA analysis of adenomatous 
hyperplasia in cirrhotic livers. Virchows Arch A Pathol Anat Histopathol, 418(5):401-
404. PMID: 1852083 
Howat AJ., Giri DD., Cotton DW., Slater DN. (1989). Nucleolar Organizer Regions in spitz 
nevi and malignant melanomas. Cancer, 63:474-478. 
Howell, WM. (1982). Selective staining of nucleolus organizer regions (NORs). In: The cell 
nucleus. Busch, H., & Rothblum, L. (Eds.), pp. 89–143, Academic press, New York. 
Ismail H., Al-Zahrany SA., Al-Ghamedy ZS., & Radway ON. (2010). Simple and rapid 
identification of liver status in HCV infection using blood biochemical markers. 
2010. Proceedings of the 25th annual meeting of the Saudi biological society, King Faisal 
University, Al-Hasa, Saudi Arabia, May 2010. 
Jagan S., Ramakrishnan G., Anandakumar P., Kamaraj S., & Devaki T. (2008). 
Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat 
hepatocellular carcinoma. Mol Cell Biochem, 319(1-2):51–59. 
Jain R., Malhotra V., Kumar N., & Sarin S. (1998). Nucleolar Organizer region in cirrhosis 
and hepatocellular carcinoma. Trop Gastroenterol, 19(3): 100–101. 
Jain S., Singhal S., Lee P., & Xu R. (2010). Molecular genetics of hepatocellular neoplasia. Am 
J Transl Res, 2(1):105-18. PMID:20182587. 
Kato A., Kubo K., Kurokawa F., Okita K., Oga A., & Murakami T. (1998). Numerical 
aberrations of chromosomes 16, 17, and 18 in hepatocellular carcinoma: a FISH and 
FCM analysis of 20 cases. Dig Dis Sci, 43(1):1-7. PMID: 9508509 
Khan N., Sood P., Vasenwala SM., Afroz N., & Verma AK. (2006). Significance of AgNOR 
score in benign and malignant soft tissue tumours. Indian J Pathol Microbiol, 
49(1):17–20. 
Kocjan G. (2010). Fine needle aspiration cytology of the pancreas: a guide to the diagnostic 
approach. Coll Antropol, 34(2):749-56. PMID: 20698166. 
Kummoona R., Jabbar A., & Kareem Al-Rahal D. (2008). Proliferative activity in oral 
carcinomas studied with Ag-NOR and electron microscopy. Ultrastruct Pathol, 
32(4):139–146. 
Kuo FY., Chen WJ., Lu SN., Wang JH., & Eng HL. (2004). Fine needle aspiration 
cytodiagnosis of liver tumors. Acta Cytol 48(2):142-8. PMID:15085744. 
Landini G. (1990). Nucleolar organizing regions (NORs) in pleomorphic adenomas of the 
salivary glands. J Oral Pathol Med, 19:257-260. 
Lee RG., Tsamandas AC., & Demetris AJ. (1997). Large cell change (liver cell dysplasia) and 
hepatocellular carcinoma in cirrhosis: matched case-control study, pathological 
analysis, and pathogenetic hypothesis. Hepatology, 26(6):1415-1422. PMID: 9397980. 
Libbrecht L., Cassiman D., Verslype C., Maleux G., Van Hees D., Pirenne J., Nevens F., & 
Roskams T. (2006). Clinicopathological features of focal nodular hyperplasia-like 
nodules in 130 cirrhotic explant livers. Am J Gastroenterol, 101(10):2341-2346. PMID: 
17032200. 
Libbrecht L., Craninx M., Nevens F., Desmet V., & Roskams T. (2001). Predictive value of 
liver cell dysplasia for development of hepatocellular carcinoma in patients with 
non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology, 39(1):66-73. PMID: 
11454046. 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
105 
Ligato S., Mandich D., & Cartun RW. (2008). Utility of glypican-3 in differentiating 
hepatocellular carcinoma from other primary and metastatic lesions in FNA of the 
liver: an immunocytochemical study. Mod Pathol, 21(5):626-31. PMID:18264086  
Lin HH., Shyu WC., Chen GL., Lin YH., Chen TJ., & Liaw YF. (1990). DNA measurements in 
chronic hepatitis, cirrhosis and hepatocellular carcinoma. Liver, 10(5):313-8. PMID: 
2175006. 
Lindner L. (1993). Improvements in the silver-staining technique for nucleolar organizer 
regions (AgNORs). J Histochem Cytochem, 41:439–445. 
Llovet JM., & Bruix J. (2008). Molecular targeted therapies in hepatocellular carcinoma. 
Hepatology, 48:1312–1327. 
Llovet JM., Burroughs A.,  & Bruix J. (2003). Hepatocellular carcinoma. Lancet, 362:1907–
1917. 
Llovet JM., Di Bisceglie AM., Bruix J., Kramer BS., Lencioni R., Zhu AX., Sherman M., 
Schwartz M., Lotze M., Talwalkar J., Gores GJ., & Panel of Experts in HCC-Design 
Clinical Trials. (2008). Design and endpoints of clinical trials in hepatocellular 
carcinoma. J Natl Cancer Inst, 100(10):698–711. PMID: 18477802. 
López-Otero A., Ruiz-Delgado GJ., Hernández-Arizpe A., Ruiz-Argüelles A., & Ruiz-
Argüelles GJ. (2010). The flow-cytometric DNA content of the plasma cells of 
patients with multiple myeloma is a prognostic factor: a single institution 
experience. Hematology, 15(6):378-381. PMID:21114899. 
Maier U., Morimura M., & Ofner L. (1990). Argyrophilic nucleolar organizer regions 
(AgNORs) in human brain tumor: Relation with grade of malignancy and 
proliferative indices. Acta Neuropathol, 80:156–162. 
Maletz N., McMorrow LE., Greco A., & Wolman SR. (1986). Ewing's sarcoma. Pathology, 
tissue culture, and cytogenetics. Cancer, 58(2):252-257. PMID: 3719518. 
Meng F., Giwereman A., & Skakkebaek W. (1996). Investigation of carcinoma in situ cells of 
testis by quantification of argyrophilic nucleolar organizer region associated 
protein (AgNORs). J Pathol, 180:206–2013. 
Mikow P., Kanavaros P., & Gorgoulis B. (1993). Nucleolar organizer region staining and 
proliferating cell nuclear antigen (PCNA) immunostaining in mucosa associated 
lymphoid tissue. Pathol Res Pract, 189:1004–1009. 
Mise K., Tashiro S., Yogita S., Wada D., Harada M., Fukuda Y., Miyake H., Isikawa M., 
Izumi K., & Sano N. (1998). Assessment of the biological malignancy of 
hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. 
Clin Cancer Res, 4(6):1475-1482. PMID: 9626465. 
Munakata S., & Hendricks J. (1994). Multilabelling technique for simultaneous 
demonstration and quantitation of Ki-67 and nucleolar organizer regions 
(AgNORs) in paraffin embedded tissue. J Histochem Cytochem, 42: 789–793. 
Munteanu M., Morra R., Imbert-Bismut F., Messous D., Thabut D., & Lebray P. (2008). 
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, 
could be improved by respecting the analytical standardizations. Clin Biochem, 
41:1113–1114. 
Nagao T., Ishida Y., Yamazaki K., & Kondo Y. (1995). Nucleolar organizer regions in 
hepatocellular carcinoma related to the cell cycle, cell proliferation and histologic 
grade. Pathol Res Pract, 191(10):967–972. 
  
Liver Biopsy 
 
104 
cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer 
Genet Cytogenet, 13(2):181-3. PMID: 6478442 
Hoso M., & Nakanuma Y. (1991). Cytophotometric DNA analysis of adenomatous 
hyperplasia in cirrhotic livers. Virchows Arch A Pathol Anat Histopathol, 418(5):401-
404. PMID: 1852083 
Howat AJ., Giri DD., Cotton DW., Slater DN. (1989). Nucleolar Organizer Regions in spitz 
nevi and malignant melanomas. Cancer, 63:474-478. 
Howell, WM. (1982). Selective staining of nucleolus organizer regions (NORs). In: The cell 
nucleus. Busch, H., & Rothblum, L. (Eds.), pp. 89–143, Academic press, New York. 
Ismail H., Al-Zahrany SA., Al-Ghamedy ZS., & Radway ON. (2010). Simple and rapid 
identification of liver status in HCV infection using blood biochemical markers. 
2010. Proceedings of the 25th annual meeting of the Saudi biological society, King Faisal 
University, Al-Hasa, Saudi Arabia, May 2010. 
Jagan S., Ramakrishnan G., Anandakumar P., Kamaraj S., & Devaki T. (2008). 
Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat 
hepatocellular carcinoma. Mol Cell Biochem, 319(1-2):51–59. 
Jain R., Malhotra V., Kumar N., & Sarin S. (1998). Nucleolar Organizer region in cirrhosis 
and hepatocellular carcinoma. Trop Gastroenterol, 19(3): 100–101. 
Jain S., Singhal S., Lee P., & Xu R. (2010). Molecular genetics of hepatocellular neoplasia. Am 
J Transl Res, 2(1):105-18. PMID:20182587. 
Kato A., Kubo K., Kurokawa F., Okita K., Oga A., & Murakami T. (1998). Numerical 
aberrations of chromosomes 16, 17, and 18 in hepatocellular carcinoma: a FISH and 
FCM analysis of 20 cases. Dig Dis Sci, 43(1):1-7. PMID: 9508509 
Khan N., Sood P., Vasenwala SM., Afroz N., & Verma AK. (2006). Significance of AgNOR 
score in benign and malignant soft tissue tumours. Indian J Pathol Microbiol, 
49(1):17–20. 
Kocjan G. (2010). Fine needle aspiration cytology of the pancreas: a guide to the diagnostic 
approach. Coll Antropol, 34(2):749-56. PMID: 20698166. 
Kummoona R., Jabbar A., & Kareem Al-Rahal D. (2008). Proliferative activity in oral 
carcinomas studied with Ag-NOR and electron microscopy. Ultrastruct Pathol, 
32(4):139–146. 
Kuo FY., Chen WJ., Lu SN., Wang JH., & Eng HL. (2004). Fine needle aspiration 
cytodiagnosis of liver tumors. Acta Cytol 48(2):142-8. PMID:15085744. 
Landini G. (1990). Nucleolar organizing regions (NORs) in pleomorphic adenomas of the 
salivary glands. J Oral Pathol Med, 19:257-260. 
Lee RG., Tsamandas AC., & Demetris AJ. (1997). Large cell change (liver cell dysplasia) and 
hepatocellular carcinoma in cirrhosis: matched case-control study, pathological 
analysis, and pathogenetic hypothesis. Hepatology, 26(6):1415-1422. PMID: 9397980. 
Libbrecht L., Cassiman D., Verslype C., Maleux G., Van Hees D., Pirenne J., Nevens F., & 
Roskams T. (2006). Clinicopathological features of focal nodular hyperplasia-like 
nodules in 130 cirrhotic explant livers. Am J Gastroenterol, 101(10):2341-2346. PMID: 
17032200. 
Libbrecht L., Craninx M., Nevens F., Desmet V., & Roskams T. (2001). Predictive value of 
liver cell dysplasia for development of hepatocellular carcinoma in patients with 
non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology, 39(1):66-73. PMID: 
11454046. 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
105 
Ligato S., Mandich D., & Cartun RW. (2008). Utility of glypican-3 in differentiating 
hepatocellular carcinoma from other primary and metastatic lesions in FNA of the 
liver: an immunocytochemical study. Mod Pathol, 21(5):626-31. PMID:18264086  
Lin HH., Shyu WC., Chen GL., Lin YH., Chen TJ., & Liaw YF. (1990). DNA measurements in 
chronic hepatitis, cirrhosis and hepatocellular carcinoma. Liver, 10(5):313-8. PMID: 
2175006. 
Lindner L. (1993). Improvements in the silver-staining technique for nucleolar organizer 
regions (AgNORs). J Histochem Cytochem, 41:439–445. 
Llovet JM., & Bruix J. (2008). Molecular targeted therapies in hepatocellular carcinoma. 
Hepatology, 48:1312–1327. 
Llovet JM., Burroughs A.,  & Bruix J. (2003). Hepatocellular carcinoma. Lancet, 362:1907–
1917. 
Llovet JM., Di Bisceglie AM., Bruix J., Kramer BS., Lencioni R., Zhu AX., Sherman M., 
Schwartz M., Lotze M., Talwalkar J., Gores GJ., & Panel of Experts in HCC-Design 
Clinical Trials. (2008). Design and endpoints of clinical trials in hepatocellular 
carcinoma. J Natl Cancer Inst, 100(10):698–711. PMID: 18477802. 
López-Otero A., Ruiz-Delgado GJ., Hernández-Arizpe A., Ruiz-Argüelles A., & Ruiz-
Argüelles GJ. (2010). The flow-cytometric DNA content of the plasma cells of 
patients with multiple myeloma is a prognostic factor: a single institution 
experience. Hematology, 15(6):378-381. PMID:21114899. 
Maier U., Morimura M., & Ofner L. (1990). Argyrophilic nucleolar organizer regions 
(AgNORs) in human brain tumor: Relation with grade of malignancy and 
proliferative indices. Acta Neuropathol, 80:156–162. 
Maletz N., McMorrow LE., Greco A., & Wolman SR. (1986). Ewing's sarcoma. Pathology, 
tissue culture, and cytogenetics. Cancer, 58(2):252-257. PMID: 3719518. 
Meng F., Giwereman A., & Skakkebaek W. (1996). Investigation of carcinoma in situ cells of 
testis by quantification of argyrophilic nucleolar organizer region associated 
protein (AgNORs). J Pathol, 180:206–2013. 
Mikow P., Kanavaros P., & Gorgoulis B. (1993). Nucleolar organizer region staining and 
proliferating cell nuclear antigen (PCNA) immunostaining in mucosa associated 
lymphoid tissue. Pathol Res Pract, 189:1004–1009. 
Mise K., Tashiro S., Yogita S., Wada D., Harada M., Fukuda Y., Miyake H., Isikawa M., 
Izumi K., & Sano N. (1998). Assessment of the biological malignancy of 
hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. 
Clin Cancer Res, 4(6):1475-1482. PMID: 9626465. 
Munakata S., & Hendricks J. (1994). Multilabelling technique for simultaneous 
demonstration and quantitation of Ki-67 and nucleolar organizer regions 
(AgNORs) in paraffin embedded tissue. J Histochem Cytochem, 42: 789–793. 
Munteanu M., Morra R., Imbert-Bismut F., Messous D., Thabut D., & Lebray P. (2008). 
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, 
could be improved by respecting the analytical standardizations. Clin Biochem, 
41:1113–1114. 
Nagao T., Ishida Y., Yamazaki K., & Kondo Y. (1995). Nucleolar organizer regions in 
hepatocellular carcinoma related to the cell cycle, cell proliferation and histologic 
grade. Pathol Res Pract, 191(10):967–972. 
  
Liver Biopsy 
 
106 
Nunez R., Garay N., Villafane C., Bruno A., & Lindgren V. (2004). Description of a flow 
cytometry approach based on SYBR-14 staining for the assessment of DNA content, 
cell cycle analysis, and sorting of living normal and neoplastic cells. Exp Mol Pathol, 
76(1):29-36. PMID:14738866. 
Nyska I. (1995). Assessment of nucleolar organizer regions by automated image analysis in 
benign and malignant colonic tumors. J Comp Pathol, 113:45–50. 
Pahlavan PS., Feldmann RE., Jr, Zavos C., & Kountouras J. (2006). Prometheus' challenge: 
molecular, cellular and systemic aspects of liver regeneration. J Surg Res, 134(2):238-
251. PMID: 16458925. 
Park YN., & Roncalli M. (2006). Large liver cell dysplasia: a controversial entity. J Hepatol, 
45(5):734-743. PMID: 16982109. 
Parkin DM., Bray F., Ferlay J., & Pisani P. (2001). Estimating the world cancer burden: 
Globocan 2000. Int J Cancer, 94:153–156. 
Parkin DM. (2004). International variation. Oncogene, 23:6329–6340. 
Patton HM., Yates K., Unalp-Arida A., Behling CA., Huang TT., Rosenthal P., Sanyal AJ., 
Schwimmer JB., & Lavine JE. (2010). Association between metabolic syndrome and 
liver histology among children with nonalcoholic fatty liver disease. Am J 
Gastroenterol, 105(9):2093-2102. PMID: 20372110. 
Pawlik TM., Gleisner AL., Anders AR., Assumpcao L., Maley W., & Choti MA. (2007). 
Preoperative assessment of hepatocellular carcinoma tumour grade using needle 
biopsy. Implications for transplant eligibility. Ann Surg, 245: 435–442. 
Pinzani M. (2010). Non-invasive systems for staging compensated cirrhosis. Arab J 
Gastroenterol, 10: S32–S34. 
Politi EN., Lazaris AC., Alexopoulou D., Lambropoulou S., Kavantzas N., & Koutselini H. 
(2004). Morphometric analysis of AgNORs in thin-layer, liquidbased liver 
specimens. Anal Quant Cytol Histol, 26(4):187–193. 
Poynard T., Yuen MF., Ratziu V., & Lai CL. (2003). Viral hepatitis C. Lancet, 362:2095–2100. 
Quinn CM., & Wright NA. (1990). The clinical assessment of proliferation and growth in 
human tumours: evaluation of methods and applications as prognostic variables. J 
Pathol, 160(2):93-102. PMID: 2181096. 
Raiker A., Green W., Shabaik A., & Perlin E. (1989). Acute promyelocytic leukaemia 
following treatment of non-Hodgkin's lymphoma. Cancer, 63(7):1402-1406. PMID: 
2646008. 
Raikhlin NT., Bukaeva IA., Probatova NA., & Smirnov EA. (2006). Argyrophilic proteins in 
the regions of nucleolar organizers are markers of cell proliferation rate. Arkh Patol, 
68(3):47–51. 
Ritter MA., Albrechtson JL., Kim YJ., & Kinsella TJ. (1994). Tumor cell kinetics in mixed 
populations. Cytometry, 16(2):118-28. PMID:7924680. 
Roncalli M., Borzio M., Brando B., Colloredo G., & Servida E. (1989). Abnormal DNA 
content in liver-cell dysplasia: a flow cytometric study. Int J Cancer, 44(2):204-207. 
PMID: 2759727. 
Roncalli M., Park YN., & Di Tommaso L. (2010). Histopathological classification of 
hepatocellular carcinoma. Dig Liver Dis, 42(3):S228-34. PMID:20547308. 
Ruà S., Comino A., Fruttero A., Torchio P., Bouzari H., Taraglio S., Torchio B., & Capussotti 
L. (1996). Flow cytometric DNA analysis of cirrhotic liver cells in patients with 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
107 
hepatocellular carcinoma can provide a new prognostic factor. Cancer, 78(6):1195-
1202. PMID: 8826940. 
Sanai FM., & Jeeffe EB. (2011). Liver biopsy for histological assessment: the case against. 
Saudi J Gastroenterol, 16(2):124-132. 
Schaffner F. (1991). Structural and functional aspects of regeneration of human liver. Dig Dis 
Sci, 36(9):1282-1286. PMID: 1893815. 
Schwint AE., Folco A., Morales A., Cabrini RL., & Itoiz ME. (1996). AgNOR mark epithelial 
foci undergoing malignant transformation in hamster cheek pouch carcinogenesis. J 
Oral Pathol Med, 25:20-24. 
Shankey T., & Rabinovitch P. (2002). DNA content flow cytometry. In: Manual clinical 
laboratory immunology, sixth edition. Rose N, Hamilton R, Detrick B (ed), p171-184, 
ISBN 1-55581-215-5, ASM press Washinton D.C. 
Shankey TV., Rabinovitch PS., Bagwell B., Bauer KD., Duque RE., Hedley DW., Mayall BH., 
Wheeless L., & Cox C. (1993). Guidelines for implementation of clinical DNA 
cytometry International Society for Analytical Cytology. Cytometry, 14(5):472-7. 
PMID: 8354117. 
Shemizu K., Izumi R., Ii T., Muraoka K., Inoue T., Fukushima W., Sakamoto K., Tani T., 
Hashimoto T., Yagi M., Miyazaki I., & Monomura A. (1995). Prognostic significance 
of nuclear organizer region in  hepatocellular carcinoma. Hepatol,  21:393–397. 
Shimamoto T., Haruma K., Tanaka S., Todo H., Yoshihara M., Sumii K., & Kajiyama G. 
(1993). Usefulness of nucleolar organizer region staining in gastric myogenic 
tumors: correlation with ploidy by DNA flow cytometry. Oncology, 50(1):52-56. 
PMID: 8421598. 
Siddiqui M., Soomro I., Kayani N., Muzaffar S., & Hasan S. (1999). Assessment of nucleolar 
organizer regions (NORs) in proliferative conditions of the liver. Pathol Res Pract, 
195(6):421–426. 
Sirri V., Roussel P., & Hernandez-Verdun D. (2000). The AgNOR proteins: qualitative and 
quantitative changes during the cell cycle. Micron, 31(2):121–126. 
Spolidorio L., Neves K., Soares C., Spolidorio D., Basso M., Malavazzi I., & Almeida O. 
(2002). Evaluation of argyrophilic nucleolar organizer regions in oral tumor 
progression. Micron, 33(7- 8):605–608. 
Tarao K., Hoshino H., Shimizu A., Ohkawa S., Nakamura Y., Harada M., Ito Y., Tamai S., 
Akaike M., & Sugimasa Y. (1994a). Role of increased DNA synthesis activity of 
hepatocytes in multicentric hepatocarcinogenesis in residual liver of 
hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res, 
85(10):1040-1044. PMID: 7961106. 
Tarao K., Ohkawa S., Shimizu A., Harada M., Nakamura Y., Ito Y., Tamai S., Hoshino H., 
Inoue T., & Kanisawa M. (1994b). Significance of hepatocellular proliferation in the 
development of hepatocellular carcinoma from anti-hepatitis C virus-positive 
cirrhotic patients. Cancer, 73(4):1149-1154. PMID: 7508816. 
Thomas RM., Berman JJ., Yetter RA., Moore GW., & Hutchins GM. (1992). Liver cell 
dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol, 
23(5):496-503 PMID: 1314776. 
Tomioka N., Kobayashi H., Kageyama H., Ohira M., Nakamura Y., Sasaki F., Todo S., 
Nakagawara A., & Kaneko Y. (2003). Chromosomes that show partial loss or gain 
in near-diploid tumors coincide with chromosomes that show whole loss or gain in 
  
Liver Biopsy 
 
106 
Nunez R., Garay N., Villafane C., Bruno A., & Lindgren V. (2004). Description of a flow 
cytometry approach based on SYBR-14 staining for the assessment of DNA content, 
cell cycle analysis, and sorting of living normal and neoplastic cells. Exp Mol Pathol, 
76(1):29-36. PMID:14738866. 
Nyska I. (1995). Assessment of nucleolar organizer regions by automated image analysis in 
benign and malignant colonic tumors. J Comp Pathol, 113:45–50. 
Pahlavan PS., Feldmann RE., Jr, Zavos C., & Kountouras J. (2006). Prometheus' challenge: 
molecular, cellular and systemic aspects of liver regeneration. J Surg Res, 134(2):238-
251. PMID: 16458925. 
Park YN., & Roncalli M. (2006). Large liver cell dysplasia: a controversial entity. J Hepatol, 
45(5):734-743. PMID: 16982109. 
Parkin DM., Bray F., Ferlay J., & Pisani P. (2001). Estimating the world cancer burden: 
Globocan 2000. Int J Cancer, 94:153–156. 
Parkin DM. (2004). International variation. Oncogene, 23:6329–6340. 
Patton HM., Yates K., Unalp-Arida A., Behling CA., Huang TT., Rosenthal P., Sanyal AJ., 
Schwimmer JB., & Lavine JE. (2010). Association between metabolic syndrome and 
liver histology among children with nonalcoholic fatty liver disease. Am J 
Gastroenterol, 105(9):2093-2102. PMID: 20372110. 
Pawlik TM., Gleisner AL., Anders AR., Assumpcao L., Maley W., & Choti MA. (2007). 
Preoperative assessment of hepatocellular carcinoma tumour grade using needle 
biopsy. Implications for transplant eligibility. Ann Surg, 245: 435–442. 
Pinzani M. (2010). Non-invasive systems for staging compensated cirrhosis. Arab J 
Gastroenterol, 10: S32–S34. 
Politi EN., Lazaris AC., Alexopoulou D., Lambropoulou S., Kavantzas N., & Koutselini H. 
(2004). Morphometric analysis of AgNORs in thin-layer, liquidbased liver 
specimens. Anal Quant Cytol Histol, 26(4):187–193. 
Poynard T., Yuen MF., Ratziu V., & Lai CL. (2003). Viral hepatitis C. Lancet, 362:2095–2100. 
Quinn CM., & Wright NA. (1990). The clinical assessment of proliferation and growth in 
human tumours: evaluation of methods and applications as prognostic variables. J 
Pathol, 160(2):93-102. PMID: 2181096. 
Raiker A., Green W., Shabaik A., & Perlin E. (1989). Acute promyelocytic leukaemia 
following treatment of non-Hodgkin's lymphoma. Cancer, 63(7):1402-1406. PMID: 
2646008. 
Raikhlin NT., Bukaeva IA., Probatova NA., & Smirnov EA. (2006). Argyrophilic proteins in 
the regions of nucleolar organizers are markers of cell proliferation rate. Arkh Patol, 
68(3):47–51. 
Ritter MA., Albrechtson JL., Kim YJ., & Kinsella TJ. (1994). Tumor cell kinetics in mixed 
populations. Cytometry, 16(2):118-28. PMID:7924680. 
Roncalli M., Borzio M., Brando B., Colloredo G., & Servida E. (1989). Abnormal DNA 
content in liver-cell dysplasia: a flow cytometric study. Int J Cancer, 44(2):204-207. 
PMID: 2759727. 
Roncalli M., Park YN., & Di Tommaso L. (2010). Histopathological classification of 
hepatocellular carcinoma. Dig Liver Dis, 42(3):S228-34. PMID:20547308. 
Ruà S., Comino A., Fruttero A., Torchio P., Bouzari H., Taraglio S., Torchio B., & Capussotti 
L. (1996). Flow cytometric DNA analysis of cirrhotic liver cells in patients with 
The Use of Flow Cytometric DNA Ploidy Analysis  
of Liver Biopsies in Liver Cirrhosis and Hepatocellular Carcinoma 
 
107 
hepatocellular carcinoma can provide a new prognostic factor. Cancer, 78(6):1195-
1202. PMID: 8826940. 
Sanai FM., & Jeeffe EB. (2011). Liver biopsy for histological assessment: the case against. 
Saudi J Gastroenterol, 16(2):124-132. 
Schaffner F. (1991). Structural and functional aspects of regeneration of human liver. Dig Dis 
Sci, 36(9):1282-1286. PMID: 1893815. 
Schwint AE., Folco A., Morales A., Cabrini RL., & Itoiz ME. (1996). AgNOR mark epithelial 
foci undergoing malignant transformation in hamster cheek pouch carcinogenesis. J 
Oral Pathol Med, 25:20-24. 
Shankey T., & Rabinovitch P. (2002). DNA content flow cytometry. In: Manual clinical 
laboratory immunology, sixth edition. Rose N, Hamilton R, Detrick B (ed), p171-184, 
ISBN 1-55581-215-5, ASM press Washinton D.C. 
Shankey TV., Rabinovitch PS., Bagwell B., Bauer KD., Duque RE., Hedley DW., Mayall BH., 
Wheeless L., & Cox C. (1993). Guidelines for implementation of clinical DNA 
cytometry International Society for Analytical Cytology. Cytometry, 14(5):472-7. 
PMID: 8354117. 
Shemizu K., Izumi R., Ii T., Muraoka K., Inoue T., Fukushima W., Sakamoto K., Tani T., 
Hashimoto T., Yagi M., Miyazaki I., & Monomura A. (1995). Prognostic significance 
of nuclear organizer region in  hepatocellular carcinoma. Hepatol,  21:393–397. 
Shimamoto T., Haruma K., Tanaka S., Todo H., Yoshihara M., Sumii K., & Kajiyama G. 
(1993). Usefulness of nucleolar organizer region staining in gastric myogenic 
tumors: correlation with ploidy by DNA flow cytometry. Oncology, 50(1):52-56. 
PMID: 8421598. 
Siddiqui M., Soomro I., Kayani N., Muzaffar S., & Hasan S. (1999). Assessment of nucleolar 
organizer regions (NORs) in proliferative conditions of the liver. Pathol Res Pract, 
195(6):421–426. 
Sirri V., Roussel P., & Hernandez-Verdun D. (2000). The AgNOR proteins: qualitative and 
quantitative changes during the cell cycle. Micron, 31(2):121–126. 
Spolidorio L., Neves K., Soares C., Spolidorio D., Basso M., Malavazzi I., & Almeida O. 
(2002). Evaluation of argyrophilic nucleolar organizer regions in oral tumor 
progression. Micron, 33(7- 8):605–608. 
Tarao K., Hoshino H., Shimizu A., Ohkawa S., Nakamura Y., Harada M., Ito Y., Tamai S., 
Akaike M., & Sugimasa Y. (1994a). Role of increased DNA synthesis activity of 
hepatocytes in multicentric hepatocarcinogenesis in residual liver of 
hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res, 
85(10):1040-1044. PMID: 7961106. 
Tarao K., Ohkawa S., Shimizu A., Harada M., Nakamura Y., Ito Y., Tamai S., Hoshino H., 
Inoue T., & Kanisawa M. (1994b). Significance of hepatocellular proliferation in the 
development of hepatocellular carcinoma from anti-hepatitis C virus-positive 
cirrhotic patients. Cancer, 73(4):1149-1154. PMID: 7508816. 
Thomas RM., Berman JJ., Yetter RA., Moore GW., & Hutchins GM. (1992). Liver cell 
dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol, 
23(5):496-503 PMID: 1314776. 
Tomioka N., Kobayashi H., Kageyama H., Ohira M., Nakamura Y., Sasaki F., Todo S., 
Nakagawara A., & Kaneko Y. (2003). Chromosomes that show partial loss or gain 
in near-diploid tumors coincide with chromosomes that show whole loss or gain in 
  
Liver Biopsy 
 
108 
near-triploid tumors: evidence suggesting the involvement of the same genes in the 
tumorigenesis of high- and low-risk neuroblastomas. Genes Chromosomes Cancer, 
36(2):139-150. PMID: 12508242. 
Trere D., Farabegoli F., & Derenzini M. (1991). AgNOR area in interphase nuclei of human 
tumor correlate with the proliferative activity evaluated by bromodeoxyuridine 
labeling and Ki-67. J Pathol, 165:53–59. 
Trere` D. (2000). AgNOR staining and quantification. Micron, 31:127–131. 
Tripathi P., Tripathi AK., Kumar A., Ahmad R., Balapure AK., Vishwakerma AL., & Singh 
RK. (2008). DNA aneuploidy study for early detection of chromosomal abnormality 
in patients with aplastic anemia: prognostic and therapeutic implications. In Vivo, 
22(6):837-44.PMID:19181017. 
Underwood J., & Giri D. (1988). Nucleolar organizer regions as diagnostic discriminate for 
malignancy. J Pathol, 156:95–96. 
Uno T., Hashimoto S., Shimono M. (1998). A study of the proliferative activity of long 
junctional epithelium using AgNOR staining. J Periodontal Res, 33:298-309. 
van Dekken H., Verhoef C., Wink J., van Marion R., Vissers KJ., Hop WC., de Man RA.,  
Ijzermans JN., van Eijck CH., & Zondervan PE. (2005). Cell biological evaluation of 
liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis. Acta 
Histochem, 107(3):161-171. PMID: 16000213. 
Vuhahula EA., Nikai H., Ogawa I., Miyauchi M., Takata T., & Ito H. (1995). Correlation 
between argyrophilic nucleolar organizer region (AgNOR) counts and histologic 
grades with respect to biologic behavior of salivary adenoid cystic carcinoma. J Oral 
Pathol Med, 24(10):437-442.   
Wakasa K., Haba T., Sasaki M., Sakurai M., Ikebe T., Hirohashi K., & Kinoshita H. (1998). 
Heperplastic foci in chronic liver disease: their proliferative activity assessed by 
nucleolar organizing. Pathol Interact, 48(1):29–32. 
Wersto RP., Chrest FJ., Leary JF., Morris C., Stetler-Stevenson MA., & Gabrielson E. (2001). 
Doublet discrimination in DNA cell-cycle analysis. Cytometry, 46(5):296-306. PMID: 
11746105 
Yu C., Fletcher C., & Goodlad G. (1992). Proliferating cell nuclear antigen (PCNA) 
immunostaining, nucleolar organizer region (AgNOR) staining and histological 
grading in gastrointestinal stromal tumors. J Pathol, 166:147–152. 
8 
Electron Microscopy of Liver Biopsies 
Theodore C. Iancu and Irena Manov 
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Israel 
1. Introduction 
During the last years of the 20th century, diagnosis in liver pathology was enriched by 
additional methodologies including immunohistopathology and confocal microscopy. 
Nevertheless, it soon became obvious that ultrastructural examinations remain essential 
in both research and diagnosis. The present chapter focuses on the use of electron 
microscopy in diagnostic hepatology and research of unsolved mechanisms. Attention 
will be directed to the correct retrieval of specimens for electron-microscopic examination 
and their processing for obtaining maximal information. The revival of interest in both 
transmission (TEM) and scanning electron microscopy (SEM) follows continuous changes 
in the subjects under examination: new diseases or additional features of old diseases; 
new therapeutic agents and their potentially hepatotoxic effects; environmental factors 
affecting the liver; identification of viruses and/or other rare noxious agents; immune 
pathology including liver transplantation and rejection; the liver in systemic-genetic 
diseases; and ultrastructural pathology in both experimental animals and cell cultures.   
We herewith wish to provide the clinician (neonatologist, pediatrician, geneticist, and 
hepatologist-gastroenterologist) with information about the value of electron-microscopic 
examination before performing a liver biopsy and thus enabling him/her to preserve a 
minute sample for a valuable study.  
In his limited size, the present chapter cannot be all-inclusive. Many areas, in which the 
contribution of electron-microscopy is limited to research investigations, have been left out. 
Similarly, areas in which histopathology and immune staining are major diagnostic tools, 
such as in hepatitis, were sidestepped. 
2. Technical aspects 
Whenever an electron microscopic examination is planned, immediate fixation of the 
retrieved specimen is essential. While most laboratories have their own preference,  
2.5% buffered glutaraldehyde is universally accepted.  Suggested primary fixative:  
2.5% glutaraldehyde in 0.1M sodium Cacodylate buffer (Add 1ml of 25% glutaraldehyde 
stock to 9 ml of buffer). The specimen should not be larger than 1 mm in each direction  
to allow for good penetration of the fixative. It is advised to avoid the tip of the cylindrical 
needle biopsy specimen which may contain sub-capsular liver area and may not  
be diagnostic. After 2 hrs. (At room temperature or in the refrigerator) continue with  
the standard steps: osmium post-fixation, dehydration, infiltration, embedding. Do not 
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freeze at any stage! (For immune-electron microscopy, keep a separate deep-frozen 
specimen.) 
Toluidine blue staining of thick (semi-thin 0.5 µm or 1.0 µm.) sections for TEM, used as guideline 
to the area of interest and further trimming: Reagents: 1% Toluidine Blue and 2% borate  
in distilled water. Ultrathin sections, 40-100 nm (regularly 60 nm for TEM) are spread mostly 
on 200 or 300 mesh copper grids and stained with uranyl acetate and lead citrate solutions. 
For iron-containing compounds, keep unstained sections or stained only 2 minutes with 
lead. 
Table I summarizes findings in biopsies of most conditions encountered in clinical cases. 
The reader can find details in the many books and atlases on hand (Johannessen, 1978; 
Tanikawa et al., 1979; Ghadially, 1997)). 
3. The liver biopsy – general features 
Hepatocytes: The large, round nuclei usually show an even, round contour and contain  
1-2 nucleoli, heterochromatin adjacent to their external border and distinct nuclear 
membranes and nuclear pores. Uneven, crenated nuclei can follow faulty fixation or other 
processing problems (Fig. 1). Chromatin margination and fragmentation can indicate 
apoptosis. In more advanced stages of damage, apoptotic and necrotic cells are seen  
(Figs. 2-6). 
3.1 Damaged and dying liver cells 
If the biopsy specimen has been retrieved and fixed correctly, it can be assumed that 
damaged liver cells indicate a pathological process. The sequences are: edema, swelling of 
mitochondria, cristolysis, flocculated matrix, nuclear chromatin clumping, margination and 
fragmentation, (apoptosis), RER denudation, dense deposits in mitochondria, peroxysomes 
and matrix, necrosis. (Figs. 1-6) 
 
 
 
 
 
Fig. 1. Delayed fixation: 
cristolysis and "extracted" 
matrix of mitochondria; 
fragmented euchromatin 
(arrow). x 8,000 
 
Fig. 2. Necrotic cells in 
periportal area.  Residual 
necrotic nucleus (arrow).      
x 5,000 
 
Fig. 3. Disintegrating cell in 
sinusoid: small nucleus, 
membraneous lysosomes 
and some collagen fibers 
(arrows).   x 6,000 
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Fig. 4. Apoptotic body: 
parts of nucleus (N), RER 
(arrow) and remaining 
mitochondria in the center.  
x 6,000 
Fig. 5. Extreme biliary 
necrosis. x 4,000 
Fig. 6. Biliary necrosis in a 
detached hepatocyte in the 
sinusoid.  x 5,000 
4. Organelle pathology (1): Mitochondria 
4.1 Shape and size 
Megamitochondria (giant mitochondria, up to 10.0 µm long), existing in numerous 
metabolic abnormalities including drug reactions and fatty liver; they are frequently 
elongated along their longitudinal axis. They may contain crystals (Figs. 7, 8), (Sternlieb, 
1979). Amoeboid shape, found in metabolic abnormalities and Reye syndrome (Partin et al., 
1971); Oncocytic transformation: mitochondrial crowding similar to an oncocytoma 
(Tandler et al., 1970) is found generally in hepatocytes in mitochondrial DNA deficiency 
(Mandel et al., 2001). 
 
 
Fig. 7. Fatty liver - NAFLD. 
Megamitochondrion with 
longitudinal crystal 
formations. x 15,000 
Fig. 8. Lactic acidosis. 
Angular mitochondrion 
with twisted and circular 
cristae. x 15,000 
Fig. 9. "Condensed 
conformation" of 
mitochondria in "edge 
artifact". x 8,000 
4.2 Content: matrix, cristae, crystals, granules, dense deposits 
Orthodox vs. Condensed mitochondria. Surrounding conditions induce mitochondrial 
changes. Mitochondria with dilated cristae and condensed (opaque) matrix are labeled in 
N 
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necrotic nucleus (arrow).      
x 5,000 
 
Fig. 3. Disintegrating cell in 
sinusoid: small nucleus, 
membraneous lysosomes 
and some collagen fibers 
(arrows).   x 6,000 
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Fig. 4. Apoptotic body: 
parts of nucleus (N), RER 
(arrow) and remaining 
mitochondria in the center.  
x 6,000 
Fig. 5. Extreme biliary 
necrosis. x 4,000 
Fig. 6. Biliary necrosis in a 
detached hepatocyte in the 
sinusoid.  x 5,000 
4. Organelle pathology (1): Mitochondria 
4.1 Shape and size 
Megamitochondria (giant mitochondria, up to 10.0 µm long), existing in numerous 
metabolic abnormalities including drug reactions and fatty liver; they are frequently 
elongated along their longitudinal axis. They may contain crystals (Figs. 7, 8), (Sternlieb, 
1979). Amoeboid shape, found in metabolic abnormalities and Reye syndrome (Partin et al., 
1971); Oncocytic transformation: mitochondrial crowding similar to an oncocytoma 
(Tandler et al., 1970) is found generally in hepatocytes in mitochondrial DNA deficiency 
(Mandel et al., 2001). 
 
 
Fig. 7. Fatty liver - NAFLD. 
Megamitochondrion with 
longitudinal crystal 
formations. x 15,000 
Fig. 8. Lactic acidosis. 
Angular mitochondrion 
with twisted and circular 
cristae. x 15,000 
Fig. 9. "Condensed 
conformation" of 
mitochondria in "edge 
artifact". x 8,000 
4.2 Content: matrix, cristae, crystals, granules, dense deposits 
Orthodox vs. Condensed mitochondria. Surrounding conditions induce mitochondrial 
changes. Mitochondria with dilated cristae and condensed (opaque) matrix are labeled in 
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‘condensed’ conformation, whereas the apparently ‘normal’ mitochondria are termed to be in 
‘orthodox’ conformation (Hackenbrock et al., 1971).  Condensed mitochondria are seen at the 
periphery of a thin section, where all cellular components appear more diluted (Fig. 9). We 
have termed this finding as edge artifact. Condensed mitochondria may be seen in 
pathological conditions (e.g. Wilson disease) and thus have diagnostic significance. 
Therefore we suggest avoiding an edge artifact by assessing mitochondria also at safe 
distance away from the edge. 
Cristolysis is a significant, non-specific, sign of mitochondrial injury, when only fragments  
of cristae remain visible, severed from inner mitochondrial membranes (see Reye 
syndrome). 
Circular or ‘curled’ cristae are classically seen in cholestasis (Figs. 10, 11); (Phillips et al., 1987); 
occasionally the cristae are twisted (Figs. 8, 11, 12.).  Other variations in amount, position 
and arrangement remain unexplained, such as: longitudinally stacked; transverse position, 
perpendicular to the outer membrane; or cartwheel arrangement (Menkes’ kinky hair 
disease) (Ghadially, 1997). 
Autolytic changes: specimens retrieved post mortem show ‘extraction’ of matrix and cristae, 
resulting in empty-looking organelles and nuclei, similar to that of defectively fixed 
specimens (Fig. 1).  Dense deposits in mitochondria have been found in Wilson disease (Fig. 
13); (Phillips et al., 1987) and in severe iron overload (Bessis & Weed, 1973). 
Matrical dense granules, a common, normal feature of mitochondria, are known to contain 
calcium, but their precise role in mitochondrial function is unknown. However, their 
generalized absence is an indication of abnormality (drug toxicity, metabolic disturbance?). 
Large granules may show a hollow center (Fig. 11). 
 
Fig. 10. Circular and 
stacked cristae in 
cholestasis. Neonatal 
hepatitis.  x 10,000 
Fig. 11. Metabolic acidosis.   
Cristolysis and hollow 
granules (arrow), also in 
mitochondrion  x 15,000 
Fig. 12. Metabolic acidosis. 
Circular and twisted 
cristae in a mega-
mitochondrion. x 20,000 
Intramitochondrial inclusions: crystalline, paracrystalline, and filamentous. Crystalline 
inclusions, have been found in nuclei, cytoplasm  and mitochondria (Ghadially, 1997)  
and show a highly ordered pattern of organization. Crystals with a less ordered 
arrangement have been named crystalloid or paracrystalline.  The appearance of the crystals 
depends ’inter alia’ on the plane of sectioning in relationship to the plane of crystal lattice  
(Figs 7, 14, 15). 
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Fig. 13. Wilson disease. 
Elongated mitochondria 
and dense deposits.            
x 15,000. 
Fig. 14. Aspirin toxicity. 
Transverse section through 
paracrystalline formations.    
x 20,000. 
Fig. 15. Aspirin toxicity. 
Crystalline deposits in 
giant, abnormal 
mitochondrion. x 20,000 
4.3 Organelle pathology (2): Peroxisomes 
Peroxisomes (microbodies) are seen in hepatocytes as round, ellipsoid, slightly angular or 
elongated organelles. They contain a homogeneous, amorphous, finely granular or 
flocculent matrix, surrounded by a single tripartite membrane. Randomly distributed in the 
cytoplasm, they may form clusters. Their diameter is 0.25-1.34 µm and they may exhibit a 
peripheral terminal or marginal plate of about 0.4 µm long along their limit membrane (Fig. 
16).  They show variations in number, size, shape and matrix (Fig. 17). The major 
pathological finding is the absence of peroxisomes in the cerebrohepatorenal syndrome of 
Zellweger. Conditions with fewer peroxisomes (Table I) comprise Infantile Refsum disease 
(Fig. 18) whereas abundant organelles were reported in Reye syndrome, alcoholic liver 
disease, clofibrate and 6-mercaptopurine therapy and cholestatic jaundice of pregnancy 
(Sternlieb, 1979).  
 
 
Fig. 16. Siderosome (arrow) 
vs. peroxysomes (P), one 
with a terminal plate 
(arrowhead) x 15,000 
Fig. 17. Metabolic acidosis. 
Longitudinal arrangement 
of cristae and multiple 
large peroxysomes (P).       x 
15,000 
Fig. 18. Infantile Refsum 
disease, Zellweger variant, 
absent peroxisomes.  Note 
trilaminar filaments and 
dense deposits.   x 20,000 
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4.4 Organelle pathology (3): Lysosomes 
These Golgi-derived organelles are of major importance in the interpretation of liver 
biopsies. Their role in autophagy (phagosomes; autophagosomes, autophagolysosomes) and 
apoptosis has been documented by numerous observations (Ghadially, 1997).  In practice, 
some lysosomes are indicative, if no diagnostic, of a group of conditions.  Within such a group, 
further differentiation requires additional (mainly genetic) information. For instance, among 
storage diseases, identifying a particular mucopolysaccharidosis can be difficult:  the 
lysosomes are similar, apparently empty, round or oval single-membrane bound vacuoles 
(Figs. 19-21.) and may contain a small electron-dense ‘nucleoid’.  Such appearances have 
been designated as “the bull’s eye” (Fig. 19). 
In some cases, the lysosome content discloses the origin of the partially degraded 
component secluded by autophagy: Glycogen storage disease type II (GSD II, acid maltase 
or lysosomal alpha–glucosidase deficiency) is typically diagnostic by the presence of 
modified glycogen molecules (Fig. 22),  (McAdams et al., 1974). Siderosomes contain ferritin  
and/or hemosiderin (Iancu, 1992) and aurosomes and platinosomes the respective metals 
(Ghadially, 1997);  lipolysosomes contain fat droplets (Hayashi & Sternlieb, 1975);  
Experiments with Thorotrast and carbon particles have demonstrated the phagocytic 
capacities of lysosomes (Ghadially, 1997). 
5. Inborn lysosomal and metabolic diseases 
5.1 Lysosomal diseases 
The established criteria for this group of conditions have been postulated by Hers (Hers, 
1963) as follows: “genetic deficiency of one of the acid hydrolases that is normally localized 
within the lysosome; consequent accumulation of undigested material within single-
membrane-bound organelles that are altered lysosomes”. The classical example of lysosomal 
storage disease, GSD II is due to lysosomal alpha-glucosidase deficiency, an enzyme 
encoded in humans by the GAA gene. 
Lysosomal storage disorders have been listed in numerous publications and recently by 
Pastores (Pastores, 2010). This classification, as well as the present Table I, is based on the 
relevant substrate involved. We have selected previously unpublished electron micrographs 
to exemplify diagnostic features. 
 
Fig. 19. "Bull's eye" 
appearance of nucleoid-
containing lysosomes in 
mucopolyscaccharidoses.  
(Hurler). x 15,000
Fig. 20.  Sinusoidal cell:  
Mucopolysaccharidosis 
(Hunter).  Note typical 
lysosomes. x 6,000 
Fig. 21. Mucopoly-
saccharidosis. "Empty 
looking" lysosomes and 
degraded phagolysosomes.  
(Morquio). x 6,000 
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Fig. 22. Acid maltase 
deficiency (Pompe). 
Monoparticulate glycogen 
in membrane-limited 
bodies (arrows). x 10,000 
Fig. 23. GM1 Gangliosi-
dosis (Landing). Filaments 
in a large lysosome; dense 
deposits, possibly related to 
TPN.   x 10,000 
Fig. 24. Sialidosis: 
numerous single-
membrane limited 
lysosomes in a sinusoid.     
x 5,000 
5.1.1 Mucopolysaccharidoses (MPS) 
This group includes diseases with intralysosomal storage and urinary excretion of partially 
degraded mucopolysaccharides.  By TEM, single-membrane-bound bodies show scarce 
flocculent and particulate precipitate lying in a lucent matrix in many tissues (Tondeur and 
Neufeld, 1975).  They are found in various diseases of the group (see Table 1), with only 
minor differences (Figs. 19-21). Of interest is the presence of a “nucleoid”, remnant after 
extraction by processing of lysosomal content (Fig. 19). The appearance of several other 
conditions with empty-looking lysosomes and occasional electron-dense deposits may 
generate diagnostic difficulties, e.g. gangliosidosis (Fig. 23) sialidosis (Fig. 24), fucosidosis, 
mannosidosis. 
5.1.2 Gaucher disease (GD) 
The most prevalent lysosomal storage disease, GD is due to a deficiency of 
glucocerebrosidase leading to accumulation of glucosylceramide in “Gaucher cells”, in the 
liver and other organs. These cells can be found in other conditions (pseudo-Gaucher cells) 
but characteristically in the three forms of GD: Type I-chronic non-neuropathic, (90% in 
Ashkenazi Jews); Type II (acute neuropathic); and Type III (subacute neuropathic). Bone 
marrow or liver biopsy examinations for diagnosis have been replaced by 
glucocerebrosidase determination in leukocytes or cultured fibroblasts, or by mutation 
analysis. Liver biopsy is reserved for hydrops fetalis in congenital GD or unclear cases of 
hepatosplenomegaly. The pale-staining cytoplasm of the large, multinucleated Gaucher 
cells, show by TEM large lysosomes containing long tubules, some twisted and intermingled 
(Fig. 25). (Chakrapani & Green, 2004) 
5.1.3 Niemann–Pick Disease (NPD) including type A (NPA), B (NPB) and C (NPC) 
NPDs of various types can begin as fetal disease or neonatal jaundice. Some types and 
mutants can show relatively late-onset hepatosplenomegaly. The histopathological 
characteristic of this group of storage diseases is the presence of “foamy cells” storing 
sphyngomyelin. While diagnosis of NPA and NPB is by sphingomyelinase assays and 
mutation analysis, NPC1 need be diagnosed by mutational analysis at the level of cDNA 
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and/or assaying cultured fibroblasts for cholesterol esterification and staining for 
unesterified cholesterol with filipin (Meiner et al., 2001). The advantage of TEM over these 
methods is that it can provide a more rapid diagnostic confirmation by identifying 
suspicious cells, usually liver or amniotic cells (Fig. 26), (Spiegel et al., 2009). 
 
Fig. 25. Part of Gaucher cell 
showing typical fibrils.        
x 10,000 
Fig. 26. Niemann-Pick C: 
membranous whorls fill 
hepatocytes.   x 4,000 
Fig. 27. "Fructose holes" in 
hereditary fructose 
intolerance. x 6,000 
5.2 Cholestasis 
Cholestasis, appearing in conditions in which the bile flow is blocked, is still differentiated 
as extra-hepatic- and intra-hepatic. There are only few differential features revealed by 
electron microscopy. 
Pre-and post-natal bile-production and secretion may be hindered by morphological and 
functional abnormalities. Neonatologists are more troubled by jaundice associated to direct-
binding (conjugated) bilirubin frequently indicating the possibility of structural abnormalities, 
such as biliary atresia. Liver biopsy is usually required to confirm this life-saving surgical 
correction. Other conditions associated with conjugated bilirubin are listed in Table 1 and 
several reviews (Balistreri, 2002); Suchy, 2004). Meanwhile, new clinical, morphological and 
genetic characteristics continue to emerge (Bull et al., 1997; Bezerra & Balistreri, 1999; Davit-
Spraul et al., 2009). Other conditions, in which basic conditions are associated with 
cholestasis, are listed for differential diagnosis (Roberts, 2004 a). 
5.2.1 Ultrastructural features of cholestasis 
Hepatocytic mitochondria show circular, concentric or curled cristae (Fig. 10, 28). With 
continuing cholestasis, bile-containing bodies are seen as clusters, mostly around bile 
canaliculi. In their outer limit, a membranous structure is occasionally identified. The bile-
containing bodies, considered lysosomes, are electron-opaque organelles, usually 0.5-2.0 
(0.1-10.0) µm diameter (Fig. 29). Bile canaliculi display distension and damaged microvilli 
(Fig. 30). In time, spicular conglomerates become visible (Fig. 31). Myelin-like membranes 
are noticeable in long-standing cholestasis (Fig. 32). 
Bile leakage into the cytosol (amorphous, without limit membrane) appears after prolonged, 
severe cholestasis. Cells other than hepatocytes (Kupffer cells, sinusoidal lining cells, stellate 
cells, bile duct epithelia) exhibit variable degrees of cholestasis, mainly as bile-containing 
lysosomes. Focal biliary cytoplasmic necrosis is the extreme form of bile-induced hepatocytic 
damage, other than biliary cirrhosis (Fig. 33). 
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Fig. 28. Hepatocyte. 
Circular and curled cristae 
in cholestasis. Peroxysomes 
(P). x 8,000 
Fig. 29. Bile-containing 
lysosomes in the 
pericanalicular area. Note 
dilated RER. x 4,000 
Fig. 30. Distension of 
canaliculus (BC) and loss of 
microvilli in cholestasis.     
x 4,000 
Fig. 31.  Severe cholestasis: 
spicular bile  x 10,000 
Fig 32. Myelin-like 
lysosomes in a degraded 
hepatocyte.   x 8,000 
Fig. 33. Focal biliary 
cytoplasmic necrosis,  
near bile canaliculi.  
x 4,000 
Fig. 34. Cholestatic 
jaundice. “Byler-like“ bile 
in PFIC-1. x 6,000 
Fig. 35. PFIC-1. “Byler-like“ 
bile. Distended canaliculus, 
injured microvilli.  
X 4,000 
Fig. 36. Bile plug 
in biliary atresia. x 4,000 
BC 
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5.2.2 PFIC-1, PFIC-2 and PFIC-3 
PFIC-1 (former Byler disease) is caused by a mutation in the ATP8B1 gene on chromosome 
18q21-22. Byler-like bile, seen in PFIC-1, is formed of coarse granular bile in distended 
canaliculi with damaged/absent microvilli (Figs. 34-35). In contrast, the bile in PFIC-2 is not 
granular but filamentous, important for differential diagnosis. Bile plugs are typically seen 
in severe obstructive cholangiopathies including biliary atresia (Fig. 36).   
PFIC-2 is caused by a mutation in the ABCB11 gene on chromosome 2q24 that encodes the 
bile salt export pump (BSEP). BSEP is the major canalicular bile acid pump, and thus the loss 
of BSEP function results in severe hepatocellular cholestasis. Both PFIC-1 and PFIC-2 are 
characterized by low gamma-glutamyl peptidase (GGT) levels. Although genetically 
distinct, PFIC1 and PFIC2 are both caused by the absence of a gene product required for 
canalicular export and bile formation. Clinically and histologically there are few differences 
between these conditions, which may both advance to cirrhosis. An important contribution 
of electron microscopy to the otherwise ample description of histopathological features of 
PFIC, is the finding of the coarsely granular “Byler bile” in dilated canaliculi that lack 
microvilli and are cuffed by a thick layer of microfilaments. “Byler bile”, is apparently 
related to the defect in canalicular bile acid transport with primary retention of hydrophobic 
bile salts. Weber suggested the microfilament collar was a feature of cholestasis in another 
ethnic group (Weber et al., 1981).  Bull and co-authors reported that “Byler bile” was found 
only in children who were homozygous for the microsatellite haplotype at 18q21-q22 (PFIC 
1)(Bull et al., 1997). It should be noted that Byler bile can be seen occasionally in cholestatic 
conditions other than PFIC 1 or PFIC 2, such as Familial Progressive benign cholestasis 
(Phillips et al., 1987).   
The absence of bile salts in the bile ducts in PFIC1 and PFIC2 and their presence in the bile 
ducts in PFIC3 accounts for the difference in biochemical tests. In PFIC3, as in most 
cholestatic diseases, exposure of duct cell membranes to bile salts results in solubilization of 
GGT, absorption of the enzyme into the circulation, and elevated serum GGT levels. In 
contrast, in PFIC1 and PFIC2 there are low levels of bile salts, the GGT is never solubilized, 
and the serum GGT is normal. Rather than defective bile acid export, patients with PFIC3 
have deficient hepatocellular phospholipid export. The lack of phospholipids produces 
destabilized micelles and promotes lithogenic bile with crystallized cholesterol which could 
produce small bile duct obstruction (Davit-Spraul et al., 2009). The histological and 
ultrastructural features are similar to other forms of PFIC, except for the absence of Byler 
bile. In PFIC-3 the bile is amorphous or filamentous. The patients become symptomatic at 
various ages, from 1 month to 20 years, and progression to cirrhosis can be rapid (first 
decade). 
Recently (Verhulst et al.), 2010), reported on the critical role of ATP8B1 (deficient in PFIC-1) 
in apical membrane organization, potentially relevant for development of cholestasis and 
extrahepatic manifestations associated with ATB8B1 deficiency (such as disorganized apical 
actin cytoskeleton and defective microvilli formation) 
5.2.3 Crigler-Najjar 
This syndrome is divided into two types: type I and type II, with the latter sometimes called 
Arias syndrome. These two types, along with Gilbert's syndrome, Dubin-Johnson syndrome, 
and Rotor syndrome, make up the five known hereditary defects in bilirubin metabolism.  Unlike 
Gilbert's syndrome, only a few hundred cases of Crigler-Najjar syndrome are known to exist 
(Kelly, 2004). 
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5.2.4 Dubin-Johnson syndrome 
Originally termed canalicular multiple organic anion transporter (cMOAT) defect, it is also 
known as multidrug resistance protein 2 (MRP2) and is a member of the ABC transporter 
superfamily. The gene that encodes the transporter is ABCC2 is found on chromosome 10. 
Rare cases of neonatal hepatitis have been reported; in older children, histology and TEM 
show typical melanin-containing pigment predominantly in the centrilobular area, around 
bile canaliculi (Fig. 37). 
5.2.5 Alagille syndrome (Arteriohepatic dysplasia) 
Described in 1975, the syndrome comprises infantile cholestasis, hepatic ductular 
hypoplasia, typical facies, peripheral pulmonic stenosis, vertebral anomalies and physical 
and mental retardation. The persistence of cholestasis is not associated to extra-hepatic 
obstruction but paucity of intralobular bile ducts is frequent.  Valencia-Mayoral et al.  
have found ultrastructural changes suggesting a block in the Golgi apparatus or in  
the pericanalicular cytoplasm (Valencia-Mayoral et al., 1984).  These TEM findings in 
Alagille syndrome appear to be distinctive when compared to other cholestatic 
syndromes. 
5.2.6 Alpha-1-antitrypsyn deficiency (A1AT) 
This disorder is a relatively common autosomal co-dominant condition causing chronic 
lung and liver disease. α1-antitrypsin is a protease inhibitor belonging to the serpin 
superfamily. It is generally known as serum trypsin inhibitor. A point-mutation induces 
aggregation-prone properties to a secretory protein so that the retained mutant protein  
is not secreted into blood or body fluids. Accumulation of the mutant A1AT in the RER  
of hepatocytes, typically seen with the TEM (Fig. 38) causes liver inflammation  
and carcinogenesis by a gain-of-toxic function mechanism. Studies performed over the 
last years have shown the importance of autophagy in disposal of mutant, a phenomenon 
also demonstrated by TEM. In infancy, A1AT is an important cause of cholestatic 
jaundice, with giant cell hepatitis, mimicking biliary atresia and Alagille syndrome 
(Mowat, 1994). 
 
Fig. 37. Dubin-Johnson 
syndrome. Electron-dense 
accumulations adjacent to 
bile canaliculus. x 5,000 
Fig. 38. Alpha-1-antitrypsin 
deficiency: amorphous 
accumulations in RER. 
x 6,000 
Fig. 39. Congenital disorder 
of glycosylation (CDG). 
Pericanalicular clusters of 
single-membrane-bound 
bodies.  x 5,000
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5.2.4 Dubin-Johnson syndrome 
Originally termed canalicular multiple organic anion transporter (cMOAT) defect, it is also 
known as multidrug resistance protein 2 (MRP2) and is a member of the ABC transporter 
superfamily. The gene that encodes the transporter is ABCC2 is found on chromosome 10. 
Rare cases of neonatal hepatitis have been reported; in older children, histology and TEM 
show typical melanin-containing pigment predominantly in the centrilobular area, around 
bile canaliculi (Fig. 37). 
5.2.5 Alagille syndrome (Arteriohepatic dysplasia) 
Described in 1975, the syndrome comprises infantile cholestasis, hepatic ductular 
hypoplasia, typical facies, peripheral pulmonic stenosis, vertebral anomalies and physical 
and mental retardation. The persistence of cholestasis is not associated to extra-hepatic 
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Fig. 37. Dubin-Johnson 
syndrome. Electron-dense 
accumulations adjacent to 
bile canaliculus. x 5,000 
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5.3 Congenital disorders of glycosylation (CDG) 
This new group of genetic diseases characterized by defective glycoprotein biosynthesis 
exemplifies the value of electron microscopic diagnosis by liver biopsy (Iancu et al., 2007)  
The patients can present either with a neurological form (psychomotor retardation, 
cerebellar hypoplasia and retinitis pigmentosa, or with a multivisceral form with 
neurological and extra-neurological manifestation including liver, cardiac, renal or 
gastrointestinal involvement).  A form with liver involvement and/or cardiomyopathy, 
enteropathy and hypoglycemia has also been reported. Elevated transaminases may focus 
attention to the liver.  The biopsy shows increased cellularity, distorted bile ducts and small- 
and medium size lipid droplet steatosis.  TEM shows, in addition, the presence of numerous 
myelinosomes.  These organelles are mainly empty whorls measuring 0.02-0.1 µm and 
forming conglomerates (“grape-like“) close to bile canaliculi (Fig. 39). Isoelectric focusing of 
transferrin provides an easy method of identification of CDG’s. 
5.4 Galactosemia, fructose intolerance, tyrosinemia 
These inherited metabolic disorders are included here because of their common presentation 
with jaundice and elevated transaminases, as evidence of liver involvement. Although TEM 
results are not always specific, if a biopsy is performed, the findings can be supportive for 
life-saving diagnosis (Phillips et al., 1987; Mowat, 1994). 
Galactosemia: enlarged hepatocytes, dilated RER, fatty liver, focal cytoplasmic degeneration, 
biliary necrosis; 
Hereditary fructose intolerance: punched-out cytoplasmic lysis - “fructose holes” (Fig. 27).   
Tyrosinemia: Increased lipid, dilated RER, pleomorphic mitochondria and focal necrosis. 
5.5 Siderosis 
Inorganic iron is revealed by TEM in unstained or slightly stained sections. The  compounds 
are electron-dense due to the presence of ferritin and/or hemosiderin (Iancu, 1983; Iancu, 
1992) and (rarely) iron-containing micelles (Fig. 40), (Bessis & Weed, 1973; Iancu, 1983; Iancu, 
1992). The octahedral storage molecule ferritin (Holoferritin = ferritin core (Fe 
hydroxyphosphate) + apoferritin protein coat) becomes visible by TEM when the core 
contains more than about 1,500 inorganic iron molecules, up to a maximum of 4,500 
molecules (iron-rich ferritin). Ferritin molecules (cores) can be seen randomly dispersed 
within the cell sap of hepatocytes, sinusoidal and Kupffer cells (Fig. 41, 42) in amounts 
depending on the origin of overload (absorptional or transfusional). The accumulation of 
iron is easier detectable in lysosomes. Iron-containing lysosomes are termed siderosomes. They 
contain electron-dense iron in 3 forms: a) ferritin molecules (mostly iron-rich variety), 
frequently associated with pseudo-membranous layers and forming arrays or hexagonal 
crystals; b) coalesced ferritin particles (after degradation of their apoferritin coat) forming 
‘clumps’ of hemosiderin with extreme electron-density; c) siderosomes in which smaller 
particles can be resolved, apparently an intermediate stage between a) and b). Yet, a strict 
electron-microscopic definition of these compounds emphasizes that hemosiderin is formed 
when the coat of apoferritin is smaller than 0.25 nm and thus the distance between two 
ferritin molecules is reduced to less than 0.5 nm (Fischbach et al., 1971) 
The TEM study of liver siderosis reveals: presence of ferritin and/or hemosiderin within 
various cells; relationship with additional conditions (e.g. cirrhosis, hepatitis, and carcinoma); 
quantification of the iron-containing compound by mass spectrometry or other analytical 
methods; and assessment of putative effect of a chelating agent. TEM confirmed that iron 
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overload from excessive absorption (hemochromatosis HFE) produces parenchymal overload 
with an initial mild reticuloendothelial (RES) overload, while transfusional iron is located 
mostly in the RES, followed by re-distribution of excess iron among both compartments. 
5.5.1 Genetic hemochromatosis (HFE) “classical” hemochromatosis, type 1 
Hemochromatosis HFE is most often caused by a mutation in the gene HFE on chromosome  
6p21.3. Four types were identified (Muir et al., 1984), with differences between the degrees 
of liver iron loading. Children as young as 4 years had juvenile forms. The various stages of 
overload were followed by TEM (Iancu et al., 1997). 
5.5.2 Other iron-loading conditions 
In homozygous β-thalassemia, excess iron originates from hemolysis, increased absorption 
and frequent blood transfusions.  In the liver, “foreign “transfused iron is channeled to the 
(RES), whereas iron from excessive absorption reaches parenchymal cells. The end-result is 
severe overload possibly followed by cirrhosis and/or hepatocellular carcinoma. In aplastic 
anemia and dialysis, iron derives from transfusions, with predominant initial RES overload, 
followed by redistribution towards hepatocytes and aggravation of liver siderosis as seen at 
the ultrastructural level. (Iancu, 1989; Iancu, 2011). 
 
 
Fig. 40. Homozygous beta-thalassemia: 
Electron-dense iron micelles within 
mitochondria. x 20,000, unstained 
Fig. 41. Genetic hemochromatosis HFE. 
Ferritin cores in a Kupffer cell, dispersed 
and/or aggregated. x 20,000, unstained 
 
Fig. 42. Hepatocyte from β-thalassemia 
major. Ferritin dispersed or coalesced in 
crystals (curved arrow). In hemosiderin, 
(arrows) ferritin particles cannot be 
resolved anymore.  x 20,000, unstained
Fig. 43. Neonatal hemochromatosis, similar 
to genetic hemochromatosis: note ferritin 
of variable electron-density ("iron-rich” vs. 
“iron-poor”) and hemosiderin "clumps" 
(arrows). x 20,000, unstained.
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Ferritin cores in a Kupffer cell, dispersed 
and/or aggregated. x 20,000, unstained 
 
Fig. 42. Hepatocyte from β-thalassemia 
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5.5.3 Neonatal hemochromatosis (NH) 
In the neonatal period, the liver normally contains relatively large amounts of ferritin and 
hemosiderin, which diminish during the first year of life. 
Neonatal hemochromatosis is a severe, frequently fatal condition.  It has been found in 
fetuses and newly born infants presenting with rapidly progressing liver failure. The 
pattern of liver siderosis is similar to that of hereditary hemochromatosis (HFE) but the 
pace of pathological changes is fulminant: there is a striking difference between the iron-
loaded hepatocytes and the sinusoidal cells which show only minor iron deposition. Perls’ 
stain reveals siderosis in extra-hepatic locations (pancreas, thyroid, heart). Until recently, 
the cause and mechanism of this condition were unknown.  Presently, NH is considered 
an alloimmune disease in which maternal antibodies damage the hepatocytes, especially 
post-partum. The siderosis is seen as secondary to the damaged liver cells and not the 
primary metabolic abnormality (Knisely & Vergani, ; Whitington, 2007). Because of the 
life-endangering condition of these infants, liver biopsy is rarely performed.  TEM reveals 
iron mainly in hepatocytes, stored similarly to other parenchymal loading disorders  
(Fig. 43). 
The role of iron in the brain and in Parkinson and Alzheimer diseases is under continuous 
study. Iron-induced lipid peroxidation and the formation of toxic free radicals appear to 
contribute to the development of the latter conditions (Zhu et al., 2007). Ongoing 
experimental work is focused on the effect of new chelating agents, capable to pass the 
blood-brain-barrier (Gal et al., 2006) and reduce the damaging effects of iron. Using cultured 
hepatoma-derived Hep3B cells loaded with inorganic iron, we could demonstrate the effect 
of a new bimodal chelator M30 capable of reducing ferritin in these cells, as seen by 
immunofluorescence (personal communications, Y Bashenko, 2009-2011). 
5.5.4 Wilson disease (WD) 
In this copper metabolism abnormality, there are numerous ultrastructural changes in liver 
cells as the liver lesions change in time, from chronic hepatitis to acute liver failure or 
cirrhosis. Alterations involve nuclei, mitochondria, peroxisomes, RER, fatty changes with 
lipolysosomes and neocholangioles with copper deposits (Figs.  44-47) (Sternlieb, 1979) 
Phillips et al., 1987). 
 
Fig. 44. Punched-out mitochondria and fat 
droplets in WD. x 6,000 
Fig. 45. Giant mitochondrion with 
punched-out areas and fat droplets.  
x 10,000 
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Fig. 46. WD: Mitochondria with crystalline 
deposits   and dense deposits (arrow) 
x 8,000 
Fig. 47.  Glycogen body (RER) frequently 
seen in WD. x 6,000 
5.6 Reye syndrome 
Around 1970, TEM had a major diagnostic role showing changes considered typical for 
Reye syndrome: generalized steatosis, glycogen depletion, increased frequency of 
peroxisomes and "amoeboid", occasionally giant mitochondria; their matrix was described 
as "flocculent" and frequently contained crystalline inclusions and lacked dense matrical 
granules (Figs. 48-49).  Towards 1980, possibly following the reduced aspirin 
consumption, the frequency of Reye syndrome decreased dramatically. However, 
sporadic cases still occurred without a clear relationship to aspirin ingestion. The 
ultrastructural findings were similar to those described in Reye syndrome, and were 
therefore named “Reye-like” (Phillips et al., 1987). In the UK, over 10% of reported cases 
with an initial diagnosis of Reye's syndrome have later been revised to an Inborn Metabolic 
Disorder (IMD) which may mimic Reye's syndrome.  IMD includes defects in fat oxidation, 
amino acid metabolism, carbohydrate metabolism and disorders of ammonia 
detoxification.  The relationship with aspirin ingestion was not firmly established, as Reye 
syndrome appeared in areas where aspirin was never used (Australia) and continued to 
appear after aspirin was discontinued (France). 
 
 
Fig. 48. Reye syndrome. Cristolysis and 
generalized lipid deposition (L) x 20,000 
Fig. 49. Reye syndrome. Expanded 
mitochondria, cristolysis, lipofuscin and 
absent matrical granules.   x 10,000 
L L
L
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Fig. 48. Reye syndrome. Cristolysis and 
generalized lipid deposition (L) x 20,000 
Fig. 49. Reye syndrome. Expanded 
mitochondria, cristolysis, lipofuscin and 
absent matrical granules.   x 10,000 
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5.7 Steatosis 
This group includes presently: 1. Alcoholic liver disease; 2.  NAFLD (non-alcoholic fatty liver 
disease) which encompasses most forms of fatty liver, including “simple steatosis“, without 
inflammation, seen in an important percent of adult population (Fig. 50), and 3. NASH, (non-
alcoholic steatohepatitis) which by definition involves inflammation and/or fibrosis (Roberts, 
2004 b) and may progress to cirrhosis more frequently than simple steatosis. 
 
Fig. 50. Fatty liver - 
NAFLD:  Large droplets 
present in hepatocytes and 
sinusoidal cells   x 4,000 
Fig. 51. Total parenteral 
nutrition. Lipid droplets (L) 
strangle a minute bile 
canaliculus (arrow). x 6,000 
Fig. 52. Total parenteral 
nutrition. Spicular 
cholesterol within dense 
bodies. Abnormal 
mitochondria. x 8,000 
 
Fig. 53. NAFLD. 
Lipofuscin- lipolysosomes 
(arrows) near the sinusoid 
(S) and bile canaliculus 
(BC).  x 4,000 
Fig. 54. Hepatocyte. Typical 
lipolysosomes, Wilson 
disease. x 6,000 
Fig. 55. Compound 
lipolysosome.  
Note extreme size 
compared to adjacent 
nuclei; x 6,000  
For electron-microscopic characterization of liver steatosis, the classical terms “large 
droplet“(macrovesicular) and “small droplet“(microvesicular) are still used. Macrovesicular 
steatosis is mostly seen in nutritional abnormalities including: kwashiorkor, obesity, 
prolonged parenteral nutrition (Figs. 51-52), diabetes mellitus, glycogenoses, Wilson disease, 
hyperlipidemias, A-(or hypo) betalipoproteinemia, familial lipoprotein deficiency, total 
lipodystrophy (Sherlock & Doodley, 1993). Microvesicular steatosis is frequently found in 
mitochondrial dysfunctions, urea cycle enzyme defects, lysosomal storage diseases, Reye- 
and Reye-like syndromes, lipodystrophies and certain drug toxicities such as salicylates and 
valproate). 
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Fat droplets of various sizes can be seen mostly, but not only, in hepatocytes. The ubiquitous 
triglyceride droplets have a round contour, are only slightly electron dense and usually have no 
surrounding limit membrane. Even in cells apparently completely filled-up with fat droplets, the 
changes in other organelles are rare, with the exception of crystal formation in mitochondria, 
seen more frequently.  Occasionally, a fat droplet can be seen in the nucleus as well.   
5.7.1 Atypical lipid-containing organelles 
Membrane-bound lipid droplets (lipolysosomes) are frequently seen in hepatocytes in 
association with triglyceride-containing droplets. 
We distinguish between several types of lipid-containing, membrane-bound bodies: 
1. Lipolysosomes as described by Hayashi and Sternlieb, and Kanai et al.(Hayashi & 
Sternlieb, 1975; Hayashi et al., 1983; Kanai et al., 1994). Electron-lucent droplets, usually 
up to 10 µm in diameter, with uniform content and surrounded by a trilaminar 
membrane. Of special interest are vesicles (attachments) to the outer leaflet of the 
surrounding membrane and associated lipofuscin (Figs. 53). 
2. Multivesicular bodies, described by Phillips et al. (1987) as lipolysosomes, containing 
numerous smaller droplets with lipidic aspect (Fig. 54).  Such lipolysosomes have been 
observed frequently in Wilson disease and in patients with NAFLD. They are 
frequently seen in hepatocytes showing increased amounts of typical lipofuscin 
3. Giant lipolysosomes (Fig. 55) which we suggest to name “compound lipolysosomes“, 
observed in  cases of extreme overweight (Haimi et al., 2011).  They appear to be formed 
by the fusion of numerous lipolysosomes of usual size, through a process similar to the 
formation of “compound siderosomes“ describe in iron overload (Roy & Ghadially, 1967). 
6. Infections and infestations (See Table 1) 
Negative staining is required for identification of some viral particles while others display 
characteristic features in cytosol or nucleus in various liver cells. In acute hepatitis, remnants 
of apoptotic hepatocytes form eosinophilic acidophilic bodies (Fig. 56). They are then expelled 
from the cell aggregate and later phagocytized by macrophages. Other cells undergo 
necrosis without an identifiable apoptotic stage (Fig. 57). 
  
 
Fig. 56. Acidophilic body (arrow) in           
the sinusoid.  Fat droplets, disintegrated 
nucleus and phagolysosomes are still 
recognizable.  x 5,000 
Fig. 57. Acute hepatitis: Membranous 
phagolysosomes in a necrotic hepatocyte.     
x 6,000 
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Fig. 58. Acute hepatitis.  Mononuclear cells 
in sinusoid. x 4,000 
Fig. 59. Echinoccocus granulosum: hooklets 
(arrows) in the liver biopsy retrieved at 
surgery. x 10,000 
The presence of inflammatory reactions, mostly of viral origin, is visualized by TEM initially 
by the presence of mononuclear cells in sinusoids (Fig. 58).  Focal cytoplasmic degeneration 
precedes changes recognizable by light microscopy, to be followed by apoptosis and 
eventually necrosis. The identification of various hepatitis etiological agents is beyond the 
routine liver biopsy examination. The occasional encounter with parasites (Fig. 59) has an 
investigational character, 
7. Drug hepatotoxicity 
With the exponential increase in the number of drugs (medication) there is a parallel increase 
in the number of side- and toxic effects reported by patients. Many of these are related to liver 
function and metabolism and to the major de-toxifying role of this organ. In drug-induced 
damage, autophagosomes are frequently seen (Fig. 60) occasionally containing mitochondria 
(Fig. 61). In this review we will exemplify only a few of these toxic changes as seen by electron 
microscopy: non-specific effects, from mild and reversible to severe and life-endangering are 
listed in Table 1. In addition, there are some specific features which enable diagnosis of the 
offending compound: amiodarone, NSAIDs, aspirin, corticosteroids. 
 
 
Fig. 60. Drug toxicity.  
Autophagosomes (arrows) 
contain fat and multiple 
membranes.  x 15,000 
Fig. 61. Valproate toxicity. 
Mitochondria secluded in 
autophagolysosome.            
x 15,000 
Fig. 62. Corticosteroid 
effect. Lipid and excessive 
glycogen in a bi-nucleated 
hepatocyte.  x 6,000 
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Condition EM findings
Artefacts  
Delayed fixation 
Inadequate fixation 
Mitochondrial matrix with dense deposits 
‘Ballooned’ mitochondria, ‘Extraction’ of 
nuclei 
Myelin-like whorls in mitochondria 
Infections/ infestations
Hepatitis, herpes-varicella group 
virus viral particles 
Hepatitis, acute (HBV) viral particles (HBsAg)Nuclear Dane particles (HBcAg) 
Infectious mononucleosis Ebstein-Barr virus
Cytomegalovirus infection Electron-dense particles in hepatocytes (no virus) 
Kala-Azar Leishmania bodies in Kupffer cells 
Malaria Schizonts in Kupffer cells
Ecchinococosis Fragments in tissue
 
Bilirubin retention syndromes
Unconjugated hyperbilirubinemia –
Inherited disorders (Constitutional, 
non-hemolytic)
 
Crigler-Najjar syndromes, type 1 & 2 Intracanalicular bile thrombi, increased intercellular space.
Gilbert’s disease Flattening of hepatocyte microvilli, reduced RER, proliferated SER.
Conjugated hyperbilirubinemia
Cholangiopathies - Cholestasis (most 
etiologies) 
Curled cristae in mitochondria; dense 
deposits in cell sap; amorphous and/or 
filamentous bile cytolysosomes mostly 
around bile canaliculi; focal biliary necrosis; 
dilated & distorted bile canaliculi with 
abnormal microvilli and bile plugs. 
Pericanalicular cytoplasm may show 
microfilaments. 
Biliary atresia - Biliary duct 
obstruction 
Extensive cytoplasmic cholestasis, 
cytoplasmic biliary necrosis; pericanalicular 
filamentous cuff. 
Cystic fibrosis 
Cholestasis in infancy; aggregates of 
osmiophilic material in lumen; collagen; 
steatosis; ductule dilatation; many stellate 
cells.
Alagille 
Numerous bile-containing cytolysosomes and 
vesicles in Golgi; canaliculi can be empty. 
 
PFIC 1 (ATP8B1) Severe cholestasis (hepatocytes, sinusoidal cells, bile ducts, granular Byler bile). 
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PFIC 2 (ABCB11) As in PFIC-1 but amorphous and filamentous bile in canaliculi. 
PFIC 3 (ABCB4) As in PFIC 1 & PFIC 2 but amorphous and filamentous bile in canaliculi. 
Dubin-Johnson syndrome Lipofuscin-like pigment, abnormal bile canaliculi. 
Rotor syndrome Megamitochondria, reduced microvilli in bile canaliculi. 
  
Carbohydrate metabolism  
Glycogen Storage Diseases (GSD) 
Type I,(I-a) III, VI, VIII, IX, X, XI 
Accumulation of cytosolic glycogen in 
hepatocytes; displacement of organelles; 
frayed α-glycogen in types VI, VIII, IX, X. 
Type IIa, b, c Abnormal glycogen-containing lysosomes: glycogenosomes. 
Type IV (amilopectinosis) Abnormal structural glycogen, collagen deposition and cirrhosis. 
Diabetes mellitus 
As for GSD I and III; micro- and 
macrovesicular steatosis. 
Hyperglycogenation of nuclei. 
Lipolysosomes, lipofuscin; mitochondrial 
crystalline inclusions. 
Hereditary fructose intolerance 
Concentric membranous arrays in 
hepatocytes; Areas of cytoplasmic damage: 
‘Fructose holes’: abundant glycogen, 
prominent lipid droplets, large autophagic 
glycogen-containing vacuoles, myelin 
figures, focal cytoplasmic degradation. 
Galactosemia 
Hepatocytes: rosette or pseudoglandular 
formation; multinuclear hepatocytes. 
Cholestasis; large lipid droplets; distended 
RER 
 
Disorders of glycoprotein 
metabolism  
Mucopolysaccharidoses : Hurler, 
Hunter, Sanfilippo, Scheie, Morquio, 
Maroteaux-Lamy 
Abnormal lysosomes in hepatocytes, RER, 
sinusoidal cells and vascular epithelia; 
empty-looking vacuoles, occasional ‘bull’s 
eye’ appearance. 
Glycoproteinoses
Fucosidosis Lysosomes with variable membranous content. 
Sialidosis (Mucolipidosis I) Fine reticular-granular content of lysosomes (hepatocytes and sinusoidal cells). 
Mannosidosis Fine reticular-granular content of lysosomes. Electron-opaque globules in Kupffer cells. 
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Salla disease “Empty lysosomes “: parenchymal & sinusoidal cells. 
Glutamyl ribose 5-phosphate 
glycoproteinosis 
Vacuoles with floccular material in Kupffer 
cells. 
 
Mucolipidoses
Mucolipidosis II (I-cell disease) Cytoplasmic membrane- bound vacuoles containing fibrillose-granular material. 
Mucolipidosis III (Pseudo-Hurler) Vacuoles in cultured fibroblasts.
Mucolipidosis IV Hepatocytes: lamellar inclusions; Kupffer cells: fibrogranular material in lysosomes. 
Alpha-1-AT deficiency Amorphous accumulations in hepatocytic RER. 
  
Disorders of lipid metabolism  
Sphingolipidoses - Gangliosidoses  
GM1 (generalized gangliosidosis) 
Landing) 
Membranous cytoplasmic bodies. Lipid-
laden histiocytes (liver).
GM2 (Tay-Sachs, Sandhoff disease) Membranous cytoplasmic bodies.
Glycosphingolipid lipidosis (Fabry 
disease) Lysosomal concentric arrays disease. 
Lactosyl ceramidosis Lysosomal lamellae.
Sulphatidosis (metachromatic 
leukodystrophy) 
Hepatocytic lamellar inclusions “Herring 
bone” 
Glucocerebrosidosis (Gaucher disease) Gaucher cells.
Ceramidosis (Farber disease) Hepatocytic vacuoles and dense bodies; curved tubular structures in Kupffer cells. 
Sphingomyelinosis (Niemann-Pick 
disease)  
(All types) Lysosomal concentric membranes in hepatocytes and sinusoidal cells. 
Abetalipoproteinemia Macrovesicular liver steatosis.Deficient trans-Golgi vacuole formation 
Familial lipoprotein deficiency Lipolysosomes in foam cells of RES. 
Acid lipase deficiency & Wolman 
disease 
Foamy histiocytes containing acicular crystal 
lipid droplets in hepatocytes and histiocytes. 
Cholesteryl ester storage disease Cholesteryl ester crystals in Kupffer cells. 
Ceroid lipofuscinosis Lipofuscin and tubular structures in lysosomes. 
Chanarin-Dorfman disease Ichthyosis, fatty liver, cirrhosis.
Steroid therapy, prolonged Macrovesicular liver steatosis.
Total lipodystrophy &
Parenteral nutrition
Macrovesicular steatosis, lipid lakes, 
cholestasis
 
Disorders of protein metabolism
Tyrosinemia Cholestasis, steatosis, abnormal MV, collagen in space of Disse.
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Aspartylglucoaminuria Large lysosomes in hepatocytes &Kupffer cells. Membranous structures in mitochondria. 
Carbamyl phosphate synthetase 
deficiency 
Concentric RER, small mitochondria with 
high matrix density. 
Lysinuric protein intolerance with 
deficient transport of basic amino acids 
Increased SER; large vesicles filled with 
fibrogranular material. 
Carnitine palmoyl transferase 
deficiency Large-droplet fatty liver. 
Hyperornithinemia Megamitochondria, abnormal shapes and membranes. 
Cystinosis Crystals in Kupffer cell lysosomes. 
Homocystinuria Mitochondria abnormal shapes, SER. proliferation, peribiliary lysosomes. 
 
Metals 
Iron 
Primary and secondary 
hemochromatosis 
Ferritin in cytosol and lysosomes 
(siderosomes) Hemosiderin only in 
lysosomes (most cell lines) 
Transfusional siderosis RES hemosiderin loading, less in parenchyma. 
Neonatal hemochromatosis
 
Aceruloplasminemia 
Heavy parenchymal siderosis, less in RES 
(distribution similar to hemochromatosis) 
Brain and systemic siderosis, including liver 
Association with lipofuscin Ferritin and hemosiderin in compound lysosomes with lipofuscin. 
Copper 
Wilson disease 
Abnormal mitochondria, abnormal 
peroxisomes, lipolysosomes, fatty liver, 
electron-dense deposits. 
Menkes’ kinky hair syndrome Cartwheel-like cristae in mitochondria. 
  
Peroxisomal disorders
Zellweger syndrome Absent peroxisomes.
Hepatic acatalasia syndrome Absent peroxisomes.
Neonatal adrenoleukodystrophy Few, small, peroxisomes.
Primary hyperoxaluria Type I Few, small, peroxisomes
Infantile Refsum’s disease Few, small peroxisomes; angulated lysosomes. 
 
Drug Toxicity – general features 
Mitochondrial changes(absent dense matrical 
granules, paracrystalline formation); RER 
dilatation, SER proliferation; increased. 
frequency of lysosomes 
(autophagolysosomes); apoptosis, focal 
necrosis, lipofuscinosis. 
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Corticosteroid therapy, high dosage, 
short term Glycogen accumulation in hepatocytes. 
  
Miscellaneous 
Kwashiorkor, protein-calorie 
malnutrition 
Large droplet fatty liver, abnormal 
mitochondria. 
Chediak-Higashi disease Abnormal inclusions in Kupffer cells and hepatocytes. 
Erythrohepatic-protoporphyria 
Amorphous or needle-like pigment  
in hepatocytes and Kupffer  
cells.
Erythroblastosis fetalis Erythroblasts and reticulocytes in liver parenchyma. 
GVH disease Immune cell infiltrate.
Langerhans Cell 
Histiocytosis Birbeck granules. 
Parenteral nutrition 
Mitochondrial changes, vesiculated SER, 
cholestasis, lipofuscin, in hepatocytes and 
Kupffer cells. 
Reye syndrome & Reye-like 
syndrome 
Microvesicular fatty liver, abnormal 
mitochondria, many peroxisomes. 
Table 1. Electron Microscopic findings in different conditions 
7.1 Corticosteroid effect 
Fatty liver has been reported among the side-effects of prolonged large-dose steroid therapy 
(Sherlock & Doodley, 1993). Three patients aged 8, 10 and 12 year respectively, treated with 
medium-high doses of corticosteroids presented with hepatomegaly and elevated 
transaminases of unknown origin.  Liver biopsy performed to elucidate these findings, 
revealed (by TEM) excessive glycogen in hepatocytes, to the extent of justifying 
hepatomegaly. The increased amount of hepatocytic glycogen displaced mitochondria and 
other components towards the nucleus and plasma membrane (Fig. 62).  The pattern was 
similar to that of glycogen storage diseases observed in type III and IX. Lipid droplets were 
scarce. After the steroid therapy was discontinued, the liver size returned to normal (Iancu 
et al., 1986). 
7.2 Amiodarone 
Changes similar to alcoholic liver injury are commonly found. Steatosis, is the  
most frequent histopathological feature. Ballooning of hepatocytes, Mallory bodies, and 
fibrosis are common. Other changes include nuclear unrest, acidophilic bodies, foam  
cells, hyperglycogenated nuclei, and portal inflammation. Characteristic lamellar 
lysosomal inclusion bodies representing phospholipidosis should be better designed  
as “myelinosomes“(Fig. 63), (Ghadially, 1997). The cytotoxic pseudoalcoholic changes 
could be an independent phenomenon in susceptible patients unable to metabolize the 
drug.  The true incidence of hepatic injury from amiodarone remains to be determined 
from prospective evaluations of pretreatment and follow-up liver biopsies (Lewis et al., 
1990). 
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Aspartylglucoaminuria Large lysosomes in hepatocytes &Kupffer cells. Membranous structures in mitochondria. 
Carbamyl phosphate synthetase 
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Concentric RER, small mitochondria with 
high matrix density. 
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fibrogranular material. 
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Hyperornithinemia Megamitochondria, abnormal shapes and membranes. 
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Corticosteroid therapy, high dosage, 
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Reye syndrome & Reye-like 
syndrome 
Microvesicular fatty liver, abnormal 
mitochondria, many peroxisomes. 
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other components towards the nucleus and plasma membrane (Fig. 62).  The pattern was 
similar to that of glycogen storage diseases observed in type III and IX. Lipid droplets were 
scarce. After the steroid therapy was discontinued, the liver size returned to normal (Iancu 
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7.2 Amiodarone 
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most frequent histopathological feature. Ballooning of hepatocytes, Mallory bodies, and 
fibrosis are common. Other changes include nuclear unrest, acidophilic bodies, foam  
cells, hyperglycogenated nuclei, and portal inflammation. Characteristic lamellar 
lysosomal inclusion bodies representing phospholipidosis should be better designed  
as “myelinosomes“(Fig. 63), (Ghadially, 1997). The cytotoxic pseudoalcoholic changes 
could be an independent phenomenon in susceptible patients unable to metabolize the 
drug.  The true incidence of hepatic injury from amiodarone remains to be determined 
from prospective evaluations of pretreatment and follow-up liver biopsies (Lewis et al., 
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Fig. 63. Amiodarone 
toxicity: lamellar phosphor-
lipidosis in a lysosome         
x 10,000 
Fig. 64. Aspirin toxicity: 
dilated RER; steatosis, 
shrunken nuclei.  x 4,000 
Fig. 65. Aspirin toxicity: 
dilatation of RER; 
crystalline deposits.  
x 10,000 
7.3 Acetylsalicylic acid (Aspirin) 
In addition to its suspected relationship to Reye syndrome, aspirin, in large doses, has been 
found to increase the level of transaminases, a reversible reaction. TEM of a liver biopsy of a 
patient disclosed hepatotoxicity: dilatation of RER, mitochondrial changes 
(megamitochondria, crystalline formation), nuclear changes and lipofuscinosis (Figs. 64-65), 
(Iancu & Elian, 1976). 
7.4 Acetaminophen (Paracetamol) 
Frequently used as a suicidal drug, paracetamol can precipitate fatal liver failure when 
dosage is beyond 8–10g. TEM of experimental animals and cultured hepatoma-derived 
cells (HepG2 and Hep3B) disclosed the different stages of dose-related toxicity. Of note, 
the anti-oxidant N-acetylcysteine did not protect cultured cells against acetaminophen-
induced apoptosis (Manov et al., 2002; Manov et al., 2004). Various aspects of 
ultrastructural damage induced by non-steroidal anti-inflammatory drugs (NSAIDs) are 
described in detail in a review of hepatotoxicity of anti-inflammatory and analgesic drugs 
(Manov et al., 2006). 
8. Conclusions 
Transmission electron microscopy of liver biopsies provides: 
1. Typical diagnostic findings for a relatively small, but important, number of 
pathological conditions. 
2. Supportive information for a larger group of suspected conditions which require 
further confirmation. 
3. Important exclusion of conditions which were considered in differential diagnosis. 
Furthermore, it remains an essential research tool in all areas of bio-pathology. 
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1. Introduction 
The liver biopsy has long been the gold standard for the evaluation of the state of liver 
diseases in patients, especially in chronic hepatitis. Hepatic fibrosis plays the most 
important role in the evolutionary process from chronic hepatitis to cirrhosis. Therefore, 
accurate assessment of the degree of hepatic fibrosis in chronic viral hepatitis is important to 
understand not only the clinical condition and prognosis of patients, but also the natural 
history of hepatitis. Information on a stage of chronic viral hepatitis C is essential to make 
prognosis and decide antiviral treatment. Semi quantitative scoring systems have been used 
in most studies that have relied upon liver biopsy to evaluate changes in fibrosis (Knodell et 
al., 1981, Desmet et al., 1994, Chevallier et al., 1994, French METAVIR, 1994, Ishak et al. 
1995). Comparative characteristic of different scoring systems is presented by Brunt (2000) 
and Goodman (2007). However, these methods cannot completely avoid the observer’s bias. 
Recent studies have reported that the estimation of fibrosis by semi quantitative scoring 
system is not always accurate and high rate of inter- and intraobsrever discrepancies takes 
place (Scheurer, 2003). The alternative to semi quantitative fibrosis scores is direct 
measurement of the amount of fibrosis, or necroinflammatory lesions, or portal zones in the 
biopsy by computer-assisted morphometric image analysis (O’Brien et al., 2000), or 
stereological morphometric analysis (Filimonova et al., 2010). Cell population analysis gives 
additional information about structure of parenchyma elements (liver plates and sinusoids). 
2. Patients and methods 
2.1 Patients 
The different groups of patients with chronic viral hepatitis C (HCV) and chronic viral 
hepatitis B (HBV) were investigated. The patients with weak, moderate and expressed 
degree of fibrosis according to Ishak (Ishak et al., 1995) and METAVIR group classification 
(French METAVIR, 1994) participated. The diagnosis of chronic HCV or chronic HBV was 
established after careful examination of patients: the anamneses of diseases and life, 
laboratory analyses, virological and morphological studies. Serum level of ALT was 
expressed. The upper limit of normal (ULN) was 41 U/L for men and 31 U/L for women. 
The classification of chronic liver diseases, accepted by the International Congress of 
Gastroenterology (Los Angeles, 1994), was used during the formulation of the diagnosis. 
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2.2 Histological evaluation 
All liver biopsies were performed according to the routine medical follow up program, 
using the standard Menghini procedure (Menghini, 1970, Mengini et al., 1975). Samples 
were formalin-fixed and paraffin-embedded. Serial paraffin sections were cut at 5 mcm. 
Criteria for adequacy of the biopsy specimens included a core length of 10 mm and at 
least 5-6 portal tracts. Hematoxylin-eosin stain was used. Each biopsy for necro-
inflammatory activity and fibrosis was assessed by two hepatologists. For each biopsy 
specimen, a numerical score was established, both for the grading of necroinflammatory 
activity and to determine the stage of fibrosis. Knodel Histology Activity Index (HAI) was 
used to grade histopathological lesions (Knodell et al., 1981). HAI was graded according 
to 3 components: periportal inflammation with or without bridging necrosis (scale, 0-10), 
intralobular degeneration and focal necrosis (scale, 0-4), and portal inflammation (scale, 0-
4). In accordance with the previously cited studies, the intensity of HAI was scaled as 
follows: A0 denoted no histological activity; A1, minimal activity (scale units, 1-3); A2, 
mild activity (scale units, 4-8); moderate activity (scale units, 9-12); and A4, severe activity 
(scale units, > 12). METAVIR group scoring system was used for detecting the stage of 
fibrosis (French METAVIR, 1994). Fibrosis was staged on a scale from F0 to F4, as follows: 
F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = few septa, F3 = numerous septa 
without cirrhosis, and F4 = cirrhosis. None of the included patients showed any signs of 
cirrhosis. 
2.3 Computer digital analysis 
Fibrosis ratio for each liver biopsy specimen was calculated using an image analysis system 
consisting of a microscope (Leica DM 2500) with attached digital camera (Leica DFC 320 R2) 
and a computer. Serial pictures of biopsy slices of patients with HBV were photographed by 
light microscope and saved electronically. The further process was performed with the 
computer program Adobe Photoshop CS 4. Image was converted into a binary image. The 
two-dimensional patterns were measured by direct pixel counting on the binary images 
under a simultaneous visual control of light microscopy. The total area of serial sections was 
the sum of the area of all microscopic fields including parenchyma and non-parenchymal 
areas. Fibrosis in the space of Disse was not calculated. We considered that non-
parenchymal elements included the sum of portal areas and intralobular infiltrates and 
necroses. 
2.4 Stereometric analysis 
The stereometric analysis is based on the determination methods of the specific volumes of 
different structure (Hamilton and Allen, 1995). Samples of biopsy from the patients with 
HBV were investigated. The calculation was carried out using the standard graticule (400 
squares). Morphometry was applicated on counting the points or intersections in the field of 
microscope at the magnification of x400. The field of vision of microscope at the 
magnification of x400 as a standard unit was accepted. In each field of sight a quantity of 
intersections of non-parenchymal liver structure – portal tracts, with nearby piecemeal and 
bridging necroses, venous vessels and intralobular necroses – were calculated. Other liver 
structures were studied together with parenchyma (liver plates and sinusoids). The 
measurement of portions (percentage) of portal areas, foci of intralobular necroses and 
vessels was estimated. The total area of the sections was the sum of the area of all 
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microscopic fields including parenchyma and non-parenchymal elements. Fibrosis in the 
space of Disse was not evaluated. 
2.5 Cell population analysis 
The comparative investigation was performed at the samples of biopsy from the patients 
with both chronic hepatitis, HCV and HBV. Proportion between the portion of the area 
occupated with liver plates and intralobular sinusoids was detected by stereometric 
morphometric analysis. The number of lytic necroses of hepatocytes, binucleate hepatocytes 
and polymorphous hepatocytes with large nuclei was calculated in composition of liver 
plates. The number of Kupffer cells and endoteliocytes was determined in composition of 
sinusoids. Calculation was performed in the standard field of vision of microscope at the 
magnification x400 in region of middle zone of liver lobule. Twenty standard fields of vision 
were investigated for each biopsy. 
2.6 Statistical analysis 
Variables, differing significantly according to the quantity of non-parencymal elements in 
the estimation group were identified by univariate analysis. Therefore, all variates were 
included in a multivariate forward stepwise regression analysis to determine the 
morphometric data. Pearson and Spearman correlation coefficients were used to evaluate 
whether changes in morphometric data were correlated with ALT. Student and Satterwhite 
criterions, Pearson and Spearman correlation соefficients were used to evaluate the structure 
of population. Statistical analysis was performed by tabulated processor Microsoft Excel 
2003 and STATISTIKA 9.0. 
3. Results 
3.1 Quantitative image analysis for evaluation of pathological changes in liver 
structure  
A biopsy is an important key factor for the prediction and tactics of treatment of patients 
with chronic viral hepatitis (Friedman, 2003, Friedman et al., 2007). Numerical fibrosis 
scoring systems (Knodell et al., 1981, French METAVIR, 1994, Ishak et al., 1995, Brunt, 2000) 
are usually used to assess the degree of activity and fibrosis stage. These systems are semi 
quantitative: the assessment of inflammatory, degenerative and fibrotic changes is 
determined in scale units. Many investigators recognize that there may be purely subjective 
error in numeral fibrosis scoring. Thus, the variability of fibrosis staged is estimated at 20% 
(Friedman, 2003). It is believed that the more indicators are presented in a given system, the 
more misunderstandings can occur.  
Consequently, the assessment activity and the stage of process were usually performed by 
two independent experts. However, correct assessment of the degree of liver damage at the 
time of initial biopsy is extremely important for a treating physician. Thus, it effects the 
choice of treatment (antiviral or symptomatic treatment) and the ability to forecast 
progression of fibrosis. 
Recently the computer morphometry has been used to assess the stage of fibrosis (Manabe et 
al., 1993; Chevallier et al., 1994; Kage et al., 1997; Pilette et al., 1998; Duchatelle et al., 1998; 
Masserolli et al., 2000; O’Brien et al., 2000). Chevallier et al. (1994) compared the 
computerized fibrosis ratio with a detailed subjective scoring system.  That incorporated 
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are usually used to assess the degree of activity and fibrosis stage. These systems are semi 
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determined in scale units. Many investigators recognize that there may be purely subjective 
error in numeral fibrosis scoring. Thus, the variability of fibrosis staged is estimated at 20% 
(Friedman, 2003). It is believed that the more indicators are presented in a given system, the 
more misunderstandings can occur.  
Consequently, the assessment activity and the stage of process were usually performed by 
two independent experts. However, correct assessment of the degree of liver damage at the 
time of initial biopsy is extremely important for a treating physician. Thus, it effects the 
choice of treatment (antiviral or symptomatic treatment) and the ability to forecast 
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evaluation of central veins, pericellular fibrosis, portal tracts, and the number and width of 
septa in patients with chronic liver diseases. Duchatelle et al. (1998) used computerized 
image analysis to measure liver fibrosis in groups of patients with chronic hepatitis C 
treated with interferon alfa. Significant correlation was observed between evaluations of 
fibrosis degree using two methods: a semi quantitative method with a staging scoring 
system and a computed image system (Kage et al., 1997).  
Pilette et al. (1998) compared fibrosis ratios and subjective scores (METAVIR) in series of 
patients with chronic liver disease in a study of the validity of serum markers of fibrosis. 
The area of fibrosis, as determined by image analysis and the semi quantitative score was 
well correlated. However, for serum markers the correlation was higher with the area of 
fibrosis than with the semi quantitative score. Authors supposed that such characteristics as 
reproducibility, rapidity, simplicity, adaptability, and exhaustiveness also favored image 
analysis. 
O’Brien et al. (2000) found an overall statistically significant correlation between fibrosis 
ratio and ordinal score, but subset analysis showed that this correlation was restricted to 
biopsy specimens with high scores (3-6, early bridging fibrosis to established cirrhosis). The 
fibrosis ratio was the total area of fibrosis divided by the total area of the section. Authors 
found that the fibrosis ratio of liver biopsy specimens calculated by digital image analysis 
was not always reflecting fibrosis in chronic hepatitis as indicated by subjective scoring 
classifications. This applied particularly to livers that were normal or in early fibrosis (stage 
0-2). 
Masserolli et al. (2000) described the design and validation of an original image analysis-
based application, FibroQuant, for automatically and rapidly quantifying perisinusoidal, 
perivenular and portalperiportal and septal fibrosis in liver histological specimens. 
Sometime morphometric image analysis was used for evaluation of fibrosis progression 
(Goodman et al., 2007, 2009). Morphometry demonstrated complex, non-linear changes in 
fibrosis over time in heterogenous cohort of patients with interferon-refractory chronic 
hepatitis C (Goodman et al., 2009). 
The purpose of this study was to explore the possibilities of using computer morphometry 
for quantitative assessment of histological parameters biopsies of patients with chronic 
hepatitis B. The group of patients with minimal, mild, moderate and severe activity, but 
without cirrhosis was studied. Two major indicators were selected for evaluation: the portal 
area or its fragments and intralobular infiltrates. 
According to portal areas we calculated next variants:  
 portal area without changes; 
 expansion of portal area without damages of limiting plate; 
 portal area with damage of limiting plate and development of short septa; 
 portal area with damage of limiting plate and development of piecemeal necroses; 
 portal area with marked bridging necroses; 
 portal area with extensive fibrosis changes; 
 portal area with extensive lymphoid infiltration; 
 occasional fibrosis septa. 
Intralobular infiltrates were divided into 2 groups:  
 lymphohistiocyte infiltrates; 
 lymphohistiocyte infiltrates with damaged hepatocytes. 
So, our calculation included the evaluation of not only fibrosis changes, but also 
inflammatory area in portal and intralobular zones.  
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Different morphological pictures of samples of biopsy from patients with chronic viral 
hepatitis B are presented at Figures 1 – 4.  
 
 
Fig. 1. Section of the liver biopsy specimen of patient with chronic hepatitis B. Portal area 
with damage of limiting plate and development of short septa. Hematoxylin-eosin. Obj.x20 
 
 
Fig. 2. Section of the liver biopsy specimen of patient with chronic hepatitis B. Portal tract 
with damage of limiting plate and development of piecemeal necroses (interface hepatitis). 
Hematoxylin-eosin. Obj.x20 
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Fig. 3. Section of the liver biopsy specimen of a patient with chronic hepatitis B. Focal 
intralobular necroses in the middle zone of liver lobule. Hematoxylin-eosin. Obj.x20 
 
 
Fig. 4. Section of the liver biopsy specimen of a patient with chronic hepatitis B. Intralobular 
necrosis of hepatocytes with participation of lymphoid infiltration. Hematoxylin-eosin. 
Obj.x40 
The special panoramic application of biopsy samples was performed by Photoshop CS4 
program for computer analysis (Figure 5). This program allows you to connect serial 
micrographs of biopsy and get a computer image of the whole biopsy.  
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The program gives the possibility to unite serial micrographs of the single biopsy sections 
and create computer image of the total biopsy. The pixel count performs on the total square 
of the biopsy after the computer montage of individual micrographs. The squares of portal 
zones and intralobular infiltrates in pixels were determined separately, after that the special 
parts (percentage) of these components were counted. Further, after identification the areas 
of portal zones and intralobular infiltrates are calculated in pixels and transformed into 
percentage. The data obtained are summarized in Table 1.   
 
 
Fig. 5. General picture of liver biopsy composed by computer microscopy (Obj.x20) using 
Adobe Photoshop CS4. This picture contains 142 standard computer microphotographs of 
biopsy. Total area of biopsy is 327342640 in pixels 
 
Biopsy 
number 
Total area 
of biopsy 
(in pixels) 
Total area of 
parenchyma,
% 
Total area of  
non-parenchymal 
elements, % 
Total area of 
portal zones 
and septa, % 
Total area of 
intralobular 
necroses, % 
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4 80293713 98.24 1.76 1.59 0.17 
5 88550390 97.65 2.35 2.20 0.15 
6 127210818 97.63 2.37 2.13 0.24 
7 257720901 97.50 2.50 2.14 0.36 
8 99280000 97.05 2.95 2.77 0.18 
9 62243476 95.81 4.19 3.03 1.16 
10 96036721 95.13 4.87 4.45 0.42 
11 327342640 88.85 11.15 9.75 1.40 
Table 1. Computer morphometric analysis of the total area of parenchymal and non-
parenchymal elements of liver biopsy in percents and total area of biopsy in chronic 
hepatitis B. The samples of biopsies are arranged in sequence of increasing of non-
parenchymal elements independently from biopsy sizes 
This study focuses on the consideration of parameters of liver non-parenchymal elements, 
which includes all types of portal zones (Figures 1 and 2) and different variants of 
intralobular infiltrates and necroses (Figures 3 and 4). Liver plates and sinusoids were 
attributed to the hepatic parenchyma. As can be seen from the Table 1, the total area of the 
samples of biopsies is variable. Thus, the maximum biopsy size in pixels was 327324640, 
whereas the minimum – only 6224347 pixels. It is already possible to determine the 
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Fig. 3. Section of the liver biopsy specimen of a patient with chronic hepatitis B. Focal 
intralobular necroses in the middle zone of liver lobule. Hematoxylin-eosin. Obj.x20 
 
 
Fig. 4. Section of the liver biopsy specimen of a patient with chronic hepatitis B. Intralobular 
necrosis of hepatocytes with participation of lymphoid infiltration. Hematoxylin-eosin. 
Obj.x40 
The special panoramic application of biopsy samples was performed by Photoshop CS4 
program for computer analysis (Figure 5). This program allows you to connect serial 
micrographs of biopsy and get a computer image of the whole biopsy.  
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The program gives the possibility to unite serial micrographs of the single biopsy sections 
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of portal zones and intralobular infiltrates are calculated in pixels and transformed into 
percentage. The data obtained are summarized in Table 1.   
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suitability of a biopsy for further work at this stage. The absolute value of the area of any 
structures (in pixels) depends on the size of biopsy. Therefore, we have calculated the 
percentage of these structures. 
Computer morphometric analysis discovered that the portions of the area of non-
parenchymal elements of different biopsies of patients with HBV strongly varied from 0.95% 
to 11.5%. The area portions of the portal zones varied from 0.65% to 9.75%. Both indexes 
increased in biopsies of given group unidirectional and linearly. Intralobular necroses 
presented in all biopsies. Their specific parts varied from 0.15 % to 1.40 %. At the same time 
the percentage part of intralobular necroses did not depend on the indexes of percentage 
parts of portal zones. We supposed that separate quantitative evaluation of portal zones and 
intralobular necroses could be useful to indicate the severity and the progression of chronic 
hepatitis. 
3.2 Histological evaluation of liver biopsies by stereometric analysis 
The application of computer morphometry is not always possible, because it demands the 
complex expensive equipment (microscope, digital video camera and computer).  
Nevertheless, the quantitative value of fibrosis development in liver is possible without 
using such complex equipment. In this case, usual light microscope may be effectively used 
for stereometric analysis (Filimonova et al., 2010). 
We used this method for quantitative study of liver biopsies of patients with chronic viral 
hepatitis B. Information about the special group of patients selected for stereometric analysis 
is given in the Table 2. 
 
Age (years) 20 ±1,3 
Sex male 
Duration of hospitalization (days)  13,5±2,6 
Duration of infection (years) 9,5±2,5 
Initial ALT 371,5±277 
Initial bilirubin 30,7±14,2 
Drug user 1 person (10%) 
Table 2. Characteristics of patients with chronic hepatitis B 
The morphological investigation of liver biopsies of the patients of this group found the 
presence of some essential changes, such as moderate fibrosis, expansion of a part of portal 
zones, increasing of the numbers of the cells with vacuolated nuclei, the appearance of the 
intralobular infiltrates, dilatation of portal veins, pronounced polymorphism of the 
hepatocytes and its nuclei. 
Morphometric analysis was used to study three indexes: determination of the area of portal 
zones, focal infiltrates, terminal hepatic venules and sublobular veins. At first we 
determined for each case the portion of selected indexes (in points of intersections), and then 
calculated the corresponding parts (in percentage) of the parenchyma, portal zones, focal 
infiltrates and vessels taken over the standard unit of microscopic fields (Table 3).  
The sum of the area of portal zones, focal infiltrates and vessels was referred to non-
parenchymal elements. The results of analysis are placed in the Tables in the sequence of 
increasing part of the non-parenchymal elements in the biopsy. 
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The amount of the fields of view of biopsies of patients with HBV varied from 141 to 350 i.e. 
was 228.3±23.55 on the average. The sum amount of intersections by morphometric analysis 
varied from 43710 to 108500 number of points i.e. was 70773±7301.51 on the average. 
The part of the non-parenchymal elements in liver biopsies of patients with chronic HBV 
varied from 2.39% to 12.46% (Table 3), but was essentially lower than in liver biopsies of 
patients with chronic HCV (Filimonova et al., 2010). The specific part of non-parenchymal 
elements did not exceed 4.62% in total, these indexes were essentially higher only from 
biopsies of two patients (8.41% и 12.46%, respectively). 
 
Biopsy 
number ALT 
Total area of 
morphometry 
(points of 
intersections)
Parenchymal 
elements, % 
Non-
parenchymal 
elements, %
Portal 
zones, %
Focal 
intralobu- 
lar infiltrates, 
%
Hepatic 
veins, % 
1 45 90520 97,61 2,39 1,39 0,25 0,75 
2 16 92380 97,24 2,76 1,25 0,19 1,33 
3 89 56420 97,22 2,78 1,09 0,66 1,04 
4 71 108500 97,18 2,82 1,54 0,99 0,30 
5 29 66960 97,14 2,86 1,64 0,13 1,10 
6 15 43710 96,76 3,24 2,33 0,13 0,78 
7 414 49290 9568 4,32 2,87 0,07 1,38 
8 41 89590 95,38 4,62 2,79 0,08 1,75 
9 - 43710 91,59 8,41 7,59 0,24 0,58 
10 2842 66650 87,54 12,46 10,98 1,05 0,43 
Table 3. Quantitative characteristic of liver biopsies of the patients with chronic hepatitis B 
according to morphometric analysis 
The mean value of the non-parenchymal elements in liver biopsies of the patients of this 
group was 4.66%; the correlation of the portion of the non-parenchymal elements with the 
level of the ALT was less obvious than in chronic HCV (Filimonova et al., 2010). The high 
level of the ALT (2842 U/L) was observed only by maximal increasing of the specific part of 
the non-parenchymal elements (up to 12.46%). 
 
Biopsy 
number 
Total area of portal 
zones (points of 
intersections) 
Area of portal 
zones, % 
Number of 
portal zones in 
biopsy 
Maximal area of 
portal zone (points 
of intersections) 
Maximal area of 
portal zone at 
single microscopic 
fields, % 
1 1262 1,39 16 236 76,13 
2 1152 1,25 32 83 26,78 
3 616 1,09 17 71 22,90 
4 1674 1,54 48 110 35,48 
5 1098 1,64 20 212 68,39 
6 1017 2,33 30 99 31,94 
7 1415 2,87 20 376 121,29 
8 2497 2,79 39 335 108,06 
9 3316 7,59 21 439 141,61 
10 7319 10,98 42 532 171,61 
Тable 4. Quantitative characteristic of portal zones of liver biopsies of the patients with 
chronic hepatitis B according to  morphometric analysis 
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infiltrates and vessels taken over the standard unit of microscopic fields (Table 3).  
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parenchymal elements. The results of analysis are placed in the Tables in the sequence of 
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The specific part of the portal zones (Table 4) of the liver of the most patients varies from 
1.09% to 2.87%, these indexes were essentially higher only from biopsies of two patients 
(7.59% и 10.98%, respectively). The mean value of specific part of the portal zones varies 
from 33.9 points to 78.8 points in general, i.e. it occupies from 11% to 25% of the standard 
sight of view. Maximal areas of portal zones varied from 22.9% till 171, 61% (or from 71 till 
532 points respectively) at single microscopic field (Table 4). The portal tracts of two patients 
with expressed activity of the process of the disease were increased to 157.9 and 174.26 
points; it was corresponded with the 51% and 56% of the square of the standard field of the 
microscope view. The focal interlobular infiltrates were observed in liver of all the patients 
(Tables 3 and 5). 
 
Biopsy number Small focal infiltrates 
Large focal 
infiltrates 
Total number 
of infiltrates 
1 6 6 12 
2 5 5 10 
3 6 15 21 
4 15 24 39 
5 5 4 9 
6 9 4 13 
7 1 3 4 
8 2 2 4 
9 3 9 12 
10 6 24 30 
Table 5. The number of focal infiltrates at one standard square unit (100 fields of sight under 
the magnification ×400) in liver biopsies of patients with chronic hepatitis B 
The specific part of focal infiltrates varied from 0.07% to 1.05%. Large focal infiltrates 
predominated in liver of approximately the half of the patients (Table 5). It is characteristic 
that the specific part of focal infiltrates did not depend on the specific part of non-
parenchymal elements and did not correlate with ALT level. The amount of focal necroses 
(15.4±3.6) in liver of these patients in 100 standard fields of the microscope view was two 
times less than in liver of patients with hepatitis C (29.6±5.2) (Filimonova et al., 2010).  
The specific square of hepatic veins varied from 0.30% to 1.75% and did not depend on the 
specific part of non-parenchymal elements (Table 3). The mean specific square of vessels 
varied from 16.05 to 56.67 points. The growth of the venules from the portal tracts occurred 
often in liver of the majority of patients with chronic HBV. 
On the whole the inflammation-necrotic changes in liver of the given selected group of the 
patients were manifested weakly; fibrosis indexes did not exceed F0 and F1, both in the 
METAVIR system and Ishak system. Bridging and piecemeal necroses presented in liver of 
only two patients (№ 7 and № 10), both of them had the high ALT index and strongly 
enlarged the specific part of non-parenchymal elements.  
So the morphometric calculation of the non-parenchymal elements in liver biopsies of 
patients with HBV allows giving the complex evaluation of the replacement level of 
functional parenchyma by necro-inflammatory and fibrosis structures. 
Stereological quantitative morphometry allows to getting more correct evaluation of some 
morphological parameters of pathologically changed liver in patients with chronic viral 
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hepatitis. It is very important for establishment of either positive of negative dynamic 
changes in liver, especially during estimation of efficiency of antiviral treatment. We 
supposed that the stereological morphometry is a suitable tool for quantitative evaluation of 
liver biopsies in therapeutics trials. 
3.3 Cell population structure of liver biopsies from the patients with both chronic 
hepatitis, HCV and HBV 
Only sufficiently large biopsies with 5-6 portal zones can be suitable for quantitative 
evaluation of parenchymal elements of liver by methods of stereological or computer 
morphometry. Nevertheless, biopsies used have frequently small sizes or consist of fine 
fragments without portal zones in clinical practice.  Quantitative analysis of parenchyma 
elements (liver plates and sinusoids cells) is advisable in these cases.  
In our investigation the cell population analysis of liver biopsies from the patients with both 
chronic hepatitis, HCV and HBV included the comparative evaluation of the specific part of 
non-parenchymal elements, analysis of the liver plates and sinusoids areas, cell population 
of liver plates and sinusoids. 
3.3.1 Comparative analysis of the specific part of non-parenchymal elements 
The specific part of non-parenchymal elements in liver biopsies of patients with HCV (Table 
6) strongly varies: from 2.16% to11.93% (mean value is 6.9 ± 0.8%).  
 
Biopsy 
number 
Non- 
parenchymal 
elements, 
% 
Liver 
plates, %
Sinusoids, 
% 
Lytic 
necroses of 
hepatocytes
Binucleate
hepatocytes
Polymorpho-
us hepato-
cytes 
Endothelio- 
cytes 
Kupffer 
cells 
1 2,16 96,77 3,23 2,70 0,90 0,40 5,80 11,10 
2 2,46 92,68 7,32 1,60 2,40 0,90 7,30 6,90 
3 3,6 94,23 5,77 3,80 2,70 0,60 8,00 9,10 
4 4,3 95,10 4,90 3,50 1,00 1,30 7,20 5,30 
5 4,63 94,90 5,10 4,60 1,50 0,80 10,20 10,90 
6 4,7 93,74 6,26 2,80 0,30 0,00 8,90 6,90 
7 5,06 95,42 4,58 5,70 1,30 0,10 12,00 6,90 
8 5,18 93,32 6,68 2,60 0,30 0,10 7,60 10,70 
9 6,64 93,55 6,45 5,20 0,30 0,50 7,70 9,80 
10 9,46 94,68 5,32 4,40 1,70 0,80 12,80 15,80 
11 9,68 94,35 5,65 5,70 0,50 0,70 9,90 8,80 
12 10,56 92,16 7,84 4,60 1,10 0,90 11,30 12,00 
13 10,89 94,94 5,06 5,50 1,30 0,00 7,20 7,00 
14 11,76 93,00 7,00 3,80 2,70 1,90 9,70 14,00 
15 11,93 92,87 7,13 3,10 0,90 0,60 10,40 9,20 
Тable 6. Cell population structure of liver plates and sinusoids in patients with chronic 
hepatitis C 
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The specific part of the portal zones (Table 4) of the liver of the most patients varies from 
1.09% to 2.87%, these indexes were essentially higher only from biopsies of two patients 
(7.59% и 10.98%, respectively). The mean value of specific part of the portal zones varies 
from 33.9 points to 78.8 points in general, i.e. it occupies from 11% to 25% of the standard 
sight of view. Maximal areas of portal zones varied from 22.9% till 171, 61% (or from 71 till 
532 points respectively) at single microscopic field (Table 4). The portal tracts of two patients 
with expressed activity of the process of the disease were increased to 157.9 and 174.26 
points; it was corresponded with the 51% and 56% of the square of the standard field of the 
microscope view. The focal interlobular infiltrates were observed in liver of all the patients 
(Tables 3 and 5). 
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that the specific part of focal infiltrates did not depend on the specific part of non-
parenchymal elements and did not correlate with ALT level. The amount of focal necroses 
(15.4±3.6) in liver of these patients in 100 standard fields of the microscope view was two 
times less than in liver of patients with hepatitis C (29.6±5.2) (Filimonova et al., 2010).  
The specific square of hepatic veins varied from 0.30% to 1.75% and did not depend on the 
specific part of non-parenchymal elements (Table 3). The mean specific square of vessels 
varied from 16.05 to 56.67 points. The growth of the venules from the portal tracts occurred 
often in liver of the majority of patients with chronic HBV. 
On the whole the inflammation-necrotic changes in liver of the given selected group of the 
patients were manifested weakly; fibrosis indexes did not exceed F0 and F1, both in the 
METAVIR system and Ishak system. Bridging and piecemeal necroses presented in liver of 
only two patients (№ 7 and № 10), both of them had the high ALT index and strongly 
enlarged the specific part of non-parenchymal elements.  
So the morphometric calculation of the non-parenchymal elements in liver biopsies of 
patients with HBV allows giving the complex evaluation of the replacement level of 
functional parenchyma by necro-inflammatory and fibrosis structures. 
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hepatitis. It is very important for establishment of either positive of negative dynamic 
changes in liver, especially during estimation of efficiency of antiviral treatment. We 
supposed that the stereological morphometry is a suitable tool for quantitative evaluation of 
liver biopsies in therapeutics trials. 
3.3 Cell population structure of liver biopsies from the patients with both chronic 
hepatitis, HCV and HBV 
Only sufficiently large biopsies with 5-6 portal zones can be suitable for quantitative 
evaluation of parenchymal elements of liver by methods of stereological or computer 
morphometry. Nevertheless, biopsies used have frequently small sizes or consist of fine 
fragments without portal zones in clinical practice.  Quantitative analysis of parenchyma 
elements (liver plates and sinusoids cells) is advisable in these cases.  
In our investigation the cell population analysis of liver biopsies from the patients with both 
chronic hepatitis, HCV and HBV included the comparative evaluation of the specific part of 
non-parenchymal elements, analysis of the liver plates and sinusoids areas, cell population 
of liver plates and sinusoids. 
3.3.1 Comparative analysis of the specific part of non-parenchymal elements 
The specific part of non-parenchymal elements in liver biopsies of patients with HCV (Table 
6) strongly varies: from 2.16% to11.93% (mean value is 6.9 ± 0.8%).  
 
Biopsy 
number 
Non- 
parenchymal 
elements, 
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Liver 
plates, %
Sinusoids, 
% 
Lytic 
necroses of 
hepatocytes
Binucleate
hepatocytes
Polymorpho-
us hepato-
cytes 
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Тable 6. Cell population structure of liver plates and sinusoids in patients with chronic 
hepatitis C 
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The piecemeal and bridging necroses are presented, as a rule, in liver biopsies of the patients 
with high index of non-parenchymal elements. The piecemeal necroses are described in 11 
cases from 15, bridging necroses in 7 cases from 15. Such distribution shows that during the 
ordinary course of the disease the piecemeal necroses arise from the beginning, the bridging 
necroses are discovered later.  
The specific part of non-parenchymal elements changes from 2.39% to 8.41% (mean value is 
3.8 ± 0.9) in liver biopsies of patients with HBV (Table 7). The piecemeal necroses were 
observed only in one biopsy, the bridging necroses in two biopsies.  
The data regarding the specific parts of non-parenchymal elements shows that liver 
damages of patients with HCV are more significant in comparison with the analogical 
indexes of patients with HBV.  
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plates, %
Sinusoids, 
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Lytic 
necroses of 
hepatocytes
Binucleate 
hepatocytes
Poly-
morphous 
hepato-
cytes 
Endothelio- 
cytes 
Kupffer 
cells 
1 2,39 91,65 8,35 6,75 1,00 1,00 6,25 7,15 
2 2,76 91,81 8,19 5,35 3,85 2,15 5,50 8,40 
3 2,78 93,29 6,71 2,05 1,80 1,15 8,05 8,45 
4 2,82 93,65 6,35 3,70 0,85 0,90 6,90 6,10 
5 2,86 85,77 14,23 1,30 4,10 2,35 7,35 6,15 
6 3,24 91,16 8,84 5,70 1,20 1,20 5,10 5,15 
7 4,32 93,87 6,13 4,91 1,36 0,91 8,64 5,73 
8 4,62 91,39 8,61 3,20 1,95 1,60 8,30 6,50 
9 8,41 86,26 13,74 3,55 4,90 1,70 8,45 8,40 
Тable 7. Cell population structure of liver plates and sinusoids in patients with chronic 
hepatitis B 
3.3.2 Analysis of the liver plates and sinusoids 
Morphometric investigation shows that the specific parts of liver plates of patients with 
HCV slightly vary from 92.16% to 96.77% (mean value is 94.1±0.31). The specific parts of 
sinusoids vary from 3.23% to 7.84% (mean value is 5.9±0.4). Such variations are more 
significant in livers of patients with HBV. The specific parts of liver plates in this case 
vary from 85.77% to 93.87% (mean value is 90.98±0.32), the specific parts of sinusoids vary 
from 6.13% to 14.23% (mean value is 9.02±0.32). Morphological and morphometric studies 
show (Figures 6 and 7; Tables 6 and 7) that the sinusoids of liver biopsies of patients with 
HCV are significantly narrowed than such of patients with HBV. Respectively the 
conditions of intralobular blood circulation are significantly differ under various types of 
hepatitis.  
Thus, the connection between the disease severity and specific parts of liver plates and 
sinusoids are not established.  
3.3.3 Cell population of liver plates 
In liver biopsies of patients with chronic HCV (Table 6)  the amount of lost hepatocytes (lytic 
necroses) in liver plates varies from 1.6% to 5.7% in standard field of vision (mean value is 
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3.97±04). The number of binucleate hepatocytes varies from 0.3 to 2.7 (mean value is 
1.26±0.2). The number of polymorphous hepatocytes in standard field of vision varies from 
0.0 to 1.9 (mean value 0.64±0.1).  
In liver biopsies of patients with HBV (Table 7) the amount of lost cells varies from 1.3 to 
6.75 (mean value is 4.06±0.59). The number of binucleate hepatocytes varies from 0.85 to 4.9 
(mean value is 2.33±0.5). The number of polymorphous hepatocytes at standard field of 
vision varies from 0.9 to 2.35 (mean value is 1.44±0.3).  
Thus, the amount of single lytic necroses of hepatocytes does not differ in liver biopsies of 
patients with HBV and with HCV. At that time the number of binucleate hepatocytes and 
polymorphous hepatocytes is certainly higher in liver biopsies of patients with HBV. This 
situation may be connected with the different level of processes of regeneration.  
3.3.4 Cell population of liver sinusoids 
The amount of endotheliocytes in sinusoids of liver biopsies of patients with HCV (Table 6) 
strongly varies: from 5.8 to 12.8 cells in standard field of sight (mean value is 9.0±0.5). The 
amount of Kupffer cells is also significantly differing from 5.3 to 15.8 in the field of sight 
(main value is 9.6±0.7). Nevertheless, the precise linear dependence between the both of 
indexes is not revealing. 
The amount of endotheliocytes in sinusoids of liver biopsies of patients with HBV (Table 7) 
weakly varies from 5.1 to 8.64 cells in standard field of sight (mean value is 7.17±0.13). The 
amount of Kupffer cells changes from 5.15 to 8.45 in the field of sight (mean value is 
6.89±0.31). 
Thus, the amount of endotheliocytes and Kupffer cells is essentially more in liver biopsies of 
patients with HCV. This circumstance is probably connected with the peculiarities of virus 
influence on the vessel component of liver parenchyma.  
The cell population structure of liver biopsies of patients with HBV and HCV changes 
unequally. So, the using of Student and Satterwhite criteria allows discovering the 
statistically significant distinctions between mean values of all the indexes with the 
exception of the amount of lost hepatocytes in liver plates. 
The coefficients of correlation between the indexes of specific parts of liver plates and the 
number of binucleate cells, between the indexes of specific parts of liver plates and the 
number of polymorphous cells are statistically significant for the cluster of liver biopsies of 
patients with HBV.  
The statistically significant coefficients of correlation Pearson does not detected for the 
cluster of liver biopsies of patients with HCV. 
The strong linear dependence between the indexes of specific parts of liver plates and the 
number of binucleate cells and the number of polymorphous cells was revealed in liver 
biopsies of patients with HBV. 
The using of Spearmen coefficients of correlation allowed establishing the connection 
between the number of cells in sinusoids and the specific part of non-parenchymal elements 
in liver biopsies of patients with HBV. This circumstance could be used for indirect 
characteristics of the development of fibrotic changes in liver. 
In total, the quantitative analysis of cell population structure in liver biopsies in the course 
of chronic hepatitis, especially in the case of defective biopsies, could be used for diagnostic 
and prognoses by expert evaluation. 
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The data regarding the specific parts of non-parenchymal elements shows that liver 
damages of patients with HCV are more significant in comparison with the analogical 
indexes of patients with HBV.  
 
Biopsy 
number 
Non- paren-
chymal 
elements, %
Liver 
plates, %
Sinusoids, 
% 
Lytic 
necroses of 
hepatocytes
Binucleate 
hepatocytes
Poly-
morphous 
hepato-
cytes 
Endothelio- 
cytes 
Kupffer 
cells 
1 2,39 91,65 8,35 6,75 1,00 1,00 6,25 7,15 
2 2,76 91,81 8,19 5,35 3,85 2,15 5,50 8,40 
3 2,78 93,29 6,71 2,05 1,80 1,15 8,05 8,45 
4 2,82 93,65 6,35 3,70 0,85 0,90 6,90 6,10 
5 2,86 85,77 14,23 1,30 4,10 2,35 7,35 6,15 
6 3,24 91,16 8,84 5,70 1,20 1,20 5,10 5,15 
7 4,32 93,87 6,13 4,91 1,36 0,91 8,64 5,73 
8 4,62 91,39 8,61 3,20 1,95 1,60 8,30 6,50 
9 8,41 86,26 13,74 3,55 4,90 1,70 8,45 8,40 
Тable 7. Cell population structure of liver plates and sinusoids in patients with chronic 
hepatitis B 
3.3.2 Analysis of the liver plates and sinusoids 
Morphometric investigation shows that the specific parts of liver plates of patients with 
HCV slightly vary from 92.16% to 96.77% (mean value is 94.1±0.31). The specific parts of 
sinusoids vary from 3.23% to 7.84% (mean value is 5.9±0.4). Such variations are more 
significant in livers of patients with HBV. The specific parts of liver plates in this case 
vary from 85.77% to 93.87% (mean value is 90.98±0.32), the specific parts of sinusoids vary 
from 6.13% to 14.23% (mean value is 9.02±0.32). Morphological and morphometric studies 
show (Figures 6 and 7; Tables 6 and 7) that the sinusoids of liver biopsies of patients with 
HCV are significantly narrowed than such of patients with HBV. Respectively the 
conditions of intralobular blood circulation are significantly differ under various types of 
hepatitis.  
Thus, the connection between the disease severity and specific parts of liver plates and 
sinusoids are not established.  
3.3.3 Cell population of liver plates 
In liver biopsies of patients with chronic HCV (Table 6)  the amount of lost hepatocytes (lytic 
necroses) in liver plates varies from 1.6% to 5.7% in standard field of vision (mean value is 
 
Quantitative Morphometric Analysis of Liver Biopsy: Problems and Perspectives 
 
149 
3.97±04). The number of binucleate hepatocytes varies from 0.3 to 2.7 (mean value is 
1.26±0.2). The number of polymorphous hepatocytes in standard field of vision varies from 
0.0 to 1.9 (mean value 0.64±0.1).  
In liver biopsies of patients with HBV (Table 7) the amount of lost cells varies from 1.3 to 
6.75 (mean value is 4.06±0.59). The number of binucleate hepatocytes varies from 0.85 to 4.9 
(mean value is 2.33±0.5). The number of polymorphous hepatocytes at standard field of 
vision varies from 0.9 to 2.35 (mean value is 1.44±0.3).  
Thus, the amount of single lytic necroses of hepatocytes does not differ in liver biopsies of 
patients with HBV and with HCV. At that time the number of binucleate hepatocytes and 
polymorphous hepatocytes is certainly higher in liver biopsies of patients with HBV. This 
situation may be connected with the different level of processes of regeneration.  
3.3.4 Cell population of liver sinusoids 
The amount of endotheliocytes in sinusoids of liver biopsies of patients with HCV (Table 6) 
strongly varies: from 5.8 to 12.8 cells in standard field of sight (mean value is 9.0±0.5). The 
amount of Kupffer cells is also significantly differing from 5.3 to 15.8 in the field of sight 
(main value is 9.6±0.7). Nevertheless, the precise linear dependence between the both of 
indexes is not revealing. 
The amount of endotheliocytes in sinusoids of liver biopsies of patients with HBV (Table 7) 
weakly varies from 5.1 to 8.64 cells in standard field of sight (mean value is 7.17±0.13). The 
amount of Kupffer cells changes from 5.15 to 8.45 in the field of sight (mean value is 
6.89±0.31). 
Thus, the amount of endotheliocytes and Kupffer cells is essentially more in liver biopsies of 
patients with HCV. This circumstance is probably connected with the peculiarities of virus 
influence on the vessel component of liver parenchyma.  
The cell population structure of liver biopsies of patients with HBV and HCV changes 
unequally. So, the using of Student and Satterwhite criteria allows discovering the 
statistically significant distinctions between mean values of all the indexes with the 
exception of the amount of lost hepatocytes in liver plates. 
The coefficients of correlation between the indexes of specific parts of liver plates and the 
number of binucleate cells, between the indexes of specific parts of liver plates and the 
number of polymorphous cells are statistically significant for the cluster of liver biopsies of 
patients with HBV.  
The statistically significant coefficients of correlation Pearson does not detected for the 
cluster of liver biopsies of patients with HCV. 
The strong linear dependence between the indexes of specific parts of liver plates and the 
number of binucleate cells and the number of polymorphous cells was revealed in liver 
biopsies of patients with HBV. 
The using of Spearmen coefficients of correlation allowed establishing the connection 
between the number of cells in sinusoids and the specific part of non-parenchymal elements 
in liver biopsies of patients with HBV. This circumstance could be used for indirect 
characteristics of the development of fibrotic changes in liver. 
In total, the quantitative analysis of cell population structure in liver biopsies in the course 
of chronic hepatitis, especially in the case of defective biopsies, could be used for diagnostic 
and prognoses by expert evaluation. 
  
Liver Biopsy 
 
150 
 
Fig. 6. The fragment of parenchyma with polymorphous hepatocytes and distorted 
sinusoids in liver of a patient with chronic hepatitis B.  Hematoxylin-eosin. Obj.x40 
 
 
Fig. 7. The fragment of parenchyma with unimorphous hepatocytes and narrow sinusoids in 
liver of a patient with chronic hepatitis C. Alcian blue. Obj.x 40 
 
Quantitative Morphometric Analysis of Liver Biopsy: Problems and Perspectives 
 
151 
4. Conclusion 
Evaluation of fibrosis in liver biopsy remains as a point for the diagnosis, monitoring of 
disease prognosis, and response to treatment. Quantitative stereological and computer 
morphometric analysis as well as cell population analysis was used for more correct 
evaluation of dynamic of liver damages in patients with chronic hepatitis B and chronic 
hepatitis C. 
Stereometric analysis of quantitative morphological changes in liver biopsies using 
conventional light microscopy yields good results. Especially effective is the application of 
quantitative analysis of elements in liver parenchyma (ratio between liver plates and 
sinusoids, counting the number of hepatocytes and sinusoidal cells in a standard field of 
view) for the analysis of non-standard biopsies (small size, fragmentation). These data are 
essential for predicting disease and an overall assessment of the liver in each case. However 
stereometric analysis is time consuming and requires special skills in work. 
Colorimetric detection of zones of differential staining of collagen (Manabe et al., 1993; 
Duchatelle et al., 1998) or immunohistochemical markers of fibrogenesis (Kweon et al., 2001) 
with subsequent determination of the area of fibrosis in the percentage of the total field is 
commonly used in computer morphometry. 
In our investigation the total registration of non-parenchymal elements in liver biopsies of 
patients with chronic viral hepatitis carried out using a special program that allowed 
quantifying the presence of fibrotic, inflammatory and necrotic changes in the liver. 
It is particularly important to evaluate separately the number and the area of focal necroses, 
which characterize the activity of intralobular hepatocyte death. We believe that the increase 
of the area of non-parenchymal elements of liver demonstrates a degree of replacement of 
functioning parenchyma by inflammatory infiltrates, necroses and scars. Our studies show 
the advisability of separate accounting bridging necroses and septa, as this may serve as a 
prognostic sign of distortion of the architectonics of liver lobules, usually preceded by 
cirrhosis. In some biopsies we observed the early development of septa without noticeable 
changes in portal tracts. Computer and stereological morphometry can also registrate the 
degree of expansion of portal tracts. 
Our research suggests that four percents or more increasing of the portion of portal zones 
area and increasing of specific parts of intralobular focal infiltrates are unfavorable factors 
for development of chronic liver diseases. 
Thus, computer morphometry is a modern and reliable method for quantifying 
inflammatory, necrotic and fibrotic changes in liver biopsies of chronic diseases. At the same 
time this method requires the creation of a single algorithm to study the reproducibility and 
easy comparison of results obtained in different laboratories. 
Some of the perspectives and problems of computer analysis of liver biopsies are 
summarized below. 
Perspectives: 
1. Computer microscopy and morphometry are ideal for digital archiving of samples of 
biopsies for comparison with repeated biopsies. 
2. Quantitative information about the parameters of the biopsy improves the accuracy in 
diagnosing of disease and allows to optimize the treatment tactics and to adjust quickly 
the course of treatment. 
3. Digital image of a biopsy can be sent by e-mail and be immediately consulted. It is also 
gives the possibility of participation of a large number of specialists for analysis of 
digital images biopsy in complicated cases, thus avoiding medical errors. 
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4. Quantitative analysis of digital images of biopsies is indispensable to study the 
effectiveness of testing new drugs developed by pharmaceutical companies. The effect 
can be calculated as a percentage. 
5. Quantitative indicators of morphological parameters of biopsies may serve as a basis 
for developing mathematical models of the dynamics of chronic liver disease. 
Problems: 
1. It is necessary to work out some common standards of the quantitative computer 
evaluations of biopsy morphological changes, including the development of fibrosis. 
That will make possible the correct comparison of the results in different studies. 
2. Comprehensive assessment and computer analysis of biopsies require the participation 
of medical specialists having the practice with chronic viral hepatitis patients and 
combining the ability to analyze the morphological changes in the liver with high skills 
as computer users. 
3. A digital image of microscopic slides has a large amount of files (up to 2 - 3 gigabytes 
per biopsy), so high-power computers are necessary for the digital processing of 
biopsies. 
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1. Introduction 
Ishak (modified Knodell score) and METAVIR scores are the most widely accepted scoring 
systems for assessment of fibrosis and necroinflammation in dealing with chronic hepatitis 
C. In METAVIR, only interface hepatitis and lobular necrosis determine the grade of 
activity, while in Ishak, portal infiltrate and confluent necrosis are included with the two 
previous parameters. Confluent necrosis is very rare in chronic hepatitis C, that in most 
patients the actual score limit is 12 instead of 18 (Ishak score), that mostly underscore the 
actual necroinflammation. Also, portal inflammatory infiltrate may reflect immunological 
response rather than necroinflammation. This may explain the discrepancy between enzyme 
elevation and necroinflammatory score as determined by Ishak score (modified HAI) in 
assessment of chronic hepatitis C biopsy specimens. On the other hand, no study has clearly 
tested such discrepancy in applying METAVIR. 
Some of the terminologies applied in METAVIR are in need of revision or declaration. For 
example; the term “septa” is used to mean actual fibrous bridges, while in Ishak score both 
terms; septa and bridges; are applied by different meaning.  Ishak et al, 1995, in their system, 
applied both terminologies (septa & bridges), however in completely different meaning. 
Septa, means expansion of portal tract edges without formation of bridges or actual 
connection between portal areas or portal area and central vein (1). On the other hand, the 
term bridge was applied to actual fibrous connection between two portal areas or portal 
area and central vein. Because of this confusion, some studies comparing both scoring 
systems have committed some mistakes.   
Some studies have compared both Ishak and METAVIR systems, but they included small 
number of patients or included hepatitis B and hepatitis C. Therefore, the objectives of this 
chapter are: 
 Revision of histological grading and staging in chronic hepatitis C. 
 Clarification of the METAVIR terminology for future applications. 
 Establishing an Ishak to METAVIR fibrosis score conversion table. 
2. Histological grading and staging in chronic hepatitis C 
The new approach to classify chronic hepatitis C involves three separate considerations. The 
first is a comment on etiology. Frequently, this cannot be determined on the basis of 
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histological appearance alone, and the diagnosis is made on the basis of other laboratory 
investigations. The second assessment relates to the severity and distribution of 
necroinflammatory activity (histological “grade”). Thirdly, an attempt should be made to 
assess the degree of fibrosis (histological “stage”) (2).   
3. Patterns of necroinflammatory activity 
Inflammatory activity in the liver can be divided into two main components. The first 
involves portal tracts (portal hepatitis) with variable extension into the adjacent periportal 
regions (periportal hepatitis). The second involves liver parenchyma (lobular hepatitis). 
These different patterns of inflammation are probably related to the different pathways 
whereby circulating inflammatory cells can gain access to the liver (3).  
3.1 Portal / periportal hepatitis 
Inflammatory cells migrating across the endothelium of portal vessels pass into portal 
connective tissue which is rich in antigen presenting dendritic cells. A predominantly portal 
inflammatory infiltrate is one of the characteristic histological features of chronic hepatitis. 
However it should kept in mind that portal hepatitis by itself does not necessarily indicate a 
diagnosis of chronic hepatitis. Mild portal inflammatory changes, indistinguishable from 
low-grade chronic viral hepatitis, can be seen in a variety of conditions including systemic 
illness, nearby space-occupying lesion and even in some livers, which otherwise would be 
considered as normal. Furthermore, a predominantly portal inflammatory infiltrate is 
sometimes present in cases of acute viral hepatitis, without any implication of chronicity (4).  
Considerable attention has focused on the extension of portal inflammatory cells into the 
adjacent liver parenchyma associated with destruction of the limiting plate and damage to 
periportal hepatocytes (interface hepatitis) (5).  
3.2 Lobular hepatitis 
Inflammatory cells migrating across the endothelium of hepatic sinusoids can gain direct 
access to the liver parenchyma causing lobular inflammation. Typically this presents as 
“spotty” inflammation dispersed randomly throughout the liver parenchyma. In some cases 
inflammatory changes are more pronounced in perivenular (acinar zone 3) region and are 
associated with areas of confluent necrosis. When areas of zone 3 necrosis link vascular 
structures, in particular portal tracts to hepatic venules, the term “bridging necrosis” is 
used. Rarely in severe cases, there may be complete destruction of hepatocytes in one or 
more acini (panacinar necrosis or multiacinar necrosis) (6). 
3.3 Functional significance of necroinflammatory activity 
The main purpose in identifying different patterns of necroinflammatory activity is that 
these may have different functional and prognostic significance in terms of progression to 
fibrosis and ultimately cirrhosis. 
Interface hepatitis has long been considered as an important lesion in the evolution of 
chronic hepatitis to cirrhosis. In the original classification proposed by De Groote et al, 1968 
(7), chronic persistent hepatitis (portal inflammation without piecemeal necrosis) was 
thought to have a favorable prognosis, whereas chronic active hepatitis (portal inflammation 
with piecemeal necrosis) was regarded as having substantial risk for progression to 
cirrhosis. Interface hepatitis with associated periportal liver cell loss and collapse of the 
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reticulin framework can readily be visualized as a mechanism for the development of 
periportal fibrosis (2).  
There have been few attempts to validate this lesion as a prognostic feature in serial 
biopsies. One study showed that the presence of interface hepatitis in initial biopsies from 
patients with chronic hepatitis correlate with subsequent development of cirrhosis (8). Two 
other studies have demonstrated an association between the severities of necroinflammatory 
activity (including interface hepatitis as a major component) in an initial biopsy and the 
development of fibrosis or cirrhosis in follow up biopsies (9). 
Bursts of lobular inflammatory activity are thought to be particularly important in 
pathogenesis of chronic hepatitis C infection, where progression to cirrhosis is common 
despite the lack of interface activity (10). For these reasons it has been suggested that the 
pattern and severity of lobular inflammation should be taken in account in assessing the 
outcome in cases of chronic hepatitis (11). 
3.4 Assessment of hepatic fibrosis 
In the majority of cases fibrosis begins as expansion of portal tracts occurring in association 
of interface hepatitis. As fibrosis progresses, there is formation of septa with the 
development of portal-portal linkage. Eventually hepatocyte nodules are completely 
surrounded by fibrous tissue. Development of established cirrhosis usually takes several 
years. However, in some situations (e.g. viral hepatitis recurring following liver 
transplantation) cirrhosis can develop much more quickly. Parenchymal fibrosis can also 
occur in presence of lobular inflammation, particularly in areas of bridging necrosis (12). 
This may be responsible of for formation of portal-central septa, which have been regarded 
as more significant in the development of cirrhosis than portal-portal linkages (13).   
4. Historical perspectives: The terminology of chronic hepatitis 
The work of the two decades preceding the Knodell HAI provided the foundation for our 
current understanding of the histopathology of chronic hepatitis. Early descriptions and 
classifications focused on differentiating acute and chronic hepatitis and on lesions that 
predicted disease progression. The first histological classification, which was published by De 
Groote in 1968 (7), codified the terminology, chronic persistent and chronic aggressive 
hepatitis. Both conditions involved portal inflammation, but were distinguished by the 
severity of piecemeal necrosis, inflammation, and structural remodeling of the liver. 
Inflammatory activity was graded as moderate or severe, but exact criteria were not given. The 
classification system also incorporated the concept that chronic persistent hepatitis had a 
generally good prognosis whereas chronic aggressive hepatitis could evolve to cirrhosis (7). 
Popper and Schaffner (1971) (14) affirmed the value of liver biopsy for diagnosis and 
prognosis and recommended use of “topographic” descriptors for hepatitis, that is, chronic 
lobular, chronic portal, or chronic periportal hepatitis. The last of these, synonymous with 
chronic aggressive hepatitis, was believed to progress, whereas chronic portal hepatitis, 
synonymous with chronic persistent hepatitis, was considered a non-progressive process. 
Chronic lobular hepatitis was a term for histological findings similar to those of acute 
hepatitis, but with a clinical duration of more than 3 months. It was thought to be non-
progressive except when seen in combination with chronic periportal hepatitis. 
The explosion of scientific information on viral and non-viral hepatitis in the last decades of 
the 20th century led pathologists to question the conventional nomenclature of chronic 
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persistent and chronic active (aggressive) hepatitis because of a growing understanding that 
etiology may be more significant than morphological classification in predicting the natural 
history of liver disease. This shift in thinking was driven largely by the apparent 
dissociation between the mild histology of non A-non B hepatitis (hepatitis C) and its 
progressive clinical course. It was found that, in many cases, the lesions of this form of viral 
hepatitis fell between those described as chronic persistent and chronic active hepatitis and 
could not be clearly categorized (15). 
The lack of severe piecemeal necrosis and confluent lobular necrosis resulted in the 
diagnosis of chronic persistent hepatitis, implying a benign course. At the same time, the 
lobular component was being recognized as more significant than portal lesions with 
respect to disease progression. Also, confluent necrosis, which when present in severe 
autoimmune hepatitis and hepatitis B confers an ominous prognosis, is uncommon in 
hepatitis C, and yet progression to fibrosis or cirrhosis occurs in all 3 diseases (2). 
5. Scoring systems currently in use 
For a system to be effective in every day diagnostic practice, it must be simple to 
understand, simple to apply, communicate effectively to the treating clinician, and clinically 
relevant (16). The system that is most appropriate for clinical practice may not be the most 
informative for investigative work (17). 
6. Histological grading and staging of chronic hepatitis (1) (Table 1) 
This scheme represents an extension of the original Knodell system, with a number of minor 
modifications. Firstly, a continuous scale is used for scoring each of the features assessed. 
Secondly, necroinflammatory activity and fibrosis are considered as separate categories. 
Thirdly, confluent necrosis is separated from periportal hepatitis and is included as a 
separate category of necroinflammatory activity. The term interface hepatitis was used in 
place of ‘‘piecemeal necrosis,’’ to reflect the growing evidence that apoptosis, not necrosis, 
occurs at the limiting plate. 
The first category (piecemeal necrosis) scores are defined as follows: 0, no piecemeal necrosis; 
1, focal piecemeal necrosis in few portal areas; 2, focal piecemeal necrosis in most portal 
areas; 3, continuous piecemeal necrosis around <50% of tracts or septa; 4, continuous 
piecemeal necrosis around >50% of tracts or septa.  
The second category (Confluent Necrosis) scores are defined as follows: 0, no confluent 
necrosis; 1, focal confluent necrosis; 2, zone 3 necrosis in some areas; 3, zone 3 necrosis in 
most areas; 4, zone 3 necrosis and occasional portal-central (P-C) bridging; 5, zone 3 necrosis 
and multiple (P-C) bridging; 6, panacinar or multiacinar necrosis. 
The third category (focal lytic necrosis, apoptosis, and focal inflammation) scores are defined 
as follows: 0, No focal necrosis; 1, one focus or less per 10x objective; 2, two to four foci per 
10x objective; 3, five to ten foci per 10x objective; 4, more than ten foci per 10x objective.  
The fourth category (portal inflammation) scores are defined as follows: 0, no portal 
inflammation; 1, mild in some or all portal areas; 2, moderate in some or all portal areas; 3, 
moderate to marked, all portal areas; 4, marked in all portal areas. By combining scores for 
each of the four individual necroinflammatory categories, histological grading scores 
ranging from 0-18 can now be achieved. The overall activity scores are defined as follows: 1-
3, minimal; 4-8, mild; 9-12, moderate; 13-18, severe (1). 
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Modified HAI Grading: Necroinflammatory Scores  
Periportal or 
Periseptal Interface 
Hepatitis 
(piecemeal necrosis) 
(A) 
Score 
Confluent 
Necrosis 
(B) 
Score 
Focal (spotty) Lytic 
Necrosis, Apoptosis, 
and Focal 
Inflammation* 
(C) 
Score Portal Inflammation (D) Score 
Absent 0 Absent 0 Absent 0 None 0 
Mild (focal, few 
portal areas) 1 
Focal confluent 
necrosis 1 
One focus or less per 
10x objective 1 
Mild, some or all 
portal areas 1 
Mild/moderate 
(focal, most portal 
areas) 
2 Zone 3 necrosis in some areas 2 
Two to four foci per 
10x objective 2 
Moderate, some or all 
portal areas 2 
Moderate 
(continuous around 
<50% of tracts or 
septa) 
3 Zone 3 necrosis in most areas 3 
Five to ten foci per 
10x objective 3 
Moderate/marked, all 
portal areas 3 
Severe (continuous 
around >50% of 
tracts or septa) 
4 
Zone 3 necrosis 
+ occasional 
portal-central 
(P-C) bridging 
4 More than ten foci per 10x objective 4 
Marked, all portal 
areas 4 
 
Zone 3 necrosis 
+ multiple P-C 
bridging 
5 
  
Panacinar or 
multiacinar 
necrosis 
6 
*Does not include diffuse sinusoidal infiltration by inflammatory cells.  
 
 
Modified Staging: architectural changes, fibrosis and cirrhosis 
Change Score 
No fibrosis  0 
Fibrous expansion of some portal areas, with or without short fibrous septa 1 
Fibrous expansion of most portal areas, with or without short fibrous septa 2 
Fibrous expansion of most portal areas with occasional portal to portal (P-P) bridging 3 
Fibrous expansion of portal areas with marked bridging [portal to portal (P-P) as well as 
portal to central (P-C)] 
4 
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) 5 
Cirrhosis, probable or definite 6 
Additional features that should be noted but not scored: bile-duct inflammation and damage; lymphoid 
follicles; steatosis, mild, moderate, or marked; hepatocellular dysplasia, large- or small-cell; adenomatous 
hyperplasia; iron or copper overload; intracellular inclusions (e.g. PAS-positive globules, Mallory bodies); 
and immunohistochemical findings. Information on viral antigens, lymphocyte subsets, or other features, 
when available, should be recorded and may be semi-quantitatively expressed. 
Modified and reprinted (1). 
Table 1. Ishak Modified HAI (1995) (1). 
The fibrosis scores are defined as follows: 0, no fibrosis; 1, fibrous expansion of some portal 
areas, with or without short fibrous septa; 2, fibrous expansion of most portal areas, with or 
without short fibrous septa; 3, fibrous expansion of most portal areas with occasional portal 
to portal bridging; 4, fibrous expansion of most portal areas with marked bridging (portal to 
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persistent and chronic active (aggressive) hepatitis because of a growing understanding that 
etiology may be more significant than morphological classification in predicting the natural 
history of liver disease. This shift in thinking was driven largely by the apparent 
dissociation between the mild histology of non A-non B hepatitis (hepatitis C) and its 
progressive clinical course. It was found that, in many cases, the lesions of this form of viral 
hepatitis fell between those described as chronic persistent and chronic active hepatitis and 
could not be clearly categorized (15). 
The lack of severe piecemeal necrosis and confluent lobular necrosis resulted in the 
diagnosis of chronic persistent hepatitis, implying a benign course. At the same time, the 
lobular component was being recognized as more significant than portal lesions with 
respect to disease progression. Also, confluent necrosis, which when present in severe 
autoimmune hepatitis and hepatitis B confers an ominous prognosis, is uncommon in 
hepatitis C, and yet progression to fibrosis or cirrhosis occurs in all 3 diseases (2). 
5. Scoring systems currently in use 
For a system to be effective in every day diagnostic practice, it must be simple to 
understand, simple to apply, communicate effectively to the treating clinician, and clinically 
relevant (16). The system that is most appropriate for clinical practice may not be the most 
informative for investigative work (17). 
6. Histological grading and staging of chronic hepatitis (1) (Table 1) 
This scheme represents an extension of the original Knodell system, with a number of minor 
modifications. Firstly, a continuous scale is used for scoring each of the features assessed. 
Secondly, necroinflammatory activity and fibrosis are considered as separate categories. 
Thirdly, confluent necrosis is separated from periportal hepatitis and is included as a 
separate category of necroinflammatory activity. The term interface hepatitis was used in 
place of ‘‘piecemeal necrosis,’’ to reflect the growing evidence that apoptosis, not necrosis, 
occurs at the limiting plate. 
The first category (piecemeal necrosis) scores are defined as follows: 0, no piecemeal necrosis; 
1, focal piecemeal necrosis in few portal areas; 2, focal piecemeal necrosis in most portal 
areas; 3, continuous piecemeal necrosis around <50% of tracts or septa; 4, continuous 
piecemeal necrosis around >50% of tracts or septa.  
The second category (Confluent Necrosis) scores are defined as follows: 0, no confluent 
necrosis; 1, focal confluent necrosis; 2, zone 3 necrosis in some areas; 3, zone 3 necrosis in 
most areas; 4, zone 3 necrosis and occasional portal-central (P-C) bridging; 5, zone 3 necrosis 
and multiple (P-C) bridging; 6, panacinar or multiacinar necrosis. 
The third category (focal lytic necrosis, apoptosis, and focal inflammation) scores are defined 
as follows: 0, No focal necrosis; 1, one focus or less per 10x objective; 2, two to four foci per 
10x objective; 3, five to ten foci per 10x objective; 4, more than ten foci per 10x objective.  
The fourth category (portal inflammation) scores are defined as follows: 0, no portal 
inflammation; 1, mild in some or all portal areas; 2, moderate in some or all portal areas; 3, 
moderate to marked, all portal areas; 4, marked in all portal areas. By combining scores for 
each of the four individual necroinflammatory categories, histological grading scores 
ranging from 0-18 can now be achieved. The overall activity scores are defined as follows: 1-
3, minimal; 4-8, mild; 9-12, moderate; 13-18, severe (1). 
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Modified HAI Grading: Necroinflammatory Scores  
Periportal or 
Periseptal Interface 
Hepatitis 
(piecemeal necrosis) 
(A) 
Score 
Confluent 
Necrosis 
(B) 
Score 
Focal (spotty) Lytic 
Necrosis, Apoptosis, 
and Focal 
Inflammation* 
(C) 
Score Portal Inflammation (D) Score 
Absent 0 Absent 0 Absent 0 None 0 
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portal areas) 1 
Focal confluent 
necrosis 1 
One focus or less per 
10x objective 1 
Mild, some or all 
portal areas 1 
Mild/moderate 
(focal, most portal 
areas) 
2 Zone 3 necrosis in some areas 2 
Two to four foci per 
10x objective 2 
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portal areas 2 
Moderate 
(continuous around 
<50% of tracts or 
septa) 
3 Zone 3 necrosis in most areas 3 
Five to ten foci per 
10x objective 3 
Moderate/marked, all 
portal areas 3 
Severe (continuous 
around >50% of 
tracts or septa) 
4 
Zone 3 necrosis 
+ occasional 
portal-central 
(P-C) bridging 
4 More than ten foci per 10x objective 4 
Marked, all portal 
areas 4 
 
Zone 3 necrosis 
+ multiple P-C 
bridging 
5 
  
Panacinar or 
multiacinar 
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6 
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Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) 5 
Cirrhosis, probable or definite 6 
Additional features that should be noted but not scored: bile-duct inflammation and damage; lymphoid 
follicles; steatosis, mild, moderate, or marked; hepatocellular dysplasia, large- or small-cell; adenomatous 
hyperplasia; iron or copper overload; intracellular inclusions (e.g. PAS-positive globules, Mallory bodies); 
and immunohistochemical findings. Information on viral antigens, lymphocyte subsets, or other features, 
when available, should be recorded and may be semi-quantitatively expressed. 
Modified and reprinted (1). 
Table 1. Ishak Modified HAI (1995) (1). 
The fibrosis scores are defined as follows: 0, no fibrosis; 1, fibrous expansion of some portal 
areas, with or without short fibrous septa; 2, fibrous expansion of most portal areas, with or 
without short fibrous septa; 3, fibrous expansion of most portal areas with occasional portal 
to portal bridging; 4, fibrous expansion of most portal areas with marked bridging (portal to 
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portal as well as portal to central); 5, marked bridging with occasional nodules (incomplete 
cirrhosis); 6, cirrhosis, probable or definite (1).   
Difficulties with the Ishak system have been noted. Use of the X10 objective for the 
evaluation of necroinflammatory foci raises concerns of reproducibility, because the size 
of the field may vary among microscopes. In addition, definitions of a “focus” of 
lymphocytic aggregates, apoptotic hepatocytes, or confluent necrosis may vary among 
pathologists (18). 
7. Algorithm for the grading of activity in chronic hepatitis (METAVIR system) 
(Table 2) 
The French METAVIR Cooperative Study Group stated that another possible approach for 
grading the necroinflammatory activity is to consider that periportal and intra-lobular 
necroinflammatory lesions are related to the same pathologic mechanism and that they must 
be globally assessed. A panel decided to define activity according to its potential predictive 
value for the occurrence of liver fibrosis. They chose to include in algorithm only two 
features (piecemeal necrosis and lobular necrosis) (19). 
Portal inflammation was excluded from the algorithm, because this feature is a prerequisite 
for the definition of chronic hepatitis even without activity. Furthermore they observed a 
strong correlation with piecemeal necrosis, making these two features redundant criteria. 
Piecemeal necrosis was chosen as the first decision criterion because of its proven potential 
value in other types of chronic hepatitis. It was then suspected that another feature, lobular 
necrosis, was of major importance in the prediction of liver fibrosis. It is believed that 
aggravation of chronic hepatitis C occurs through a burst of lobular necrosis, a lesion that is 
frequently present in chronic hepatitis C. The two lesions were therefore combined to 
propose a simple algorithm that defined activity.      
In several existing classifications, the degree of piecemeal and lobular necrosis was 
independently assessed and their scores then added, thus giving each of these two lesions 
the same weight in the definition of activity. The METAVIR system included both piecemeal 
necrosis and lobular necrosis in the definition of activity, but with different values. The 
rationale for overweighting the piecemeal necrosis item by comparison with lobular necrosis 
is that piecemeal necrosis is the major discriminating factor used to grade activity, as shown 
by stepwise discriminate analysis.   
The first criterion (piecemeal necrosis) scores are defined as follows: 0, absent; 1, focal 
alteration of the periportal plate in some portal tracts; 2, diffuse alteration of the periportal 
plate in some portal tracts or focal lesion around all portal tracts; 3, diffuse alteration of the 
periportal plate in all portal tracts.  
The second criterion (focal lobular necrosis) scores are defined as follows: 0, less than one 
necroinflammatory foci per lobule; 1, at least one necroinflammatory foci per lobule; 2, 
several necroinflammatory foci per lobule or confluent or bridging necrosis. The overall 
activity scores are defined as follows: 0, No activity; 1, mild; 2, moderate; 3, severe (20).   
The fibrosis scores are defined as follows: F0, no fibrosis; F1, portal fibrosis without septa; 
F2, portal fibrosis with rare septa; F3 numerous septa without cirrhosis; F4, cirrhosis (19). 
The METAVIR system has the advantage of simplicity, reproducibility and application to a 
large number of biopsies (20). This score is composed of a two-letter and two-number 
coding system: A= histological activity and F= fibrosis (Table 2).  
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Algorithm for evaluation of histological activity 
                                                                                              
A=0 
PMN=0                                                   LN=1                  
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                                                LN=2                                                        
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PNN=1                                                    LN=0,1                  
A=1 
                                                   LN=2                                                       
A=2 
                                                 LN=0,1                                                    
A=2 
PMN=2                                      LN=2                                                               
 
PMN=3                                                    LN=0,1,2                  
A=3 
 
PMN, piecemeal necrosis; 0, none; 1, mild; 2, moderate; 3, severe; LN, lobular necrosis; 0, no or mild;  
1, moderate; 2, severe; A, histological activity; 0, none; 1, mild; 2, moderate; 3, severe. 
 
Fibrosis Scoring 
Score Description 
0 No fibrosis 
1 Stellate enlargement of portal tract but without septa formation 
2 Enlargement of portal tract with rare septa formation 
3 Numerous septa formation 
4 Cirrhosis 
Modified and reprinted (20). 
Table 2. The METAVIR System. 
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portal as well as portal to central); 5, marked bridging with occasional nodules (incomplete 
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independently assessed and their scores then added, thus giving each of these two lesions 
the same weight in the definition of activity. The METAVIR system included both piecemeal 
necrosis and lobular necrosis in the definition of activity, but with different values. The 
rationale for overweighting the piecemeal necrosis item by comparison with lobular necrosis 
is that piecemeal necrosis is the major discriminating factor used to grade activity, as shown 
by stepwise discriminate analysis.   
The first criterion (piecemeal necrosis) scores are defined as follows: 0, absent; 1, focal 
alteration of the periportal plate in some portal tracts; 2, diffuse alteration of the periportal 
plate in some portal tracts or focal lesion around all portal tracts; 3, diffuse alteration of the 
periportal plate in all portal tracts.  
The second criterion (focal lobular necrosis) scores are defined as follows: 0, less than one 
necroinflammatory foci per lobule; 1, at least one necroinflammatory foci per lobule; 2, 
several necroinflammatory foci per lobule or confluent or bridging necrosis. The overall 
activity scores are defined as follows: 0, No activity; 1, mild; 2, moderate; 3, severe (20).   
The fibrosis scores are defined as follows: F0, no fibrosis; F1, portal fibrosis without septa; 
F2, portal fibrosis with rare septa; F3 numerous septa without cirrhosis; F4, cirrhosis (19). 
The METAVIR system has the advantage of simplicity, reproducibility and application to a 
large number of biopsies (20). This score is composed of a two-letter and two-number 
coding system: A= histological activity and F= fibrosis (Table 2).  
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8. Problems with histological scoring 
There are a number of problems which apply to all the scoring systems currently in use. 
 Lack of scientific validation: 
A fundamental problem with histological “scoring” is that the numbers which are generated 
do not represent measurement of continuous variable. Instead, they simply represent 
different categories of severity. This contrasts with biochemical measurements, for example, 
serum transaminases, for which a true numerical progression can be more readily justified 
(21).  
 Observer variation:  
There are problems in obtaining reproducible results, even when scoring system is applied 
by experts in the field of liver pathology. In general, better reproducibility has been obtained 
for scoring fibrosis than for scoring inflammatory activity. This is probably due to imprecise 
terminology which is used in individual histological features. Terms such as “occasional”, 
“some”, or “mild’, “moderate and “severe” are used without defining precisely what these 
mean (22).  
 Sampling Variation:  
Much of the knowledge regarding this problem has come from the examination of 
hepatectomy specimens obtained at liver transplantation. Sampling variation exist, both for 
the grade of necroinflammatory activity and for the stage of fibrosis. For example, small 
areas of multiacinar necrosis can often be found in a liver which otherwise show a relatively 
inactive cirrhosis. These areas are typically subcapsular in location but may be also present 
elsewhere. If a needle biopsy is taken from one of these areas, a “falsely high” inflammatory 
score may be obtained. Chronic viral hepatitis may affect the liver uniformly, but 
considerable variation in the severity of fibrosis can be seen when whole liver are available 
for examination (2).   
 Etiological considerations: 
The scoring systems currently in common use incorporate histological features which may 
be seen in all types of chronic hepatitis. However, different types of chronic hepatitis have 
marked differences in natural history and response to therapy. These differences in behavior 
may be reflected by different patterns of histological damage. For example, ballooning, 
rosetting, and giant cell transformation may be regarded as signs of severe damage in cases 
of autoimmune hepatitis, even in the absence of conspicuous inflammatory activity. Direct 
cytopathic damage (e.g. ballooning or fatty change) may be important in the pathogenesis of 
fibrosis in chronic hepatitis C infection (2).  
9. Terminology in METAVIR 
Terminology in METAVIR as regard fibrosis stage assessment is not clear and confusing; 
with narrow range (F0-F4). F3 indicates numerous septa, however, in practical application 
early (developing) cirrhosis is included too, irrespective of being not described in the score 
details. On the other hand, Ishak fibrosis score is wider (0-6), more sensitive, as well clearly 
separate incomplete (developing, early) cirrhosis from established cirrhosis (1,20,23). 
Rozario and Ramakrishna, 2003(24) have built their analysis, tables and comparison on the 
inaccurate idea that F2 of METAVIR (rare septa) is equal to stage 2 of Ishak. However, the 
correct is that, F1 stage of METAVIR is equal to stages 1&2 of Ishak, and F2 of METAVIR is 
equal to stage 3 of Ishak (occasional bridging fibrosis). This resulted in a defect that may 
affect the idea and the conclusion (4). 
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Applying semi-quantitative terminology reflecting grades of necroinflammatory injury as 
recorded by Ishak may underestimate the severity of these changes. In Ishak scoring, 6 
points out of the 18 are related to confluent necrosis, which is a rare event in chronic 
hepatitis C. 
Elzbieta  and Marek, 2005 (25) reported that, the comparison of three histological scoring 
systems used to evaluate chronic hepatitis (Batts and Ludwig, Ishak et al. and METAVIR 
scoring systems) revealed a high coefficient of positive correlation between the respective 
scales. Thus, the systems seem comparable in the estimation of the inflammation grade and 
stage of fibrosis. Table 2 may be advised for converting fibrosis score from Ishak to 
METAVIR. 
Goodman in his review 2007(26), considered Ishak stage 5 (incomplete cirrhosis) to be 
included in METAVIR F4 stage, that is different from the opinion of Bedossa and others of 
METAVIR group. This is a pitfall that may affect the results of some research studies.  
10. Current applications of Ishak and METAVIR scoring systems 
In assessment of regression of fibrosis after autoimmune hepatitis treatment, Abdalla et al, 
2009 have reported higher sensitivity of Ishak compared with METAVIR in detection of 
fibrosis regression (27). They also found statistically higher sensitivity for quantitative 
assessment of fibrosis by analysis of digitalized pictures of sirus red. Czaja and Carpente 
2004, reported a sensitivity of Ishak in assessment of fibrosis regression (28). Esmat et al, 
2007 (applying Ishak fibrosis score) have demonstrated a correlation between fibrosis score 
and hyaluronic acid level (29). Tsochatzis1 et al 2011, in their meta-analysis of diagnostic 
accuracy of elastography for the diagnosis of severity of fibrosis in chronic liver disease, the 
different stages of fibrosis (scoring systems) were converted to comparable stages in 
METAVIR (30). Goodman 2007, suggested application of METAVIR in routine work, and 
Ishak score in clinical trials, because of higher sensitivity in fibrosis assessment (28). 
Lefkowitch 2007 and Guido et al, 2011, suggested application of any of the scoring systems, 
that is not home made, and the clinicians with whom they work prefer (31,32). 
Although liver biopsy has long been regarded as a gold standard procedure, it has obvious 
limitations. It represents an approximation of liver fibrosis for the whole liver and is, 
therefore, not the gold standard for fibrosis assessment. Nevertheless, it is the best 
procedure currently available (33). Germani et al 2010 recommend liver pathologists to 
perform computer-assisted digital analysis of Sirius red-stained histological sections in 
addition to the scoring system established to describe the stage of the liver disease (34). 
11. Conclusions 
Regarding fibrosis: 
 Ishak and METAVIR are nearly identical; however, Ishak is of a wider scale.   
 The term “Septa” in METAVIR is equal to “bridging fibrosis” in Ishak. 
 F3 stage in METAVIR score includes incomplete (developing) cirrhosis. 
Regarding necroinflammatory injury 
 METAVIR is more sensitive to severe activity and more reproducible. However, 
without numerical scoring that let it less effective for monitoring minor changes.      
 Ishak modified HAI has a wider scale. However, 6 points of it (confluent necrosis) are 
nearly out of the chronic hepatitis C scope. This minimizes the actual scoring to 12 
points instead of 18 in practical application.  
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 The proposed table is advised for unidirectional converting fibrosis scores from Ishak to 
METAVIR. 
 METAVIR F3 stage may better be subdivided into F3a: Marked bridging fibrosis and 
F3b: incomplete (early cirrhosis) (developing cirrhosis). 
More work is needed in: 
 Assessing the validity of the current scoring systems in post-liver transplant patients 
with recurrent HCV especially those with a back ground of graft pathologies such as 
rejection and those with associated HBV or cytomegalovirus and HIV infections. 
 Convertibility of the results of these scoring systems and image pattern of contrast 
enhanced ultrasound of the liver. 
 
 
 
 
 
 
 
 
Modified and reprinted (19). 
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Fig. 1. The METAVIR Fibrosis staging system. F0 is normal liver (no fibrosis).  
F1 = portal fibrosis. F2 = few septa. F3 = many septa. F4 = cirrhosis. 
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Fig. 2. Portal tract expansion by fibrosis, Masson trichrom stain. 
 
 
Fig. 3. Bridging fibrosis , Masson trichrom stain. 
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with recurrent HCV especially those with a back ground of graft pathologies such as 
rejection and those with associated HBV or cytomegalovirus and HIV infections. 
 Convertibility of the results of these scoring systems and image pattern of contrast 
enhanced ultrasound of the liver. 
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Fig. 1. The METAVIR Fibrosis staging system. F0 is normal liver (no fibrosis).  
F1 = portal fibrosis. F2 = few septa. F3 = many septa. F4 = cirrhosis. 
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Fig. 2. Portal tract expansion by fibrosis, Masson trichrom stain. 
 
 
Fig. 3. Bridging fibrosis , Masson trichrom stain. 
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Fig. 4. Multiple portal-portal bridges, , Masson trichrom stain. 
 
 
 
 
 
Fig. 5. Regenerating nodules rimmed by fibrosis, Masson trichrom stain. 
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Fig. 6. Regenerating nodules rimmed by dense fibrosis, Masson trichrom stain. 
 
 
 
 
Fig. 7. Interface hepatitis, H&E stain. 
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Fig. 7. Interface hepatitis, H&E stain. 
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Fig. 8. Evident interface hepatitis with apoptosis, H&E stain. 
 
 
Fig. 9. Confluent necrosis, reticulin collapse , sirus red stain. 
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1. Introduction 
Liver biopsy (LB) is an important procedure in the diagnosis and treatment of liver diseases. 
At present, there are two minimally invasive techniques for liver tissue sampling: image-
guided percutaneous liver biopsy (PLB) and transjugular liver biopsy (TJLB) [1-4]. Both 
techniques have several disadvantages, such as the risk of bleeding and subcapsular 
hematoma in the former, and the small sample size, longer procedure time and the need for 
considerable interventional skill in the latter. Recently, innovative intra-abdominal 
procedures that require no incision of the anterior abdominal wall have become possible by 
accessing the peritoneal cavity through natural orifices  [5,6]. Natural orifice translumenal 
endoscopic surgery (NOTES) for access to the peritoneal cavity was first reported by Kalloo 
et al. [7]. To develop a new strategy for minimally invasive LB in humans, we have 
investigated a novel procedure for transgastric liver biopsy (TGLB) using the NOTES 
technique in experimental animals. 
2. Materials and methods 
The aim of this study was to determine the technical feasibility of peroral TGLB using a 
flexible endoscope. This experimental study was approved by the animal care 
institutional review board at the Dokkyo Medical University. The utility of transgastric 
peritoneoscopy was evaluated in three 15-kg farm pigs and five 8-kg dogs. 
Under general anesthesia with an endotracheal intubation, a forward-viewing, double-
channel endoscope (GIF-2T-240, Olympus, Tokyo) was advanced into the esophagus and 
stomach. Puncture of the gastric wall was performed with a 3-mm cutting-wire needle knife 
(KD-10Q-1, Olympus). The puncture site was enlarged to 8mm with a balloon dilator (CRE 
W.G. esophageal balloon 5839, Boston Scientific) and the endoscope was advanced into the 
peritoneal cavity. The peritoneal cavity was inflated with air through the endoscope. The 
liver was easily visualized by retroflexion of the endoscope (Fig.1). 
LB was performed using routine biopsy forceps (FB-230K, Olympus) from the edge of the 
liver (Fig.2) and hemostasis of biopsy sites was achieved using electrocautery with the 
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biopsy forceps (Fig.3). A gastric orifice was closed by endoscopic clips (HX-610-135, HX-610-
090L, Olympus). The animals were sacrificed and necropsy was performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Retroflexion of the endoscope easily visualized the liver 
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Fig. 2. Liver biopsy was performed using routine biopsy forceps from the edge of the liver. 
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Fig. 2. Liver biopsy was performed using routine biopsy forceps from the edge of the liver. 
 
Liver Biopsy 
 
174 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. An adequate sample was retrieved by biopsy forceps. 
3. Results 
None of the eight animals developed complications, including adjacent organ injury or 
bleeding, during incision of the gastric wall, entry into the peritoneal cavity, and the closure 
of the gastric wall. Visualization of the intraperitoneal organs through the endoscope using 
standard endoscopic techniques had no problems. Peritoneoscopy revealed a good 
operative view of abdominal cavity in all possible directions. LB was successfully performed 
without any trouble bleedings and yielded adequate samples for histopathologic 
examination in all cases. Minor bleeding occurred in three cases and was stopped by an 
endoscopic electrocoagulation (Fig 4).  
Necropsy revealed no particular damages to other intraperitoneal organs related with this 
transgastric procedure. The acute experiments demonstrated the technical feasibility of this 
approach. 
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Fig. 4. Hemostasis was confirmed at the site of liver biopsy. 
4. Discussion 
In general, LB is a necessary procedure to evaluate the chronic liver disease, and a standard 
one to diagnose liver tumors pathologically. In performing LB, there are two procedures 
consisting of percutaneous and transjugular routes. However, those procedures revealed 
several disadvantages including post procedural hemorrhage, small sample size for 
diagnosis, the differences of the severity of fibrosis in the sites of LB, and so on [2]. We have 
to resolve or minimize those issues in this era. Recently, endoscopic approach in LB became 
attractive with minimally invasiveness to human bodies and no skin damage. We 
introduced TGLB by NOTES [5-7] as an endoscopic approach, and reported the evaluation 
of TGLB in diagnostic and therapeutic aspects for liver diseases. 
The method of PLB is divided into blind, ultrasound (US) or computed tomographic 
guidance. Those results greatly depend on the skills of the gastroenterologist, hepatologist 
or radiologist as an operator and the technical possibilities including the quality of the 
ultrasonography itself. However, the most careful event is complications after PLB. 
Piccinino et al. [8] reported that 61% of the complications appeared in the first 2 hours after 
the biopsy, 82% in the first 10 hours, and 96% in the first 24 hours. We should have the strict 
observation for the first 24 hours after PLB. Several large studies showed that the rate of 
major complication after PLB ranged from 0.09% to 2.3%, severe complications appeared in 
0.57%, and mortality ranged from 0.03% to 0.11% [9-11]. And the complications of blind PLB 
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are significant high rates compared with those of US-guided one [12-14], PLB under US 
guidance is recommended as a reasonable and cost-efficient procedure [1, 13, 15]. In fact, 
morbidity and mortality rates are not high. Furthermore, regarding bleeding after PLB, 
Alotaibi et al. [4] described that the positive color Doppler sign in US indicated bleeding 
along a biopsy tract and US-guided compression was effective in achieving appropriate 
hemostasis, and tract-plugging means that the biopsy tract is filled with Gelfoam or other 
thrombotic agents, it is an important procedure to decrease the risk of bleeding and 
subcapusular hematoma in PLB [2]. Nevertheless, in patients with ascites, abnormal 
coagulation profiles, another procedure is considered because of the high risk due to 
bleeding complications.  
The TJLB via the internal jugular vein approach using the method described by McAfee et 
al. [16] is thought to be a safer biopsy option in patients with ascites, coagulopathy, 
thrombocytopenia or medical conditions with bleeding disorders such as hemophilia being 
considered as contraindications for PLB [17,18] because the patients will “bleed” back into 
the vein rather than into the abdomen. However, TJLB is a limited technique as a result of 
small sample size and caliber, longer procedure time, and the need for a skilled 
interventional radiologist [18]. Furthermore, it is also not without complications, which arise 
when the liver capsule or capsular veins are perforated, and does not prevent this risk, and 
it actually seems to increase risk in ascitic patients [3]. Therefore, the TJLB still needs a 
further study to evaluate indication, technique and complications.    
The attractive points of LB by NOTES technique consist of no skin damage in the outside 
of the body and the direct observation of biopsy site in the inside of the body against PLB 
or TJLB. In clinically, the introduction of NOTES is required to resolve the identification 
of safe access to the peritoneal cavity, the complete closure of access route, the prevention 
of infection, the intra-abdominal orientation, the development of a multitasking platform, 
the management for the accidental complications, the outlining physiologic unanticipated 
events and the training of NOTES as White paper from American Society for 
Gastrointestinal Endoscopy and Society of American Gastrointestinal and Endoscopic 
Surgeons declared, [5,6]. In particular, infection or bacterial contamination in the 
abdomen due to the open of the digestive tract is a great concern in NOTES. However, 
transgastric peritoneoscopy being developed by Kalloo et al. [7, 19] showed no association 
with serious infection or other complications in the peritoneal cavity during their long-
term survival experiments. Furthermore, Hazey et al. [20] reported that although 
contamination in the abdomen was documented, no clinically significant episode of the 
peritoneal cavity was observed without abscess formation or infectious complications 
during laparoscopic Roux-en-Y gastric bypass.  From those findings, although the peroral 
TGLB required to add the artificial injury for normal organs, it will become one of 
alternatives to another LB methods.  
In fact, there are several successful experimental reports of liver biopsy using a pig model 
[19, 21-23]. Mintz et al. [22] reported that LB can be performed safely and obtained from the 
edge of the liver using routine endoscopic punch biopsy forceps, and adequate hemostasis 
also obtained by an electrocautery. This report was similar to our procedure and results. In 
clinical, Hazey et al. [20] reported that LB was uneventfully performed from the transgastric 
access route in a patient who underwent a diagnostic laparoscopic evaluation of pancreatic 
mass. Steele et al. [24] also reported that LB from segments II, III, or IVb under flexible 
transgastric peritoneoscopy during Roux-en-Y gastric bypass for morbid obesity was 
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performed in 3 patients with only minor bleeding from the liver biopsy sites. Exploration of 
the peritoneal cavity with a flexible endoscope and a LB took 2.1 min to 6.0 with a mean of 
4.1 min. The postoperative period in all patients was uneventful without any local or 
systemic complications. Above those findings revealed that LB could be a feasible and safe 
procedure without any critical complications even in humans. 
In conclusion, this approach to peritoneal cavity is technically feasible and has the potential 
to be an alternative to routine LB. Transgastric endoscopic approach has a wide range of 
diagnostic and therapeutic interventions.  
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are significant high rates compared with those of US-guided one [12-14], PLB under US 
guidance is recommended as a reasonable and cost-efficient procedure [1, 13, 15]. In fact, 
morbidity and mortality rates are not high. Furthermore, regarding bleeding after PLB, 
Alotaibi et al. [4] described that the positive color Doppler sign in US indicated bleeding 
along a biopsy tract and US-guided compression was effective in achieving appropriate 
hemostasis, and tract-plugging means that the biopsy tract is filled with Gelfoam or other 
thrombotic agents, it is an important procedure to decrease the risk of bleeding and 
subcapusular hematoma in PLB [2]. Nevertheless, in patients with ascites, abnormal 
coagulation profiles, another procedure is considered because of the high risk due to 
bleeding complications.  
The TJLB via the internal jugular vein approach using the method described by McAfee et 
al. [16] is thought to be a safer biopsy option in patients with ascites, coagulopathy, 
thrombocytopenia or medical conditions with bleeding disorders such as hemophilia being 
considered as contraindications for PLB [17,18] because the patients will “bleed” back into 
the vein rather than into the abdomen. However, TJLB is a limited technique as a result of 
small sample size and caliber, longer procedure time, and the need for a skilled 
interventional radiologist [18]. Furthermore, it is also not without complications, which arise 
when the liver capsule or capsular veins are perforated, and does not prevent this risk, and 
it actually seems to increase risk in ascitic patients [3]. Therefore, the TJLB still needs a 
further study to evaluate indication, technique and complications.    
The attractive points of LB by NOTES technique consist of no skin damage in the outside 
of the body and the direct observation of biopsy site in the inside of the body against PLB 
or TJLB. In clinically, the introduction of NOTES is required to resolve the identification 
of safe access to the peritoneal cavity, the complete closure of access route, the prevention 
of infection, the intra-abdominal orientation, the development of a multitasking platform, 
the management for the accidental complications, the outlining physiologic unanticipated 
events and the training of NOTES as White paper from American Society for 
Gastrointestinal Endoscopy and Society of American Gastrointestinal and Endoscopic 
Surgeons declared, [5,6]. In particular, infection or bacterial contamination in the 
abdomen due to the open of the digestive tract is a great concern in NOTES. However, 
transgastric peritoneoscopy being developed by Kalloo et al. [7, 19] showed no association 
with serious infection or other complications in the peritoneal cavity during their long-
term survival experiments. Furthermore, Hazey et al. [20] reported that although 
contamination in the abdomen was documented, no clinically significant episode of the 
peritoneal cavity was observed without abscess formation or infectious complications 
during laparoscopic Roux-en-Y gastric bypass.  From those findings, although the peroral 
TGLB required to add the artificial injury for normal organs, it will become one of 
alternatives to another LB methods.  
In fact, there are several successful experimental reports of liver biopsy using a pig model 
[19, 21-23]. Mintz et al. [22] reported that LB can be performed safely and obtained from the 
edge of the liver using routine endoscopic punch biopsy forceps, and adequate hemostasis 
also obtained by an electrocautery. This report was similar to our procedure and results. In 
clinical, Hazey et al. [20] reported that LB was uneventfully performed from the transgastric 
access route in a patient who underwent a diagnostic laparoscopic evaluation of pancreatic 
mass. Steele et al. [24] also reported that LB from segments II, III, or IVb under flexible 
transgastric peritoneoscopy during Roux-en-Y gastric bypass for morbid obesity was 
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performed in 3 patients with only minor bleeding from the liver biopsy sites. Exploration of 
the peritoneal cavity with a flexible endoscope and a LB took 2.1 min to 6.0 with a mean of 
4.1 min. The postoperative period in all patients was uneventful without any local or 
systemic complications. Above those findings revealed that LB could be a feasible and safe 
procedure without any critical complications even in humans. 
In conclusion, this approach to peritoneal cavity is technically feasible and has the potential 
to be an alternative to routine LB. Transgastric endoscopic approach has a wide range of 
diagnostic and therapeutic interventions.  
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1. Introduction 
During the past 60 years the role and importance of liver biopsy have changed. In 1950s the 
introduction of liver puncture biopsy was absolute innovation, e.g. in Latvia, and had an 
invaluable significance. The possibility to compare and/or oppose alterations of liver 
structure and liver function was achieved and it caused the information explosion. The 
spectrum of morphological research included investigations of liver tissue damage on 
different levels that explained the mechanisms of biochemically detected cytolysis and 
cholestasis syndrome, fibrosis and liver cirrhosis development. Relatively, in least degree 
the morphological phenomena of apoptosis and its role in acute and chronic liver diseases 
were examined. 
Frequently conventional liver function tests are limited to quantifying hepatic function. 
Despite major progress in the diagnostics and therapy of liver diseases of different 
etiologies, the assessment of liver function continues to present a major clinical problem. 
Most of liver function tests are not sufficiently specific and do not accurately predict liver 
failure and outcome of it.  
Liver biopsy is an essential part of the diagnostics and follow-up of many liver diseases 
giving clinically important information as well as scientific data. At present, it is the most 
specific test to assess the nature and severity of liver damage (Bravo et al., 2001). However, 
the role of liver biopsy in the evolution of medical science is dynamic. It became possible 
with the development of methods able to bring sufficient amount of liver tissue as well as to 
ensure the safety of the procedure itself. The methods used to obtain liver tissue include 
transcutaneous needle biopsy and transvenous approach via jugular or femoral vein. 
Occasionally, liver can be biopsied during laparoscopy or open abdominal surgery. Aseptics 
and antiseptics are of importance. There is an obvious necessity to ensure the monitoring of 
the patient and control of possible albeit rare complications. It seems reasonable to expect 
further developments in the field of liver morphology that might include both in-depth 
studies of tissue (Dioguardi et al., 2008) as well as elaboration of novel, completely different 
diagnostic methods. 
The indications for liver biopsy include 1) the grading and staging of chronic viral hepatitis, 
alcohol-related liver damage, non-alcoholic steatohepatitis and autoimmune hepatitis; 2) 
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evaluation of hemochromatosis and Wilson’s disease; 3) diagnostics of biliary diseases; 4) 
evaluation of patient with abnormal biochemical liver tests; 5) evaluation of medication 
toxicity; 6) diagnosis of focal liver lesion; 7) evaluation of liver transplant; 8) evaluation of 
patient with fever of unknown origin (Bravo et al., 2001). Liver biopsy ensure accurate 
diagnosis in 90% of patients with abnormal biochemical liver tests (Hultcrantz&Gabrielsson, 
1993) and is informative in transplant patients revealing rejection, recurrence of primary 
disease, drug toxicity and other causes of liver damage (Brown et al., 2000). 
The general limitations of liver biopsy represent the risk of complications (Poynard et al., 
2004), sampling error (Poynard et al., 2004; Skripenova et al., 2007) and inter- and intra-
observer variability (Poynard et al., 2004). However, the risk of serious complications is low 
(Shiha et al., 2009) - 3 per 1000 (Poynard et al., 2004), and the general risk of complications is 
estimated as 1% (Standish et al., 2006). The described risk of mortality has been between 
0.1% - 0.01% (Standish et al., 2006). The variability can be reduced by scoring systems, and 
sampling error can be partially limited by keeping the standards. Namely, liver biopsy can 
be considered representative if it contains at least 11 portal fields or measures at least 1 cm 
(Skripenova et al., 2007). If the tissue fragment is markedly less than 1 cm, immediate 
rebiopsy can be performed.  
Liver biopsy allows to perform visual examination of tissue structure. To ensure this, the 
logistics is mostly routine, not placing high requirements. The biopsied tissues are fixed in 
formalin and embedded in the paraplast. The paraffin blocks and stained sections can be 
archived thus providing several benefits. The biopsy can be re-evaluated and/or sent for 
second opinion. The second opinion can be obtained faster by application of full slide 
scanning and exchange of electronic files. The tissues can be later subjected to any novel 
examination methods in accordance with the development of medical science and practice. 
Scientific studies can also benefit from those materials, especially in large medical centres. 
The turnover time for liver biopsy is reasonable - 24 hours for routine logistics or 4 hours 
using fast processing.  
The informativity of biopsy is highly dependent on the applied protocol of visualisation 
methods. The routine protocol could include haematoxylin-eozin (Gamble&Wilson, 2002), 
PAS (Totty, 2002), Masson’s trichrome (Jones, 2002) and Perls’ stain (Churukian, 2002) 
although modifications can definitely exist. Reticulin stain (Jones, 2002) can be advised. 
Stains for Wilson’s disease can be applied to selected cases (Churukian, 2002). 
Immunohistochemistry for cytokeratins 7 and / or 19 helps to highlight bile ducts and is 
very useful in the assessment of general morphology, bile duct damage, ductopenia, 
ductular reaction. Viral antigens should be sought for (Desmet&Rosai, 2004). The 
differential diagnostics of focal lesions involves the need to differentiate between benign 
and malignant lesion, primary and metastatic malignancy including the complex question of 
identifying the origin of cancer of unknown primary. Thus, wide spectrum 
immunohistochemistry and search for chromosomal translocations are the requirements for 
diagnostics. 
Further, we will describe in short the informativity of biopsy in different clinical situations, 
with the emphasis on the limitations. 
The application of serologic and virologic examination has mostly replaced the use of biopsy 
for the diagnostics of acute viral hepatitis. If biopsy is performed, the type and degree of 
hepatocellular damage, the inflammatory acivity and presence or absence of regeneration 
can be assessed (Desmet&Rosai, 2004). Predominance of lobular parenchymal lesions is 
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characteristic. The alternative diagnoses or combined liver lesion can be revealed in biopsy. 
It can be clinically reasonable to perform liver biopsy in order to differentiate between acute 
and chronic hepatitis. If marked fibrosis is present the morphological diagnosis is 
straightforward. However, this situation can also represent one of the limits of 
morphological diagnosis as the portal infiltrate in acute hepatitis may be marked and cause 
some degree of damage to limiting plate thus resembling chronic active hepatitis. In turn, 
some cases of chronic hepatitis show only mild changes. In case of severe acute hepatitis, the 
biopsy might reveal bridging or submassive necrosis. However, the condition of the patient 
can preclude the biopsy in such situations. The representativity of biopsy can be the limiting 
factor in the evaluation of submassive liver necrosis due to focality of lesions.  
In case of chronic hepatitis, semiquantitative scoring systems provide useful prognostic 
information, improve the consistency of reporting the disease activity and stage and ensure 
acceptable intra- and interobserver variability. The examples of such systems include the 
Histological Activity (HAI) index or Knodell index (Knodell et al., 1981), the Scheuer scoring 
system (Scheuer, 1991), the modified HAI by Ishak (Ishak et al., 1995) and METAVIR system 
(Bedossa&Poynard, 1996). The extent of liver fibrosis can be evaluated directly in the biopsy. 
This assessment is highly accurate in cirrhosis, bridging fibrosis and portal fibrosis and 
yields clinically unexpected data only occasionally. Liver biopsy is the procedure of choice 
to assess the amount of fibrosis in the tissue (Shiha et al., 2009). The biopsy allows assessing 
even slight tissue damage. Even mild hepatitis can progress as reflected by increasing level 
of fibrosis in repeated liver biopsies (Ryder et al., 2004). Liver steatosis is frequently found in 
chronic hepatitis patients and can contribute to the elevation of transaminases level in blood. 
The degree and type of liver steatosis can be assessed separately from the 
necroinflammatory activity. Biopsy can also reveal combined liver damage. The limitations 
of biopsy in the diagnostics of chronic viral hepatitis are represented by the lack of specific 
morphologic changes, particularly regarding chronic viral hepatitis C. Thus, the biopsy 
must be used in conjunction with serologic and virologic data.  
Liver biopsy can be used for the diagnosis of steatosis and steatohepatitis. Quantitative 
evaluation is possible for steatosis and fibrosis. Although fat stains can be used high quality 
routine histological slides stained with haematoxylin and eozin and PAS usually ensure the 
diagnosis. The limitations are caused by inability to distinguish between non-alcoholic 
steatohepatitis and alcohol – related hepatitis in abstaining patient.  
Liver biopsy is considered important in establishing the diagnosis of autoimmune hepatitis 
(Oo et al., 2010). The information about features typical for autoimmune hepatitis is helpful 
as reflected by inclusion of these data in the diagnostic criteria. The absence of biliary 
abnormalities or steatosis is also of importance helping to exclude alternative diagnoses. The 
effect of immunosuppresion can be predicted (Feld, 2005) and monitored by biopsy (Oo et 
al, 2010). Biopsy is recommended before treatment withdrawal (Carpenter&Czaja, 2002; 
Montano-Loza et al, 2007; Czaja&Carpenter, 2003). Due to lack of specifity and possibility of 
plasma cell paucity in autoimmune hepatitis, the serologic data must be evaluated together 
with the biopsy. 
Examination of liver biopsy for biliary diseases represents a complex problem. The most 
common questions target primary sclerosing cholangitis and primary biliary cirrhosis. 
Primary sclerosing cholangitis is a chronic cholestatic liver disease that typically affects 
young and middle-aged men, frequently suffering from inflammatory bowel disease 
(Silveira&Lindor, 2008a, 2008b). Although the disease is rare, it is among frequent 
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(Oo et al., 2010). The information about features typical for autoimmune hepatitis is helpful 
as reflected by inclusion of these data in the diagnostic criteria. The absence of biliary 
abnormalities or steatosis is also of importance helping to exclude alternative diagnoses. The 
effect of immunosuppresion can be predicted (Feld, 2005) and monitored by biopsy (Oo et 
al, 2010). Biopsy is recommended before treatment withdrawal (Carpenter&Czaja, 2002; 
Montano-Loza et al, 2007; Czaja&Carpenter, 2003). Due to lack of specifity and possibility of 
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young and middle-aged men, frequently suffering from inflammatory bowel disease 
(Silveira&Lindor, 2008a, 2008b). Although the disease is rare, it is among frequent 
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indications for liver transplantation in Europe and USA, and is dangerous for the increased 
risk of cholangiocarcinoma. The evaluation of liver biopsy for primary sclerosing cholangitis 
can both bring information and face problems. Primary sclerosing cholangitis is 
characterised by loss of medium and large-sized bile ducts. The fibro-obliterative lesions 
and lack of bile duct in the portal area adjacent to large artery and vein are characteristic. 
However, ducts of such size are not typically captured in a percutaneous liver biopsy. The 
concentric periductal fibrosis is characteristic but present in less than 15% of patients. 
However, the evaluation of autoantibodies is also not very helpful thus increasing the role 
of biopsy. 
The primary biliary cirrhosis (Hohenester et al., 2009; Kumagi&Heathcote, 2008) is an 
immune-mediated chronic progressive inflammatory liver disease characterised by the 
destruction of small portal bile ducts leading to progressive cholestasis, fibrosis and 
cirrhosis. Serum antimitochondrial autoantibodies are highly characteristic. Histologically, 
biliary duct damage and ductopenia are typical. Biopsy is not mandatory, but can be helpful 
in revealing typical picture, excluding other causes of liver damage and providing stage 
information. 
Hereditary haemochromatosis, a group of inherited disorders that result in progressive iron 
overload, occurs mostly due to mutations in the HFE gene (Clark et al., 2010). The tests are 
available to reveal the two clinically relevant mutations C282Y and H63D. However, the 
penetrance of the disease seems to be low: 28.4% for males and 1.2 % in females 
homozygous for C282Y (Clark et al., 2010). Liver biopsy can determine the severity of liver 
disease; reveal other causes and HFE-mutation negative hemochromatosis.  
In case of Wilson’s disease, liver biopsy can be implemented in the primary diagnostic 
work-up. As clinically the course of fibrosis has been found difficult to follow, repeated 
biopsies are advocated for monitoring (Yokoyama et al., 2010). 
In addition, liver biopsy is valuable in the evaluation of focal liver damage including the 
important and complex question of tumour diagnostics and differential diagnostics. Liver 
cell tumours and tumour-like lesions represent a wide diagnostic area, including focal 
nodular hyperplasia, liver cell adenoma, hepatocellular carcinoma, hepatoblastoma, bile 
duct tumours, epithelioid hemangioendothelioma and other lesions. In the diagnostics of 
hepatocellular carcinoma, the sensitivity and specifity of liver biopsy is 96% and 95%, 
correspondingly (Bialecki&Bisceglie, 2005). In contrast, the application of other methods can 
result in false-positive diagnosis with the rate as high as 33% (Hayashi et al., 2004). In case of 
malignancy, metastasis should always be considered. The implementation of 
immunohistochemistry has resulted in higher diagnostic yield of liver biopsy for neoplastic 
lesions. The identification of the primary origin of metastatic tumours can be reached in a 
fraction of cases. Inflammatory focal lesions as echinococcosis or liver abscess can be 
diagnosed reliably.  
As shown, liver biopsy is used and should be used as a part of the complex examination for 
the analysis of the etiology, activity and extent of diffuse and focal liver damage as well as 
assessment of the treatment results. 
Liver biopsy is an invasive method, there are potential adverse effects and complications. 
Certain precautions and means minimize the risks of adverse events. Biopsy conducted by a 
trained physician, use of only a limited number of passes and ultrasound quidance can 
significantly decrease the risk of complications, thereby enhancing the safety of biopsy 
(Bedossa&Carrat, 2009). 
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The main drawbacks (Bedossa, 2009; Reddy&Schiff, 2002; Rousselet et al., 2005; 
Colli&Fraqeulli, 2009) of liver biopsy as a diagnostic procedure lie in sampling and 
observation errors. Observer variation is a potential limitation of biopsy that is related to the 
discordance between pathologists in biopsy interpreation. 
The main alternatives to liver biopsy that have been developed in the past 10 years are 
based on two very different concepts: serum markers and liver stiffness (Manning&Afdhal, 
2008). These are noninvasive procedures. 
Biochemical marker combinations are being developed as alternatives to liver biopsy in 
patients with liver diseases, especially with chronic liver diseases. Noninvasive tests are 
being developed to replace liver biopsy, and thus avoid the risk of biopsy-related adverse 
events. Noninvasive tests also have the potential to avoid limitations of liver biopsy 
including the risk of sampling errors and inter- and intra-pathologist variability. 
Although clinicians already use liver biopsy substitutes - surrogate markers in their 
practices, offers are waiting for more valid tests (Mehta et al., 2009), especially for staging 
fibrosis and apoptosis identification and confirmation. 
Fibrosis is not an autonomous feature, but rather a tissue lesion resulting from other 
pathologic mechanisms such as inflammatory, degenerative or dystrophic processes 
leading to other pathologic mechanisms such as hepatocellular carcinoma and portal 
hypertension. 
The physiological process of apoptosis (programmed cell death) can be transformed into a 
pathological process, which can stimulate hepatic fibrosis, e.g. in hepatitis C, or can 
contribute  to treatment failure (Schinoni et al., 2006). Over the last years, the importance of 
apoptosis for the pathogenesis of various diseases has been extensively investigated. 
Apoptosis is a greek term that means „the fall of the old leaves of the autumn trees”. This 
term describes the process by which undesirable, damaged old cells are eliminated from 
multicellular organisms. 
Apoptosis differs from cellular necrosis, because it is actively controlled, and the membrane 
integrity is maintained, avoiding extravasation of intracellular material and an inflammatory 
response. In order to discover the probable mechanisms by which hepatitis viruses and other 
agents perpetuate in the liver, apoptosis in liver disorders should be investigated. Apoptosis is 
the first step in hepatic lesions, and fibrosis is the final response of hepatic stellate cells to this 
process. There may be a direct relationship between these two processes. 
Apoptosis and cell necrosis can be differentiated by morphology. However, liver diseases 
are often accompanied by a combination of both processes, so that there is mostly no clear 
borderline. Apoptosis assessment is still not frequent in liver biopsy. At the same time 
several apoptosis biochemical markers in blood are available at present (cytochrome C, 
cytokeratin-18 neoepitopes etc.), but are not widely used in the practice. 
Fibrosis is a consequence of the necroinflammatory process. The process of fibrogenesis 
results in an increase in the extracellular matrix of: 1) collagen, 2) glycoproteins and 3) 
proteoglycans (e.g. hyaluronic acid). 
Fibrotic status is usually assessed by liver biopsy, which has numerous disadvantages (Bottero 
et al., 2009), therefore prompting the development of several noninvasive methods for 
assessing fibrosis. However, the etiology of liver disease and the existence of co-morbidities 
impact the performance of non-invasive markers and cut-off values (Bottero et al., 2009). 
Liver biopsy is currently the gold standard for assessment of liver fibrosis, yet it faces 
competition from non-invasive markers, which are easier to use, more acceptable to patient 
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and repeatable over time. Besides, biopsy sample is usually too small to diagnose the 
disease accurately and diagnostic opinions often differ among pathologists (Rousselet et al., 
2005). As a result, a morphological examination does not always provide an accurate 
diagnosis. Recently, blood hyaluronic acid has been available for the assessment of liver 
fibrosis as a rapid and less invasive method. 
The specific course of disease might be explained also by the diverse immunogenetic 
backgrounds of the individual patient. The host ability to react to viral antigens has often 
been associated with the human leukocyte antigen (HLA), mainly HLA class II antigens. 
Many studies suggest that the cellular immune response, e.g. to HCV, particularly the T 
helper (Th) lymphocyte response, plays a crucial role. The cell-receptors recognize only 
peptides bound to HLA class II molecules. Polymorphisms due to amino acid substitutions 
at specific positions may intervene within the HLA class II molecule and interact with both 
the peptide and T-cell-receptor; therefore, the HLA type characterizing each individual may 
influence the subject’s immune response to particular pathogens. Certain HLA alleles have 
been shown to influence the outcome of other chronic viral infections, and a few recent 
studies have examined class II HLA alleles in the context of HCV clearance. The present 
study, which considers the relationship between HCV and HLA class II antigens from the 
locus DRB1* of view, aimed to investigate whether diferences of HLA class II antigens exist 
among HCV – infected patients with respect to healthy controls. The possibility that these 
antigens are associated with resistance or susceptibility to chronic HCV infection was also 
considered. The HLA class III human leukocyte antigens (DRB1*) are central to the host 
immune response and thus are ideal candidate genes to investigate for associations with 
HCV outcomes. During the study we investigated whether human leukocyte antigen (HLA-
DRB1) alleles were associated with the response to PEG-interferon+Ribavirin (combined 
therapy) and Realdiron therapy in patients with chronic hepatitis C. 
Our aim was to identify the new non-invasive methods to be used for the assessment of 
liver function in acute and chronic liver diseases and to evaluate the clinical diagnostic and 
prognostic accuracy of these methods, including immunogenetic methods, to cover 
advantages and disadvantages of noninvasive alternatives to liver biopsy, and to share 
experience and impressions accumulated in area of hepatology. 
2. Materials and methods 
During the process of apoptosis the sequential activation of caspases (they all are proteases 
that cleave proteins at aspartic acid residue) creates an expanding cascade of proteolytic 
activity which leads to digestion of structural proteins in cytoplasm and generates, e.g. 
apoptotic cytokeratin 18 (CK-18) neoepitopes. 
To define the role of apoptosis in the development of acute and chronic HBV and HCV 
infection, the quantitative detection of serum CK-18 neoepitope was performed by using 
noninvasive method for caspase-generated CK-18 fragments determination (M30-
Apoptosense®, ELISA kit, PEVIVA, Sweden) in 11 patients with acute hepatitis B, 14 - with 
acute hepatitis C, 132 - with chronic hepatitis C and, for comparison, in 23 patients with 
acute alcoholic hepatitis, all treated in the Infectology Center of Latvia. 
The mitochondrial pathway involvement in the process of apoptosis was evaluated by 
determination of serum cytochrome C according to „Human cytochrome C ELISA”, Bender 
MedSystems (Austria) in 129 patients with chronic hepatitis C, in 12 patients with acute 
hepatitis B and in 29 patients with acute alcoholic hepatitis. 
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Serum hyaluronic acid (HA) as a potential marker of fibrosis evolution was measured by 
ELISA (Corgenix Inc., Colorado, USA) according to description of manufacturer in 16 
patients with acute hepatitis B, 9 – with acute hepatitis C, 22 – with acute alcoholic hepatitis 
and 132 patients with chronic hepatitis C. 
The study was conducted in compliance with the Declaration of Helsinki and in accordance 
with Good Clinical Practice guidelines and local regulations and was approved at the Ethics 
Committee of Riga Stradins University (Riga, Latvia). 
Diagnosis was based on modern immunochemical hepatitis marker assays and clinical, 
biochemical and morphological findings. Results were expressed as means±SE. For the  
comparison of two groups the unpaired Student’s t-test was used; p≥0.05% was considered 
significant. 
168 patients were enrolled in immunogenomic study and divided into four groups. Group A 
included 59 patients with HCV infection, treated with PEG-interferon + Ribavirin. Group B 
consisted of 45 patients with HCV infection and the same treatment regimen, but ineffective. 
Group C consisted of 30 patients with HCV infection (effective Realdiron therapy). Group D 
included 34 patients with HCV infection treated with Realdiron (non-responders). In group 
E, 100 healthy donors were included as the control group. 
HLA typing low-resolution for HLA- DRB1* was performed by polymerase chain reaction 
(PCR) with amplification using sequence-specific primers (SSP). PCR products were separated 
on 3% agarose, the amplified bands were visualized, and the DRB1 type was deduced.  
The distribution of HLA-DRB1* genes in all five groups (A, B, C, D and E controls) was 
compared using the chi-squared test with Yates’ correction or Fisher’s Exact. Odd ratios 
(OR) were calculated according to the Woolf’s formula. All reported p-values were 
compared to a level of significance set to 0.05. 
3. Results and discussion 
Performed studies showed very high serum level of CK-18 neoepitope in patients with acute 
hepatitis B (1362.3±108.9 U/L), that is higher than in patients with alcoholic hepatitis 
(1003.9±104.3 U/L; 0.02<p<0.05). CK-18 neoepitope concentration in acute hepatitis C 
(712.2±124.4 U/L) and chronic hepatitis C (232.3±15.8 U/L; 0.001<p<0.01) was significantly 
lower (Table 1). Besides, about 1/3 of chronic hepatitis C patients had normal serum ALT 
activity, but elevated serum CK-18 neoepitope concentration. 
Normally, cytochrome C is not detectable in serum, but 47.45% of patients with chronic 
hepatitis C had the increased level (0.29 ±0.05 ng/ml) of this apoptosis indicator (Table 1). 
Serum concentration of cytochrome C was even higher in acute hepatitides of viral and toxic 
etiologies. 
 
Patients Cytokeratin-18 U/L(mean±SE)
Cytochrome C ng/ml 
(mean±SE) 
Acute hepatitis B 1362.3±108.9 (n=11) 1.52±1.14 (n=14) 
Acute hepatitis C 712.2±124.4 (n=14) 3.15±1.84 (n=3) 
Chronic hepatitis C 232.3±15.8 (n=132) 0.29±0.05 (n=129) 
Acute alcoholic hepatitis 1003.9±104.3 (n=23) 0.59±0.19 (n=58) 
Reference intervals for: Cytokeratin-18 – 47.1-103.9 U/l, Cytochrome C -0 
Table 1. Level of apoptosis markers in serum from patients with acute and chronic liver 
diseases. 
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Very high serum concentration of HA was found in patients with acute alcoholic hepatitis 
(1015.50±58.83 ng/ml). Serum HA level was significantly higher in acute hepatitis B 
(228.13±51.71 ng/ml) than in acute hepatitis C (58.33±27.22 ng/ml, p<0.001). The level of 
serum HA in patients with chronic hepatitis was 103.82±15.47 ng/ml (Table 2). 
 
Patient group Number of patients 
Hyaluronic acid 
ng/ml 
(mean±SE) 
Acute hepatitis B 16 228.13±1.71 
Acute hepatitis C 9 58.33±27.22 
Chronic hepatitis C 132 103.82±15.47 
Acute alcoholic hepatitis 22 1015.50±58.83 
Reference interval: 0-75 ng/ml 
Table 2. Serum hyaluronic acid in patients with acute and chronic liver diseases. 
In the present study we identified HLA-DRB1 alleles associated with the risk of HCV 
infection or protection in comparison with healthy subjects. Some differences in the strength 
of those markers are presented in Table 3. 
HLA DRB1*07 (OR=7.0, p<0.0001), HLA-DRB1*03 (OR=1.95, p<0.035) and HLA-DRB1*05 
(OR=1.66, p<0.026) alleles were observed with the highest frequency, but DRB1*06, 
(OR=0.56, p<0.034) and DRB1*15 alleles (OR=0.59, p<0.020) - with the lowest frequency 
among patients with HCV infection. 
Table 4 shows the association of different alleles of HLA class II genes with HCV  
infection and therapy. One hundred four patients received PEG-interferon + Ribavirin 
therapy. Fifty nine patients were characterized as responders, and the remaining 45 as  
non-responders. 
 
Alleles 
DRB1* 
HCV 
(n=336) 
Controls 
(n=200) 
Odds 
Ratio (p) 
*01 48 31 0.91 <0.701** 
*15 49 45 0.59 <0.020 
*03 43 14 1.95 <0.035 
*04 39 23 1.01 <0.970** 
*05 83 33 1.66 <0.026 
*06 29 28 0.56 <0.034 
*07 42 4 7.0 <0.000 
*08 3 14 0.12 <0.000 
*09 0 2 - - 
*10 0 5 - - 
**Cornfield not accurate. Extract limits preferred. 
Bold-face type highlihts statistically significant associations for patient’s vs controls. 
p-probability (l-p) *100%, OR – odds ratio 
n=number of haplotypes (eg, 336 alleles from 168 individuals). Nature of valve lesions was not reported 
on 2 patients. 
Table 3. The frequency of identified DRB1* alleles in HCV patients and control subjects. 
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DRB1* alleles *01 *15 *03 *04 *05 *06 *07 
Patients in total 
n=168  
(general group) 
0.18 0.59/ (0.020) 
1.95/ 
(0.035)  
1.66/ 
(0.026 
0.56/ 
(0.034) 
7.0/ 
(0.000) 
Effective PEG 
INF+Ribavirin 
therapy  
(group A) n=59 
0.14 0.14 0.13 1.79/ 0.014 0.21 
4.29/ 
(0.003) 0.03 
Noneffective PEG 
INF+Ribavirin 
therapy  
(group B) n=45 
0.16 0.16 0.12 0.08 0.62/ 0.013 0.06 0.18/ 0.005 
Effective Realdiron 
therapy (group C) 
n=30 
2.58/ 
0.071 0.13 0.13 0.08 0.22 0.07 0.13 
Noneffective 
Realdiron therapy 
(group D) n=34 
0.09 0.16 0.13 0.53/ 0.065 0.77 0.74 1.15 
Control subjects 
(group E) n=100 0.16 0.23 0.07 0.12 0.17 0.15 0.02 
Bold-face type highlights statistically significant associations for patient’s vs controls. 
gf (gene frequency), p (probability), OR (odds ratio) and value are reported only for significant 
associations (p<0.05). n=number of haplotypes (eg, 336 alleles from 168 individuals). 
Table 4. Association of different alleles of HLA class II genes with HCV infection and therapy. 
Sixty four patients received Realdiron therapy. Thirty patients were characterized as 
responders, and the remaining 34 as non-responders. All individuals in the study were 
genotyped for HLA class II DRB1*alleles. 
HLA-DRB1*06(OR=4.29, p<0.003)and HLA-DRB1*04 (OR=1.79, p<0.014) Major 
Histocompatibility class II alleles were significantly associated with the effective response  
to PEG interferon + Ribavirin therapy in patients.  Our results therefore provide evidence that 
the presence of HLA-DRB1*06 and HLA-DRB1*04 is an important additional factor for 
predicting a long-term response to PEG-interferon + Ribavirin therapy in patients with chronic 
hepatitis C. 
The results of class II HLA distribution in patients with HCV are presented in Table 4. 
HLA-DRB1*01 was detected among patients of group C and D and it was significantly 
associated (OR=2.58, p<0.071)with the effective response to Realdiron therapy in chronic 
hepatitis C patients. HLA-DRB1*04 (OR=0.53, p<0.065) was found as an indicator of non-
responders to Realdiron therapy in group D. In both groups - C and D, the frequency of the 
remaining HLA antigens was of minor importance. 
Liver biopsy is not always possible or reproducible, it cannot be performed frequently and is 
a costly invasive procedure with a certain, although low, risk of serious complications. 
Histological examination of the liver does not provide information about the dynamics of 
hepatic fibrogenesis, liver biopsy provides only static information about fibrotic process. 
Non-invasive markers that reflect fibroproliferative activity in the liver and the treatment 
response would be preferable. Serum hyaluronic acid has been identified as a potential 
marker of fibrosis evolution. 
The clinical benefit of the existing markers may be limited by the etiology or stage of disease. 
Hyaluronate can be used as a specific marker to detect liver fibrosis (Afdhal&Nunes, 2004) and 
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Very high serum concentration of HA was found in patients with acute alcoholic hepatitis 
(1015.50±58.83 ng/ml). Serum HA level was significantly higher in acute hepatitis B 
(228.13±51.71 ng/ml) than in acute hepatitis C (58.33±27.22 ng/ml, p<0.001). The level of 
serum HA in patients with chronic hepatitis was 103.82±15.47 ng/ml (Table 2). 
 
Patient group Number of patients 
Hyaluronic acid 
ng/ml 
(mean±SE) 
Acute hepatitis B 16 228.13±1.71 
Acute hepatitis C 9 58.33±27.22 
Chronic hepatitis C 132 103.82±15.47 
Acute alcoholic hepatitis 22 1015.50±58.83 
Reference interval: 0-75 ng/ml 
Table 2. Serum hyaluronic acid in patients with acute and chronic liver diseases. 
In the present study we identified HLA-DRB1 alleles associated with the risk of HCV 
infection or protection in comparison with healthy subjects. Some differences in the strength 
of those markers are presented in Table 3. 
HLA DRB1*07 (OR=7.0, p<0.0001), HLA-DRB1*03 (OR=1.95, p<0.035) and HLA-DRB1*05 
(OR=1.66, p<0.026) alleles were observed with the highest frequency, but DRB1*06, 
(OR=0.56, p<0.034) and DRB1*15 alleles (OR=0.59, p<0.020) - with the lowest frequency 
among patients with HCV infection. 
Table 4 shows the association of different alleles of HLA class II genes with HCV  
infection and therapy. One hundred four patients received PEG-interferon + Ribavirin 
therapy. Fifty nine patients were characterized as responders, and the remaining 45 as  
non-responders. 
 
Alleles 
DRB1* 
HCV 
(n=336) 
Controls 
(n=200) 
Odds 
Ratio (p) 
*01 48 31 0.91 <0.701** 
*15 49 45 0.59 <0.020 
*03 43 14 1.95 <0.035 
*04 39 23 1.01 <0.970** 
*05 83 33 1.66 <0.026 
*06 29 28 0.56 <0.034 
*07 42 4 7.0 <0.000 
*08 3 14 0.12 <0.000 
*09 0 2 - - 
*10 0 5 - - 
**Cornfield not accurate. Extract limits preferred. 
Bold-face type highlihts statistically significant associations for patient’s vs controls. 
p-probability (l-p) *100%, OR – odds ratio 
n=number of haplotypes (eg, 336 alleles from 168 individuals). Nature of valve lesions was not reported 
on 2 patients. 
Table 3. The frequency of identified DRB1* alleles in HCV patients and control subjects. 
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associations (p<0.05). n=number of haplotypes (eg, 336 alleles from 168 individuals). 
Table 4. Association of different alleles of HLA class II genes with HCV infection and therapy. 
Sixty four patients received Realdiron therapy. Thirty patients were characterized as 
responders, and the remaining 34 as non-responders. All individuals in the study were 
genotyped for HLA class II DRB1*alleles. 
HLA-DRB1*06(OR=4.29, p<0.003)and HLA-DRB1*04 (OR=1.79, p<0.014) Major 
Histocompatibility class II alleles were significantly associated with the effective response  
to PEG interferon + Ribavirin therapy in patients.  Our results therefore provide evidence that 
the presence of HLA-DRB1*06 and HLA-DRB1*04 is an important additional factor for 
predicting a long-term response to PEG-interferon + Ribavirin therapy in patients with chronic 
hepatitis C. 
The results of class II HLA distribution in patients with HCV are presented in Table 4. 
HLA-DRB1*01 was detected among patients of group C and D and it was significantly 
associated (OR=2.58, p<0.071)with the effective response to Realdiron therapy in chronic 
hepatitis C patients. HLA-DRB1*04 (OR=0.53, p<0.065) was found as an indicator of non-
responders to Realdiron therapy in group D. In both groups - C and D, the frequency of the 
remaining HLA antigens was of minor importance. 
Liver biopsy is not always possible or reproducible, it cannot be performed frequently and is 
a costly invasive procedure with a certain, although low, risk of serious complications. 
Histological examination of the liver does not provide information about the dynamics of 
hepatic fibrogenesis, liver biopsy provides only static information about fibrotic process. 
Non-invasive markers that reflect fibroproliferative activity in the liver and the treatment 
response would be preferable. Serum hyaluronic acid has been identified as a potential 
marker of fibrosis evolution. 
The clinical benefit of the existing markers may be limited by the etiology or stage of disease. 
Hyaluronate can be used as a specific marker to detect liver fibrosis (Afdhal&Nunes, 2004) and 
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has been found to correlate with severity of the disease (Lackner C. et al., 2005). Findings of 
Kawamoto et al. (2006) suggest that hyaluronate can be used to assess severe liver fibrosis or 
cirrhosis, but it would be difficult to assess liver fibrosis at its early stage. 
According to Suzuki et al. (2005), hyaluronic acid has been reported to have a high 
diagnostic performance in assessing the severity of hepatic fibrosis in patients with alcoholic 
liver disease. 
In the context of above mentioned our findings don’t  contradict with conclusions of those 
investigators, particularly, in case of acute alcoholic hepatitis, when level of hyaluronic acid 
in blood serum is very high (see Table 2). 
Performed parallel histological investigations of liver biopsies from patients with chronic 
hepatitis C illustrated the heterogeneity of hepatic fibrosis degree. Serum HA levels didn’t 
significantly correlate with the degree of hepatic fibrosis found in these patients. HA could 
be a marker of hepatic fibrosis progression. In chronic liver diseases, serial HA levels have 
been advocated as the means to monitor disease progression and to limit the need for 
follow-up liver biopsy. 
The results of performed investigation on main apoptosis markers (cytokeratin-18 
neoepitope, cytochrome C) demonstrated very significant involvement of apoptosis  
(including mitochondrial way) in pathogenesis of acute hepatitis, independently of 
etiology. This presumption was confirmed by high level of apoptosis markers in serum 
(see Table 1). The delineation of the signalling patways that mediate apoptosis has 
changed the paradigms of understanding of many liver diseases (Schattenberg et al., 
2006). Apoptosis is the normal physiological response to many chemical, physical and 
biological stimuli. Mitochondria and cell surface receptors mediate the two main 
pathways of apoptosis (Reed, 2000). Hypoxia has been shown to promote apoptosis 
(Holmgren L. et al., 1995). As apoptosis is closely involved in the process of liver disease 
progression, the treatment of ischemic injury remains one of the most challenging areas of 
hepatology today. 
Apoptosis defines a type of cell death distinct from the more conventional necrotic death on 
the basis of characteristic morphological features. Although these descriptions and 
distinctions are useful, there is a great deal of overlap between apoptosis and necrosis in 
morphological features and biochemical events. Indeed, apoptosis is frequently followed by 
secondary necrosis of cells, especially, if there is failure of clearance or ingestion of apoptotic 
bodies (Bennett, 2002). 
One of the aims of our study was to confirm the influence of HLA class II genes on the 
progression of HCV infection and to assess a possible relationship between these genes 
and different therapies. For this purpose we used the PCR-SSP test which permits the 
routine determination of the distribution of HLA class II genes. We confirmed that the 
frequency of HLA-DRB1*06 (4.29/0.003)and *04(1.79,0.014) was significantly higher in 
patients from group A than in patients from group B. In general group HLA-DRB1*07 and 
HLA-DRB1*05 alleles were observed.HLA-DRB1*07 was found as an indicator of non-
responders to PEG-interferon + Ribavirin therapy (group B). 
In all HCV patient groups, a correlation was found between certain HLA genes and the 
extent of liver damage. Among the host-related factors which have an important role in 
determining the outcome of HCV infection, certain HLA class II genes appear crucial for 
resolution or progression of hepatitis C.  
Accumulation evidence regarding the limitations of biopsy have led some to suggest that 
non-invasive markers should replace biopsy as the initial method for disease staging. But 
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further research is needed to evaluate the long-term effectiveness of the these strategies 
before a global recommendation can be made (Mehta et al., 2009). It is widely appreciated 
that substantial error has been observed when biopsy specimens have been compared to the 
full liver (Colloredo et al., 2003). 
There are several advantages in using non-invasive markers: they can be used to accurately 
define an appropriate time for treatment initiation, they can help monitoring and assess the 
therapeutic efficacy of antiviral treatment in case of liver fibrosis and cirrhosis, etc., they are 
crucial to evaluate the performance of non-invasive markers used for diagnosis of liver 
fibrosis and apoptosis in HAV, HBV, HCV, HIV-infected patients. 
A number of radiological methods are used in diagnosis of various chronic liver diseases. 
The first of them most often is ultrasonography (US). Signs of liver cirrhosis in B-mode 
image are well known. They are the irregularity and nodularity of liver surface, coarse 
nodularity of parenchyma structure, lobus caudatus hypertrophy, as well as symptoms of 
portal hypertension such as splenomegaly, ascites and portocaval shunts. The specificity of 
the method in detection of cirrhosis is in the range from 80% to 100%, sensitivity – from 43% 
to 88% (Needleman et al, 1986; Giorgio et al., 1986; Di Lelio et al., 1989; Gaiani et al., 1997; 
Colli et al., 2003; Vigano M. et al., 2005). Irregularity and nodularity of the liver surface 
caused by altering foci of regeneration nodules and necrosis (Poff et al., 2008) can be better 
assessed using high-frequency linear probe (Colli et al., 2003.; Nishiura et al., 2005).  
Nodularity of the structure is a prognostic sign of increased risk of developing 
hepatocellular carcinoma. This symptom is more common in liver cirrhosis of HDV hepatitis 
origin (51%), less common in other causes of diseases (9%) (Caturelli et al., 2003). A 
significant sign of liver cirrhosis is splenomegaly. The spleen size which overexceeds 15 cm 
is a symptom with 98% specificity and 57% sensitivity (O’Donohue et al., 2004). By 
combining sonographic symptoms of B-mode imaging in a common system several 
researchers have gained increment of specificity of the method (Nishiura et al., 2005). Liver 
cirrhosis is characterized by changes in liver size and its proportion:  atrophy of the right 
lobe and the medial segment of the left lobe as well as hypertrophy of lobus caudatus and the 
lateral segment of the left lobe (Giorgio et al., 1986; Lafortune et al., 1998). In total, the 
diagnostic accuracy of US in detection of liver cirrhosis is high enough, while its 
applicability in precirrhotic stages of the disease is limited.  
As chronic liver disease progresses, numerous processes occur in the structure altering 
liver blood flow. Under normal conditions liver receives 70-75% of blood through the 
portal vein, 25-30% through the hepatic artery, leaving a very small fraction for such tiny 
blood vessels as aberrant gastric veins, particularly the right (Matsui et al., 1995) which 
occurs in about 6-14 % of patients, a.phrenica dx, parabiliary veins (Couinaud, 1988), 
gallblader vein, which sometimes is drained directly to the liver. As a result of cirrhotic 
and fibrotic processes presinusoidal and sinusoidal occlusion develops there which 
increases resistance for the blood flow through the liver. A portal hypertension develops,  
if the pressure gradient overexceeds 10 mm H2O (Zwiebel&Pellerito, 2005). Due to the 
increased resistance as the portal blood flow diminishes, there is a compensatory 
increment of the flow in the hepatic artery (Burton-Opitz, 1911; Kock et al., 1972). As a 
result of the increment of the pressure in the portal vein, its size and pulsations are 
altered, blood flow slows down and later changes its direction from hepatopetal to 
hepatofugal. Increase in pressure in the portal vein is compensated through portocaval 
anastomoses. The hepatic artery itself does not have such a mechanism. It is compensated 
through very tiny (under normal conditions) anastomoses between portal and arterial 
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has been found to correlate with severity of the disease (Lackner C. et al., 2005). Findings of 
Kawamoto et al. (2006) suggest that hyaluronate can be used to assess severe liver fibrosis or 
cirrhosis, but it would be difficult to assess liver fibrosis at its early stage. 
According to Suzuki et al. (2005), hyaluronic acid has been reported to have a high 
diagnostic performance in assessing the severity of hepatic fibrosis in patients with alcoholic 
liver disease. 
In the context of above mentioned our findings don’t  contradict with conclusions of those 
investigators, particularly, in case of acute alcoholic hepatitis, when level of hyaluronic acid 
in blood serum is very high (see Table 2). 
Performed parallel histological investigations of liver biopsies from patients with chronic 
hepatitis C illustrated the heterogeneity of hepatic fibrosis degree. Serum HA levels didn’t 
significantly correlate with the degree of hepatic fibrosis found in these patients. HA could 
be a marker of hepatic fibrosis progression. In chronic liver diseases, serial HA levels have 
been advocated as the means to monitor disease progression and to limit the need for 
follow-up liver biopsy. 
The results of performed investigation on main apoptosis markers (cytokeratin-18 
neoepitope, cytochrome C) demonstrated very significant involvement of apoptosis  
(including mitochondrial way) in pathogenesis of acute hepatitis, independently of 
etiology. This presumption was confirmed by high level of apoptosis markers in serum 
(see Table 1). The delineation of the signalling patways that mediate apoptosis has 
changed the paradigms of understanding of many liver diseases (Schattenberg et al., 
2006). Apoptosis is the normal physiological response to many chemical, physical and 
biological stimuli. Mitochondria and cell surface receptors mediate the two main 
pathways of apoptosis (Reed, 2000). Hypoxia has been shown to promote apoptosis 
(Holmgren L. et al., 1995). As apoptosis is closely involved in the process of liver disease 
progression, the treatment of ischemic injury remains one of the most challenging areas of 
hepatology today. 
Apoptosis defines a type of cell death distinct from the more conventional necrotic death on 
the basis of characteristic morphological features. Although these descriptions and 
distinctions are useful, there is a great deal of overlap between apoptosis and necrosis in 
morphological features and biochemical events. Indeed, apoptosis is frequently followed by 
secondary necrosis of cells, especially, if there is failure of clearance or ingestion of apoptotic 
bodies (Bennett, 2002). 
One of the aims of our study was to confirm the influence of HLA class II genes on the 
progression of HCV infection and to assess a possible relationship between these genes 
and different therapies. For this purpose we used the PCR-SSP test which permits the 
routine determination of the distribution of HLA class II genes. We confirmed that the 
frequency of HLA-DRB1*06 (4.29/0.003)and *04(1.79,0.014) was significantly higher in 
patients from group A than in patients from group B. In general group HLA-DRB1*07 and 
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further research is needed to evaluate the long-term effectiveness of the these strategies 
before a global recommendation can be made (Mehta et al., 2009). It is widely appreciated 
that substantial error has been observed when biopsy specimens have been compared to the 
full liver (Colloredo et al., 2003). 
There are several advantages in using non-invasive markers: they can be used to accurately 
define an appropriate time for treatment initiation, they can help monitoring and assess the 
therapeutic efficacy of antiviral treatment in case of liver fibrosis and cirrhosis, etc., they are 
crucial to evaluate the performance of non-invasive markers used for diagnosis of liver 
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Nodularity of the structure is a prognostic sign of increased risk of developing 
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origin (51%), less common in other causes of diseases (9%) (Caturelli et al., 2003). A 
significant sign of liver cirrhosis is splenomegaly. The spleen size which overexceeds 15 cm 
is a symptom with 98% specificity and 57% sensitivity (O’Donohue et al., 2004). By 
combining sonographic symptoms of B-mode imaging in a common system several 
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lateral segment of the left lobe (Giorgio et al., 1986; Lafortune et al., 1998). In total, the 
diagnostic accuracy of US in detection of liver cirrhosis is high enough, while its 
applicability in precirrhotic stages of the disease is limited.  
As chronic liver disease progresses, numerous processes occur in the structure altering 
liver blood flow. Under normal conditions liver receives 70-75% of blood through the 
portal vein, 25-30% through the hepatic artery, leaving a very small fraction for such tiny 
blood vessels as aberrant gastric veins, particularly the right (Matsui et al., 1995) which 
occurs in about 6-14 % of patients, a.phrenica dx, parabiliary veins (Couinaud, 1988), 
gallblader vein, which sometimes is drained directly to the liver. As a result of cirrhotic 
and fibrotic processes presinusoidal and sinusoidal occlusion develops there which 
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if the pressure gradient overexceeds 10 mm H2O (Zwiebel&Pellerito, 2005). Due to the 
increased resistance as the portal blood flow diminishes, there is a compensatory 
increment of the flow in the hepatic artery (Burton-Opitz, 1911; Kock et al., 1972). As a 
result of the increment of the pressure in the portal vein, its size and pulsations are 
altered, blood flow slows down and later changes its direction from hepatopetal to 
hepatofugal. Increase in pressure in the portal vein is compensated through portocaval 
anastomoses. The hepatic artery itself does not have such a mechanism. It is compensated 
through very tiny (under normal conditions) anastomoses between portal and arterial 
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system, which are located in the liver sinusoides, vasa vasorum of the portal vein and 
peribiliary vascular plexes. If transhepatic resistance overexceeds resistance of 
portosystemic collaterals, a shunting of arterial flow to the portal system starts to occur 
(Sacerdoti et al., 1995; Piscaglia et al., 1997). Flow characteristics and their changes in liver 
blood vessels are well detectable in doplerographic examinations. Veins of portal systems 
- v.portae, v.mesenterica sup., v.lienalis, as well as hepatic artery and liver veins are well 
visible in approximately 93-95% of patients undergoing liver sonography (Zwiebel & 
Pellerito, 2005). 
A number of parameters and indexes are offered to assess and detect portal hypertension. 
They are: diameter of the portal vein, change of the size of v.portae and v.lienalis during the 
respiratory cycle, flow rate and direction in the portal vein, pulsitility of Doppler spectral 
waveform as well as congestation index, respectively: ratio between cross-sectional area of 
the portal vein and the flow velocity within it, the resistance index in the hepatic artery, 
portal and hepatic artery velocity rate, etc. Many studies have been performed regarding 
utility of all these parameters in diagnostics of liver cirrhosis, however the results are still 
controversial. 
One of the signs of liver cirrhosis and portal hypertension is hepatofugal flow in the portal 
vein, i.e., the flow away from the liver. This sign is found in 3–23% of cirrhosis patients 
(Kawasaki et al., 1989; Gaiani et al., 1991; Taourel et al., 1998; von Herbay et al., 2001). 
Incidence of this symptom depends on the severity of the disease. The flow direction in the 
portal vein is influenced also by development of the paraumbilical shunts, retaining the 
hepatopetal flow in cirrhosis patients. Hepatofugal flow can also be found in patients with 
extrahepatic shunts (splenorenal, oesophageal, retroperitoneal, etc.).  
The portal flow velocity, which is an easily assessable measure, is a variable parameter.  
In healthy subjects in various studies it ranges from 13.7 cm/s to 22 cm/s (O’Donohue  
et al., 2004; Walsh et al., 1998; Bernatik et al., 2002). With the development of liver 
cirrhosis it declines. For the diagnosis of liver cirrhosis using a cut-off value of 13 to  
15 cm/s the sensitivity is 74.5% to 88%, the specificity - 53% to 96% (Zironi et al.,  
1992; Schneider et al., 2005; Iwao et al., 1997). In precirrhotic stages there is no significant 
difference in velocity of the portal flow from healthy subjects (Bernatik et al., 2002; 
Schneider et al., 2005). 
Under normal conditions the flow in the portal vein is continuous and hepatopetal but its 
velocity is slightly pulsatile during the heart cycle. These pulsations cause a pressure 
change in the right atrial flow initiated by fluctuations in the lower vena cava which 
through the liver veins and sinusoides are transmitted to v.portae. Pronounced pulsations 
in the portal vein in patients with right heart diseases serve as the evidence of such 
explanation of the pulsation mechanism (Görg et al., 2002). Besides, there is also influence 
of the adjacent hepatic artery pulsations and respiratory cycle phases. Presinusoidal 
obstruction, collagenisation of the Disse space and enlargement of hepatocytes due to 
liver fibrosis and cirrhosis may prevent the transmission of pulsations from the heart and 
liver veins. Flatened Doppler waveform of the portal vein could therefore be a sign of 
liver fibrosis and cirrhosis. Undulating Doppler waveform of the portal vein in healthy 
subjects is found in 63.8%-100% of cases. The degree of pulsatility of the portal vein 
quantitatively is characterized by two indexes: the ratio between minimal and maximal 
flow velocity as well as pulsation index (PI) in which the maximal flow rate is extended to 
the difference between the minimum and the maximum flow rate. The minimum and 
maximum velocity ratio >0.54 for healthy subjects is higher than 90% of cases (Gallix et 
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al., 1997). In liver cirrhosis patients reduced hepatic vein pulsatility is found significantly 
more often than in patients with lower degrees of fibrosis or in healthy subjects, however, 
the incidence in different studies varies considerably. Distinguishing between various 
degrees of severity of fibrosis in this manner fails (Schneider et al., 2005; Barkat, 2004; 
Maktanir et al., 2005). 
In a number of studies the measurement of size of the portal vein is used as one of the 
methods of detecting portal hypertension. In most cases in healthy subjects the portal vein is 
smaller than in patients suffering from cirrhosis and various degrees of liver fibrosis, 
although these differences are not statistically significant and a large overlap of values is 
found (O’Donohue et al., 2004; Lim et al., 2005; Kutlu et al., 2002). Similar results were 
gained when determining the liver congestation index, calculated by extending v.portae 
diameter to the average blood flow velocity in it (Walsh et al., 1998; Lim et al., 2005), 
although some studies provide evidence of the ability of this feature to differentiate liver 
cirrhosis from other conditions (Kutlu et al., 2002). 
As the sinusoidal resistance increases and the portal flow decreases there is a 
compensatory increment of the flow in the liver artery. Since the increase of resistance 
also affects the arterial system, changes occur in haemodynamic parameters recordable in 
Doppler waveform as well as increase of the resistance index and growth of the volume. 
Under normal conditions a Doppler waveform of hepatic artery of healthy subjects is of 
low pulsitility with antegrade flow within whole diastole. Resistance index (RI), 
determined by extending the peak systolic and end-diastolic velocity difference to the 
peak systolic velocity in healthy subjects ranges from 0.5 to 0.7 (Vilgranin, 2001). In 
cirrhotic patients RI within different studies ranges from 0.68 to 0.98, in precirrhotic stages 
of the disease - from 0.58 to 0.73 (O’Donohue et al., 2004; Bernatik et al., 2002; Haktanir et 
al., 2005; Lim et al., 2005; Pierce&Sewell, 1990). The overlap of these parameters 
significantly limits the use of dopplerographic parameters of hepatic arteries in 
diagnostics. No studies have yielded results that would reliably differentiate various 
degrees of fibrosis from each other.  
In some trials a number of other arterial flow factors have been used, as the mean flow 
velocity (cm/s), minute volume flow (ml/min), liver perfusion index (hepatic artery and 
common liver flow ratio), however, they have not gained wide acceptance. 
One of the most widely used liver vascular ultrasound examination is hepatic vein 
dopplerography. In most cases liver veins are easily visible tubular structure, with 
diameter changing during the respiratory cycle. In healthy subjects 2 cm away from the 
inflow to v. cava inferior it is 4-6 mm but less than 1 cm (Bolondi et al., 1991). In cases  
of various diseases, such as the right heart diseases, circulatory congestion in the large 
vasculatory circle, severe liver steatosis, Budd-Chiary syndrome, etc. vein size may vary. 
Blood flow in liver veins is markedly pulsating, changing directions with different phases 
of the cardiac cycle. During the diastole of the heart atria and ventriculi it is antegrade, 
respectively towards the heart, or away from the liver. During the atrial systole the flow  
is retrograde or towards the liver. Healthy liver is elastic and easily responds to the 
pressure changes in liver veins during heart cycle phases. In the Doppler waveform of 
liver veins these fluctuations are reflected as two antegrade waves followed by a single 
retrograde wave.  Haemodynamics of the liver veins is detailed in the L.Bolondi study in 
1991. (Fig.1) 
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Fig. 1. Mechanism of wave formation in VHDx Doppler waveform. Simultaneous record of 
ECG, phonocardiogram and Doppler waveform of the jugular vein (adapted from Bolondi L 
et al, Radiology 1991; 178:513-516.)  
Wave A (+) – atrial systole. Retrograde flow in VCI and VH. Wave C (+) - a small positive 
wave in the descendent part or the A wave which is caused by  closing of tricuspidal valves. 
Wave X (-) – ventricular systole and atrial relaxation (diastole). Antegrade flow during 
filling of the atrium. Wave V (+) – atrial filing. The peak of the wave shows opening of 
tricuspidal valves at the beginnning of ventricular diastole. Wave Y (-) – ventricular diastole. 
Atrial emptying towards ventriculi. 
In order to assess the Doppler waveform of hepatic veins a number of methods are 
recommended. The most widespread method was introduced by Bolondi. He advised to 
divide all curves into 3 groups: triphasic, showing a positive wave due to retrograde flow 
during the atrial systole, biphasic, with no positive wave, but with saved pulsations, and 
fully flattened or monophasic appearance. This method is simple, easy to use and 
reproducible. 
Flow type of hepatic veins, respectively, shape of Doppler waveform of liver veins, is 
dependent on a number of diseases and conditions. Incidence of flattened curve 
significantly increases during pregnancy and increases as pregnancy progresses (Roobottom 
et al., 1995). In case of regurgitation and insuficience of tricuspidal valves during ventricular 
systole the blood is pushed backwards to atria and – further – to v.cava inferior and to 
hepatic veins. In their Doppler waveform the systolic wave X reduces, disappears and 
becomes retrograde and interacts with wave A (Abu-Yousef, 1991). Also, in case of 
constrictive pericarditis changes in hepatic vein Doppler waveform are seen (von Birbra et 
al., 1989).  
Pathological processes within liver veins themselves, as Budd-Chiari syndrome and veno-
occlusive disease or sinusoidal obstruction syndrome, are seen and diagnosed by B-mode 
and Doppler ultrasound methods. Unlike Budd-Chiari syndrome, in cases of veno-occlusive 
disease main liver veins can be patent (Desser et al., 2003). 
Flow in liver veins is influenced by intra-abdominal and intrathoracic pressure. In patients 
with triphasic waveform during deep inspiration and Valsalva test the waveform often 
paves and becomes monophasic or biphasic (Techgraber et al., 1997). Due to this reason liver 
vein examination is held during mild, superficial inspiration or mild expiration following 
mild inspiration. 
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One of the basic factors influencing the type of liver flow is the physical condition of the liver, 
its hardness and elasticity. With increase in hardness and decrease in elasticity liver tissue 
looses compliance with hepatic venous pulsations caused by variations in pressure within them.  
Haemodynamically it is expressed as loss of changing of flow direction during atrial systole in 
v.cava inferior and hepatic veins what can be registered by Doppler ultrasound. The feasibility 
that the hepatic veins Doppler waveform assesses changes in liver structure, resp., fibrosis and 
cirrhosis, has been investigated by many researchers, and the results are generally better than in 
other hepatic circulatory dopplerographic measurements, although not very clear.  
Flattened, resp., biphasic or monophasic hepatic vein Doppler waveforms in liver cirrhosis 
patients with varying forms of cirrhosis, occur in 50% (Bolondi et al., 1991) to 85% (Barkat, 
2004) cases. With increasing severity of cirrhosis, the frequency of flattened curves increases 
(von Herbay et al., 2001; Barkat, 2004). The sensitivity and specificity of the method to detect 
cirrhosis are 37%-75% and respectively 41%-100%, respectively (Colli et al., 2003; Schneider 
et al., 2005; Arada et al., 1997). In precirrhotic stages of the disease with increase of fibrosis 
stage the incidence of flattened waveform tends to increase. In some studies this increase is 
statistically significant (O’Donohue et al., 2004; Schneider et al., 2005), while in others it is 
insignificant, there is overlap between the results (Bernatik et al., 2002; Lim et al., 2005). This 
leads to critical assessment of hepatic vein Doppler ultrasound ability to detect the 
precirrhotic forms or differentiate between degrees of fibrosis, while the diagnosis of 
cirrhosis flattened Doppler waveform is a key symptom. (Fig.2, 3) 
 
 
Fig. 2. Triphasic VHDx Doppler waveform in 29 y.o. patient with mild (Knodell F1) liver 
fibrosis and without liver steatosis (S-0). 
Liver steatosis also should be taken into account when assessing liver veins Doppler 
ultrasound results. The increased fat in the liver increases the pressure on the hepatic veins 
and reduces liver tissue compliance to venous pulsations. In patients with severe liver steatosis 
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(> 66% of hepatocytes affected by fat) flattened hepatic vein Doppler waveform is found 
significantly more frequently than in patients without steatosis or those with mild forms in 
respectively 90% vs. 5% -20% of cases (Schneider et al., 2005). Sensitivity of the method in 
detecting severe steatosis is 88%, specificity 74% (Schneider et al., 2005). It should be noted that 
appearance of liver steatosis in B-Mode ultrasound image has been researched much, 
however, its effect on blood flow types in hepatic veins, the dependence on the morphological 
forms of steatosis (macrovesicular or microvesicular) has been assessed much less frequently. 
(Fig.4) 
 
 
Fig. 3. Monophasic VHDx Dopler waveform in 53 y.o. patient with moderate severity of 
liver fibrosis (Knodell F-3) and severe mixed type (macro – microvesiculare) steatosis  (S3). 
There are no typical steatosis signs in B- mode image 
 
 
Fig. 4. Biphasic VDHx waveform in 44 y.o. patient with moderate liver steatosis (S-2) and 
mild fibrosis (F-1). In B-Mode image appearance of expressed steatosis is visible: increased 
liver exhogenicity, impaired visualization of deeper tissues and diaphragmal line. 
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4. Conclusion 
Evaluation of apoptosis by estimating CK-18 neoepitope level should be included into 
hepatitis virus infection and toxic liver damage management algorithm. Apoptosis, not only 
necrosis, is essentially involved in liver damage development mechanisms in acute and 
chronic HBV and HCV infection. Monitoring of serum apoptotic CK-18 neoepitope level 
might be useful for the appropriate estimation of liver diseases therapy efficacy and open 
new approach to apoptosis therapeutic regulation. 
If in alcoholic hepatitis apoptosis may be a principal cause of cell death, then in acute 
hepatitis B cell death would be associated with both cell apoptosis and cell necrosis.  
As fibrotic process is dynamic, serum hyaluronic acid  levels may show fibrogenesis rather 
than developed and formed fibrosis. Circulating HA measurement has been proposed for 
operative monitoring of fibrotic lesion dynamics in acute and chronic liver damages. 
The punctual identification of immunogenetic factors may prove to be useful in predicting 
disease evolution, in guiding the appropriate therapy for patients with poor prognosis, and 
in encouraging the development of untherapeutic strategies. 
As regards to the potential of US to assess the diagnosis of diffuse liver disease, it must be 
concluded that the method is applied to the detection of manifest cirrhosis. In detection of 
precirrhotic stages and differentiation between them the options are greatly restricted and 
the liver biopsy cannot be replaced. Liver vein Dopplerography can be applied in liver 
screening examinations to detect occult liver diseases. It can be also applied in follow-up of 
diffuse liver diseases, however, this suggestion still requires further studies. 
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1. Introduction 
Liver biopsy is considered the gold standart for the diagnosis of cirrhosis, it has important 
limitations ,such as being invasive,having the potential for complications and false-negative 
results or underestimating disease severity due to sampling error. 
Liver biopsy is recomended in patiens with abnormal liver tests,for evaluation of chronic 
hepatitis, of alcohol liver disease, icterus of unknown origin, hepatomegaly,splenomegaly, 
ascites, cholestatic liver disease, toxic liver damage,metabolic disorders.Liver biopsy has 
limitations including small but significant morbidity and mortality rates,inter- and intra-
observer variation in patology reporting. The most important contraindications of liver 
biopsy are trombopenia, abnormal parameters of hemocoagulation, important ascites, liver 
hemangioma and cysts, acute cholangitis, biliary obstruction ,severe obesity, respiratory 
insufficiency, heart failure,Chilaiditi´s sy, uncooperative patient.(1) 
Complication of liver biopsy and their incidence: 
Pain (0,056 -22%)-pleural, peritoneal, diaphragmatic 
Bleeding-intraperitoneal(0,03-0,7%). 
- intrahepatic or subcapsular ( 0,059-23%) 
- hemobilia(0,059-0,2%) 
Biliary peritonitis(0,03-0,22%) 
Bacteriemia 
Sepsis(0,088 %) and liver absces 
Pneumothorax or pleural effusion (0,08-0,28%) 
Hemothorax (0,18-0,49%) 
Arteriovenous fistula (5,4%) 
Subcutaneous emphysema(0,014%) 
Reaction to anaestetic (0,029 %) 
Beakage of needle (0,02-0,059%) 
Biopsy of other organs: 
- lungs (0,001-0,014%). 
- gallbladder(0,034-0,117%), 
- kidney ( 0.029-0,096%) 
- colon (0.0038-0,044%) 
Death (0,0088-0,3%) 
Noninvasive methods of investigation of liver offer an atractive alternative to the liver 
biopsy, as they are less invasive than liver biopsy,repeatable. 
  
Liver Biopsy 
 
202 
Mogawer, S., Hamdy, H., Elwakil, R. (2009). Liver fibrosis: consensus 
recommendations of the Asian Pacific Association for the study of the liver 
(APASL). Hepatol Int, Vol.3, pp.323 – 333 
Silveira M.G.&Lindor, K.D. (2008). Primary sclerosing cholangitis. Can J Gastroenterol, 
Vol.22, No.8, pp689 – 698 
Silveira, M.G.&Lindor KD. (2008). Clinical features and management of primary sclerosing 
cholangitis. World J Gastroenterol, Vol.14, No.2, pp.3338 – 3349 
Skripenova, S., Trainer, T.D., Krawitt, E.L.&Blaszyk, E. (2007). Variability of grade and stage 
in simultaneously paired liver biopsies in patients with hepatitis C. J Clin Pathol, 
Vol.60, pp.321 – 324. Doi: 10.1136/jcp2005.036020 
Standish, R.A., Cholongitas, E., Dhillon, A., Burroughs, A.K.&Dhillon, A.P. (2006). An 
appraisal of the histopatological assessment of liver fibrosis. Gut, Vol.55, pp.569 – 
578 
Suzuki, A., Mendes, F. & Lindor, K. (2005). Diagnostic model of esophageal varices in 
alcoholic liver disease. Eur. J. Gastroenterol. Hepatol., Vol.17, No.3, pp.307-309 
Taourel, P., Blanc, P., Dauzat, M., Pradel, J. et al. (1998). Doppler study of mesenteric, 
hepatic and portal circulation in alcoholic cirrhosis: relationship between 
quantitative Doppler measurements and severity of portal hypertension and liver 
failure. Hepatology, Vol.28, pp.932-936 
Techgraber, U.K., Gebel, M., Benter, T. et al. (1997). Effect of respiration exercises and food 
intake on hepatic vein circulation. J Ultrasound Med, Vol.16, pp.549-554 
Totty, B.A. (2002). In: Theory and practice of histological techniques, 5th ed. Bancroft, 
J.D.&Gamble (Eds.), 163-200, M. Churchill Livingstone, Edinburgh (International 
edition) 
Vigano, M., Visentin, S., Aghemo, M. et al. (2005). US features of liver surface nodularity as a 
predictor of severe fibrosis in chronic hepatitis C. Radiology, Vol.234, pp.641 
Vilgrain, V. (2001). Ultrasound of diffuse liver disease and portal hypertension. Eur 
Radiology, Vol.11, pp.1563-77 
von Birbra, H., Schober, K., Jenni, R. et al. (1989). Diagnosis of constrictive pericarditis by 
pulsed Doppler echocardiography of hepatic vein. Am J Cardiol, Vol.63, pp.483-488 
von Herbay, A., Frieling, T. et al. (2001). Association between duplex Doppler sonographic 
flow pattern in right hepatic vein and various liver diseases. J Clin Ultrasound, 
Vol.29, pp.25-30 
Walsh, K.M., Leen, E., Mac Sween, R.N. et al. (1998). Hepatic blood flow changes in chronic 
hepatitis C measured by duplex Doppler color sonography: relationship to 
histological features. Dig Dis Sci, Vol.43, No.12, pp.2584-90 
Yokoyama, S.C., Finegold, M.J., Sturniolo, G.C., Kim, K., Mescoli, C., Rugge, M.&Medici, V. 
(2010). Wilson disease: histopathological correlations with treatment on follow-up 
liver biopsies. World J Gastroenterol, Vol.16, No.12, pp.1487 – 1494 
Zironi, G., Gaiani, S., Fenyves, D., Rigamonti, A., Bolondi, L. et al. (1992). Value of 
measurement of mean portal flow velocity by Doppler flowmetry in the diagnosis 
of portal hypertension. J of Hepatology, Vol.16, pp.298-303 
Zwiebel, W.&Pellerito, J.S. (2005). Introduction to vascular ultrasound. Elsevier Suonders. 5th 
ed. pp.585-590 
13 
Noninvasive Alternatives of Liver Biopsy 
Květoslava Aiglová 
II. internal department, FN Olomouc 
Czech Republic 
1. Introduction 
Liver biopsy is considered the gold standart for the diagnosis of cirrhosis, it has important 
limitations ,such as being invasive,having the potential for complications and false-negative 
results or underestimating disease severity due to sampling error. 
Liver biopsy is recomended in patiens with abnormal liver tests,for evaluation of chronic 
hepatitis, of alcohol liver disease, icterus of unknown origin, hepatomegaly,splenomegaly, 
ascites, cholestatic liver disease, toxic liver damage,metabolic disorders.Liver biopsy has 
limitations including small but significant morbidity and mortality rates,inter- and intra-
observer variation in patology reporting. The most important contraindications of liver 
biopsy are trombopenia, abnormal parameters of hemocoagulation, important ascites, liver 
hemangioma and cysts, acute cholangitis, biliary obstruction ,severe obesity, respiratory 
insufficiency, heart failure,Chilaiditi´s sy, uncooperative patient.(1) 
Complication of liver biopsy and their incidence: 
Pain (0,056 -22%)-pleural, peritoneal, diaphragmatic 
Bleeding-intraperitoneal(0,03-0,7%). 
- intrahepatic or subcapsular ( 0,059-23%) 
- hemobilia(0,059-0,2%) 
Biliary peritonitis(0,03-0,22%) 
Bacteriemia 
Sepsis(0,088 %) and liver absces 
Pneumothorax or pleural effusion (0,08-0,28%) 
Hemothorax (0,18-0,49%) 
Arteriovenous fistula (5,4%) 
Subcutaneous emphysema(0,014%) 
Reaction to anaestetic (0,029 %) 
Beakage of needle (0,02-0,059%) 
Biopsy of other organs: 
- lungs (0,001-0,014%). 
- gallbladder(0,034-0,117%), 
- kidney ( 0.029-0,096%) 
- colon (0.0038-0,044%) 
Death (0,0088-0,3%) 
Noninvasive methods of investigation of liver offer an atractive alternative to the liver 
biopsy, as they are less invasive than liver biopsy,repeatable. 
  
Liver Biopsy 
 
204 
Noninvasive approaches to assess histology in liver disease include clinical symptoms and 
signes, routine laboratory tests, serum markers of fibrosis and inflammation, quantitative 
assay of liver function and radiologic imaging methods.None of these tests or markers alone 
is accurate or reliable in predicting histology, in particular, liver fibrosis. 
An ideal noninvasive ,diagnostic test should be simple, readily available, inexpensive and 
accurate. 
2. Serum tests 
Serum tests are used for assessment of steatosis, hepatitis, cirrhosis, metabolic and 
autoimmune disorders for prediction of liver fibrosis. 
The group of routine tests includes liver enzymes- ALT, AST, ALP, GMT, level of bilirubin, 
platelets count, markers of infectious diseases, autoantibodies. 
Results of serum tests and derived mathematical models are always compared with 
histological findings. 
2.1 Markers of liver fibrosis 
Markers of the I st class, non-routine, are based on knowledge about fibrogenesis, they are 
components of extracellular matrix, which are overproduced by activated stellate cells. 
2.1.1 Non-routine markers 
Hyaluronic acid 
Hyaluronic acid (HA) concentrations have been shown to be higher in cirrhotic and fibrotic 
patients, sensitivity is 88 %, specificity 78% for cirrhosis. 
Most of hyaluronic acid in the blood is produced in the stellatae cells of the liver and is also 
cleared by the liver. Only small fraction of HA is eliminated via the kidneys and spleen. It is 
extracted from sinusoidal endothelial cells within 2-9 minutes. Its concentration in a normal 
liver tissue is low, but in fibrotic liver is 2 to10-fold increased.(2) 
HA serum concentrations rise significantly in case of cirrhosis. The cutoff is 60g/L. 
HA is not suggested to replace liver biopsy, but is useful for long-term monitoring of 
disease progression. 
Non- routine tests,which reflect fibrosis ,are extracellular matrix remodeling markers: 
amino-terminal propeptide of type III collagen(PIIIP),matrix metalloproteinase(MMP),tissue 
inhibitor of matrix metalloproteinase(TIMP),type IV collagen(CL-4).Markers are used alone 
or in combination with serum chemistries. 
Index of PIIIP/MMP-1 significantly correlates with fibrosis score and is considered better 
than hyaluronic acid and TIMP-1. 
Laminin 
Laminin -a major,noncollagenous,high mollecular-mass glycoprotein of basement 
membranes, increases in fibrotic liver. Increases in laminin concentration are positively 
correlated with the extent of fibrotic transition of the liver. 
Discrimination between fibrotic and cirrhotic stages of chronic liver diseases by means of 
laminin assay is better than the aminoterminal propeptide of type III procollagen.The 
increase of laminin is relatively independent of etiology of the disease(3) 
YKL-40 
YKL-40 can be used for diagnosing liver fibrosis,mild stage of fibrosis(value < 186,4), severe 
stage of fibrosis(186,4 < value < 284,8) and F4 (284,8 < value).(3) 
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YKL-40 is thought to contribute to tissue remodeling or degradation of the extracellular 
matrix.(4) 
Alpha-2-macroglobulin 
Alpha-2-macroglobulin (A2M) is a proteinase inhibitor and acute–phase protein.Cells 
synthetising A2M are hepatocytes, activated Ito cells and granuloma cells.Fibrosis is 
associated with an increase of A2M,which is considered very informative marker.A2M is 
included in Fibrotest,Actitest, PGAA index,Patel score,Fibrometer, Hepascore. 
Amino-terminal propeptide of type III collagen 
Amino-terminal propeptide of type III collagen(PIIIP) is marker of deposition rate of type III 
collagen. The serum concentration of PIIINP reflects the turnover of type IIIcollagen. 
Matrix metalloproteinase(MMP) 
Changes of MMP reflect „pathologic“ matrix degradation in liver. The most important 
enzymes are MMP -2(also called gelatinase A or 72-kDa type IV collagenase) and MMP-
9(gelatinase B or 92-kDa type IV collagenase), which reflects type IV collagen. Markedly 
increased expression of MMP-2 is characteristic of cirrhosis.(5) 
Tissue inhibitor of matrix metalloproteinase(TIMP) 
Significant increases of TIMP 1 and TIMP 2 have been observed in chronic liver disease at 
any stage of the fibrotic process.(5) 
Type IV collagen(CL-4) 
CL-4 is a sensitive marker for active fibrosis and the elevation of serum type IV-collagen 
level reflects the enhancement of type IV-collagen synthesis and deposition in the liver 
tissue at the stage of active fibrosis in liver disease. 
Elevated serum amino-terminal propeptide of type III collagen ,prolylhydroxylase(PH), 
collagen type IV and matrix metalloproteinase-1 were seen in cirrhosis of various cause, 
laminin and CL-IV in alcoholic hepatitis, hyaluronic acid,tissue inhibitor of 
metalloproteinase TIMP-1and TIMP-2, in chronic hepatitis. Serum CL-IV, MMP-2 and 
TIMP-1(but not laminin, MMP-1or MMP-3) were elevated in hereditary hemochromatosis, 
and only CL-IV and MMP -2 correlated with severity of hepatic fibrosis. 
Prolylhydroxylase is marker of collagen synthesis, reflects the grade of fibrosis. 
Type VI collagen 
Type VI collagen is a minor but essential matrix component in the liver.Type VI collagen 
gene expression, together with other connective tissue components, including type I 
collagen, is activated in the early stages of the fibrotic process. Type VI collagen 
accumulation may contribute to the distorted architecture and functional impairment of the 
liver in hepatic fibrosis.(6) 
Tenascin 
is the extracellular matrix glycoprotein .A significant correlation was observed between the 
serum tenascin levels and serum levels of various extracellular matrix proteins such as type 
III procollagen N –aminoterminal peptide(PIIIP), laminin and the 7Sdomain of type IV 
collagen. A strong positive correlation was observed between the serum tenascin levels and 
histological findings,particullarly in the degree of hepatic fibrosis (7) 
Undulin 
Undulin is a constituent of the hepatic extracellular matrix of normal human liver. Undulin 
is distributed as densely packed fibers in portal tract stroma, and as fine fibers along 
sinusoids,and around central veins.Undulin ribonucleic acid expression is low in normal 
liver,and confined to mesenchymal cells of portal tract stroma, vessel walls and 
perisinusoidal space. In fibrotic liver , undulin deposition and gene expression are enhanced 
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in fibrotic stroma and area of fibrogenesis identified by the presence of active septa and 
inflammatory infiltrate.Undulin participates in rearrangement of connective tissue occuring 
in hepatic fibrosis.(8) 
Fibronectin 
Fibronectin plays a role in liver fibrosis, which was studied in Egyptian patiens with chronic 
HCV infection.The efficiency of fibronectin for disciminating patiens with liver fibrosis from 
those with non fibrosis livers was 75%.Serum fibronectin can differentiate HCV infected 
patiens with liver fibrosis from patiens with non fibrosis(9). 
 
Marker SerumUrineBiopsyMethod Clinical application 
Prolylhdroxylase + - + REA, RIA (+) 
Monoaminoxidase + - (+) Enzymatic - 
Lysyloxidase + - + RIA - 
Lysylhydroxylase + - - RIA - 
Galaktosylhydroxylysylglukosyltransferase + - + RIA - 
Collagenpeptidase + - + Enzymatic - 
N-acetyl-beta-D-glukosaminidase + + + Enzymatic (+) 
Collagen typ I   
N-terminal propeptide (PINP) + - + ELISA - 
C-terminal propeptide (PICP) + - + RIA - 
Collagen typ III   
Intact procollagen + - -  
N-terminal propeptide (PIIINP)   
Globular domain of propeptide (Col-1) + - - RIA + 
Collagen typ IV   
NC1-fragment [C-terminal] (PIVP) + + - ELISA, RIA (+) 
7S domain (7S collagen) + + - RIA (+) 
Collagen typ VI + + + RIA - 
Laminin, P1-fragment + - - RIA, EIA (+) 
Undulin + - - EIA - 
Vitronectin + - - EIA - 
Tenascin + - - ELISA - 
YKL-40 + - + RIA, ELISA (+) 
(pro) MMP-2 + - - ELISA (+) 
TIMP-1, TIMP-Ě + - - ELISA (+) 
Hyaluronic acid + - - RLA, ELISA ++ 
Fig. 1. Non-routine tests of liver fibrosis (30) 
2.1.2 Routine tests 
ALT,AST have been the most often used enzymes indicating hepatocellular damage.Activity 
of ALT is higher than AST,the exception is in alcohol liver disease and Rey´s syndrom. 
Aminotransferases are elevated 3-20 fold in acute and chronic hepatitis, toxic liver 
damage.Elevation less than3-fold is in steatosis. nonalcoholic steatohepatitis, chronic 
hepatitis.Mild elevation is in cholestatic liver disease, liver cirrhosis. 
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AST/ALT ratio(de Ritis index) is usefull in alcohol liver disease,because AST/ALT > 2 is 
specific test for alcohol liver disease. AST/ALT < 1 is typical for viral hepatitis, but increase 
> 1 indicates progresssion to cirrhosis.  
Single markers often correlate with fibrosis in large groups of patients, but do not 
sufficiently assess the amount of fibrosis in a single individual,especially in longitudinal use 
over time. 
Haptoglobin 
is a plasma glycoprotein which specially binds hemoglobin and is synthesized in the 
liver.Haptoglobin is the acute-phase protein and is strongly and negatively associated with 
fibrosis 
Apolipoprotein A1 
is synthesized by the liver and is responsible for cholesterol transport. It is included in 
extracellular matrix and its level is decreased at increasing stages of fibrosis. 
Total bilirubin 
is formed during decomposition of hemoglobin in the cells of the reticuloendothelial system 
especially in the spleen and Kupfer cells of the liver. Increase in its level suggests 
hepatocellular failure,except case of hemolysis. 
Apolipoprotein A1, haptoglobin,bilirubin are components of mathematical models for prediction of 
liver fibrosis. 
Forns index was developed to discriminate patiens with and without significant fibrosis 
with a noninvasive method.The cohort included 476 consecutive untreated patiens with 
chronic hepatitis C who underwent a liver biopsy.The study was designed to assess the 
accuracy of noninvasive method aimed to discriminate between patiens with and without 
significant liver fibrosis(stages 2-4 versus 0-1) The model consisted of combination of 4 
variables identified by comparative analysis of patients with and without significant 
fibrosis: age,gamaglutamyltransferase, platelet count,cholesterol level(10). With these 
variables were constructed a simple score adressed to select patients at very low risk of 
having significant fibrosis. 
7,811-3,131.ln(platelet count)+0,781.ln(GMT)+3,467.ln(age)-0,014.(cholesterol). 
Two cutoff values were chosen to identify absence (less than 4,21)and presence (greater 
than6,9) of significant fibrosis.A score below 4,2 identified patiens at very low risk of having 
significant fibrosis with a96% certainty. 
The age as a marker of liver fibrosis was used, because fibrosis progression is time 
dependent. The duration of HCV infection would be a more precise indicator of fibrosis 
than age. A low platelet count is a marker of severe fibrosis. Thrombocytopenia in patiens 
with advanced liver disease seems to be related to the development of portal hypertension 
and the decreased production of thrombopoetin. In this study ,increased GGT was an 
independent predictor of bile duct damage, because HCV infection frequently cause bile 
duct damage and steatosis. Patiens with bile duct lesions have significantly higher fibrosis 
score. 
Wai et al. considered platelet count and AST level as the most important predictors of 
fibrosis and analyse the relationship between these two factors and the stage of hepatic 
fibrosis.(11) 
Regression formula for prediction of signifiant fibrosis: 
 Risk score = 2.318 + 0,274.ln(AST level[/ULN])-0,375.ln (platelet count [109/L]) 
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Risk score=2,411+ 0,100.ln(AST level[/ULN])-0,436.ln(platelet count [109/L]) 
APRI = 
9
AST(/ULN) 100
PLT(10 /L)
  
The APRI was accurate in predicting both fibrosis and cirrhosis,with area under ROC of 0,8 
and 0,898 in the training set, and 0,88 and 0,94 in the validations set. 
The study of Wai included 270 patients.APRI predictive model consists of objective and 
readily available laboratory variables. The finding of decreased platelet count and increased 
AST level with progression of liver fibrosis has been reported in many studies.With 
increasing fibrosis and worsering portal hypertension, there are increased sequestration and 
destruction of platelets in the enlarging spleen.Progression of liver fibrosis may reduce the 
clearance of AST, leading to increased serum AST levels.The APRI was accurate in 
predicting both signifiant fibrosis and cirrhosis.with area under ROC of 0,80 and 0,89 in the 
training set,and 0,88 and 0,94 in the validation set. Although was not definied one single 
cut-off value to predict the only study endpoint, using values below the lower cut-off level 
and above the higher cut-off level, a prediction of absence of cirrhosis could be made in 81 % 
of patients.Similary, a prediction of absence or presence of significant fibrosis could be made 
in 51 % of patiens.The major advantage of the APRI is its simplicity. APRI can be 
determined in the clinic or bedside without the help of a calculator. 
FibroTest 
is a patented biomarker test that uses the results of six blood serum tests to generate a score 
that is correlated with the degree of liver damage in people with variety of liver disease. 
FibroTest has the same prognostic value as a liver biopsy. 
FibroTest was presented in 2002. Study included 125 patients with chronic hepatitis 
C.Serum tests were taken at time of biopsy.The score was computed from age, sex and 
serum alpha2 macroglobulin,bilirubin, gamaglutamyltransferase activity, apolipoprotein A1 
and haptoglobin.(12) 
The equation for calculating FibroTest is 
z = 4,467 x log10 [alpha2macroglobulin(g/L)] - 1,357 x log 10 [haptoglobin(g/L)] + 
 1,017 x log10[GMT(IU/L)] + 0,0281 x [age(years)] + 1,737 x log10[bilirubin(mol/L)] -
1,184 x [apolipoprotein A1(g/L)] + 0,301 x sex(female=0,male=1) - 5,54 
At the recommended cutoff values, the negative predictive value of a FibroTest score < 0,1 
for the presence of fibrosis stages F2 toF4 was 85%, the positive predictive value of a score 
>0,6 was78% and a score of 0,6 gave a likehood ration of 6,4. 
The laboratory or physician connects to the BioPredictive website for calculation of the test 
results and prints the results sheet, which is available immediately and is accompanied by 
an interpretation aid and precautions for use. 
In clinical practice it has been suggested that the FibroTest score might be applied to patiens 
who either have contraindications or risk liver biopsy for the management of their 
HCV.FibroTest score could not accurately predict either the presence or absence of 
significant fibrosis and cold not reliably be used to reduce the need for liver biopsy. 
Other tests derived from FibroTest are:  
ActiTest-diagnostic for necrotico-inflammatory hepatitis 
SteatoTest –diagnostic for liver steatosis 
NashTest-diagnostic for NASH inflammation 
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AshTest diagnostic for Alcoholic liver disease inflammation 
FibroTest is independent of ethnic origin,sex,genotypes,viral load,transaminases or the 
presence of comorbidities. The test has been validated for the general population,including 
children,patiens with renal insufficiency, hemophiliacs, patiens with chronic inflammatory 
disease. 
The test is not applicable in 1 to5% of cases, in patiens with acute viral hepatitis 
A,B,C,D,E,drug-induced hepatitis, extrahepatic cholestasis, severe hemolysis, Gilbert´s 
syndrome with high unconjugated hyperbilirubinemia,acute inflammatory syndrome. 
FibroTest has comparable diagnostic value as 25 mm biopsy,while being noninvasive and 
easily repeatable. 
ActiTest includes parameters of FibroTest plus the level of ALT.  
SteatoTest was constructed using a combination of the 6 components of FibroTest-ActiTest 
plus body mass index,serum cholesterol,triglycerides and glucose adjusted for age and 
gender.(13)  
NashTest was developed using patented algorithms combining 13 parameters: 
age,sex,heigh,weight,and serum levels of triglycerides,cholesterol, A2M,apolipoproteinA1, 
haptoglobin, GMT, ALT, AST, total bilirubin.(14) 
AshTest is calculated using A2M, haptoglobin, apolipoprotein A1, total bilirubin, GMT, ALT 
and AST,with parameters adjusted for patienst´s gender and age. 
FibroMAX  is used for monitoring liver health in patients with viral, metabolic or alcoholic 
hepatitis when symptoms or risk factors are difficult to interpret. 
FibroMAX is a combination of five algorithm tests – FibroTest, ActiTest, 
SteatoTest,NashTest, and AshTest. FibroMAX uses a unique combination of serum marker 
tests and other patient ´s data including age, gender, weight and height. The test results and 
patient´s data are entered into patented algorithms, which accurately determine the level of 
liver disease. Serum markers measured by FibroMax include Alpha 2-macroglobulin, 
Haptoglobin, Apolipoprotein A1, Total bilirubin, Gamma Glutamyl Transpeptidase (GGT), 
Alanine Amino Transferase (ALT), Aspartate aminotransferase (AST), Fasting Glucose, 
Triglycerides, total cholesterol. The serum marker levels are analysed using BioPredictive 
algorithms to create the FibroMAX Test Report. 
As FibroMax  includes a Fasting Glucose test, fasting is required before sample collection.  
Fib-4 
combines standard biochemical tests-platelets,ALT,AST and age.The Fib 4 test was studied 
in cohort of 847 HCV patiens, also was performed liver biopsy and FibroTest. An Fib4 index 
value higher than 3,25 had a positive predictive value to confirm the existence of signifiant 
fibrosis F3-F4 of 82,1% with with a specificity of 98,2%. An Fib -4 index lower than 1,45 had 
a negative predictive value of 94,7 % to exclude severe fibrosis with a sensitivity of 74,3%. 
The FIB-4 index was strongly correlated to the FibroTest results for a score <1.45 or >3.25. 
For values outside 1,45-3,25 the Fib-4 index is a simple,accurate and inexpensive 
method.(15) 
Hepascore 
is based on serum levels of alpha2macroglobulin, hyaluronic acid, 
gammaglutamyltransferase, total bilirubin, along with age and sex.(16) 
The logistic regression model of: 
y = exp [-4,185818-(0,0249 x age) + (0,7464 x sex) + (1,0039xA2M) +  
(0,032 x hyaluronic acid) + (0,0691 x bilirubin) -(0,0012x GGT)] 
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Risk score=2,411+ 0,100.ln(AST level[/ULN])-0,436.ln(platelet count [109/L]) 
APRI = 
9
AST(/ULN) 100
PLT(10 /L)
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The Hepascore was calculated from the following equation: 
y/1+y 
Hepascore higher than 0,5 is 67 % sensitive and 92 % specific for the presence of significant 
fibrosis, score lower than 0,5 is 88% sensitive and 74 % specific for excluding advanced fibrosis. 
The cutoff point of 0,84 was applied for detection of cirrhosis. 
Hepascore has been shown to be accurate as liver biopsy in patiens with hepatitis C virus 
infection. Hepascore is applicable to the assessment of fibrosis in alcoholic and non-alcoholic 
fatty liver disease. Hepascore will allow more frequent monitoring to detect progression of 
liver disease and also response to therapy. 
PGA  
is a simple biological index combining a specific test for severe liver disease-protrombin 
time, a sensitive test of alcoholic liver disease-serum gammaglutamyl transpeptidase,and a 
test for liver fibrosis-serum apolipoprotein A1.The test was evaluated in a training sample of 
333 drinkers and validated in 291 other drinkers.All patiens underwent a liver biopsy.The 
PGA index varied from 0 to12. When PGA was less than or equal to 2, the probability of 
cirrhosis was 0% and the probability of normal liver or minimal changes 83%.When PGA 
was greater than or equal to 9, the probability of normal liver or minimal changes was 0% 
and the probability of cirrhosis 86 %. 
The diagnostic accuracy of this index was later improved by the addition of 
alpha2macroglobulin.(17) 
PGAA 
includes protrombin time,gamaglumatyltranspeptidase, apolipoprotein A 1 and 
alpha2macroglobulin. 
Fibrometer 
generates a score of fibrosis with an equivalence in F Metavir stage. 
FibroMeters are blood tests for liver fibrosis with several specificities:two main diagnostic 
targets(fibrosis stages and area of fibrosis),adaptation to specific causes, and results 
confirmed by an expert system. 
FibroMeters comprise six different tests: on effort paging and on effort quantitation of liver 
fibrosis in each of the free main cause of chronic liver disease- chronic viral hepatitis, 
alcoholic liver disease and nonalcoholic fatty liver disease. 
There are 6 different main Fibrometers. 
FibroMeter V(Band C virus and co-infection HCV/HIV) 
score of fibrosis: age,gender,alpha2macroglobulin, prothrombin time, platelets,AST,urea, 
GGT,ALT 
score of cirrhosis: age, gender,alpha2macroglobulin,prothrombin time, platelets,AST,urea, 
GGT,ALT 
activity: alpha2macroglobulin, prothrombin time,platelets, ALT 
Fibrometer A(alcohol) 
score of fibrosis: age, gender,alpha2macroglobulin, hyaluronic acid,prothrombin time 
percentage of fibrosis: alpha2macroglobulin,hyaluronic acid, platelets, hyaluronic acid 
FibroMeter S(metabolic steatosis) 
score of fibrosis: age,grade, patiens weight, platelets, AST,ALT,ferritin,glucose 
percentage of fibrosis: hyaluronic acid, prothrombin time, platelets, AST, ALT, glucose 
FIBROspect II was first described for hepatitis C patients in 2004. Fibrospect uses three 
serum markers, alpha 2 macroglobulin, hyaluronic acid and Tissue inhibitor of matrix 
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metalloproteinase, to calculate a score. When applied to 696 patients with hepatitis C, a 
score <0.36 excluded significant fibrosis with a negative predictive value of 76% and a score 
>0.36 detected significant fibrosis with a positive predictive value of 74%. 
Fortunato 
The test is based on concenrations of six biochemical markers- fibronectin, prothrombin, 
pseudocholinesterase, ALT, manganese superoxid dismutase, N- acetyl- beta- 
glucosaminidase.(18) 
Following equation was developed  
discriminant score = PCHE(kat/L) x 0,00011 + fibronectin(mg/L) x 0,039 +  
ln prothrombin activity(%) x 3,51 + ln ALT(kat/L) x 0,49-ln beta NAG(kat/L) x 0,51 – 
 ln MnSOD(kat/L) x 1,29 – 9,41 
Fortunato et al. studied two cohorts-54 patients with chronic hepatitis and 49 patients with 
cirrhosis.All patiens underwent percutaneous liver biopsyand laboratory tests. 
The cutoff value was -0,22 (less than -0,22 indicated cirrhosis, greater than -0,22 indicated 
chronic hepatitis). 
Prothrombin activity and PCHE are markers of liver protein synthetic activity, which is 
gradually impaired during the cirrhotic evolution of chronic hepatitis. 
b-NAG and fibronectin are markers of fibrosis . The increase in serum b-NAG activity in 
cirrhotic patients is attributable to the increased accumulation of collagen typical of the 
disease. b-NAG is known to be important for the collagen pathways . By contrast, the 
reduction of circulating fibronectin in cirrhotic patients is likely related to the impaired 
protein synthesis that occurs in cirrhotic liver . Mn-SOD is located mainly in the 
mitochondrial matrix, a site of reactive oxygen species production; it is involved in the 
antioxidative pathways of human cells . 
Mn-SOD mRNA concentrations in peripheral blood mononuclear cells and serum Mn-SOD 
concentrations are higher in patients with hepatitis C viral infections than inhealthy 
controls. Serum ALT could be considered a signal of liver cytolysis, which differs in chronic 
hepatitis and cirrhosis. 
Fibronectin, ALT, PCHE, prothrombin activity, Mn-SOD, and b-NAG blood concentrations 
are easily and rapidly analyzed 
Patel 
developed the model using levels of extracellular matrix remodeling proteins. Study 
included 294 patients with chronic hepatitis C and was validated in an external cohort of 402 
patients. The aim of this study was to evaluate the diagnostic accuracy of a panel of these 
markers in chronic hepatitis C patients develop a predictive algorithm that differentiates 
no/mild (METAVIR F0-F1) from moderate/severe ( F2-F4) fibrosis,and valid the model in 
external cohort.(19) 
Hyaluronic acid, TIMP -1 and alpha2macroglobulin were selected as having the best 
accuracy for F2-F4 fibrosis. At an index cut-off >0.36 and prevalence for F2–F4 of 52%, 
results in all 696 patients indicated positive and negative predictive values of 74.3 and 75.8% 
with an accuracy of 75%. 
Pohl score 
 Positive : AAR ≥1 and platelet count <150 ×109/L 
 AAR = AST/ALT 
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The Hepascore was calculated from the following equation: 
y/1+y 
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glucosaminidase.(18) 
Following equation was developed  
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ln prothrombin activity(%) x 3,51 + ln ALT(kat/L) x 0,49-ln beta NAG(kat/L) x 0,51 – 
 ln MnSOD(kat/L) x 1,29 – 9,41 
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chronic hepatitis). 
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are easily and rapidly analyzed 
Patel 
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Pohl score 
 Positive : AAR ≥1 and platelet count <150 ×109/L 
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Cirrhosis disciminant score 
The CDS was developed by Bonacini.The CDS includes platelets.ALT/AST ratio, and 
prothrombin time. The CDS of 8 or higher had a sensitivity of 46% and specificity of 98% for 
diagnosis of histological fibrosis scores of 3 or 4.(20,21) 
 
CDS 
Platelet count (×109/L): >340 = 0; 280–339 = 1; 220–279= 2;  
160–219 = 3; 100–159 = 4;  
40–99 = 5; <40 = 6 
  ALT/AST ratio: >1.7 = 0; 1.2–1.7 = 1; 0.6–1.19 = 2;<0.6 = 3 
  INR: <1.1 = 0; 1.1–1.4 = 1; >1.4 = 2 
  CDS is the sum of the above (possible value 0–11). 
 
AP index Age (years): <30 = 0; 30–39 = 1; 40–49 = 2; 50–59= 3;  60–69 = 4; ≥70 = 5 
  Platelet count (×109/L): ≥225 = 0; 200–224 = 1; 175–199= 2;  150–174 = 3; 125–149 = 4; <125 = 5 
  AP index is the sum of the above (possible value 0–10). AP index of 6 or higher is significant for advanced fibrosis 
Enhanced liver fibrosis (ELF) test 
originaly combined age and three markers of liver fibrosis-hyaluronic acid, aminoterminal 
propeptide of type III collagen and tissue inhibitor of matrix metalloproteinase 1.The test 
was investigated on international multicenter cohort study. Subsequently the ELF team have 
established that Age could be omitted from the algorithm to generate the Enhanced Liver 
Fibrosis test or ELF Test. Performance was excellent for alcoholic liver disease and non 
alcoholic fatty liver disease.(22) 
Combinations of serum markers for fibrosis calculated by algorithms, which give a 
discriminant score for fibrosis, represent a new group of liver function tests, which 
provide an alternative to an invasive liver biopsy. Providing they are properly validated, 
scores generated from combinations of serum tests represent a method for medical 
laboratory science to add value to laboratory reports. Clinicians must interpret 
conventional liver function tests carefully with only the individual reference ranges 
customarily provided by the laboratory for guidance. Experienced clinicians learn to 
make judgements and interpretations of conventional liver function tests, which are well 
beyond the scope of the reference ranges, and often difficult for less experienced 
clinicians. An advantage of algorithm-based scores is that a properly validated score 
represents evidence-based medicine as it incorporates clinical experience in the 
presentation of the reset. 
ELFGA index  
Includes parameters: age, aminoterminal propeptide of type IIIcollagen, haptoglobin, tissue 
inhibitor of matrix metalloproteinase 1. 
FibroIndex 
combines aspartate aminotransferase(AST), platelet count and gamaglobulin measurements.  
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Koda et al developed the FibroIndex to predict significant fibrosis.The authors collected 
clinical data on 402 consecutive patiens with chronic HCV-liver biopsy and blood samples 
taken no more than three days before the biopsy. Patiens were excluded if they had HIV or 
hepatitis B co-infection,drank more than10g of alcohol per day,had other liver disease, 
previous interferon therapy, or clinical evidence of cirrhosis, such as gastroesophageal 
varices, ascites, or hepatic encephalopathy.The investigators used multivariate logistic 
regression analysis to identify independent risk factors for fibrosis.(24) 
FibroIndex = 1,738 - 0,064(plateles[ x 104/mm3]) + 0,005(AST[IU/L]) +  
0,463(gamma globulin[g/dl]) 
The index was tested in two validation sets.The investigators found that the areas under the 
receiver operating characteristic curves of the FibroIndex for predicting significant fibrosis 
were 0,83 and 0,82 for the validation set.The predictive value of the FibroIndex was better 
than either the Forns index or the aminotransferase to platelet ratio index.  
Fibrosis Probability Index 
FPI includes age, AST, past alcohol intake,cholesterol insulin rezistence,which was 
calculated from fasting serum insulin and plasma glucose determinations using the 
homeostasis model assessment(HOMA-IR) method:  
fasting insulin(mU/mL) x plasma glucose (mmol/L). 
An FPI was constructed using these independent predictors to determine the probability 
(0,0-1,0) of patient having signifiant fibrosis. 
SHASTA index 
Kelleher et al.developed a biomarker assay in a cohort of 95 HIV/HCV co-infected patients 
utilising Serum Hyaluronic acid, AST and Albumin (SHASTA). As with other biomarker 
assays, optimal results were noted in the extreme categories. Using a cutoff of 0.8 resulted in 
a specificity of 100% and a positive predictive value of 100% but this applied to less than 5% 
of patients. At the other end of the spectrum a cutoff of <0.30 was associated with a 
sensitivity of >88% and a negative predictive value of >94%. Overall 42% of patients could 
be correctly classified at either extreme but 58% would not be classifiable with scores 
between 0.3 and 0.8. The SHASTA index in HIV/HCV has similar accuracy to FibroTest and 
in this study performed significantly better than the APRI test(25) 
The Sequential Algorithm for Fibrosis Evaluation  
(SAFE) combines the APRI and Fibrotest-Fibrosure tests . In a large multicenter study 
validating this algorithm to detect significant fibrosis (stage F2 or greater by the F0–F4 
METAVIR scoring system), its accuracy was 90.1%, the area under the receiver operating 
characteristic curve was 0.89 (95% CI 0.87–0.90), and it reduced the number of liver biopsies 
needed by 46.5%. When the algorithm was used to detect cirrhosis, its accuracy was 92.5%, 
the area under the curve was 0.92 (95% CI 0.89–0.94), and it reduced the number of liver 
biopsies needed by 81.5%.  
FibroFast 
A simple noninvasive score (FibroFast) was developed and evaluated on the basis of several 
simple blood biomarkers (ALT:AST ratio, albumin, alcaline phosphatase, and platelets 
count) that can be easily used by clinicians to predict severe fibrosis or cirrhosis in patients 
with chronic HCV infection . The validation of 1,067 cases from several international centers 
(Egypt, Italy, Brazil, Romania, and UAE) showed that the sensitivity of FibroFast was 61.5%, 
specificity 81.1%, positive predictive value 59%, and negative predictive value 82.6%. New 
cut-off scores of FibroFast were developed that allow the diagnosis of cirrhosis (F4) and F0–
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Koda et al developed the FibroIndex to predict significant fibrosis.The authors collected 
clinical data on 402 consecutive patiens with chronic HCV-liver biopsy and blood samples 
taken no more than three days before the biopsy. Patiens were excluded if they had HIV or 
hepatitis B co-infection,drank more than10g of alcohol per day,had other liver disease, 
previous interferon therapy, or clinical evidence of cirrhosis, such as gastroesophageal 
varices, ascites, or hepatic encephalopathy.The investigators used multivariate logistic 
regression analysis to identify independent risk factors for fibrosis.(24) 
FibroIndex = 1,738 - 0,064(plateles[ x 104/mm3]) + 0,005(AST[IU/L]) +  
0,463(gamma globulin[g/dl]) 
The index was tested in two validation sets.The investigators found that the areas under the 
receiver operating characteristic curves of the FibroIndex for predicting significant fibrosis 
were 0,83 and 0,82 for the validation set.The predictive value of the FibroIndex was better 
than either the Forns index or the aminotransferase to platelet ratio index.  
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FPI includes age, AST, past alcohol intake,cholesterol insulin rezistence,which was 
calculated from fasting serum insulin and plasma glucose determinations using the 
homeostasis model assessment(HOMA-IR) method:  
fasting insulin(mU/mL) x plasma glucose (mmol/L). 
An FPI was constructed using these independent predictors to determine the probability 
(0,0-1,0) of patient having signifiant fibrosis. 
SHASTA index 
Kelleher et al.developed a biomarker assay in a cohort of 95 HIV/HCV co-infected patients 
utilising Serum Hyaluronic acid, AST and Albumin (SHASTA). As with other biomarker 
assays, optimal results were noted in the extreme categories. Using a cutoff of 0.8 resulted in 
a specificity of 100% and a positive predictive value of 100% but this applied to less than 5% 
of patients. At the other end of the spectrum a cutoff of <0.30 was associated with a 
sensitivity of >88% and a negative predictive value of >94%. Overall 42% of patients could 
be correctly classified at either extreme but 58% would not be classifiable with scores 
between 0.3 and 0.8. The SHASTA index in HIV/HCV has similar accuracy to FibroTest and 
in this study performed significantly better than the APRI test(25) 
The Sequential Algorithm for Fibrosis Evaluation  
(SAFE) combines the APRI and Fibrotest-Fibrosure tests . In a large multicenter study 
validating this algorithm to detect significant fibrosis (stage F2 or greater by the F0–F4 
METAVIR scoring system), its accuracy was 90.1%, the area under the receiver operating 
characteristic curve was 0.89 (95% CI 0.87–0.90), and it reduced the number of liver biopsies 
needed by 46.5%. When the algorithm was used to detect cirrhosis, its accuracy was 92.5%, 
the area under the curve was 0.92 (95% CI 0.89–0.94), and it reduced the number of liver 
biopsies needed by 81.5%.  
FibroFast 
A simple noninvasive score (FibroFast) was developed and evaluated on the basis of several 
simple blood biomarkers (ALT:AST ratio, albumin, alcaline phosphatase, and platelets 
count) that can be easily used by clinicians to predict severe fibrosis or cirrhosis in patients 
with chronic HCV infection . The validation of 1,067 cases from several international centers 
(Egypt, Italy, Brazil, Romania, and UAE) showed that the sensitivity of FibroFast was 61.5%, 
specificity 81.1%, positive predictive value 59%, and negative predictive value 82.6%. New 
cut-off scores of FibroFast were developed that allow the diagnosis of cirrhosis (F4) and F0–
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F3 with the highest possible accuracy (>95%). FibroFast with the new two cut-off scores 
could be an alternative to liver biopsy in about one-third of the patients, with sensitivity 
95% and specificity 95% . 
 
Index, score Parameters Disease Senzitivity % 
Specificity 
% 
PGAA 
Prothrombin time, GGT, 
apolipoprotein A1, alfa-2-
macroglobulin 
Alcohol 79 89 
Bonacini Ratio ALT/AST, INR, platelet count HCV 46 98 
De Ritis Ratio AST/ALT HCV 53 100 
PGA Prothrombin time, GGT, apolipoprotein A1 Mixed 91 81 
Fortunato 
Fibronectin, prothrombin time, 
PCHE, ALT, Mn-SOD, beta-
NAG 
HCV  94 
Fibrotest 
Haptoglobin, alfa-2-
macroglobulin, apolipoprotein, 
A1, GGT, bilirubin 
HCV, 
HBV 75 85 
Pohl Ratio AST/ALT, platelet count HCV 41 99 
Actitest Fibrotest + ALT HCV   
Forns Age, platelet count, GGT, cholesterol HCV 94 51 
WAI (APRI) AST, ALP, platelet count HCV 89 75 
Rosenberg  
ELF-test 
PIIINP, hyaluronic acid, TIMP-
1 Mixed 90 41 
Patel Hyaluronic acid, TIMP-1, alfa-2-macroglobulin HCV 77 73 
Sud (fibrosis 
probability 
index, FPI) 
Age, AST, cholesterol, insulin 
resistence (HOMA), past 
alcohol intake 
HCV 96 44 
Leroy PIIINP, MMP-1 HCV 60 92 
Fibrometer 
Platelet count, prothrombin 
index, AST, alfa-2-
macroglobulin, hyaluronic 
acid, urea, age 
Mixed 81 84 
Hepascore 
Bilirubin, GGT, alfa-2-
macroglobulin, hyaluronic 
acid, age, gender 
HCV 63 89 
Testa Ratio platelet count/spleen diameter HCV 78 79 
FIB-4 Platelet count, AST, ALT, age HCV, HIV 70 74 
Fig. 2. Routine tests of liver fibrosis (30) 
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3. Imaging methods 
3.1 Ultrasound 
Ultrasound has been used for noninvasive investigation of liver, for detection of focal 
lesions, assessment the degree of liver fibrosis, description of trombosis of portal vein. 
Ultrasonographic parameters may represent an alternative to serum markers for the 
noninvasive assessment of liver disease severity and stage by finding signs of portal 
hypertension as splenomegaly, ascites, or a patent umbilical vein, and by examining the 
size, nodular liver surface, echogenicity and echotexture of the liver parenchyma.   
The sensitivity of liver ultrasound scans in the diagnosis of fatty liver is almost 100 %. The 
correlation of fatty liver in ultrasound scans and liver biopsy tissue examination is 73.6 %. 
So, the degree of fatty infiltration observed in ultrasound scans is significantly correlated 
with degree of fatty accumulation of liver. 
Some studies have shown an association between ultrasonography score and detection of 
cirrhosis with sensitivities ranging 87,5% to 100% and specificities ranging from 81,5% to 
93,5%. 
Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast mediumto 
traditional medical sonography. Ultrasound contrast agents rely on the different ways in 
which sound waves are reflected from interfaces between substances. This may be the 
surface of a small air bubble or a more complex structure. Commercially available contrast 
media are gas-filled   microbubbles that are administered intravenously to the systemic 
circulation. Microbubbles have a high degree of echogenicity, which is the ability of an 
object to reflect the ultrasound waves. The echogenicity difference between the gas in the 
microbubbles and the soft tissue surroundings of the body is immense. Thus, ultrasonic 
imaging using microbubble contrast agents enhances the ultrasound  backscatter, or 
reflection of the ultrasound waves, to produce a unique sonogramwith increased contrast 
due to the high echogenicity difference. Contrast-enhanced ultrasound can be used to image 
blood perfusion  in organs, measure blood flow rate in the heart and other organs, and has 
other applications as well.(26) 
Vyas found that portal venous blood flow(PVBF), portal flow velocity(PFV) and gastric 
mucosal blood flow(GMBF) were all significantly slower in cirrhotic patiens and PVBF and 
PFV were lower in Child class B/C than class A. 
Schneider et al. found that Doppler ultrasound alone was unable to discriminate between 
degrees of fibrosis, but portal venous undulations could predict liver cirrhosis with 
increased sensitivity(76,5%).(27) 
Hirata et al. derived an arterio-portal(A/P)ratio by evaluating hepatic hemodynamics, 
which was higher in patients with cirrhosis compared with controls and demonstrated 
statistically significant differences in A/P ratio when comparing severe-to-mild or moderate 
fibrosis. 
Hepatic vein transit times(HVTT) is using an ultrasound microbubble contrast agent as a 
tracer and has been investigated for grading liver disease. 
Abbatista found that HVTT was significantly shorter in cirrhotic patients than in non -
cirrhotic patients and distinguished between these patients with high accuracy 
These results show that unenhanced Doppler ultrasound in not reliable in discrimination of 
varying degree of fibrosis, but that results can be improved with additional measurements 
such as heart pulsation at the liver surface and portal venous flow measurements. 
High-resolution ultrasound of liver surface(LSS) can be used for investigation of liver 
cirrhosis. Liver surface is studied at the left liver lobe and is scored as smooth, irregular, 
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High-resolution ultrasound of liver surface(LSS) can be used for investigation of liver 
cirrhosis. Liver surface is studied at the left liver lobe and is scored as smooth, irregular, 
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nodular. The smooth liver surface excludes cirrhosis, in case of irregular surface the results 
are indeterminate, the diagnosis of cirrhosis is when the surface is nodular. 
The result can be improved with quantification,when the liver surface is semi-automatically 
measured. 
The combination of ultrasonography and laboratory tests can improved the discrimination 
of patients with severe fibrosis and cirrhosis. Festa et al. investigated the cohort of 1143 
patients with chronic hepatitis C, who underwent liver biopsy, laboratory tests and US. 
All indices had specificity rate of > or =90% in excluding bridging fibrosis/cirrhosis, 
whereas sensitivity was acceptable (51%) for only platelet counts <140 000/L. None of the 
ultrasonographic parameters singularly evaluated and reached an acceptable sensitivity 
rate. For ruling cirrhosis in or out, specificity rate was > or =82% for all tests, with the 
highest value reported by portal vein size. Low platelet counts plus nodular liver surface 
had the best sensitivity. 
Ratio platelet/spleen diameter can be also beneficial 
Acoustic radiation force impulse elastography 
ARFI imaging technology involves the mechanical excitation of tissue using short-duration 
acoustic pulses (push pulses) in a region of interest chosen by the examiner, producing shear 
waves that spread away from the region of interest, generating localized, micron-scale 
displacements in the tissue . Simultaneously, detection waves of lower intensity than that of 
the push pulse are generated. The push pulse uses a few hundred cycles and different 
voltage compared to the short cycle B-mode pulse. The moment of interaction between the 
shear waves and detection waves marks the period of time elapsed between the generating 
of shear waves and their entire crossing of the region of interest. By recording the shear 
wave front at several locations and correlating these measurements with the elapsed time, 
the shear wave velocity (m/s) can be quantified; generally, the stiffer a region in the tissue, 
the greater the shear wave velocity as it travels through this region. 
ARFI elastography has a good accuracy of diagnosis of liver fibrosis in chronic liver 
disease,might be available for the prediction of chronic liver disease related events such as 
hepatocellular carcinoma, esophageal varix.(28) 
3.2 Elastography 
Elastography is a noninvasive method measuring the mean stiffness of hepatic tissue ,a 
parameter, which correlates hihgly with liver fibrosis. 
Transient elastography -FibroScan, Echosens, France , is equipped with a probe consisting in 
an ultrasonic transducer mounted on the axis of the vibrator. The probe is placed between 
two ribs in intercostal positions (sixth-eight intercostal area) on the right lobe of liver.A 
region of the liver selected for the test must be free from blood vessels structures of greater 
than 5 mm in diameter and should be homogenous.The sensor is focused at the zone of 25-
65 mm from the surface of the skin. Vibrations of mild amplitude and low frequency are 
transmitted from the vibrator to the tissue by the transducer itself. This vibration induces an 
elastic shear wave , which propagates through the tissue. In the meantime, pulse-echo 
ultrasonic acquisitions are performed to follow the propagation of the shear wave and 
measure its velocity ,which is directly related to the tissue stiffness. The harder the tissue, 
the faster the shear wave propagates. After correct installation of the sensor,10 reliable 
measurements are taken and based on thein results, the software calculates the value of 
hepatic elasticity. The results are expressed in kilopascals(kPA) and median values are 
representative of liver stiffness.Following the previous studies TE was considered to exclude 
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cirrhosis at<12 kPa, indeterminate at 12-18 kPa, and to diagnose cirrhosis if >18kPa. 
FibroScan provides accurate prediction of hepatic fibrosis in patiens with chronic viral 
hepatitis,chronic cholestatic disease, provides accurate prediction of cirrhosis and its 
severity in patiens with chronic liver disease. 
 
 
Fig. 3. Fibroscan (31) 
3.3 Magnetic resonance imaging 
Magnetic resonance imaging has been used for description of focal lesions- hemangiomas, 
liver tumors, malignant and also liver adenomas, focal nodular hyperplasia, for evaluation 
of liver fibrosis, for description of portal vein as MR splenoportography. 
In MRI investigation is also often necessary using of contrast medium. Sensitivity of MRI for 
detection of liver focal lesions is 80-100%, sensitivity is higher than sensitivity of US or CT, 
specificity is more than 96%. 
As contrast medium is often used gadollinium, superparamagnetic iron oxide(SPIO). 
Sequential administration of gadolinium and SPIO is used for investigation of liver 
fibrosis.Although SPIO-based images were highly accurate(85%) for detectiong fibrosis 
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contrast agents yielded even greater accuracy (93%) overall.  
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imaging for the evaluation of acute ischemic stroke. With the advent of the echo-planar MRI 
technique, it became possible to be applied in the abdomen for the characterization of focal 
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nodular. The smooth liver surface excludes cirrhosis, in case of irregular surface the results 
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cirrhosis at<12 kPa, indeterminate at 12-18 kPa, and to diagnose cirrhosis if >18kPa. 
FibroScan provides accurate prediction of hepatic fibrosis in patiens with chronic viral 
hepatitis,chronic cholestatic disease, provides accurate prediction of cirrhosis and its 
severity in patiens with chronic liver disease. 
 
 
Fig. 3. Fibroscan (31) 
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(ADC) of water, a parameter that is dependent on the tissue structure, has been introduced 
in the assessment of liver fibrosis. The ADC value is lower in livers with heavier fibrosis 
because of the restriction of water diffusion in fibrotic tissue. Lewin et al. assessed the 
performance of DWMRI in 54 patients with chronic HCV infection with reference to several 
other non-invasive methods.In discriminating significant fibrosis, the area under the curve 
(AUC) values were 0.79 for DWMRI, 0.87 for transient elastography, 0.68 for the FibroTest, 
0.81 for aspartate aminotransferase to platelet ration index, 0.72 for the Forns index and 0.77 
for hyaluronate. DWMRI performed better in discriminating between patients staged F3–F4, 
when the AUC value increased to 0.92, the same as in transient elastography. But besides 
fibrosis, it seems that ADC values might also reflect the intensity of inflammation, necrosis 
and steatosis. However, DWMRI still benefits from the intrinsic advantages of MRI. (29) 
MR Spectroscopy 
Based on its anatomical location and increased metabolic demands, the liver is considered 
an ideal organ for MR spectroscopy investigation. 
In vivo MRspectroscopy is most commonly used to assess signals from hydrogen (1H) and 
phosphorus (31P). Although 1H-based MR spectroscopy allows for quantification of certain 
metabolites and lipids, 31P-based MR spectroscopy provides insights on processes including 
cell turnover and energy state based on substantial concentrations 
within hepatocytes. Within the spectrum of 31P compounds, 6 discrete signals have frequently 
been analyzed by MR spectroscopy in human subjects, including (1) phosphomonoesters 
(PME), (2) inorganic phosphate, (3)phosphodiesters (PDE), (4) adenosine triphosphate (ATP), 
alpha-ATP, and beta-ATP. The chemical precursors phosphocholine, phosphoethanolamnine, 
adenosine monophosphate, and glycolytic intermediates,such as glucose-6-phosphate 
contribute to the PME peak. Glycerophosphorylcholine, glycerophosphorylethanolamine and 
mobile phospholipids from the endoplasmic reticulum are the main components of the PDE 
peak. Both PME and PDE appear to provide information on cellular degradation.The 
methodology used for performing MR spectroscopy has varied over time and between studies. 
MR spectroscopy of the liver is performed using a whole body MRI system at field strengths of 
1.5 Tesla (T) or higher. 
After a standard MR imaging for localization, special MR pulse sequences are applied to 
generate spectroscopic data within the appropriate anatomical location and volume (defined 
by voxels) of interest. As with diffusion-weighted imaging, an examination will take 45 to 60 
minutes. 
The spectral analysis of data requires processing to reduce noise and perform analysis. 
Metabolite concentrations can be expressed in absolute or relative terms. In general, the 
peak area of a metabolite signal is directly related to its concentration. Because the absolute 
quantitation of metabolites is difficult to achieve in vivo, many studies have used metabolite 
ratios for assessing spectral profiles.Peak areas in a spectrum are referenced to standards for 
correlation with MR signal intensities. An internal standard such as adenosine triphosphate 
(ATP) can be used, given its natural occurrence in tissue. 
MR spectroscopy is recomended for investigation of diffuse liver disease, such as chronic 
hepatitis, steatosis non alcoholic fatty liver disease, for quantifying liver fat.There are also 
studies about the use of liver MR spectoroscopy for tumor assessment.The principal 
metabolite that has been targeted in focal liver disease is choline. Choline is elevated in 
tumors,because Choline is cell membrane compoment and increased cell turnover is 
associated with malignancy 
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(A) MR elastography of the liver in a healthy volunteer and a patient with cirrhosis. The 
middle column of images shows wave image data in the liver and spleen, superimposed 
on the corresponding anatomical images. The resulting elastograms are shown in the far 
right column. Elastograms show a higher mean stiffness of the fibrotic liver compared 
with the normal liver (12.1 ± 1.2 kPa versus 1.8 ± 0.3 kPa, respectively). (Adapted from Yin 
M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of 
hepatic fibrosis with magnetic resonance elastography. Clin Gastro Hepatol 2007. In 
press).  
(B) MR elastography of the liver in patients with obesity and ascites. The top row 
demonstrates a patient with obesity (BMI = 36) and stage 2 fibrosis on liver biopsy with a 
mean liver stiffness of 3.2 ± 0.8 kPa. The bottom row illustrates a patient with ascites. 
Excellent shear wave illumination of the liver was obtained, and the mean liver stiffness was 
11.3 ± 2.8 kPa. (Adapted from Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, 
Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. 
Clin Gastro Hepatol 2007;5:1207-1213.e2.)  
MR elastography(MRE) 
is used for evaluation of the degree of liver fibrosis. The technic use is simile to that used in 
ultrasound elastography in that it uses a vibrafon device to induce a shear wave in the 
liver.The wave is detected by a modified magnetic resonance paging machine, and a color –
coded image is generated that depicts the wave velocity,and hence stiffness,throughout the 
organ. MRE demonstrated that patients with hepatic fibrosis have higher liver stiffness 
measurements than healththy volunters and that those with mild fibrosis were also able to 
be differentiated form those with moderate to advanced fibrosis,with mean hepatic shear 
elasticity being 2,24±0,23kPa in patiens with F0-F1 fibrosis, 2,56 ±0,24 kPa with F2-F3 fibrosis 
and 4,68 ±1,61 kPa in patiens with F4 fibrosis. MRE was found to have a higher technical 
succes rate than US elastography. 
Computed tomography 
CT imaging of liver provides specific method of noninvasive diagnosis of diffuse liver 
disease and also focal lesions of liver.Hepatic steatosis can be definied with a 76 % 
predictive value. Density of liver in steatosis is lower than density of intrahepatal vessels.CT 
imaging does not provide any information on the stage of fibrosis.CT imaging helps in 
diagnosis of cirrhosis according the nodular,irregular margin of liver.Pathological 
accumulation of iron increases density of liver parenchyma, but accumulation of copper 
does not change the density. 
Single photon emission computed tomography(SPECT) 
SPECT was tested in HIV-HCV co-infected patients,also in cirrhotic patients, in an effort to 
correlate histological severity of liver fibrosis with SPECT results.Cirrhotic patients showed 
a signifiant decrease of total liver uptake and a signifiant increase in total spleen 
uptake.Spleen volume was best at detecting liver cirrhosis, but total liver uptake correlated 
better with chronic liver disease severity. 
4. Breath tests 
There are several 13C breath tests for non-invasive investigation of hepatocellular function. 
13 C-methacetin breath test (MBT) is essentially a microsomal liver function test. The patient 
ingest 75g 13C-methacetin dissolved in 200 ml water. Breath samples are collected at 
baseline and 15 min after ingestion of substrate. During the test period,the patient is in rest 
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and fasts to avoid influences due to variations in CO2 production and food intake. 13C-
methacetin is rapidly metabolised by healthy liver cells into acetaminophen and by a single 
dealkylation, and the increase of CO in breath samples can be quantified by isotope ratio 
mass spectrometry or nondispersive isotope-selective infrared spectroscopy. The 13 C-
methacetin –breath test is more expensive than biochemical markers,but is also widely 
available.The breath samples can be sent to specialized centres or can be directly analysed as 
bedside test by nondispersive isotope-selective infrared spectrometers. The 13 C methacetin-
breath test is more practicable than other 13 C based liver function tests because it can be 
performed as a simple two-point measurements as known from the 13C urea breath test. 
The rapid metabolism of methacetin allows a short sampling interval for the breath 
test.Methacetin undergoes a high hepatic extraction rate,which makes the methacetin breath 
test susceptible to variations in hepatic blood flow. (27)  
13C methacetin-breath tests measure the functional metabolit capacity of residual hepatic 
cells and indirectly reflex how many hepatic cells are already lost .MBT has high sensitivity 
(93,5-95 %) and specificity (95-96,7%) for identifying cirrhotic patients, but can not differ 
patiens with early fibrosis and advanced fibrosis as determined by liver biopsy. 
Another breath test is the 13C-aminopyrine breath test (ABT), where the aminopyrine is 
another substrate for labelling with the 13C isotope, much like the MBT.  
5. Conclusion 
Liver biopsy is curerrently the most beneficial method in diagnostic of liver dieases.Non-
invasive methods of assessment of liver fibrosis,cirrhosis, steatosis are not able to replace 
liver biopsy because of their limitations.Increasing application of serum tests, imaging 
methods and breath tests is based on their advantages as absence of pain,of risk of 
complications, easy repeatability.  
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1. Introduction 
Liver fibrogenesis is the consequence of all hepatic lesions, regardless of etiology. 
Progressive scars, which are the response to constant liver injuries lead to cirrhosis, 
disorganize  the normal liver architecture through fibrosis bands, parenchyma nodules and 
blood vessel distortions. For this reason, liver fibrosis is a central parameter which expresses 
the severity of liver diseases, regardless of etiology; it is a key element which predicts the 
evolution of liver diseases towards cirrhosis.  
Irrespective of the cirrhosis etiology, the clinical evolution is similar, towards major 
complications such as: portal hypertension and hepatocellular insufficiency. Due to these 
complications, cirrhosis is the seventh death cause within general mortality. Cirrhosis also 
encourages the development of hepatocellular carcinoma, an aggressive neoplasm which 
causes death in a few months in the absence of early diagnosis. That is why liver fibrosis is a 
major criterion in initiating the etiologic treatment of chronic liver diseases.  
A long time ago, liver fibrosis was deemed irreversible. This axioma has been discarded for 
quite some time; at present, fibrosis is considered to be a bidirectional dynamic 
phenomenon: fibrogenesis and fibrinolysis. Thus, it is possible to reshape the scar healing 
tissue. Due to this dynamic process, it is necessary to quantify fibrosis in order to set the 
therapeutic decision and especially to monitor the efficiency of anti fibrotic treatments. 
There are several methods to diagnose liver fibrosis: liver biopsy, serum biomarkers, breath 
tests and hepatic elastography. Liver biopsy is currently essential in diagnosis of 
inflammatory and metabolic liver diseases. It provides particularly invaluable informations 
for disease diagnosis and patient monitoring.  
The role of liver biopsy is still a controversial issue being an invasive method with well-
known risks and complications. Although liver biopsy is considered the golden standard for 
chronic liver diseases, it is worth mentioning that the histological tested fragment is 
however a small part of the liver, and the scar lesions, which are secondary to chronic 
inflammatory processes are unevenly distributed in the liver mass. Thus, liver biopsy  is a 
method neither ideal nor sufficient to diagnose and determine the stage of liver fibrosis. In 
this context, a noninvasive method to assess liver fibrosis is more than welcome. 
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Noninvasive tests can be classified in several ways based on the modality of the test (serum 
blood tests or imaging) or the constituents of the tests (direct markers versus indirect 
markers of fibrosis). With the evolution of noninvasive tests, the performance can improve 
particularly with the use of combination or serial noninvasive tests.  
In this  chapter the role of liver biopsy and non-invasive tests to assess  liver fibrosis and to 
manage the treatment of patients with chronic liver disease is discussed. 
2. Liver biopsy 
Liver biopsy was first described by Paul Ehrlich, 130 years ago, as a diagnostic tool of the 
chronic liver disease. It can be performed using blind percutaneous technique, computer 
tomography or ultrasound-guided, transjugular, open surgical, laparoscopic and even 
endoscopic approaches.  
Microscopic  examination of liver tissue often provides the definitive diagnosis and leads to 
effective management of the liver disorders. Because fibrosis is tissue damage, biopsy is by 
definition the only direct tool to assesses liver fibrosis. 
2.1 When is liver biopsy useful? 
The major indication for performing a liver biopsy is to clarify the nature of liver disease. In 
some instances, liver biopsy is performed to establish the effect of the treatment in known 
liver disease. In chronic viral hepatitis, the knowledge of liver fibrosis stage is important for 
prognosis and for decision  about the antiviral treatment.  Significant fibrosis (F≥ 2) in these 
patients is an indication for antiviral treatment.  
In patients with alcoholic liver diseases, the clinical features and the values of serum 
aminotransferases are poorly correlated with the liver diseases stage and the long-term 
prognosis strictly depends on the severity of histological lesions.  In alcoholic liver disease, 
the biopsy can reveal fatty liver infiltration, large shape of hepatocytes, the presence of 
Mallory bodies, or polimorfonuclear infiltrates in portal spaces, and also histological 
features specific to cirrhosis. On the other side, fatty liver infiltration occurs in various 
etiologic situations: obesity, diabetes, consumption of alcoholic beverages, chronic HCV 
infection  and the liver biopsy may provide  distinct etiologic information. 
In patients with chronic hepatitis C there is a low correlation between symptoms, serum 
aminotransferases and histological modifications; thus, serum aminotransferases may have 
normal values, but liver histology is suggestive for severe fibrosis or cirrhosis. Liver biopsy 
ensures a certain diagnosis in more than 90% of the patients with unexplainable increase of 
serum aminotransferases. In the same time, it is useful in evaluating infectious complications, 
drug toxicity or the reoccurrence of the primary disease in the transplanted liver. 
In patients who present space replacing liver formations, the indication of liver biopsy is still 
debatable. It is useful to establish  the origin of metastasis when the primary tumor is not 
known, to confirm the metastases in case of diagnosed cancers before and after surgical 
resection. It is also able to certify the benign nature of liver formations.  
In patients with nonresected hepatocellular carcinoma, echographic guidance allows  
specific therapeutically approach like: alcoholization, radiofrequency, chemoembolization. 
In conclusion, liver biopsy is recommended in diagnosis of: 
Infiltrative liver diseasestuberculosis, sarcoidosis, lymphoma, amyloidosis; 
Hereditary disorders: Wilson disease (determining the amount of intrahepatocyte copper 
deposits), hemochromatosis (determining the amount and quality of intrahepatocyte iron 
deposits),  alpha-1 antitrypsin deficiency; 
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Liver cholestasis primary billiary cirrhosis, primary sclerosing cholangitis;. 
Diagnostic uncertainty (abnormal liver tests with no clear etiology: the increase of serum 
aminotransferases, bilirubin, alkaline phosphatase or glutamiltranspeptidase. 
Coexisting disorders: Human immunodeficiency virus [HIV] and hepatitis C virus 
infection, alcoholic liver disease and hepatitis C 
Overlap  syndrome: Primary biliary cirrhosis with autoimmune hepatitis. 
Fatty liver: liver biopsy can distinguish between benign steatosis and progressive 
steatohepatitis; 
Space replacing processes discovered by chance during a routine imagistic check up.  
Periodic needle biopsy is also valuable in the management of a few diseases. 
In autoimmune hepatitis, monitoring the plasma cell score on liver biopsy may help predict 
relapse; 
Liver transplantation: possible complications occurring  after the liver transplant rejection 
or the disease recurrence (Carey & Carey, 2010). 
2.2 The liver biopsy interpretation 
Histologic assessment of a liver biopsy specimen remains the “gold standard” for 
quantifying fibrosis that is essential to guide management and predict prognosis in patients 
with chronic liver injury . 
There is a wide range of methods used to interpret a liver biopsy. For morphological 
analysis of liver liver biopsy is necessary to use either ordinary staining (hematoxilin-eozin), 
or special ones: Masson’s trichrome stain (for fibrosis), Pass stain (for glycogen), Pearls stain 
(for intrahepatocyte iron deposits) and rhodamin (for hepatocyte copper). 
Immunohistochemical  and in situ mRNA hybridization methods to identify specific matrix 
components can be employed for experimental aim and have some utility in assessing 
fibrosis progression. 
The most important role of liver biopsy is the assessment of necroinflammation (grade) 
and fibrosis (stage). The morphological features of chronic viral hepatitis are portal 
fibrosis, portal and periportal mononuclear inflammation and necroinflammatory changes 
within the parenchyma with a an irregular distribution between one lobule and another. 
There is also regenerative activity in an irregular distribution. The degree of necrosis 
depends on the disease activity –more severe during exacerbations and lesser in quiescent 
stages. Fibrosis progresses to cirrhosis and the periseptal inflammatory activity continues 
with cirrhosis . 
A number of numerical scoring systems have been used to evaluate the amount of 
inflammation and degree of fibrosis in liver biopsy specimens from patients with chronic 
liver disease. Histological scores such as Metavir, Knodell, Ishak and Desmet/ Scheuer 
systems were created to standardize the interpretation of liver biopsies. The Knodell system 
was the first staging system, having a total of 18 for necroinflammation and a total of 4 for 
fibrosis (0-4). However, this system is noncontiguous and no longer used. Instead, the Ishak 
system had more details for necroinflammation (0-18) and expanded scores for fibrosis(0-6). 
This may be  helpful  in clinical studies when fine gradations of fibrosis pattern are required 
to demonstrate change, but this system is not commonly used in clinical practice. These 
scores are semi- quantitative scales for evaluation of a complex pathobiological process: 
fibrosis, necroinflammation and finally nodule formation.  The Metavir system is simpler  
with a combination score for inflammation including periportal and lobular activity (A0-A3) 
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and a fibrosis score on a scale of F0-F4. Metavir is the most used system in clinical practice 
today. The accuracy of grading and staging is dependent on the adequacy of the specimen 
and the experience of the pathologist. 
Bedossa considers that the advantages of using the scores for liver biopsy interpretation 
consist in :an increase of reproducibility between pathologists, a standardization of biopsies 
reports, an homogeneity between liver centers, and a better comparison of consecutive 
biopsies for monitoring disease follow-up . The scores also serve as reference for choosing 
and validation of non invasive methods for liver fibrosis assessment. 
 
Appearance 
Ishak stage: 
Categorical description 
ISHAK METAVIR 
 
No fibrosis (Normal) 0 F0 
 
Fibrosis expansion of some portal areas 
± short fibrous septa 1 F1 
 
Fibrosis expansion of most portal areas 
± short fibrous septa 2 
F2 
 
Fibrosis expansion of most portal areas 
with occasional portal to portal(P-P) 
bridging 
3 
 
Fibrosis expansion of portal areas with 
marked portal to portal(P-P) bridging 
as well as portal to central( P-C) 
4 
F3 
 
Marked bridging (P-P and/or P-C) 
with occasional nodules (incomplete 
cirrhosis) 
5 
 
Cirrhosis, probable or definite 6 F4 
Table 1. Scoring systems in liver fibrosis.( Standish RA et al.,2006) 
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Fig. 4. Fibrosis stage 4 
2.3 Complications of liver biopsy  
Liver biopsy is a safe procedure if it is carried out by experienced gastroenterologists. 
Froehlich et al noticed a lower rate of complications in the case of doctors who performed 
over 50 biopsies in a year. Although the liver is a highly irrigated organ,  complications 
after the biopsy are rarely. Thus, it was noted that over 60% of the complications occur 
within two hours and over 90% within the first 24 hours after the procedure. Within out 
patients who present complications, 1-3% require hospitalization, often after Tru-cut type 
needle use. 
Complications may be minor (pain or vagal reactions, blood hypotension) or major. 
Significant complications, defined as those resulting in hospital admission or prolonged 
hospitalisation, occur in 1-5% of patients. The mortality rate is reported between 1:1000 
and 1:10000. The complications of liver biopsy and their frequency are indicated in table 
no. 2 
2.4 Limits of liver biopsy  
The hepatic function is compromised to a minimum until the development of cirrhosis. The 
presence of clinical manifestations such as ascites and encephalopathy are clear evidences of 
the advanced disease.  
So far, only liver biopsy has been able to determine the severity of pre-cirrhotic stages. 
However, the role of liver biopsy as a golden standard in diagnosing liver diseases seems 
to be controversial due to the development of modern imagistic techniques: 
ultrasonography, computer tomography, nuclear magnetic resonance and the appearance of 
noninvasive serum markers.  
Liver biopsy may be the golden standard in assessing liver fibrosis, but it is not 24 karat 
gold. We have to mention that the biopsy needle takes a small fragment from the liver. It is 
important to take into account that a biopsy is merely a sample of the entire liver and the 
scarring in chronic liver disease is typically irregularly distributed in the liver. For this 
reason, the perfect liver biopsy should remove a fragment into a known area  of the disease 
or multiple  fragmentes  in many areas of a diseased liver.  
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Complications of liver biopsy  
Pain at the right hypochondrium, shoulder  0.056-83% 
Arterial hypotension   
Hemorrhagic complications  
sub capsular hematoma: 0.05% 
intrahepatic hematoma: 0.05% 
intraperitoneal bleeding: 0.03% 
hemobilia: 0.05% 
Bacteriemia 0.08% 
Death 0.001-0.0001% 
Bile peritonitis  0.03-0.22% 
Pneumothorax, hemothorax 0.08-0.28% 
Subcutaneous emphysema   0.014% 
Subphrenic abscess   
Anaphylactic shock (hydatid cyst)  
Break of the biopsy needle  0.02% 
Biopsy of other organs  
lungs-0.001% 
bile -0.003% 
colon-0.003% 
kidneys-0.09% 
Table 2. The complications of liver biopsy 
The liver biopsy removes only about 1/50 000th of the liver and can miss the diagnosis of 
cirrhosis in 20% to 30% of patients. That is why, many investigators recommend a biopsy 
length at least 15 mm, containing sixt or eight portal tracts, to improve the diagnostic 
accuracy. Both the size of the biopsy and the number of biopsies taken have a major effect 
on diagnosis accuracy. Although widely used, liver biopsy can be a source of errors given 
by the small size of the samples or the inappropriate sizes of the needle.The length of the 
fragment is proportional to the length of the needle used (18 gauge)  and the size of the liver 
fragment is essential in assessing the hepatic architecture. There are several studies which 
revealed a decrease of diagnosis accuracy in biopsies smaller than 2 cm.  In a study which 
comprised 10.000 virtual biopsies, Bedossa and collaborators showed that the staging of 
liver fibrosis is accurate in 65% of the cases when the analyzed biopsy fragment was at least 
15 mm long, in 75% of the cases when the fragment was at least 25 mm length and that the 
best length should be 40 mm. The same study, in which laparoscopic biopsies were collected 
from both lobes of patients with chronic hepatitis C, estimated that biopsy specimens with a 
minimum 4 cm or greather in length would reliably avoid sampling error. However, in 
many specialized hepatology centers, the biopsy fragment does not meet the best criteria for 
an accurate histological analyse. Surgical wedge biopsy provides adequate tissue volume to 
overcome this problem. 
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Another limitation of the liver biopsy is that is very sensitive to analysis errors. Several 
studies have investigated the interobserver and intraobserver variability in the 
histological diagnosis of liver diseases. To minimize the analysis errors and to standardize 
the histological evaluation, staging scores for fibrosis, such as the METAVIR, Ishak and 
Scheuer systems, were created. Nevertheless, liver biopsy is associated with error in 
fibrosis staging in up to 20% of patients and a misdiagnosis of cirrhosis in up to 15 % of 
patients. In example of the resulting sampling errors that can occur, were considered the 
two most common chronic liver diseases: hepatitis C and fatty liver disease. Regev et al 
(2002) performed laparoscopically  guided biopsy of the right and left hepatic lobes in a 
serie of 124 patients with chronic hepatitis C. The two fragments of the same patient were 
interpreted by the same anatomopathologist who was not awared about the identity of 
the biopsy fragment.  Differences of more than one Metavir stage of fibrosis was present 
in 33,1% of cases and more than 2 stages in 2.4%. In 14.5%, cirrhosis was diagnosed in one 
lobe but not the other. As regards liver diseases of other etiologies than the viral one, 
differences  were even bigger. In a study on patients with nonalcoholic fatty liver disease, 
Ratziu et al found that differences of more than one stage Metavir was present in 
approximately 40% of paired liver biopsy; in the patients with primary sclerosing 
cholangitis or primary biliary cirrhosis, ≥1 fibrosis stage discordances occurred in up to 
60% of paired liver biopsy. 
Clearly, needle liver biopsy is far from an ideal test. For these reasons it is necessary to 
develop some semi-automated systems to assess additional histological and 
immunohistochemical features.   
Another limit of the liver biosy is related to  slow rate of fibrosis progression; from normal 
liver to cirrhosis it takes more than 20 years. Follow-up biopsy is too insensitive to detect 
changes in fibrosis progression or regression within weeks to months and even years.  
From another point of view, liver biopsy is an invasive procedure with certain unavoidable 
risks and complications. For both, the physician and the patient, the decision to proceed 
with liver biopsy is not a trivial one. There is an urgent need for a noninvasive diagnostic 
procedure for liver fibrosis because this is currently the main limitation of antifibrotic drug 
testing in clinical trials. 
3. Noninvasive methods for the evaluation of liver fibrosis  
Liver biopsy has been used in more than a century for the staging and diagnosis of acute or 
chronic liver diseases. In order to monitor patients with chronic liver diseases, liver biopsy 
has been increasingly less used because of the sampling and interpretation errors, the 
patient’s high emotional cost and especially because it captures only one moment in a 
diffuse and evolutive hepatic process. In this context, the identification of a noninvasive 
method for the evaluation of liver fibrosis is a challenging  option.  
Noninvasive testes are an attractive alternative to liver biopsy for staging and monitoring of 
chronic liver diseases. A noninvasive method which provides the same information as liver 
biopsy is also desirable in cases when the latter is not possible.  
The purpose of any noninvasive technique is to replace liver biopsy. These methods have 
the advantage of representing the liver in its entirely unlike puncture which analyzes only a 
limited fragment of liver. They also provide information related to the hepatic function: 
secretion, bile excretion or endothelial uptake.  
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Considering the slowly evolution of chronic liver diseases, the information provided 
through liver puncture is not enough to monitor the disease at short time intervals  ue to the 
minimal histological changes. Noninvasive tests have to be sensitive enough to detect the 
minor changes of the dynamic fibrosis process.  
Another indication of noninvasive tests is that they evaluate the efficiency of antifibrotic 
treatments, which cannot be performed through repeated hepatic punctures. It is important 
to have safe and efficient methods to objectify liver fibrosis from several perspectives. In the 
first place, patients with liver fibrosis are part of a high risk group as regards liver diseases 
mortality. In the second place, the prognosis of chronic liver diseases depends on the 
severity and related risk factors. In the third place, when the etiologic factor can be removed, 
it is important to introduce the antifibrotic therapy as soon as possible to reverse the hepatic 
lesions.  
The criteria used in evaluating the severity of liver diseases through other procedures than 
liver biopsy are not specified yet. That is why, for now, potential noninvasive methods must 
be relatively well correlated with the biopsy. The errors of this histological method prevent 
the perfect correlation between the biopsy and noninvasive tests in the diagnosis and 
staging of liver fibrosis. The best correlation occurs in biopsies > de 2.5 cm, the correlation 
index (r) being 0.85. For the interpretation of noninvasive tests, it is important to consider 
the fact that liver biopsy may fail in 20% of the cases, especially for intermediary forms of 
liver fibrosis. This is the reason why many experts believe that the noninvasive methods 
whose ROC (Receiver Operator Characteristic) curve is 0.85-0.90 are as effective as the 
histological exam in the accurate staging of liver fibrosis.  
The two major categories of noninvasive tests include: serum fibrosis markers and hepatic 
elasticity imaging (elastography). 
The results of noninvasive tests will be interpreted in the clinical context; in case of 
discrepancies, liver biopsy is recommended. 
3.1 Serum fibrosis markers 
The physiopathology‘s knowledge of liver fibrosis has determined a high number of 
biomarkers used to diagnose it. Depending on the elements they represent, there are two 
marker categories: direct (representing components of extracellular matrix) or indirect 
(reflecting hepatic inflammation and function).  
In order to be sensitive and specific, therefore ideal for the diagnosis of liver fibrosis, Afdhal 
N.H (2007) considers that biomarkers have to meet the following requirements: 
 they should be specific hepatic tests; 
 the results should not be influenced by the alteration of the hepatic, renal or 
reticuloendothelial function; 
 they should reflect fibrosis regardless of etiology;  
 they should be reproducible and  easy to perform; 
 they should be sensitive enough to differentiate among various fibrosis stages; 
 the risks for patients should be minimum; 
 the cost should be low. 
Due to the high number of molecules involved in liver fibrosis  efforts were made to compile 
the serum markers within panels for clinical use. More indicators and sophisticated scores 
utilizing direct and indirect markers have been developed to enhance the detecting and 
noninvasive staging of liver fibrosis. The most widely known of these are listed in table no.3. 
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Panel Liver Disease Se Sp PPV NPV 
AST/ALT 
ratio AST/ALT 53% 100% 100% 81% 
Forns test Platelets, GGT, Cholesterol 94% 51% 40% 96% 
APRI Index AST, Platelets 41% 95% 88% 64% 
PGA Index Platelets, GGT, apo A 91% 81% 85% 89% 
FibroTest GGT, haptoglobin, bilirubin, apoA,  alpha2-macroglobulin 
87% 59% 63% 85% 
Fibrospect Hyaluronic acid, TIMP-1, alpha2-macroglobulin 83% 66% 72% 78% 
FPI AST, Cholesterol, HOMA-IR 85% 48% 70% 69% 
ELF ECM proteins and proteinases 90% 41% 35% 92% 
Abbreviations: Se,  sensitivity, Sp, specificity, PPV, positive predictive value, NPV, negative predictive 
value, AST, aspartate aminotransferase, ALT, alanine aminotransferase, GGT, Gamma glutamyl 
transferase, apoA, apolipoprotein A1, TIMP-1, tissue inhibitors of metalloproteinase 1, HOMA-IR, 
homeostasis model assessment of insulin resistance, EMC, extracellular matrix molecules 
Table 3. Diagnostic performances of serum markers panels for hepatic fibrosis compared to 
the referenced standard of liver biopsy (Adapted from Rockey DC& Bissel DM, 2006).   
The serum markers of fibrosis are an attractive, noninvasive and affordable alternative, 
replacing at least part of the liver biopsies used in clinical practice. Crockett et al (2006) 
made a comparison between liver biopsy and serum markers, considering the advantages 
and disadvantages of the two methods used alternatively to diagnose and stage liver 
fibrosis. 
 
Factor Liver biopsy Serum markers 
Cost 2200$ Laboratory cost 
Risks Significant Minimal 
Contraindications 
Multiple: bleeding diathesis, morbid 
obesity, ascites, extrahepatic biliary 
obstruction 
Conditions with high rate of 
false positivity 
Accuracy 80% 60-80% 
System 
requirements 
Operator, pathology laboratory, 
pathologist 
Clinical laboratory, phlebo-
tomy, materials. 
Specimen 
adequacy 
Length of liver fragment at least 15 
mm with  6-8 portal tracts Blood sample 
False positives Interobserver variability 
Sepsis, nonhepatic infla-
mmation, hemolysis, trom-
bocitopenia 
False negatives Sampling variability Varies per test 
Time for results 24-72 hours minimum 1-2 hours minimum 
Table 4. Comparison of liver biopsy and serum markers of fibrosis 
The ability of serum tests of fibrosis are similar, with area under the receiver operating 
characteristic curve 0.8-0.85. Compared to biopsy, current serum biomarkers represent the 
whole liver, permit only crude staging sparing about 30-40% patients for biopsy and reflect 
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also liver function (secretion, endotelial uptake).Although their accuracy value are 
improving they cannot supplant direct analysis of the liver. They have some limitatios:  
 They reflect the rate of matrix turnover and tend to be more elevated when there is high 
inflammatory activity; 
 None of the molecules is liver specific, so concurrent sites of inflammation may 
contribute to serum level; 
 Serum levels are influenced by clearance rates; 
The clinical usefulness of serological tests is to set quickly whether fibrosis is mild or severe, 
being less efficient in intermediary fibrosis stages. Most serum markers are more efficient in 
identifying fibrosis that in infirming it. That is why, when fibrosis is severe, regardless of the 
invasive or noninvasive diagnosis method, patients without signs of portal hypertension 
should  start etiologic treatment.  
So far, there is no ideal noninvasive test. Serum markers are based on probability 
calculations and thus they are less specific. Their diagnosis performances increase through 
the combined use of several serum markers tests.  
Using the algorithms based on the sequential combination of serum markers, diagnosis 
accuracy in detecting significant fibrosis can increase to 93-95%, and the liver biopsies could 
be avoided in 50% of the patients with chronic liver diseases. As clinical experience 
accumulates we shall expect that serum markers will begin to replace many of the liver 
biopsies used today for prognostic and treatment purpose.  
Are serum markers ready for the first line fibrosis diagnosis? Overall, the serum assay 
approach remains promising, in part because these tests may represent an “integrated 
readout of liver activity rather than a minute sampling of the type obtained by 
conventional liver biopsy. Initially established as a niche especially in patients who have a 
high risk of complications from liver biopsy, by continued refinement, biomarkers are 
very close to become first line method  for the diagnosis and monitoring of liver fibrosis. 
(Schiff, 2007). 
3.2 Elastography imaging 
Elastography is a much simpler method used to stage liver fibrosis than the X ray methods 
which are commonly used. This technique is quick and noninvasive. It helps to determine 
the stiffness of the hepatic tissue. It is well-known that the stiffness of the hepatic tissue is 
closely related to the stage of liver fibrosis. Touching the firm edge of the liver is a clinical 
parameter used for many years to diagnose cirrhosis. 
3.2.1 Transient Elastography (TE) 
Fibro scan is a device which measures hepatic stiffness through transient elastography. It 
determines the elasticity of a hepatic volume equal to a cylinder with the diameter of 1 cm 
and the length of 4 cm, being thus 100 times larger than the standard biopsy fragment and, 
as such, more representative for the entire hepatic parenchyma.  
Fibro scan uses an ultrasound transducer fixed on the axes of a vibrator which induces a low 
frequency vibration (50 MHz). The vibration transmitted to the hepatic tissue produces an 
elastic wave which propagates inside the liver. The propagation of this wave is followed by 
an ultrasound impulse and the measurement of its speed determines, through direct 
correlation, the tissue stiffness. The more rigid the liver, the higher the propagation speed. 
The results are expressed as kilopascal. Since a larger area of hepatic tissue is studied, 
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whole liver, permit only crude staging sparing about 30-40% patients for biopsy and reflect 
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also liver function (secretion, endotelial uptake).Although their accuracy value are 
improving they cannot supplant direct analysis of the liver. They have some limitatios:  
 They reflect the rate of matrix turnover and tend to be more elevated when there is high 
inflammatory activity; 
 None of the molecules is liver specific, so concurrent sites of inflammation may 
contribute to serum level; 
 Serum levels are influenced by clearance rates; 
The clinical usefulness of serological tests is to set quickly whether fibrosis is mild or severe, 
being less efficient in intermediary fibrosis stages. Most serum markers are more efficient in 
identifying fibrosis that in infirming it. That is why, when fibrosis is severe, regardless of the 
invasive or noninvasive diagnosis method, patients without signs of portal hypertension 
should  start etiologic treatment.  
So far, there is no ideal noninvasive test. Serum markers are based on probability 
calculations and thus they are less specific. Their diagnosis performances increase through 
the combined use of several serum markers tests.  
Using the algorithms based on the sequential combination of serum markers, diagnosis 
accuracy in detecting significant fibrosis can increase to 93-95%, and the liver biopsies could 
be avoided in 50% of the patients with chronic liver diseases. As clinical experience 
accumulates we shall expect that serum markers will begin to replace many of the liver 
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very close to become first line method  for the diagnosis and monitoring of liver fibrosis. 
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Fibro scan is a device which measures hepatic stiffness through transient elastography. It 
determines the elasticity of a hepatic volume equal to a cylinder with the diameter of 1 cm 
and the length of 4 cm, being thus 100 times larger than the standard biopsy fragment and, 
as such, more representative for the entire hepatic parenchyma.  
Fibro scan uses an ultrasound transducer fixed on the axes of a vibrator which induces a low 
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The results are expressed as kilopascal. Since a larger area of hepatic tissue is studied, 
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diagnosis errors related to the sample size which occur in standard liver biopsy are 
eliminated, even in disorders with focal liver fibrosis. 
This technology has many of the features of a noninvasive  ideal method in evaluating liver 
fibrosis, with a series of advantages: it is quick, reproducible, painless and safe.  
Transient elastography is a relative new method. The first clinical data related to this 
technology were published in 2002. Numerous studies on patients with chronic hepatitis C 
demonstrated that elastography is a safe method for detecting severe fibrosis (Casterra, 
2010). Although it is limited in differentiate the intermediary fibrosis stages, its major 
advantage is that it accurately detects persons with significant fibrosis. 
Usually, 10 measurements are carried out for each patient, the total exam duration being 5-
10 minutes. The success rate is automatically calculated by the machine as a ratio between 
the number of successful measurements and the total number of measurements. The 
recommendations of the manufacturers of this technology are that transient elastography 
can only be validated if there are 10 measurements with a success rate of at least 60%. 
However, recent studies have suggested that 3 validated measurements have the same value 
as 10 measurements for cirrhosis diagnosis; the minimum number of measurements for 
significant fibrosis has still to be set. It is considered that 10 validated measurements and a 
success rate of at least 60% can be obtained in 90% of exams.  
Transient elastography is easy to interpret; the coefficient of concordance for the same 
examiner is 96-98% (the correlation coefficient in the same class) and between examiners, the 
coefficient of concordance is of 89-98%. Measurements validation depends on the IQR 
(interquartile range),  <30%) and the success rate of measurements,  >60%.  
The largest study of hepatic elastography  evaluated 327 patients with chronic infection C 
(Ziol et al, 2005) . For each patient, fibrosis was staged by means of 2 methods: Fibro scan 
and liver biopsy. Metavir scoring system for histological staging of liver fibrosis  served as 
reference. The conclusion was that elastography is a reliable tool to detect significant fibrosis 
or cirrhosis. Table no. 5 indicates the diagnosis performance of Fibro scan in detecting 
significant fibrosis, as well as the authors who reported these results. 
 
Study Liver disease 
No 
patients 
Prevalence of 
significant 
fibrosis 
AUROC Limit KPa Se/Sp 
Gomez-
Dominguez et al. Mixt 94 82 0.74 4.0 94/33 
Fraqelli et al Mixt 200 50 0.86 7.6 81/76 
Chang et al Mixt 120 44 0.86 9.0 83/85 
Castera et al HCV 183 74 0.83 7.1 67/89 
Ziol et al HCV 251 65 0.79 8.8 56/91 
Yoneda et al NAFLD 67 49 0.87 6.6 83/81 
Abbreviations: HCV, hepatitis virus C, Se, sensitivity, Sp,specificity, NAFLD – non alcoholic fatty liver 
disease 
Table. 5. Fibroscan performance in detecting significant fibrosis (Guha & Rosenberg,2008) 
When comparing with liver biopsy, TE is non-invasive, easy to repeat, reproducible, 
without contraindications, highly performant technique for detecting cirrhosis. Its 
disadvantage is that unlike liver biopsy, TE is unable to discriminate between intermediate 
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stages of fibrosis. Comparing with serum markers, TE has lower applicability: failure in 5% 
of cases and unreliable results in 15% of cases.( Casterra, 2010). The known limits of this 
method are: the impossibility to conduct measurements in case of ascites (elastic waves do 
not propagate in liquids) and in patients with narrow intercostals spaces (it is necessary to 
insert the probe in the intercostals space). Another significant limiting factor is obesity (body 
mass index >28Kg/m2) due to the diminishing of the surface fat tissue signal. False positive 
results appear in case of acute hepatitis, extra hepatic cholestasis and congestive heart 
failure (Casterra, 2010). The combination between TE and serum markers increases 
diagnostic accuracy for liver fibrosis.  
3.2.2 Magnetic Resonance Elastography 
Magnetic resonance elastography (MRE) has the same basic principles as sonographic 
elastography. By using a probe (pneumatic or electromagnetic), placed directly on the 
patient’s abdominal wall, a shear wave is created. A specialized system of magnetic 
resonance measures the sequential propagation of the shear wave and transforms the data 
analyzed as an elastogram (color – encoded images). The analysis contains the liver in its 
entirety and allows assessing of fibrosis distribution, which is usually heterogeneous. 
Although until now the number of publications related to this method has been reduced, the 
results look promising. A study  which compared MRE with the APRI index in patients with 
viral or alcoholic liver diseases has  shown that MRE is more sensitive in detecting moderate 
and severe fibrosis than the APRI index. Among 96 patients with liver biopsy and 
noninvasive examinations  the reproducibility of both TE and MRE were excellent. The 
elasticity imaging techniques had greater diagnostic accuracy than APRI for detecting liver 
fibrosis. MRE was also found to be more accurate than TE for significant fibrosis (F≥2) and 
for cirrhosis diagnosis (Huwart 2008). 
The problems related to this technique refer to the increased exposure time (the exam takes 
60 minutes), the significant capital invested in the equipment and the computerized analysis 
system, the standardized measurement threshold and method reproducibility. In contrast 
with TE, MRE can be successfully performed in obese patients (BMI > 40 kg/m2 ). 
Furthermore, MRE had in part higher diagnostic accuracy in detecting significant fibrosis 
(F≥2) as compared with TE by examining of larger liver parenchyma areas (Huwart, 2008). 
Although modern magnetic resonance technique is not the most pragmatic noninvasive 
methods it is a promising method as regards the diagnosis potential of liver fibrosis. The 
acknowledgment of its diagnosis sensitivity still requires large population studies. 
3.2.3 Acoustic Radiation Force Imaging (ARFI) 
A new technique used to determine liver elasticity is ARFI elastography. The elastographic 
analysis model combines two technologies, ‘Virtual Touch tissue imaging™’ and ‘Virtual 
Touch tissue quantification™’, which allow the quantitative and qualitative analysis of liver 
elasticity. Using the Virtual Touch application, the tissue gets compressed via acoustic 
energy. It enables the physician to evaluate the mechanical characteristics of deep tissue and 
tissue changes. ARFI imaging (Virtual Touch tissue quantification ) measures liver stiffness 
within a defined region of interest (central window of 5mm axial by 4mm width), while 
performing real-time B-mode imaging. Transmission of short-duration (~262 sec) 
longitudinal acoustic pulses  with a fixed transmit frequency of 2.67 MHz leads micron-scale 
displacements in liver tissue, which results in a shear –wave propagation, away from the 
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diagnosis errors related to the sample size which occur in standard liver biopsy are 
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demonstrated that elastography is a safe method for detecting severe fibrosis (Casterra, 
2010). Although it is limited in differentiate the intermediary fibrosis stages, its major 
advantage is that it accurately detects persons with significant fibrosis. 
Usually, 10 measurements are carried out for each patient, the total exam duration being 5-
10 minutes. The success rate is automatically calculated by the machine as a ratio between 
the number of successful measurements and the total number of measurements. The 
recommendations of the manufacturers of this technology are that transient elastography 
can only be validated if there are 10 measurements with a success rate of at least 60%. 
However, recent studies have suggested that 3 validated measurements have the same value 
as 10 measurements for cirrhosis diagnosis; the minimum number of measurements for 
significant fibrosis has still to be set. It is considered that 10 validated measurements and a 
success rate of at least 60% can be obtained in 90% of exams.  
Transient elastography is easy to interpret; the coefficient of concordance for the same 
examiner is 96-98% (the correlation coefficient in the same class) and between examiners, the 
coefficient of concordance is of 89-98%. Measurements validation depends on the IQR 
(interquartile range),  <30%) and the success rate of measurements,  >60%.  
The largest study of hepatic elastography  evaluated 327 patients with chronic infection C 
(Ziol et al, 2005) . For each patient, fibrosis was staged by means of 2 methods: Fibro scan 
and liver biopsy. Metavir scoring system for histological staging of liver fibrosis  served as 
reference. The conclusion was that elastography is a reliable tool to detect significant fibrosis 
or cirrhosis. Table no. 5 indicates the diagnosis performance of Fibro scan in detecting 
significant fibrosis, as well as the authors who reported these results. 
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disease 
Table. 5. Fibroscan performance in detecting significant fibrosis (Guha & Rosenberg,2008) 
When comparing with liver biopsy, TE is non-invasive, easy to repeat, reproducible, 
without contraindications, highly performant technique for detecting cirrhosis. Its 
disadvantage is that unlike liver biopsy, TE is unable to discriminate between intermediate 
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stages of fibrosis. Comparing with serum markers, TE has lower applicability: failure in 5% 
of cases and unreliable results in 15% of cases.( Casterra, 2010). The known limits of this 
method are: the impossibility to conduct measurements in case of ascites (elastic waves do 
not propagate in liquids) and in patients with narrow intercostals spaces (it is necessary to 
insert the probe in the intercostals space). Another significant limiting factor is obesity (body 
mass index >28Kg/m2) due to the diminishing of the surface fat tissue signal. False positive 
results appear in case of acute hepatitis, extra hepatic cholestasis and congestive heart 
failure (Casterra, 2010). The combination between TE and serum markers increases 
diagnostic accuracy for liver fibrosis.  
3.2.2 Magnetic Resonance Elastography 
Magnetic resonance elastography (MRE) has the same basic principles as sonographic 
elastography. By using a probe (pneumatic or electromagnetic), placed directly on the 
patient’s abdominal wall, a shear wave is created. A specialized system of magnetic 
resonance measures the sequential propagation of the shear wave and transforms the data 
analyzed as an elastogram (color – encoded images). The analysis contains the liver in its 
entirety and allows assessing of fibrosis distribution, which is usually heterogeneous. 
Although until now the number of publications related to this method has been reduced, the 
results look promising. A study  which compared MRE with the APRI index in patients with 
viral or alcoholic liver diseases has  shown that MRE is more sensitive in detecting moderate 
and severe fibrosis than the APRI index. Among 96 patients with liver biopsy and 
noninvasive examinations  the reproducibility of both TE and MRE were excellent. The 
elasticity imaging techniques had greater diagnostic accuracy than APRI for detecting liver 
fibrosis. MRE was also found to be more accurate than TE for significant fibrosis (F≥2) and 
for cirrhosis diagnosis (Huwart 2008). 
The problems related to this technique refer to the increased exposure time (the exam takes 
60 minutes), the significant capital invested in the equipment and the computerized analysis 
system, the standardized measurement threshold and method reproducibility. In contrast 
with TE, MRE can be successfully performed in obese patients (BMI > 40 kg/m2 ). 
Furthermore, MRE had in part higher diagnostic accuracy in detecting significant fibrosis 
(F≥2) as compared with TE by examining of larger liver parenchyma areas (Huwart, 2008). 
Although modern magnetic resonance technique is not the most pragmatic noninvasive 
methods it is a promising method as regards the diagnosis potential of liver fibrosis. The 
acknowledgment of its diagnosis sensitivity still requires large population studies. 
3.2.3 Acoustic Radiation Force Imaging (ARFI) 
A new technique used to determine liver elasticity is ARFI elastography. The elastographic 
analysis model combines two technologies, ‘Virtual Touch tissue imaging™’ and ‘Virtual 
Touch tissue quantification™’, which allow the quantitative and qualitative analysis of liver 
elasticity. Using the Virtual Touch application, the tissue gets compressed via acoustic 
energy. It enables the physician to evaluate the mechanical characteristics of deep tissue and 
tissue changes. ARFI imaging (Virtual Touch tissue quantification ) measures liver stiffness 
within a defined region of interest (central window of 5mm axial by 4mm width), while 
performing real-time B-mode imaging. Transmission of short-duration (~262 sec) 
longitudinal acoustic pulses  with a fixed transmit frequency of 2.67 MHz leads micron-scale 
displacements in liver tissue, which results in a shear –wave propagation, away from the 
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region of excitation. Maximum movement is estimated by ultrasound detection fascicles 
adjacent to the central acoustic pulse. By measuring the maximum movement amplitude as 
compared to the time of each side fascicle, the shear – wave speed of the tissue can be 
reconstructed. Results expressed in meters per second are displayed by the machine 
(Friedrich-Rust, 2009).  
Preliminary results indicate that ARFI imaging technology is a promising method for the 
diagnosis of significant fibrosis in patients with chronic hepatitis C.( Friedrich-Rust, 2009, 
Fierbinteanu-Braticevici, 2009). The benefits of ARFI imaging as compared with Fibro scan 
consist in: lesser time consuming (new software allowed to the 12 measurements per 1min) 
and successful measurements in difficult patients (obese) because of subcostal scanning. 
Another advantage of ARFI imaging is that it is integrated into a conventional 
ultrasonography (US) system and can thus be performed during standard US examinations 
of the liver, which are routinely performed in patients with chronic liver disease. Further 
studies on large number of patients are needed in order to specify the role of ARFI 
elastography for noninvasive staging of liver fibrosis. 
3.3 Breath tests 
Taking into account that the liver has a complex and high metabolic capacity, translated into 
detoxification, synthesis, metabolization, storage, a unique  classical test  may not reflects all 
these sides. More, each function may be different affected in  various stages of the liver 
disease,  so that the determination of the reserve capacity of the liver appears to reflect a 
global functional image. During the last decade, several dynamic tests have been proposed 
to improve the functional diagnosis of liver diseases. Although numerous tests which 
explore a specific hepatic function have been used, these methods were not introduced in 
the clinical practice. 
The introduction of breath tests that use marked carbon (C13 ) attached to various substrata 
(aminopyrin, phenylalanin, methacetine, phenacetyne, galactose) was due to the need to 
have a quick and practical test to determine the functional hepatic reserve. While neither of 
these tests allows quantification of a global liver function, each has been shown to reflect the 
most important partial liver functions i.e. cytosolic, microsomal or mitochondrial function. 
The principle of breath tests is simple. An ingested substrate attached to C13 or C14, 
administered orally or parenterally is converted by the liver in 13 CO2 or 14CO2. The marked 
CO2 is collected at different time intervals in an alkaline environment which serves as a trap. 
The hepatic metabolism of the bonding substrate may be determined from a semi 
quantitative perspective by multiplying the specific CO2 activity in the exhaled air  within a 
given time interval. An ideal compound for this purpose is metabolized solely by the liver 
and therefore reflects liver function. 
In the beginning, breath tests required sophisticated and expensive mass spectrometers that 
were no longer used. 13C can now be measured with non dispersive infrared spectrometry, a 
simple and cost-saving method which provides information correlated with those of the 
mass spectrometry. Functional hepatic tests, including breath tests, together with clinic 
scores, had been proved to be helpful in diagnosis and prognosis of the patients with 
advanced hepatic disease. As regard the role of methacetin breath test  (MBT) in the 
assessement of fibrosis in patients with chronic hepatitic C, our study indicated that the 
methacetin breath test parameters didn’t allow differentiation of patients without fibrosis 
from those with mild fibrosis (F1). This limit was overcome by the fact that MBT was highly 
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correlated with significant fibrosis (≥ F2) which is considered the hallmark of progressive 
liver disease and a stronger indication for treatment.  
Additional studies are required to assess the role  of these tests as an alternative to liver 
biopsy in the diagnosis and follow-up of hepatic injury in patients with chronic liver 
diseases. 
4. Conclusion 
Liver biopsy remains an important tool in the evaluation and management of liver disease. 
However it  is invasive,  can cause significant complications and clearly, needle liver biopsy 
is far from an ideal test. Even though it is an imperfect “gold standard”, liver biopsy 
remains an important tool in the evaluation and management of liver disease. 
For this reason, the efforts to estimate the hepatic lesion stage through noninvasive methods 
are justified. Noninvasive investigations, such as various biomarkers, fibrosis scoring 
panels, imaging techniques and breath tests offer considerable promise in their ability to 
detect and to stage liver fibrosis. Until now, not even one noninvasive test can be considered 
enough sensitive to predict by itself the severity of acute or chronic liver diseases. That is 
why combining various noninvasive tests is promising and many times they can avoid liver 
biopsy. Further testing and validation are needed for these noninvasive procedures to refine 
their role of clinical practice and supplant the need for liver biopsy in chronic liver diseases. 
Now, when many non - invasive procedures have been studied, the question is if that do we 
still need a liver biopsy? We think that the answer is „yes”, because despite its limitations, 
the liver biopsy remains an invaluable procedure of the clinician, whenever  the etiology of 
liver disease is in impass. Liver biopsy is still needed if laboratory testing and imaging 
studies are inconclusive. It may take many years, if at all, until liver biopsy will be fully 
replaced. 
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stiffness at current clinical medicine in Europe. The principal of TE is simple: TE measures the 
propagation speed of elastic shear wave within the liver parenchyma. The velocity of the wave 
propagation correlates directly to tissue stiffness; that is, the harder the tissue is, the faster the 
shear wave spread.  
In this chapter, we introduce a new US-based approach for non-invasive assessment of liver 
fibrosis using real-time tissue elastography (RTE) that can be performed simultaneously with 
conventional ultrasound probes during routine US examination. RTE is technically different 
from TE: echo signals representing tissue strain before and under mild compression are 
compared and analyzed. RTE was developed in Japan for the visual assessment of tissue 
elasticity integrated in a sonography machine. The technique is based on the Combined 
Autocorrelation Method that calculates the relative hardness of tissue rapidly from the degree 
of tissue distortion and displays this information as a color image [Shiina T, 2002]. The 
distortion of tissue is transferred to a color-coded image according to its magnitude and 
superimposed translucently on the conventional B-mode image. Such a simultaneous display 
of tissue elasticity and B-mode images enables us to evaluate the anatomical correspondence 
between these modalities. The RTE image is constructed by the amount of displacement of the 
reflected ultrasound echoes under compression. Although US-based elastography is unable to 
demonstrate physical elasticity directly, it shows the relative degree of tissue strain when 
subtle compression is applied. In hard tissue, the amount of displacement of the reflected 
ultrasound echoes is low, whereas, in soft tissue, the amount of displacement is high because 
soft tissue can be compressed more than hard tissue.  
This technology has already been proved to be diagnostically valuable in detecting space 
occupying lesions in the breast, prostate, and pancreas. In 2007, Friedrich-Rust applied this 
technique to measure liver stiffness and reported its usefulness for the detection of significant 
fibrosis (≧F2, area under the receiver operating characteristic curve; AUC 0.93) in combination 
with AST to platelet ratio index (APRI). In 2010, we reported that AUC for no significant 
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fibrosis (F0-1) was 0.89 and 0.92 in RTE and TE, respectively, and AUC for cirrhosis (F4) was 
0.93 and 0.95 in RTE and TE, respectively, in 101 patients with chronic hepatitis C. 
We report here an update of the RTE system as a tool for the noninvasive assessment of liver 
stiffness together with an overview of recent advancement in this area in the literature. 
 
 
Fig. 1. The principle of real time tissue elastography, illustrated here by a spring model. 
2. Methods  
2.1 Real-time tissue elastography  
The principle underlining RTE is shown in Figure 1, which indicates a spring model [Ophir 
J, 1991]. When a spring is compressed, displacement in each section of the spring depends 
on the stiffness of the spring: a soft spring compresses more than a hard spring. The strain 
distribution can be measured by spatially differentiating the displacement at each location. 
Although the tissue displacement is usually generated by manual compression and 
relaxation of the probe in practice, we were able to improve the acquisition of RTE images 
representing the distortion of liver tissue as a result of the beating of the heart or pulsing of 
the abdominal aorta. 
RTE is carried out using a high-end model of Hitachi ultrasound system (Hitachi Medical, 
Chiba, Japan). The developed software with a complex algorithm is able to process all the 
data coming from the lesion as radiofrequency impulses in a very short time and minimize 
the artifacts due to lateral dislocations, allowing accurate measurement of the degree of 
tissue distortion. We used Hitachi EUB-8500 and an EUP-L52 Linear probe (3–7 MHz; 
Hitachi Medical) for RTE. 
This system is currently commercially available for the diagnosis of mammary neoplasm. 
Patients were examined in a supine position with the right arm elevated above the head, 
and were instructed to hold their breath. The examination was performed on the right lobe 
of the liver through the intercostal space, and liver biopsy and Fibroscan were also 
performed at the same site. The RTE equipment displays two images simultaneously; one 
shows the regions of interest (ROI) as a colored area and the other indicates the conventional 
B-mode image (Fig. 2A). We chose an area where the tissue was free from large vessels and 
near the biopsy point. The measurement was xed to a rectangle 30 mm in length and 20 
mm in breadth placed 5-10 mm below the surface of the liver (Fig. 2A). The color in the ROI 
was graded from blue (representing hard areas) to red (representing soft areas) (Fig. 2A). 
We stored the RTE images as moving digital images for 20–40 s. Ten static images captured 
by the observer at random from the moving images using AVI2JPG v6.10 converter software 
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(Novo, Tokyo, Japan) were analyzed using the novel software Elasto_ver 1.5.1,which was 
developed and donated by Hitachi Medical, on a personal computer. Numerical values of 
pixels were from 0 to 255 (256 stepwise grading) according to color mapping from blue (0) to 
red (255), and a histogram of the distribution was generated (Fig. 2B). The scale ranged from 
red for components with the greatest strain (i.e., softest components) to blue for those with 
no strain (i.e., hardest components). Green indicated average strain in the ROI, and therefore 
intact liver tissue was displayed as a diffuse homogeneous green pattern. An appearance of 
unevenness in the color pattern was considered to reflect a change in the liver stiffness. For 
quantification, all pixel data in the colored image were transferred into a histogram and 
binary image (Fig. 2B).  
 
 
Fig. 2. Procedure of image analyses for real-time tissue elastography. 
(A) The ROI was fixed to a rectangle of approximately 20-30 mm length x 20 mm breadth 
with a 400–600 mm2 area placed 5-10 mm below the surface of the liver. Left; RTE image, 
right; B-mode image. (B) The color-coded images from the ROI of RTE were analyzed by the 
software Elasto_ver1.5.1. The colors ranged from blue to red indicating the relative 
gradients from hardness to softness. Mean and Standard deviation were calculated by a 
histogram, which was generated by 256 stepwise grading derived from the color image. 
Area and Complexity were calculated from the binary image. Area was derived from the 
percentage of white regions (asterisks, i.e. hard area). Complexity was calculated as 
periphery2/Area. Median value of the data were kept as representative of RTE parameters. 
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Colored RTE images are usually classified into several patterns in the diagnosis of breast 
disease. We paid attention to the pattern change of RTE color images according to the 
progression of fibrosis. We proposed three patterns for representing the stages of liver fibrosis: 
a diffuse soft pattern, an intermediate pattern, and a patchy hard pattern (Fig. 3). The diffuse 
soft pattern indicated a homogeneously light-green colored image. The intermediate pattern 
represented a partially mottled and dotted image with blue spots on a light green background. 
The patchy hard pattern comprised mixed images with a patchwork effect of light green, red, 
and blue. Normal or minimally fibrotic liver exhibited a homogeneous RTE image that was 
colored light green (diffuse soft pattern). According to the progression of liver fibrosis, the 
homogeneous pattern transitioned to a patchy pattern consisting of a blue-colored area 
(patchy hard pattern), which may suggest a decrease of homogeneity. 
 
 
Fig. 3. Representative colored images of real-time tissue elastography according to the 
progression of liver fibrosis. 
Normal or minimally fibrotic liver exhibited a homogenous RTE image that was colored 
light green. According to the progression of liver fibrosis, the homogenous pattern 
transitioned to a patchy pattern consisting of a blue-colored area, which may suggest a 
collapse of homogeneity. A relatively homogeneous light green image indicated a diffuse 
soft pattern in RTE. A partially mottled and dotted image with blue and red spots in the 
light green background indicated an intermediate pattern. A mixed image with light green, 
blue, and red colors indicated patchy hard pattern.  
2.2 Transient elastography 
Liver stiffness was also measured by TE (Fibroscan; Echosens SA, Paris, France). Briefly, 
patients were placed in a horizontally supine position and a probe was placed on the skin 
above the right intercostal space. The velocity of shear waves, which were generated 
temporarily and passed though the liver, was combined with Young’s modulus for the 
automated calculation of elasticity [Yeh WC, 2002]. The measurement depth was between 25 
and 65 mm. The results that were obtained in ten valid measurements with a success rate of 
at least 60% and an interquartile range under 30% were considered successful. Failure was 
defined as when less than ten valid measurements were obtained. A median of 10 valid 
measurements was regarded as the liver stiffness for a given subject and expressed in 
kilopascals (kPa). 
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3. Results 
3.1 Our results 
Our results were expressed as Mean and Standard Deviation (SD), which indicates the mean 
and the standard deviation of the histogram, respectively. In another analysis, the data were 
transformed into a binary image and the results were described as Area, which indicates the 
percentage of hard tissue and represents the hard tissue domain divided by the ROI and 
Complexity (complex ratio of the shape of an extracted hard tissue domain in the ROI 
calculated as periphery2/area of the hard tissue domain). The four image features were 
calculated automatically by Elasto_ver 1.5.1 (Hitachi Medical). Mean, SD, and Complexity 
were described in arbitrary units [a.u.]. 
Figure 4 shows box plots of the RTE values corresponding to fibrosis stage in 126 patients with 
chronic hepatitis C. The Mean decreased in proportion to the increase of fibrosis score 
(Jonckheere–Terpstra test, p<0.0001). SD, Area, and Complexity increased in proportion to the 
increase of fibrosis score (Jonckheere–Terpstra test, p< 0.0001). The significant differences 
between each fibrosis stage were as follows: F1 versus F3 and F4, and F2 versus F4 for every 
parameter; F1 versus F2 and F2 versus F3 for Mean; and F3 versus F4 for Complexity (Tukey–
Kramer test, p<0.05).  No significant difference was found between the activity of chronic 
hepatitis and the fibrosis stages for any parameters (Tukey–Kramer test). The AUC of RTE 
parameters for no signicant brosis (F0–1) and cirrhosis (F4) in 121 patients who were also 
examined successfully by TE, together with the corresponding sensitivities, specicities, and 
positive and negative predictive values are presented in Table 1. 
 
 
F1, n=62. F2, n=19. F3, n=19. F4, n=20. F scale was divided by METAVIR score. 
Fig. 4. Parameter analyses measured by real-time tissue elastography for each fibrosis stage. 
Box plots of each value of RTE corresponding to fibrosis stages F1-4. The top and bottom of 
the boxes indicate the 1st and 3rd quartiles. The length of the box represents the interquartile 
range within which 50% of values are located. The lines through the middle of the boxes 
represent the median. A) Mean, B) SD, C) Area, and D) Complexity.  
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 F=0-1     F=4  
 Mean SD Area Complexity TE Mean SD Area Complexity TE 
Cut-of 110.1 61.2 25.8 23.2 10.1 106.9 63 29.5 24.9 13.3 
AUC 0.89 0.81 0.87 0.81 0.92 0.91 0.84 0.91 0.93 0.95 
Sensitivity [%] 84.1 70.5 81.8 77.3 88.6 82.8 75.9 79.3 79.3 89.7 
Specificity [%] 82.7 73.1 80.8 75 86.5 85.1 77.6 80.6 80.6 86.6 
Accuracy [%] 83.3 71.9 81.3 76 87.5 84.4 77.1 80.2 80.2 87.5 
TE, transient elastography. 
Table 1. Results of comparisons between four image features of real time tissue elastography 
and transient elastography. 
3.2 Search results 
A PubMed search was conducted in February 2011 for full papers published in journals 
written in English in the past 5 years. The following keywords were used in combination: 
“real-time tissue elastography” and “liver”. The first author’ names, patient’s selection 
critera, patient number, and diagnostic accuracies are summarized in Table 2. The primary 
outcome was the identification of the degree of fibrosis defined as stages F1 to F4 according 
to the METAVIR score. 
Two articles were reported by Friedrich-Rust in 2007 and 2009, one article was from China, 
and three articles including ours were from Japan. Three of the articles described studies 
conducted in patients with chronic liver disease, one article limited the subjects to those 
with chronic hepatitis B, and two articles including our report included only subjects with 
chronic hepatitis C. There are two ways to calculate the results of RTE: one is the ratio of 
strain distribution between the ROI of liver parenchyma and that of other areas, and the 
other is the analysis of color images in ROI. Koizumi’s report showed the best sensitivity 
and specificity until now; 83.8 % and 90.9 %, respectively for F1, and 90.9% and 91.5 %, 
respectively, for F4. They used the ratio between the tissue compressibility of the liver 
parenchyma and that of intrahepatic small vessel. Only two articles Friedrich-Rust’s in 2009 
and ours in 2010 compared the diagnostic value of RTE with TE. Others compared the value 
of RTE with serum fibrosis markers represented by APRI.  
4. Discussion 
Liver biopsy has long been the gold standard for the assessment of hepatic fibrosis and will 
remain important in the diagnosis of liver disease with unknown etiology. However, 
because of complications, sampling error, and interobserver variability, the role of liver 
biopsy in the assessment and quantification of fibrosis in viral liver diseases is thought to be 
less valuable. Many modern noninvasive tests including serum markers and imaging 
methods are expected to become increasingly important in the near future. 
A large number of serum markers have been identified for the assessment of hepatic fibrosis. 
In clinical practice, type IV collagen 7s, type III procollagen N-terminal peptide (P-III-P), and 
hyarulonic acid are commonly utilized as direct serum markers for human liver fibrosis, 
although it is difficult to distinguish each pathological fibrosis stage using one of these 
extracellular matrix products. On the other hand, the European Liver Fibrosis (ELF) study 
reported a marker composed of the combination of P-III-P, hyarulonic acid, and tissue 
inhibitor of metalloproteinases, which achieved the diagnostic power of AUC 0.80 for Scheuer 
3-4 [Guha IN, 2008.]. Reported indirect serum markers of liver fibrosis include AAR 
(AST/ALT ratio), APRI (AST-to-platelet ratio index), Forns score, FibroTest, and the HALT-C 
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model, which are composed of several parameters commonly measured in clinical practice. 
FibroTest is currently the most carefully evaluated noninvasive serum fibrosis marker panel 
that is commercially available. FibroTest is an algorithm composed of 6 parameters, including 
haptoglobin, α2-macroglobulin, apolipoprotein-A1, γ-glutamyltransferase, bilirubin, and  
γ-globulin, and its diagnostic power for ≧F2 was reported to be AUC 0.87 [Imbert-Bismut F, 
2001.]. While the diagnostic accuracy was high, the FibroTest costs more than APRI and the 
Forns score, and requires two uncommon parameters. In APRI, using the cutoffs proposed by 
Wai et al. [Wai CT, 2003.], approximately 50% of patients could be correctly classied as 
having cirrhosis without a liver biopsy. With the Forns score, the AUC for the prediction of 
significant fibrosis (Scheuer classication, F2) was 0.86 in the test set and 0.81 in the validation 
set [Forns X, 2002]. Although direct, indirect, and combined serum marker systems consist of 
multiple biomarkers, they are all characterized by an AUC for the ROC clustering around 0.85 
in recent studies. [Afdhal NH and Curry M, 2007]. 
 
Author, year Patients selection Patients Control Calculation 
Fibrosis 
stage AUC
Sensitivity 
[%] 
Specificity 
[%] 
PPV 
[%] 
NPV 
[%] 
Friedrich-
Rust M, 2007 
viral 
hepatitis  79 20 
elasticity score, 
stepwise 
multivariate 
logistic regression 
F=1 
F=4 
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Table 2. Diagnostic accuracy of real time tissue elastography in individual studies. 
Standard US, CT, and MRI have long been used to survey liver morphology. These 
modalities are able to detect changes in the liver parenchyma when there is early cirrhosis 
and signs of portal hypertension. However, these methods are not useful to identify the 
presence of mild fibrosis. In this regard, elastography is sensitive for evaluating liver fibrosis 
based on the fact that, as the liver becomes progressively fibrotic, it becomes harder and less 
elastic. The technique based on US and MRI easily and noninvasively measures the relative 
values of liver stiffness. TE has been used most frequently worldwide and has established a 
role in clinical practice for detecting advanced fibrosis instead of liver biopsy. A pioneering 
report from Castera in 2005 showed that the AUC of TE was 0.84 for the diagnosis of F1 and 
0.94 for the diagnosis of cirrhosis. Although MR elastography (MRE) was shown to be 
superior to APRI and TE for determining the stage of fibrosis in patients with underlying 
liver diseases [Huwart L, 2008], MRE cannot be performed on patients with an iron 
overloaded liver because of background noise. In addition, MRE takes more time and costs 
more than the US-based elastographies. 
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 F=0-1     F=4  
 Mean SD Area Complexity TE Mean SD Area Complexity TE 
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Table 1. Results of comparisons between four image features of real time tissue elastography 
and transient elastography. 
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outcome was the identification of the degree of fibrosis defined as stages F1 to F4 according 
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A large number of serum markers have been identified for the assessment of hepatic fibrosis. 
In clinical practice, type IV collagen 7s, type III procollagen N-terminal peptide (P-III-P), and 
hyarulonic acid are commonly utilized as direct serum markers for human liver fibrosis, 
although it is difficult to distinguish each pathological fibrosis stage using one of these 
extracellular matrix products. On the other hand, the European Liver Fibrosis (ELF) study 
reported a marker composed of the combination of P-III-P, hyarulonic acid, and tissue 
inhibitor of metalloproteinases, which achieved the diagnostic power of AUC 0.80 for Scheuer 
3-4 [Guha IN, 2008.]. Reported indirect serum markers of liver fibrosis include AAR 
(AST/ALT ratio), APRI (AST-to-platelet ratio index), Forns score, FibroTest, and the HALT-C 
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model, which are composed of several parameters commonly measured in clinical practice. 
FibroTest is currently the most carefully evaluated noninvasive serum fibrosis marker panel 
that is commercially available. FibroTest is an algorithm composed of 6 parameters, including 
haptoglobin, α2-macroglobulin, apolipoprotein-A1, γ-glutamyltransferase, bilirubin, and  
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significant fibrosis (Scheuer classication, F2) was 0.86 in the test set and 0.81 in the validation 
set [Forns X, 2002]. Although direct, indirect, and combined serum marker systems consist of 
multiple biomarkers, they are all characterized by an AUC for the ROC clustering around 0.85 
in recent studies. [Afdhal NH and Curry M, 2007]. 
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Four published reports have compared the diagnostic accuracy of RTE with serum markers 
including APRI. RTE was shown to be superior to APRI in determining the stage of liver 
fibrosis in all of these studies except for the first report by Friedrich-Rust in 2007. It is 
believed that the more sensitive probes have been developed which could mitigate the deep 
attenuation of the ultrasound image and without requiring external stress. Accordingly, we 
were able to avoid the influence of the liver surface inside the ROI which is hard and 
therefore assessed as a harder area and to improve the acquisition of the color image 
representing the distortion of liver tissue due to the heartbeat or the pulse of the abdominal 
aorta without interobserver variability. 
Although Friedrich-Rust (2009) reported that RTE was inferior in determining the stage of 
liver fibrosis compared to TE, our results presented in Table 1 indicated that the 
performance of RTE compares favorably with that of TE for detecting the degree of liver 
fibrosis in patients with chronic hepatitis C. TE has been reported to have several limitations 
and disadvantages in evaluating patients with obesity and ascites. In fact, in our study, we 
achieved successful evaluation of all patients with RTE, while five patients (F1, 2; F3, 1; F4, 
2) failed to receive TE measurements due to obesity and liver atrophy. Koizumi also 
reported that RTE could be employed in patients with BMIs greater than 30 kg/m2. 
Although the results from RTE were conducted by the image of color map, the results were 
calculated by either the ratio of strain distribution between ROI of the liver parenchyma and 
that of another area or by the image analysis of ROI. The method of Kanamoto which was 
used intercostal muscle as the reference for the ratio was inferior to the other method, since 
the area is considered to be influenced by instability of tissue distortion of subcutaneous fat 
and by the liver surface which is one of the hardest areas in liver parenchyma. In contrast, 
Koizumi adopted the hepatic vein as a reference and obtained the best sensitivity and 
specificity for characterizing the stage of fibrosis in related articles. Other studies utilized 
image analysis using exclusive software and reported different results. Thus the best 
method for the analysis and unit of RTE remains unclear, but may be revealed by future 
multicenter studies using larger patient cohorts.  
In the future, the combination of image modalities with serological parameters will further 
improve the accuracy in differentiating fibrosis stages. Interestingly, Castera reported that 
the best results were achieved by a combination of TE with the FibroTest. Although acoustic 
radiation force impulse, which is a most recent technology, TE, and MRE are all based on 
shear wave propagation, RTE is constructed by an original theory which is based on tissue 
distortion. Friedrich-Rust reported in 2007 that the best diagnostic accuracy was obtained by 
combining the variables used for the calculation of the RTE elasticity score with the platelet 
count and GGT.  
Elastography will be applicable to the screening of hepatocellular carcinoma (HCC) and the 
complication of cirrhosis. In the METAVIR and Desmet’s histological scoring systems, 
cirrhosis is classified as a single category, F4. However, the degree of fibrosis that indicates 
the amount of extracellular matrix materials including collagen that may be closely 
associated with the function of hepatocytes and portal hypertension may vary among 
patients with cirrhosis. Foucher reported in 2006 that liver stiffness (kPa) measured by TE in 
cirrhotic patients correlates well with clinical parameters indicating the severity of cirrhosis; 
27.5 kPa was the cutoff value for the presence of esophageal varices stage 2 or 3, 37.5 kPa for 
liver function Child B or C, 49.1 kPa for a past history of ascites, and 62.7 kPa for bleeding 
from esophageal varices. Masuzaki prospectively observed that, in 866 patients with chronic 
hepatitis C, HCC developed in 77 cases within 3 years of observation, and 0.4% of HCC was 
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detected in patients whose liver stiffness at entry was less than 10 kPa and 38.5% of it was 
more than 25 kPa, indicating the usefulness of liver stiffness measurement as a tool for 
predicting the development of HCC. Because RTE is expected to stage cirrhosis in greater 
detail with clinical relevance, it may be useful for detecting and assessing the risk of 
cirrhotic complications and the development of HCC. 
Although noninvasive assessment of liver fibrosis is already established in patients with 
chronic hepatitis C, it is still necessary to improve assessment in other highly prevalent 
diseases, such as non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). We 
reported that the AUC of AAR, age-platelet index, APRI, and cirrhosis discriminant score 
for predicting cirrhosis were 0.81, 0.87, 0.79, and 0.95, respectively, in 50 patients with 
NASH and 0.56, 0.65, 0.76, and 0.78, respectively, in 100 patients with chronic hepatitis C 
[Fujii H 2009]. RTE will be expected to play a major role in elastography for these patients, 
since it is not influenced by obesity or BMI.  
5. Conclusion  
We have described a convenient and noninvasive procedure, RTE, for the visual assessment 
of liver stiffness. The performance of RTE compared favorably to TE for detecting the degree 
of liver fibrosis in patients with chronic hepatitis C. We suggest that RTE could also be used 
as a routine imaging method to evaluate the degree of liver fibrosis in patients with liver 
diseases other than chronic hepatitis C. Future studies on larger patient cohorts will be 
necessary for the validation of RTE analysis, and the combination of RTE parameters with 
other clinical values including serum biomarkers will enable improvement of accuracy in 
assessing hepatic fibrosis. 
6. Acknowledgment 
We thank Ms. Akiko Tonomura and Mr. Junji Warabino, Hitachi Medical Co., for the 
technical support for RTE. Hiroyasu Morikawa was supported by a research grant from 
Osaka City University (2009). Norifumi Kawada was supported by Research on Hepatitis, 
Health and Labour Science Research Grants from the Ministry of Health, Labour and 
Welfare of Japan (2008–2009) and by a Thrust Area Research Grant from Osaka City 
University.(2008–2009). 
7. References 
Afdhal NH and Curry M (2007) Technology evaluation: a critical step in the clinical 
utilization of novel diagnostic tests for liver fibrosis. J Hepatol 46: 543–54 
Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M. (2005) Prospective 
comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the 
assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50. 
Forns X, Ampurdane`s S, Llovet JM, Aponte J,  Quinto´ L, Marti´nez-Bauer E, et al. 
Identification of chronic hepatitis C patients without hepatic  fibrosis by a simple 
predictive model. Hepatology. 2002;36:986–92. 
Foucher J, Chanteloup E, Vergniol J, Caste´ra L, Le Bail B, Adhoute X. (2006) Diagnosis of 
cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403–8 
 
Liver Biopsy 
 
248 
Four published reports have compared the diagnostic accuracy of RTE with serum markers 
including APRI. RTE was shown to be superior to APRI in determining the stage of liver 
fibrosis in all of these studies except for the first report by Friedrich-Rust in 2007. It is 
believed that the more sensitive probes have been developed which could mitigate the deep 
attenuation of the ultrasound image and without requiring external stress. Accordingly, we 
were able to avoid the influence of the liver surface inside the ROI which is hard and 
therefore assessed as a harder area and to improve the acquisition of the color image 
representing the distortion of liver tissue due to the heartbeat or the pulse of the abdominal 
aorta without interobserver variability. 
Although Friedrich-Rust (2009) reported that RTE was inferior in determining the stage of 
liver fibrosis compared to TE, our results presented in Table 1 indicated that the 
performance of RTE compares favorably with that of TE for detecting the degree of liver 
fibrosis in patients with chronic hepatitis C. TE has been reported to have several limitations 
and disadvantages in evaluating patients with obesity and ascites. In fact, in our study, we 
achieved successful evaluation of all patients with RTE, while five patients (F1, 2; F3, 1; F4, 
2) failed to receive TE measurements due to obesity and liver atrophy. Koizumi also 
reported that RTE could be employed in patients with BMIs greater than 30 kg/m2. 
Although the results from RTE were conducted by the image of color map, the results were 
calculated by either the ratio of strain distribution between ROI of the liver parenchyma and 
that of another area or by the image analysis of ROI. The method of Kanamoto which was 
used intercostal muscle as the reference for the ratio was inferior to the other method, since 
the area is considered to be influenced by instability of tissue distortion of subcutaneous fat 
and by the liver surface which is one of the hardest areas in liver parenchyma. In contrast, 
Koizumi adopted the hepatic vein as a reference and obtained the best sensitivity and 
specificity for characterizing the stage of fibrosis in related articles. Other studies utilized 
image analysis using exclusive software and reported different results. Thus the best 
method for the analysis and unit of RTE remains unclear, but may be revealed by future 
multicenter studies using larger patient cohorts.  
In the future, the combination of image modalities with serological parameters will further 
improve the accuracy in differentiating fibrosis stages. Interestingly, Castera reported that 
the best results were achieved by a combination of TE with the FibroTest. Although acoustic 
radiation force impulse, which is a most recent technology, TE, and MRE are all based on 
shear wave propagation, RTE is constructed by an original theory which is based on tissue 
distortion. Friedrich-Rust reported in 2007 that the best diagnostic accuracy was obtained by 
combining the variables used for the calculation of the RTE elasticity score with the platelet 
count and GGT.  
Elastography will be applicable to the screening of hepatocellular carcinoma (HCC) and the 
complication of cirrhosis. In the METAVIR and Desmet’s histological scoring systems, 
cirrhosis is classified as a single category, F4. However, the degree of fibrosis that indicates 
the amount of extracellular matrix materials including collagen that may be closely 
associated with the function of hepatocytes and portal hypertension may vary among 
patients with cirrhosis. Foucher reported in 2006 that liver stiffness (kPa) measured by TE in 
cirrhotic patients correlates well with clinical parameters indicating the severity of cirrhosis; 
27.5 kPa was the cutoff value for the presence of esophageal varices stage 2 or 3, 37.5 kPa for 
liver function Child B or C, 49.1 kPa for a past history of ascites, and 62.7 kPa for bleeding 
from esophageal varices. Masuzaki prospectively observed that, in 866 patients with chronic 
hepatitis C, HCC developed in 77 cases within 3 years of observation, and 0.4% of HCC was 
The Current Status of  
Non-Invasive Assessment of Liver Fibrosis: Real Time Tissue Elastography 
 
249 
detected in patients whose liver stiffness at entry was less than 10 kPa and 38.5% of it was 
more than 25 kPa, indicating the usefulness of liver stiffness measurement as a tool for 
predicting the development of HCC. Because RTE is expected to stage cirrhosis in greater 
detail with clinical relevance, it may be useful for detecting and assessing the risk of 
cirrhotic complications and the development of HCC. 
Although noninvasive assessment of liver fibrosis is already established in patients with 
chronic hepatitis C, it is still necessary to improve assessment in other highly prevalent 
diseases, such as non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). We 
reported that the AUC of AAR, age-platelet index, APRI, and cirrhosis discriminant score 
for predicting cirrhosis were 0.81, 0.87, 0.79, and 0.95, respectively, in 50 patients with 
NASH and 0.56, 0.65, 0.76, and 0.78, respectively, in 100 patients with chronic hepatitis C 
[Fujii H 2009]. RTE will be expected to play a major role in elastography for these patients, 
since it is not influenced by obesity or BMI.  
5. Conclusion  
We have described a convenient and noninvasive procedure, RTE, for the visual assessment 
of liver stiffness. The performance of RTE compared favorably to TE for detecting the degree 
of liver fibrosis in patients with chronic hepatitis C. We suggest that RTE could also be used 
as a routine imaging method to evaluate the degree of liver fibrosis in patients with liver 
diseases other than chronic hepatitis C. Future studies on larger patient cohorts will be 
necessary for the validation of RTE analysis, and the combination of RTE parameters with 
other clinical values including serum biomarkers will enable improvement of accuracy in 
assessing hepatic fibrosis. 
6. Acknowledgment 
We thank Ms. Akiko Tonomura and Mr. Junji Warabino, Hitachi Medical Co., for the 
technical support for RTE. Hiroyasu Morikawa was supported by a research grant from 
Osaka City University (2009). Norifumi Kawada was supported by Research on Hepatitis, 
Health and Labour Science Research Grants from the Ministry of Health, Labour and 
Welfare of Japan (2008–2009) and by a Thrust Area Research Grant from Osaka City 
University.(2008–2009). 
7. References 
Afdhal NH and Curry M (2007) Technology evaluation: a critical step in the clinical 
utilization of novel diagnostic tests for liver fibrosis. J Hepatol 46: 543–54 
Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M. (2005) Prospective 
comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the 
assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50. 
Forns X, Ampurdane`s S, Llovet JM, Aponte J,  Quinto´ L, Marti´nez-Bauer E, et al. 
Identification of chronic hepatitis C patients without hepatic  fibrosis by a simple 
predictive model. Hepatology. 2002;36:986–92. 
Foucher J, Chanteloup E, Vergniol J, Caste´ra L, Le Bail B, Adhoute X. (2006) Diagnosis of 
cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403–8 
 
Liver Biopsy 
 
250 
Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. (2007) 
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral 
hepatitis. AJR Am J Roentgenol. 2007;188:758-64. 
Friedrich-Rust M, Schwarz A, Ong M, Dries V, Schirmacher P, Herrmann E, Samaras P, 
Bojunga J, Bohle RM, Zeuzem S, Sarrazin C. (2009) Real-time tissue elastography 
versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver 
disease. Ultraschall Med. 2009 ;30 :478-84. 
Fujii H, Enomoto M, Fukushima W, Ohfuji S, Mori M, Kobayashi S, Iwai S, Morikawa H, 
Tamori A, Sakaguchi H, Ikura Y, Ueda M, Kawada N. (2009) Noninvasive 
laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis 
C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol. 
2009;44 :608-14 
Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty 
liver disease: Validating the European Liver Fibrosis Panel and exploring simple 
markers. Hepatology. 2008;47:455-460. 
Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E. (2008) Magnetic resonance 
elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 
2008;135:32–40 
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, et al. 
Biochemical markers of liver brosis in patients with hepatitis C virus infection: a 
prospective study. Lancet.2001;357:1069–75. 
Kanamoto M, Shimada M, Ikegami T, Uchiyama H, Imura S, Morine Y, Kanemura H, 
Arakawa Y, Nii A. (2009) Real time elastography for noninvasive diagnosis of liver 
fibrosis. J Hepatobiliary Pancreat Surg. 2009;16(4):463-7. 
Koizumi Y, Hirooka M, Kisaka Y, Konishi I, Abe M, Murakami H, Matsuura B, Hiasa Y, Onji 
M. (2011) Liver fibr osis in patients with chronic hepatitis C: noninvasive diagnosis 
by means of real-time tissue elastography--establishment of the method for 
measurement. Radiology. 2011 ;258 :610-7. 
Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, 
Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. (2009) Prospective risk assessment 
for hepatocellular carcinoma development in patients with chronic hepatitis C by 
transient elastography. Hepatology. 2009 ;49 :1954-61. 
Morikawa H, Fukuda K, Kobayashi S, Fujii H, Iwai S, Enomoto M, Tamori A, Sakaguchi H, 
Kawada N. (2010) Real-time tissue elastography as a tool for the noninvasive 
assessment of liver stiffness in patients with chronic  hepatitis C. J Gastroenterol. 
2010 Aug 10. [Epub ahead of print] 
Ophir J, Céspedes I, Ponnekanti H, Yazdi Y, Li X. (1991) Elastography: a quantitative method 
for imaging the elasticity of biological tissues. Ultrason Imaging. 1991;13:111-34. 
Shiina T, Nitta N, Ueno E, Bamber JC. (2002) Real time tissue elasticity imaging using the 
combined autocorrelation method. J Med Ultrason 2002;29:119–128. 
Wai CT, Greenson JK, Fontana RJ, Kalbeisch JD, Marrero JA, Conjeevaram HS, et al. A 
simple noninvasive index can predict both signicant brosis and cirrhosis in 
patients with chronic hepatitis C. Hepatology. 2003;38:518–26. 
Wang J, Guo L, Shi X, Pan W, Bai Y, Ai H. (2011) Real-time elastography with a novel 
quantitative technology for assessment of liver fibrosis in chronic hepatitis B. Eur J 
Radiol. 2011 Jan 6. [Epub ahead of print] 
Yeh WC, Li PC, Jeng YM, Hsu HC, Kuo PL, Li ML. (2002) Elastic modulus measurements of 
human liver and correlation with pathology. Ultrasound Med Biol. 2002; 28 : 467–74. 
16 
Noninvasive Alternatives for the  
Assessment of Liver Fibrosis 
Lungen Lu and Kun Zhou 
Department of Gastroenterology, Shanghai First People’s Hospital,  
Shanghai Jiaotong University School of Medicine 
China 
1. Introduction 
Chronic liver diseases (CLD) are common and may lead to fibrosis, cirrhosis, and hepatic 
malignancy. Detection and staging of liver fibrosis is crucial for management of patients 
with CLD. At present, liver biopsy is the standard method for staging fibrosis, but biopsies 
are poorly tolerated because they are invasive and associated with some discomfort and 
complications. In addition, limitations of biopsy include intra- and inter-observer variation 
and sampling error1,2. In recent years, a great interest and many studies have been dedicated 
to the development of noninvasive tests to substitute liver biopsy for fibrosis assessment 
and follow-up. Unfortunately, all of them have limitations and pitfalls. To discuss their 
advantages and deficiencies will be helpful in scientific research and clinical practice. 
2. Invasive measurements 
2.1 Liver biopsy 
Liver biopsy has been considered as the gold standard to confirm the clinical diagnosis, to 
assess the severity of necro-inflammation and fibrosis, to identify cofactors and 
comorbidities, and to monitor the efficacy of treatments since the first liver biopsy was 
performed by Paul Ehrlich in 1883 3. The procedure is particularly useful for diagnosing the 
earlier stages of fibrosis and identifying patients at high risk of progressing fibrosis, but it 
has also a number of limitations. The patient acceptance is pretty low because biopsy is 
expensive, invasive and associated with some discomfort and complications. Pain appears 
in about one fourth of patients, other complications including bleeding, biliary peritonitis, 
pneumothorax and a mortality rate about 0.01% 4. Sampling error of at least 24% is reported 
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1. Introduction 
Chronic liver diseases (CLD) are common and may lead to fibrosis, cirrhosis, and hepatic 
malignancy. Detection and staging of liver fibrosis is crucial for management of patients 
with CLD. At present, liver biopsy is the standard method for staging fibrosis, but biopsies 
are poorly tolerated because they are invasive and associated with some discomfort and 
complications. In addition, limitations of biopsy include intra- and inter-observer variation 
and sampling error1,2. In recent years, a great interest and many studies have been dedicated 
to the development of noninvasive tests to substitute liver biopsy for fibrosis assessment 
and follow-up. Unfortunately, all of them have limitations and pitfalls. To discuss their 
advantages and deficiencies will be helpful in scientific research and clinical practice. 
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assess the severity of necro-inflammation and fibrosis, to identify cofactors and 
comorbidities, and to monitor the efficacy of treatments since the first liver biopsy was 
performed by Paul Ehrlich in 1883 3. The procedure is particularly useful for diagnosing the 
earlier stages of fibrosis and identifying patients at high risk of progressing fibrosis, but it 
has also a number of limitations. The patient acceptance is pretty low because biopsy is 
expensive, invasive and associated with some discomfort and complications. Pain appears 
in about one fourth of patients, other complications including bleeding, biliary peritonitis, 
pneumothorax and a mortality rate about 0.01% 4. Sampling error of at least 24% is reported 
usually because of specimen fragmentation or inadequate length. Colloredo et al concluded 
that an optimum specimen should be at least 20 mm in length with 11 complete portal 
tracts1. Even with adequate-sized biopsies, the interpretation might be unreliable, because 
the distribution of necro-inflammation and fibrosis is not homogeneous, and liver biopsy 
samples only 1:50 000th of the mass of the liver.  
Several semi-quantitative scoring systems have been proposed to describe and quantify the 
necro-inflammation, steatosis and fibrosis in the liver, particularly for chronic viral hepatitis. 
These include the Knodell histological activity index (HAI) first proposed in 1981, then 
modified to the Scheuer system, the METAVIR system and the Ishak modified HAI 5. 
However, all the scoring systems could only provide qualitative descriptors to stage fibrosis, 
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and the staging of certain histopathological changes differ in different systems (Table 1). 
This could cause considerable intra- and inter-observer variation and difficulty in 
comparison 2.  
 
Pathologic Features Knodell Scheuer  METAVIR  Ishak 
No fibrosis 0 0 0 0 
Enlargement of some portal tracts 1 1 1 1 
Enlargement of most portal tracts 1 1 1 2 
Periportal septa  1 2 1 2 
Occasional portal-portal septa 3 2 2 3 
Numerous septa (portal-portal and/or portal-central) 3 3 3 4 
Occasional nodules 4 4 4 5 
Definite cirrhosis 4 4 4 6 
Table 1. Scoring systems for staging fibrosis 
Using computerized digital image analysis, the amount of fibrosis in liver biopsy specimens 
can be evaluated by a quantitative score 6-9. Though it is thought to be less reliable in 
determining early stage fibrosis, recent advances such as a higher resolution digital camera 
can improve discrimination between the varying stages of liver fibrosis, including mild 
fibrosis 8. It may be a more precise method than semi-quantitative histological stages for 
monitoring fibrosis progression or regression during clinical therapeutic trials 9. 
Considering the irregular shape of specimens, fractal and spectral dimension analysis can 
also be used to improve accuracy 10.  
The detection of genes correlated with fibrosis from biopsy samples regains interest for liver 
biopsy. The changes in liver gene expression can indicate fibrosis progression precisely at an 
early stage 11. Genetic studies have identified possible genetic polymorphisms that influence 
the progression of liver fibrosis 12. The identification of panels of key genes correlating with 
differences in the progression of CLDs could lead to establishing excellent 
prognostic/diagnostic tools. 
2.2 Hepatic venous pressure gradient 
Hepatic venous pressure gradient (HVPG), as an expression of intrahepatic resistance, does 
not exceed 5 mmHg in absence of significant fibrotic evolution. The measurement of HVPG 
is a validated, safe and highly reproducible technique. It may be considered as a dynamic 
marker of disease progression in patients with HCV and an end point in antiviral therapy, 
irrespective of antiviral response 13. However, the technique is invasive, expensive, requires 
technical expertise, and has low patient acceptance. 
3. Serological tests 
The limitations of liver biopsy led to the searching of noninvasive tests for assessment of 
liver fibrosis. Afdhal and Nunes et al 14 suggest the following criteria for an ideal marker of 
liver fibrosis: it should be liver specific; should not be influenced by alterations in liver, 
renal, or reticuloendothelial function; should measure one or more of the processes related 
to fibrosis (stage of fibrosis, activity of matrix deposition, or activity of matrix removal); and 
should be easy to perform. 
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3.1 Direct serum markers 
The key step in the pathophysiology of liver fibrosis is the balance between ECM 
deposition and removal. Accumulation of ECM results from both increased synthesis and 
decreased degradation. The principal ECM constituents are synthesized by activated 
HSCs, while broken down by a family of enzymes known as matrix metalloproteinases 
(MMPs). Many studies have been dedicated to find serum ECM markers for fibrosis 
assessment. 
Hyaluronic acid (HA), a glycosaminoglycan distributed in the connective tissue, is a 
component of the liver extracellular matrix, which is synthesized and degraded in the liver 
sinusoidal cells. The high levels of HA observed in patients with chronic liver disease, have 
been related with a decreased function of the endothelial sinusoidal cells. Many studies 
showing a close relationship between liver fibrosis and HA levels.  
These similar markers of fibrosis incuding: ⑴ collagens: N-terminal peptide of type Ⅲ pro-
collagen (PⅢNP), type Ⅳ collagen 7s domain(Ⅳ-7S) 15, ⑵ proteoglycans: hyaluronic acid 
(HA) 16, ⑶ glycoproteins: laminin (LN) 17, human cartilage glycoprotein 39 (YKL-40) 18, ⑷ 
collagenases and their inhibitors: MMPs, tissue inhibitor of metalloproteinases (TIMPs) 19, ⑸ 
cytokines: transforming growth factor β1 (TGF-β1), platelet-derived growth factor (PDGF), 
tumor necrosis factor β (TNF-β).  
The clinical applications of such markers appear innovative, they are useful to assess the 
speed of liver fibrogenesis and estimate the response to anti-viral therapies or anti-fibrotic 
drugs. But most of them are insensitive in milder fibrosis, and it must be stressed that these 
markers reflect fibrogenesis and fibrolysis more than fibrosis itself. In other words, there 
may be a highly active fibrotic process in the liver, although fibrotic tissue has not yet been 
developed, or there may be heavy fibrosis in the liver but fibrotic activity is temporarily 
discontinued.  
3.2 Serum marker panels 
Since present direct markers could not satisfy the clinical need of measuring the fibrosis yet, 
an alternative approach turns out to be combining a number of serum markers to generate 
algorithms capable of evaluating fibrosis. A large number of panels have been suggested by 
groups worldwide 20-49 (Table 2).  
These panels are mainly based on two kinds of markers, direct and indirect. Direct markers 
are those directly linked to the modifications in ECM metabolism, such as HA and PⅢNP. 
Indirect markers include a broad range of blood tests which have no direct link with liver 
fibrosis. They reflect liver dysfunction or other phenomena caused by fibrosis rather than 
fibrosis per se. Generally speaking, indexes including direct markers, such as the 
Fibrometer, may perform a higher accuracy, but indexes composed by only indirect markers 
are effective as well, and usually more useful because they are based on routine blood tests 
easy to be performed in a hospital general laboratory. 
The diagnostic value of the models was assessed by calculating the area under the receiver 
operating characteristic curves (AUROC). Most studies reported an AUROC >0.80 in 
differentiating significant fibrosis (fibrosis spread out the portal tract with septa) from 
no/mild fibrosis (no fibrosis or portal fibrosis without septa), improved performance with a 
higher AUROC value was showed in differentiating between no cirrhosis and cirrhosis. But 
it must be underlined that the AUROC values in table 2 came from each different designed 
study and are not suitable to make a comparison.  
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Index, Author, year, reference Patients no. CLDs markers in panel AUROC(T-V) a  
AAR, Williams, 1988 20 177 Mixed AST/ALT-ratio (AAR) n/a 
PGA index, Poynard , 1991 21 624 Alcohol  PT, GGT, apoA1 n/a 
PGAA index, Naveau , 199422 525 Alcohol  PT, GGT, apoA1, A2M n/a 
CDS index, Bonacini, 1997 23 75 HCV PLT, AAR, PT n/a 
AP index, Poynard 1997 24 620 HCV Age, PLT 0.763-0.690 
BAAT score, Ratziu 2000 25 93 NAFLD Age, BMI, ALT, TG 0.84 
Fortunato, 2001 26 103 HCV Fibronectin, prothrombin, ALT, PCHE, Mn-SOD, β-NAG n/a 
Pohl, 2001 27 211 HCV AAR, PLT n/a 
FibroTest, Imbert-Bismut, 2001 28 339 HCV A2M, Hpt, GGT,  ApoA1, bilirubin 0.836-0.870 
Kaul 2002 29 264 HCV PLT, AST, sex, spider naevi n/a 
Forns index, Forns, 2002 30 476 HCV  Age, GGT, cholesterol, PLT 0.86-0.81 
APRI, Wai, 2003 31 270 HCV AST, PLT  0.80-0.88 
ELF-score, Rosenberg, 200432 1021 Mixed Age, HA, PⅢNP, TIMP-1 0.804 
FIBROSpect II, Patel, 2004 33 696 HCV HA, TIMP-1, A2M 0.831-0.823 
FPI, Sud, 2004 34 302 HCV Age, AST, TC, HOMA-IR, past alcohol intake 0.84-0.77 
MP3, Leroy, 2004 35 194 HCV PⅢNP, MMP-1 0.82 
HALT-C, Lok, 2005 36 1141 HCV PLT, AAR, INR 0.78-0.81d 
Hepascore, Adams, 2005 37 221 HCV Bilirubin, GGT, HA, A2M, age, sex 0.85-0.82 
Fibrometer, Cales, 2005 38 383 Mixed PLT, PI, AST, A2M, HA, urea, age 0.883-0.892 
SHASTA index, Kelleher, 2005 39 95 HCV/HIV HA,AST and albumin 0.878 
Sakugawa, 2005 40 112 NAFLD Ⅳ-7S, HA n/a 
Hui,2005 41 235 HBV BMI, PLT, albumin, TB, ALP 0.803-0.765 
SLFG, Zeng, 2005 42 372 HBV A2M, age, GGT, HA 0.84-0.77 
FIB-4, Sterling, 2006 43 832 HCV/HIV Age, AST, ALT, PLT 0.765b 
Virahep-C, Fontana, 2006 44 399 HCV age, AST, ALP,PLT 0.837-0.851 
Mohamadnejad, 2006 45 276 HBV HBV DNA levels, ALP, albumin, PLT, 0.91-0.85 
FibroIndex, Koda, 2007 46 402 HCV PLT, AST, γ- globulin 0.828-0.835 
Alsatie, 2007 47 286 HCV diabetes mellitus, PLT, AST, INR, bilirubin 0.79-0.75
c 
Esmat, 2007 48 220 HCV HA, age 0.84b 
NAFLD fibrosis score, Angulo, 
2007 49 733 NAFLD 
Age, BMI, PLT, albumin, AAR, 
hyperglycemia 0.88-0.82 
a The area under the receiver operating characteristic curves (AUROC) for the diagnosis of significant 
fibrosis (stage 2-4 by the METAVIR or Scheuer classification, 3-6 by the Ishak score). T-V means the 
AUROC values of training group and validation group.  
b Differentiation advanced fibrosis (Ishak 4-6) from mild to moderate fibrosis (Ishak 0-3).  
c Differentiation advanced hepatic fibrosis (defined as F3-F4 by METAVIR) from milder (F0-F2).  
d Differentiation cirrhosis from no cirrhosis. 
Abbreviations used: CLD, Chronic liver disease; ROC, receiver operating characteristic; AUROC, area 
under the ROC curve; AAR, AST/ALT-ratio; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; PT, prothrombin time; GGT, γ-glutamyltransferase; apoA1, apolipoprotein A1; A2M, 
α2-macroglobulin; PLT, platelet count; TG, triglycerides; PCHE, pseudocholinesterase; Mn-SOD, 
manganese superoxide dismutase; β-NAG, N-acetyl β-glucosaminidase; Hpt, haptoglobin; HA, 
hyaluronic acid; PⅢNP, N-terminal peptide of type Ⅲ pro-collagen; TIMP-1, tissue inhibitor of 
metalloproteinase 1; TC, total cholesterol; HOMA-IR, Homeostasis Model Assessment insulin 
resistance(fast glucose×plasma gluc/22.5); MMP-1, metalloproteinase 1; INR, international normalized 
ratio; PI, Prothrombin index; Ⅳ-7S, type Ⅳ collagen 7s domain; BMI, body mass index; TB, total 
bilirubin; ALP, alkaline phosphatase.  
Table 2. Studies of serum markers panels for assessment of liver fibrosis 
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Chronic hepatitis B (CHB) is the most frequent infectious cause of CLD worldwide. More 
than 400 million people are chronically infected with HBV. The virus is responsible for more 
than 300,000 cases of liver cancer every year and for similar numbers of gastrointestinal 
haemorrhage and ascites 50. Predictive models designed specially for CHB patients have 
been proposed by the Shanghai Liver Fibrosis Group (SLFG) 42, Hui et al 41 and 
Mohamadnejad et al 45. But few of these models mentioned above has been widely validated 
and implemented in clinical practice. In our study of the S index 51, a simpler noninvasive 
model  based on routine laboratory markers,  we compare its diagnostic value with that of 
some typical models (Fig. 1), We noticed that the SLFG model and Hepascore performed 
better in identifying significant fibrosis than the Forns score and APRI, but the superiority 
was not so significant in identifying advanced fibrosis or cirrhosis. The result was similar to 
a validation study in CHC patients 52, indicating that such special tests might improve the 
sensitivity of a diagnostic model in predicting early fibrosis. But including tests unavailable 
in daily practice makes standardization, validation and routine bedside use difficult.  
 
Fig. 1. ROC curves in the prediction of significant fibrosis  
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bilirubin; ALP, alkaline phosphatase.  
Table 2. Studies of serum markers panels for assessment of liver fibrosis 
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Chronic hepatitis B (CHB) is the most frequent infectious cause of CLD worldwide. More 
than 400 million people are chronically infected with HBV. The virus is responsible for more 
than 300,000 cases of liver cancer every year and for similar numbers of gastrointestinal 
haemorrhage and ascites 50. Predictive models designed specially for CHB patients have 
been proposed by the Shanghai Liver Fibrosis Group (SLFG) 42, Hui et al 41 and 
Mohamadnejad et al 45. But few of these models mentioned above has been widely validated 
and implemented in clinical practice. In our study of the S index 51, a simpler noninvasive 
model  based on routine laboratory markers,  we compare its diagnostic value with that of 
some typical models (Fig. 1), We noticed that the SLFG model and Hepascore performed 
better in identifying significant fibrosis than the Forns score and APRI, but the superiority 
was not so significant in identifying advanced fibrosis or cirrhosis. The result was similar to 
a validation study in CHC patients 52, indicating that such special tests might improve the 
sensitivity of a diagnostic model in predicting early fibrosis. But including tests unavailable 
in daily practice makes standardization, validation and routine bedside use difficult.  
 
Fig. 1. ROC curves in the prediction of significant fibrosis  
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There are still some limitations of these marker panels to be considered. First, the design of 
every study differed in population characteristic, patient selection, significant fibrosis 
prevalence, blood test inclusion, biochemical measurement and liver histological 
assessment, resulted in various panels with different markers and parameters. The 
agreement among these indexes is poor and validation study is needed to choose a proper 
panel and cutoff value for clinical use. Second, none of the studies controlled for degree of 
necro-inflammatory activity, most of the panels include markers likely to reflect or be 
affected by inflammation in the liver, which is much more mobile than fibrosis stage. Third, 
the formulae are easy to fail because many markers included will be influenced by 
extrahepatic diseases or conditions such as inflammation, haemolysis, cholestasis, 
hypercholesterolaemia and renal failure. Finally, few of the studies include treated patients. 
It is not clear whether these indexes are suitable for assessing treatment response. However, 
a few studies by Poynard et al suggested that Fibrotest could also be used as surrogate 
markers of the histological impact of treatments in patients infected by HCV and HBV 53, 54. 
These indexes, in their current form, are not able to give us the exact stage of fibrosis in most 
studies. Their main value is to reduce the need for liver biopsy by distinguishing significant 
fibrosis from no/mild fibrosis, and telling the presence of cirrhosis. It does not seem 
appropriate to completely replace liver biopsy with serum marker panels at the present time, 
but it can be anticipated that these indexes will become very useful in the clinical management 
of CLDs by offering an attractive alternative to liver biopsy, as they are noninvasive, 
convenient, inexpensive, and may allow dynamic assessment of fibrosis. Validation in larger 
cohorts of patients with different CLDs is needed before an index will be proposed for 
extensive clinical use. 
3.3 Proteomics and glycomics 
Over the last 5-6 years, it was reported that the use of proteomic patterns in serum to 
distinguish individual stages of fibrosis could achieve perfect diagnostic sensitivity and 
specificity. Using a proteome-based fingerprinting model generated by surface-enhanced laser 
desorption/ ionization time-of-flight (SELDI-TOF) ProteinChip arrays,  Poon et al 55 achieved 
an AUROC of 0.93 in identifying significant fibrosis. Another proteomic index combining eight 
peaks established by Morra et al 56 could diagnosis advanced fibrosis with an AUROC of 0.88, 
significantly greater than the FibroTest AUROC of 0.81. Besides, The SELDI-TOF ProteinChip 
technology is useful for the early detection and prediction of HCC in patients with chronic 
HCV infection 57. Similar technologies were also used to generate profiles of serum N-glycan 
profile for identifying liver fibrosis 58, 59. Further studies identifying the altered peaks in these 
models to understand their origins may help to find new biomarks for fibrosis, or even 
improve our understanding in the mechanism of liver fibrosis.  
4. Radiological tests 
Since significant structural changes are present only in advanced CLDs, the routine 
examinations by Ultrasound (US), computed tomography (CT) and magnetic resonance 
imaging (MRI) could bring specific findings, but with very limited sensitivity. Thus, 
persistent efforts were made to search for technological developments.  
4.1 Perfusion examinations 
MR and Doppler US techniques are studied to find sensitive perfusion changes in the 
progression of fibrosis 60. For example, the circulatory changes will result in a decrease of 
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hepatic vein transit time (HVTT), which can be measured by microbubble-enhanced US 61. 
Using HVTT measurements, Lim et al achieved 100% sensitivity and 80% specificity for 
diagnosis of cirrhosis, and 95% sensitivity and 86% specificity for differentiation of mild 
hepatitis from more severe liver disease 62. Progressive liver fibrosis gradually obliterates 
normal intrahepatic vessels and sinusoids and slows passage of blood through the 
parenchyma. In addition, as portal hypertension develops, portal venous flow to the liver 
decreases, hepatic arterial flow increases, and intrahepatic shunts form. These physiologic 
alterations can be detected with kinetic models of dynamic image data sets acquired rapidly 
after bolus intravenous injection of paramagnetic extracellular contrast agents. Several 
perfusion parameters can be estimated by MR perfusion imaging, a recent study applied a 
dual-input kinetic model for the noninvasive assessment of liver fibrosis. The dual-input 
approach models two sources of blood flow into the liver, via the he patic artery and portal 
vein, and assumes a single tissue compartment. Significant differences were found in several 
perfusion parameters between patients with and without advanced fibrosis 63. 
4.2 Liver stiffness measurement 
In chronic liver disease, progressive deposition of interconnecting collagen fibers 
throughout the liver produces a lattice-like framework that increases parenchymal rigidity. 
Because liver stiffness cannot be reliably assessed with external physical palpation, an 
imaging approach is required. There are two main imaging methods for measuring hepatic 
stiffness. One is US-based transient elastography; the other is MR elastography. 
The FibroScan, a new medical device based on one-dimensional transient elastography 64, 
which assesses fibrosis through liver stiffness measurement (LSM). A special probe 
generates an elastic shear wave propagating through the liver tissue, the harder the tissue, 
the faster the shear wave propagates. Transient elastography could accurately predict 
different stages of fibrosis or cirrhosis (AUROC: 0.79 for F ≥ 2, 0.91 for F ≥ 3, and 0.97 for F = 
4. by the METAVIR scoring system) 65.  
The major advantage of transient elastography compared with serum markers and marker 
panels is that it measures directly on the liver and there is no interference from extrahepatic 
diseases or conditions. Further more, the test is standardized and completely noninvasive. 
Though assessing earlier fibrosis is the common shortcoming of various noninvasive tests, 
Colletta et al reported that the agreement between transient elastography and liver biopsy was 
much better than FibroTest in normal transaminases HCV carriers with early stages of fibrosis66. 
Compared to liver biopsy, transient elastography is painless, rapid, has no risk of 
complications, and is therefore very well accepted. Transient elastography measures liver 
stiffness of a volume which is 100 times bigger than the biopsy specimen. The high 
reproducibility (intra- and inter-observer agreement intraclass correlation coefficient was 
0.98 67) and acceptance of transient elastography makes it an attractive alternative to biopsy 
for individual follow-up.  
There are also some physical limitations of transient elastography. The signal penetrates 
only 25–65 mm, makes obesity (particularly the fatness of the chest wall) the most important 
cause of failure68. But new technological developments may overcome the limitation. 
Additional limitations include a narrow intercostal space and ascites. The main reason that 
transient elastography can not totally replace liver biopsy is that it is only a means to stage 
disease. It is unable to diagnose liver disease by distinguishing subtle diagnostic differences. 
Nor can transient elastography identify cofactors and comorbidities or grade necro-
inflammation and steatosis. But it represents a totally different approach to assess fibrosis 
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There are still some limitations of these marker panels to be considered. First, the design of 
every study differed in population characteristic, patient selection, significant fibrosis 
prevalence, blood test inclusion, biochemical measurement and liver histological 
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technology is useful for the early detection and prediction of HCC in patients with chronic 
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profile for identifying liver fibrosis 58, 59. Further studies identifying the altered peaks in these 
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Since significant structural changes are present only in advanced CLDs, the routine 
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imaging (MRI) could bring specific findings, but with very limited sensitivity. Thus, 
persistent efforts were made to search for technological developments.  
4.1 Perfusion examinations 
MR and Doppler US techniques are studied to find sensitive perfusion changes in the 
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hepatic vein transit time (HVTT), which can be measured by microbubble-enhanced US 61. 
Using HVTT measurements, Lim et al achieved 100% sensitivity and 80% specificity for 
diagnosis of cirrhosis, and 95% sensitivity and 86% specificity for differentiation of mild 
hepatitis from more severe liver disease 62. Progressive liver fibrosis gradually obliterates 
normal intrahepatic vessels and sinusoids and slows passage of blood through the 
parenchyma. In addition, as portal hypertension develops, portal venous flow to the liver 
decreases, hepatic arterial flow increases, and intrahepatic shunts form. These physiologic 
alterations can be detected with kinetic models of dynamic image data sets acquired rapidly 
after bolus intravenous injection of paramagnetic extracellular contrast agents. Several 
perfusion parameters can be estimated by MR perfusion imaging, a recent study applied a 
dual-input kinetic model for the noninvasive assessment of liver fibrosis. The dual-input 
approach models two sources of blood flow into the liver, via the he patic artery and portal 
vein, and assumes a single tissue compartment. Significant differences were found in several 
perfusion parameters between patients with and without advanced fibrosis 63. 
4.2 Liver stiffness measurement 
In chronic liver disease, progressive deposition of interconnecting collagen fibers 
throughout the liver produces a lattice-like framework that increases parenchymal rigidity. 
Because liver stiffness cannot be reliably assessed with external physical palpation, an 
imaging approach is required. There are two main imaging methods for measuring hepatic 
stiffness. One is US-based transient elastography; the other is MR elastography. 
The FibroScan, a new medical device based on one-dimensional transient elastography 64, 
which assesses fibrosis through liver stiffness measurement (LSM). A special probe 
generates an elastic shear wave propagating through the liver tissue, the harder the tissue, 
the faster the shear wave propagates. Transient elastography could accurately predict 
different stages of fibrosis or cirrhosis (AUROC: 0.79 for F ≥ 2, 0.91 for F ≥ 3, and 0.97 for F = 
4. by the METAVIR scoring system) 65.  
The major advantage of transient elastography compared with serum markers and marker 
panels is that it measures directly on the liver and there is no interference from extrahepatic 
diseases or conditions. Further more, the test is standardized and completely noninvasive. 
Though assessing earlier fibrosis is the common shortcoming of various noninvasive tests, 
Colletta et al reported that the agreement between transient elastography and liver biopsy was 
much better than FibroTest in normal transaminases HCV carriers with early stages of fibrosis66. 
Compared to liver biopsy, transient elastography is painless, rapid, has no risk of 
complications, and is therefore very well accepted. Transient elastography measures liver 
stiffness of a volume which is 100 times bigger than the biopsy specimen. The high 
reproducibility (intra- and inter-observer agreement intraclass correlation coefficient was 
0.98 67) and acceptance of transient elastography makes it an attractive alternative to biopsy 
for individual follow-up.  
There are also some physical limitations of transient elastography. The signal penetrates 
only 25–65 mm, makes obesity (particularly the fatness of the chest wall) the most important 
cause of failure68. But new technological developments may overcome the limitation. 
Additional limitations include a narrow intercostal space and ascites. The main reason that 
transient elastography can not totally replace liver biopsy is that it is only a means to stage 
disease. It is unable to diagnose liver disease by distinguishing subtle diagnostic differences. 
Nor can transient elastography identify cofactors and comorbidities or grade necro-
inflammation and steatosis. But it represents a totally different approach to assess fibrosis 
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and therefore could be combined with other noninvasive modalities to better assess liver 
fibrosis. The combined use of transient elastography and FibroTest to evaluate liver fibrosis 
could avoid a biopsy procedure in most patients with chronic hepatitis C 69.  
Magnetic resonance elastography (MRE) is a technique using a modified phase-contrast 
magnetic resonance imaging sequence to image propagating shear waves in tissue 70. The 
technique has been previously applied to quantitatively assess the viscoelastic properties of 
the breast, brain, and muscle in humans. Several recent studies showed that MRE is also a 
feasible method to assess the stage of liver fibrosis. Liver stiffness as measured with MR 
elastography increases as the stage of fibrosis advances. The differences in stiffness between 
patients with early stages of fibrosis (F0 vs F1 vs F2) are small and there is overlap between 
groups, but the differences between groups with higher stages (F2 vs F3 vs F4) are large, 
with little overlap between groups71. MRE has several potential advantages compared with 
ultrasound transient elastography. It can be performed in obesity patients. It can assess 
larger volumes and provide full three-dimensional information about the viscoelastic 
parameters of tissues. With MR techniques, a comprehensive examination of the liver can be 
performed, including MRE, contrast-enhanced MRI to detect hepatocellular carcinomas and 
perfusion MRI to assess liver function.  
4.3 Real-time elastography 
Real-time elastography is another ultrasound technique developed by Hitachi Medical 
Systems that can reveal the physical property of tissue using conventional ultrasound probes 
during a routine sonography examination. In the first study assessing real-time elastography 
for the detection of liver fibrosis 72, the AUROC was 0.75 for the diagnosis of significant 
fibrosis. Much higher diagnostic accuracy (AUROC = 0.93) was obtained by a mathematic 
combination of the elasticity score and two routine laboratory values (platelet count and GGT), 
which provided a more superior way to combine serological and radiological tests together. 
4.4 Double contrast material-enhanced magnetic resonance imaging 
The conspicuity of gadolinium-enhanced lesions is increased in the setting of decreased 
signal intensity from the uninvolved liver parenchyma following superparamagnetic iron 
oxide (SPIO) injection. This MRI technique has been used to improve detection of focal 
hepatic lesion and hepatocellular carcinoma 73, 74. Recently, Aguirre et al 75 examined 101 
CLD patients who underwent double-enhanced MR imaging to detect hyperintense 
reticulations, which are postulated to represent septal fibrosis. They achieved an accuracy of 
greater than 90% for the diagnosis of advanced hepatic fibrosis compared with 
histopathological analysis. Clinical trials are currently under way to prospectively assess 
fibrosis staging with this technique. 
4.5 Diffusion weighted magnetic resonance imaging 
Diffusion weighted magnetic resonance imaging (DWMRI) has been widely used in brain 
imaging for the evaluation of acute ischemic stroke. With the advent of the echo-planar MRI 
technique, it became possible to be applied in the abdomen for characterization of focal 
hepatic lesions 76. Recently, using DWMRI to measure the apparent diffusion coefficient 
(ADC) of water, a parameter that is dependent on the tissue structure, is introduced in the 
assessment of liver fibrosis 77. The ADC value is lower in livers with heavier fibrosis because 
of the restriction of water diffusion in fibrotic tissue. Lewin et al assessed the performance of 
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DWMRI in 54 patients with chronic HCV infection with reference to several other 
noninvasive methods 78. In discriminating significant fibrosis patients, the AUC values were 
0.79 for DWMRI, 0.87 for transient elastography, 0.68 for FibroTest, 0.81 for APRI, 0.72 for 
the Forns index, and 0.77 for hyaluronate. DWMRI performed better in discriminating 
patients staged F3-F4, the AUC value increased to 0.92, the same as transient elastography. 
But besides fibrosis, it seems that ADC values might also reflect the intensity of 
inflammation, necrosis and steatosis. Because technical factors lead to differences in 
estimated ADC, reported ADCs are variable, with considerable overlap between normal and 
abnormal ranges. Thus, there is a need to develop site- and technique-specific normal ranges 
and to standardize methods across imaging centers.   
Several other MR techniques have also been introduced in the area of fibrosis assessment, 
such as ultrashort echo time (UTE) MRI 79 and magnetic resonance spectroscopy (MRS) 80. 
New MR imaging contrast agents that specifically target collagen or other extracellular 
matrix macromolecules may be developed. A collagen-specific MR imaging contrast agent 
could act as a fibrosis-imaging agent, and these agents may have higher efficacy for fibrosis 
assessment than the current methods 81. All such data may provide valuable information for 
guiding antifibrotic therapy development and monitoring patients in clinical trials. 
5. Conclusion 
The increasing of potentially effective managements for CLDs such as antiviral and antifibrotic 
therapies has led to an urgent need for a rapid, safe and repeatable tool to assess fibrosis of 
CLDs and to follow-up progression or regression of fibrosis during treatment. Liver biopsy 
has been the gold standard for the assessment of hepatic fibrosis, but the invasive procedure 
has considerable limitations and fails to satisfy the current needs. Many noninvasive methods 
have been proposed with the aim of substituting liver biopsy. The numerous advances in 
serological, radiological techniques and their combinations have allowed to satisfactorily 
identify patients without a liver biopsy. But each of them has some deficiencies and the liver 
biopsy will still have an important role to play. Applying new techniques for the detection of 
fibrosis may potentially circumvent the pitfalls and deficiencies of the existing surrogates 
mentioned above. These include serum proteomics, glycomics and new imaging techniques 
such as molecular imaging technique for the imaging of cellular biochemical processes 82, 
diffraction-enhanced imaging technique for the imaging of soft tissues 83, photonic imaging 
technique for three-dimensional whole-body images 84. However, further studies are needed to 
develop or validate noninvasive tests that can accurately reflect the full spectrum of hepatic 
fibrosis in CLDs. But an incorrigible defect in our studies will be the questionable gold 
standard we have to use. More errors are due to the histological staging 85. Mathematical 
modeling suggested that assuming either 80% or 90% diagnostic accuracy of liver biopsy, 
noninvasive tests cannot achieve an AUROC better than 0.9 and are likely to perform between 
0.75 and 0.9 86, exactly where they are today. We may find a better surrogate for liver biopsy, 
but how can we prove it will be a question. Laparoscopic biopsy can decrease sampling error 
and increases the reliability of histopathologic assessment 87. Using automated image analysis 
to assess texture features and shape representation of the fibrosis structural expansion can turn 
the current semiquantitative methods of liver fibrosis assessment into real quantitative ones 
with significant reduction in variability and subjectivity 88. Validating noninvasive tests against 
not only histological stage scores but also digital image analysis and clinical outcomes may 
also be a better choice. 
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and therefore could be combined with other noninvasive modalities to better assess liver 
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with little overlap between groups71. MRE has several potential advantages compared with 
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DWMRI in 54 patients with chronic HCV infection with reference to several other 
noninvasive methods 78. In discriminating significant fibrosis patients, the AUC values were 
0.79 for DWMRI, 0.87 for transient elastography, 0.68 for FibroTest, 0.81 for APRI, 0.72 for 
the Forns index, and 0.77 for hyaluronate. DWMRI performed better in discriminating 
patients staged F3-F4, the AUC value increased to 0.92, the same as transient elastography. 
But besides fibrosis, it seems that ADC values might also reflect the intensity of 
inflammation, necrosis and steatosis. Because technical factors lead to differences in 
estimated ADC, reported ADCs are variable, with considerable overlap between normal and 
abnormal ranges. Thus, there is a need to develop site- and technique-specific normal ranges 
and to standardize methods across imaging centers.   
Several other MR techniques have also been introduced in the area of fibrosis assessment, 
such as ultrashort echo time (UTE) MRI 79 and magnetic resonance spectroscopy (MRS) 80. 
New MR imaging contrast agents that specifically target collagen or other extracellular 
matrix macromolecules may be developed. A collagen-specific MR imaging contrast agent 
could act as a fibrosis-imaging agent, and these agents may have higher efficacy for fibrosis 
assessment than the current methods 81. All such data may provide valuable information for 
guiding antifibrotic therapy development and monitoring patients in clinical trials. 
5. Conclusion 
The increasing of potentially effective managements for CLDs such as antiviral and antifibrotic 
therapies has led to an urgent need for a rapid, safe and repeatable tool to assess fibrosis of 
CLDs and to follow-up progression or regression of fibrosis during treatment. Liver biopsy 
has been the gold standard for the assessment of hepatic fibrosis, but the invasive procedure 
has considerable limitations and fails to satisfy the current needs. Many noninvasive methods 
have been proposed with the aim of substituting liver biopsy. The numerous advances in 
serological, radiological techniques and their combinations have allowed to satisfactorily 
identify patients without a liver biopsy. But each of them has some deficiencies and the liver 
biopsy will still have an important role to play. Applying new techniques for the detection of 
fibrosis may potentially circumvent the pitfalls and deficiencies of the existing surrogates 
mentioned above. These include serum proteomics, glycomics and new imaging techniques 
such as molecular imaging technique for the imaging of cellular biochemical processes 82, 
diffraction-enhanced imaging technique for the imaging of soft tissues 83, photonic imaging 
technique for three-dimensional whole-body images 84. However, further studies are needed to 
develop or validate noninvasive tests that can accurately reflect the full spectrum of hepatic 
fibrosis in CLDs. But an incorrigible defect in our studies will be the questionable gold 
standard we have to use. More errors are due to the histological staging 85. Mathematical 
modeling suggested that assuming either 80% or 90% diagnostic accuracy of liver biopsy, 
noninvasive tests cannot achieve an AUROC better than 0.9 and are likely to perform between 
0.75 and 0.9 86, exactly where they are today. We may find a better surrogate for liver biopsy, 
but how can we prove it will be a question. Laparoscopic biopsy can decrease sampling error 
and increases the reliability of histopathologic assessment 87. Using automated image analysis 
to assess texture features and shape representation of the fibrosis structural expansion can turn 
the current semiquantitative methods of liver fibrosis assessment into real quantitative ones 
with significant reduction in variability and subjectivity 88. Validating noninvasive tests against 
not only histological stage scores but also digital image analysis and clinical outcomes may 
also be a better choice. 
  
Liver Biopsy 
 
260 
6. References 
[1] Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological 
evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J 
Hepatol. 2003; 39: 239-44. 
[2] The French METAVIR Cooperative Study Group. Intraobserver and interobserver 
variations in liver biopsy interpretation in patients with chronic hepatitis C. 
Hepatology. 1994; 20: 15-20. 
[3] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001; 344: 495-500. 
[4] McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage 
after percutaneous liver biopsy. Gastroenterology. 1990; 99: 1396-400. 
[5] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the 
Knodell histology activity index and beyond. Hepatology. 2000; 31: 241-6. 
[6] Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological 
semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver 
biopsy specimens: comparison with morphometric studies. Hepatology. 1994; 20: 349-
55. 
[7] Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: 
quantitative image analysis vs semi-quantitative scores. Comparison with serum 
markers. J Hepatol. 1998; 28: 439-46. 
[8] Lazzarini AL, Levine RA, Ploutz-Snyder RJ, Sanderson SO. Advances in digital 
quantification technique enhance discrimination between mild and advanced liver 
fibrosis in chronic hepatitis C. Liver Int. 2005; 25: 1142-9. 
[9] Goodman ZD, Becker RL, Jr., Pockros PJ, Afdhal NH. Progression of fibrosis in advanced 
chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007; 45: 
886-94. 
[10] Dioguardi N, Franceschini B, Aletti G, Russo C, Grizzi F. Fractal dimension rectified 
meter for quantification of liver fibrosis and other irregular microscopic objects. Anal 
Quant Cytol Histol. 2003; 25: 312-20. 
[11] Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis 
in patients with chronic hepatitis C. Gastroenterology. 2005; 129: 2064-75. 
[12] Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver 
fibrosis: a critical appraisal. Hepatology. 2003; 37: 493-503. 
[13] Burroughs AK, Groszmann R, Bosch J, et al. Assessment of therapeutic benefit of antiviral 
therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? 
Gut. 2002; 50: 425-7. 
[14] Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 
2004; 99: 1160-74. 
[15] Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV 
collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of 
metalloproteinases in patients with chronic viral liver disease: relationship to liver 
histology. Hepatology. 1994; 20: 780-7. 
[16] Pares A, Deulofeu R, Gimenez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in 
alcoholic liver disease and is useful as a marker of fibrosis. Hepatology. 1996; 24: 1399-
403. 
[17] Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as 
markers of liver disease in chronic hepatitis C. J Hepatol. 2000; 32: 325-30. 
 
Noninvasive Alternatives for the Assessment of Liver Fibrosis 
 
261 
[18] Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and 
response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients 
with HCV-associated liver disease. World J Gastroenterol. 2005; 11: 476-81. 
[19] Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and 
tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with 
chronic hepatitis C. Relationship to interferon response. J Hepatol. 1997; 26: 574-83. 
[20] Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in 
chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988; 95: 734-9. 
[21] Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic 
liver disease in drinkers. Gastroenterology. 1991; 100: 1397-402. 
[22] Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and 
hepatic fibrosis. Diagnostic interest. Dig Dis Sci. 1994; 39: 2426-32. 
[23] Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for 
diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus 
infection. Am J Gastroenterol. 1997; 92: 1302-4. 
[24] Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence 
of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and 
CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997; 4: 199-208. 
[25] Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 
2000; 118: 1117-23. 
[26] Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six 
biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. 
Clin Chem. 2001; 47: 1696-700. 
[27] Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase 
levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C 
virus infection. Am J Gastroenterol. 2001; 96: 3142-6. 
[28] Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical 
markers of liver fibrosis in patients with hepatitis C virus infection: a prospective 
study. Lancet. 2001; 357: 1069-75. 
[29] Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to 
diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol. 2002; 97: 2623-8. 
[30] Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients 
without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36: 986-92. 
[31] Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both 
significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 
38: 518-26. 
[32] Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver 
fibrosis: a cohort study. Gastroenterology. 2004; 127: 1704-13. 
[33] Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum 
markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic 
hepatitis C patients. J Hepatol. 2004; 41: 935-42. 
[34] Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C 
using measures of insulin resistance in a probability index. Hepatology. 2004; 39: 1239-
47. 
[35] Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their 
inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with 
chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 
2004; 99: 271-9. 
  
Liver Biopsy 
 
260 
6. References 
[1] Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological 
evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J 
Hepatol. 2003; 39: 239-44. 
[2] The French METAVIR Cooperative Study Group. Intraobserver and interobserver 
variations in liver biopsy interpretation in patients with chronic hepatitis C. 
Hepatology. 1994; 20: 15-20. 
[3] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001; 344: 495-500. 
[4] McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage 
after percutaneous liver biopsy. Gastroenterology. 1990; 99: 1396-400. 
[5] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the 
Knodell histology activity index and beyond. Hepatology. 2000; 31: 241-6. 
[6] Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological 
semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver 
biopsy specimens: comparison with morphometric studies. Hepatology. 1994; 20: 349-
55. 
[7] Pilette C, Rousselet MC, Bedossa P, et al. Histopathological evaluation of liver fibrosis: 
quantitative image analysis vs semi-quantitative scores. Comparison with serum 
markers. J Hepatol. 1998; 28: 439-46. 
[8] Lazzarini AL, Levine RA, Ploutz-Snyder RJ, Sanderson SO. Advances in digital 
quantification technique enhance discrimination between mild and advanced liver 
fibrosis in chronic hepatitis C. Liver Int. 2005; 25: 1142-9. 
[9] Goodman ZD, Becker RL, Jr., Pockros PJ, Afdhal NH. Progression of fibrosis in advanced 
chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007; 45: 
886-94. 
[10] Dioguardi N, Franceschini B, Aletti G, Russo C, Grizzi F. Fractal dimension rectified 
meter for quantification of liver fibrosis and other irregular microscopic objects. Anal 
Quant Cytol Histol. 2003; 25: 312-20. 
[11] Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis 
in patients with chronic hepatitis C. Gastroenterology. 2005; 129: 2064-75. 
[12] Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver 
fibrosis: a critical appraisal. Hepatology. 2003; 37: 493-503. 
[13] Burroughs AK, Groszmann R, Bosch J, et al. Assessment of therapeutic benefit of antiviral 
therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? 
Gut. 2002; 50: 425-7. 
[14] Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 
2004; 99: 1160-74. 
[15] Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV 
collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of 
metalloproteinases in patients with chronic viral liver disease: relationship to liver 
histology. Hepatology. 1994; 20: 780-7. 
[16] Pares A, Deulofeu R, Gimenez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in 
alcoholic liver disease and is useful as a marker of fibrosis. Hepatology. 1996; 24: 1399-
403. 
[17] Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as 
markers of liver disease in chronic hepatitis C. J Hepatol. 2000; 32: 325-30. 
 
Noninvasive Alternatives for the Assessment of Liver Fibrosis 
 
261 
[18] Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and 
response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients 
with HCV-associated liver disease. World J Gastroenterol. 2005; 11: 476-81. 
[19] Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and 
tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with 
chronic hepatitis C. Relationship to interferon response. J Hepatol. 1997; 26: 574-83. 
[20] Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in 
chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988; 95: 734-9. 
[21] Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic 
liver disease in drinkers. Gastroenterology. 1991; 100: 1397-402. 
[22] Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and 
hepatic fibrosis. Diagnostic interest. Dig Dis Sci. 1994; 39: 2426-32. 
[23] Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for 
diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus 
infection. Am J Gastroenterol. 1997; 92: 1302-4. 
[24] Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence 
of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and 
CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997; 4: 199-208. 
[25] Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 
2000; 118: 1117-23. 
[26] Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six 
biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. 
Clin Chem. 2001; 47: 1696-700. 
[27] Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase 
levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C 
virus infection. Am J Gastroenterol. 2001; 96: 3142-6. 
[28] Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical 
markers of liver fibrosis in patients with hepatitis C virus infection: a prospective 
study. Lancet. 2001; 357: 1069-75. 
[29] Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to 
diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol. 2002; 97: 2623-8. 
[30] Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients 
without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36: 986-92. 
[31] Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both 
significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 
38: 518-26. 
[32] Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver 
fibrosis: a cohort study. Gastroenterology. 2004; 127: 1704-13. 
[33] Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum 
markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic 
hepatitis C patients. J Hepatol. 2004; 41: 935-42. 
[34] Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C 
using measures of insulin resistance in a probability index. Hepatology. 2004; 39: 1239-
47. 
[35] Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their 
inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with 
chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 
2004; 99: 271-9. 
  
Liver Biopsy 
 
262 
[36] Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C 
based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005; 
42: 282-92. 
[37] Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver 
fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51: 1867-73. 
[38] Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of 
liver fibrosis. Hepatology. 2005; 42: 1373-81. 
[39] Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-
infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005; 43: 
78-84. 
[40] Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical 
markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J 
Gastroenterol. 2005; 11: 255-9. 
[41] Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without 
significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 
2005; 100: 616-23. 
[42] Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive 
patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005; 42: 1437-
45. 
[43] Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to 
predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 
43: 1317-25. 
[44] Fontana RJ, Kleiner DE, Bilonick R, et al. Modeling hepatic fibrosis in African American 
and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 
2006; 44: 925-35. 
[45] Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis 
and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol. 
2006; 101: 2537-45. 
[46] Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a 
practical index for predicting significant fibrosis in patients with chronic hepatitis C. 
Hepatology. 2007; 45: 297-306. 
[47] Alsatie M, Kwo PY, Gingerich JR, et al. A multivariable model of clinical variables 
predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2007; 41: 416-21. 
[48] Esmat G, Metwally M, Zalata KR, et al. Evaluation of serum biomarkers of fibrosis and 
injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007; 46: 620-7. 
[49] Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system 
that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45: 846-54. 
[50] Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003; 362: 2089-94. 
[51] Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver 
fibrosis in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology. 
2010; 25: 1569-77. 
[52] Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for 
fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a 
pragmatic approach classification without liver biopsies. J Viral Hepat. 2006; 13: 659-
70. 
[53] Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate 
markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b 
and ribavirin. Hepatology. 2003; 38: 481-92. 
 
Noninvasive Alternatives for the Assessment of Liver Fibrosis 
 
263 
[54] Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate 
markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic 
hepatitis B infection. Am J Gastroenterol. 2005; 100: 1970-80. 
[55] Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic 
hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 
2005; 51: 328-35. 
[56] Morra R, Munteanu M, Bedossa P, et al. Diagnostic value of serum protein profiling by 
SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the 
diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol 
Ther. 2007; 26: 847-58. 
[57] Kanmura S, Uto H, Kusumoto K, et al. Early diagnostic potential for hepatocellular 
carcinoma using the SELDI ProteinChip system. Hepatology. 2007; 45: 948-56. 
[58] Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. 
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum 
protein glycomics. Nat Med. 2004; 10: 429-34. 
[59] Kam RK, Poon TC, Chan HL, Wong N, Hui AY, Sung JJ. High-throughput quantitative 
profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic 
fingerprint of liver fibrosis. Clin Chem. 2007; 53: 1254-63. 
[60] Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow 
parameters measured with MR imaging and Doppler US: correlations with degree of 
cirrhosis and portal hypertension. Radiology. 2003; 229: 409-14. 
[61] Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis 
by transit-time analysis of an ultrasound contrast agent. Lancet. 1999; 353: 1579-83. 
[62] Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a 
microbubble agent can predict disease severity non-invasively in patients with 
hepatitis C. Gut. 2005; 54: 128-33. 
[63] Miyazaki S, Yamazaki Y, Murase K. Error analysis of the quantification of hepatic 
perfusion using a dual-input single-compartment model. Physics in Medicine and 
Biology. 2008; 53: 5927-46. 
[64] Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive 
method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29: 1705-13. 
[65] Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by 
measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005; 41: 48-
54. 
[66] Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect 
progression of fibrosis among HCV carriers with normal aminotransferases. 
Hepatology. 2005; 42: 838-45. 
[67] Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in 
the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007; 56: 
968-73. 
[68] Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of 
liver stiffness measurement using FibroScan in a prospective study of 2114 
examinations. Eur J Gastroenterol Hepatol. 2006; 18: 411-2. 
[69] Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, 
Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. 
Gastroenterology. 2005; 128: 343-50. 
[70] Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic 
resonance elastography by direct visualization of propagating acoustic strain waves. 
Science. 1995; 269: 1854-7. 
  
Liver Biopsy 
 
262 
[36] Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C 
based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005; 
42: 282-92. 
[37] Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver 
fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51: 1867-73. 
[38] Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of 
liver fibrosis. Hepatology. 2005; 42: 1373-81. 
[39] Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-
infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005; 43: 
78-84. 
[40] Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical 
markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J 
Gastroenterol. 2005; 11: 255-9. 
[41] Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without 
significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 
2005; 100: 616-23. 
[42] Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive 
patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005; 42: 1437-
45. 
[43] Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to 
predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 
43: 1317-25. 
[44] Fontana RJ, Kleiner DE, Bilonick R, et al. Modeling hepatic fibrosis in African American 
and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 
2006; 44: 925-35. 
[45] Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis 
and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol. 
2006; 101: 2537-45. 
[46] Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a 
practical index for predicting significant fibrosis in patients with chronic hepatitis C. 
Hepatology. 2007; 45: 297-306. 
[47] Alsatie M, Kwo PY, Gingerich JR, et al. A multivariable model of clinical variables 
predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2007; 41: 416-21. 
[48] Esmat G, Metwally M, Zalata KR, et al. Evaluation of serum biomarkers of fibrosis and 
injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007; 46: 620-7. 
[49] Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system 
that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45: 846-54. 
[50] Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003; 362: 2089-94. 
[51] Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver 
fibrosis in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology. 
2010; 25: 1569-77. 
[52] Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for 
fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a 
pragmatic approach classification without liver biopsies. J Viral Hepat. 2006; 13: 659-
70. 
[53] Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate 
markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b 
and ribavirin. Hepatology. 2003; 38: 481-92. 
 
Noninvasive Alternatives for the Assessment of Liver Fibrosis 
 
263 
[54] Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate 
markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic 
hepatitis B infection. Am J Gastroenterol. 2005; 100: 1970-80. 
[55] Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic 
hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 
2005; 51: 328-35. 
[56] Morra R, Munteanu M, Bedossa P, et al. Diagnostic value of serum protein profiling by 
SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the 
diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol 
Ther. 2007; 26: 847-58. 
[57] Kanmura S, Uto H, Kusumoto K, et al. Early diagnostic potential for hepatocellular 
carcinoma using the SELDI ProteinChip system. Hepatology. 2007; 45: 948-56. 
[58] Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. 
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum 
protein glycomics. Nat Med. 2004; 10: 429-34. 
[59] Kam RK, Poon TC, Chan HL, Wong N, Hui AY, Sung JJ. High-throughput quantitative 
profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic 
fingerprint of liver fibrosis. Clin Chem. 2007; 53: 1254-63. 
[60] Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow 
parameters measured with MR imaging and Doppler US: correlations with degree of 
cirrhosis and portal hypertension. Radiology. 2003; 229: 409-14. 
[61] Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis 
by transit-time analysis of an ultrasound contrast agent. Lancet. 1999; 353: 1579-83. 
[62] Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a 
microbubble agent can predict disease severity non-invasively in patients with 
hepatitis C. Gut. 2005; 54: 128-33. 
[63] Miyazaki S, Yamazaki Y, Murase K. Error analysis of the quantification of hepatic 
perfusion using a dual-input single-compartment model. Physics in Medicine and 
Biology. 2008; 53: 5927-46. 
[64] Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive 
method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29: 1705-13. 
[65] Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by 
measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005; 41: 48-
54. 
[66] Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect 
progression of fibrosis among HCV carriers with normal aminotransferases. 
Hepatology. 2005; 42: 838-45. 
[67] Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in 
the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007; 56: 
968-73. 
[68] Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of 
liver stiffness measurement using FibroScan in a prospective study of 2114 
examinations. Eur J Gastroenterol Hepatol. 2006; 18: 411-2. 
[69] Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, 
Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. 
Gastroenterology. 2005; 128: 343-50. 
[70] Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic 
resonance elastography by direct visualization of propagating acoustic strain waves. 
Science. 1995; 269: 1854-7. 
  
Liver Biopsy 
 
264 
[71] Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of Hepatic Fibrosis With Magnetic 
Resonance Elastography. Clinical Gastroenterology and Hepatology. 2007; 5: 1207-13.e2. 
[72] Friedrich-Rust M, Ong MF, Herrmann E, et al. Real-time elastography for noninvasive 
assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol. 2007; 188: 
758-64. 
[73] Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and 
characterization with combination gadolinium- and superparamagnetic iron oxide-
enhanced MR imaging. Radiology. 2003; 228: 719-26. 
[74] Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: 
comparison of combined contrast-enhanced MR imaging and combined CT during 
arterial portography and CT hepatic arteriography. Eur Radiol. 2004; 14: 447-57. 
[75] Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive 
diagnosis with double contrast material-enhanced MR imaging. Radiology. 2006; 239: 
425-37. 
[76] Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusion-weighted MR 
imaging with a single-shot echoplanar sequence: detection and characterization of 
focal hepatic lesions. AJR Am J Roentgenol. 1998; 170: 397-402. 
[77] Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient 
measurements with diffusion-weighted magnetic resonance imaging for evaluation 
of hepatic fibrosis. J Magn Reson Imaging. 2005; 22: 80-5. 
[78] Lewin M, Poujol-Robert A, Boelle PY, et al. Diffusion-weighted magnetic resonance 
imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology. 2007; 46: 658-
65. 
[79] Chappell KE, Patel N, Gatehouse PD, et al. Magnetic resonance imaging of the liver with 
ultrashort TE (UTE) pulse sequences. J Magn Reson Imaging. 2003; 18: 709-13. 
[80] Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The 
relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. 
Hepatology. 2003; 37: 788-94. 
[81] Caravan P. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) 
contrast agents: Design and mechanism of action. Accounts of Chemical Research. 2009; 
42: 851-62. 
[82] Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular 
imaging techniques in body imaging. Radiology. 2007; 245: 333-56. 
[83] Meuli R, Hwu Y, Je JH, Margaritondo G. Synchrotron radiation in radiology: radiology 
techniques based on synchrotron sources. Eur Radiol. 2004; 14: 1550-60. 
[84] Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the 
evolution of whole-body photonic imaging. Nat Biotechnol. 2005; 23: 313-20. 
[85] Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant 
results between biochemical markers and biopsy in patients with chronic hepatitis C. 
Clin Chem. 2004; 50: 1344-55. 
[86] Afdhal NH, Curry M. Technology evaluation: a critical step in the clinical utilization of 
novel diagnostic tests for liver fibrosis. J Hepatol. 2007; 46: 543-5. 
[87] Pagliaro L, Rinaldi F, Craxi A, et al. Percutaneous blind biopsy versus laparoscopy with 
guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci. 
1983; 28: 39-43. 
[88] Matalka, II, Al-Jarrah OM, Manasrah TM. Quantitative assessment of liver fibrosis: a 
novel automated image analysis method. Liver Int. 2006; 26: 1054-64. 
17 
Non-Invasive Assessment of the Liver –  
Serum Markers and Imaging Techniques 
Anna Mania, Paweł Kemnitz, Katarzyna Mazur-Melewska,  
Magdalena Figlerowicz and Wojciech Służewski 
Department of Infectious Diseases and Child Neurology,  
University of Medical Sciences, Poznan,  
Poland 
1. Introduction 
Management and prognosis of the liver diseases highly depends on the advancement of the 
liver lesions. It is particularly important to distinguish patients at greatest risk of developing 
liver cirrhosis, liver failure and hepatocellular carcinoma. Liver biopsy remains the gold 
standard for evaluating the liver tissue. It allows not only for establishing the grade of 
inflammatory activity and the stage of fibrosis, but also for more accurate differential 
diagnosis and detection of coexisting liver diseases. Needle biopsy removes, however, only 
about 1/50,000 of the liver tissue and carries the risk of sampling error. Furthermore, the 
specimen should be sufficient in length (20-25 mm), width, fragmentation and number of 
complete portal tracts (at least 11) [Cholongitas et al., 2006]. Moreover, liver assessment is 
affected by significant interpretative error and interobserver variability of histological 
interpretation. Besides, many patients are reluctant to experience repeated biopsies, which 
limits the ability to monitor disease progression and the effects of treatments. 
Search for new non-invasive approaches have been initiated as a result of the limitations 
of the liver biopsy. Non-invasive tests for the assessment of the severity of chronic liver 
diseases seem to be an attractive option designed to replace liver biopsy in the near 
future.  
Ideal non-invasive marker of particular liver lesion should be reliable, liver specific, 
inexpensive and easy to perform. In addition, it should allow not only to diagnose particular 
liver problem but also to monitor its progression. Recently extensive research is performed 
to evaluate non-invasive techniques for the detection of liver fibrosis, necroinflammatory 
activity and steatosis in various liver diseases.  This chapter revises currently used non-
invasive techniques of liver assessment. 
2. Serum biochemical markers 
2.1 Serum markers of fibrosis in hepatitis 
The progression of liver fibrosis is a complex wound-healing process, that involves various 
types of cells and their mediators that eventually leads to the deposition and accumulation 
of various extracellular matrix (ECM) components.   
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Serum biochemical tests including direct and indirect markers of fibrosis have been most 
widely investigated. Certain markers, especially cytokines, growth factors, metaloproteinases 
and their inhibitors may reflect balance or imbalance between fibrogenesis and fibrinolysis, 
revealing information about the progression of the disease.  
2.2 Direct markers 
Direct markers include profibrotic cytokines as transforming growth factor beta-1 (TGF 
beta-1), ECM components – glycoproteins as hyaluronan (HA), laminin, metaloproteinases 
their tissue inhibitors and others. Some of them demonstrated associations with liver 
fibrosis.  
Fibryl-forming collagens accumulate in the process of liver fibrosis being important 
components of extracellular matrix.  The most extensively studied collagen is PIIINP, an 
aminotreminal peptide of procollagen III, that is cleaved from procolagen III during its 
secretion by fibroblasts. Therefore, it is mainly considered to be a marker of fibrogenensis, 
rather than fibrosis. PIIINP was found proportional to the liver fibrosis in several studies. 
However, this parameter should be validated in further studies, as it is too early to 
recommend its use as a single marker [Leroy et al., 2004].  
Transforming growth factor beta 1 (TGF-beta 1) is a cytokine that activates fibrogenesis and 
inhibits fibrinolysis. This protein stimulates mesenchymal cells and increases production of 
ECM components. TGF-beta 1 was found to be related to the liver fibrosis in patients with 
CHC and CHB [Marek et al., 2003].   
Laminin is a glycoprotein of ECM consisting of 3 different polipeptide chains α, β, and γ. 
Laminins take part in the cellular adhesion, stimulate cellular growth and act as cellular 
mediators. This protein is also considered to be a marker of the liver fibrosis. In various 
studies it was found to be related to the degree of the liver fibrosis in patients with CHC 
[Walsh et al., 2000]. 
Hyaluronic acid (HA) a glycosaminoglycan produced by fibroblasts that seems to be a 
major component of extracellular matrix. Liver sinusoidal cells are responsible for 
degradation of its particles. Therefore elevated HA serum levels may reflect endothelial 
dysfunction associated with the progression of fibrosis. Several studies proved correlation 
between HA serum levels and hepatic fibrosis, it has, however limitations in 
distinguishing exact stages [Patel et al., 2003]. HA was validated in HCV, HBV and 
HCV/HIV coinfected patients. Serum concentrations of HA were found to be related to 
the level of fibrosis. However, in lower fibrosis stages serum HA levels may overlap, 
therefore the parameter is more reliable in advanced stages of fibrosis [Resino et al., 2010]. 
HA< 60 ug/l exclude fibrosis and extensive fibrosis, whereas values >110 ug/l predicted 
cirrhosis [McHutchinson et al., 2002]. 
Metaloproteinases (MMPs) and their tissue inhibitors (TIMPs) are proteins involved in the 
regulation of fibrogenesis and fibrinolysis. MMPs are secreted by fibroblasts and Kupfer 
cells in inactive form that requires further cleavage for functional capability. They are 
involved in degradation of extracellular matrix components and are regulated by tissue 
inhibitors (TIMPs). MMP-2 is an enzyme up-regulated by collagen type II, that was found to 
be positively related to the liver fibrosis. Similar correlations were found for TIMP-1 and 
TIMP-2. Moreover, TIMP-1 was found to be very sensitive and displayed good specificity 
for the detection of liver cirrhosis [Boeker et al., 2002]. In combination with HA and PIIINP, 
TIMP-1 showed good accuracy for the diagnosis of extensive fibrosis and cirrhosis [Leroy et 
al., 2004].  
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Although direct markers are less expensive than the liver biopsy, they are still costly and are 
not available in most clinical settings. Therefore, none of those biomarkers is  until now  in 
frequent use except for research studies.   
2.2.1 Indirect markers 
Indirect markers associated with fibrosis, such as routine biochemistry, platelets, and alpha-
2-macroglobulin, are widely available in daily clinical practice. Biochemical tests mainly 
include aspartate (AST) and alanine aminotransferase (ALT) activity and prothrombine 
time. They are either tested alone or in combination, which enhances their value. 
Prothrombine time, a well-known marker of hepatic dysfunction, was negatively correlated 
to fibrosis even in its earlier stages [Croquet et al. 2002]. Thrombin is believed to be trapped  
by the hepatic sinusoidal capillary network and bind to the receptors on the surface of 
activated hepatic stellate cells. 
AST levels usually increase in patients with liver fibrosis as a result of reduced clearance by 
sinusoidal capillary network. AST/ALT ratio was found related to the presence of liver 
cirrhosis with high predictive values for ratio exceeding 1. Nevertheless, not all studies 
confirm such results. Diagnostic value of AST/ALT ratio was improved by its combination 
with platelet count below 150 G/l. Number of platelets declines with the progression of liver 
fibrosis as a consequence  of sequestration in the spleen but also reduced thrombopoetin 
production.  
Indirect markers are cost-free, thus they have not been tested in less advanced cases of liver 
fibrosis. Recent studies combine these markers to produce valuable scores.  Several indirect 
markers and have been incorporated into composite panels that have been developed to 
evaluate the presence hepatic necroinflammation and fibrosis.  
FibroTest- Acti-Test consisting of the panel of selected biochemical markers was designed to 
evaluate liver fibrosis and necroinflammatory activity in chronic hepatitis C (CHC) 
[Poynard et al., 2002; Myers et al., 2003]. The test consist of six biochemical markers: alfa2-
macroglobulin (A2-M), haptoglobin (HPT), gamma glutamyltranspeptidase (GTP), total 
bilirubin, apolipoprotein A1 (ALP-A1) and ALT that are adjusted to the patient age and 
gender in a patented algorithm. No single blood test possesses sufficient negative or positive 
predictive value to substitute for liver biopsy, especially for the diagnosis of moderate 
fibrosis (F2).  Each of the components adds complementary value to, the estimation of 
fibrosis and necroinflammatory activity. A2-M is a protein synthesized by hepatocytes, 
stellate cells and granulomas, which serum concentration increases during stellate cell 
activation in the course of fibrogenesis. As proteinases inhibitor it can increase fibrosis by 
inhibiting the breakdown of extracellular matrix proteins. HPT is a protein synthesized by 
the liver which serum level decreases with fibrosis. This decline does not depend on 
hemolysis or hepatic insufficiency. In the circumstances of the liver fibrosis HPT synthesis is 
decreased by hepatic growth factor.  ALP-A1 is a protein synthesized by hepatocytes, 
responsible for the transport of the cholesterol. In liver fibrosis, its release is hampered by 
the ECM collagen fibers, moreover its transcription is equally reduced. Serum 
apolipoprotein A1 levels declines in the presence of fibrosis. Bilirubin is a pigment resulting 
from the degradation of hemoglobin, which in normal conditions is taken up from the 
blood, conjugated and excreted in bile. Bilirubin increases in liver fibrosis. Hepatitis C virus 
infection modifies the transporters of bilirubin that could explain the increase observed in 
the early stages of fibrosis. GTP  is an enzyme synthesized by hepatocytes, which increases 
with fibrosis on unknown mechanisms, that are independent of the growth in 
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aminotransferases and bilirubin. It is believed that epidermal growth factor stimulates the 
synthesis of GTP during of fibrogenesis. ALT is an enzyme synthesized by hepatocytes, 
which increases in serum when necrosis and hepatic tissue inflammation occur. Fibrotes-
Actitest was proven to have high predictive value in CHC patients before and after antiviral 
treatment [Poynard et al., 2001], in patients with persisting normal ALT activity [Colletta et 
al., 2005], coinfected with HIV [Myers et al., 2003]. The test was also found useful in chronic 
hepatitis B (CHB) [Myers et al., 2003], alcoholic liver disease [Naveau et al., 2005], 
nonalcoholic fatty liver disease (NAFLD) [Ratziu et al., 2006] and hemochromatosis 
[Adhoute X et al., 2006].  The test was also confirmed to other  single direct and indirect 
markers as well as the test panels. Its main disadvantage are false positive results induced 
by ribavirin treatment on HPT levels. Numerous publications were released concerning this 
method of assessment in various liver diseases. It enables direct extrapolation from the 
results of the test to the stages of fibrosis in different scoring systems (Table 1). The test is 
available on commercial bases. Thus, the chief researcher involved in validation of the test 
has financial interests in its manufacturing company.   
 
Fibrotest METAVIR fibrosis stage estimate 
Knodell fibrosis stage 
estimate 
Ishak fibrosis stage 
estimate 
0.75-1.00 F4 F4 F6 
0.73-0.74 F3-F4 F3-F4 F5 
0.59-0.72 F3 F3 F4 
0.49-0.58 F2 F1-F3 F3 
0.32-0.48 F1-F2 F1-F3 F2-F3 
0.28-0.31 F1 F1 F2 
0.22-0.27 F0-F1 F0-F1 F1 
0.00-0.21 F0 F0 F0 
Table 1. Conversion between the results of FibroTest and fibrosis stages in METAVIR, 
Knodell and Ishak scoring systems. Fibrosis scoring systems. 
Beside Fibrotest-Actitest, more panels of direct and indirect markers were developed.  
FibroSpect evaluates liver fibrosis by analyzing the following parameters: hyaluronic acid, 
tissue-inhibited matrix metalloproteinase inhibitor-1 and α-2 macroglobulin [Patel et al., 
2004]. The score is licensed and commercially available in the USA. Validated in several 
studies, the test was proven to be effective for excluding significant fibrosis and cirrhosis. 
Positive predictive values for detecting fibrosis were found much lower than negative 
values for excluding significant fibrosis or cirrhosis [Zaman et al., 2007]. 
Fibrosure combines quantitative results of the following parameters: A2-M, HPT, GTP, total 
bilirubin, ALP-A1 and ALT with a patient’s age and gender in a patented artificial 
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intelligence algorithm to create a measure of fibrosis and necroinflammatory activity in the 
liver. The test is an American form of Fibrotest and provides continuous numerical 
assessment of liver fibrosis and necroinfalmmatory activity corresponding to METAVIR 
scoring system. Values <0.48 exclude significant fibrosis while a score >0.78 is highly 
predictive for the liver cirrhosis. Values <0.36 indicate minimal activity, while  scores>0.62 a 
specific for severe necroinflammatory activity [Poynard et al., 2004].  
Hepascore includes bilirubin, GTP, A-2M, HA, age and gender [Adams et al. 2005]. A score 
>0.5 indicated significant fibrosis with 92% of specificity and 67% of sensitivity. While scores 
<0.5 had 74% specificity and 88% sensitivity to exclude advanced fibrosis.  A cutoff of 0.84 
had a 71% specificity and 89% of sensitivity for the prediction of liver cirrhosis.  However, 
there was a significant overlap between patients with mild and moderate fibrosis.  
Fibroindex was a proposed score that includes: platelets, AST levels and gammaglobulin 
according to the formula: Fibroindex=1.738 – 0.064 x platelets (104/mm3) + 0.005 x AST 
(IU/l) + 0.463 x gammaglobulin (g/dl). Two threshold were proposed for the diagnosis of 
significant fibrosis. A score >1.25 confirmed fibrosis with 94% of specificity and >2.25 with 
97% of specificity [Koda et al. 2007].  
Forns score combines: age, GTP, cholesterol level, platelet count according to the formula: 
Forns score=7.811-3.131 x ln platelets (g/l) +0.781 x ln GTP(IU/l)+3.647 x ln age(years)-0.014 
x cholesterol [Forns et al. 2002]. A score <4.2 excluded and a score>6.9 confirmed significant 
fibrosis. The main limitation of the scale is that the result is indefinite in  many patients and 
no thresholds were created for the diagnosis of extensive fibrosis or cirrhosis. Thus, lipid 
abnormalities observed in hepatitis  patients raise concerns related to the utility of the scale 
and requires further validation for the use in routine clinical practice. 
APRI score is AST/platelets ratio calculated as (AST/upper normal limit X 100/platelet 
count) [Wai et al 2003] originally proposed for hepatitis C patients. In original study a score 
<0.5 ruled out significant fibrosis, a score <1.0  excluded cirrhosis and a score >2.0 suggested 
cirrhosis with good predictive value. Nevertheless, subsequent studies in hepatitis C and 
HIV coinfected patients had much poorer outcome. This score was found to be useful to 
exclude significant fibrosis and particularly cirrhosis with around 90% certainty also in HCV 
infected  hemodialysis patients [Schiavon  et al., 2007]. The results were, however much 
worse in alcoholic patients as alcohol may have direct effects on AST activity and platelet 
count. Therefore this limitation should be taken into account in daily clinical practice 
[Trabut et al., 2009]. APRI may be used as an easy first-line investigation, however, not as 
the only tool as it has moderate diagnostic utility for the prediction of fibrosis in HCV-
infected patients. Its major role appears to be the exclusion of significant fibrosis and 
cirrhosis, which can be achieved with acceptable accuracy in at least one third and three 
quarters of patients, respectively [Shaheen and Myers, 2007]. 
FIB-4 uses the following formula: (age X AST/platelets X ALT)1/2 [Vallet-Pichard et al., 
2007]. Values <1.45 ruled out extensive fibrosis and >3.25 confirmed the diagnosis with 
around 90% of accuracy in comparison to the histological results in the Ishak scoring 
system. Significant proportion of patients fell into indeterminate range of results.  
Although these test give promising results in detecting advanced fibrosis their ability to 
replace liver biopsy is still not probable as some of them have not been sufficiently validated 
[Bourliere 2006]. Some of the scores like APRI may be influenced by other factors like for 
example alcohol abuse that may influence on the level of indirect markers in the scale. 
Diagnostic panels were presented in Table 2. 
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0.59-0.72 F3 F3 F4 
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cirrhosis with good predictive value. Nevertheless, subsequent studies in hepatitis C and 
HIV coinfected patients had much poorer outcome. This score was found to be useful to 
exclude significant fibrosis and particularly cirrhosis with around 90% certainty also in HCV 
infected  hemodialysis patients [Schiavon  et al., 2007]. The results were, however much 
worse in alcoholic patients as alcohol may have direct effects on AST activity and platelet 
count. Therefore this limitation should be taken into account in daily clinical practice 
[Trabut et al., 2009]. APRI may be used as an easy first-line investigation, however, not as 
the only tool as it has moderate diagnostic utility for the prediction of fibrosis in HCV-
infected patients. Its major role appears to be the exclusion of significant fibrosis and 
cirrhosis, which can be achieved with acceptable accuracy in at least one third and three 
quarters of patients, respectively [Shaheen and Myers, 2007]. 
FIB-4 uses the following formula: (age X AST/platelets X ALT)1/2 [Vallet-Pichard et al., 
2007]. Values <1.45 ruled out extensive fibrosis and >3.25 confirmed the diagnosis with 
around 90% of accuracy in comparison to the histological results in the Ishak scoring 
system. Significant proportion of patients fell into indeterminate range of results.  
Although these test give promising results in detecting advanced fibrosis their ability to 
replace liver biopsy is still not probable as some of them have not been sufficiently validated 
[Bourliere 2006]. Some of the scores like APRI may be influenced by other factors like for 
example alcohol abuse that may influence on the level of indirect markers in the scale. 
Diagnostic panels were presented in Table 2. 
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Score Parameters involved Formula Reference 
Fibrotest-
Actitest 
alfa2-macroglobulin
haptoglobin 
GTP 
total bilirubin 
apolipoprotein A1 
ALT 
Age 
gender
Patented and commercially 
used 
Poynard 
et al.  2002 
FibroSpect 
hyaluronic acid
tissue-inhibited matrix 
metalloproteinase 
inhibitor-1 
α-2 macroglobulin
Licensed and commercially 
used 
Patel  et 
al. 2004 
FibroSure 
alfa2-macroglobulin
haptoglobin 
GTP 
total bilirubin 
apolipoprotein A1 
ALT
The USA patented form of 
Fibrotest-Actitest 
Poynard 
et al 2004 
Hepascore 
Bilirubin
GTP 
α-2 macroglobulin 
hyaluronic acid 
age 
gender
Hepascore=y/1+y;
y=exp [4.185818 –(0.0249 x 
age +(0.7464 x sex + 1.0039 x 
α2-macroglobulin +(0.0302x_ 
hyaluronic acid)+(0.0691 x 
bilirubin)-(0.0012 x GGT)]
Adams et 
al. 2005 
Fibroindex 
PLT 
AST 
gammaglobulin 
Fibroindex= 1.738 – 0.064 x 
PLT (104/mm3) + 0.005 x AST 
(IU/l) + 0.463 x 
gammaglobulin (g/dl)
Koda et 
al. 2007 
APRI AST PLT 
APRI = AST level (/ULN)      
x100 
PLT (109/L)
Wai et al. 
2003 
FIB-4 
Age
AST 
ALT 
PLT
FIB-4=  (age X AST/PLT X 
ALT)1/2 
Vallet-
Pichard et 
al. 2007 
Abbreviations: AST – aspartate aminotransferase, ALT – alanine aminotransferase, GTP- gamma 
glutamyltranspeptidase, UNL – upper normal limit, PLT – platelet count 
Table 2. Serum diagnostic panels of direct and indirect markers. 
2.3 Serum markers of steatosis 
Several studies proposed various tests to distinguish between simple steatosis and NASH in 
patients with NAFLD. The most important parameters are acute phase proteins as they 
enable to establish NASH. Several markers of inflammation were extensively studied in 
relation to fatty liver disease. C-reactive protein (CRP) is an acute phase parameter that is 
produced in the liver and increases in various inflammatory conditions. The evaluation of 
serum CRP levels was found to be associated with NASH and helps to differentiate this 
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condition from simple steatosis. Furthermore, high levels of high-sensitivity CRP were 
found to be associated with extensive liver fibrosis in NASH [Yoneda et al. ,2007].  
Nevertheless, study conducted in children with liver steatosis revealed that fatty liver itself 
may not be a cofactor in stimulating inflammatory markers in obese patients. Obese children 
with NAFLD may have simple steatosis and their increased inflammatory markers are 
therefore compatible with those expected in obesity [Neuman et al. ,2010]. 
Another acute phase protein used to distinguish NASH from non-NASH patients is plasma 
pentraxin-3 (PTX 3) a novel marker that seems to be promising in assessing the severity of 
fibrosis. Plasma PTX-3 levels were, however, found increased not only in NASH, but also in 
other cardiovascular and inflammatory conditions and vasculites [Yoneda et al., 2008].  
Interleukin-6 seems to be another marker playing an important role in fatty liver disease. 
This biomarker is a cytokine synthesized in hepatocytes, endothelial cells, adipocytes and 
cells of the immune system, that rises in NAFLD and indicates inflammatory activity and 
liver fibrosis [Wieckowska et al. , 2008].  
Tumor necrosis factor-alpha (TNF-alpha) is another proinflammatory cytokine which role in 
NASH was clearly established. As levels of TNF-alpha are increased in NASH, anti-TNF-
alpha therapy was found effective in the improvement of liver histology and normalization 
of aminotransferase levels. 
Cytokeraitn-18  is  a marker of hepatic apoptosis  and is utility in the detection of NASH is 
based on the observation that apoptosis is prominent in NASH and absent in simple 
steatosis. Its use is, however, so far limited to research areas [Wieckowska et al. , 2008].  
As oxidative stress has been found to play an important role in NASH pathogenesis several 
parameters were evaluated in various studies:  vitamin E levels, glutathione peroxidase 
activity and superoxide dismutase activity [Hardwick et al.,2010]. None of these markers 
reflect liver histology in NASH, therefore its clinical value is still questionable and were not 
entirely defined yet. The assessment of the liver fibrosis is an important component in the 
evaluation of NASH as end stage liver disease is constantly present in this state. Several 
matrix components have been studied in various trials: HA, TGF beta-1, TIMP and other 
markers. Nevertheless so far none of them entered clinical use.  
To avoid liver biopsy several noninvasive panels of serological markers have been 
developed to assess the presence of hepatic necroinflammation and steatosis. SteatoTest is a 
quantitative test designed to estimate liver steatosis especially in patients with metabolic 
syndrome [62]. NASH test is a variation of SteatoTest and ActiTest for the differentiation of 
simple steatosis from NASH and should be performed only if SteatoTest is positive. The 
scores combine various parameters. The NASH test combines total bilirubin, GGT, α2-
macroglobulin, apolipoprotein A1, haptoglobin and ALT, and is adjusted for age and 
gender plus weight, height, AST, serum glucose, triglycerides, cholesterol and SteatoTest. 
NASH FibroSURE is the USA patented algorithm combining quantitative results of 10 
biochemical parameters,  including A2M, HPT, ALP-A1, bilirubin, GTP, ALT, AST, total 
cholesterol, triglycerides, and fasting glucose, in relation to the age, gender, height, and 
weight. The registered algorithm  provides quantitative alternate markers for liver fibrosis, 
hepatic steatosis, and NASH. Markers of fibrosis are corresponding to METAVIR scoring 
system. Marker of hepatic steatosis varies from S0 to S3 and is corresponding to 0% to >66%. 
In a study conducted on patients with significant (>5%) steatosis score a value >0.5 
confirmed steatosis with high sensitivity and specificity [Poynard et al., 2005]. The test also 
provides a diagnostic assessment of the presence of NASH using three broad categories N0-
N2 corresponding to “Not NASH,” “Borderline NASH,” and “NASH” per the Kleiner 
classification [Kleiner et al.;2005]. 
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2.3 Serum markers of steatosis 
Several studies proposed various tests to distinguish between simple steatosis and NASH in 
patients with NAFLD. The most important parameters are acute phase proteins as they 
enable to establish NASH. Several markers of inflammation were extensively studied in 
relation to fatty liver disease. C-reactive protein (CRP) is an acute phase parameter that is 
produced in the liver and increases in various inflammatory conditions. The evaluation of 
serum CRP levels was found to be associated with NASH and helps to differentiate this 
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condition from simple steatosis. Furthermore, high levels of high-sensitivity CRP were 
found to be associated with extensive liver fibrosis in NASH [Yoneda et al. ,2007].  
Nevertheless, study conducted in children with liver steatosis revealed that fatty liver itself 
may not be a cofactor in stimulating inflammatory markers in obese patients. Obese children 
with NAFLD may have simple steatosis and their increased inflammatory markers are 
therefore compatible with those expected in obesity [Neuman et al. ,2010]. 
Another acute phase protein used to distinguish NASH from non-NASH patients is plasma 
pentraxin-3 (PTX 3) a novel marker that seems to be promising in assessing the severity of 
fibrosis. Plasma PTX-3 levels were, however, found increased not only in NASH, but also in 
other cardiovascular and inflammatory conditions and vasculites [Yoneda et al., 2008].  
Interleukin-6 seems to be another marker playing an important role in fatty liver disease. 
This biomarker is a cytokine synthesized in hepatocytes, endothelial cells, adipocytes and 
cells of the immune system, that rises in NAFLD and indicates inflammatory activity and 
liver fibrosis [Wieckowska et al. , 2008].  
Tumor necrosis factor-alpha (TNF-alpha) is another proinflammatory cytokine which role in 
NASH was clearly established. As levels of TNF-alpha are increased in NASH, anti-TNF-
alpha therapy was found effective in the improvement of liver histology and normalization 
of aminotransferase levels. 
Cytokeraitn-18  is  a marker of hepatic apoptosis  and is utility in the detection of NASH is 
based on the observation that apoptosis is prominent in NASH and absent in simple 
steatosis. Its use is, however, so far limited to research areas [Wieckowska et al. , 2008].  
As oxidative stress has been found to play an important role in NASH pathogenesis several 
parameters were evaluated in various studies:  vitamin E levels, glutathione peroxidase 
activity and superoxide dismutase activity [Hardwick et al.,2010]. None of these markers 
reflect liver histology in NASH, therefore its clinical value is still questionable and were not 
entirely defined yet. The assessment of the liver fibrosis is an important component in the 
evaluation of NASH as end stage liver disease is constantly present in this state. Several 
matrix components have been studied in various trials: HA, TGF beta-1, TIMP and other 
markers. Nevertheless so far none of them entered clinical use.  
To avoid liver biopsy several noninvasive panels of serological markers have been 
developed to assess the presence of hepatic necroinflammation and steatosis. SteatoTest is a 
quantitative test designed to estimate liver steatosis especially in patients with metabolic 
syndrome [62]. NASH test is a variation of SteatoTest and ActiTest for the differentiation of 
simple steatosis from NASH and should be performed only if SteatoTest is positive. The 
scores combine various parameters. The NASH test combines total bilirubin, GGT, α2-
macroglobulin, apolipoprotein A1, haptoglobin and ALT, and is adjusted for age and 
gender plus weight, height, AST, serum glucose, triglycerides, cholesterol and SteatoTest. 
NASH FibroSURE is the USA patented algorithm combining quantitative results of 10 
biochemical parameters,  including A2M, HPT, ALP-A1, bilirubin, GTP, ALT, AST, total 
cholesterol, triglycerides, and fasting glucose, in relation to the age, gender, height, and 
weight. The registered algorithm  provides quantitative alternate markers for liver fibrosis, 
hepatic steatosis, and NASH. Markers of fibrosis are corresponding to METAVIR scoring 
system. Marker of hepatic steatosis varies from S0 to S3 and is corresponding to 0% to >66%. 
In a study conducted on patients with significant (>5%) steatosis score a value >0.5 
confirmed steatosis with high sensitivity and specificity [Poynard et al., 2005]. The test also 
provides a diagnostic assessment of the presence of NASH using three broad categories N0-
N2 corresponding to “Not NASH,” “Borderline NASH,” and “NASH” per the Kleiner 
classification [Kleiner et al.;2005]. 
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Other tests combine both direct and indirect markers or other clinical parameters: age, 
gender, BMI, AST, AST/ALT ratio, hyaluronan [Palekar et al., 2006] or adiponectin and 
collagen type IV [Shimada et al., 2007].  
Various test panel were compared with one another. The results are, however, ambiguous  
and vary from study to study. Although patented commercial tests seem to present a higher 
diagnostic value, simply non-patented panels are much easier available.  
3. Transient elastography 
Non-invasive assessment of the liver fibrosis is also possible by transient elastography. The 
technique is performed by device called Fibroscan that enables the assessment of the liver 
stiffness. The device holds an ultrasound probe in a vibrating piston that induces elastic 
vibrations propagating through the liver. The reflected waves captivated by a transducer 
enable to measure the liver elasticity that is inversely related to the speed of the waves 
[Sandrin 2003]. After several measurements, calculated mean value enables the exact 
assessment of liver fibrosis. This  method was proven precise enough when compared to the 
liver biopsy and evaluates a portion of the liver 500 times bigger than conventional method 
[Castera 2005]. Transient elastography is described in detailed in another chapter of this book. 
It was also used in combination with serum markers of fibrosis. The Fibro-Stiffness index is 
a panel consisting of liver stiffness measured by Fibroscan, platelet count and prothrombin 
time. The method demonstrated superior diagnostic performance to liver stiffness obtained 
by elastography alone, the APRI, the Forns score and the FibroIndex for significant and 
severe fibrosis and liver cirrhosis. The diagnostic value of the Fibro-Stiffness index for liver 
cirrhosis was increased by combination with serum HA levels [Ichino et al., 2010]. 
Various test panles were validated either compared to elastography or used simultaneously 
with this method. The most promising results were obtained were both serum markers and 
elastography were used together. 
4. Imaging techniques  
Conventional imaging techniques that include ultrasound with Doppler, CT and MRI can be 
used to evaluate advanced liver cirrhosis. Their ability to detect minor lesions is, however, 
limited [Hussain 2005]. 
4.1 Hepatic ultrasound  
Ultrasonography is simple, inexpensive, easy to reproduce and can be repeatedly used to 
assess changes over time. It is a first-line imaging technique, a simple non-invasive method, 
that is widely used in clinical practice to detect fatty infiltration of the liver. It assesses the 
presence of steatosis detecting a hyperechogenic parenchyma of the liver displayed as 
“bright liver “ or “blurring of the vascular margins”. An ultrasound index for quantitative 
assessment of the liver steatosis is the hepato-renal contrast. Normal liver shows an 
echostructure similar to renal parenchyma. In liver steatosis the increased echogenity forms 
hepato-renal contrast.  Severity of liver steatosis was assessed according to a discrepancy in 
ultrasonographic liver-kidney densities. The hepato-renal index was supposed to quantify 
the severity of liver steatosis to a lower limit of 5% [Webb et al. , 2007].   
Spleen longitudinal parameter is another simple, noninvasive and easy to perform 
parameter, that could differentiate between NAFLD and NASH better than serum markers 
with values exceeding 11.6 cm for predicting NASH.  
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When the degree of steatosis is less than 30%, sensitivity of this technique is low. Moreover, 
it is impossible to detect inflammatory changes of the hepatic parenchyma and to 
differentiate  between simple steatosis and staeatohepatitis. Therefore, it is very difficult to 
distinguish between the liver steatosis  and liver fibrosis as both changes look similar on 
ultrasound. 
The biggest limitation of this technique is morbid obesity as ultrasonographic examination is 
difficult to perform in such patients.  Ultrasonography is, however, insufficient for detecting 
early and intermediate stages of fibrosis.  
4.1.1 Doppler ultrasound 
Doppler ultrasound is another helpful tool in the diagnosis of steatosis. Hepatic parenchyma 
perfusion abnormalities were observed in NASH. Altered hepatic hemodynamics can be 
described by various parameters including, among others, hepatic vein Doppler pattern and 
Doppler perfusion index (DPI), which is a ratio between hepatic arterial blood flow and total 
liver blood flow. DPI allows for the detection of overt liver metastatic disease and helps to 
differentiate between benign and malignant focal hepatic lesions [Kyriakopoulou  et al. 
,2008]. DPI was also found predictive of the liver steatosis in patients with NAFLD in the 
study conducted on a small group of patients, therefore it requires further evaluation 
[Dugoni et al. 2007]. Conventional Doppler ultrasound examination of hepatic vasculature 
is, unfortunately not a good tool to evaluate mild and moderate fibrosis. Data reporting the 
use of hepatic vein blood flow pattern assessment suggests improvements in detecting 
advanced fibrosis and cirrhosis [Bertzigotti et al., 2010].  
4.1.2 Contrast-enhanced ultrasonography 
This technique allows to overcome limitations of simple ultrasonography. Hepatic vein 
transit times (HVTT) were evaluated with microbubble contrast agent and were found to 
predict disease severity in patients with hepatitis C. The uptake of another contrast agent 
levovist was decreased in NASH due to  cell injury, when compared to NAFLD. The study 
was, however conducted on a small group of patients and should be validated on a larger 
cohort to establish the role of this technique in clinical practice. 
4.2 Computed tomography 
Computed tomography (CT) provides improved resolution of early liver cirrhosis in the 
absence of portal hypertension but remains unhelpful in a detection of fibrosis. Even more 
advanced variations as helical and multidetector row CT reveal early morphological 
changes with cirrhosis but do not identify fibrosis. 
Nevertheless, this  conventional technique is a helpful tool in detecting steatosis. Moreover, 
non-contrast enhanced CT is the best way to identify and characterize hepatic steatosis. 
Changes in signal sensitivity are related to the liver density, therefore as liver density 
decreases, the liver steatosis increases. Although abdominal ultrasound is more sensitive in 
the diagnosis of fatty liver disease, CT scans are more adequate when the fat deposition is 
focal.  They may also be used to evaluate thickened abdominal fatty tissue and to measure 
the fat in the liver [Davidson et al., 2006]. CT scans may also be used to visualize enlarged 
spleen and portal hypertension, which may suggest advanced fibrosis. Calculation of the 
liver-to-spleen attenuation ratio allows grading of steatosis [Park et al., 2006]. As the images 
appear enhanced, non-contrast CT is chosen for detecting steatosis. Focal fatty lesions may 
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Other tests combine both direct and indirect markers or other clinical parameters: age, 
gender, BMI, AST, AST/ALT ratio, hyaluronan [Palekar et al., 2006] or adiponectin and 
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and vary from study to study. Although patented commercial tests seem to present a higher 
diagnostic value, simply non-patented panels are much easier available.  
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Non-invasive assessment of the liver fibrosis is also possible by transient elastography. The 
technique is performed by device called Fibroscan that enables the assessment of the liver 
stiffness. The device holds an ultrasound probe in a vibrating piston that induces elastic 
vibrations propagating through the liver. The reflected waves captivated by a transducer 
enable to measure the liver elasticity that is inversely related to the speed of the waves 
[Sandrin 2003]. After several measurements, calculated mean value enables the exact 
assessment of liver fibrosis. This  method was proven precise enough when compared to the 
liver biopsy and evaluates a portion of the liver 500 times bigger than conventional method 
[Castera 2005]. Transient elastography is described in detailed in another chapter of this book. 
It was also used in combination with serum markers of fibrosis. The Fibro-Stiffness index is 
a panel consisting of liver stiffness measured by Fibroscan, platelet count and prothrombin 
time. The method demonstrated superior diagnostic performance to liver stiffness obtained 
by elastography alone, the APRI, the Forns score and the FibroIndex for significant and 
severe fibrosis and liver cirrhosis. The diagnostic value of the Fibro-Stiffness index for liver 
cirrhosis was increased by combination with serum HA levels [Ichino et al., 2010]. 
Various test panles were validated either compared to elastography or used simultaneously 
with this method. The most promising results were obtained were both serum markers and 
elastography were used together. 
4. Imaging techniques  
Conventional imaging techniques that include ultrasound with Doppler, CT and MRI can be 
used to evaluate advanced liver cirrhosis. Their ability to detect minor lesions is, however, 
limited [Hussain 2005]. 
4.1 Hepatic ultrasound  
Ultrasonography is simple, inexpensive, easy to reproduce and can be repeatedly used to 
assess changes over time. It is a first-line imaging technique, a simple non-invasive method, 
that is widely used in clinical practice to detect fatty infiltration of the liver. It assesses the 
presence of steatosis detecting a hyperechogenic parenchyma of the liver displayed as 
“bright liver “ or “blurring of the vascular margins”. An ultrasound index for quantitative 
assessment of the liver steatosis is the hepato-renal contrast. Normal liver shows an 
echostructure similar to renal parenchyma. In liver steatosis the increased echogenity forms 
hepato-renal contrast.  Severity of liver steatosis was assessed according to a discrepancy in 
ultrasonographic liver-kidney densities. The hepato-renal index was supposed to quantify 
the severity of liver steatosis to a lower limit of 5% [Webb et al. , 2007].   
Spleen longitudinal parameter is another simple, noninvasive and easy to perform 
parameter, that could differentiate between NAFLD and NASH better than serum markers 
with values exceeding 11.6 cm for predicting NASH.  
 
Non-Invasive Assessment of the Liver – Serum Markers and Imaging Techniques 
 
273 
When the degree of steatosis is less than 30%, sensitivity of this technique is low. Moreover, 
it is impossible to detect inflammatory changes of the hepatic parenchyma and to 
differentiate  between simple steatosis and staeatohepatitis. Therefore, it is very difficult to 
distinguish between the liver steatosis  and liver fibrosis as both changes look similar on 
ultrasound. 
The biggest limitation of this technique is morbid obesity as ultrasonographic examination is 
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liver-to-spleen attenuation ratio allows grading of steatosis [Park et al., 2006]. As the images 
appear enhanced, non-contrast CT is chosen for detecting steatosis. Focal fatty lesions may 
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be detected by dual-energy CT scans or by contrast enhanced CT. Figure 1 provides picture 
of multiple fatty lesions in the liver. 
However the difficulty to identify intermediate fibrotic stages and the uselessness in the 
follow-up of the patients due to the exposure to radiation are major limitations of CT. 
 
Fig. 1. Computed tomography with multiple focal lesions in the liver (A) of lower density 
than the liver parenchyma after contrast-enhancement (B) corresponding to hemangiomas.  
4.3 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) reliably identifies cirrhosis but does not show earlier 
stages of fibrosis. Specific features on MRI including hepatic vein narrowing, caudate to 
right lobe ratio, and expanded gallbladder fossa, reliably identify cirrhosis but remain 
absent in earlier stages of fibrosis [Numminen et al., 2005]. This technique provides an 
accurate and fast evaluation of the liver steatosis even if the degree is low (around 3%). 
Good correlation between liver steatosis, MRI and liver biopsy have also been recently 
demonstrated [Hussain 2005]. Phase-contrast imaging is used for the quantitative 
assessment of fatty infiltrations in various liver diseases. Lower intensity in T1-weighted 
images may be used in the detection of focal fat depositions [Szczepaniak  et al., 2005].  
Significant number of technological advances in developing clinical applications for MRI of 
the liver have been made over the past decade. Recent improvements focused on using the 
physiological and biomechanical properties of human liver tissue to improve the detection 
of focal and diffuse pathological conditions of this organ. New techniques such as magnetic 
resonance (MR) spectroscopy, diffusion-weight MR, MR elastography are evaluated to 
examine fibrosis [Talwalkar 2008].   
4.3.1 Contrast-enhanced magnetic resonance imaging 
The development of contrast-enhanced imaging of the liver have been enabled by the 
introduction of gadolinium chelates to clinical practice. Changes in hepatic parenchyma 
were described in various studies after contrast-enhanced imaging by MRI [Gandhi et al., 
2006]. Early irregular enhancement corresponds to the increased necroinflammatory activity 
in the liver histology due to higher numbers of macrophages. Whereas, a postponed, 
heterogeneous enhancement is related to hepatic fibrosis as a result of bright-appearing 
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reticulations. This finding may be explained by a reduced distribution of gadolinium in 
extracellular spaces of the liver [Semelka et al., 2001]. Contrast enhancement depends on the 
contrast agents. Supermagnetic iron oxide (SPIO) contrast media result in hypointensity 
within hepatic parenchyma as they accumulate in reticulo-endothelial cells [Yamashita et al., 
1996]. The most interesting findings were, however, obtained by sequential administration 
of gadolinium followed by SPIO contrast agents. Highly accurate SPIO-based images were 
even improved in accuracy for the detection of liver fibrosis architecture [Aguirre et al., 
2006]. Further validation of semi quantitative fibrosis criteria is required to verify the 
diagnostic performance of this technique.  
4.3.2 Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) has been available for the last twenty years 
allowing evaluation of metabolism of various tissues. The liver is considered to be an ideal 
organ for MRS due to its anatomical location and increased metabolic demands. MRS is 
usually used to evaluate signals from hydrogen, which allows for quantitative assessment of 
lipids and from phosphorus, which reflects cellular turnover and energy state [Solga et al., 
2005]. MRS of the liver is performed after a standard MR imaging for localization. Special 
MR pulse sequences are used to produce spectroscopic data within the suitable anatomical 
location and volume of interest. Peak area of metabolite signal is directly related to its 
concentration, which may be expressed in absolute or relative conditions. As the absolute 
quantification is difficult to obtain in vivo, many studies use metabolite ratios for the 
evaluation of spectral profiles. Peak areas of the spectrum are compared to standards for 
correlation with the strength of MR signal. The most widely used standard is adenozyne 
triphosphate (ATP), taking into account its natural distributions in the tissues. Changes in 
phospholipids metabolism, reflected in increased phosphomonoesters signal or increased 
phopsphomonoesters/phosphodiesters ratio in patients with liver cirrhosis, are believed to 
be associated with regenerating activity – extensive membrane remodeling.  
MRS represents useful method for highly accurate noninvasive measurement of liver 
steatosis [Friedrich-Rust 2010]. This technique measures the fat proton fraction and hepatic 
trigliceryde level. Concentration exceeding 5% is a limit of the detection of steatosis. MRS 
describes metabolic processes of cellular regeneration, therefore it can assess the disease 
severity in NASH. This technique is probably more accurate for the diagnosis of NAFLD but 
it requires further validation in humans.   
The studies have to be, however, repeated and validated on the larger number of patients 
with various liver diseases using unified methods. 
4.3.3 Diffusion weight magnetic resonance imaging 
Diffusion-weighted magnetic resonance imaging (DWI) has been widely used for the early 
detection of cerebral ischemia. This technique measures the freedom of water proton 
diffusion in tissues and was recently facilitated to be used for abdominal imaging 
[Naganawa et al., 2005]. As collagen is not reach in unbound water, therefore in the liver 
fibrosis the amount of water proton diffusion is restricted in affected tissue.  DWI produces 
a signal inversely related to the freedom of water proton diffusion. Tissues with reduced 
distribution are brighter than normal. The strength of diffusion weighting is described by 
“b” value of the sequence, which rises with time and amplitude of the gradients responsible 
for the diffusion. Apparent diffusion coefficient (ADC) of water proton in tissues may be 
calculated from DWI images. It is determined by the grade of the log intensity set against b 
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value [Girometti et al., 2007]. Possibility to display the calculated ADC values as images 
enable the quantitative analysis by the measurements of the mean values within region of 
interest. This measurement is usually performed in the right hepatic parenchyma, where 
major vessels are not present.  
Patients with liver cirrhosis were found to have lower ADC compared to healthy 
individuals. Nevertheless, the results of the studies in patients with various stages of fibrosis 
are ambiguous with respect to demonstrating a specific relationship between ADC values 
and fibrosis stage [Koinuma et al., 2005].  
Before the DWI becomes more widely used in clinical practice, the studies would have to be 
conducted on a larger number of patients and properly validated in relation to different 
hardware and sequencing profiles as currently comparisons are difficult.  It was also 
detected that significant hepatic iron accumulation may considerably reduce signal intensity 
making DWI impossible in patients with hemochromatosis [Aube et al., 2004]. Fat 
suppression techniques are necessary in DWI performed in the liver steatosis as otherwise 
imaging is seriously affected.  
4.3.4 Magnetic resonance elastography 
Many pathological  processes as malignancies and liver fibrosis result in increased liver 
stiffness, which may be detected by physical examination on palpation. Normal liver tissue 
is similar to fatty tissue on palpation, whereas cirrhotic liver is much harder. Recent reports 
suggest that the stiffness of hepatic matrix may influence continued differentiation of 
hepatic stellate cells and the production of fibrosis. Beside ultrasonography-based 
elastography, a MR-based elastography was described for evaluation of the stiffness of 
various tissues. The technique uses a phase-contrast method to display the propagation 
characteristics of acoustic sheer waves generated within the organ of interest [Kruse et al., 
2000]. Elastography is usually added to a conventional MR examination of the abdomen 
with pneumatic or electromechanical driver placed on abdominal wall in the supine patient. 
The device is used to generate  mechanical waves that propagate in the liver at various 
frequencies [Yin et al., 2007]. A specialized  phase contrast MRI sequence,  is subsequently 
used to image the propagating waves in the liver with motion-encoding gradients that are 
oscillated along with applied movements enabling clear imaging of the waves with very 
small amplitudes. Provided images represent displacement generated by shear wave 
propagation in the tissue. They are subsequently processed using a particular inversion 
algorithm to produce quantitative images describing the tissue stiffness called elastograms. 
The imaging allows for the measurement of mean elasticity values within the liver, 
presented in in kilopascals, as in the case of ultrasound-based transient elastography. 
Mean liver stiffness in patients with chronic liver diseases was found significantly increased, 
compared to healthy volunteers in various studies [Klatt et al., 2006]. A quadratic 
relationship between histological fibrosis stage and elasticity measurements were observed 
in the studies using ultrasound-based transient elastography. MR elastography was 
detecting stages 2 to 4 with good sensitivity and specificity. Thus, no relationship between 
hepatic steatosis and liver stiffness was found. MR elastography was a useful tool to exclude 
the presence of the liver fibrosis suggesting that this technique could be valuable in finding 
indications for the liver biopsy [Yin et al., 2007].  
Several advantages of this method were observed in relation to its potential use in different 
populations: potential assessment of entire hepatic parenchyma, operator independence and 
the ability to obtain a conventional abdominal MRI at the same time. Correspondingly to 
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other techniques, the equipment and sequences have to be standardized in order to increase 
the accuracy of the results and enable comparison of different studies. Further assessment is 
also necessary to characterize the procedure including its reproducibility among patients 
with progressive liver disease.  
4.3.5 Multi-echo magnetic resonance 
Multi-echo MRI allows simultaneous T2 and fat content evaluation. This method can be 
used to define the fat-to-water ratio as well as T2 values [O’Regan et al., 2008].  
4.3.6 Magnetic resonance cholangiopancreatography 
Magnetic resonance cholangiopancreatography (MRCP) is a well-established non-invasive 
imaging method that creates images of the biliary tree and pancreatic duct without the 
necessity of intravenous contrast. The images are corresponding to those from endoscopic 
retrograde cholangiopancreatography (ERCP). The most common indications for this 
technique include choledocholithiasis, primary sclerosing cholangitis or stricture of bile 
ducts and others. MRCP also plays an important role in other conditions involving 
cholangiohepatitis, inborn malformations, tumors and other cysts. The biggest advantage of 
this technique is the lack of contrast administration, relative operator independence and 
possibility to evaluate both sides of obstructed ducts with exact stricture size and 
morphology. Example of MRCP imaging was presented in Figure 2.  
 
 
Fig. 2. MRCP image showing the liver of patient with primary sclerosing cholangitis and 
numerous fibrous septa within the liver with coexisting splenomegaly. 
A reliable and valuable noninvasive method to assess hepatic fibrosis would be a very 
useful clinical tool.  Several MR techniques or their combinations are still evaluated to meet 
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these requirements and are very promising. Further research is, however necessary to create 
true functional hepatic imaging.  
Clinical utility of imaging techniques is still under evaluation. Advanced MRI techniques 
are available in tertiary medical centers  and it will probably take time before they become 
widely available.  Furthermore, even  with this technique some patients may be unable or 
unwilling to undergo the examination. 
5. Conclusions 
Combination of non-invasive methods like Fibro-test and elastography may substitute the 
liver biopsy in a near future. They are reliable in patients either with no or progressed 
fibrosis. Evaluation of intermediate states is, however, difficult. For this reason the liver 
biopsy remains a most valuable tool in evaluation of the liver and according to current 
guidelines treatment decisions should be made after liver biopsy. Thus, non-invasive 
methods may be still an option for patients with contraindications to the liver biopsy or a 
helpful monitoring tool for those who are reluctant or unable to undergo repeated biopsies. 
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biopsy remains a most valuable tool in evaluation of the liver and according to current 
guidelines treatment decisions should be made after liver biopsy. Thus, non-invasive 
methods may be still an option for patients with contraindications to the liver biopsy or a 
helpful monitoring tool for those who are reluctant or unable to undergo repeated biopsies. 
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Transient Elastography for Assessment of  
Non-Alcoholic Fatty Liver Disease  
Ludovico Abenavoli 
University “Magna Græcia” of Catanzaro, 
Italy 
1. Introduction  
In 1958, Menghini published the first description of liver biopsy (LB) as it pertained to the 
study of fibrosis. Since then, LB has become the “gold  standard” in the evaluation of liver 
fibrosis. However, the use of LB has several limitations, including physical and mental 
discomfort of patients, which may lead to a high percentage of refusals, non-negligible 
morbidity and occasional mortality. Fibrosis is evaluated by histological semiquantitative 
scores, among which the METAVIR fibrosis scoring system is the most used; it is able to 
detect different degrees of fibrosis, from absence of fibrosis (F0) to cirrhosis (F4), and shows 
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morbidity and occasional mortality. Fibrosis is evaluated by histological semiquantitative 
scores, among which the METAVIR fibrosis scoring system is the most used; it is able to 
detect different degrees of fibrosis, from absence of fibrosis (F0) to cirrhosis (F4), and shows 
a better intra- and inter-observer reproducibility than other scales (i.e., Brunt, Knodell, Ishak 
and Scheuer). However these scores do not provide a dynamic picture of the disease, but 
only information about diagnosis and prognosis, such as the necroinflammatory activity and 
the presence of steatosis (Abenavoli et al, 2007). 
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epidemiologic burden (Argo & Caldwell, 2009). NAFLD is also not a new condition, but was 
not appreciated in early reports. It represents the most common chronic liver disease in the 
general population and is expected to increase in the future as a result of an ageing population, 
the improving control of other major causes of chronic liver disease and the epidemics of 
obesity and diabetes (Abenavoli et al, 2011). Steatosis consists of an accumulation of fat in the 
liver cells, and is not a disease in and of itself. It is an aggravating factor in certain pathological 
situations of varying degrees of gravity, and becomes dangerous when associated with 
inflammation or fibrosis. It is reversible, however, through diet and exercise. In fact NAFLD, 
may present as a spectrum ranging from asymptomatic steatosis with elevated or normal 
aminotransferases to steatohepatitis [non-alcoholic steatohepatitis (NASH)], all the way to 
cirrhosis with complications of liver function to hepatocellular carcinoma. NAFLD occurs in 
60-95% patients with obesity, in 28-55% patients with type 2 diabetes mellitus (T2DM) and in 
27-92% patients with dyslipidemia. Insulin resistance with compensatory hyperinsulinemia is 
the common denominator of obesity, T2DM and dyslipidemia and it can play a pathogenetic 
role in NAFLD. Accordingly, it has been reported that insulin resistance is the single 
laboratory finding most closely associated with NAFLD in a large series of patients, 
irrespective of body mass index (BMI), fat distribution, or glucose tolerance. Indeed, NAFLD 
has been recently proposed as an additional feature of the metabolic syndrome. 
Currently liver steatosis, can be detected only by ultrasound (US) and quantified only by 
performing a biopsy. LB is still considered the “gold standard” for distinguishing between the 
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broad range of NAFLD. However LB is not recommended in NAFLD patients, because of its 
cost, the potential risk of bleeding, and the absence of consensus regarding the histopatological 
criteria that firmly define NASH and differentiate between NAFLD entities. Due to the 
remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing 
new therapies for fatty liver, non-invasive, simple, reproducible, and reliable non-invasive 
techniques are needed. In this way US is widely used in the diagnosis of patients with 
suspected liver disease because it is highly accurate, relatively inexpensive and non-invasive. 
Based on these characteristics, US has been the first-line imaging technique suitable both in the 
clinical setting and for epidemiological studies. In particular US is the least expensive modality 
for detecting changes associated with NAFLD. However, echography-based US techniques 
begin to become sensitive at moderately high levels of steatosis (33% or more) and suffer from 
low intra- and inter-operator repeatability (Schwenzer et al, 2009). 
Vibration-controlled transient elastography ([VCTE], Fibroscan®, Echosens, Paris, France) is 
a non-invasive technique which measures liver stiffness, and allows the assessment of the 
extent of hepatic fibrosis. VCTE has been proposed for the measurement of liver stiffness, 
considered to be one of the direct consequences of the brotic evolution of chronic liver 
disease (Sandrin et al, 2003).  
A few meta-analyses have suggested liver stiffness measurement (LSM) through VCTE to be a 
reliable tool to detect advanced liver brosis and early liver cirrhosis (Friedrich-Rust et al, 
2008). In NAFLD patients, various degrees of hepatic steatosis may attenuate the elastic shear 
wave, but it does not change its underlying speed which is the parameter used for stiffness 
measurement. Literature showed a clearly positive correlation between liver stiffness and the 
severity of liver fibrosis in patients with NAFLD. Rapid, non-invasive estimation of the stage 
of fibrosis in NAFLD patients, especially NASH patients, is of major clinical interest because 
such patients have been shown to be at a high risk of developing complications. Recently, a 
new measurement technique, the controlled attenuation parameter (CAP®, EchoSens, Paris, 
France), which provides good accuracy with even low levels of steatosis in the liver has been 
introduced. Because of its sensitivity at early phases of steatosis. CAP could provide a means 
to monitor the progression or regression of steatosis.  
The combination of the measurement of liver attenuation parameter (CAP) and liver 
stiffness (VCTE) could provide a means to follow NAFLD patients throughout the course of 
the disease and observe independently the effects of steatosis and liver injury effects that are 
signs of the worsening of the disease. 
2. Transient elastography for staging liver disease 
The development of non-invasive tools to evaluate liver disease stages, has emerged as a 
major clinical and research priority. The quest for accurate techniques to stage NAFLD 
stems from a variety of recent data. First, the prevalence of NAFLD has grown to epidemic 
proportions. It is currently one of the most common chronic liver diseases worldwide. It is 
strongly associated with metabolic syndrome and obesity, and may progress to cirrhosis 
and hepatocellular carcinoma. The prognosis depends heavily on histological severity. 
Although patients with simple steatosis have excellent prognosis, those with NASH tend to 
progress and have hepatic complications. In Western countries, one in three men and nearly 
every other woman is affected by NAFLD. Second, it is well reported that NAFLD exists as a 
spectrum consisting of two major phenotypes that have drastically different natural 
histories. The majority of patients present simple steatosis, which has a benign clinical 
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course. However 10-20% of these individuals present NASH that can evolve into cirrhosis. 
Third, according to literature, several problems for the management of NAFLD patients in 
clinical practice still exist: how to diagnose NAFLD and its type, how to select patient 
candidates for treatment and how to treat the patients selected. Discovery and validation of 
new diagnostic tools for NAFLD have several potential benets, including reduced risk, 
reduced cost, as well as insights into disease mechanisms and pathogenesis. More accurate 
detection and diagnosis of NAFLD will help focus service provision for what is already a 
very common condition. 
The limitations of LB (invasive procedure, sampling errors, interobserver variability and non-
dynamic evaluation) have stimulated the search for non-invasive approaches for the 
assessment of steatosis and liver fibrosis in patients with NAFLD. A variety of new methods, 
including serum markers, imaging techniques such as US, computed tomography, magnetic 
resonance imaging and VCTE, and more recently, CAP, have been proposed. In particular 
VCTE has shown excellent results for the diagnosis of severe brosis and cirrhosis and 
moderate results for the diagnosis of signicant brosis in patients with NAFLD/NASH. 
The stiffness of a body is defined as the ability of the body to deform itself under the action 
of a mechanical force (Abenavoli et al, 2007). The stiffness of a soft tissue can be estimated 
on the basis of the speed of propagation of a transverse shear elastic wave. The higher is the 
speed of propagation of that wave, the higher is the stiffness of the tissue. VCTE measures 
such speed of propagation in relatively homogenous organs like the liver, by using US 
pulses to localise the shear elastic wave at different times. The measuring device is equipped 
with a probe consisting of an ultrasonic transducer mounted on the axis of a vibrator. A 
low-frequency at 50 Hz and mild amplitude vibration, referred to as “shots”, is transmitted 
from the vibrator to the tissue by the transducer itself. This vibration induces an elastic shear 
wave which propagates through the tissue. In the meantime, ultrasonic acquisitions are 
performed by an echographic transducer, using a frequency at 3.5MHz, to determine the 
propagation of the shear wave. The propagation speed is transformed into stiffness by a 
formula derived by the physics of the propagation of a transverse shear elastic wave of a 
given frequency (50 Hz) through the soft tissue and expressed in kiloPascals (kPa). The 
probe is applied perpendicularly to the skin (with a little gel film) through one of the right 
side intercostal spaces along the mid-axillary line. The measurement of the speed is taken 
along a cylinder of tissue ranging from 25 to 65 millimetres of depth under the skin. This 
corresponds to a volume of liver tissue approximately 100 times greater than an LB 
specimen and represents about 1% of the total organ volume. The examination is non-
invasive and can be performed on ambulatory patients, in an outpatient setting or at the 
bedside of a hospitalized patient. VCTE can be performed indifferently by hepatologists or 
medical staff (physician, resident, medicine student, nurse) after a single training session 
provided by a specifically certified trainer. Results of the measurements range from 1.3 and 
75.4 kPa. The manufacturer currently recommends that fibrosis score should be established 
from the median value of at least 10 successful acquisitions, with the rate of valid measures 
always higher than 50%. The intra- and inter-observer coefficients of variation are 3.2 and 
3.3%, respectively, indicating very good reproducibility and operator independence.  
3. Elastography assessment of fatty liver 
A prospective study (Kim et al., 2007) aimed to assess the ability of VCTE to identify 
histologic parameters, including steatosis, in asymptomatic healthy individuals such as 
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broad range of NAFLD. However LB is not recommended in NAFLD patients, because of its 
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criteria that firmly define NASH and differentiate between NAFLD entities. Due to the 
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techniques are needed. In this way US is widely used in the diagnosis of patients with 
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clinical setting and for epidemiological studies. In particular US is the least expensive modality 
for detecting changes associated with NAFLD. However, echography-based US techniques 
begin to become sensitive at moderately high levels of steatosis (33% or more) and suffer from 
low intra- and inter-operator repeatability (Schwenzer et al, 2009). 
Vibration-controlled transient elastography ([VCTE], Fibroscan®, Echosens, Paris, France) is 
a non-invasive technique which measures liver stiffness, and allows the assessment of the 
extent of hepatic fibrosis. VCTE has been proposed for the measurement of liver stiffness, 
considered to be one of the direct consequences of the brotic evolution of chronic liver 
disease (Sandrin et al, 2003).  
A few meta-analyses have suggested liver stiffness measurement (LSM) through VCTE to be a 
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2008). In NAFLD patients, various degrees of hepatic steatosis may attenuate the elastic shear 
wave, but it does not change its underlying speed which is the parameter used for stiffness 
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of fibrosis in NAFLD patients, especially NASH patients, is of major clinical interest because 
such patients have been shown to be at a high risk of developing complications. Recently, a 
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France), which provides good accuracy with even low levels of steatosis in the liver has been 
introduced. Because of its sensitivity at early phases of steatosis. CAP could provide a means 
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stiffness (VCTE) could provide a means to follow NAFLD patients throughout the course of 
the disease and observe independently the effects of steatosis and liver injury effects that are 
signs of the worsening of the disease. 
2. Transient elastography for staging liver disease 
The development of non-invasive tools to evaluate liver disease stages, has emerged as a 
major clinical and research priority. The quest for accurate techniques to stage NAFLD 
stems from a variety of recent data. First, the prevalence of NAFLD has grown to epidemic 
proportions. It is currently one of the most common chronic liver diseases worldwide. It is 
strongly associated with metabolic syndrome and obesity, and may progress to cirrhosis 
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Although patients with simple steatosis have excellent prognosis, those with NASH tend to 
progress and have hepatic complications. In Western countries, one in three men and nearly 
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spectrum consisting of two major phenotypes that have drastically different natural 
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course. However 10-20% of these individuals present NASH that can evolve into cirrhosis. 
Third, according to literature, several problems for the management of NAFLD patients in 
clinical practice still exist: how to diagnose NAFLD and its type, how to select patient 
candidates for treatment and how to treat the patients selected. Discovery and validation of 
new diagnostic tools for NAFLD have several potential benets, including reduced risk, 
reduced cost, as well as insights into disease mechanisms and pathogenesis. More accurate 
detection and diagnosis of NAFLD will help focus service provision for what is already a 
very common condition. 
The limitations of LB (invasive procedure, sampling errors, interobserver variability and non-
dynamic evaluation) have stimulated the search for non-invasive approaches for the 
assessment of steatosis and liver fibrosis in patients with NAFLD. A variety of new methods, 
including serum markers, imaging techniques such as US, computed tomography, magnetic 
resonance imaging and VCTE, and more recently, CAP, have been proposed. In particular 
VCTE has shown excellent results for the diagnosis of severe brosis and cirrhosis and 
moderate results for the diagnosis of signicant brosis in patients with NAFLD/NASH. 
The stiffness of a body is defined as the ability of the body to deform itself under the action 
of a mechanical force (Abenavoli et al, 2007). The stiffness of a soft tissue can be estimated 
on the basis of the speed of propagation of a transverse shear elastic wave. The higher is the 
speed of propagation of that wave, the higher is the stiffness of the tissue. VCTE measures 
such speed of propagation in relatively homogenous organs like the liver, by using US 
pulses to localise the shear elastic wave at different times. The measuring device is equipped 
with a probe consisting of an ultrasonic transducer mounted on the axis of a vibrator. A 
low-frequency at 50 Hz and mild amplitude vibration, referred to as “shots”, is transmitted 
from the vibrator to the tissue by the transducer itself. This vibration induces an elastic shear 
wave which propagates through the tissue. In the meantime, ultrasonic acquisitions are 
performed by an echographic transducer, using a frequency at 3.5MHz, to determine the 
propagation of the shear wave. The propagation speed is transformed into stiffness by a 
formula derived by the physics of the propagation of a transverse shear elastic wave of a 
given frequency (50 Hz) through the soft tissue and expressed in kiloPascals (kPa). The 
probe is applied perpendicularly to the skin (with a little gel film) through one of the right 
side intercostal spaces along the mid-axillary line. The measurement of the speed is taken 
along a cylinder of tissue ranging from 25 to 65 millimetres of depth under the skin. This 
corresponds to a volume of liver tissue approximately 100 times greater than an LB 
specimen and represents about 1% of the total organ volume. The examination is non-
invasive and can be performed on ambulatory patients, in an outpatient setting or at the 
bedside of a hospitalized patient. VCTE can be performed indifferently by hepatologists or 
medical staff (physician, resident, medicine student, nurse) after a single training session 
provided by a specifically certified trainer. Results of the measurements range from 1.3 and 
75.4 kPa. The manufacturer currently recommends that fibrosis score should be established 
from the median value of at least 10 successful acquisitions, with the rate of valid measures 
always higher than 50%. The intra- and inter-observer coefficients of variation are 3.2 and 
3.3%, respectively, indicating very good reproducibility and operator independence.  
3. Elastography assessment of fatty liver 
A prospective study (Kim et al., 2007) aimed to assess the ability of VCTE to identify 
histologic parameters, including steatosis, in asymptomatic healthy individuals such as 
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potential liver donors, and to compare these ndings with results in liver disease patients. 
Forty-seven patients with abnormal liver function and/or hepatitis symptoms and 80 living 
related potential liver donors were consecutively enrolled, and LB and a LSM was 
performed in each subject. Histologic parameters were evaluated according to METAVIR 
score by a single pathologist. In liver disease patients, stiffness was signicantly correlated 
with brosis stage (P< 0.001), and the optimal stiffness cut-off values for F≥2, F≥3, and F=4 
were 7.35, 8.85, and 15.1 kPa respectively. In potential liver donors, stiffness was not 
correlated with brosis ( P = 0.851). In the latter group, the area under the receiver-operating 
characteristics curve (AUROC) was 0.70 (95%, condence interval [CI],  0.58-0.81), and the 
optimal stiffness cut-off value was 4.00 kPa for F ≥ 2, which was lower than that in liver 
disease patients. Steatosis was not correlated with stiffness (P = 0.463) in potential liver 
donors. The Authors concluded that VCTE presets limited value for detecting steatosis in 
asymptomatic healthy individuals. 
Nobili et al. (2008) have been assessed the value of VCTE in a cohort of pediatric patients 
with NASH. TE was performed in 50 consecutive biopsy-proven NASH patients age 
13.6±2.44 years). The AUROC for the prediction of different degrees of liver fibrosis on the 
basis of Brunt score, were 0.977, 0.992, and 1, for respectively “any”, significant and 
advanced fibrosis. Calculation of multilevel likelihood ratios shows that VCTE values <5, 
<7, and <9 kPa, suggest the presence of “any” brosis, signicant brosis, and advanced 
brosis, respectively. VCTE values between 5 and 7 kPa predict a brosis stage of 1, but 
with some degree of uncertainty. VCTE values between 7 and 9 kPa predict brosis stages 1 
or 2, but cannot discriminate between these two stages. VCTE values of at least 9 kPa are 
associated with the presence of advanced brosis. In summary this study reported the 
reliability of VCTE to predict the presence of “any” brosis, signicant brosis, and 
advanced brosis in these special populations. 
Yoneda et al. (2008) have been investigated the usefulness of LSM in the evaluation of liver 
brosis in NAFLD patients. VCTE was performed for liver stiffness measurement in 97 
NAFLD patients. The Authors have also investigated the relationship between LSM and the 
serum levels of hyaluronic acid and type IV collagen 7s domain. Liver stiffness was well 
correlated with the different stage of METAVIR score (P<0.0001). The AUROC were 0.927 
for ≥F1, 0.865 for ≥F2, 0.904 for ≥F3, 0.991 for ≥F4. Only brosis stage was strictly correlated 
with liver stiffness measurement by multiple regression analysis. Liver stiffness was also 
strongly correlated with the serum levels of type IV collagen 7s domain (r=0.525, P<0.0001) 
and hyaluronic acid (r=0.457, P<0.0001). These data show a signicant correlation between 
liver stiffness measurement and brosis stage in NAFLD patients, as conrmed by the 
results of LB.  
Lupsor et al. (2010) assess VCTE performance in NASH patients, as well as the factors 
determining the discordance between the VCTE-predicted and the brosis stage evaluated 
by the Brunt system. LB and VCTE were performed on 72 consecutive NASH patients. LSM 
ranged from 2.80 to 16.90 kPa. In the univariate analysis, LSM was correlated with brosis 
(P<0.0001), steatosis (P<0.0001), ballooning (P=0.001) and lobular inammation (P=0.002). In 
multivariate analysis, only brosis signicantly correlated with LS (P<0.0001). The median 
LSM values according to the brosis stages were: 4.90 kPa (range: 2.80-7.30) for F0; 6.15 kPa 
(4.80-12.50) for F1; 6.90 kPa (3.30-16.90) for F2 and 14.00 kPa (10.70-14.10) for F3, with 
signicant difference between stages, except for F1-F2 (P=0.249). Cut-off values were 
calculated for predicting each brosis stage: 5.3kPa (AUROC=0.879) for F1; 6.8kPa 
(AUROC=0.789) for F2; and 10.4kPa (AUROC=0.978) for F3. Patients with false positive 
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results had a signicantly higher ALT level than those with concordant results (P=0.039). 
These data show that steatosis degree, ballooning and inammation do not inuence LSM. 
In NAFLD patients, various degrees of hepatic steatosis may attenuate the elastic shear wave, 
possibly leading again to an underestimation of liver damage. Wong et al. (2010) aimed to 
evaluate the accuracy of VCTE in the diagnosis of brosis and cirrhosis in patients with 
NAFLD and to study factors associated with discordance between LSM and histology. Two 
hundred forty-six consecutive patients from two ethnic groups had successful LSM and 
satisfactory liver biopsy specimens. The AUROC of VCTE for F3 or higher and F4 disease was 
0.93 and 0.95, respectively, and was signicantly higher than that of other prediction scores 
(e.g. aspartate aminotransferase–to–alanine aminotransferase ratio, aspartate 
aminotransferase–to–platelet ratio index, FIB-4, BARD, and NAFLD brosis scores). AUROC 
ranged from 0.62 to 0.81, P < 0.05 for all comparisons. At a cut-off value of 7.9 kPa, the 
sensitivity, specicity, and positive and negative predictive values for F3 or greater disease 
were 91%, 75%, 52%, and 97%, respectively. LSM was not affected by hepatic steatosis, 
necroinammation, or body mass index. Discordance of at least two stages between VCTE and 
histology was observed in 33 (13.4%) patients. By multivariate analysis, a LB length less than 
20 mm and F0-2 disease, rather than VCTE, were associated with discordance. Unsatisfactory 
LB specimens rather than VCTE account for most cases of discordance. However, when the 
diagnostic characteristics were compared using an “intention to diagnose” approach with the 
inclusion of subjects who had unsuccessful TE acquisition, the sensitivity and specicity values 
were not dissimilar from the clinical/biochemical models, although 95% CIs were not 
provided for statistical comparison.  
Subsequently a prospective study by Gaia et al. (2011) assess the accuracy and the efcacy of 
VCTE for the detection of brosis in patients with liver disease of different etiology (chronic 
hepatitis B - CHB, C- CHC and NAFLD) and evaluate the effect of steatosis on LSM. VCTE 
was performed in 219 consecutive patients with chronic liver disease (35% CHC, 32% CHB, 
and 33% NAFLD) within 6 months of the liver biopsy. LSM was related to the brosis stage 
in each group (CHC: P=0.596, P<0.001; CHB: P =0.418, P<0.001; NAFLD: P=0.573, P<0.001), 
but the correlation was less strong in CHB and NAFLD than in CHC patients. Median LSM 
values were 7 kPa (3.2–26) in HCV patients (n=77), 7.6 kPa (3.7–30.7) in HBV patients (n=70), 
6.6 kPa (3.0–44.3) in NAFLD patients (n=72) compared to 4.35 kPa (range 2.6–7) in controls 
(n=40), (P<0.001). The median values of LSM according to brosis stage evaluated by 
METAVIR were in the 72 NAFLD patients: F0: 5.3 kPa (3.0–9.7), F1: 6.15 kPa (3.2–12.1), 
F2:7.75 kPa (4.3–13.9), F3:6.5 kPa (4.3–10.3), F4:11.9 kPa (7.9–44.3), (P=0.001). VCTE 
underestimated the stage of brosis in 75% of patients with F3 and steatosis >33%. At 
multiple logistic regression analysis, in CHC and CHB patients, LSM was the only 
predictive variable of severe brosis/cirrhosis (odds ratio [OR]=1.42, P=0.003 and OR=1.354, 
P=0.003, respectively), while in NAFLD subjects BMI and AST (OR=1.433, P=0.002 and 
OR=1.053, P=0.020, respectively) but not LSM were independently related with advanced 
brosis and cirrhosis. This study conrms that VCTE can be considered a valid support to 
detect brosis in chronic liver disease related to HCV but it should be interpreted cautiously 
in CHB and NAFLD patients. 
4. Elastography assessment of NAFLD in obese patients 
LSM can be influenced by metabolic syndrome even in the absence of biological features in 
NAFLD. It would be important to identify the rates and factors associated with unreliable 
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potential liver donors, and to compare these ndings with results in liver disease patients. 
Forty-seven patients with abnormal liver function and/or hepatitis symptoms and 80 living 
related potential liver donors were consecutively enrolled, and LB and a LSM was 
performed in each subject. Histologic parameters were evaluated according to METAVIR 
score by a single pathologist. In liver disease patients, stiffness was signicantly correlated 
with brosis stage (P< 0.001), and the optimal stiffness cut-off values for F≥2, F≥3, and F=4 
were 7.35, 8.85, and 15.1 kPa respectively. In potential liver donors, stiffness was not 
correlated with brosis ( P = 0.851). In the latter group, the area under the receiver-operating 
characteristics curve (AUROC) was 0.70 (95%, condence interval [CI],  0.58-0.81), and the 
optimal stiffness cut-off value was 4.00 kPa for F ≥ 2, which was lower than that in liver 
disease patients. Steatosis was not correlated with stiffness (P = 0.463) in potential liver 
donors. The Authors concluded that VCTE presets limited value for detecting steatosis in 
asymptomatic healthy individuals. 
Nobili et al. (2008) have been assessed the value of VCTE in a cohort of pediatric patients 
with NASH. TE was performed in 50 consecutive biopsy-proven NASH patients age 
13.6±2.44 years). The AUROC for the prediction of different degrees of liver fibrosis on the 
basis of Brunt score, were 0.977, 0.992, and 1, for respectively “any”, significant and 
advanced fibrosis. Calculation of multilevel likelihood ratios shows that VCTE values <5, 
<7, and <9 kPa, suggest the presence of “any” brosis, signicant brosis, and advanced 
brosis, respectively. VCTE values between 5 and 7 kPa predict a brosis stage of 1, but 
with some degree of uncertainty. VCTE values between 7 and 9 kPa predict brosis stages 1 
or 2, but cannot discriminate between these two stages. VCTE values of at least 9 kPa are 
associated with the presence of advanced brosis. In summary this study reported the 
reliability of VCTE to predict the presence of “any” brosis, signicant brosis, and 
advanced brosis in these special populations. 
Yoneda et al. (2008) have been investigated the usefulness of LSM in the evaluation of liver 
brosis in NAFLD patients. VCTE was performed for liver stiffness measurement in 97 
NAFLD patients. The Authors have also investigated the relationship between LSM and the 
serum levels of hyaluronic acid and type IV collagen 7s domain. Liver stiffness was well 
correlated with the different stage of METAVIR score (P<0.0001). The AUROC were 0.927 
for ≥F1, 0.865 for ≥F2, 0.904 for ≥F3, 0.991 for ≥F4. Only brosis stage was strictly correlated 
with liver stiffness measurement by multiple regression analysis. Liver stiffness was also 
strongly correlated with the serum levels of type IV collagen 7s domain (r=0.525, P<0.0001) 
and hyaluronic acid (r=0.457, P<0.0001). These data show a signicant correlation between 
liver stiffness measurement and brosis stage in NAFLD patients, as conrmed by the 
results of LB.  
Lupsor et al. (2010) assess VCTE performance in NASH patients, as well as the factors 
determining the discordance between the VCTE-predicted and the brosis stage evaluated 
by the Brunt system. LB and VCTE were performed on 72 consecutive NASH patients. LSM 
ranged from 2.80 to 16.90 kPa. In the univariate analysis, LSM was correlated with brosis 
(P<0.0001), steatosis (P<0.0001), ballooning (P=0.001) and lobular inammation (P=0.002). In 
multivariate analysis, only brosis signicantly correlated with LS (P<0.0001). The median 
LSM values according to the brosis stages were: 4.90 kPa (range: 2.80-7.30) for F0; 6.15 kPa 
(4.80-12.50) for F1; 6.90 kPa (3.30-16.90) for F2 and 14.00 kPa (10.70-14.10) for F3, with 
signicant difference between stages, except for F1-F2 (P=0.249). Cut-off values were 
calculated for predicting each brosis stage: 5.3kPa (AUROC=0.879) for F1; 6.8kPa 
(AUROC=0.789) for F2; and 10.4kPa (AUROC=0.978) for F3. Patients with false positive 
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results had a signicantly higher ALT level than those with concordant results (P=0.039). 
These data show that steatosis degree, ballooning and inammation do not inuence LSM. 
In NAFLD patients, various degrees of hepatic steatosis may attenuate the elastic shear wave, 
possibly leading again to an underestimation of liver damage. Wong et al. (2010) aimed to 
evaluate the accuracy of VCTE in the diagnosis of brosis and cirrhosis in patients with 
NAFLD and to study factors associated with discordance between LSM and histology. Two 
hundred forty-six consecutive patients from two ethnic groups had successful LSM and 
satisfactory liver biopsy specimens. The AUROC of VCTE for F3 or higher and F4 disease was 
0.93 and 0.95, respectively, and was signicantly higher than that of other prediction scores 
(e.g. aspartate aminotransferase–to–alanine aminotransferase ratio, aspartate 
aminotransferase–to–platelet ratio index, FIB-4, BARD, and NAFLD brosis scores). AUROC 
ranged from 0.62 to 0.81, P < 0.05 for all comparisons. At a cut-off value of 7.9 kPa, the 
sensitivity, specicity, and positive and negative predictive values for F3 or greater disease 
were 91%, 75%, 52%, and 97%, respectively. LSM was not affected by hepatic steatosis, 
necroinammation, or body mass index. Discordance of at least two stages between VCTE and 
histology was observed in 33 (13.4%) patients. By multivariate analysis, a LB length less than 
20 mm and F0-2 disease, rather than VCTE, were associated with discordance. Unsatisfactory 
LB specimens rather than VCTE account for most cases of discordance. However, when the 
diagnostic characteristics were compared using an “intention to diagnose” approach with the 
inclusion of subjects who had unsuccessful TE acquisition, the sensitivity and specicity values 
were not dissimilar from the clinical/biochemical models, although 95% CIs were not 
provided for statistical comparison.  
Subsequently a prospective study by Gaia et al. (2011) assess the accuracy and the efcacy of 
VCTE for the detection of brosis in patients with liver disease of different etiology (chronic 
hepatitis B - CHB, C- CHC and NAFLD) and evaluate the effect of steatosis on LSM. VCTE 
was performed in 219 consecutive patients with chronic liver disease (35% CHC, 32% CHB, 
and 33% NAFLD) within 6 months of the liver biopsy. LSM was related to the brosis stage 
in each group (CHC: P=0.596, P<0.001; CHB: P =0.418, P<0.001; NAFLD: P=0.573, P<0.001), 
but the correlation was less strong in CHB and NAFLD than in CHC patients. Median LSM 
values were 7 kPa (3.2–26) in HCV patients (n=77), 7.6 kPa (3.7–30.7) in HBV patients (n=70), 
6.6 kPa (3.0–44.3) in NAFLD patients (n=72) compared to 4.35 kPa (range 2.6–7) in controls 
(n=40), (P<0.001). The median values of LSM according to brosis stage evaluated by 
METAVIR were in the 72 NAFLD patients: F0: 5.3 kPa (3.0–9.7), F1: 6.15 kPa (3.2–12.1), 
F2:7.75 kPa (4.3–13.9), F3:6.5 kPa (4.3–10.3), F4:11.9 kPa (7.9–44.3), (P=0.001). VCTE 
underestimated the stage of brosis in 75% of patients with F3 and steatosis >33%. At 
multiple logistic regression analysis, in CHC and CHB patients, LSM was the only 
predictive variable of severe brosis/cirrhosis (odds ratio [OR]=1.42, P=0.003 and OR=1.354, 
P=0.003, respectively), while in NAFLD subjects BMI and AST (OR=1.433, P=0.002 and 
OR=1.053, P=0.020, respectively) but not LSM were independently related with advanced 
brosis and cirrhosis. This study conrms that VCTE can be considered a valid support to 
detect brosis in chronic liver disease related to HCV but it should be interpreted cautiously 
in CHB and NAFLD patients. 
4. Elastography assessment of NAFLD in obese patients 
LSM can be influenced by metabolic syndrome even in the absence of biological features in 
NAFLD. It would be important to identify the rates and factors associated with unreliable 
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LSM or LSM failure, as the results may provide guidance to referral physicians regarding 
the optimal candidates for LSM. The knowledge would also assist clinicians to counsel 
patients before arranging LSM. However, studies have shown that BMI>28 is an 
independent risk factor for a LSM failure (Foucher et al, 2006). In a prospective pilot study 
on VCTE in NAFLD, de Lédinghen et al. (2010) aimed to assess the feasibility of LSM when 
using a new XL-probe on patients with a BMI≥30 kg/m2 is used. In this study 99 patients 
(mean  BMI 40.5 kg/m2) were included. LSM was successful in 45% of the cases with the M 
probe, versus 76% of the cases with the XL-probe (P<0.001). Fifty-nine percent of those who 
could not be measured (<10 valid measurements) using the M-probe could successfully be 
measured using the XL-probe. In the 44 patients successfully measured with both probes, 
LSM was correlated with the platelet count, prothrombin time, gamma-glutamyltransferase, 
aspartate aminotransferase, fasting glucose, AST platelet ratio index, Forns score and FIB-4. 
The XL-probe allows providing a higher rate of LSM than the M-probe in patients with an 
increased BMI and shows promising results for the evaluation of liver brosis. 
 
Lead author Yoneda (N 97)* Nobili (N 50)° Lupsor (N 72)° Wong (N 246)° 
F≥ 2     
AUROC 0.86 0.99 0.78 0.84 
Optimal cut-off (kPa) 6.6 7.4 6.8 7.0 
Sensitivity (%) 88 100 100 79 
Specificity (%) 74 92 97 76 
PPV (%) 79 80 71 70 
NPV (%) 85 100 100 84 
F≥ 3     
AUROC 0.90 1.0 0.978 0.93 
Optimal cut-off (kPa) 9.8 10.2 10.4 8.7 
Sensitivity (%) 85 100 100 84 
Specificity (%) 81 100 97 83 
PPV (%) 64 100 71 59 
NPV (%) 93 100 100 95 
F≥ 3     
AUROC 0.99 - - 0.95 
Optimal cut-off (kPa) 17.5   10.3 
Sensitivity (%) 100 - - 92 
Specificity (%) 97 - - 88 
PPV (%) 75 - - 46 
NPV (%) 100 - - 99 
Table 1. Analysis of VCTE cut-off for the diagnosis of NAFLD in adult patients. (AUROC: 
area under receiver operative curve; PPV: positive predictive value; NPV: negative 
predictive value. Histological evaluation by *METAVIR and °Brunt score). 
In this way Wong et al. (2011) have recently investigated the rates of unreliable LSM and 
LSM failure in patients suffering from chronic liver diseases. They also aimed to evaluate 
the factors including BMI and central obesity associated with unreliable LSM and LSM 
failure. Among 3205 Chinese patients with LSM, 370 (12%) with liver steatosis, 371 
(11.6%) and 88 (2.7%) had unreliable LSM and LSM failure, respectively. The rates started 
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to increase when BMI≥28.0 kg/m2. Comparing patients with BMI≥28.0-29.9 kg/m2 vs 
those with BMI≥30.0 kg/m2, the rates of unreliable LSM (16.4% vs 18.9%; P=0.62) and LSM 
failure (11.8% vs 17.8%; P=0.16) were similar. BMI≥28.0 kg/m2 was the most important 
factor associated with unreliable LSM (OR=2.9, 95% CI=2.1–3.9, P<0.0001) and LSM 
failure (OR=10.1, 95% CI=6.4–14.2, P<0.0001). Central obesity, dened as waist 
circumference >80 cm in women and >90 cm in men, was another independent risk factor 
of unreliable LSM (OR=1.3, 95% CI=1.0–1.6, P=0.04) and LSM failure (OR=5.8, 95% 
CI=2.9–11.5, P<0.0001). 
5. Controlled attenuation parameter and liver steatosis 
Fat affects US propagation, however this is the most common liver imaging technique used 
to detect the presence of steatosis. In B-mode images, steatosis appears as an increased 
parenchymal echogenicity caused by the increased reflectivity induced by fatty 
accumulation. This increased echogenicity is determined by the sonographer, most of the 
time by comparison with kidney echogenicity. Such as procedure it is highly operator- 
and machine-dependant. Many studies have reported averaged specificity and sensitivity 
of the technique as around 60-70%. Other studies have reported better specificity and 
sensitivity up to 95%, and therefore its performance in clinical practice is still 
controversial. Another limitation of US is that it cannot quantify steatosis and can only 
detect steatosis from around 30% of fatty infiltration, where there is a clinical relevance to 
detect lower extent of liver fat. 
Furthermore, some studies have shown that liver fibrosis can induce an increased liver 
echogenicity without posterior beam attenuation. It is therefore impossible to distinguish 
between increased echogenicity caused by an extensive fibrosis from increased echogenicity 
caused by fatty infiltration. A quantitative attenuation parameter can overcome this 
limitation. 
Recently a new parameter has been developed to detect and quantify degree of liver 
steatosis. This parameter is based on the US properties of the radiofrequency 
backpropagated signals acquired by the VCTE. It is called controlled attenuation 
parameter (CAP), because it was devised to specifically target the liver (Sasso et al, 2010). 
This coefficient is an estimate of the total US (go-and-return path) at 3.5 MHz and is 
expressed in decibel per meters (dB.m-1). CAP is evaluated using the same radio-
frequency data and in the same region of interest than the ones used for LSM and it is 
only appraised if the acquisition is valid. CAP is VCTE guided and obtains an ultrasonic 
attenuation value of the liver only. Therefore, CAP can be assessed by an operator who 
does not have any ultrasound imaging skills. Furthermore, CAP has been designed to be 
immediate, reproducible and operator and machine-independent. Performance of CAP 
was evaluated by Sasso et al. on 115 patients, taking the histological grade of steatosis as 
reference. Among those patients, 42 were CHC, 17 CBV, 39 with alcoholic liver disease 
and 17 with NAFLD. Mean BMI was 25 ± 4 kg/m2. CAP was significantly correlated to 
steatosis (P=10-16). AUROC was equal to 0.91 and 0.95 for the detection of more than 10% 
and 33% of steatosis, respectively. These data show that CAP can efficiently separate 
several steatosis grades. CAP appears to be a promising diagnostic tool for non-invasive 
assessment and quantification of steatosis, enhancing the spectrum of the non-invasive 
method for the exploration and follow-up of patients with fatty liver. However validation 
of this novel indicator is ongoing in a large multi-etiology cohort study. 
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to increase when BMI≥28.0 kg/m2. Comparing patients with BMI≥28.0-29.9 kg/m2 vs 
those with BMI≥30.0 kg/m2, the rates of unreliable LSM (16.4% vs 18.9%; P=0.62) and LSM 
failure (11.8% vs 17.8%; P=0.16) were similar. BMI≥28.0 kg/m2 was the most important 
factor associated with unreliable LSM (OR=2.9, 95% CI=2.1–3.9, P<0.0001) and LSM 
failure (OR=10.1, 95% CI=6.4–14.2, P<0.0001). Central obesity, dened as waist 
circumference >80 cm in women and >90 cm in men, was another independent risk factor 
of unreliable LSM (OR=1.3, 95% CI=1.0–1.6, P=0.04) and LSM failure (OR=5.8, 95% 
CI=2.9–11.5, P<0.0001). 
5. Controlled attenuation parameter and liver steatosis 
Fat affects US propagation, however this is the most common liver imaging technique used 
to detect the presence of steatosis. In B-mode images, steatosis appears as an increased 
parenchymal echogenicity caused by the increased reflectivity induced by fatty 
accumulation. This increased echogenicity is determined by the sonographer, most of the 
time by comparison with kidney echogenicity. Such as procedure it is highly operator- 
and machine-dependant. Many studies have reported averaged specificity and sensitivity 
of the technique as around 60-70%. Other studies have reported better specificity and 
sensitivity up to 95%, and therefore its performance in clinical practice is still 
controversial. Another limitation of US is that it cannot quantify steatosis and can only 
detect steatosis from around 30% of fatty infiltration, where there is a clinical relevance to 
detect lower extent of liver fat. 
Furthermore, some studies have shown that liver fibrosis can induce an increased liver 
echogenicity without posterior beam attenuation. It is therefore impossible to distinguish 
between increased echogenicity caused by an extensive fibrosis from increased echogenicity 
caused by fatty infiltration. A quantitative attenuation parameter can overcome this 
limitation. 
Recently a new parameter has been developed to detect and quantify degree of liver 
steatosis. This parameter is based on the US properties of the radiofrequency 
backpropagated signals acquired by the VCTE. It is called controlled attenuation 
parameter (CAP), because it was devised to specifically target the liver (Sasso et al, 2010). 
This coefficient is an estimate of the total US (go-and-return path) at 3.5 MHz and is 
expressed in decibel per meters (dB.m-1). CAP is evaluated using the same radio-
frequency data and in the same region of interest than the ones used for LSM and it is 
only appraised if the acquisition is valid. CAP is VCTE guided and obtains an ultrasonic 
attenuation value of the liver only. Therefore, CAP can be assessed by an operator who 
does not have any ultrasound imaging skills. Furthermore, CAP has been designed to be 
immediate, reproducible and operator and machine-independent. Performance of CAP 
was evaluated by Sasso et al. on 115 patients, taking the histological grade of steatosis as 
reference. Among those patients, 42 were CHC, 17 CBV, 39 with alcoholic liver disease 
and 17 with NAFLD. Mean BMI was 25 ± 4 kg/m2. CAP was significantly correlated to 
steatosis (P=10-16). AUROC was equal to 0.91 and 0.95 for the detection of more than 10% 
and 33% of steatosis, respectively. These data show that CAP can efficiently separate 
several steatosis grades. CAP appears to be a promising diagnostic tool for non-invasive 
assessment and quantification of steatosis, enhancing the spectrum of the non-invasive 
method for the exploration and follow-up of patients with fatty liver. However validation 
of this novel indicator is ongoing in a large multi-etiology cohort study. 
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6. Conclusion  
LB will still be part of clinical practice in the coming years, but progress in medicine will 
challenge previously entrenched assumptions and will change our current approach to liver 
diseases in the next future. Non-invasive assessment of liver brosis is currently a reality in 
patients with CHC. In other highly prevalent diseases, such as NAFLD there is still room for 
improvement, although in the next few years LB will likely be supplanted in most cases. 
Many imaging techniques can be used to identify liver steatosis, such as computed 
tomography scans, magnetic resonance imaging or proton nuclear magnetic resonance. 
However all of these imaging tools present some important limitations: they are not easily 
available and their costs are relatively expensive (Sasso et al, 2010).  
VCTE is a simple, non-invasive and inexpensive method used to measure LS. The accuracy 
and reproducibility of VCTE score is excellent for the diagnosis of cirrhosis; it is probably 
the most accurate non-invasive method for the early detection of cirrhosis. It is a user-
friendly technique that can be performed without any preparation in the less than five 
minutes in clinic or at the bedside, with immediate results and high patient acceptance, it is 
very likely that in future it will become the most widely used technique for staging liver 
disease. A panel discussion is in progress to define the role of VCTE in the staging of liver 
disease. In particular, there are a few methodological approaches that need to be 
implemented in future studies designed to further validate LSM. A new statistical approach 
is needed in order to obtain reliable and clinically useful information from LSM (Vizzuti et 
al, 2009). In fact, most of the published studies reported the cut-off values selected by binary 
measures, like sensitivity and specificity. However, it seems insufficiently informative to 
discriminate the optimal cut-off value in a wide range of values, specially in a context of 
liver steatosis. A new parameter measuring the US attenuation could be interesting and 
might be related to steatosis. This indicator, called CAP, has been developed to process the 
raw ultrasonic signals stored in the VCTE examination file. Performance of CAP has to be 
validated into specific etiologic groups. In addiction influence of the steatosis topography 
and other histologic constituents, specific to each etiology has to be considered. Large 
cohorts are required to determine appropriate threshold to detect and quantify steatosis. 
Further technological improvements are requested for better application of this technique in 
specific populations, such as patients with increased BMI, along with efforts to improve and 
standardize the procedure and adequate operator training. 
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6. Conclusion  
LB will still be part of clinical practice in the coming years, but progress in medicine will 
challenge previously entrenched assumptions and will change our current approach to liver 
diseases in the next future. Non-invasive assessment of liver brosis is currently a reality in 
patients with CHC. In other highly prevalent diseases, such as NAFLD there is still room for 
improvement, although in the next few years LB will likely be supplanted in most cases. 
Many imaging techniques can be used to identify liver steatosis, such as computed 
tomography scans, magnetic resonance imaging or proton nuclear magnetic resonance. 
However all of these imaging tools present some important limitations: they are not easily 
available and their costs are relatively expensive (Sasso et al, 2010).  
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and reproducibility of VCTE score is excellent for the diagnosis of cirrhosis; it is probably 
the most accurate non-invasive method for the early detection of cirrhosis. It is a user-
friendly technique that can be performed without any preparation in the less than five 
minutes in clinic or at the bedside, with immediate results and high patient acceptance, it is 
very likely that in future it will become the most widely used technique for staging liver 
disease. A panel discussion is in progress to define the role of VCTE in the staging of liver 
disease. In particular, there are a few methodological approaches that need to be 
implemented in future studies designed to further validate LSM. A new statistical approach 
is needed in order to obtain reliable and clinically useful information from LSM (Vizzuti et 
al, 2009). In fact, most of the published studies reported the cut-off values selected by binary 
measures, like sensitivity and specificity. However, it seems insufficiently informative to 
discriminate the optimal cut-off value in a wide range of values, specially in a context of 
liver steatosis. A new parameter measuring the US attenuation could be interesting and 
might be related to steatosis. This indicator, called CAP, has been developed to process the 
raw ultrasonic signals stored in the VCTE examination file. Performance of CAP has to be 
validated into specific etiologic groups. In addiction influence of the steatosis topography 
and other histologic constituents, specific to each etiology has to be considered. Large 
cohorts are required to determine appropriate threshold to detect and quantify steatosis. 
Further technological improvements are requested for better application of this technique in 
specific populations, such as patients with increased BMI, along with efforts to improve and 
standardize the procedure and adequate operator training. 
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1. Introduction 
Chronic liver diseases result in fibrosis ultimately leading to cirrhosis, a liver end stage 
disease with high mortality and life threatening complications such as hepatocellular 
carcinoma. Thus far, no treatment options exist to cure and stop fibrosis progression except 
organ replacement by liver transplantation. This clinically unsatisfactory situation justifies 
the enormous interest in quantifying and monitoring fibrosis progression. Though liver 
biopsy remains the gold standard for assessing liver fibrosis, non invasive procedures are 
being developed for many years to overcome its complications (Bravo et al. 2001), sampling 
error and interobserver variability (Abdi et al. 1979; Bedossa et al. 2003; Cadranel et al. 
2001). Fibrosis and activity marker scores based on several blood parameters from a simple 
blood test have been developed to assess liver fibrosis and activity as obtained by liver 
biopsy Many efforts have been invested to identify serum markers that allow the diagnosis 
of cirrhosis from simple blood tests (Poynard et al. 2004). However those scores are indirect 
and reflect the fibrogenetic activity. Thus they do not correlate with the absolute amount of 
fibrotic tissue within the liver. 
It is now well established that fibrosis increases liver stiffness. Liver palpation (Fig. 1) is a 
routine medical practice that has been used since the beginning of medicine to assess liver 
stiffness. Though, palpation suffers from major limitations: it is highly subjective, very 
operator dependent and sometimes even impossible to perform. Recently, quantitative 
elastography emerged as a means to assess liver fibrosis non-invasively. Nowadays 
Vibration-Controlled Transient Elastography (VCTE™) is by far the most clinically 
validated quantitative elastography technique and VCTE™ based device, Fibroscan® 
(Echosens, France), has emerged as the reference tool for liver stiffness measurement. As a 
fact, Fibroscan® is more and more used in routine clinical practice as an alternative method 
to liver biopsy in patients with chronic liver diseases. 
The chapter is organized as follows: Section 2 covers quantitative elastography; the main 
quantitative elastography techniques are described with a strong focus on the most clinically 
validated technique: VCTE™. Fibroscan® device is described in Section 3; the examination 
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Liver Biopsy 
 
294 
procedure is described. Advantages and limitations of the device are detailed. Applications 
of VCTE™ in hepatology are described in Section 4. The role of liver stiffness as a clinically 
relevant parameter will be pointed out. In Section 5, the pressure-stiffness-fibrosis sequence 
hypothesis is addressed. Eventually, discussion and conclusion are drawn in Section 6 and 
Section 7, respectively. 
 
 
Fig. 1. Liver hand palpation: “The living are soft and yielding; the dead are rigid and stiff”, 
Lao Tzu, (6th century BCE). 
2. Quantitative elastography  
2.1 Elastography techniques 
It was a matter of time to see the development and emergence of sophisticated techniques 
such as elastography to quantitatively and non-invasively measure liver stiffness. 
Elastography is a recent field of research that started in the 80s to propose a reproducible 
and operator-independent alternative technique to hand palpation. Elastography techniques 
may be divided into two groups: qualitative elastography and quantitative elastography.  
Qualitative elastography is now widely available on ultrasound scanners, it provides a 
qualitative color image that gives an interpretation of stiffness without providing any 
number. Basically, while the operator moves the ultrasound transducer at the skin surface of 
the body, the scanner measures the quasi static displacements within the tissues. A map 
representing the inverse of the displacement is displayed usually in color: the larger the 
displacement, the softer the tissue. While this technique may be helpful in radiology to 
identify focal lesions, it is definitively not adapted to quantify stiffness. 
Quantitative elastography techniques rely on the use of low frequency shear waves. Indeed 
the velocity of these mechanical waves is directly related to the stiffness. Thus all 
quantitative elastography techniques combine a means to generate shear waves and an 
imaging technique to measure the propagation of the generated shear waves. 
2.2 Physics of elastography 
From a physical and mechanical point of view, stiffness can be defined as the shear 
modulus, µ, or the Young’s modulus, E. These moduli describe the mechanical response of a 
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medium under shear stress and longitudinal stress, respectively. The theory of linear 
elasticity is based on this relationship between stress and strain and states that the 
deformation of a material is directly proportional to the applied stress, σ = Eε, where σ is the 
stress applied to the material, and ε is the strain induced in the material. The Young’s 
modulus E is expressed in kilopascals (kPa) and represents the resistance of material to 
deformation. This law, known as Hooke’s law, gives the relationship between the strain ε, 
the Young’s modulus and the stress σ. A rod, length L, of elastic material can be seen as a 
linear spring. Under a stress σ, it will experience an extension ΔL: 
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The relationship between the Young’s modulus E, the Poisson coefficient υ and the Lamé 
coefficients λ and µ (also known as compression and shear moduli), is given by: 
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Biological tissues are mainly composed of water. The compression modulus λ is several 
Giga Pascal; it is thus very large compared to the shear modulus of soft biological tissues 
(several kilo Pascal) (Sarvazyan et al. 1995). With λ >> µ, it yields that υ ≈ 0.5 which is 
characteristic of a quasi-incompressible medium. Eventually, in soft medium, the 
Young‘s modulus E simplifies to: 
 3E µ  (2.3) 
Interestingly, under some simplification hypothesis, the shear modulus can be deduced 
from the shear wave velocity, Vs, and the mass density, ρ: 
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Since the soft body tissues mass density is almost constant (1000 kg/m3), the 
Young‘s modulus E can be obtained by measuring the velocity of shear waves. Thus shear 
waves are the foundation of quantitative elastography techniques. 
2.3 Background of quantitative elastography 
Quantitative elastography techniques, also called dynamic elastography techniques, have 
the advantage of allowing a quantitative imaging and better resolution than the static 
elastography techniques. However, they require more complex equipment for the 
generation of shear waves (monochromatic, transient) and imaging devices (ultrafast 
ultrasound, magnetic resonance imaging) able to measure shear wave induced displacement 
with a high resolution. There are basically two groups of quantitative elastography 
techniques depending on the shear wave generation method: remote generation using 
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radiation force and mechanical vibration. The shear wave frequency content may also be 
different: harmonic or transient.  
In transient elastography techniques, the propagating shear wave results from a transient 
(impulsive or short tone burst) excitation of the tissue. Indeed, an important feature of 
transient elastography techniques is that the vibration be transient to avoid reflections and 
interferences occurring within the tissues. The transient shear wave travels through the 
tissues within tens of milliseconds which implies that the ultrasound-based imaging 
modality be ultrafast to follow its propagation. Harmonic elastography techniques are using 
a continuous vibration at a fixed frequency. Several quantitative elastography techniques 
(see Table 1) were proposed to assess liver stiffness as a marker of pathological state. 
Advantages and limitations of quantitative elastography techniques are summarized in 
Table 2. 
 
 Imaging modality Shear wave generation mode Frequency
Vibration-Controlled 
Transient Elastography 
(VCTE™) 
Ultrasound Mechanical vibration Transient 
Fixed 
50 Hz 
Magnetic Resonance 
Elastography 
(MRE) 
Magnetic resonance 
imaging 
Mechanical vibration 
Harmonic 
Fixed 
60 Hz 
Acoustic Radiation  
Force Impulse (ARFI) Ultrasound 
Radiation force 
Transient Wideband 
Supersonic Shear  
Imaging (SSI) Ultrasound 
Radiation force 
Transient Wideband 
Table 1. Quantitative elastography techniques for liver stiffness measurement. 
 
 Advantages Limitations 
Vibration-Controlled 
Transient Elastography 
(VCTE™) 
Ease of use 
Highly standardized 
Controlled shear frequency 
Transient shear wave 
Large clinical validation 
Ascites 
Magnetic Resonance 
Elastography 
(MRE) 
Controlled shear frequency 
Penetration depth 
2D stiffness map 
Cost 
Acoustic Radiation  
Force Impulse (ARFI) 
Image guidance 
Transient shear wave 
Absence of shear wave control 
High intensity ultrasound 
Penetration depth 
Limited clinical validation 
Supersonic Shear  
Imaging (SSI) 
Image guidance 
Transient shear wave 
Absence of shear wave control 
High intensity ultrasound 
Penetration depth 
Absence of clinical validation 
Table 2. Advantages and limitations of quantitative elastography techniques. 
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2.3.1 Radiation force based elastography 
Radiation force based elastography uses high intensity ultrasound beams to induce 
displacements and tissue heating inside the liver remotely. Acoustic radiation force is 
applied to absorbing and/or reflecting materials in the propagation path of acoustic waves. 
This phenomenon is caused by a transfer of momentum from the acoustic wave to the 
propagation medium. The spatial distribution of the radiation force field is determined by 
both the acoustic excitation parameters and the tissue properties.  
ARFI technique (Nightingale et al. 2003; Palmeri et al. 2008) involves the mechanical 
excitation of tissue using localized, focused, impulsive radiation force excitations. This 
results in shear-wave propagation away from the region of excitation. The mechanical 
excitation occurs along the acoustic wave propagation path and within the focal region of 
the acoustic beam. The resulting displacement response is ultrasonically tracked through 
time using an abdominal ultrasound transducer combined with a dedicated ultrasound 
scanner. Direct inversion methods are then applied to estimate the associated shear 
velocity.  
Supersonic shear imaging (Bercoff et al. 2004; Muller et al. 2009) relies on the use of 
radiation force and a high frame rate ultrasound scanner (Sandrin et al. 2002). The medium 
is illuminated by a supersonic Mach cone: ultrasounds are focused successively at different 
increasing depths. The different spherical waves generated by each focus then interfere 
along a Mach cone in which the source is spreading faster than the shear wave generated 
and creates a plane wave front in the imaging plane. The ultrasound imaging system is then 
used to visualize the entire imaging plane with a good temporal resolution in a single 
acquisition typically 5000 to 20000 frames per second. Maps of the Young’s modulus are 
estimated by inverse problems from the time of flight of the shear wave front.  
Generating shear waves within the liver using radiation force requires high intensity 
ultrasound beams which induce liver tissue heating. Thermal safety issues related to 
incident radiation force pulses have been studied (Fahey et al. 2006; Palmeri & Nightingale 
2004). It required the development of special cooling time sequences to prevent overheating 
of liver tissues. As a consequence of the relative low energetic transfer efficacy, the 
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radiation force and mechanical vibration. The shear wave frequency content may also be 
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 Imaging modality Shear wave generation mode Frequency
Vibration-Controlled 
Transient Elastography 
(VCTE™) 
Ultrasound Mechanical vibration Transient 
Fixed 
50 Hz 
Magnetic Resonance 
Elastography 
(MRE) 
Magnetic resonance 
imaging 
Mechanical vibration 
Harmonic 
Fixed 
60 Hz 
Acoustic Radiation  
Force Impulse (ARFI) Ultrasound 
Radiation force 
Transient Wideband 
Supersonic Shear  
Imaging (SSI) Ultrasound 
Radiation force 
Transient Wideband 
Table 1. Quantitative elastography techniques for liver stiffness measurement. 
 
 Advantages Limitations 
Vibration-Controlled 
Transient Elastography 
(VCTE™) 
Ease of use 
Highly standardized 
Controlled shear frequency 
Transient shear wave 
Large clinical validation 
Ascites 
Magnetic Resonance 
Elastography 
(MRE) 
Controlled shear frequency 
Penetration depth 
2D stiffness map 
Cost 
Acoustic Radiation  
Force Impulse (ARFI) 
Image guidance 
Transient shear wave 
Absence of shear wave control 
High intensity ultrasound 
Penetration depth 
Limited clinical validation 
Supersonic Shear  
Imaging (SSI) 
Image guidance 
Transient shear wave 
Absence of shear wave control 
High intensity ultrasound 
Penetration depth 
Absence of clinical validation 
Table 2. Advantages and limitations of quantitative elastography techniques. 
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2.3.1 Radiation force based elastography 
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longitudinal. Diffraction effects from the piston-like transducer result in longitudinally 
polarized shear wave on the axis of symmetry (Sandrin et al. 2004). The displacements 
induced by the shear wave in the medium are measured using cross-correlation of 
successive ultrasound lines acquired at high frame rate. A spatial-temporal strain map is 
computed from the recorded displacements. The shear wave speed is calculated based on 
the slope of the wave front visualized in the strain map.  
 
 
Fig. 2. The low frequency shear wave (blue) and the ultrasound beams (red) are generated 
by the same piston-like transducer. Under the assumption of homogeneity, the symmetry 
considerations impose that the displacements on the axis of the transducer be purely 
longitudinal (white arrow).  
This technique is implemented in a standalone clinical device: Fibroscan®. It is the unique 
device that does not require integration into a conventional imaging system. Fibroscan® 
device is detailed in the next section. 
2.4 The importance of the vibration control in quantitative elastography 
The proper use of shear wave velocity analysis for clinical diagnosis requires the control of 
various physical parameters and in particular the control of the vibration to ensure an 
accurate, reliable and reproducible assessment of tissue stiffness. The control must be done 
on the shape, frequency and amplitude of the vibration. Of course, in VCTE, the amplitude 
of the vibration may be adapted to the morphology of the patients to increase the 
penetration depth of the shear wave. 
Furthermore, as stiffness value depends on shear wave frequency, the shape of the vibration 
must be controlled to obtain a consistent measurement that can be used for diagnostic 
purposes whatever the mechanical properties of the organ under investigation or the 
etiology of the patient. Provided that the shape of the vibration be constant, a reference 
frequency is obtained and a comparison of the shear wave propagation parameters can be 
performed independently of the organ conditions, etiology, patient and operator.  
2.5 The difficult process of liver stiffness measurement standardization  
The development and clinical validation of non-invasive methods for assessing liver fibrosis 
in patients with chronic liver diseases were eased by the fact that liver biopsy is not a perfect 
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gold standard. However, standardization of elastography procedures is a challenging aspect 
of the success of elastography in the medical field and more precisely in hepatology. 
Radiation force based elastography techniques such as ARFI and SSI are attractive 
techniques since they are intrinsically image-guided and do not require the use of an 
external vibrator. Actually these attractive aspects of the technology may result in significant 
loss of performances.  
As a matter of fact, using an image guided system in which the operator has a full freedom 
of choice of the region of measurement will increase the operator dependency of the 
technique. While VCTE™ may look less sophisticated, it is based on a highly standardized 
procedure that can be followed not only by physicians but also by nurses. A short training is 
required before using Fibroscan®. This standardization favors the consistency of the results 
obtained whatever the operator, the studied population and the etiology of the patients.  
Shear waves remotely generated using radiation force are wide band with frequencies 
ranging from 100 Hz to 500 Hz. Indeed with radiation force, the frequency of the shear 
waves can not be controlled precisely. Thus the frequency content of the generated shear 
wave will vary as a function of parameters such as the acoustic attenuation, the nature of 
reflecting materials, the mechanical properties of the tissues through which the ultrasound 
and shear waves travel, the depth of the region of measurement, etc. Some of these 
parameters are obviously etiology-dependent. As a consequence, measured stiffness will 
vary. Moreover, it is now well described that liver stiffness increases when the shear wave 
frequency increases (see Fig. 3). Thus, the higher the frequency is, the higher the measured 
stiffness will be. 
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Fig. 3. Preliminary result: elastic modulus of a fresh pig liver sample as a function of 
frequency (courtesy of RheoLution inc). 
Eventually, though a direct conversion of liver stiffness values measured with transient 
elastography techniques based on radiation force and mechanical vibration is tempting, this 
task might be a very challenging task. Indeed, theoretically Young’s modulus as provided 
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by VCTE™ could be deduced from the shear velocity as measured by radiation force-based 
technique (ARFI, SSI, etc.). However, this relationship is only valid at a given frequency: 
    23 SE f V f  (2.6) 
As a matter of fact, while shear wave frequency in VCTE™ is 50 Hz, shear wave frequency 
using radiation force is not controlled. Thus, as the frequencies may be significantly 
different with these techniques, a direct conversion of radiation-force-based shear wave 
velocity to VCTE™ Young’s modulus is not possible. The Young’s modulus obtained with 
VCTE™ and radiation-force based elastograhy will differ. Therefore liver stiffness 
thresholds used for clinical decision support will have to be reevaluated. 
The success of VCTE™ and the good performances reported in many studies all over the 
world is certainly due to its high standardization and high control of the shear wave shape. 
3. Fibroscan® device 
In this Section, the Fibroscan® device is described from a technical point of view. The 
operating principle is detailed with appropriate figures. Tables are included to provide 
parameters of the different probes available associated with measurement depths, operating 
ultrasound frequency, probe diameter, etc. A list of the special controls used in the Fibroscan® 
to ensure high performances is included. The examination procedure is described. 
3.1 The device 
Transient elastography measures shear wave velocity and thus determines tissue stiffness 
by using ultrasound to follow the propagation of a low frequency shear wave generated in a 
tissue by an external vibrator (Sandrin et al. 2002; Ziol et al. 2005).  The Fibroscan® (Fig. 4) is 
composed of an integrated computer and dedicated electronics for ultrasound emission end 
reception, vibrator command and signal processing.  
 
Fig. 4. The Fibroscan® and its M-probe. 
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The Fibroscan® probe contains an ultrasonic transducer used both as receiver and emitter 
which is mounted on a mechanical vibrator to generate a low frequency (50 Hz) shear wave. 
During the propagation of the low frequency shear wave, the radiofrequency (RF) data are 
acquired at a repetition frequency of 6000 Hz. The displacements induced in the medium are 
computed from the RF data using an autocorrelation method and derived versus depth in 
order to provide a strain rate image called elastogram (Fig. 5(c)). Analysis of the strain 
image yields the shear wave velocity and thus elasticity using the formula E = 3ρVs² where 
E, ρ = 1000 kg/m3, and Vs are the Young’s modulus, the mass density and the shear wave, 
respectively. In order to compute the shear wave velocity, a time-of-flight algorithm is used 
(Sandrin et al. 2003). The system enables to measure stiffness values (Young’s modulus) 
between 1.5 kPa and 75 kPa.  
 
 
                                   (a)                     (b)                                           (c) 
Fig. 5. (a) TM-mode, (b) A-mode and (c) elastogram images. The elastogram is a 2D 
graphical representation of the strain rates as a function of depth and time. The slope of the 
shear wave is represented by a white dotted line. 
As shown in Table 3, four types of examination with specific depth and ultrasound 
frequency are available according to the morphology of the patient: skin-capsule distance 
(SCD) and thoracic perimeter (TP). 
 
Probe Exam.Type Criteria Examination depth Frequency 
S Small 1 (S1) TP ≤ 45 cm From 15 mm to 40 mm 5 MHz Small 2 (S2) 45 cm < TP ≤ 75 cm From 20 mm to 50 mm 
M Medium (M) 75 cm < TP ≤ 110 cm and SCD < 2.5 cm From 25 mm to 65 mm 3.5 MHz 
XL XL 2.5 cm ≤ SCD < 3.5 cm From 35 mm to 75 mm 2.5 MHz 
Table 3. Fibroscan® examination parameters. 
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3.2 Examination procedure 
During the examination, the patient is lying in dorsal decubitus and the right arm in 
maximal abduction so as to enlarge the intercostals space in which the probe is placed 
(Fig. 6). The ribs play an important role since they prevent the application of large 
pressure on the liver by the probe. Indeed, biological tissues have a non linear elastic 
behavior when they are submitted to large strains. This nonlinearity would result in a 
biased measurement of the stiffness. This phenomenon also explains why elasticity 
measurements cannot be performed on the left lobe of the liver which is not protected by 
the ribs. 
 
 
Fig. 6. During Fibroscan® examination, the patient is lying in dorsal decubitus and the right 
arm in maximal abduction so as to enlarge the intercostals space in which the probe is 
placed. 
The probe should be placed between the rib bones opposite to the right lobe of the liver in 
the middle of the parenchyma far from the border of the liver. The measurement point 
should actually be similar to the location where the liver biopsy would be performed. 
Measurements performed too close to the borders the liver stiffness should be avoided as 
they will be overestimated. 
The Fibroscan® device provides A-mode and M-mode images which should be used to 
find a liver portion suitable for the examination (Fig. 7). This liver area should be at least 
60 mm deep and free of large vascular structures. In the case of a standard examination, 
the stiffness measurements are performed between 25 mm and 65 mm below the skin 
surface. The force applied by the probe on the skin is controlled during the whole 
examination and must be comprised between 4 N and 8 N in order to trigger a stiffness 
measurement. 
During the examination, the operator should be careful about keeping the probe 
perpendicular to the skin surface or the liver stiffness may be overestimated (Fig. 8). The 
perpendicularity along both axes should be checked by looking at the probe. The operator 
should also check on the A-mode and TM-mode that the area is homogeneous and free of 
vessels structures (Fig. 9). 
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                                (a)                            (b) 
Fig. 7. The operator uses (a) TM-mode and (b) A-mode images to localize the 
measurement point. TM-mode represents the ultrasonic amplitude in log scale as a 
function of depth and time. A-mode is the real time ultrasonic line amplitude in log scale 
as a function of depth. 
 
 
Fig. 8. During the examination, the operator should be careful about keeping the probe 
perpendicular to the skin surface or the liver stiffness may be overestimated. 
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Fig. 9. The good window of acquisition is localized using A-mode and TM-mode displays. 
When all the conditions mentioned above are met, the operator can trigger a 
measurement. An acquisition is almost instantaneous; it lasts a tenth of second. The 
software automatically rejects elastograms not fulfilling quality criteria and if the 
measurements are invalid, no result is displayed. The result of the examination is the 
median of all valid stiffness measurements within the current examination. The Inter 
Quartile Range (IQR) of all valid measurements and the success rate are also computed. 
Echosens recommends that a minimum of 8 valid measurements be obtained to get a 
consistent liver stiffness estimate. 
Fibroscan® examination typically lasts between 2 and 5 minutes with recent devices. The 
liver explored volume by VCTE can be roughly approximated to be a cylinder of length 
40 mm and diameter 10 mm (the actual value depends on the shear wavelength and 
examination type). This volume is 200 times larger than a 20 mm long and 1 mm diameter 
biopsy specimen. 
Main limitations of Fibroscan® are the presence of ascites and obesity. Actually shear waves 
do not propagate through liquids. Thus Fibroscan® examination fails in some patients with 
ascites. However this limitation is counter balanced by the fact that ascites is already in itself 
an indication of liver pathological state. Thick subcutaneous tissues can result in a strong 
aberration of ultrasound and/or shear waves. As a result, it may be impossible to acquire 
enough valid measurements with Fibroscan® in some obese patients. However, a new 
probe, called XL probe, is now available to overcome this limitation. XL probe measures 
60 % of the patients not measured with M probe (de Ledinghen et al. 2010). 
4. Applications in hepatology 
A review of literature is made. In this review, the use of liver stiffness measured with 
Fibroscan® is studied for diagnosis, prognostic, prognosis and treatment follow-up 
purposes.  
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4.1 Repeatability and reproducibility 
Several groups have reported that liver stiffness measurements using Fibroscan® are 
repeatable and reproducible. The intra operator variability has been assessed (Boursier et al. 
2008; Fraquelli et al. 2007) with intra-class correlation coefficient of 0.94 and 0.98 on 20 and 
200 patients, respectively. The same publications as well as (Huwart et al. 2006) also 
evaluated the inter operator reproducibility with intra-class correlation coefficient ranging 
from 0.93 to 0.98. It shows that liver stiffness measurement using Fibroscan® is not 
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Fig. 10. The stiffer the liver the faster the shear wave (white line). From 3.4 kPa in a healthy 
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shear wave front gets steeper as the stiffness increases. 
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4.2.2 General population 
Roulot (Roulot et al. 2010; Roulot et al. 2008) performed a study which aimed at detecting 
fibrosis in the general population. 1368 subjects attending a free check up in a medical center 
were measured. Liver biopsy was proposed to subjects (N=80) with stiffness values above 
8 kPa. 28 subjects accepted to go through liver biopsy. Interestingly, all of them had fibrosis 
and cirrhosis was found in all subjects with stiffness above 14.6 kPa. Among the 72 subjects 
between 8 kPa and 14.6 kPa : 45 were overweight with metabolic syndrome, 18 were 
alcoholic, 5 had HCV and 4 had HBV. 
4.3 Prognosis value 
4.3.1 Complication of cirrhosis 
In addition to being related to portal hypertension assessed by HVPG measurement (Bureau 
et al. 2008; Carrion et al. 2006; Vizzutti et al. 2008), liver stiffness was shown to be related to 
other complications of cirrhosis. In a study (Foucher et al. 2006) on 144 patients with biopsy 
proven cirrhosis or bridging fibrosis, liver stiffness measurement had an AUROC of 0.90, 
0.89, 0.71 and 0.88 for the detection of Child-Pugh score A versus BC, past history of ascites, 
presence of hepatocellular carcinoma and past history of ascites, respectively.  
4.3.2 Liver transplantation 
Rigamonti et al (Rigamonti et al. 2008) reported that liver stiffness accurately predicts 
fibrosis progression in liver transplanted patients with recurrent hepatitis C, suggesting that 
protocol liver biopsy might be avoided in patients with improved or stable transient 
elastography values during follow-up..  
4.3.3 Survival 
Vergniol et al (Vergniol et al.) followed 1457 patients (median 47.3 months) and 
demonstrated that the prognostic value of liver stiffness on survival was superior to that of 
liver biopsy. As a good predictive factor of survival, liver stiffness may help physician to 
evaluate earlier the severity of chronic liver diseases, to decide with stronger arguments of a 
liver transplantation or a portosystemic shunt and to evaluate more precisely the surgical 
risk of our cirrhotic patients. 
4.4 Treatment follow-up 
Fibroscan® was successfully used to assess liver fibrosis in patients during HCV or HBV 
therapy (Barreiro et al. 2006; Oliveri et al. 2008; Soriano et al. 2006). Ogawa et al (Ogawa et 
al. 2009) demonstrated that liver stiffness values measured by Fibroscan(r) may predict a 
progressively better clinical outcome for patients with successful virological and 
biochemical responses. Vergniol et al (Vergniol et al. 2009) suggested that Fibroscan(r) 
should be useful for assessing treatment efficacy in clinical trials of new drugs. 
Recently, Berends et al (Berends et al. 2007) reported that Fibroscan(r) accurately predicted 
the absence of significant liver fibrosis in methotrexate users. 
5. The pressure-stiffness-fibrosis sequence hypothesis 
5.1 Factors influencing liver stiffness 
As reported in the literature, liver stiffness is very well correlated with liver fibrosis. 
However studies showed that other factors influence liver stiffness. Several groups reported 
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that liver stiffness significantly increases during inflammatory episodes (Arena et al. 2008; 
Oliveri et al. 2008; Sagir et al. 2008). They showed that during several months monitoring, 
liver stiffness values paralleled those of ALT in patients with hepatitis exacerbation and 
observed a progressive decrease during antiviral therapy. Millonig (Millonig et al. 2009; 
Millonig et al. 2008) reported that mechanical cholestasis drastically and reversibly increases 
liver stiffness and that liver stiffness is influenced by central venous pressure and thus liver 
congestion, for example due to cardiac insufficiency. 
5.2 Physical point of view 
From a physical point of view, liver stiffness is obviously mainly driven by the liver 
extracellular matrix which provides structural support to the liver. However, since the liver 
is self-contained in a non extensible Glisson’s capsule, stiffness is definitively influenced by 
pressure that can be either hydrostatic or osmotic. The amount of collagen contained in the 
matrix yields a static stiffness. As shown in Fig. 11, on top of this static stiffness, hydrostatic 
and osmotic pressure effects will add a pressure-related stiffness term which results from 
body flood dynamics: blood flow, interstitial liquids, etc. On one hand, central venous 
pressure is directly related to hydrostatic pressure resulting from heart beating. On the other 
hand, flow of fluid from plasma to interstitial fluid is driven by osmotic pressure. During 
inflammatory episodes, accumulation of interstitial liquid and inflammatory infiltrate 
increases osmotic pressure. 
 
 
Fig. 11. Liver stiffness is composed of two components: static stiffness due to the 
extracellular matrix and dynamic stiffness linked to hydrostatic pressure and osmotic 
pressure. 
5.3 Molecular mechanism 
A study from Sakata (Sakata et al. 2004) supports the pressure-matrix-stiffness sequence 
hypothesis (Mueller & Sandrin 2010). Under this hypothesis, pressure results in increased 
mechanical stretching which induces transforming growth factor (TGF)-β synthesis in 
hepatic stellate cells, which is known to be highly expressed under profibrogenic 
conditions. Therefore, increased dynamic stiffness due to pressure induces mechanical 
stretches which stimulate the production of collagen (fibrotic tissue) which results in a 
static stiffness increase as if the liver was adapting its structure to inner body mechanical 
conditions.  
Among the numerous questions that still need to be answered on this very exciting subject, 
one of the more interesting may be the understanding of the respective roles of portal 
fibrosis and perisinusoidal fibrosis in liver stiffness. 
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6. Discussion 
Liver stiffness measurement using Fibroscan® has been studied in all major causes of 
chronic liver diseases: chronic hepatitis C, chronic hepatitis B, HIV – HCV co-infection, 
alcoholic liver disease (ALD), non alcoholic fatty liver disease (NAFLD), biliary disease, etc.  
6.1 The keys of Fibroscan® success and its limitations 
The success of liver stiffness measurement using Fibroscan® may be explained by several 
factors. First of al, it is a bedside procedure which lasts between 2 and 5 minutes and gives an 
immediate result. Second, the procedure is highly standardized with dedicated training which 
provides low operator dependence compared to ultrasound guided procedures, as an 
example. Third it offers new perspectives as liver stiffness is providing more information to 
physicians than fibrosis. Furthermore, it can be used for diagnosis, prognostic and follow-up. 
As any other procedure, liver stiffness measurement using Fibroscan® is having limitations. 
Main physical limitation is linked to the presence of ascites as liquids prevent the 
propagation of shear waves. As a consequence, shear waves are stopped before they can 
enter liver. Another limitation is related to obesity and more specifically to a large skin to 
liver capsula distance. In this case, ultrasound and shear wave aberration may occur and 
significantly reduce the success rate of liver stiffness measurements. A new probe, XL probe, 
was released to overcome this issue and demonstrated a significant improvement of the 
measurement success in obese patients.  
6.2 Liver stiffness is a clinically relevant parameter by itself 
In 2003, liver stiffness measured using Fibroscan® was introduced as an alternative to liver 
biopsy in order to assess liver fibrosis non-invasively. Nowadays liver stiffness is considered 
as a novel objective physical parameter that will eventually be used like arterial pressure or 
temperature. Primarily related by liver fibrosis, liver stiffness is influenced by venous 
pressure, inflammation and mechanical cholestatis. It is now part of the tools a physician 
may use to diagnose liver diseases. For this purpose, it should obviously be interpreted in 
the full context of clinical, imaging and laboratory findings (Fig. 12).  
 
 
Fig. 12. Liver stiffness should always be interpreted in the context of clinical, imaging and 
laboratory findings. 
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As explained earlier in this chapter, liver stiffness is not only affected by the liver matrix but 
also by pressure increase which may be attributed to several factors from congestion to 
inflammation. Furthermore, there are very disruptive elements that suggest that liver 
stiffness may not only be the consequence fibrosis deposits within the liver but also one of 
the causes of fibrogenesis as it has been demonstrated that hepatic stellate cells tend to 
generate fibrosis when they are under mechanical stress. For these reasons liver stiffness 
shall not be considered as a secondary endpoint; liver stiffness is a clinically relevant 
parameter by itself. 
6.3 Recent developments 
Even though liver stiffness provides an alternative to liver biopsy for fibrosis staging, it can 
not yield very important histologic features such as macrovesicular steatosis, ballooned 
hepatocytes, inflammation, etc. Recently, a new parameter, Controlled Attenuation 
Parameter (CAP), was designed to quantify liver steatosis using Fibroscan®. This 
measurement is performed at the exact same location where liver stiffness is measured and 
showed good performances for steatosis quantification (Sasso et al. 2010). 
The need for small animal non-invasive preclinical tools is growing. Obviously a Fibroscan® 
based instrumentation device adapted to small animal would have very interesting 
applications for the development of new drugs and for the study of drug-induced liver 
injury. Recently, Bastard (Bastard et al. 2011) demonstrated that VCTE™ can be adapted for 
small animal liver stiffness measurements.  
7. Conclusion 
Initially studied for its potential benefit for breast and prostate cancer, quantitative 
elastography eventually led to a promising diagnostic device in hepatology. The name 
Fibroscan® was invented at the time when liver stiffness measurement was intended to 
serve as an alternative to fibrosis staging using liver biopsy. Obviously, today the name 
Fibroscan® is misleading as liver stiffness has become a clinically relevant parameter by 
itself. Liver stiffness opened new possibilities in the field of hepatology: in routine and in 
research. These possibilities were made possible because of key advantages of non-invasive 
liver stiffness measurement with Fibroscan®. Among the important outcomes, the possible 
differentiation between early and advanced cirrhosis, the good prognostic value of liver 
stiffness on patient survival and the follow-up of patients undergoing treatments can be 
pointed out. Liver stiffness shall continue to be studied in many ways and will help 
physicians to better understand the natural history of liver diseases. With significant 
developments in the field of hepatology, for example the steatosis quantification, 
Fibroscan® may become the companion of hepatologists in their day to day clinical practice 
and research projects. 
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1. Introduction 
The use of simulation to train skills has grown exponentially in the last few decades, 
especially in medicine, where simulator models can provide a platform where trainees can 
practice procedures without risk or harm to patients. Potential advantages of computer 
based simulator models over other forms of medical simulators include: (i) anatomical 
fidelity; (ii) the ability to train in an environment wherein physiological behavior is 
observed, something that is not possible using in-vitro phantoms; (iii) variability of anatomy 
and pathology which is important to the acquisition of experience; (v) quantification of 
metrics relating to task performance that can be used to monitor trainee performance 
throughout the learning curve; and (vi) cost effectiveness.  
The work described herein was conducted as part of the CRaIVE collaboration (Gould et al., 
2004), the aim of which is to develop simulator models specific to interventional radiology 
(IR). Our use of the term ‘interventional radiology’ is intended to encompass all micro-
surgical, minimally invasive procedures that use percutaneous needle access for biopsy or 
for guidewire and catheter introduction and manipulation, and where medical imaging (i.e. 
ultrasound, fluoroscopy, computed tomography) is used for intra-procedural guidance. A 
frequently performed, IR technique is liver biopsy, where a needle is inserted into the liver 
to acquire a tissue sample for histological diagnosis of conditions such as cancer, 
inflammation, cirrhosis etc.  
In this chapter we present a detailed description of a simulator framework for liver biopsy 
using patient-specific data. Key features of this simulator include the incorporation of 
modifiable respiratory movements and real-rime haptic interaction. We first present an 
overview of the current state of the art of medical simulators. Subsequent sections are 
intended to provide a complete description of parameters required to design a medical 
simulator for liver biopsy, detailing methods used to produce a computer-based model of 
both patient respiration and haptic interaction, as well as their integration into the final 
simulator. 
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2. State of the art 
Various simulators exist to train IR practitioners (interventional radiologists). In the case of 
liver biopsy, which has the added challenge of respiratory motion, only non computer-
based simulators currently exist (Müller et al., 2007). As outlined in the introduction, there 
are, however particular benefits of using computer-based medical simulators. We focus 
below on different aspects in the literature that are considered to be integral to the accurate 
simulation of liver biopsy. 
Although liver displacement due to respiratory motion has not been incorporated into 
existing liver biopsy simulators, previous authors have sought to model respiration for a 
range of applications, including animated entertainment (Zordan et al., 2004) and medical 
applications. These latter models described in the literature focus on medical augmented 
reality (Santhanam et al., 2007) and pre-procedural planning of radiological interventions 
(Didier et al., 2007; Hoestettler et al., 2008). For future simulators to find application within 
clinical practice, they must be able to offer a realistic real time depiction of anatomical 
structures and their dynamic interaction. Thus, our aim was a simulator that is fast enough 
to support real-time, or near real-time, computer graphics techniques and interaction, but 
realistic enough for the specific medical application. 
To date, needle insertion simulators have been developed for a range of applications 
(Abolhassani et al., 2007). In one example, complex mechanical models are used to simulate 
needle insertion and soft-tissue behavior in the setting of pre-procedural training and 
planning (Chentanez et al., 2009). Experimental data has also been used by others to model 
the force evolution during needle manipulation (Maurin et al., 2004). The requirement for a 
liver biopsy simulator to incorporate respiratory motion does, however, limit us to a 
relatively simplistic needle model. 
The incorporation of force feedback in simulators has been recently reviewed (Coles et al., 
2010). Application of this technology is intended to enhance the user’s immersion in a 
virtual reality environment. Commercial devices are already available for both basic 
laparoscopic tasks and interventional radiology procedures. Figure 1 illustrates two 
examples of these simulators: the LAP Mentor by Simbionix for laparoscopic procedures 
(www.simbionix.com) and the Mentice VIST for endovascular IR procedures 
(www.mentice.com). Increased access to commercial haptic devices has helped support the 
application of this technology in new simulators. 
 
      
       (a)                                   (b) 
Fig. 1. Existing micro-surgical simulators: (a) LAP Mentor by Simbionix, (b) VIST by 
Mentice. 
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3. Construction of the virtual patients 
We now focus on the construction of the proposed virtual environment, defining the 
anatomy used in our simulation as well as the software framework, prior to detailing the 
simulation of organ behavior in a breathing patient during needle insertion. 
3.1 Strategy and input data 
The initial objective was to construct virtual patients for use in the proposed liver biopsy 
simulator. To achieve this, it was necessary to first construct a patient database for 
visualization of organ position and motion (graphic rendering), and subsequently to adapt this 
environment to support tool-tissue interactions within a collision detection loop (haptics 
rendering). This use of patient imaging data was passed by the local research ethics committee. 
A computer-based simulator was constructed based on the database, and depicting the 
anatomy of a virtual patient. In the current project we chose to extract this information from 
medical imaging of patients. Three-dimensional computed tomography (CT) scans of 
patients attending the Centre Léon Bérard (Lyon, France) and the Marie Curie Institute 
(Paris, France) were acquired. Scan parameters were as follows: size 512x512xNz with Nz 
varying from 140 to 200, and voxel dimensions 0.976mm x 0,976mm x 2mm.  
In addition to the liver, it is necessary to also include the ribcage and thoracic diaphragm, as 
they are essential to modeling respiratory motion. The strategy adopted for data acquisition 
was as follows: (i) retrieval of anonymized scan data for recruited patients after obtaining 
informed written consent; (ii) extraction of organ contours from scans; and (iii) computation 
of a more simplistic representation of organ geometry via a meshing process. Each of these 
steps is illustrated in Figure 2 using the ribcage as an example. 
 
          
              (a)                                      (b)                                            (c) 
Fig. 2. Construction of the virtual patient using the ribcage as an example: (a) 3D CT scan 
showing the ribcage, (b) Voxels resulting from segmentation of the ribcage, (c) Polygonal 
mesh used in the simulation. 
3.2 Segmentation 
Contour data can be extracted from medical imaging either by automatic or manual 
segmentation. The current project utilized automatic segmentation for bony anatomy (spine 
and rib cage), and manual segmentation for the liver and diaphragm, where interpretation 
by a medical expert is required. 
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3.2.1 Bones, lungs and skin segmentation 
All segmentation during the current project was performed using ITK-snap, an open-source 
program developed by the University of Pennsylvania (Yushkevich et al., 2005). Using this 
program, automatic segmentation is achieved by a process based on the level set technique. 
This method is divided into three steps: (i) bounded region is defined in order to drive the 
contour evolution. This boundary is given by the double-threshold image binarization 
method. (ii) Spherical seeds of different diameters are placed at different locations inside the 
previously defined boundaries, and (iii) an evolution function is applied to these seeds. This 
time-depending function, Ct, is defined by equation (1).  
 ( K)t IC g n  
  (1) 
where  and  are tunable parameters that have been respectively set to 1.0 and 0.2; gI is the 
force intensity based on the image gradient; K is the force intensity based on the contour 
curvature; and n is the contour normal. 
Due to the high density of bone, segmentation of this tissue was performed using the 
automatic method with a double threshold  (lower and upper) based on high Hounsfield 
density. The same method is used to segment the lungs. As the lungs are composed 
primarily of air, a double threshold based on low Hounsfield density is employed. The air-
tissue interface at the skin can likewise be segmented by this method based on low 
Hounsfield density. 
3.2.2 Liver segmentation 
Segmentation of the liver by automated methods poses a far greater challenge, because of 
the difficulty in performing the initial step of the level set algorithm due to the similarity 
between the density of the liver and its surrounding organs and tissues. Whilst methods 
exist to overcome this problem (Chen et al., 2009; Foruzana et al., 2009; Rusko et al., 2009), 
they are seldom satisfactory. Consequently, manual segmentation of organs such as the 
liver, whilst time consuming, is preferred. Manual segmentation can be more reliably and 
easily performed by using graphic tablets, such as the Cintiq 21UX Tablet PC (Wacom Co 
Ltd., Saitama, Japan) that was used in the current project. Such tablets, used in combination 
with a pressure sensitive stylus, permit a trained expert performing the segmentation to 
trace, freehand, the border of the liver in consecutive CT scan images in the sagittal, coronal 
and axial view. As with automatic segmentation, manual segmentation was performed 
using the ITK-snap software. 
3.2.3 Diaphragm segmentation 
Due to its thickness, typically 3mm (1-2 pixels), it is often difficult to visualize the thoracic 
diaphragm in standard CT scan images. Moreover, the density of the fibro-muscular tissue 
which makes up the diaphragm is similar to that of other surrounding organs and tissues. 
Segmenting of this structure, therefore, presented a major challenge. The most effective way 
of manually segmenting the diaphragm was to isolate its boundaries with surrounding 
structures, namely the liver, lungs and thoracic wall. For the diaphragm, manual 
segmentation in the sagittal, coronal and axial planes is particularly desirable as it helps to 
ensure a smooth contour. Important anatomical relationships of the diaphragm include: (i) 
the spine in the region of the twelfth thoracic vertebra; diaphragmatic crura are 
demonstrable in the axial plane (see Figure 3.a); (ii) the inner aspect of the ribs and the costal 
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margin; (iii) the overlying visceral and parietal pleura, including the potential space of  
the pleural reflection; (iv) the liver; (v) the heart / pericardium and lungs, (vi) stomach and 
(vii) spleen (See Figure 3.b and 3.c). 
 
            
 (a)                                        (b)                                                   (c) 
Fig. 3. Manual segmentation of the diaphragm: red line depicts (a) diaphragmatic crural 
attachments to the spine, (b) relationship to the lungs, pleura and ribs within the thorax, and 
(c) inferior aspect of the heart. 
3.3 Meshing 
For this project we have segmented scans from five patients with liver cancer, each with 
variation in both normal anatomy and tumour location. Data acquired from segmentation 
leads to the creation of ‘stacks’ of voxels that can be labeled according to the organ or structure 
they depict. These data are subsequently transformed into 3D models via a process of 
meshing, itself divided into three clear stages: (i) marching cubes algorithm; (ii) decimation; 
and (iii) smoothing. Marching cubes is a computer graphics algorithm for extracting a 
polygonal mesh of an isosurface from voxels. This isosurface comes directly from the label 
boundaries that are the result of segmentation. Decimation consists of replacing a large group 
of polygonal elements by a smaller group, given some constrains of curvature and position 
accuracy. The last technique, smoothing, is a methods used to diminish sharp edges within the 
model by “blurring” the angles between triangular elements. 
3.4 Implementation 
Once fully acquired and preprocessed, this 3D organ framework is implemented in object-
oriented C++. We use the application programming interface H3D (SenseGraphics, 2008) as 
this environment combines both visual and haptic rendering. The H3D visual rendering is a 
superior layer to OpenGL, permitting the fast depiction of sets of triangles as organ meshes. 
The haptic rendering is also a superior layer to OpenHaptics, the software provided with 
the haptic device used in this project, the Phantom Omni (SensAble, Wilmington, USA). 
H3D uses the XML format called X3D to represent a scene or, in this particular instance, a 
set of organs, with different programmable behaviors. Figure 4 shows two examples of 
virtual patients that were developed within this framework. 
The steps described up to this point have led to the creation of static models of the organs 
and tissues required for construction of the proposed liver biopsy simulator. Using a 
suitable deformation model, this static 3D representation of the organs and tissues can be 
manipulated without difficulty to allow deformation, either during breathing, or when there 
is interaction with a surgical instrument. In addition, it is required that force feedback is 
rendered to the user while inserting a needle through the body of the virtual patient. The 
next two sections of this chapter detail the methods used to achieve these goals. 
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of polygonal elements by a smaller group, given some constrains of curvature and position 
accuracy. The last technique, smoothing, is a methods used to diminish sharp edges within the 
model by “blurring” the angles between triangular elements. 
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Once fully acquired and preprocessed, this 3D organ framework is implemented in object-
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this environment combines both visual and haptic rendering. The H3D visual rendering is a 
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the haptic device used in this project, the Phantom Omni (SensAble, Wilmington, USA). 
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The steps described up to this point have led to the creation of static models of the organs 
and tissues required for construction of the proposed liver biopsy simulator. Using a 
suitable deformation model, this static 3D representation of the organs and tissues can be 
manipulated without difficulty to allow deformation, either during breathing, or when there 
is interaction with a surgical instrument. In addition, it is required that force feedback is 
rendered to the user while inserting a needle through the body of the virtual patient. The 
next two sections of this chapter detail the methods used to achieve these goals. 
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Fig. 4. Example of two virtual patients with transparent skin (light brown), lungs (pink), 
bones (white), liver (dark brown) and thoracic diaphragm (red) 
4. Respiration simulation 
In order to create a simulator which convincingly recreates conditions of liver biopsy, it is 
necessary to model liver displacement by respiration. In the current project this was 
achieved by applying dynamic behavior to previously segmented anatomy. This motion is 
defined by a sinusoidal curve that mimics normal tidal breathing in a patient. The curve 
M(t) modeled in equation (2), is used to defined the  motion of respiratory muscles. 
 ( ) sin(2 )M t A ft  (2) 
Where A is the muscle amplitude and f the respiration frequency. As is common during 
real liver biopsy, the clinician can instruct the virtual patient to perform an end tidal 
breath hold, whereupon motion due to respiration stops. In the following section we first 
introduce the mechanism of normal human respiration, and subsequently discuss details 
of the soft-tissue deformation technique that was used, as well as the handling of 
deformation for each organ. 
4.1 Description of the natural respiration process 
Respiration is a process consisting of the cyclical inflation and deflation of the lungs. The 
lungs are in effect passive organs whose motion is driven by muscles within the chest wall 
and diaphragm. The lungs are surrounded by the pleural cavity, bound by the visceral (lung 
surface) and parietal (chest wall and diaphragm) pleural membrane and containing a small 
volume of pleural fluid. Surface tension within the pleural fluid ensures close apposition of 
the lung surfaces with the chest wall and diaphragm, allowing for optional lung inflation. 
During inhalation, the active downwards contraction of the diaphragm and outwards 
motion of the chest wall (mainly due to contraction of the intercostal muscles) results in a 
negative pressure being generated within the thorax, which is in turn responsible for lung 
expansion. In comparison, exhalation, for the most part, is a passive process facilitated by 
relaxation of diaphragmatic and chest wall muscles. 
The upper portion of the liver is attached to the diaphragm via a collection of ligaments (see 
Figure 5). The falciform ligament extends upwards on the anterior surface of the liver from a 
notch in the lower margin, as far back as the posterior surface. On the superior aspect of the 
liver, the falciform ligament extends medially as the left triangular ligament and laterally as 
the coronary ligament. The coronary ligament is formed of both an upper and lower layer 
which meet at the apex of the liver, where they form the right triangular ligament. 
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                     (a)                            (b) 
Fig. 5. Positions of liver ligaments; (a) anterior and (b) posterior views of the liver 
The diaphragm is a sheet-like structure formed of both a tendinous (central) and a muscular 
(peripheral) part. During contraction, the diaphragm flattens, enlarging the volume of the 
thoracic cavity and causing the lungs to expand and inflate. When relaxed, the diaphragm is 
pulled upwards by the elastic recoil of the lung tissue. Due to its ligamentous attachments 
and close anatomical relationship, during normal respiration the liver follows the 
downwards and upwards motions of the diaphragm (Moore &Dalley, 2009).  
The liver is also surrounded by the lower portion of the chest wall, which comprises ribs 
(bony elements) and costal cartilage (cartilaginous component of the rib cage), and 
associated muscle and other soft tissues. All twelve pairs of ribs are attached posteriorly to 
their respective thoracic vertebrae. Anteriorly, ribs 1 to 10 attach to the sternum via costal 
cartilage. Ribs 11 and 12 are considered ‘floating ribs’ as they have no anterior connection to 
the sternum. The rib cage, whilst rigid, is able to move in what is classically described as a 
combination of ‘bucket handle’ and ‘pump handle’ motions. Contraction of chest wall 
muscles generates an outwards and upwards motion of the anterior chest wall, causing 
expansion of the thoracic cavity. The attachments of the ribs to the thoracic vertebrae act as a 
pivot for this movement. Motions and deformations that are described from the diaphragm, 
ribcage and liver are shown in Figure 6. 
 
       
            (a)                                     (b)                        (c) 
Fig. 6. Physiological behavior and motion of the: a) diaphragm, b) ribcage and c) liver. The 
black arrows represent the organ deformations during breathing. 
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cartilage. Ribs 11 and 12 are considered ‘floating ribs’ as they have no anterior connection to 
the sternum. The rib cage, whilst rigid, is able to move in what is classically described as a 
combination of ‘bucket handle’ and ‘pump handle’ motions. Contraction of chest wall 
muscles generates an outwards and upwards motion of the anterior chest wall, causing 
expansion of the thoracic cavity. The attachments of the ribs to the thoracic vertebrae act as a 
pivot for this movement. Motions and deformations that are described from the diaphragm, 
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Fig. 6. Physiological behavior and motion of the: a) diaphragm, b) ribcage and c) liver. The 
black arrows represent the organ deformations during breathing. 
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Both the diaphragm and the ribcage are therefore independently involved in the process of 
normal respiration and, as such, their motions influence the position of the liver. 
Accordingly, a model of respiratory motion is essential to the development of a realistic 
simulation of liver biopsy. 
4.2 Soft-tissue behavior simulation 
Modeling soft-tissue behavior for computer-based simulators has been widely studied over 
the last few decades. Efforts have primarily focused on improving mechanical fidelity so as 
to best mimic reality. Some algorithms use, directly, the continuous mechanics equations 
that are adopted in the field of mechanical engineering, whilst others use the time-
consuming finite element formulation (Bro-Nielsen, 1996). Algorithms that use fewer 
equations have also been developed, including the boundary element method (James & Pai, 
1999) and the mass-tensor method (Cotin et al., 1998), but their computing time still remains 
high. Another approach that attempts to minimize computational time, requires that the 
object being modeled is no longer considered as a continuous body, but rather as one that is 
discretized. The most recognized example of such a model is the mass-spring method, 
which consists in linking discrete elements by springs and then using the proportional 
spring interaction law (Zordan et al., 2004). A similar method is the particle-system, where 
the elements are no longer connected, but are restricted by a repulsion/attraction law that 
helps to ensure the systems stability (Amrani et al., 2000). We have chosen to use the 
Chainmail (Meier et al., 2005) method as it is one of the fastest available for simulation of 
soft tissue behavior.  
A full description of the Chainmail method can be found in (Gibson, 1997). The primary aim 
of this method is to simulate soft tissues as if they were a sheet of medieval chain mail, 
composed of small, interconnected metal rings. The expected behavior is as follows: when a 
chain element is moved, it may influence its neighbors; if the initial motion is too small, only 
the first element is moved but, if this motion is large enough, neighboring elements may 
also moved (see Figure 7). 
 
     
            (a)                             (b) 
Fig. 7. Chainmail behavior: the blue element is moved and the red elements may move 
depending on the first element displacement amplitude and direction. Element 
displacement that is (a) small enough to not influence its neighbors and (b) large enough to 
influence its neighbors. 
Mathematically, this model can be described by the mechanical parameters of compression, 
 stretching, ; and shearing, . If we focus on an axis, i, and on the motion of two elements 
along this axis, the second element will not move if the length between the elements remains 
below a quantity imax and above a quantity imin defined by , and . Consequently, 
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compression is observed when the length becomes small enough i.e. imin is equal to  times 
the initial length with <1. Stretching is observed when the length becomes high enough i.e. 
imax is equal to  times the initial length with >1. Finally, shearing is observed when the 
combined displacement in the other axes becomes high enough i.e. imax is equal to  times 
the initial combined displacement with >1. The behavior defined by the Chainmail 
algorithm is given by equations (3-8). 
 min 2 2 1 2 1 2 1( * * ( ))x x x x y y z z         (3) 
 max 2 2 1 2 1 2 1( * * ( ))x x x x y y z z         (4) 
 min 2 2 1 2 1 2 1( * * ( ))y y y y x x z z         (5) 
 
max 2 2 1 2 1 2 1( * * ( ))y y y y x x z z         (6) 
 
min 2 2 1 2 1 2 1( * * ( ))z z z z x x y y         (7) 
 
max 2 2 1 2 1 2 1( * * ( ))z z z z x x y y         (8) 
These equations give the minimum and maximum location of elements linked at a moving 
element, whose position goes from (x1, y1, z1) before displacement, to (x2, y2, z2) after 
displacement. 
4.3 Rib cage simulation 
Due to their rigid nature, it is not necessary to use soft-tissue deformation to model 
movement of the ribs. Their motion can instead be based on kinematics laws. Furthermore, 
we assume each rib to have only rotation and no translation, unlike the finite helical axis 
model used by previous authors (Didier et al., 2007). As this model is only defined by 
rotational motion, it is comparably simpler (Wilson et al., 2001). In this project, rotational 
parameters are independently defined for each rib; and are composed of a rotation center, 
two rotation axes, a minimal rotation angle and a maximal rotation angle. The first axis 
defines a ribs ‘bucket handle’ rotation (angle ) and the second axis defines the ‘pump 
handle’ rotation (angle ), as seen in Figure 6. These angles have been previously defined by 
other authors (Wilson et al., 2001) using patient data. The statistical amplitude angles, max 
and max, are presented on Table 1. 
 
Rib number max max
2 14,3 13,7
3 11,4 13,3
4 10,7 10,1
5 9,6 8,9
6 9,4 6,9
7 7,9 6,6
8 7,9 6,2
9 6 6,3
Table 1. List of angle amplitude for each rib and in the two rotation plans 
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Both the diaphragm and the ribcage are therefore independently involved in the process of 
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compression is observed when the length becomes small enough i.e. imin is equal to  times 
the initial length with <1. Stretching is observed when the length becomes high enough i.e. 
imax is equal to  times the initial length with >1. Finally, shearing is observed when the 
combined displacement in the other axes becomes high enough i.e. imax is equal to  times 
the initial combined displacement with >1. The behavior defined by the Chainmail 
algorithm is given by equations (3-8). 
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These equations give the minimum and maximum location of elements linked at a moving 
element, whose position goes from (x1, y1, z1) before displacement, to (x2, y2, z2) after 
displacement. 
4.3 Rib cage simulation 
Due to their rigid nature, it is not necessary to use soft-tissue deformation to model 
movement of the ribs. Their motion can instead be based on kinematics laws. Furthermore, 
we assume each rib to have only rotation and no translation, unlike the finite helical axis 
model used by previous authors (Didier et al., 2007). As this model is only defined by 
rotational motion, it is comparably simpler (Wilson et al., 2001). In this project, rotational 
parameters are independently defined for each rib; and are composed of a rotation center, 
two rotation axes, a minimal rotation angle and a maximal rotation angle. The first axis 
defines a ribs ‘bucket handle’ rotation (angle ) and the second axis defines the ‘pump 
handle’ rotation (angle ), as seen in Figure 6. These angles have been previously defined by 
other authors (Wilson et al., 2001) using patient data. The statistical amplitude angles, max 
and max, are presented on Table 1. 
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We have applied such methodology during the current project on datasets acquired from 
patient scans. To achieve this, we initially computed the rotation parameter during a 
preprocessing stage and chose to use a mechanical approach by computing the inertia 
matrix. This matrix, M, is defined by equation (9). It corresponds to integrations over the 
volume of each rib; x, y and z being the position of a within a rib. 
 
2 2
2 2
2 2
y z dv xydv xzdv
M xydv x z dv zydv
xzdv zydv y x dv
    
     
     
 (9) 
These moments of inertia represent the rigidity of a 3D object and are widely used in solid 
mechanics. The Eigen vectors of this matrix directly give the principal axes of the objects. 
The two highest Eigen values give the axis that contains the largest proportion of matter and 
is therefore of most interest to us. We define the ‘rib plane’ as that which is given by these 
two Eigen vectors (see Figure 8).  
 
 
Fig. 8. Rib rotation algorithm. Inputs are: (i) Eigen vectors; (ii) rotation angles  and (iii) 
rotation center; and (iv) initial rib location. The output is the rib at its final position. 
The rotation centers are found by a heuristic method. First, we compute the higher Eigen 
value of the spine inertia matrix, the associated axis gives the axial line of the spine. The 
rotation center is then given by the intersection between this line and the rib plane. From 
this pre-computation stage, we can determine for each rib the rotation center and the two 
axes. The next step is to apply a dynamic behavior to each rib based on these patient-
customized parameters. At each time step, the new coordinates of the rib points are 
computed with Rodrigues' rotation formula (Koks, 2006). These two rotations are time-
dependant and their angle values are derived from equation (2) taking  and as 
parameters. The results are given by equations (10) and (11). Acquired behavioral data was 
stored and accessed in X3D format. 
 max( ) sin(2 )t ft    (10) 
 max( ) sin(2 )t ft    (11) 
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4.4 Diaphragm simulation 
Diaphragmatic behavior has been modeled using various techniques, including geometrical 
methods based on external sensors (Hoestettler et al., 2008); Mass-spring systems with 
incompressibility constraints (Zordan et al., 2004); and nature-inspired tensegrity (Villard et 
al., 2008). These methods are time-consuming and their accuracy is beyond that which is 
required by the current application. Accordingly, we have developed a faster method that 
still reflects the physiological parameters discussed in section 4.1. 
During normal inhalation, the peripheral muscular portion of the diaphragm contracts 
pulling downwards on the central tendon and increasing intrathoracic volume. In 
comparison, during exhalation, the central tendon of the diaphragm retracts upwards into 
the chest as the muscle relaxes. We have, however, proposed a model whereby the central 
tendon of the diaphragm assumes an active role, with a sinusoidal up and down motion 
derived from equation (2), whilst the muscular portion remains passive. As the central 
tendon of the diaphragm is naturally stiff, our model assumes it to be a rigid structure. The 
motion function, T(t), of the model, where t is the time as given by equation (12). The 
translation amplitude, dmax, was set at 2cm. 
 max( ) sin(2 )T t d ft  (12) 
In contrast, the muscle portion of the diaphragm follows an elastic behavior based on the 
Chainmail algorithm detailed in section 4.2. This also preserved the natural deformation of 
the muscle during the contraction-relaxation cycle. The portion of the diaphragm, which is 
attached to the spine, is programmed to remain motionless. Illustrations of diaphragm 
behavior, as programmed by our model, are presented in Figure 9. 
 
 
Fig. 9. Programmed diaphragmatic behavior: the central tendon of the diaphragm, presented 
here in white, is considered to have a stiff translation in the longitudinal plane. In comparison, 
the muscular portion (red), with the exception of regions directly attached to the spine, 
passively deform in response to tendon displacement. The initial and final positions of the 
diaphragm are depicted above by opaque and transparent boundaries respectively. 
4.5 Liver simulation 
The final organ whose behavior needs to be detailed is the liver. Whilst the liver is entirely 
passive during respiration, its upper border lies immediately adjacent to the diaphragm and 
is attached to its inferior surface via a series of ligaments (refer to details in section 4.1). To 
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here in white, is considered to have a stiff translation in the longitudinal plane. In comparison, 
the muscular portion (red), with the exception of regions directly attached to the spine, 
passively deform in response to tendon displacement. The initial and final positions of the 
diaphragm are depicted above by opaque and transparent boundaries respectively. 
4.5 Liver simulation 
The final organ whose behavior needs to be detailed is the liver. Whilst the liver is entirely 
passive during respiration, its upper border lies immediately adjacent to the diaphragm and 
is attached to its inferior surface via a series of ligaments (refer to details in section 4.1). To 
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model this interaction we chose to apply coupling forces as opposed to displacement 
constrains, allowing continuous smooth deformation that would otherwise have been hard 
to reproduce. Coupling between the liver and diaphragm was characterized in a pre-
computing step using X3D data. A threshold distance of 5mm was established, below which 
a connection force is applied. Internal deformations of the liver due to respiration were 
modeled by the Chainmail algorithm. 
Our model also allowed deformation of the liver under the influence of an external force 
applied by the biopsy needle. This interaction primarily occurs between the tip of the needle 
and what is in real life a thin fibrous layer covering the liver, referred to as the liver capsule. 
This layer is deformed as the operator attempts to introduce the biopsy needle into the body 
of the liver. Once perforated, however, this layer no longer shows deformation. Again, we 
use the Chainmail algorithm to model this interaction by applying the needle tip 
displacement to the three closest points on the liver surface. In reality, the greatest influence 
on needle insertion is not the visual displacement of the liver capsule, but haptic interaction. 
In the next section we focus on the method used to render this important ‘force feedback’ 
experienced by the operator during needle insertion. 
5. Haptic rendering 
As in many simulators, we have attempted to enhance the user’s immersion through the 
addition of haptic rendering. This is achieved by the operator interacting with the virtual 
environment through a haptic device that resembles tools used during the actual task. In 
this section we introduce the synchronization between the visual feedback and the haptic 
device, as well as explain the computation and rendering to the user of the physical forces. 
5.1 Needle avatar 
In this project a haptic device is used to simulate the liver biopsy needle. This device 
generates two important parameters used by our framework; namely, the position (P) and 
the direction (D) of the needle. The needle avatar is then linked to the stylus that the user is 
manipulating. At each time step, P and D are recorded and the needle is displayed. When 
the needle is inserted into the patient’s body, a force feedback (F) is computed and rendered 
back to the user (see Figure 10).  
 
 
Fig. 10. Commercially available haptic device. The haptic device is driven by the position (P) 
and direction (D) of the stylus that are determined by the user’s movements, and renders 
back a force (F) processed by the computer. 
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5.2 Soft-tissue force feedback 
Haptic rendering is often based on collision detection and collision response algorithms. The 
combination of these methods could not, however, be directly applied during the current 
project as it would have resulted in a model that was too complex due to the number of 
organs and tissues potentially traversed by the needle. In addition, it would need haptic 
sub-layers, for example the organs inside the skin or the tumor inside the liver. Such an 
option is currently not fully supported by haptics APIs. 
We chose instead the method implemented in (Vidal et al., 2008), where force is no longer 
dependent on collision detection, but is always computed while the needle is inside the 
patient’s body and never while outside. In the same way, no classical collision response 
force algorithm is performed. Instead, force is computed using the initial 3D CT scan data, 
without the mesh environment information. As the biopsy needle is inserted into the virtual 
patient, it is possible to access the corresponding voxel Hounsfield densities, provided the 
medical image remains appropriately registered to the polygonal information. Longitudinal 
force is then determined on line by means of the voxel gradient as it is similar to matter 
density. The operator can therefore feel the boundaries between tissue planes as they are 
traversed by the advancing needle  
Soft tissues are not only responsible for forces generated along the long axis of the needle 
(needle axial forces), they also apply a constraining force that inhibits lateral movement of 
the needle. Consequently, once the needle has been inserted more than a few millimeters 
into the virtual patient, lateral movement of needle is greatly constrained by the influence 
of the surrounding tissue(s), such that it is almost impossible to deviate from the initial 
trajectory. In our model we have added constraining forces in order to reproduce this 
phenomenon. The direction of the force (Fa) acting upon the needle is computed from the 
initial position (P0) and direction (D0) of insertion and from current position (Pt). Thus, the 
relationship describing the soft-tissue force feedback is given by equation (13). 
 00
0
( ) * sin( )a t
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P P
 

 (13) 
 
 
Fig. 11. Needle insertion force in Newtons with the penetration depth in millimeters 
(equation (14). 
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5.3 Liver force feedback 
Haptic feedback is of particular importance during needle insertion into the substance of the 
liver. As was described in section 4.5, the liver is covered by a fibrous capsule that offers 
considerable resistance to continued passage of the needle. This resistance is, however, 
dramatically reduced at the moment of capsule penetration. Thereafter, continued needle 
insertion deeper into the liver is subjected to increasing resistance. In this project we have 
simulated this behavior by adding a needle axial force whose value is extracted from 
(Maurin et al., 2004). Experimental data were acquired with a force sensor during IR 
procedures (Karuppasamy et al., 2008) and fitted to a mathematical model. It defines the 
force, Fn, varying with the penetration depth d. This force is defined piecewise, before and 
after penetration with two sets of parameters and that define equation (14). The 
corresponding curve is shown on Figure 11. 
 ( )( ) ( ) dnF d e
       (14) 
6. Resulting simulator 
The final simulator encompasses all of the elements described in the preceding sections: a 
collection of virtual patients and their organs, segmented from CT scans of actual patients 
and represented by meshes; cyclical deformation of theses meshes in accordance with a 
model of respiration; a virtual needle that can be manipulated with six degrees of freedom 
via the arm of a haptic device. As the needle passes through the different tissues, the 
operator is able to determine additional information about their nature through haptic 
feedback. Furthermore, as this needle is inserted into the capsule of the liver, deformation of 
the organ’s surface can be observed and felt. The biopsy is triggered by the operator 
pressing one of the buttons in the Omni haptic interface. In the following sections we 
present a complete description of the final simulator, including patient-customised anatomy 
and physiology. We also add a module to measure the user performance. Finally, we 
present a review of feedback received from both expert and trainee interventional 
radiologists. 
 
 
Fig. 12. Liver biopsy simulator using the Sensegraphics Immersive Workbench and Phantom 
Omni haptic device 
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6.1 Immersive Workbench 
In developing this simulator particular emphasis was made on selecting algorithms that are 
suitably fast. This has, ultimately, allowed the simulator to be real time, offering 500Hz and 
20Hz for haptic and graphic rendering respectively. To achieve a superior ergonomic and 
3D immersive experience, the simulator framework has been integrated with the 
Sensegraphics Immersive Workbench1 (see Figure 12). This system required active 3D 
glasses with a shuttering system synchronized with a CRT monitor to visualize the virtual 
environment in 3D. As is shown in Figure 12, the monitor is positioned at a 45° angle above 
a horizontal semi-transparent mirror. With this configuration, the user is able to view the 3D 
target object collocated with their hand and the haptic device. 
6.2 Patient specific physiology 
The final 3D simulator has been designed to take into account variability in the speed and 
strength of factors contributing to motion. This has allowed the simulator to match 
diaphragmatic or thoracic breathing patterns and the overlap that exists between these two 
dynamic processes (see Figure 13). 
 
 
Fig. 13. Patient customized anatomy with inhalation motion and needle avatar controlled 
via a haptic device 
The respiration is mathematically monitored by time-dependant functions defined by 
equations (10), (11) and (12). The breathing frequency could be changed by modifying the 
shared parameter f. The user can change from quiet breathing to hyperventilation. In the 
same way the influence of the diaphragm is linked to the dmax parameter of equation (12) 
and the thoracic behavior is tuned with a scalar value linked to the max and max parameters 
of respectively equations (10) and (11). Figure 14.a shows the panel displayed to the user in 
order to set a respiration pattern. 
                                                 
1 http://www.sensegraphics.com/ 
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6.3 Performance metrics 
As previously stated, simulators such as the one described here, provide a valuable and safe 
environment in which trainees may practice and be assessed. To support this application, a 
number of computer-based metrics are provided, including: time taken; number of times 
contact is made with designated ‘no-go’ areas (representing errors of needle tip location); 
number of attempted needle insertions; and biopsy accuracy (adequacy of tissue sample 
obtained). The time taken for the procedure begins when the task is initialized and finishes 
when the biopsy sample is acquired. The number of times voxels designated as ‘no go’ areas 
are crossed by the biopsy needle is also determined. ‘No go’ voxels include the lungs, 
costophrenic recess, colon, gallbladder, neurovascular bundles (located below the ribs), and 
bone. A further metric counts the number of attempted needle insertions; these are repeated 
whenever the operator perceives a failure to locate the biopsy target on the needle trajectory, as 
defined by the insertion point and the direction of the virtual needle. The final metric computed 
by the simulator was biopsy precision. In the current simulator, the tumor is modeled by a 
spherical body of 15mm. Four levels of precision are defined depending on the distance between 
the site of biopsy and the center of the tumor. Biopsy samples taken from within 5mm of the 
centre of the tumor are considered to contain “Necrotic debris”, that is a feature of tumors as 
they outgrow their blood supply. Biopsies taken from within 5-10mm of the tumor centre are 
judged as being a “good specimen” because this is the region of actively growing tumour cells, 
whilst tissues 10-15mm from the center may contain “some tumor cells”. Any biopsy that is 
>15mm from the centre of the tumor will contain normal cells and hence is regarded as “not 
pathologic”. All metrics described are displayed to the operator on completion of the 
procedure, allowing objective assessment of their performance (see Figure 14.b) 
 
                       
              (a)                                         (b) 
Fig. 14. Simulator user interface. a) Tuning of patient breathing pattern b) Metrics display. 
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6.4 Qualitative evaluation  
In order to evaluate the simulator, we invited both expert and trainee interventional 
radiologists to use it to perform a number of tasks. A review of the main comments made by 
clinicians is presented below. 
Feedback received for each module of the simulator was generally positive. Most clinicians 
reported that the inclusion of movement due to respiration was an important feature of the 
simulator and considered that the realism of the procedure was enhanced when this 
function was active. Many comments were made about the haptic rendering, which was 
considered to satisfactorily reflect the forces experienced during liver biopsy in patients.  
It was suggested that the simulator was most suitable for first and second year trainees who 
generally have limited opportunity to practice and maintain their technical skills in this 
procedure. By using the simulator, clinicians felt that trainees would be able to acquire and 
maintain both core practical skills and confidence, within a safe environment, remote from 
patients. The general consensus of all clinicians was that simulators, such as this, are needed 
and that there is a place for them in training curricula. Indeed the Royal College of 
Radiologists and British Society of Interventional Radiologists in the UK are actively 
developing training opportunities using simulation  
We also received a number of comments relating to potential improvement of the simulator. 
Several clinicians noted that, during this procedure, they would tend to rest their hands on 
the patients body, something that was not possible with a virtual patient. One clinician 
reported difficulty in pressing the button on the Omni haptic device used to trigger biopsy, 
whilst another found it difficult to manouvre the same device. 
7. Future work 
Future work must both address issues raised by clinicians during the evaluation stage, as 
well as modifying the existing framework to allow simulation of other interventional 
radiology procedures within the abdomen.  We also intend to develop new methods of 
automatic segmentation that will aid in the isolation of anatomical structures, including the 
diaphragm. It is intended that this will enhance the retrieval of 3D data from CT scans, 
widening the application of this technology to allow patient specific pre-procedural training 
and planning. Finally, refinement of the respiratory model will allow the described 
framework to be used in other applications including the administration of targeted 
radiotherapy. Further thorough and systematic validation is also required and to this end a 
skills transfer study has recently commenced. 
8. Conclusion 
In conclusion, we have presented here a new framework of a liver biopsy simulator that 
includes respiratory motion. This framework is composed of 3D virtual organs extracted from 
patient data. In addition, organ motion due to respiration and haptic feedback during needle 
insertion is computed on-line and in real time within a virtual reality environment. An 
immersive workbench permits the operator to perform the procedure in a 3D environment 
that allows co-location of their hands with the virtual target. The feedback of experienced and 
trainee clinicians who were invited to use the simulator was obtained to evaluate the 
simulator’s strengths and weaknesses. As a direct consequence of its efficacy, the simulator 
framework described here has been applied in two other medical simulators that are based on 
fluoroscopic (Villard et al., 2009) and ultrasound (Bello et al., 2009) image guidance. 
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1. Introduction  
The prognosis of chronic liver disease depends on the progression of liver fibrosis. Liver 
biopsy is recommended as the gold standard method for determining fibrosis stage, 
prognosis and therapeutic indications in patients with chronic liver disease. However, liver 
biopsy is an invasive procedure associated with a risk of potentially serious complications. 
Approximately 1–3% of patients require hospitalization for complications, and a quarter of 
them report pain after percutaneous liver biopsy. The diagnostic accuracy of liver biopsy for 
assessing liver fibrosis is influenced by the quality of the biopsy samples. In addition, there 
are several absolute or relative contraindications to liver biopsy, including severe 
coagulopathy. A safe and non-invasive alternative to liver biopsy is therefore needed for 
assessing liver fibrosis in daily clinical practice. 
2. Principle of acoustic radiation force impulse  
Acoustic radiation force impulse (ARFI) imaging is a radiation force-based imaging method 
that is provided by conventional B-mode ultrasonography (Acuson S2000; SIEMENS 
Medical Solutions) (Fig. 1). ARFI imaging involves transmission of an initial ultrasonic pulse 
at diagnostic intensity levels to obtain a baseline signal for later comparison. A short-
duration (approximately 0.3 s), high-intensity acoustic ‘pushing pulse’ is then transmitted 
by the same transducer, followed by a series of diagnostic intensity pulses, which are used 
to track the displacement of the tissue caused by the pushing pulse (Nightingale et al., 2001, 
Palmeri et al., 2005, Dahl et al., 2007). The response of the tissue to the radiation force is 
observed using conventional B-mode imaging pulses, and it is possible to display the 
quantitative shear-wave velocity (Vs; m/s) of ARFI displacement. This velocity (m/s) is 
proportional to the square root of tissue elasticity. Because the velocity of the shear wave 
depends on tissue stiffness, it is possible to apply ARFI technology to elastography. This 
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technology was named “Virtual Touch Tissue Quantification” by SIEMENS. Previous 
reports have also referred to it as ARFI elastography or ARFI elastometry. In this chapter, 
we use the term ARFI elastography. 
3. Protocol of ARFI elastography 
ARFI imaging involves targeting an anatomic region to be examined for its elastic properties 
using a region-of-interest (ROI) cursor measuring 10×5 mm at the same time as or after 
performing real-time B-mode imaging (Fig. 2). This enables a comprehensive range of tissue 
strain analytic parameters to be assessed, allowing quantitative values of the mechanical 
stiffness (elasticity) properties of tissues to be measured. In general, the stiffer a region of 
tissue, the greater the shear-wave speed as it travels through this region. ARFI elastography is 
performed using a curved array at 4 MHz for B-mode imaging. The right lobe of the liver is 
examined through the intercostal space with the patient lying in the dorsal decubitus position, 
with their right arm maximally abducted. A measurement depth of 2–3 cm below the liver 
capsule is chosen to standardize the examination. No consensus has yet been reached 
regarding the ROI position and the approach point on the body surface, but our experience 
indicates that measurement at 2–3 cm depth from the right intercostals seems to produce 
stable results. According to a recent report, there was no significant difference in ARFI 
measurements between the intercostal and abdominal approaches; however, the intercostal 
approach had the highest success rates (Popescu et al., 2011). Although different values of 
ARFI measurements were reported for each depth under the liver capsule, the differences 
were not significant (Sporea et al., 2010). Boursier et al. reported that the reproducibility of 
measurements in the right lobe was high, but measurements in the left lobe included cases 
with outliers (Boursier et al., 2010). Further studies are needed to determine the depth of ROI 
for the appropriate stratification of liver fibrosis stages. The Acuson S2000 has a memory 
capability, and more than five successful acquisitions should thus be performed for each 
patient; the median or mean value can then be calculated to produce a reliable measurement. 
4. Reproducibility of ARFI elastography 
According to previous reports, ARFI elastography has high reproducibility. Boursier et al. 
reported that the interobserver reproducibility of ARFI was excellent (interclass correlation 
coefficient = 0.91) and no training effect was observed in terms of ARFI measurements 
(Boursier et al., 2010). Friedrich-Rust et al. found 87% agreement regarding ARFI 
elastography-derived stages between two examiners (Friedrich-Rust et al., 2009).  
5. ARFI elastography in normal healthy subjects 
Several studies have determined the normal range of ARFI measurements for healthy 
subjects. Popescu et al. reported a mean shear-wave velocity of 1.15 ± 0.21 m/s (Popescu et 
al., 2011). The study by Takahashi et al. included 25 healthy controls, and found a mean 
shear-wave value of 1.08 ± 0.13 m/s (Takahashi et al., 2010). The mean shear-wave velocity 
in the study by Horster et al., which included 68 healthy volunteers with a mean age of 28 
years, was 1.19 m/s (range, 0.77–1.63 m/s) (Horster et al., 2010), while Goertz et al. obtained 
a mean value of 1.09 m/s (range, 0.79–1.32 m/s) in 20 healthy subjects. Kim et al. included 
133 subjects with normal livers in their series and derived a mean value of 1.08 ± 0.15 m/s 
(Goertz et al., 2010, Kim et al., 2010). No correlations between ARFI values and age, gender 
or body mass index (BMI) have been identified. 
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6. Diagnostic accuracy for liver fibrosis 
Ultrasonography-based evaluation offers several advantages, including ready availability, 
real-time examination, relatively low cost and lack of ionizing radiation. Recent studies have 
indicated the clinical feasibility of ARFI elastography for assessing liver fibrosis (Table 1). 
The results demonstrated that shear-wave velocity measured by ARFI elastography offers a 
reliable and non-invasive method for estimating liver fibrosis in chronic liver diseases. In 
particular, liver stiffness assessed by shear-wave velocity was significantly correlated with 
liver fibrosis according to the pathological scoring system. Furthermore, the staging of liver 
fibrosis in chronic liver diseases could be accurately classified based on shear-wave velocity. 
Friedrich-Rust et al. reported that the area under the receiver operating characteristic curve 
for the accuracy of ARFI elastography was 0.91 for the diagnosis of both moderate fibrosis 
(F≥2) and cirrhosis, respectively. According to their report, the cut-off value for liver 
cirrhosis was 1.75 m/s in all subjects, and 1.75 m/s in subjects with hepatitis C virus (HCV) 
infection (Friedrich-Rust et al., 2009). Other reports have identified variable cut-off values 
for cirrhosis, ranging from 1.6–1.95 m/s (Table 1). In the studies by Takahashi et al. and 
Sporea et al., which included 47 (85%) and 54 (76%) HCV-positive subjects, respectively, the 
cut-off value for cirrhosis was 1.8 m/s (Takahashi et al., 2010, Sporea et al., 2010). The study 
by Yoneda et al. included subjects with non-alcoholic fatty liver disease (NAFLD), and 
found a cut-off value for cirrhosis of 1.9 m/s, which was higher than in other studies 
(Yoneda et al., 2010). It is possible that differences in background chronic liver diseases 
might account for the variations in cut-off values. In addition, different distributions of 
fibrosis stages among subjects in different studies may affect the results of ROC analysis, 
and direct comparison of cut-off values among studies should therefore be avoided. The 
Obuchowski measure, which allows for differential penalization of more serious 
misdiagnoses, was recently reported (Obuchowski et al., 2005). This method allows the 
diagnostic accuracy of ARFI elastography among studies with different distributions of 
fibrosis stages to be compared (Lambert et al., 2008). However, because the Obuchowski 
measure is statistically technical, analysis with commercially-based medical statistical 
software might be difficult. Further studies on the correlations between different liver 
disease etiologies and the results of ARFI elastography are needed, as are standardized 
measurement protocols and statistical methods. Nonetheless, ARFI elastography appears to 
offer good diagnostic accuracy for staging liver fibrosis.  
               
  AUROC Cut-off for cirrhosis 
Author Subjects FS 0–1vs FS 2–4 FS 0–2 vs. FS 3–4 FS 0–3 vs. FS 4 (m/s) 
Friedrich- 
Rust et al. HCV, HBV 0.84 0.91 0.91 1.75 
Takahashi et al. HCV, HBV, NASH 0.94 0.94 0.96 1.8 
Yoneda et al. NAFLD - 0.97 0.98 1.9 
Sporea et al. HCV, HBV 0.65  0.87 1.8 
Goertz et al. HCV, HBV 0.85 0.92 0.87 - 
Fierbinteanu-
Braticevici et al. HCV 0.92 0.99 0.99 1.95 
Rifai et al. HCV, HBV, NAFLD - - 0.82 1.6 
Table 1. Diagnostic accuracy of ARFI for liver fibrosis 
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found a cut-off value for cirrhosis of 1.9 m/s, which was higher than in other studies 
(Yoneda et al., 2010). It is possible that differences in background chronic liver diseases 
might account for the variations in cut-off values. In addition, different distributions of 
fibrosis stages among subjects in different studies may affect the results of ROC analysis, 
and direct comparison of cut-off values among studies should therefore be avoided. The 
Obuchowski measure, which allows for differential penalization of more serious 
misdiagnoses, was recently reported (Obuchowski et al., 2005). This method allows the 
diagnostic accuracy of ARFI elastography among studies with different distributions of 
fibrosis stages to be compared (Lambert et al., 2008). However, because the Obuchowski 
measure is statistically technical, analysis with commercially-based medical statistical 
software might be difficult. Further studies on the correlations between different liver 
disease etiologies and the results of ARFI elastography are needed, as are standardized 
measurement protocols and statistical methods. Nonetheless, ARFI elastography appears to 
offer good diagnostic accuracy for staging liver fibrosis.  
               
  AUROC Cut-off for cirrhosis 
Author Subjects FS 0–1vs FS 2–4 FS 0–2 vs. FS 3–4 FS 0–3 vs. FS 4 (m/s) 
Friedrich- 
Rust et al. HCV, HBV 0.84 0.91 0.91 1.75 
Takahashi et al. HCV, HBV, NASH 0.94 0.94 0.96 1.8 
Yoneda et al. NAFLD - 0.97 0.98 1.9 
Sporea et al. HCV, HBV 0.65  0.87 1.8 
Goertz et al. HCV, HBV 0.85 0.92 0.87 - 
Fierbinteanu-
Braticevici et al. HCV 0.92 0.99 0.99 1.95 
Rifai et al. HCV, HBV, NAFLD - - 0.82 1.6 
Table 1. Diagnostic accuracy of ARFI for liver fibrosis 
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AUROC, area under the receiver operating characteristic curve; FS, fibrosis stage; HCV, 
hepatitis C virus; HBV, hepatitis B virus; NAFLD, non-alcoholic fatty liver disease. Fibrosis 
stage was assessed using the Metavir scoring system, except in the case of Yoneda et al., 
who used the method of Brunt.  
7. Factors influencing ARFI elastography measurements 
The degree of liver fibrosis is the most significant factor determining shear-wave velocity. 
However, several other factors can affect shear-wave velocity. Rifai et al. reported that 
shear-wave velocity was faster in patients with significant liver inflammation compared 
with those with no significant inflammation (Rifai et al., 2011). They suggested that liver and 
spleen sizes were positively correlated with the results of ARFI elastography measurements. 
Takahashi et al. reported that serum aspartate aminotransferase and alanine 
aminotransferase levels as well as pathological liver inflammation were positively correlated 
with ARFI elastography measurements (Takahashi et al., 2010). These results suggest that 
pathological and serological liver inflammation might affect shear-wave velocity. However, 
it should be noted that significant proportions of patients in those studies had viral 
hepatitis, and the severity of pathological fibrosis has been shown to correlate with 
pathological inflammation in viral hepatitis. Further studies including larger sample sizes 
are needed to evaluate the impact of inflammation on ARFI elastography measurements in 
patients with the same severities of fibrosis stage.  
Pathological liver steatosis is a significant factor affecting ARFI elastography measurements 
in NAFLD. Yoneda et al. suggested that shear-wave velocity in NAFLD with no fibrosis was 
slower than in healthy controls. Additionally, NAFLD with mild liver fibrosis was 
associated with almost normal shear-wave velocities (Yoneda et al., 2010, Palmeri et al., 
2011). They suggested that steatosis might make the liver softer because of fat deposition in 
the liver parenchyma. Palmeri et al. showed that hepatocyte ballooning and inflammation in 
NAFLD had no significant effects on shear-wave velocity (Palmeri et al., 2011).  
8. Comparison with other non-invasive methods 
Several scoring systems or indexes based on serum biochemical markers have been 
proposed for the non-invasive prediction of liver fibrosis in chronic liver disease. 
Additionally, transient elastography (FibroScan) has recently been developed as a non-
invasive method for the evaluation of liver fibrosis, by assessing liver stiffness based on a 
mechanical wave generated by vibration. The diagnostic accuracy of ARFI has been shown 
to be comparable with that of previously reported non-invasive scoring systems such as 
AST to Platelet Ratio Index (APRI), Fib-4 and Forn’s index (Takahashi et al, 2010). Several 
studies have reported both ARFI and FibroScan measurements. The results of ARFI 
elastography were highly correlated with those of FibroScan measurements, though the 
success rate of ARFI measurements was higher than that for FibroScan. To the best of our 
knowledge, few reports have compared the diagnostic accuracies of ARFI and FibroScan, 
based on the gold standard of liver biopsy. Sporea et al. suggested that the accuracy of ARFI 
elastography was acceptable but lower than that of FibroScan (Sporea et al., 2010), while 
Friedrich-Rust et al. and Rifai et al. found no significant differences in diagnostic accuracy 
between the two techniques (Table 2) (Friedrich-Rust et al., 2009, Rifai et al., 2011). It thus 
remains unclear which form of elastography is more reliable; however, a prospective 
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multicenter study and meta-analysis are currently underway. Nonetheless, ARFI 
elastography appears to be useful because of its fewer limitations and the integration of 
elastography and conventional B-mode ultrasonography.    
 
  FS 0–1 vs. FS 2–4 FS 0–3 vs. FS 4 
Author Subjects ARFI FibroScan ARFI FibroScan 
Friedrich-Rust et al. HCV, HBV 0.82 0.84 0.91 0.91 
Sporea et al. HCV, HBV 0.65 0.73 0.87 0.94 
Rifai et al. HCV, HBV, NAFLD - - 0.82 0.84 
Table 2. Diagnostic accuracy of ARFI and FibroScan for liver fibrosis 
AUROC, area under the receiver operating characteristic curve; FS, fibrosis stage; HCV, 
hepatitis C virus; HBV, hepatitis B virus; NAFLD, non-alcoholic fatty liver disease. Fibrosis 
stage was assessed using the Metavir scoring system, except in the case of Yoneda et al., 
who used the method of Brunt.        
9. Limitations and possible contraindications of ARFI elastography  
No significant limitations or contraindication of ARFI elastography for liver assessment 
have been reported to date. However, the Japan Society of Ultrasonics in Medicine 
recommends that ARFI elastography should be avoided after contrast-enhanced 
ultrasonography with some kinds of contrast agents, because of the risk of cavitation. The 
limitations of transient elastography, such as narrow intercostal spaces, ascites and obesity, 
do not appear to apply to the use of ARFI elastography, according to our data and the 
results of previous reports. However, the success rate of ARFI measurements in subjects 
with a BMI >40 kg/m2 was reportedly only 58% (Palmeri et al., 2011). Further studies are 
needed to allow more precise evaluation of the limitations of ARFI elastography.  
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multicenter study and meta-analysis are currently underway. Nonetheless, ARFI 
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Acoustic radiation force impulse (ARFI) is a radiation force-based impulse that is provided 
by conventional B-mode ultrasonography, using an Acuson S2000. The ARFI method can be 
used for elastography. The technology was named “Virtual Touch Tissue Quantification” by 
SIEMENS. 
 
 
Fig. 2. Measurement window for ARFI elastography 
10. Conclusion  
In conclusion, the novel, non-invasive ultrasonic ARFI elastography technique, coupled 
with conventional ultrasonography, could offer a reliable method for the assessment of liver 
fibrosis in patients with chronic liver diseases. ARFI elastography could be useful for real-
time evaluation of liver fibrosis as an alternative to liver biopsy. 
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1. Introduction 
Different types of disease for example viral hepatitis, ethanol and biliary tract disease can 
produce liver fibrosis (Stalnikowitz & Weissbrod AB, 2003). Liver fibrosis can be divided 
into those diseases in which the fibrosis is portal based and those that are central based. 
Chronic viral hepatitis (viral and autoimmune), chronic cholestatic diseases and 
hemochromatosis are the major portal based diseases and steatohepatitis and chronic 
venous outflow obstruction of any cause can causes central based diseases (Benyon & 
Arthur, 2001). Chronic viral hepatitis (especially hepatitis B and C) and autoimmune 
hepatitis are the major causes of liver fibrosis, especially in developing countries. 
The hepatitis B virus (HBV) belongs to the Hepadnaviridae family (Marco et al, 1999) and it 
is estimated worldwide HBV infection prevalence is to be around 350 million chronic 
carriers (Kao & Chen, 2002). Infection with the hepatitis C virus (HCV) in the general 
population varies from 0.2% to 18% (Neighbors, 2007). HCV can infect liver cells and is able 
to cause severe inflammation of the liver with serious complications. Autoimmune hepatitis 
(AIH) similar to the above mentioned diseases, is a chronic disease that is associated with 
some autoantibodies such as antinuclear antibodies (ANA), liver-kidney microsomal 
antibodies (LKM), anti mithochondial antibody (AMA), soluble liver antigen (SLA), smooth 
muscle antibodies (SMA) and hypergammaglobulinemia. The prevalence of this disesesis is 
between 0.1 and 1.2 cases per 100,000 in Western Europe and North America but only 0.08–
0.015 cases per 100,000 in Japan (Manna & Strassburg, 2001). 
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1. Introduction 
Different types of disease for example viral hepatitis, ethanol and biliary tract disease can 
produce liver fibrosis (Stalnikowitz & Weissbrod AB, 2003). Liver fibrosis can be divided 
into those diseases in which the fibrosis is portal based and those that are central based. 
Chronic viral hepatitis (viral and autoimmune), chronic cholestatic diseases and 
hemochromatosis are the major portal based diseases and steatohepatitis and chronic 
venous outflow obstruction of any cause can causes central based diseases (Benyon & 
Arthur, 2001). Chronic viral hepatitis (especially hepatitis B and C) and autoimmune 
hepatitis are the major causes of liver fibrosis, especially in developing countries. 
The hepatitis B virus (HBV) belongs to the Hepadnaviridae family (Marco et al, 1999) and it 
is estimated worldwide HBV infection prevalence is to be around 350 million chronic 
carriers (Kao & Chen, 2002). Infection with the hepatitis C virus (HCV) in the general 
population varies from 0.2% to 18% (Neighbors, 2007). HCV can infect liver cells and is able 
to cause severe inflammation of the liver with serious complications. Autoimmune hepatitis 
(AIH) similar to the above mentioned diseases, is a chronic disease that is associated with 
some autoantibodies such as antinuclear antibodies (ANA), liver-kidney microsomal 
antibodies (LKM), anti mithochondial antibody (AMA), soluble liver antigen (SLA), smooth 
muscle antibodies (SMA) and hypergammaglobulinemia. The prevalence of this disesesis is 
between 0.1 and 1.2 cases per 100,000 in Western Europe and North America but only 0.08–
0.015 cases per 100,000 in Japan (Manna & Strassburg, 2001). 
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1.1 Hepatic fibrosis  
In response to liver injury, because of any cause, accumulation of extracellular matrix (ECM) 
proteins (collagen types, proteoglycans, fibronectin and laminin) will occur. The ECM 
scaffold is taken down by some special matrix proteinases while activated stellate cells (SC) 
undergo apoptosis and try to restore the normal tissue structure. Hepatic SC will produce 
matrix metalloproteinases (MMPs) to regulate the extracellular degradation of matrix 
proteins. Ultimately, as a result of an imbalance between fibrogenesis and fibrolysis, 
collagen deposition will occurs and scar will form. When scarring progressed, architectural 
distortion, liver fibrosis and ultimately cirrhosis will occur (Stalnikowitz & Weissbrod, 
2003). Figure 1 illustrates this phenomenon. 
1.2 Hepatic inflammation 
After liver cell injury, recruitment of leukocytes will takes place (Marra, 1999). Leukocytes 
together with kupffer cells will produce compounds that modulate stellate cell behavior. 
Nitric oxide (NO) and inflammatory cytokines, such as tumor necrosis factor α (with 
stimulatory ability on the stellate cell for collagen synthesis) will produce by monocytes and 
macrophages. In addition, kupffer cells can stimulate matrix synthesis by stellate cells 
through the actions of transforming growth factor β (TGF-β) and reactive oxygen species 
(ROS) (Stalnikowitz & Weissbrod, 2003; Granger & Kubes, 1994) –Figure 1. 
 
 
Fig. 1. Proposed mechanism of activation of hepatic stellate cells leading to fibrosis and 
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Fibrosis stage Score 
No fibrosis 0 
Fibrous expansion of some portal areas, with or without short fibrous septa 1 
Fibrous expansion of most portal areas, with or without short fibrous septa 2 
Fibrous expansion of most portal areas with occasional portal to portal (P-P) 
bridging 3 
Fibrous expansion of portal areas with marked bridging [portal to portal (P-P) 
as well as portal to central (P-C)] 4 
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete 
cirrhosis) 5 
Cirrhosis, probable or definite 6 
Table 1. Modified Knodell score system for liver fibrosis staging (Knodell et al., 1981). 
Liver biopsy, as a clinical tool, has some major limitations (Rossi et al., 2007). Most famous 
limitations of liver biopsy are: fibrosis staging systems (with this assumption that there is a 
linear increase in the severity of fibrosis between stages) (Rosenberg et al., 2004), sampling 
error (a 10–15 mg sample of tissue represents a tiny fraction of an organ weighing 1500 g) 
(Regev et al., 2002) and inter-observer variation amongst pathologists in categorizing the 
degree of fibrosis (Westin et al., 1999). 
For assessment of liver fibrosis, in addition to invasive method (liver biopsy), there are some 
serum-based noninvasive markers individually or in an algorithm-based score. Noninvasive 
markers in assessment of liver necroinflammatory injuries are the best markers, because 
they can analyze frequently during the treatment protocol of liver fibrosis and also for 
highlighting the efficacy of treatment.  
The most famous individual markers for assessment of liver fibrosis are: liver function tests 
(aspartate aminotransferase: AST and alanine aminotransferase: ALT) that reflect hepatocyte 
damage, bilirubin and alkaline phosphatase that show biliary obstruction and albumin and 
prothrombin time (PT) that reveal biosynthetic function of liver. These tests only provide 
information about important aspects of liver function but they do not assess severity of liver 
fibrosis or cirrhosis (Rossi et al., 2007).  Other serum markers such as α-2-Macroglobulin 
(Naveau et al., 1994), apolipoprotein A1 (Poynard et al., 1991), haptoglobin (Bismut et al., 
2001), matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) (Leroy et al., 
2004), hyaluronic acid, collagen markers, aminoterminal propeptide of type III procollagen 
(PIIINP) and laminin (LN) are proposed, too, as surrogate indices instead of liver biopsy 
(Gressner et al., 2007). New researches indicated that these individuals’ serum markers have 
limited accuracy in predicting hepatic fibrosis and proposed that the individual markers are 
useful for establishing the presence, but not absence, of fibrosis. Due to the limitations of 
individual markers to assess liver fibrosis, algorithms or indices combining the results of 
panels of markers have been studied which reportedly improve diagnostic accuracy. The 
serum marker panels have been proposed as an alternative to liver biopsy (Crockett et al., 
2006; Castera & Pawlotsky, 2005).  
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Some of the available serum marker panels include HCV FibroSURE, ASH FibroSURE, 
NASH FibroSURE, FIBROSpect II, Hepascore, Forns score, APRI, AAR, AP, SHASTA, Fibro 
Q and FIB4 index and European Liver Fibrosis Group (ELFG) algorithm. Some are beyond 
the scope of this chapter; however five of them that evaluated in this study, briefly are 
discussed here. In this study the serum levels of LN and PIIINP, in addition to the five 
serum marker panels of liver necroinflammatory injury and the histologicall evaluation of 
liver biopsies according to the modified Knodell score system were studied. 
1.3.1 Laminin (LN) 
One of the main glycoproteins of the basement membrane is laminin (LN). This molecule 
participates in a series of biological events such as the maintenance of the cytoskeleton (Rosa 
& Parise, 2008). Hpatocytes and sinusoidal cells are able to synthesis of LN (Rosa & Parise, 
2008; Gressner et al., 2007). Deposition of LN and collagen determine the formation of a true 
basement membrane along sinusoids in the liver. Increased in production of LN in the liver 
and a lack of degradation of this glycoprotein by liver endothelial cells, are the major causes 
of elevated serum levels of this protein in fibrotic and cirrhotic liver. It is proposed that 
laminin serum concentration is a sensitive screening test for hepatic fibrotic disease (Rosa & 
Parise, 2008).  
1.3.2 Aminoterminal propeptide of type III procollagen: PIIINP  
During the processing of type III procollagen, the PIIINP molecule is produced by a specific 
N-proteinase. There are evidences that proposed purified preparations of the PIIINP 
molecule will degrade by scavenger receptors located on the liver endothelial cells. In 
various clinical situations such as liver fibrosis, metabolism of type III collagen will alter, 
therefore measurement of PIIINP concentration in serum will has some clinical application. 
Some studies revealed that there is a significantly increased serum level of PIIINP in 
patients with liver fibrosis and cirrhosis. It proposed that these increased serum levels are 
related to increased hepatic synthesis of connective tissue components and also a decreased 
in hepatic clearance ability (Smedsr et al., 1990).  
1.3.3 Serum marker panels/models 
1.3.3.1 Age-platelet (AP) index 
AP index is a simple index that derived from age and platelet counts and is calculate as 
follow:  
Age (years) <30 = 0; 30-39 = 1; 40-49 = 2; 50-59 = 3; 60-69 = 4; ≥70 = 5,  
Platelets counts (109/l):  ≥225 = 0; 200-224 = 1; 175-199 = 2;  
150-174 = 3; 125-149 = 4; <125 = 5  
The sum of age and platelet counts scores according to the above mentioned scoring system, 
named AP index (Poynard et al,. 1997). 
1.3.3.2 AST to platelet ratio index (APRI) 
Several studies have suggested that the APRI may be a useful noninvasive marker of hepatic 
fibrosis in patients with chronic liver disease. APRI Score was initially described by Wai et al 
(Wai et al., 2003) and calculated by this formula:  
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APRI = ((AST /upper limit of normal) / platelet count (109 / L)) × 100) 
1.3.3.3 AAR index 
Another simple index that used for evaluation of liver fibrosis is AAR index. One can 
calculate this index by dividing the levels of AST to ALT (Williams et al., 1988).  
1.3.3.4 Fibro Q 
Fibro Q is another index that dependent to age (years), AST level, platelet count and also PT 
International Normalized Ratio (INR) and can be calculating by the following formula 
(Hsieh et al., 2009).  
Fibro Q = [(10 × age (years) × AST × PT INR)/ (PLT × ALT)]. 
1.3.3.5 FIB4 
FIB-4 is an index that is dependent to age (years), AST and ALT levels (U/L) and platelet 
count (Sterling et al., 2006). It can be calculated simply by the following formula. 
FIB-4 = [age (year) × AST (U/L)] / [PLT (109/L) × ALT (U/L))1/2). 
The aim of this study was identify the efficiency of the extracellular matrix components i.e. 
LN and PIIINP in comparison with five noninvasive fibrosis models (AP, APRI, AAR, Fibro 
Q and FIB4 index) and to recognize the most important model for discrimination of patients 
with liver fibrosis (chronic hepatitis B, C and auto immune hepatitis (AIH) patients) vs. 
control and also for discrimination of patients with severe liver fibrosis (stage≥3) vs. mild 
liver fibrosis (stage≥2).  
2. Methods 
2.1 Study population 
Sixty-two patients; (35 men and 27 women, mean ± SD: 35.4 ± 11.3 years) were enrolled in 
this study. Among these patients 35 patients had hepatitis B, 14 had hepatitis C and 13 were 
autoimmune hepatitis (AIH). The patients were selected from the persons who referred to 
Liver and Gastrointestinal Disease Research Center of Tabriz, Babol and Gorgan (Gonbad) 
University of Medical Sciences for diagnosis of the disease. 
Control sera for the determination of LN and PIIINP were obtained from 20 healthy 
volunteer’s person who referred to the Tabriz University of Medical Sciences (10 women 
and 10 men, mean ± SD: 42 ± 14.7 years). Control groups had normal serum levels of 
aminotransferases and alkaline phospahtase. None of the controls had a history of 
gastrointestinal bleeding and chronic liver disease, smoking (never smoker), alcohol intake 
(never drinker), a family history of hepatitis and liver disease, active intravenous drug abuse 
and a liver transplantation, according to the information’s gathered in the questionnaire 
form. Persons who smoked (>1 cigarette/day) and drunk alcohol (>1 gr/day), were 
classified as smoker and alcohol drinker. 
All of the subjects were informed about the study and their consents were taken. This study 
was approved by Tabriz Medical University Ethical Committee.  
2.1.1 Inclusion criteria 
Patients were included in the study, if they were positive for serum hepatitis B surface 
antigen (HBs-Ag) or HCV antibodies, and having persistently elevated serum 
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aminotransferases greater than 1.5 times the upper limit of the reference range for at least six 
months. AIH patients were diagnosed according to the International Autoimmune Hepatitis 
Group Report protocol (Manna & Strasburg, 2001). For assessment of liver fibrosis scores, all 
patients underwent liver biopsy as part of the normal diagnostic procedure and were 
subsequently sub-classified according to the score for the histological activity index (HAI). 
2.1.2 Exclusion criteria 
Patients with a history of gastrointestinal bleeding and other chronic liver disease (such as 
Wilson’s disease, hemochromatosis, alpha1-antitrypsin deficiency, biliary disease, 
hepatocellular carcinoma), active intravenous drug abuse, and liver transplantation were 
excluded.  
2.2 Blood collection and sample preparation  
Blood samples (7ml) were collected after an overnight fast. After analyzing cell blood counts 
(CBC) on aliquots of whole blood, on remainder the samples, serum was separated (at 2500 
g for 5 minutes) within one hour of blood collection. Standard LFT, including AST and ALT 
and hepatitis serology were performed on aliquots of each sample and recorded. Routine 
LFT and hepatitis serology was assayed using commercial available kits. Briefly AST and 
ALT were measured by colorimetric test (Ziestchem kit, Iran) with 2, 4 DNPH (2, 4 
dinitrophenylhydrazone) with Apel spectrophotometer (PD303S, Japan). 
The hepatitis serology markers were analyzed by an ELISA reader (Norahan Fajr, Iran) and 
the following Kits. The AIH serology markers that analyzed were: antinuclear antibody 
(ANA; Biazyme ELISA kit, Birmingham, UK) and anti-LKM-1 (LKM-1: type 1 liver and 
kidney microsomes, Euroimmun ELISA kit, Germany), hepatitis B serology markers were: 
hepatitis B surface antigen (HBsAg; Diakey, shinjin Medics Inc. ELISA kit, Korea), hepatitis 
B Surface Antibody (HBsAb; Diakey, shinjin Medics Inc. ELISA kit, Korea) and hepatitis B 
Core Antibody (HBcAb; Dia-Pro ELISA kit, Italy) and hepatitis C serology marker was: 
HCV antibody (HCVAb; Diakey, shinjin Medics Inc. ELISA kit, Korea). HCV RNA was 
assayed using a PCR kit (Roche Diagnostics, Mannheim, Germany) by an Eppendorf 
Thermocycler (Mastercycler Personal) according to the manufacturer’s instructions. Two 
primers (Sinagene, Tehran, Iran) with the following sequences were used: first primer 
sequence 5’-GCA GAA AGC GTC TAG CCA TGG CGT-3’ and second primer sequence 5’-
CTC GCA AGC ACC CTA TCA GGC AGT-3’. 
The rest of the blood samples were stored at –20ºC. The controls were dealt with in the same 
manner.  
2.3 Determination of serum LN and PIIINP  
2.3.1 LN assay 
Serum LN concentrations were assayed using a LN EIA Kit (Takara Bio, product number: 
MK107) on an ELISA reader (BDSL, Immunoscan, Lab System, Switzerland) and the amount 
of LN was determined by a standard curve. The intra assay and inter-assay variability (CV) 
of the procedure according to the manufacturer, were 4.0 -5.7% and 0.3-5.0%, respectively.  
2.3.2 PIIINP assay 
Serum PIIINP levels were assayed by a PIIINP ELISA Kit (USCN life and technology 
company, product no: E0573h) on an ELISA reader (BDSL, Immunoscan, Lab System, 
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Switzerland). Briefly, a monoclonal antibody specific for PIIINP had been precoated onto a 
microplate. Standards and samples were pipetted into the wells and any PIIINP present was 
bound by the immobilized antibody. An enzyme-linked polycolonal antibody specific for 
PIIINP was added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells and color developed in proportion to 
the amount of PIIINP bound in the initial steps. The color development was stopped and the 
intensity of the color was measured and ultimately the amount of PIIINP was determined 
by a standard curve. The intra assay variability (CV) of the procedure according to the 
manusfacturer declares was 4-5-5.0%.  
2.4 Histological assessment of liver damage 
Sixty-two patients underwent a percutaneous liver biopsy with a Trucut needle number 16 
guided by B type ultrasound for assessing the presence and severity of liver disease. The 
biopsy fragments were fixed in a 10% formalin solution for 12 hours and embedded in 
paraffin. Sections were stained with hematoxylin-eosin, Masson’s trichrome and reticulin 
stain. Specimens were graded and staged according to the modified Knodell scoring system 
(Knodell et al., 1981) by a pathologist who was blinded to the results of serum indices in the 
study subjects. The grading system was scored from 0 to 18 and was based on sum of four 
indices: 
1. Periportal or periseptal interface hepatitis (piecemeal necrosis, score 0-4)  
2. Confluent necrosis (score 0-6) 
3. Focal (spotty) lytic necrosis, apoptosis, and focal inflammation (score 0-4) 
4. Portal inflammation (score 0-4). 
The fibrosis score were determined on the basis of the table 1.  
2.5 Statistical analysis 
The SPSS 12.0 statistical package (SPSS for Windows 12.0, SPSS, Chicago,  IL, USA) was 
used on statistical analysis. Data were expressed as mean ± SD, and P less than 0.05 was 
considered statistically significant. The mean patient serum LN and PIIINP levels between 
different types of chronic hepatitis and healthy controls were compared with analysis of 
variance (ANOVA). Five serum markers panels were calculated as mentioned in the 
introduction section 1.3.3. To assess the diagnostic accuracy of LN and PIIINP and also five 
serum marker panels for discrimination chronic hepatitis patients with severe liver fibrosis 
from healthy individuals, and also discrimination of patients with severe liver fibrosis vs. 
mild liver fibrosis, we plotted the receiver operating characteristic curve (ROC). Receiver 
operating characteristic curves were generated by plotting the relationship of the true 
positivity (sensitivity) and the false positivity (1- specificity) at various cut-off points of the 
tests. An AUC of 1.0 is characteristic of an ideal test, whereas 0.5 indicates a test of no 
diagnostic value (Zweig & Campbell, 1993). Taking sensitivity and specificity into account, 
the cut-off points were selected according to max number of sensitivity add specificity. The 
diagnostic accuracy, sensitivity, specificity, positive predictive values (PPV) and negative 
predictive values (NPV) also were calculated.  
3. Results 
Histological examination of liver for fibrosis scoring revealed that 10, 19, 11, 9, 8, 4 and 1 
patient were at stages 0, 1, 2, 3, 4, 5 and 6 of liver fibrosis, respectively. In the other hand, 
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CTC GCA AGC ACC CTA TCA GGC AGT-3’. 
The rest of the blood samples were stored at –20ºC. The controls were dealt with in the same 
manner.  
2.3 Determination of serum LN and PIIINP  
2.3.1 LN assay 
Serum LN concentrations were assayed using a LN EIA Kit (Takara Bio, product number: 
MK107) on an ELISA reader (BDSL, Immunoscan, Lab System, Switzerland) and the amount 
of LN was determined by a standard curve. The intra assay and inter-assay variability (CV) 
of the procedure according to the manufacturer, were 4.0 -5.7% and 0.3-5.0%, respectively.  
2.3.2 PIIINP assay 
Serum PIIINP levels were assayed by a PIIINP ELISA Kit (USCN life and technology 
company, product no: E0573h) on an ELISA reader (BDSL, Immunoscan, Lab System, 
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Switzerland). Briefly, a monoclonal antibody specific for PIIINP had been precoated onto a 
microplate. Standards and samples were pipetted into the wells and any PIIINP present was 
bound by the immobilized antibody. An enzyme-linked polycolonal antibody specific for 
PIIINP was added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells and color developed in proportion to 
the amount of PIIINP bound in the initial steps. The color development was stopped and the 
intensity of the color was measured and ultimately the amount of PIIINP was determined 
by a standard curve. The intra assay variability (CV) of the procedure according to the 
manusfacturer declares was 4-5-5.0%.  
2.4 Histological assessment of liver damage 
Sixty-two patients underwent a percutaneous liver biopsy with a Trucut needle number 16 
guided by B type ultrasound for assessing the presence and severity of liver disease. The 
biopsy fragments were fixed in a 10% formalin solution for 12 hours and embedded in 
paraffin. Sections were stained with hematoxylin-eosin, Masson’s trichrome and reticulin 
stain. Specimens were graded and staged according to the modified Knodell scoring system 
(Knodell et al., 1981) by a pathologist who was blinded to the results of serum indices in the 
study subjects. The grading system was scored from 0 to 18 and was based on sum of four 
indices: 
1. Periportal or periseptal interface hepatitis (piecemeal necrosis, score 0-4)  
2. Confluent necrosis (score 0-6) 
3. Focal (spotty) lytic necrosis, apoptosis, and focal inflammation (score 0-4) 
4. Portal inflammation (score 0-4). 
The fibrosis score were determined on the basis of the table 1.  
2.5 Statistical analysis 
The SPSS 12.0 statistical package (SPSS for Windows 12.0, SPSS, Chicago,  IL, USA) was 
used on statistical analysis. Data were expressed as mean ± SD, and P less than 0.05 was 
considered statistically significant. The mean patient serum LN and PIIINP levels between 
different types of chronic hepatitis and healthy controls were compared with analysis of 
variance (ANOVA). Five serum markers panels were calculated as mentioned in the 
introduction section 1.3.3. To assess the diagnostic accuracy of LN and PIIINP and also five 
serum marker panels for discrimination chronic hepatitis patients with severe liver fibrosis 
from healthy individuals, and also discrimination of patients with severe liver fibrosis vs. 
mild liver fibrosis, we plotted the receiver operating characteristic curve (ROC). Receiver 
operating characteristic curves were generated by plotting the relationship of the true 
positivity (sensitivity) and the false positivity (1- specificity) at various cut-off points of the 
tests. An AUC of 1.0 is characteristic of an ideal test, whereas 0.5 indicates a test of no 
diagnostic value (Zweig & Campbell, 1993). Taking sensitivity and specificity into account, 
the cut-off points were selected according to max number of sensitivity add specificity. The 
diagnostic accuracy, sensitivity, specificity, positive predictive values (PPV) and negative 
predictive values (NPV) also were calculated.  
3. Results 
Histological examination of liver for fibrosis scoring revealed that 10, 19, 11, 9, 8, 4 and 1 
patient were at stages 0, 1, 2, 3, 4, 5 and 6 of liver fibrosis, respectively. In the other hand, 
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35% of patients to be suffering from significant fibrosis (stage ≥3). In addition 32.2% of 
patients had liver inflammation grades ≥5. Hepatitis serology revealed that 56.4% of the 
patients were suffering from chronic hepatitis B, 22.5% from chronic hepatitis C and 20.9% 
from autoimmune hepatitis. In table 2 characteristics of chronic hepatitis patients and 
controls are shown. The results of laboratory tests showed that the serum levels of AST and 
ALT in patients groups were significantly higher than in the control group (p<0.001) but the 
differences in platelet count and prothrombin time were not significant.  
The results also showed increased serum LN and PIIINP levels in patients, as compared 
with the healthy controls (p<0.001). 
 
P value Controls (n=20) Patients (n=62) Variables 
- 10 / 10 35 / 27 Male/Female (n) 
- 42.0 ± 14.7 35.4 ± 11.3 Age in years 
0.051 179.7± 25.5 225.7± 122.4 Platelet count (10 9/L) 
0.345 13.15± 1.47 13.56± 1.65 Prothrombin time (s) 
<0.001 27.3 ± 6.4 143.0 ± 145.6 ALT, IU/L 
<0.001 28.3 ±  6.5 101.1 ± 143.1 AST, IU/L 
<0.001 46.1 ± 10.1 91.9 ± 20.9 Laminin, ng/ml 
<0.001 4.5 ± 1.1 6.8 ± 1.7 PIIINP,  ng/ml 
Table 2. Characteristics of the patient and control groups included in the study. 
The mean serum LN and PIIINP concentrations in patients with HBV, HCV, AIH and 
healthy controls are presented in Table 3. These results showed statistically increased serum 
LN and PIIINP levels in patients as compared with healthy controls (P < 0.001). 
The patient’s serum LN and PIIINP levels in different stages of liver fibrosis are presented in 
Table 4. Almost in all stages of hepatic fibrosis, the serum levels of LN and PIIINP, were 
higher than those of the healthy group (p<0.05). In stage 0 of liver fibrosis the LN and PIIINP 
serum concentrations did not differ compare from the healthy controls. In fibrosis stage 6, 
which was represented by only one patient, the serum levels of LN and PIIINP are presented. 
 
Disease LN PIIINP 
HBV 92.0 ± 20.1* 6.6 ± 1.9* 
HCV 92.8 ± 24.1* 7.4 ± 1.5* 
AIH 90.6 ± 18.4* 6.8 ± 1.4* 
Total 91.9 ± 20.9* 6.8 ± 1.7* 
Healthy controls 46.1 ± 10.1 4.5 ± 1.1 
* P value ≤ 0.001. 
Table 3. Comparison of LN and PIIINP serum concentration in different types of chronic 
hepatitis and control group. Data are presented as Mean ± SD (ng/ml).  
Comparison of Five Liver Fibrosis Indexes with Serum Levels of  
Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis Patients 
 
351 
Figure 2 (a and b), are illustrated scatter plots for serum LN and PIIINP level (ng/ml) in 
hepatitis patients in various grades of inflammation. According to these figures, patients in 
higher grades of liver inflammation had higher serum concentrations of LN and PIIINP and 
the highest level were observed in grades of 5-12 of liver inflammation. We had no patient 
in inflammation grades of 13-18. 
 
 
              (a)                (b) 
Fig. 2. Scatter plots for serum LN (a) and PIIINP (b) level (ng/ml) in patients at various 
grades of inflammation. 
 
Stage LN PIIINP 
0 63.0 ±12.1 4.5 ± 0.5 
1 85.7 ± 6.3* 6.1 ± 0.9* 
2 94.0 ± 10.2** 7.0 ± 0.8* 
3 100.6 ± 8.6** 7.7 ± 0.6** 
4 104.2 ± 20.2** 8.0 ± 1.5** 
5 130.2 ± 13.7** 9.8 ± 0.8** 
6† 143.0 12.5 
Total 91.9 ± 20.9** 6.8 ± 1.7** 
† There was only one patient in stage 6 of liver fibrosis. 
* P value ≤ 0.05 
** P value ≤ 0.001 
Table 4. Serum concentrations (ng/ml) of LN and PIIINP in various stages of liver fibrosis. 
Data are presented as Mean ± SD (ng/ml). 
A cut-off point of 52.0 ng LN/ml and 5.0 ng PIIINP/ml for the discrimination of patients 
with liver fibrosis from those without liver fibrosis showed a good accuracy, AUC, 
sensitivity, specificity, PPV and NPV (Table 5).  
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Marker AUC P Sen Sp PPV NPV Accu 
AAR 0.907 0.001 86 76 77 69 85 
AP 0.632 0.179 68 55 64 45 59 
APRI 0.818 0.001 79 82 78 69 79 
FIB4 0.754 0.001 77 81 76 65 76 
FibroQ 0.957 0.001 89 90 85 79 87 
LN 0.974 0.001 94 78 91 86 89 
PIIINP 0.873 0.001 85 70 89 60 81 
(AUC, area under the ROC curve; Sen, sensitivity; Sp, specificity; PPV, positive predictive value ;NPV, 
negative predictive value; Accu, accuracy). 
Table 5. Accuracy of tests for discrimination of patients with liver fibrosis vs. control. 
We selected other cut-off points (92.5 ng LN/ml and 8.9 ng PIIINP/ml) for the 
discrimination of patients with mild fibrosis (stage 0-2) from severe fibrosis (stage 3-6) and 
the results are presented in Table 6. For comparison of the AUC of the serum marker panels 
(i.e. AP, AAR, APRI, FIB4 and FiroQ) with the AUC of the serum HA and LN levels, the 
AUC of these parameters were also calculated and the results are presented in table 5 and 6, 
too.  
 
Marker AUC P Sen Sp PPV NPV Accu 
AAR 0.491 0.947 45 44 32 56 54 
AP 0.518 0.137 56 50 45 39 59 
APRI 0.268 0.107 29 22 31 28 33 
FIB4 0.232 0.110 27 28 26 31 29 
FibroQ 0.491 0.997 44 45 33 55 56 
LN 0.879 0.005 86 71 87 69 82 
PIIINP 0.911 0.002 89 72 85 71 83 
(AUC, area under the ROC curve; Sen, sensitivity; Sp, specificity; PPV, positive predictive value ;NPV, 
negative predictive value; Accu, accuracy). 
Table 6. Accuracy of tests for discrimination of patients with severe liver fibrosis vs. mild 
liver fibrosis.  
Figures 3 and 4 are illustrated the results of ROC analysis of LN (a) and PIIINP (a) for 
discrimination of patients with liver fibrosis vs. control and also for discrimination of 
patients with severe liver fibrosis vs. mild liver fibrosis, respectively. 
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Fig. 3. ROC analysis of LN (a) and PIIINP (b) for discrimination of patients with liver 
fibrosis vs. control.  
 
     
       a           b 
Fig. 4. ROC analysis of LN (a) and PIIINP (b) for discrimination of patients with severe liver 
fibrosis vs. mild liver fibrosis. 
4. Discussion 
Mean serum LN and PIIINP levels in chronic hepatitis B, C and auto immune hepatitis were 
significantly higher than in healthy controls (p <0.001). Patients with higher stages of liver 
fibrosis had higher serum LN and PIIINP concentrations and the correlations between 
serum LN and PIIINP concentrations with liver fibrosis stages were linear and strong (data 
not presented). Also, the mean serum LN and PIIINP concentrations in the stages 2, 3, 4 and 
5 of the liver fibrosis showed statistically significant differences as compared with the 
healthy group. We didn’t observe such a statistically differences in the stage 0 of liver 
fibrosis. In fibrosis Stage 6, which was represented by only one patient, we could not 
compare this single patient with the control group.  
In addition, we observed that patients who had greater inflammation grades had higher 
serum LN and PIIINP concentrations (according to the figure 2) and the correlation of serum 
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serum LN and PIIINP concentrations with liver fibrosis stages were linear and strong (data 
not presented). Also, the mean serum LN and PIIINP concentrations in the stages 2, 3, 4 and 
5 of the liver fibrosis showed statistically significant differences as compared with the 
healthy group. We didn’t observe such a statistically differences in the stage 0 of liver 
fibrosis. In fibrosis Stage 6, which was represented by only one patient, we could not 
compare this single patient with the control group.  
In addition, we observed that patients who had greater inflammation grades had higher 
serum LN and PIIINP concentrations (according to the figure 2) and the correlation of serum 
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LN and PIIINP with the inflammation grades were linear (correlation data not presented). 
These findings suggest that patients with higher serum LN and PIIINP concentrations might 
have higher liver fibrosis stage and inflammation grade. Therefore we can conclude that 
when liver damage develops, the liver more poorly metabolized the LN and PIIINP. 
Patients in early stage of liver fibrosis possibly metabolized better LN and PIIINP in the 
liver than those with advanced liver fibrosis stages. 
A cut-off point of 52.0 ng LN/ml and 5.0 ng PIIINP/ml for the discrimination of patients 
with liver fibrosis from those without liver fibrosis showed a good AUC (0.974 and 0.873, 
respectively), accuracy, sensitivity, specificity, PPV and NPV. Also serum marker panels in 
selected cut points (cut points not presented) showed reasonably good AUC (AP: 0.632, 
AAR: 0.907, APRI: 0.818, FIB4: 0.754 and Fibro Q: 0.957), accuracy, sensitivity, specificity, 
PPV and NPV. It means that all of these serum markers, individually or in a panel model, 
can discriminate between persons with liver fibrosis and healthy individuals. 
A cut-off point of 92.5 ng LN/ml and 8.9 ng PIIINP/ml for discrimination of patients with 
mild fibrosis from those with severe fibrosis showed the AUCROC (p-value) of 0.879 (0.005) 
and 0.911 (0.002), respectively. It means that LN and PIIINP can discriminate between 
patients with mild fibrosis from those with severe fibrosis. But the AUCROC (p-value) of 
serum panel markers for discrimination of severe liver fibrosis (stage≥3) than mild liver 
fibrosis (stage≥2) revealed a different pattern as follows: AAR=0.491 (0.947), AP=0.518 
(0.137), APRI=0.268 (0.107), FIB-4=0.232 (0.110) and Fibro Q=0.491 (0.997). It seems only the 
LN and PIIINP performed better at excluding advanced fibrosis than mild fibrosis. 
The reported researches about these markers is controversial, but in recent years there is  
increasing evidences that show these markers can be used for assessing the liver fibrosis 
stages (Gressner et al.,2007).  Serum level of LN, have been used by several authors as a non-
invasive marker to assess liver fibrosis in patients with viral hepatitis. LN determination 
together with PIIINP, hydroxyproline, prothrombin activity, and AST/ALT ratio has been 
used in the diagnosis of advanced fibrosis in chronic hepatitis C patients (Rosa & Parise et 
al., 2008). Serum levels of PIIINP were studied in viral hepatitis patients and studies showed 
strong correlation between its levels and histological stage of hepatic fibrosis. Also PIIINP 
levels were in correlation with aminotransferase levels (Bensen et al., 1987). 
Murawaki reported that differences in serum ALT and PIIINP levels between stage F0 (no 
fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis) and F3 (severe fibrosis) in patients with 
chronic hepatitis C were statistically significant (P-value: <0.005, <0.0002, respectively) 
(Murawaki et al., 2001).  In a study by Attallah, mean level of PIIINP and LN in severe liver 
fibrosis stages were greater than mild liver fibrosis stages (Attallah et al., 2007). As well in 
additional reports, LN concentrations were increased in early stages of chronic liver disease 
and the highest concentrations were in active cirrhosis and chronic active hepatitis (Castera 
et al., 2000). 84).  
The grater serum markers, in higher liver inflammation grades, reported by others (Parsian 
et al., 2009, Parsian et al., 2010). Zheng reported that serum fibrosis indices (PIIINP and LN) 
increased as the grade of inflammation aggravated (Zheng et al., 2002). Cai  reported that 
LN was in correlation with liver histopathopathological injuries and inflammation grades 
(Cai et al., 2004). Also increased serum level of PIIINP and its association with the severity 
of liver necroinflammation in other studies reported (Murawaki et al., 1994). 
Reported diagnostic criteria are not reliable and to some extent are controversial. There is 
some studies reported that PIIINP has reached a limited clinical application, but no 
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widespread acceptance (Collazos & Diaz, 1994). Sensitivities of about 76.0–78.0% and 
specificities of 71.0–81.0% have been reported, which can be increased up to 88.0%, if 
combined with additional collagen fragment markers.  
Zheng reported that in ROC curves analysis the AUC of PIIINP and LN was 0.800 and 0.463, 
respectively. The analysis also showed that PIIINP have greater diagnosis performances 
than LN according to fibrosis staging (Zheng et al., 2002). Guechot reported that PIIINP and 
HA serum concentrations correlated with the histological grades of liver fibrosis in 
untreated patients with chronic viral hepatitis C (P <0.001). In addition, ROC curves showed 
that serum HA had greater diagnostic performance than PIIINP both for discriminating 
patients with extensive liver fibrosis from those with no or mild fibrosis (AUC: 0.864 vs. 
0.691, P <0.001) or for discriminating patients with cirrhosis from those without cirrhosis 
(AUC: 0.924 vs. 0.734, P <0.001) (Guechot et al., 1996).  
There are various studies about the efficiency of serum marker panels. In a retrospective 
study, Snyder reported that APRI (with AUROC=0.887) is a simple biochemical index that 
has been shown to be useful and accurate in about 50% of patients with HCV (Snyder et al., 
2007). Yilmaz reported that the APRI had an acceptable accuracy for the assessment of liver 
fibrosis in patients with chronic hepatitis C (CHC), but not in those with chronic hepatitis B 
(CHB) (Yilmaz et al., 2011). Wai evaluated the APRI in a cohort of 270 patients with CHC 
and reported that the AUCROC of the APRI for predicting significant fibrosis and cirrhosis 
were 0.80–0.88 and 0.89–0.94, respectively and concluded that the APRI can obviate liver 
biopsy in approximately 50% of patients (Wai et al., 2003).  
In another study it has been shown that the AUCROC of the APRI for predicting significant 
fibrosis and cirrhosis were 0.76 and 0.82, respectively (Shaheen et al., 2008). The results of 
our study showed that APRI had sensitivity of 79.0% and specificity 82.0% for 
discrimination of patients with liver fibrosis vs. control and sensitivity of 29.0% and 
specificity 22.0% for discrimination of patients with severe liver fibrosis vs. mild liver 
fibrosis. In a study by Hsieh, the authors evaluated 140 patients with chronic viral hepatitis 
and calculated the APRI, AAR, and FibroQ for assessment of liver fibrosis (Hsieh et al., 
2009). They concluded that FibroQ performed better than APRI, but was equal to AAR, in 
the prediction of significant fibrosis: [AUCROC (p-value): 0.783 vs 0.631 (0.02) and 0.783 vs 
0.733 (p = 0.26), respectively] and cirrhosis [AUCROC (p-value): 0.791 vs 0.634 (p = 0.03), 
and 0.791 vs 0.782 (p =0.47), respectively). Liu demonstrated a low accuracy of APRI and 
AAR for predicting significant fibrosis in viral hepatitis C carriers with persistently normal 
ALT levels. The AUCROC in differentiating significant fibrosis were only 0.673 for APRI 
and 0.504 for AAR (Liu et al., 2006). In a study by Martinez, the performances of APRI and 
FIB-4 index were validated in 340 patients who underwent antiviral therapy (Martinez et al., 
2011). APRI and FIB-4 showed comparable diagnostic accuracies for significant fibrosis 
(AUROC: 0.83 and 0.85, respectively). To identify cirrhosis, FIB-4 index showed a 
significantly better performance over APRI score (AUROC: 0.89 vs. 0.83).  
In another study Zhang assessed the diagnostic value of FIB-4 in 212 chronic hepatitis B by 
comparing their results with histological features (Zhang et al., 2010). The AUCROC (p-
value) of FIB-4 for significant fibrosis, extensive fibrosis and cirrhosis were 0.733 (< 0.01), 
0.746 (< 0.01), 0.756 (< 0.01), respectively. They concluded that the FIB-4 index is an accurate 
and inexpensive method to assess liver fibrosis in chronic hepatitis and may reduce the need 
for liver biopsy. Ladep compared the diagnostic validity of AP, APRI and AAR index to 
histology fibrosis stage among 90 CHB patients (Ladep et al., 2007). The PPV of AAR, API 
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LN and PIIINP with the inflammation grades were linear (correlation data not presented). 
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widespread acceptance (Collazos & Diaz, 1994). Sensitivities of about 76.0–78.0% and 
specificities of 71.0–81.0% have been reported, which can be increased up to 88.0%, if 
combined with additional collagen fragment markers.  
Zheng reported that in ROC curves analysis the AUC of PIIINP and LN was 0.800 and 0.463, 
respectively. The analysis also showed that PIIINP have greater diagnosis performances 
than LN according to fibrosis staging (Zheng et al., 2002). Guechot reported that PIIINP and 
HA serum concentrations correlated with the histological grades of liver fibrosis in 
untreated patients with chronic viral hepatitis C (P <0.001). In addition, ROC curves showed 
that serum HA had greater diagnostic performance than PIIINP both for discriminating 
patients with extensive liver fibrosis from those with no or mild fibrosis (AUC: 0.864 vs. 
0.691, P <0.001) or for discriminating patients with cirrhosis from those without cirrhosis 
(AUC: 0.924 vs. 0.734, P <0.001) (Guechot et al., 1996).  
There are various studies about the efficiency of serum marker panels. In a retrospective 
study, Snyder reported that APRI (with AUROC=0.887) is a simple biochemical index that 
has been shown to be useful and accurate in about 50% of patients with HCV (Snyder et al., 
2007). Yilmaz reported that the APRI had an acceptable accuracy for the assessment of liver 
fibrosis in patients with chronic hepatitis C (CHC), but not in those with chronic hepatitis B 
(CHB) (Yilmaz et al., 2011). Wai evaluated the APRI in a cohort of 270 patients with CHC 
and reported that the AUCROC of the APRI for predicting significant fibrosis and cirrhosis 
were 0.80–0.88 and 0.89–0.94, respectively and concluded that the APRI can obviate liver 
biopsy in approximately 50% of patients (Wai et al., 2003).  
In another study it has been shown that the AUCROC of the APRI for predicting significant 
fibrosis and cirrhosis were 0.76 and 0.82, respectively (Shaheen et al., 2008). The results of 
our study showed that APRI had sensitivity of 79.0% and specificity 82.0% for 
discrimination of patients with liver fibrosis vs. control and sensitivity of 29.0% and 
specificity 22.0% for discrimination of patients with severe liver fibrosis vs. mild liver 
fibrosis. In a study by Hsieh, the authors evaluated 140 patients with chronic viral hepatitis 
and calculated the APRI, AAR, and FibroQ for assessment of liver fibrosis (Hsieh et al., 
2009). They concluded that FibroQ performed better than APRI, but was equal to AAR, in 
the prediction of significant fibrosis: [AUCROC (p-value): 0.783 vs 0.631 (0.02) and 0.783 vs 
0.733 (p = 0.26), respectively] and cirrhosis [AUCROC (p-value): 0.791 vs 0.634 (p = 0.03), 
and 0.791 vs 0.782 (p =0.47), respectively). Liu demonstrated a low accuracy of APRI and 
AAR for predicting significant fibrosis in viral hepatitis C carriers with persistently normal 
ALT levels. The AUCROC in differentiating significant fibrosis were only 0.673 for APRI 
and 0.504 for AAR (Liu et al., 2006). In a study by Martinez, the performances of APRI and 
FIB-4 index were validated in 340 patients who underwent antiviral therapy (Martinez et al., 
2011). APRI and FIB-4 showed comparable diagnostic accuracies for significant fibrosis 
(AUROC: 0.83 and 0.85, respectively). To identify cirrhosis, FIB-4 index showed a 
significantly better performance over APRI score (AUROC: 0.89 vs. 0.83).  
In another study Zhang assessed the diagnostic value of FIB-4 in 212 chronic hepatitis B by 
comparing their results with histological features (Zhang et al., 2010). The AUCROC (p-
value) of FIB-4 for significant fibrosis, extensive fibrosis and cirrhosis were 0.733 (< 0.01), 
0.746 (< 0.01), 0.756 (< 0.01), respectively. They concluded that the FIB-4 index is an accurate 
and inexpensive method to assess liver fibrosis in chronic hepatitis and may reduce the need 
for liver biopsy. Ladep compared the diagnostic validity of AP, APRI and AAR index to 
histology fibrosis stage among 90 CHB patients (Ladep et al., 2007). The PPV of AAR, API 
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and APRI scores were 52%, 63% and 54%, with sensitivities of 60, 11 and 96%, respectively 
and interestingly the diagnostic accuracy of AAR for cirrhosis was 100%. They concluded 
non-invasive fibrosis markers are not as sensitive for diagnosing significant fibrosis in 
chronic hepatitis B compared to hepatitis C patients and might have a limited utility for use 
in hepatitis B endemic populations.  
Lackner evaluated diagnostic accuracies of AAR, AP and APRI index in 211 patients with 
chronic hepatitis C and observed that diagnostic accuracy of APRI for prediction of significant 
fibrosis was superior to that of AAR and AP (Lackner et al., 2005).  Fujii calculated AAR, AP, 
APRI indices in 100 patients with HCV. The AUC of the AAR, AP and APRI index for predicting 
cirrhosis were respectively 0.555, 0.652 and 0.761. They concluded that these indices are good as 
noninvasive laboratory tests to predict cirrhosis in patients with HCV (Fujii et al., 2009).  
Mahassadi conducted a prospective cohort study to determine the diagnostic accuracy of 
APRI, AAR, AP and FIB-4 index for the prediction of significant fibrosis or cirrhosis in 117 
patients with CHB. APRI and FIB-4 index ruled out significant fibrosis with high specificity 
of 84.7% and 86.1%, respectively and NPV of 78.2% and 72.9%, respectively. More 
accurately, APRI or FIB-4 index ruled out cirrhosis with high sensitivity of 94.4% and 88.9% 
and high NPV of 98.1% and 96.3%, respectively in another cut points. They suggested that 
APRI and FIB-4 index are simple readily available indices for assessment of liver fibrosis in 
CHB patients (Mahassadi et al., 2010).  
Kim determined the clinical performances of AAR, AP and APRI index for the prediction of 
liver fibrosis in chronic viral liver diseases in 225 patients with chronic viral liver diseases 
(180 with hepatitis B virus, 43 with hepatitis C virus, and 2 with hepatitis B+C virus) that 
underwent a liver biopsy procedure. The AUCROC for APRI, ARR were 0.822, 0.756, 0.642, 
respectively, for predicting significant fibrosis and were 0.691, 0.711 and 0.794, respectively, 
for predicting extensive fibrosis. They concluded these serum markers were useful for 
predicting significant or extensive liver fibrosis in chronic viral liver diseases and APRI was 
most useful for the prediction of significant fibrosis (Kim et al., 2009).  
As it is clear, numerous researchers have attempted to validate these findings, but the 
results were conflicting. Some researches as mentioned earlier, found a good AUCROC of 
these serum marker panels for discrimination between patients with mild fibrosis and those 
with severe fibrosis, but we didn’t observe. The differences in patient populations, including 
the prevalence of significant fibrosis, differences in the reference ranges for AST, differences 
in the etiology and cause of liver fibrosis and also the pattern of the studies may in part ex-
plain these discrepancies (Yilmaz et al., 2011). 
In summary, we observed that all serum markers including AAR, AP, APRI, FIB-4, FibroQ, 
LN, and PIIINP were useful for predicting liver fibrosis in chronic hepatitis patients 
compared with the healthy control, But we didn’t observe such a similar pattern for 
discrimination between patients with mild fibrosis and those with severe fibrosis and only 
LN and PIIINP performed better at excluding advanced fibrosis than mild fibrosis and 
patients with liver fibrosis than healthy individuals. Therefore serum LN and PIIINP 
measurement together with these tests could be used for predicting of liver fibrosis as 
alternate to liver biopsy, when liver biopsy is damaging. 
5. Conclusions 
Our findings suggest that measurement of serum LN and PIIINP concentrations can 
discriminate between patients with liver fibrosis and healthy individuals and between 
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patients with mild fibrosis and those with severe fibrosis. An increase in serum LN and 
PIIINP concentrations above the predictive value is associated with liver fibrosis. In 
addition, the values of the AAR, AP, APRI, FIB-4 and FibroQ score and serum LN and 
PIIINP levels for discrimination between patients with liver fibrosis and healthy individuals 
are in the same order, but there is not such a similar pattern for discrimination between 
patients with mild fibrosis and those with severe fibrosis. It seems only the extracellular 
matrix components i.e. LN and PIIINP performed better at excluding advanced fibrosis than 
mild fibrosis and patients with liver fibrosis than healthy individuals. Therefore, serum LN 
and PIIINP levels together with the AAR, AP, APRI, FIB-4 and FibroQ score could be an 
additional non-invasive tool for evaluation of liver fibrosis, when liver biopsy is 
contraindicated. These indices may also be used for the assessment of therapeutic efficiency 
in chronic hepatitis patients, if liver biopsy cannot be performed. 
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1. Introduction 
Determination of the extent of progress of hepatic fibrosis and inflammation is important in 
clinical practice, where it may reflect the severity of liver disease and predict response to 
treatment. Percutaneous liver biopsy is the gold standard for grading and staging of liver 
disease which has been used for more than hundred years. The aim of this review is to know 
the safety and the complications related to such procedure in clinical practice. From 
experience and review of literatures, liver biopsy is frequently cited as a simple and safe 
procedure that may be performed at the bedside and as outpatient. Complications were 
more often experienced by those with relative contraindications and increased number of 
passes and if performed by less-experienced individuals. (1) 
The complications after liver biopsy were reported to be more frequent in the presence of 
vascular liver lesions, biliary radical dilatation and in the presence of ascites.  
Ultrasonography is a simple technique and recommended to detect vascular liver lesions, 
cystic lesions in the liver like echinococcal, biliary tree anatomy and to exclude presence of 
massive ascites which all is considered to be contraindications to liver biopsy and to 
determine the most suitable biopsy site. (2, 3) 
Before biopsy the patient should understand the whole procedure and the possible 
complications and to sign the consent form and also need to be cooperative during the 
procedure. 
The history before the procedure is very important, like history of unexplained bleeding and 
family history of bleeding tendencies or blood diseases like hemophilia and the patient 
should be off medications that increase bleeding tendencies for certain time, like 
acetylsalicylic acid, non steroidal anti-inflammatory drugs and colpidogrel. (3) The operator 
should know about the coagulation profiles and platelets level of the patient before the 
procedure.   
1-5% of patients require hospitalization for complications and approximately 60% of 
complications occur within the first 2 hours following the procedure, and 96% within the 
first 24 hours. (3, 4, 5) 
The morbidity and mortality related to liver biopsy was reported to be 0.08-0.34% and  
0-0.19% respectively. (2) 
Liver biopsy can be obtained by different techniques other than percutaneous, like Fine 
needle aspiration, trsnsjugular and laparoscopic especially if there are relative 
contraindications to percutaneous liver biopsy.  
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2. Percutaneous liver biopsy complications 
2.1 Pain 
The most common complication is pain at biopsy site and shoulder and usually dull,  
mild and brief. A study using the visual analogue scale confirmed that the procedure is 
distinctly unpleasant, with 20% of the patients indicating that they experienced severe pain 
and approximately 1-5 % of the patients requiring admission from pain and most recover 
with only supportive measures. Ongoing, severe pain in the abdomen should alert  
the physician to the possibility of a more serious complication, such as bleeding or 
peritonitis. (3, 6, 7, 8, 9, 10) 
The overall frequency of pain requiring analgesics appears to be around 30-50% in patients 
not receiving prebiopsy medications. (7, 10) 
Outside of frank trauma to adjacent organs or severe bleeding, the mechanism of postbiopsy 
pain is uncertain and the biopsy site pain is likely to be a nociceptive pain that originates 
from the skin, the nociceptive innervated liver capsule, or both and high anxiety levels have 
been shown to exacerbate acute postoperative pain. (10, 11, 12) 
The right-shoulder pain after liver biopsy is well known but has never been fully 
characterized. In other words, pain in the right shoulder begins, reaches its peak, and 
subsides together with the biopsy site pain. This may indicate that the right-shoulder pain is 
likely to be a viscerosomatic referred pain, rather than an indication of a severe 
complication, such as intraabdominal bleeding. (13) 
It has been noticed in 2 studies that women tended to report higher pain level than men at 
all time points tested, the cause for the sex differences in pain perception is unknown. (13, 14) 
Analgesia before liver biopsy is usually avoided due to worries of masking pain that might 
indicative of abdominal symptoms and complications and still no consensus as to pain 
prevention and treatment for patients undergoing liver biopsy. 
The practice of conscious sedation is variable, the midazolam-treated patients had a 
numerically lower mean pain score and significantly lower mean memory score than the 
untreated patients.  (15) 
It was noticed in the study by Brouillette DE et al, that patients receiving midazolam 
admitted to experiencing less discomfort during the biopsy procedure and had less memory 
for the procedure. More importantly, 79% of those receiving midazolam stated they would 
have little or no trouble undergoing a subsequent percutaneous liver biopsy as compared to 
55% of those given saline. These data suggest that midazolam reduces subject anxiety and 
perceived discomfort before and during percutaneous liver biopsy produces partial amnesia 
for the biopsy experience and thereby may improve patient acceptance of follow-up liver 
biopsies. (16) 
One possible way to improve pain control is to assess the anxiety level before the procedure, 
to adjust the dose of the anxiolytic drug accordingly, to add conscious sedation to those who 
are at a high level of stress, to infiltrate the biopsy site with long-acting local anesthetics, and 
to administer adequate analgesics for as long as needed. (13) 
2.2 Bleeding 
Of the serious complications, bleeding post liver biopsy is considered to be the most 
common cause. Bleeding is usually presented as subcapsular or parenchymal hematoma, 
free intraperitoneal hemorrhage, hemobilia or rarely hemothorax. 
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Most complications and, in particular, hemorrhage and bile peritonitis, will be recognized 
within 4 hr after biopsy. Delayed bleeding has been reported as late as 15 days after  
biopsy. (17) 
It has been reported in two large studies of patients post liver biopsy that bleeding occur in 
0.32 - 0.35% with morbidity related to hemorrhage of 0.24 % and around 0.11% had 
mortality from severe bleeding. (5, 18) 
It has been found in some series that malignancy, cirrhosis, older age, and more than three 
passes were predictable risk factors for postbiopsy bleeding. (5, 8, 18) 
Subclinical bleeding in the form of subcapsular or intrahepatic hematomas can be seen in up 
to 23% of patients and this is usually detectable by ultrasound 24 hours after biopsy. These 
hematomas are generally small and are not associated with significant hemodynamic 
compromise. (11) 
The initial indications of bleeding are right upper quadrant abdominal pain that require 
analgesia and changes in vital signs with drop in blood pressure and rise in pulse rate.(19) 
Most cases of fatal hemorrhage especially free intraperitoneal resulted from perforation of 
portal or hepatic veins or aberrant arteries. It may also occur as a result of a tear in the liver 
when the patient breathes deeply during the biopsy. (20, 21) Free intraperitoneal hemorrhage 
can occur in 0.32% and this can be suspected clinically when the patient experienced 
abdominal pain, hypotension and tachycardia and can be confirmed by ultrasound or 
computed tomography. (22) 
Hemorrhage usually stops spontaneously and patient is managed by measures to improve 
the hemodynamic status with intravenous fluids and blood products if needed. If bleeding 
is severe, selective angiography of the hepatic artery, besides establishing the diagnosis also 
provides the opportunity for embolisation or balloon occlusion of the segmental artery 
involved. (21) 
Surgical exploration is indicated if hemodynamic instability persists despite the above 
measures and the laparotomy rate amongst patients who bled range from 6% to 25%. (21, 23, 24) 
The least common of the hemorrhagic complications is hemobilia and in one study by 
Piccinino F, et al reported 4 patients with hemobilia out of 86,276 liver biopsies.  
Hemobilia is a term first used in 1946 by Sandblom to describe bleeding into the bile 
ducts.(22)  
Hemobilia usually suspected when a post procedure fall in hemoglobin is associated  
with the classic triad of abdominal pain, hyperbilirubinemia, and unexplained 
gastrointestinal bleeding with average onset of approximately five days after biopsy. (3, 5, 25) 
The bleeding is usually arterial in origin and can be venous in patients with  
portal hypertension. Biopsy can induce hematoma or pseudoaneurysm into bile duct and 
delayed bleeding can occur from gradual dissolution of that clot, while acute bleeding 
which is less common is secondary to simultaneous perforation of intrahepatic bile ducts 
and blood vessels. (25) Clinical presentation ranges from chronic anemia to rapid massive 
bleeding with hematemsis and/or melena and rarely patient may present with only 
hematochezia. 
Diagnosis is usually suspected in patients with history of recent liver biopsy and most of 
endoscopic and radiological modalities including angiography can help in diagnosis. 
Hemobilia can stop spontaneously and if patient still have continuous or intermittent 
bleeding then immediate selective angiography needed as diagnostic and therapeutic and 
considered to be the cornerstone of management. (26) 
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2.3 Biliary peritonitis 
Biliary peritonitis is the second most frequent serious complication after hemorrhage and 
can occur in 0.03%–0.22% and usually occur in the presence of biliary obstruction and can be 
in other patients secondary to gallbladder perforation. (24, 27) The patient is usually presented 
with severe abdominal pain and vasovagal hypotension immediately postbiopsy and this 
may be followed by fever, leukocytosis and ileus. Painless bile collection in the peritoneal 
cavity has been described. Radiolgical investigations like ultrasonography or computed 
tomography scan may identify an intra-abdominal collection of bile, and bile leaks may be 
demonstrated by ERCP. Conservative management is recommended with intravenous 
fluids, antibiotics and pain control and in case of clinical deterioration surgery may be 
needed. (27) 
2.4 Pulmonary complications 
Pulmonary complications post liver biopsy is considered to be rare and this can occur if 
needle biopsy passed in the costophrenic angle above the reflection of between the parietal 
and the visceral pleura. The patients can develop pneumothorax and hemothorax and also 
hydrothorax can be developed in cirrhotic patient with ascites by passage of ascitic fluid 
through the puncture site on diaphragm. (20, 21) The incidence of pneumothorax and/or 
pleural effusion occur in the range of 0.08 – 0.28% and the symptoms usually mild and 
pulmonary collapse not exceeding 10%. (28) Hemothorax post liver biopsy is also rare with 
incidence of 0.18%–0.49% and this can be managed conservatively and rarely need 
thoracotomy. (28, 29, 30) 
There is no role for angiogram with embolisation of diaphragmatic vessel for the treatment 
of hemothorax, as blood supply to the parietal diaphragm arises from vessels from the chest 
wall and abdominal wall. (31) 
2.5 Sepsis 
Sepsis and septic shock post liver biopsy is considered to be rare and can develop 
occasionally in patients with biliary obstruction. Inconsequential transient bacteremia has 
been reported in 5.8 to 13.48% of patients, therefore prophylactic antibiotics are not 
recommended for the routine use in patients undergoing liver biopsy, including those with 
risk factor for endocarditis. (28, 32, 33)  
2.6 Other complications 
Other rare complications after percutaneous liver biopsy include perforation of abdominal 
organs which is well tolerated and not require specific treatment, subphrenic abscess, and 
pancreatitis secondary to hemobilia. Needle track seeding following biopsy of malignant 
tumor of liver have been reported and some authors recommend liver biopsy only for 
patients who are not a candidate for surgical resection.  (21, 34, 35) 
3. Fine needle aspiration 
Fine needle aspiration (FNA) is a technique used under ultrasound or CT scan guidance in 
those patients with focal hepatic lesions and at risk of bleeding. The diagnosis accuracy 
range from 80 – 95% and the cytologic findings that are negative for cancer do not rule it 
out. An important precaution is to choose the path of the needle in which normal tissue is 
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interposed between the liver capsule and the lesion and to make as few needle passes as 
possible. FNA biopsy is generally a very safe procedure, even in patients with hemangiomas 
and echinococcal cysts and is associated with a low risk of seeding of the needle tract with 
malignant cells. (3, 36, 37, 38, 39)   
4. Transjugular liver biopsy 
Transjugular liver biopsy was first described experimentally in 1964 and in human subjects 
at 1967 and usually through transjugular catheterization of the hepatic veins. Liver tissue is 
obtained from within vascular system and this minimizes the risk of bleeding. (40, 41) It is 
performed in a vascular catheterization laboratory with video fluoroscopy equipment and 
cardiac monitoring because of the risk of cardiac arrhythmia as the catheter passes through 
the right atrium. The duration of the procedure is between 30 and 60 minutes and adequate 
specimen was obtained in 97%. (3, 42) Although not easy, this technique is safe and preferable 
in the management of selected patients with coagulopathy and risk of bleeding, moderate to 
severe ascites, massive obesity, small cirrhotic liver and patients with suspected vascular 
tumor. (43) 
The total complication rate in 7469 transjugular liver biopsies reported in 62 series published 
between 1978 and 2006 was 7.1%, 3.5% were related to liver puncture while 3.3% were not. 
(43) The major complications of transjugular liver biopsy are rare and occur between 0.01 to 
0.2% and may include large hepatic hematoma, intraperitoneal hemorrhage, inferior vena 
cava perforation, renal vein perforation, ventricular arrhythmia, pneumothorax and 
respiratory arrest. The patients may also get some minor complications like pyrexia, 
abdominal pain, neck hematoma, transient Horner’s syndrome, transient dysphonia, 
subclinical capsular perforation, formation of a fistula from the hepatic artery to the portal 
vein or the biliary tree and all these complications can occur in 0.01 – 1.6%. Deaths can occur 
in 0.1% of patients mainly secondary to intraperitoneal hemorrhage or ventricular 
arrhythmia. (43) 
5. Laparoscopic liver biopsy 
A laparoscopic liver biopsy is another method for obtaining liver tissue and may be done 
solely or may be part of another operative procedure and this allows direct inspection of the 
liver surface prior to the biopsy, demonstrate cirrhosis in almost all patients and allow direct 
compression of the biopsy site if bleeding is excessive. (44) 
It has also been used in centers where access to transjugular liver biopsy is not available, for 
patients with abnormal clotting parameters, and also in patients who have a combination of 
a focal liver lesion and a coagulopathy where a histological diagnosis is essential in the 
management of that patient. (42) The complications of laparoscopic liver biopsy include 
vasovagal reaction, seizure, abdominal wall hematoma, abdominal viscus perforation, 
hemobilia, splenic laceration, bleeding and prolonged abdominal pain. (45)  
6. Conclusion 
We conclude that in properly selected patients and after exclusion of risk factors for 
complications, liver biopsy is considered to be safe outpatient procedure and still the gold 
standard method and definitive diagnostic test for difficult cases of liver diseases. 
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1. Introduction  
The liver is the second largest organ in the body after the skin and has important storage, 
detoxification and synthetic functions. Liver diseases encompass a multitude of pathologies 
and the management of these diseases involves diagnostic and therapeutic investigations 
and interventions; some of which are invasive. Histological assessment  of the liver and 
lesions within  via liver biopsies are an important tool in the armamentarium of invasive 
investigations for liver diseases of both a surgical and non-surgical nature. 
Liver biopsy has been used for over 100 years  in the assessment of liver diseases (Valori and 
Elias 1989). Paul Ehrlich performed one of the first percutaneous liver biopsies in the late 
19th century in Germany to assess glycogen levels in the liver of a diabetic patient (Grant 
and Neuberger 1999). However, the procedure did not really gain popularity until Menghini 
refined the technique in the mid 20th century(Menghini 1958). In the last fifty years the 
techniques for liver biopsy has been continuously refined and although today there are 
several biochemical and imaging techniques to assess liver disease biopsy remains 
important in assessment. Today, widespread application allows for blind, open and image 
guided liver biopsies, although ultrasound guided biopsies are considered superior 
(Younossi, Teran, Ganiats and Carey 1998). Image guided percutaneous liver biopsies 
remains the mainstay of this procedure while open biopsies may be undertaken as an 
adjunct to laparoscopic or other open surgical procedures. There are presently various 
techniques and equipment for percutaneous liver biopsies and this procedure is performed 
by both gastroenterologists/hepatologists and radiologists. The choice of technique and 
equipment is however operator dependent. 
2. Indication    
In the past the indications for liver biopsies and the practice thereof varied significantly 
between institutions. This was born out in an audit conducted by the British society of 
Gastroenterology and the Royal College of Physicians of London (Gilmore, et al. 1995). 
Subsequent to this the British Society of Gastroenterology published guidelines on the use of 
liver biopsy in an attempt to standardize indications and technique for this procedure 
  
Liver Biopsy 
 
370 
[43] Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy—indications, 
adequacy, quality of specimens, and complications—a systematic review. Journal of 
Hepatology. 2007;47 (2):284–294 
[44] Pagliaro L, Rinaldi F. Craxi A, Di Piazza S, Filippazzo G, Gatto G, et al. Percutaneous 
blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis: a 
prospective randomized trial. Dig Dis Sci 1983; 28: 39-43. 
[45] Vargas C, Jeffers LJ, Bernstein D, et al. Diagnostic laparoscopy: a 5-year experience in a 
hepatology training program. Am J Gastroenterol 1995;90:1258-62. 
24 
Complications of Liver Biopsy 
Daren Subar1, Ali Khan2 and Derek O’Reilly1,3 
1Department of Hepatopancreaticobiliary Surgery, 
 North Manchester General Hospital, Crumpsall, Manchester 
 2Department of Radiology, 
 North Manchester General Hospital, Crumpsall, Manchester  
3Cancer Studies Research Group, The University of Manchester,  
Manchester Academic Health Science Centre, Manchester 
 UK 
1. Introduction  
The liver is the second largest organ in the body after the skin and has important storage, 
detoxification and synthetic functions. Liver diseases encompass a multitude of pathologies 
and the management of these diseases involves diagnostic and therapeutic investigations 
and interventions; some of which are invasive. Histological assessment  of the liver and 
lesions within  via liver biopsies are an important tool in the armamentarium of invasive 
investigations for liver diseases of both a surgical and non-surgical nature. 
Liver biopsy has been used for over 100 years  in the assessment of liver diseases (Valori and 
Elias 1989). Paul Ehrlich performed one of the first percutaneous liver biopsies in the late 
19th century in Germany to assess glycogen levels in the liver of a diabetic patient (Grant 
and Neuberger 1999). However, the procedure did not really gain popularity until Menghini 
refined the technique in the mid 20th century(Menghini 1958). In the last fifty years the 
techniques for liver biopsy has been continuously refined and although today there are 
several biochemical and imaging techniques to assess liver disease biopsy remains 
important in assessment. Today, widespread application allows for blind, open and image 
guided liver biopsies, although ultrasound guided biopsies are considered superior 
(Younossi, Teran, Ganiats and Carey 1998). Image guided percutaneous liver biopsies 
remains the mainstay of this procedure while open biopsies may be undertaken as an 
adjunct to laparoscopic or other open surgical procedures. There are presently various 
techniques and equipment for percutaneous liver biopsies and this procedure is performed 
by both gastroenterologists/hepatologists and radiologists. The choice of technique and 
equipment is however operator dependent. 
2. Indication    
In the past the indications for liver biopsies and the practice thereof varied significantly 
between institutions. This was born out in an audit conducted by the British society of 
Gastroenterology and the Royal College of Physicians of London (Gilmore, et al. 1995). 
Subsequent to this the British Society of Gastroenterology published guidelines on the use of 
liver biopsy in an attempt to standardize indications and technique for this procedure 
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(Grant, et al. 1999). Similar guidelines have since been published by the American 
Association for the Study of Liver Diseases (Rockey, Caldwell, Goodman, Nelson and Smith 
2009). These indications are beyond the remit of this chapter and can be sourced from the 
guidelines.  
3. Methods   
There are various methods for performing liver biopsies. In the main most liver biopsies 
are performed percutaneously. In the UK this method is performed by radiologists under 
image guidance. In support of image guided biopsies  Vautier et al suggests that the ideal 
liver biopsy is one that is performed under ultrasonic guidance (Vautier, Scott and Jenkins 
1994). However there are still some clinicians who practice liver biopsies without image 
guidance. In a survey conducted by Muir et al about current practice of liver biopsy 53.2% 
of clinicians still performed liver biopsies without image guidance (Muir and Trotter 
2002). Guided liver biopsies are undertaken with real time imaging  using ultrasound or 
CT scans. Real time imaging allows for accurate biopsy of lesions and avoidance of major 
vascular, biliary or bowel structures and thus reduce the incidence of complications.  This 
can be via the transthoracic or the subcostal route and may be plugged or unplugged. 
Plugged percutaneous liver biopsies involves the injection of a gelatin substance into the 
biopsy cavity after withdrawal of the specimen. It reduces the complication of bleeding 
and can be used in patients with impaired coagulation (Fandrich, Davies and Hall 1996). 
In patients with coagulopathy in whom a percutaneous biopsy is considered 
inappropriate a transvenous (transjugular or transfemoral) approach can be used (Lebrec, 
Goldfarb, Degott, Rueff and Benhamou 1982, Sawyerr, et al. 1993).  Laparoscopic liver 
biopsy is used in centres where expertise in the transvenous approach is unavailable for 
patients with a bleeding coagulopathy. A general anaesthetic is necessary where the 
laparoscopic approach is contemplated. In many instances it is undertaken when a liver 
lesion is found incidentally during diagnostic or staging laparoscopy. It can also be used 
in assessing the degree of cirrhosis of the future liver remnant in patients who are 
undergoing staging laparoscopy for consideration of liver resection for hepatocellular 
carcinoma. Laparoscopic liver biopsy allows direct visualisation of the area to be biopsied 
and immediate control of any haemorrhage. The complications of this procedure includes 
those associated with the anaesthesia, the laparoscopy and the biopsy. In our institution, 
we believe that all percutaneous liver biopsies should be image guided. As a 
result of the associated risks our patients are admitted for post biopsy 
observation for 6 hours as per the British society of Gastroenterology and the 
American Gastroenterological Association guidelines(Grant, et al. 1999, Rockey, 
et al. 2009). In other centres in the USA percutaneous liver biopsy is performed as 
an outpatient procedure with one of the stipulations being the patient is able to 
return to the hospital within 30 minutes if symptoms of a complication 
develop(Jacobs and Goldberg 1989). 
4. Complications      
The complications of liver biopsy can be divided into those in the immediate, early or late 
period (Table 1).  The overall reported complication rate varies significantly (Galati, et al. 
1994, Gilmore, et al. 1995, Grant, et al. 1999).  These can range from minor complications 
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such as pain and transient hypotension to major complications such as visceral perforation 
or significant bleeding which may lead to death. The incidence of major complications was 
reported to be as high as 4% with a mortality rate ranging from 0.01% to 0.33%(McGill, 
Rakela, Zinsmeister and Ott 1990). Differences in complication rate has been reported 
between blind and ultrasound guided liver biopsies with ultrasound guided biopsies 
proving superior for both accuracy and risk of complications(Riley 1999, Al Knawy and 
Shiffman 2007).  
 
Immediate Early(within 24 hours) Late 
Death Death Needle tract seeding of Tumour cells 
Pain Pain Biliary fistula 
Bleeding Bleeding Septicaemia 
Septicaemia Septicaemia Biloma 
Perforation of  nearby 
organs Biliary peritonitis Pleural effusion 
Pneumothorax 
Haemothorax Haemobilia Intrahepatic arterio-venous fistula 
Needle fracture   
Table 1. Complications of Liver Biopsy 
In addition, it is well documented that the risk of complications increases with the increase in 
the number of needle passes necessary for sampling(McGill, et al. 1990). Blind biopsies require 
more needle passes than ultrasound guided biopsies and have been statistically proven to 
increase the risk of complications(Cadranel, Rufat and Degos 2000, Mayoral and Lewis 2001).  
The issue of the relationship of needle size or type to complication rate remains controversial. 
McGill et al compared  a 1.6mm diameter needle to a 1.9mm needle and found no difference in 
the incidence of  of haematomas(McGill, et al. 1990). The same is true for the study by Forsell 
et al (Forssell, Bonkowsky, Anderson and Howell 1981). However prior to this, the multicentre 
retrospective study conducted by Piccinino suggested a higher incidence of bleeding with 
cutting type needles (Piccinino, Sagnelli, Pasquale and Giusti 1986). 
Finally, as with most invasive procedures the most significant factor in the incidence of 
complications associated with liver biopsy is operator experience. In the nationwide survey 
conducted in Switzerland on the practice and complications of liver biopsy Froelich et al 
reported  that no complications occurred with internists performing more than 50 biopsies a 
year but a 1.68% complication rate with internists performing less than 12 biopsies a year 
(Froehlich, Lamy, Fried and Gonvers 1993). The national audit of percutaneous liver biopsy 
conducted in England and Wales confirms Froelich’s findings.  It was found that the 
frequency of complications was 3.2% for biopsies performed by operators with less than 20 
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previous biopsy procedures. In contrast, it was only 1.1% when performed by those who 
had conducted more than 100 biopsies(Gilmore, et al. 1995).   
From the large retrospective study conducted by Piccinino it was reported that 61% of 
complications occurred within the first 2 hours after biopsy and 96% in the first 24 hours 
(Piccinino, et al. 1986). Arturo et al suggests that up to 3% of patients may require 
hospitalization for complications of liver biopsy, more so if the procedure is performed with 
a tru-cut needle(Bravo, Sheth and Chopra 2001). For the purpose of this chapter we are 
going to focus on the complications associated with percutaneous liver biopsy as this is the 
commonest method in use. The specific complications associated with other methods will be 
briefly discussed at the end.  
4.1 Mortality 
Liver biopsy associated mortality is reportedly related to haemorrhage or biliary peritonitis 
(Vautier, et al. 1994, Shah, Mayberry, Wicks, Rees and Playford 1999). The reported 
incidence of mortality varies (Grant, et al. 1999) and to date the true incidence is not known. 
Three month post biopsy mortality rate is reported to be as high as 19%(Gilmore, et al. 
1995).  This is probably a result of the primary indication for the liver biopsy; i.e. liver failure 
and malignancy and not necessarily a result of the biopsy itself. Although logic would 
suggest that image guided biopsy would result in a statistically lower mortality rate 
compared to blind biopsies, this has actually never been born out in published reports.  
Griffiths et al(Griffiths, Viiala and Olynyk 2002) and others  reported the mortality 
associated with liver biopsies to range from 0.01% to 0.1%(Piccinino, et al. 1986, McGill, et al. 
1990). However, this is for both blind and guided biopsy.  
Other authors have also refuted the claim that image guided biopsies reduces mortality rates. 
Centinkaya et al published a retrospective study of  205 patients who had either blind or  
guided biopsies of the liver and no difference was found in the incidence of mortality(0% in 
each group) (Züleyha Akkan Çetinkaya 2010).  Indeed, most of the published data on 
mortality is from retrospective studies. In 1991 the national audit undertaken in England and 
Wales looked at the outcome of 1504 liver biopsies. Two patients died as a result of blind 
biopsy whereas there were no directly related deaths in the image guided cohort. This was  
not statistically significant however(Gilmore, et al. 1995). In 2010 West and Card published an 
epidemiological study on the mortality rates in elective percutaneous liver biopsy(West and 
Card 2010). Again this was a study based on restrospective data analysis. In it the all  
cause seven day mortality was 0.2% but mortality directly related to liver biopsy was 1 in 
10,000. 
In effect, the true incidence of biopsy related mortality and the effect of image guidance on 
the incidence of mortality is not known. Vautier et al(Vautier, et al. 1994) suggested that a 
large study involving an estimated 10,000 patients would be needed to demonstrate any 
statistical difference.   
4.2 Pain 
Pain is the most common complication after percutaneous liver biopsy. The incidence  
of pain during liver biopsy is reported to be as high as 84%(Eisenberg, et al. 2003).  This 
pain can be acute and can last for more than 24 hours after the procedure(Castera, Negre, 
Samii and Buffet 1999). Eisenberg et al reported that 40% of patients in their prospective 
study experienced pain 24 hours after the procedure. Indeed, if the pain is due to hepatic 
friction rub the pain may last for a few weeks (Chuah 1996).  The intensity of this pain is 
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mainly mild to moderate(Farrell, et al. 1999, Cadranel, et al. 2000) but can be severe.  
In a study conducted by Christine Janes in 1993, of the four hundred and five patients 
who had liver biopsies as outpatients, five of the thirteen patients (1.2%) requiring  
post-procedure hospitalization was as a result of pain(Janes and Lindor 1993).  A similar 
figure of 1.2% was quoted for the experience of severe pain by Christopher Pokorny in  
his study of radiologically guided liver biopsy, however none of these patients were 
admitted to hospital(Pokorny and Waterland 2002).   The pain can be localized to the site 
of the biopsy or commonly be referred to the right shoulder tip. There is also a distinct  
sex difference in the experience of pain. The intensity of pain is reportedly higher in 
women although the cause of this is unknown (Cadranel, et al. 2000). In addition, 
Eisenberg et al demonstrated that there was a linear correlation between the level of  
pre-biopsy anxiety and the intensity of the experienced pain.  It is possible that there is a 
positive correlation between levels of anxiety and gender but this has yet to be assessed 
and reported.  
The etiology of post liver biopsy pain is thought to be multi-modal. Pain can indicate post 
biopsy peritoneal irritation if bleeding or peritoneal soiling from biliary leakage of visceral 
perforation occurs.  However, pain at the biopsy site may emanate from stimulation of 
nocioceptive fibres in the skin and liver capsule. In contrast, shoulder tip pain may be 
viscerosomatic in origin(Hederstrom, Forsberg, Floren and Prytz 1989). The use of 
ultrasound guided biopsy has been reported to decrease the incidence of post biopsy pain. 
In the study conducted by Lindor et al nine patients required post biopsy hospitalization 
when ultrasound was not used compared to two patients in the biopsy under ultrasound 
guidance group. More importantly, of the nine patients, seven were hospitalized for 
pain(Lindor, et al. 1996). This view is supported by the review of the literature on blind 
versus ultrasound guided biopsy by Knawy et al. They found that ultrasound guidance 
resulted in a 10.9%  decrease in biopsy pain (P<0.0001)  and a decrease in pain related 
morbidity (1.8% vs 7.7%) (Al Knawy, et al. 2007). 
Interestingly, both local anaesthetic with or without conscious sedation has been used in an 
attempt to control pain and in spite of this pain continues to be the commonest complication 
of liver biopsy. Conscious sedation has however shown some promise in reducing pain 
during and after liver biopsy. It is also possible that the administration of anxiolytics pre-
biopsy may alleviate some of the pain experienced. Despite pain being a significant issue 
there is no published data on the optimization of pain control in patients undergoing liver 
biopsy.   
4.3 Bleeding 
Bleeding after percutaneous liver biopsy is a well documented complication second only  
to pain(Chuah 1996). This can be minor or be significant enough to warrant intervention.  
The reported incidence of bleeding varies significantly (Piccinino, et al. 1986, Chuah, Moody, 
Wicks and Mayberry 1994, Thampanitchawong and Piratvisuth 1999) and is the main cause  
of mortality after biopsy(Froehlich, et al. 1993). McGill reports it to be between 2%-4% in  
their 21 year experience with a mortality rate of 0.01%-0.03%(McGill, et al. 1990). The 
admission of those with bleeding is about 0.2%. The fatalities are usually due to inadvertent 
perforation of the hepatic or portal vein or aberrant hepatic artery. It may also result from a 
laceration in the liver if the biopsy needle is intrahepatic while the patient inhales 
deeply(Chuah 1996). 
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The risk is reportedly increased with the presence of ascites (Grant, et al. 1999) probably as a 
result of the dilutional effect of the ascitic fluid on clotting factors however the incidence is 
not affected by the use of ultrasound (Stone and Mayberry 1996). Like the use of ultrasound, 
the risk of haemorrhage is not related to needle diameter or type (Froehlich, et al. 1993). 
However, the relationship between coagulopathy and bleeding remains controversial. In the 
United States the conventional approach is to withhold percutaneous biopsy if the INR is 
greater than 1.5 (Rockey, et al. 2009). The survey conducted by Chuah et al suggested that 
coagulopathy should be corrected prior to biopsy (Chuah, et al. 1994). This is supported by 
other studies. Caldwell et al reviewed 2740 percutaneous liver biopsies in patients with 
hepatitis C. They recorded 16 out of 29 adverse events caused by severe bleeding. 
Statistically, the factors that were associated with increased bleeding included a platelet 
count of less than 60,000, INR greater than 1.3, the presence of varices and low albumin 
(Caldwell and Northup 2010). They suggested that the increase in bleeding with low 
albumin and varices is likely to be due to the changes in hepatic vasculature and not a 
clotting abnormality.  
Although one other study has corroborated the cut off value of platelet count as 60,000 
(Sharma, McDonald and Banaji 1982) there are other studies that suggest otherwise. 
Sherlock et al reports a cut off platelet count of 80,000 and Sue et al a cut off count of 50,000 
(Grant, et al. 1999). In the retrospective study conducted by Pornpen et al they found that 
coagulopathy was related to bleeding complications and death (Thampanitchawong, et al. 
1999). The bleeding complication rate increased from 3.6% to 10.5% and the death rate 
increased from 1% to 7% when the thrombin time increased by greater than 3 seconds over 
control and the prothrombin time increased by more than 10 seconds over control. The  
same was true for patients with a platelet count of greater than 70,000. However,  
platelet count was the only independent variable on logistic regression analysis.  
In effect, the absolute cut off point is unknown. In addition to this it is thought that platelet 
function also plays a more important role in the risk of bleeding after biopsy than platelet 
number (Tripodi, et al. 2006).  Other risk factors include multiple passes with the biopsy 
needle, the presence of cirrhosis (Janes, et al. 1993) and the use of cutting needles (Piccinino, 
et al. 1986).  
In contrast, Ewe et al and others demonstrated no effect of bleeding abnormalities on the 
risk of bleeding with either laparoscopic or percutaneous liver biopsy (Ewe 1981, McVay 
and Toy 1990, Dillon, Simpson and Hayes 1994).  Even in Caldwell’s study three of the 
patients with haemorrhagic complications after biopsy had a platelet count of over 150,000.  
Finally, the question of ultrasound reducing the risk of haemorrhage remains unanswered. 
Several studies have demonstrated that ultrasound reduces the incidence of complications, 
none of these studies reported any specific difference in haemorrhage(Lindor, et al. 1996, 
Stone, et al. 1996, Manolakopoulos, et al. 2007). In our unit, we accept a platelet count of 
greater than 80,000 and an INR of less than 1.5 in order to proceed to biopsy.  
The haemorrhage associated with percutaneous liver biopsy can present as intraperitoneal 
bleeding, intrahepatic bleeding, haemobilia and subcapsular haematoma(Figure 1) (Caldwell, 
et al. 2010).  Intraperitoneal bleeding although rare, when clinically significant generally 
becomes apparent within the first 2-3 hours after biopsy(Van Thiel, Gavaler, Wright and 
Tzakis 1993) and is usually heralded by a drop in haemoglobin of greater than 2g/dL or 
haemodynamic instability(Knauer 1978).  If intraperitoneal haemorrhage is suspected the 
patient should be resuscitated, have imaging studies (CT or ultrasound) to confirm this and if 
resuscitation fails then angiography and embolisation or less commonly surgery to halt 
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bleeding. Intrahepatic or subcapsular haematomas tend to be asymptomatic(Raines, Van 
Heertum and Johnson 1974) and occurs in about 23% of patients(Minuk, Sutherland, Wiseman, 
MacDonald and Ding 1987). However, large haematomas can present with pain or signs of 
intravascular depletion i.e hypotension and tachycardia(Van Thiel, et al. 1993). In the main 
these haematomas can be treated conservatively with resuscitation and correction of 
coagulopathy or thrombocytopenia if it exists. 
 
 
 
Fig. 1. This patient with hepatitis C became haemodynamically unstable following a 
percutaneous liver biopsy. A superselective angiogram of the liver shows a subcapsular 
bleed, which was embolized with microcoils (red arrows).  
Although post biopsy haemorrhage  usually presents itself within the fist 2-3 hours there 
have been reports of delayed bleeding (Reichert, Weisenthal and Klein 1983). Yeo et al 
described a case of a patient who was hepatitis C positive with haemophilia who presented 
10 days after an image guided percutaneous liver biopsy(Yeo, Tan, Dan and Wai 2008). He 
presented to the emergency department complaining of hypochondrial pain and 
investigations demonstrated a haemothorax and subcapsular haematoma. He 
decompensated and had an emergency resuscitative thoracotomy.  In another case a 46 year 
old gentleman who represented 4 days after percutaneous biopsy with right hypochondrial 
pain. He was diagnosed with a bleeding pseudoaneurysm of the right hepatic artery which 
was embolised. Subsequently, he continued to bleed and had a laparotomy which 
demonstrated a right hepatic lobe laceration (Ren, Piao and Jin 2006). Although this is very 
rare there have been other reports of post biopsy pseudoaneurysm formation(Figure 2 a & 
b)(Kowdley, Aggarwal and Sachs 1994, Own, Balzer and Vogl 2005). Surprisingly, Terjung 
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et al reported the incidence of delayed bleeding in their series to be 70%(Terjung, et al. 2003). 
In their series they defined delayed bleeding as occurring after 24 hours. This is a 
particularly high incidence and it may well reflect the definition criteria or the enthusiasm 
with which patients are investigated for haemorrhage. There may well be a large cohort of 
post biopsy delayed haemorrhage who are asymptomatic and therefore the true incidence is 
not known.   
 
 
 
(a)    (b) 
Fig. 2. (a & b) CT scans on a patient with a past history of a percutaneous liver biopsy 
showing a ruptured pseudoaneurysm with active bleeding.   
Haemobilia is a rare complication of liver biopsy and was first reported by in 1967 by Cox 
(Cox 1967).  In 1991 Merrell and Schneider described the evolution of haemobilia and 
suggested a lag time between biopsy and presentation to be about 5 days. Interestingly, 
haemobilia after biopsy has been associated with acute pancreatitis(Pena, Horn and Cross 
2009). It is thought that the pancreatitis is induced in the same manner as gallstones; 
impairment of pancreatic drainage. The treatment required is ERCP and sphincterotomy. 
Angiography has also been used to stem the bleeding but only in a few cases.  
4.4 Septicaemia 
Septicaemia is a result of bacteraemia during needle biopsy. It can also result from the 
development of intrahepatic abscesses (Figure 3). The incidence of bacteraemia is reported to 
be as high as 13 % (McCloskey, Gold and Weser 1973, Le Frock, Ellis, Turchik, Zawacki and 
Weinstein 1975). However more commonly the figure is quoted to be less than 1% (Larson, et 
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al. 1997). It is more common in patients with biliary abnormalities including biliary 
obstruction, cholangitis and those who have had biliary bypass(Bubak, Porayko, Krom and 
Wiesner 1991, Larson, et al. 1997, Bravo, et al. 2001). However, one of these studies was in 
patients who had liver transplant and therefore may be immunosuppressed and at higher risk 
of infections.  McCloskey et al reported an incidence of liver biopsy related septicaemia of 
2.9%. They suggested that in patients with liver disease there is a defect in the defence 
mechanisms related to a deficiency of complement and inhibition of chemotaxis among others 
(McCloskey, et al. 1973). In those with septicaemia the commonest organism cultured from the 
blood is E. Coli (Moreira Vicente, Hernandez Ranz, Ruiz Del Arbol and Bouza 1981) although 
polymicrobial organism infection has been reported (Dhawan, Thadepalli, Ulmer and Akhtar 
1983) including klebsiella and streptococcus. 
 
 
 
Fig. 3. This patient presented with right upper quadrant pain and pyrexia 4 days following a 
percutaneous liver biopsy. Note the liver mass associated with air within and surrounding 
the mass. The patient was treated for a liver abscess. Note echogenic contents within the 
pleural sac indicative of blood or pus (arrow).     
Although bacteraemia with or without septicaemia is a rare but recognized complication of 
liver biopsy the question of whether prophylactic antibiotics is warranted remains 
unanswered. This is mainly because there are no randomized trials examining this and most 
of the reported data are either case reports or retrospective studies. It is probably 
worthwhile in patients who are immunocompromised (e.g transplant patients). It would be 
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considered prudent to delay this invasive procedure if possible in patients who have 
confirmed sepsis. In addition, patients with obstructive jaundice or who are considered at 
risk should also probably have prophylactic antibiotics. 
4.5 Pulmonary complications 
The transthoracic approach traverses the pleural space. The incidence of complications 
was reported to be 25% in the Swiss survey (Froehlich, et al. 1993). Hydrothorax occurs as 
a result of leakage of ascitic fluid via the biopsy tract into the pleural cavity  
(Zamcheck and Sidman 1953). Pneumothoraces tend to occur in about 0.35% of cases 
(Piccinino, et al. 1986) (Figure 4). In addition, haemothoraces are also possible but rare 
with a reported incidence of 0.018% (Piccinino, et al. 1986). It is thought to be a result of 
injury to the diaphragmatic vessels (Majid 1990) and the event usually declares itself early 
on.  
 
 
B
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Fig. 4. Attempted liver biopsy on a 36-year old female with non-specific hepatic dysfunction. 
The needle entered the pleural cavity. Ultrasound examination shows blood in the pleural 
sac (B) at various stages of organization. The diaphragm is marked by a red arrow.  
4.6 Visceral perforation 
Visceral perforation includes puncture of the colon, kidney, lung or gallbladder. Piccinino et 
al reported the incidence of visceral perforation to be between 0.01%-0.1%(Piccinino, et al. 
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1986). This is supported by others (van der Poorten, et al. 2006). These complications can 
resolve with conservative management or can result in peritonitis requiring surgery. 
 
 
K
 
Fig. 5. Attempted liver on a 16 year old with a Riedle’s lobe. The needle has entered the 
kidney (white arrow) the kidney is labelled K. The patient subsequently developed 
intractable haematuria and had to have several blood transfusions.  
4.7 Needle fracture 
Fracture of the needle is a very rare complication. Robert Peters reported a case of a 
Menghini needle fracture during liver biopsy in 1968 leaving the distal end in the patient’s 
chest wall (Peters 1968).  Subsequent to that Purow et al in 1977 and Lazar et al in 1978 
reported this as a complication of liver biopsy (Grant, et al. 1999). It is thought to be a result 
of thrusting the needle onto the rib in the transthoracic  approach.  However, there have 
only been a few reported cases of needle fracture. Indeed,  a search of the literature has not 
resulted in any reported cases in the last decade. This is probably due to the increasing 
expertise in those carrying out liver biopsies and possibly the use of image guidance.  
4.8 Arteriovenous fistula 
Traumatic arteriovenous fistulas in relation to the biliary vasculature has been described as 
early as 1952(Strickler, Lufkin and Rice 1952). The incidence is reported to be as high as 50% 
if an angiogram is performed within one week of the biopsy (Hellekant 1976). A number of 
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other authors have quoted a much lower incidence(Okuda, et al. 1978). This is probably a 
function of the fact that these lesions are not investigated unless the patients are symptomic 
and they tend to resolve spontaneously(Hurwitz and Thompson 2002).  These patients tend 
to present as delayed haemorrhage in the form of frank intraperitoneal haemorrhage with 
shock, intrahepatic haematoma with pain and anaemia or haemobilia (Ormann, Starck and 
Pausch 1991). However, late presentations occur in the form of portal hypertension for 
arterio-portal fistulas and congestive cardia failure in the case of hepatic arteriovenous 
fistulas(Wallace, Medellin and Nelson 1972). The occurrence of fistulas is not isolated to 
percutaneous liver biopsy. Guarkuqi et al described a case of fatal haemobilia after 
transjugular liver biopsy in a patient with alcoholic cirrhosis 1 day after biopsy(Gurakuqi, et 
al. 2008). The haemobilia itself can cause pancreatitis(Machicao, Lukens, Lange and Scolapio 
2002) and may result from an arteriovenous fistula(Cacho, et al. 1996) or a portobiliary or 
arteriobiliary fistula.  Interestingly, arteriovenous fistulas after liver biopsy have been 
described elsewhere. In 1975 Satava et al described a case of an arteriovenous fistula of the 
omentum after liver biopsy. Whatever the presentation of the fistula, the main components 
of treatment is resuscitation, investigation and treatment.  Treatment in the form of 
embolisation is usually successful and if not then surgery with the aim of ligation of the 
arterial component is the next best step.  
4.9 Tumour seeding 
Advances in imaging, operative procedures and chemotherapeutic agents has increased the 
pool of patients suitable for Liver resection of primary and secondary liver cancers and the 
long term survival.  Needle track seeding is well documented in the literature (Davies, 
Tulgan, Parkinson, Goel and Budnitz 1968, Evans, Harries and Hobbs 1987)(Figure 6). This 
has been reported in both biopsies for primary or secondary liver tumours(Park, et al. 1989, 
Smith 1991, Vergara, Marucci, Marcarino, Brunello and Capussotti 1993, Jones, Rees, John, 
Bygrave and Plant 2005). It is thought that needling a tumour could implant up to 100,000 
tumour cells along the tract(Ryd, Hagmar and Eriksson 1983). The occurrence of needle 
track seeding after tumour biopsy is known to result in poorer long term survival(Cresswell, 
Welsh and Rees 2009) and convert a potentially resectable lesion to being unresectable. In 
spite of this there are still reported incidences of patients undergoing biopsy of liver lesions 
before being referred to a specialist unit (Al-Leswas, O'Reilly and Poston 2008). The 
incidence of tumour seeding has been reported to be has high as 19% and in one study 
significantly reduced 4-year survival from 46.7% to 32.5% (Jones, et al. 2005). The same 
holds true for hepatocellular carcinoma.  The meta-analysis and systematic review by Silva 
et al reported a seeding rate 2.7% in biopsy of hepatocellular carcinoma(Silva, et al. 2008). In 
addition, the long term survival is also significantly affected with 5 year survival reported to 
decrease from 52% to 24%(Young, et al. 2007).  
It is clear that modern day practice of surgery dictates that all patients with liver lesions 
should be referred to a specialist centre for investigation and management. The advances in 
MRI, PET and CT along with ultrasound and measurement of tumour markers without 
histology have reported accuracies of over 97% and should provide enough information in 
the majority of cases for management decisions to be made(Torzilli, et al. 2004). The only 
real indication for biopsy of suspicious liver lesions would be in patients who are 
considered to be irresectable by a specialist centre and a histological diagnosis is necessary 
to determine consideration for chemotherapy.  
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Fig. 6. This patient with a colorectal cancer had a small subcapsular lesion shown on a CT. 
At laparoscopy the subcapsular lesion was biopsied, which was positive for a metastasis. 
The patient had a laparotomy 3 weeks latter. The picture shows multiple tiny serosal 
deposits  
4.10 Biliary fistulas 
Biliary fistulas are a rare complication of liver biopsy. They can be divided into intenal or 
external fistulas. Internal fistulas occur between the biliary tree and an adjacent sturcture. 
These include arterio-biliary or bilio-venous fistulas. These patients can present with 
haemobilia or pancreatitis. In one large series percutaneous liver biopsy has been reported 
to cause haemobilia in 4 out of 68,276 patients (Piccinino et al 1986). The reported incidence 
of this is between 0 to 1% (Rossi et al 2002) and can usually be managed by embolisation of 
the vessel. More rarely, biliovenous fistulas can present as bile pulmonary embolism with 
fatal consequences (Brown and Walsh 1952). Fistulas can also develop between the biliary 
tree and an adjacent organ or cavity such as a bronchobiliary or pleurobiliary fistula 
(Ferguson and Thomas 1967). They can present as bilioptysis and can be managed 
conservatively by ERCP to decompress the biliary tree and allow preferential flow of bile 
into the duodenum or, failing that, surgical intervention (Chong et al. 2008). Biliary fistulas 
can also present bilio-cutaneous fistulas (Hatzidakis et al 2006). The true incidence is not 
known. The management of these fistulas also varies and will depend on the underlying 
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pathology. The options for management include conservative, allow the fistula to heal 
spontaneously, radiological by embolisation of the fistula tract (Hatzidakis et al) or surgical. 
5. Transvenous liver biopsy 
Transvenous liver biopsy can be undertaken via the femoral or the more commonly 
described transjugular route. It was first described by Dotter in 1964(Dotter 1964) but the 
first major series was reported by Rosch et al in 1973(Rosch, Lakin, Antonovic and Dotter 
1973). The transvenous route was introduced as an alternative to the percutaneous route 
when there are concerns about coagulopathy or significant ascites and in those with 
morbid obesity(Rockey, et al. 2009). The transjugular route has the added advantage of 
being able to measure the hepatic venous wedge pressure where necessary. The basic 
principle of the procedure is the same for both techniques. The procedure is usually 
performed by a radiologist under fluoroscopic guidance. The inferior vena cava(IVC) is 
cannulated and via this one of the hepatic veins (usually the right) is entered and a biopsy 
is taken from within the liver. The technical failure rate is reported to be 3.2% 
(Kalambokis, et al. 2007).  
The reported complication for the transjugular is as high as 20% (Grant, et al. 1999) with  
major complications occurring between 1.3 to 2.7% (Gamble, Colapinto, Stronell, Colman 
and Blendis 1985, McAfee, Keeffe, Lee and Rosch 1992). However, the most recent review of 
the literature reports a complication rate of 6.7% in adult series, comparable to complication 
rates reported in other series(Thampanitchawong, et al. 1999). The complications were 
described as both liver puncture related and non-liver puncture related and the incidence 
for both were similar. The non-liver puncture related complications are associated with the 
process of cannulating the jugular or hepatic vein or technical failure. In their retrospective 
study Soyer et al suggests that the complications associated with cannulation of the jugular 
vein can be minimized by the use of ultrasonic guidance(Soyer, Fargeaudou, Boudiaf and 
Rymer 2008). These include skin haematoma, pneumothorax, Horner’s syndrome, 
dysphonia, cholangitis and cardiac arrhythmias. One particular risk associated with this 
route is perforation of the liver capsule and intraperitoneal haemorrhage(McAfee, et al. 
1992). Even if the procedure was attempted via the femoral route capsular perforation was 
still a noted complication(Khosa, et al. 2003). Khosa suggested that this complication could 
be avoided if biopsies were taken within a central area of the liver and biplane fluoroscopy 
was used. The same would probably hold true for the transjugular route. In addition, 
Papatheodoridis et al suggested that capsular penetration was more frequent with the 
Menghini needle as a result of difficulty in controlling the depth of penetration 
(Papatheodoridis, Patch, Watkinson, Tibballs and Burroughs 1999). In their series capsular 
penetration only resulted in minor complications. The mortality rate is about 0.09% and like 
percutaneous liver biopsy was due to haemorrhage. In contrast, some deaths with 
transjugular biopsy were also related to ventricular arrhythmias as a result of manipulation 
of the catheter through the right atria and ventricle.  
One of the few comparative studies between transjugular and percutaneous biopsy was 
reported in 1994 by Hong-Chaing Meng et al. In this study the complication rate for the 
transjugular route was 7% and 9% for the percutaneous route suggesting that transjugular 
biopsy was at least as safe as percutaneous liver biopsy and re-affirmed the idea that it is a 
safe alternative in patients in whom percutaneous biopsy is contra-indicated. Interestingly, 
Atar et al reported a comparative study of plugged percutaneous liver biopsy and 
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transjugular biopsy and found no difference in major complications in either group(Atar, et 
al. 2010). They suggested that the plugged percutaneous biopsy technique should be used 
instead of the transjugular route when available. 
The use of the transvenous route for liver biopsy is well established. However, this 
technique is only practiced in a few centres mainly by radiologists or hepatologists with 
significant experience in the technique.  The indications for this procedure is restricted and 
as yet the percutaneous route is still the procedure of choice as it is simpler,  requires less 
specialized equipment and is therefore cheaper.    
6. Laparoscopic liver biopsy 
Laparoscopic liver biopsy is a well established method. It is usually undertaken when liver 
lesions are found incidentally during laparoscopy for diagnostic or staging purposes. In 
addition, staging of patients with cirrhosis and hepatocellular carcinoma who are being 
considered for resection can have a biopsy of the future liver remnant. Laparoscopic liver 
biopsy had the added advantage of direct view of the liver which reduces sampling errors 
and bleeding after biopsy allowing better control(Denzer, et al. 2007). This is supported by 
Nord et al who reported a significant decrease in sampling errors of laparoscopic biopsy 
compared to the percutaneous route in cirrhotic patients(Tobkes and Nord 1995).   
The risks of laparoscopic liver biopsy can be divided into the risks of any laparoscopic 
procedure and the risks of liver biopsy. Beckmann et al did a comparative study with 
laparoscopic, transjugular and percutaneous liver biopsy. They found that the complication 
rate was similar for all groups (2.7%, 2.9% and 3% respectively)(Beckmann, et al. 2009). 
However, in their study the transjugular route had a low success rate and they suggested 
that the laparoscopic route as an alternative especially in patients with severe coagulopathy 
(Denzer, Helmreich-Becker, Galle and Lohse 2003). The only randomized study comparing 
laparoscopic with percutaneous biopsy was reported by Denzer et al(Denzer, et al. 2007). 
This study was undertaken in cirrhotics but found a slightly higher but not significant 
difference in total complication rate between the groups (8.8% vs 5.8%).  
The main risks that we divulge to our patients specific to any laparoscopic procedure are 
bowel or aortic/inferior vena cava perforation, bleeding, post-operative shoulder tip pain 
and port-site pain and hernias. Specifically for laparoscopic liver biopsy our unit informs 
patients of the risk of bleeding or biliary leak. As a general rule we do not undertake 
laparoscopic biopsies of possible malignant lesions unless we know that the tumour is 
inoperable and a histological diagnosis is needed prior to starting chemotherapy.  
7. Conclusion 
The role of liver biopsy in the investigation of liver disease has changed over time. This is 
due to the advances in other non-invasive imaging techniques providing adequate 
information for diagnosis. It is still however a very important investigative tool in certain 
circumstances. These indications have been laid out in the American Association for the 
study of Liver Disease and the British Society of Gastroenterology. It is mainly carried out 
under image guidance although some centres still practice blind biopsies. Importantly, it is 
not without its risks and complications that both physicians and surgeons should be aware 
of. The role of bleeding parameters and other adopted protocols may not necessarily be 
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route is perforation of the liver capsule and intraperitoneal haemorrhage(McAfee, et al. 
1992). Even if the procedure was attempted via the femoral route capsular perforation was 
still a noted complication(Khosa, et al. 2003). Khosa suggested that this complication could 
be avoided if biopsies were taken within a central area of the liver and biplane fluoroscopy 
was used. The same would probably hold true for the transjugular route. In addition, 
Papatheodoridis et al suggested that capsular penetration was more frequent with the 
Menghini needle as a result of difficulty in controlling the depth of penetration 
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penetration only resulted in minor complications. The mortality rate is about 0.09% and like 
percutaneous liver biopsy was due to haemorrhage. In contrast, some deaths with 
transjugular biopsy were also related to ventricular arrhythmias as a result of manipulation 
of the catheter through the right atria and ventricle.  
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transjugular route was 7% and 9% for the percutaneous route suggesting that transjugular 
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transjugular biopsy and found no difference in major complications in either group(Atar, et 
al. 2010). They suggested that the plugged percutaneous biopsy technique should be used 
instead of the transjugular route when available. 
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significant experience in the technique.  The indications for this procedure is restricted and 
as yet the percutaneous route is still the procedure of choice as it is simpler,  requires less 
specialized equipment and is therefore cheaper.    
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lesions are found incidentally during laparoscopy for diagnostic or staging purposes. In 
addition, staging of patients with cirrhosis and hepatocellular carcinoma who are being 
considered for resection can have a biopsy of the future liver remnant. Laparoscopic liver 
biopsy had the added advantage of direct view of the liver which reduces sampling errors 
and bleeding after biopsy allowing better control(Denzer, et al. 2007). This is supported by 
Nord et al who reported a significant decrease in sampling errors of laparoscopic biopsy 
compared to the percutaneous route in cirrhotic patients(Tobkes and Nord 1995).   
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laparoscopic, transjugular and percutaneous liver biopsy. They found that the complication 
rate was similar for all groups (2.7%, 2.9% and 3% respectively)(Beckmann, et al. 2009). 
However, in their study the transjugular route had a low success rate and they suggested 
that the laparoscopic route as an alternative especially in patients with severe coagulopathy 
(Denzer, Helmreich-Becker, Galle and Lohse 2003). The only randomized study comparing 
laparoscopic with percutaneous biopsy was reported by Denzer et al(Denzer, et al. 2007). 
This study was undertaken in cirrhotics but found a slightly higher but not significant 
difference in total complication rate between the groups (8.8% vs 5.8%).  
The main risks that we divulge to our patients specific to any laparoscopic procedure are 
bowel or aortic/inferior vena cava perforation, bleeding, post-operative shoulder tip pain 
and port-site pain and hernias. Specifically for laparoscopic liver biopsy our unit informs 
patients of the risk of bleeding or biliary leak. As a general rule we do not undertake 
laparoscopic biopsies of possible malignant lesions unless we know that the tumour is 
inoperable and a histological diagnosis is needed prior to starting chemotherapy.  
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The role of liver biopsy in the investigation of liver disease has changed over time. This is 
due to the advances in other non-invasive imaging techniques providing adequate 
information for diagnosis. It is still however a very important investigative tool in certain 
circumstances. These indications have been laid out in the American Association for the 
study of Liver Disease and the British Society of Gastroenterology. It is mainly carried out 
under image guidance although some centres still practice blind biopsies. Importantly, it is 
not without its risks and complications that both physicians and surgeons should be aware 
of. The role of bleeding parameters and other adopted protocols may not necessarily be 
 
Liver Biopsy 
 
386 
rooted in good quality evidence and there is scope for well designed randomized trials in 
certain aspects of this procedure. Finally, any patient discovered to have a lesion  in the liver 
either from radiological investigation or during surgery should be referred to a specialist 
hepato-biliary unit for further evaluation. 
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1. Introduction 
The role of liver biopsy (LB), the traditional gold standard for assessing liver disease, 
continues to evolve1-4. Fewer biopsies are being done for diagnosis as noninvasive tests such 
as new imaging techniques and accurate serological tests can now be done instead in many 
cases2-4. Most biopsies are currently performed for parenchymal disease not to make specific 
diagnosis but to assess the liver damage (the degree of inflammation, fibrosis) or the 
response to therapy5. In contrast to past when nearly all biopsies were done for diagnostic 
purpose, presently more than 50% are being done for staging versus 15% for diagnosing the 
parenchymal liver disease5. In addition, biopsies are often done to help in guiding the 
management of hepatitis C and nonalcoholic steatohepatitis and to assess the response to 
therapy2, 3. The increased use of liver transplantation as standard treatment of end stage 
liver disease of diverse etiologies has led to more biopsies being performed to differentiate 
the cause of graft dysfunction and to assess the suitability of potential liver donors for 
transplantation1-3. The dramatic increase in obesity, diabetes, hyperlipidaemia and 
hypertension (the metabolic syndrome) in western societies and its accompanying fatty liver 
problems are requiring liver biopsy for histological assessment2. Evaluation of liver 
histology remains very important as LB is reported to change the clinical diagnosis in 8-14%, 
management in 12-18% and frequency of liver test monitoring in 36% of cases5. Hence the 
main indication are a) chronic hepatitis- for grading, staging, establishing a therapeutic 
strategy and monitoring therapy, b)unexplained abnormal liver function tests or 
hepatomegaly and c) follow up of patients after liver transplantation. However no liver 
biopsy is free of risk as it is an invasive procedure. Rational assessment of overall risk in LB 
however is hampered by the wide variation in the indication and its outcome reported in 
the existing literature.  
2. Factors that may influence the risk of complication following liver biopsy 
Several factors my influence the risk of complication following liver biopsy and are listed in 
table 1 
Uncooperative patient- The risk of bleeding is enhanced in an uncooperative patient who may 
inadvertently move when the biopsy needle is in the liver leading to tear or laceration1-4. In 
such uncooperative patients if liver biopsy was required it could be achieved by performing 
the procedure under moderate or deep sedation or under general anaesthesia6, 7. A 
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transjugular approach is an alternative option8. Conscious sedation for LB are performed 
using midazolam and fentanyl or mepverdine6,7. This adds to small risk and the cost of 
conscious sedation to the procedure. However patients are found to be remarkably 
cooperative and usually breathe somewhat superficially and will hold their breath if 
instructed6,7. However while sedation may allay anxiety and pain there is no strong 
evidence to suggest that it either increases or reduces the risk of major complications. It 
however makes an uncooperative patient cooperative1. 
 
Factors that may influence the risk of complication following liver biopsy 
 Patient cooperation 
 Coagulation status / bleeding disorders 
 Operator experience 
 Advanced age 
 Certain pathologies (liver cirrhosis, amyloidosis, malignancy, renal failure) 
 Use of image guidance 
 ascites 
 Type of technique (percutaneous / transvenous) 
 Number of needle passes 
 Needle diameter (large needle) 
 Type of needle (cutting or Automatic) 
 Blind technique 
Table 1. 
Ascites-_Moderate to severe ascites_is likely to make it difficult to hit the liver via the 
standard intercostal approach. In such patients, options would include total therapeutic 
paracentesis performed immediately prior to palpation /percussion guided transcutaneous 
biopsy or transvenous or laparoscopic biopsy9.There are however reports of successful LB 
under CT scan or US guidance without increasing the risk of bleeding9. 
Mass lesion-  Although LB in patients with mass lesion is generally safe, biopsy of known 
vascular lesion should be avoided10. Similarly biopsy of potentially malignant lesion should 
be avoided because it is believed that tumour vessels are more likely to bleed. However 
with the use of ultrasound colour Doppler to guide the site of biopsy, large tumour vessels 
and liver vessels can be identified and avoided1,11,12. Biopsy of malignant lesion is also 
associated with a risk of tumour spread usually along the biopsy tract. The risk is estimated 
to be around 0 to 0.13%12 and the risk decreases with use of co-axial approach (i.e. utilization 
of a 17 gauze introducer and 18 gauze biopsy needle introduced along a co-axial plane13. 
Impaired haemostasis- Standard percutaneous liver biopsy is often withheld in patients with a 
PT-INR above 1.51-4. However while alteration in haematological parameters are of utmost 
importance when considering the risk associated with liver biopsy, strict cutoffs for PT-INR 
may not be prudent in light of the risk associated with plasma infusion1-4. While it is often 
presumed that abnormal increase in the PT-INR correlates with an increased risk of bleeding 
and that correcting the abnormal PT-INR with plasma replacement therapy or agents such 
as recombinant activated factor V11 will reduce or eliminate the risk of bleeding, the 
available data in the literature are not sufficient to support this presumption particularly in 
mild coagulopathy defined as INR of less than 2.014-15. Hence it is not clear whether 
prolongation of the INR in chronic liver disease while of prognostic significance actually 
represents a net diathesis or not2. Thus better tests are needed to more acutely define the net 
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bleeding risks in these patients. A new measure of coagulation in liver disease has recently 
been introduced, the INRLiver16,17 . It recalculates the international sensitivity index from a 
reference point of patients with liver disease rather than Coumadin –treated patients as has 
been the convention16.17. Whether this test will provide a reliable measure of bleeding risk 
remains to be determined. Therefore a large randomized controlled trial of plasma 
replacement therapy in patients undergoing invasive therapy appears to be warranted1. 
There are however several conditions which are more definitely associated with enhanced 
risk of bleeding and therefore warrant additional caution. These include patients with factor 
V11 (FV11) or 1X (F1X) deficiency, von Willebrand’s disease, other hereditary bleeding 
disorders and those with sickle cell anaemia17. Patients with known underlying 
coagulopathy requiring liver biopsy represents a challenge but liver biopsy can be 
performed in these patients with definitive factor replacement. Nonetheless the risk benefit 
ratio must be carefully considered on a case by case basis 
2.1 Ultrasound guided LB 
This has been done to reduce the risk of both minor and major complications by avoiding 
large intra-hepatic vessels and other structures in the vicinity (gall bladder, colon, lung) and 
by decreasing the passes to sample a good specimen18-21. Ultrasound (US) may influence in 
selecting the site of puncture as was noted in 15% of cases in one study19. The main causes 
for the change in site were due to ascites or small liver. US guided liver biopsy is reported to 
be performed in 56% of cases in France and in 76% of cases in USA20,21. This could either be 
performed as US guided or US assisted LB. US guided LB is particularly reserved for small 
liver, interposition of colon or lung, focal liver lesion (Haemangioma or cysts) or in patients 
with increased risk of bleeding19-21.  
3. Post biopsy care and complications 
Rate of complications vary in different case series and relate in part to operator experience 
although the most experienced clinician still will encounter complications1-4. The risk of 
major complications is listed in table 2. Intraoperative needle biopsy observation indicates 
that almost all patients have transient bleeding from the capsular puncture site1,2. Following 
outpatient LB the period of observation varies among different institution but usually does 
not exceed 6 hours1-4. Patients who have had uneventful single pass biopsy may be 
discharged after 3 hours observation and if patients require analgesia may need observation 
for at least 4 hours2-4. The majority of major complications requiring hospitalization have 
been shown in prospective observational series to occur within 3 hours of biopsy, although 
later complication can occasionally ensue1-4. 
3.1 Complications 
Pain- Pain is the most common complication of percutaneous liver biopsy and is seen in up 
to 84% of patients including those with mild discomfort22. Often pain can be managed with 
small amounts of narcotics typically codeine1-4. The pain immediately after the procedure at 
times can be very distressing and some patients remember the procedure as a very 
unpleasant experience. Moderate to severe pain however is seen in 1-5% of the patients and 
should raise the possibility of a complication such as active bleeding or trauma to adjacent 
structures like gall bladder23. The mechanism of pain following percutaneous biopsy is most 
likely a result of bleeding or perhaps bile extravasation from the liver puncture wound with 
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transjugular approach is an alternative option8. Conscious sedation for LB are performed 
using midazolam and fentanyl or mepverdine6,7. This adds to small risk and the cost of 
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subsequent capsular swelling although the exact mechanism for the pain remains uncertain 
in most cases2-4. The site of biopsy (intercostal or subcostal) did not influence the incidence 
of pain24. However the use of US guidance, premedication with midazolam and fenatnyl 
and self delivering of mixture of N2o and oxygen via mask decreased significantly the 
incidence of post biopsy pain and anxiety24,25. For LB performed with US guidance the 
incidence of pain decreased from 47% to 35%. The 2 factors that were demonstrated to be 
associated with increased use of post procedure analgesics are, cutting biopsy needles and 
less experienced operator25,26. Other controversial factors associated with more pain are 
larger needle, increasing number of biopsy passes, hepatitis C infection, younger age and 
history of intravenous drug abuse27. The use of automatic cutting needles are associated 
with a low incidence of postbiopsy pain with a reported incidence 31.4 to 34.3% in 
comparison to hand held needles( 40.6 to 52.6%)25,26.Besides the above factors the patient 
characteristics play an important role in pain medication requirement after LB . Thus 
previous intravenous drug abusers and those with significant anxiety prior to LB are 
associated with 9 and 4 fold increase in post biopsy analgesia respectively27. 
 
Scenario Reported frequency (%) 
Pain at biopsy site or right shoulder 
(pleuritic, peritonel, diaphragmatic) 
0.056-22 
Haemorrhage  
 -intraperitoneal 0.03-0.7 
 -intrahepatic or subcapsular  0.59 -0.23 
 -haemobilia 0.058-0.2 
Bile peritonitis 0.03-0.22 
Pneumothorax and /or pleural effusion 0.08-0.28 
Haemothorax 0.18-0.49 
Arteriovenous fistula  5.4 
Anaesthetic reaction  0.029 
Biopsy of adjacent organs 0.001-0.044 
lung -0.001- 0.014 
gall bladder -0.034- 0.117 
kidney -0.029- 0.096 
colon  -0.0038- 0.0044 
Reaction to anaesthetic agent  0.029 
Breakage of needle 0.02- 0.059 
Death 0.0083-0.03 
Table 2. Potential complications and the range in reported frequencies 
A decision about when to investigate with imaging and or to hospitalize the patient for 
observation due to pain should be made on a case by case basis1-4. When pain is severe 
enough to require hospitalization radiological evaluation is usually warranted. While some 
would prefer the use of ultrasound as an initial investigation due to the ease with which it 
can be performed , others would perform an abdominal CT with contrast to be more 
definitive1-4(figure 1). 
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Fig. 1. CT scan revealing intraperitoneal bleeding following subcostal percutaneous liver 
biopsy. The bleeding was successfully managed conservatively 
Bleeding- Bleeding could either be major or minor. The risk of major bleeding is reported to 
be around 0.16%1-4,28-30. Major bleeding is severe bleeding defined clinically by change in 
vital signs with radiographic evidence of intraperitoneal bleeding that requires 
hospitalization with the likelihood of transfusion or even radiologic intervention or surgery. 
Such bleeding has been estimated to occur in between 1 in 2500, to 1 in 10,000 biopsies after 
intercostal percutaneous approach for diffuse nonfocal liver disease23,31-33. Minor bleeding is 
less severe bleeding which is characterized by pain or reduced blood pressure or 
tachycardia but not requiring transfusion or intervention and occurs in approximately in 1 
in 500 biopsies. About 18 to 20% of intrahepatic and perihepatic bleeding is also detected on 
ultrasonography28. Severe bleeding is usually clinically evident within 2 to 4 hours but late 
haemorrhage can occur even up to one week after biopsy34. Premature clot dissolution due 
to liver disease associated with hyperfibrinolysis has been proposed to play a role in some 
patients especially those with delayed bleeding, although this has not been extensively 
studied35. Some degree of bleeding occur after all percutaneous liver biopsies based on 
observation made on laparoscopy. 
Bleeding can manifest as haemoperitoneum(0.3 to 0.7%), intrahepatic haematoma(0.59 to 
0.23%) or haemobilia(0.058- 0.2%) 28-30(figure 1). Bleeding into peritoneal cavity produces 
pain, hypotension or less frequently may be asymptomatic. Intrahepatic haemtoma occurs in 
1 to 23% of cases and are localized to intrahepatic or subcapsular region28,29. Usually they 
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subsequent capsular swelling although the exact mechanism for the pain remains uncertain 
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are small and asymptomatic but larger haematomas may cause pain from stretching of the 
liver capsule, hypotension or a delayed decrease in haematocrit28,29. The incidence of 
haematoma after LB seems to be high after LB with larger needles30. Conservative treatment 
of haematoma together with a close follow up by US is generally sufficient1-2,36. The least 
common of the haemorrhagic complications is haemobilia which presents with the classical 
triad of upper gastrointestinal bleeding, pain and jaundice4,18,36. It may appear acutely 
following simultaneous perforation of adjacent intrahepatic bile ducts and blood vessels or 
more commonly much later following the erosion of haematoma or psuedoaneurysm into a 
bile duct37. This occurs typically 5 days following the biopsy31. Haemobilia is a very rare 
event with a frequency of 0.0006 to 0.023% in large series31,37,38. If bile is checked routinely 
after LB, haemobilia may be detected in 10% of cases31,37,38. Large volume of haemobilia may 
cause acute pancreatitis, although this is a very rare event with only 5 cases being reported 
in the literature39. 
The risk of bleeding is influenced by several factors including bleeding disorders, 
advanced age, ascites, high number of passages, large needle size, blind technique and 
certain liver pathologies including liver cirrhosis , amyloidosis, malignancy and renal 
failure1-4,28,31. The factors that are also related to the risk of bleeding include arterial 
bleeding and operator experience. Whether cutting needle(eg Trucut and automated 
variants) have a different risk than aspiration needles(eg, Menghini or Jamshidi) is 
unknown although some retrospective data suggest that cutting needle may be associated 
with slightly greater risk31. At particular risk for bleeding are patients with chronic renal 
failure, those with underlying coagulopathy due to congenital abnormalities in 
coagulation parameter (such as haemophilics) and those with cirrhosis who may have 
acquired abnormalities in coagulation parameter. Use of DDAVP immediately before liver 
biopsy (0.3ug/kg ) body weight in patients with renal failure undergoing invasive 
procedure is useful40,41. In patients on chronic renal replacement therapy, dialysis is often 
performed prior to liver biopsy1,2. Although platelet count less than 60,000/cmm, INR 
greater than 1.3 and bleeding time > 10 minutes are well known practical contraindication 
to percutaneous LB, bleeding from liver does not correlate with the indices of peripheral 
coagulation when these are mildly impaired thus making bleeding an unpredictable 
event42,43. The accurate prediction of bleeding based on coagulation indices is problematic 
as the available data suggest poor relationship between bleeding and common laboratory 
tests (such as platelets, PT-NR etc)42,43. As a result there is wide variation in “acceptable” 
prebiopsy coagulation parameter44. Whether the use of prophylactic blood products alters 
the risk of bleeding is currently unknown1-3. Furthermore because of the conventional 
parameter of coagulation correlate poorly with risk of bleeding, recommendation 
regarding correction of coagulation indices is limited and tempered by the risk of blood 
product exposure42,43. 
Transvenous liver biopsy (typically with jugular approach) is often recommended in 
patients with known or suspected bleeding diathesis because it is commonly perceived to be 
safer8. However a recent systematic review reported minor and major complication in 6.5% 
and 0.6% respectively among the 7649 patients who underwent transvenous biopsy and 
may be related to capsular piercing with subsequent haemorrhage32. However as this study 
was retrospective, there may have been a selective bias (i.e. it is highly likely that patients 
suspected to be at risk of bleeding would have been preferred for transvenous rather than 
percutaneous biopsy).  
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3.2 Miscellaneous 
A number of other complications have been reported after liver biopsy. These include 
pneumothorax, hemothorax, perforation of any of the several viscous organs, bile 
peritonitis, infection (bacteraemia. abscess, sepsis), haemobilia, intrahepatic arteriovenous 
fistula, neuralgia and rare complication such ventricular arrhythmias with transvenous 
biopsy1-4. 
3.2.1 Infective complications 
Transient bacteraemia which has been reported in 5.8 to 13.5% of patients after LB, is in 
most cases harmless31. Intrahepatic abscess, septicaemia and septic shock are much rare 
events occurring only in patients with biliary obstruction and cholangitis or when the colon 
is incidentally punctured18. Infectious complication appear to be increased in post transplant 
patients who underwent choledochojejunostomy during liver transplantation45. There is 
however no recommendations of prophylactic antibiotics in patients scheduled for LB 
except in those with valvular heart disease 
3.2.2 Complications in the thorax 
Haemothorax, pneumothorax, leakage of ascites in the pleural cavity, subcutaneous 
emphysema occur after injury of pleura or lung or right diaphragm18,31,46. Haemothorax can 
occur even in US assisted LB when the patient changes his position or takes a deep 
inspiration after the site of puncture was set, the cause of bleeding being an injury to a 
diaphragmatic vessel46 . Pneumothorax is critical to recognize immediately after biopsy in 
presence of reduced breath sounds and typical radiographic findings because it can lead to 
immediate catastrophic outcome if not promptly recognized and treated18,31. 
3.2.3 Puncture of other viscera 
This occurs rarely (0.01 to0.1%) and involves usually gall bladder, colon, and right kidney. 
The incidence is significantly reduced when LB is performed under US guidance49,48 . Bile 
peritonitis , formation of bilioma or bilious pleural effusion occur mainly in patients with 
biliary obstruction although they are reports of them occurring even in patients without 
biliary obstruction or when the gall bladder is incidentally punctured48,49.  
Other very rare complications include reaction to the anaesthetic agents, breakage of the 
needle and arterioportal fistula, neuralgia and ventricular arrythmias 42,45. 
Death- Is very uncommon after percutaneous biopsy but precise figure vary widely in the 
literature ranging from 0.009% to 0.11% .and is usually related to haemorrhage10,20,24,31,41,45,49. 
Mortality after transvenous biopsies was 0.0009% (9 in 10,000) in a recent report of 7649 
transvenous biopsies but again may reflect the selection of higher risk patients for this 
intervention40. The main cause of death after LB is intraperitoneal bleeding mainly occurring 
in patients with malignancy or cirrhosis45. The incidence of fatal complications can be 
significantly reduced by careful post biopsy observation with prompt recognition of 
bleeding and aggressive subsequent therapy which may involve transfusion followed by 
therapeutic embolisation or laparotomy18 
3.3 Management 
The most critical aspect of management of complications such as bleeding, pneumothorax 
and visceral perforation is to recognize that one these complications has occurred. 
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are small and asymptomatic but larger haematomas may cause pain from stretching of the 
liver capsule, hypotension or a delayed decrease in haematocrit28,29. The incidence of 
haematoma after LB seems to be high after LB with larger needles30. Conservative treatment 
of haematoma together with a close follow up by US is generally sufficient1-2,36. The least 
common of the haemorrhagic complications is haemobilia which presents with the classical 
triad of upper gastrointestinal bleeding, pain and jaundice4,18,36. It may appear acutely 
following simultaneous perforation of adjacent intrahepatic bile ducts and blood vessels or 
more commonly much later following the erosion of haematoma or psuedoaneurysm into a 
bile duct37. This occurs typically 5 days following the biopsy31. Haemobilia is a very rare 
event with a frequency of 0.0006 to 0.023% in large series31,37,38. If bile is checked routinely 
after LB, haemobilia may be detected in 10% of cases31,37,38. Large volume of haemobilia may 
cause acute pancreatitis, although this is a very rare event with only 5 cases being reported 
in the literature39. 
The risk of bleeding is influenced by several factors including bleeding disorders, 
advanced age, ascites, high number of passages, large needle size, blind technique and 
certain liver pathologies including liver cirrhosis , amyloidosis, malignancy and renal 
failure1-4,28,31. The factors that are also related to the risk of bleeding include arterial 
bleeding and operator experience. Whether cutting needle(eg Trucut and automated 
variants) have a different risk than aspiration needles(eg, Menghini or Jamshidi) is 
unknown although some retrospective data suggest that cutting needle may be associated 
with slightly greater risk31. At particular risk for bleeding are patients with chronic renal 
failure, those with underlying coagulopathy due to congenital abnormalities in 
coagulation parameter (such as haemophilics) and those with cirrhosis who may have 
acquired abnormalities in coagulation parameter. Use of DDAVP immediately before liver 
biopsy (0.3ug/kg ) body weight in patients with renal failure undergoing invasive 
procedure is useful40,41. In patients on chronic renal replacement therapy, dialysis is often 
performed prior to liver biopsy1,2. Although platelet count less than 60,000/cmm, INR 
greater than 1.3 and bleeding time > 10 minutes are well known practical contraindication 
to percutaneous LB, bleeding from liver does not correlate with the indices of peripheral 
coagulation when these are mildly impaired thus making bleeding an unpredictable 
event42,43. The accurate prediction of bleeding based on coagulation indices is problematic 
as the available data suggest poor relationship between bleeding and common laboratory 
tests (such as platelets, PT-NR etc)42,43. As a result there is wide variation in “acceptable” 
prebiopsy coagulation parameter44. Whether the use of prophylactic blood products alters 
the risk of bleeding is currently unknown1-3. Furthermore because of the conventional 
parameter of coagulation correlate poorly with risk of bleeding, recommendation 
regarding correction of coagulation indices is limited and tempered by the risk of blood 
product exposure42,43. 
Transvenous liver biopsy (typically with jugular approach) is often recommended in 
patients with known or suspected bleeding diathesis because it is commonly perceived to be 
safer8. However a recent systematic review reported minor and major complication in 6.5% 
and 0.6% respectively among the 7649 patients who underwent transvenous biopsy and 
may be related to capsular piercing with subsequent haemorrhage32. However as this study 
was retrospective, there may have been a selective bias (i.e. it is highly likely that patients 
suspected to be at risk of bleeding would have been preferred for transvenous rather than 
percutaneous biopsy).  
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3.2 Miscellaneous 
A number of other complications have been reported after liver biopsy. These include 
pneumothorax, hemothorax, perforation of any of the several viscous organs, bile 
peritonitis, infection (bacteraemia. abscess, sepsis), haemobilia, intrahepatic arteriovenous 
fistula, neuralgia and rare complication such ventricular arrhythmias with transvenous 
biopsy1-4. 
3.2.1 Infective complications 
Transient bacteraemia which has been reported in 5.8 to 13.5% of patients after LB, is in 
most cases harmless31. Intrahepatic abscess, septicaemia and septic shock are much rare 
events occurring only in patients with biliary obstruction and cholangitis or when the colon 
is incidentally punctured18. Infectious complication appear to be increased in post transplant 
patients who underwent choledochojejunostomy during liver transplantation45. There is 
however no recommendations of prophylactic antibiotics in patients scheduled for LB 
except in those with valvular heart disease 
3.2.2 Complications in the thorax 
Haemothorax, pneumothorax, leakage of ascites in the pleural cavity, subcutaneous 
emphysema occur after injury of pleura or lung or right diaphragm18,31,46. Haemothorax can 
occur even in US assisted LB when the patient changes his position or takes a deep 
inspiration after the site of puncture was set, the cause of bleeding being an injury to a 
diaphragmatic vessel46 . Pneumothorax is critical to recognize immediately after biopsy in 
presence of reduced breath sounds and typical radiographic findings because it can lead to 
immediate catastrophic outcome if not promptly recognized and treated18,31. 
3.2.3 Puncture of other viscera 
This occurs rarely (0.01 to0.1%) and involves usually gall bladder, colon, and right kidney. 
The incidence is significantly reduced when LB is performed under US guidance49,48 . Bile 
peritonitis , formation of bilioma or bilious pleural effusion occur mainly in patients with 
biliary obstruction although they are reports of them occurring even in patients without 
biliary obstruction or when the gall bladder is incidentally punctured48,49.  
Other very rare complications include reaction to the anaesthetic agents, breakage of the 
needle and arterioportal fistula, neuralgia and ventricular arrythmias 42,45. 
Death- Is very uncommon after percutaneous biopsy but precise figure vary widely in the 
literature ranging from 0.009% to 0.11% .and is usually related to haemorrhage10,20,24,31,41,45,49. 
Mortality after transvenous biopsies was 0.0009% (9 in 10,000) in a recent report of 7649 
transvenous biopsies but again may reflect the selection of higher risk patients for this 
intervention40. The main cause of death after LB is intraperitoneal bleeding mainly occurring 
in patients with malignancy or cirrhosis45. The incidence of fatal complications can be 
significantly reduced by careful post biopsy observation with prompt recognition of 
bleeding and aggressive subsequent therapy which may involve transfusion followed by 
therapeutic embolisation or laparotomy18 
3.3 Management 
The most critical aspect of management of complications such as bleeding, pneumothorax 
and visceral perforation is to recognize that one these complications has occurred. 
 
Liver Biopsy 
 
400 
Suspicion of a potential complication should be high when the patient complains of pain 
that is out of proportion to the clinical events that surrounded the biopsy and is 
associated with drop in blood pressure and tachycardia and is then confirmed by 
radiological investigation. All complications are supported by initial resuscitation. 
Bleeding is most often managed expectantly with placement of wide bore intravenous 
cannula, volume resuscitation and blood transfusion as necessary. Angiographic 
embolisation and surgery may be required in some of these patients with persistent 
bleeding. Pneumothorax may be self limiting but may require more aggressive 
intervention depending on the severity of symptoms. Visceral perforation is usually 
managed expectantly in most situations. Observation is all that may be required although 
occasionally surgical intervention may be needed in the case of gall bladder puncture 
with persistent bile leak or in case of secondary peritonitis 
4. Recommendations 
1. The person who performs the LB should be acutely aware of the multiple potential 
complications (including death) that may occur after liver biopsy and it is of outmost 
importance to discuss these appropriately with the patient’s beforehand (class 1. Level 
C evidence) 
2. Percutaneous liver biopsy with or without image guidance is appropriate only in 
cooperative patients and this technique should not be utilized in uncooperative 
patients(claas 1 level C) 
3. Uncooperative patients who require liver biopsy should undergo the procedure under 
general anaesthesia or via transvenous route(class 1 level C) 
4. In patients with clinically evident ascites requiring a liver biopsy a transvenous 
approach is generally recommended although percutaneous biopsy (after removal of 
ascites) or laparoscopic biopsy are acceptable alternatives(class 1 level C) 
5. Haematological abnormalities particularly low platelet count (levels less than 50,000-
60,000/ml) should be dealt with platelet transfusion prior to the procedure. This applies 
for both percutaneous and transvenous approach 
6. The use of prophylactic or rescue strategies such as plasma, fibrinolytic inhibitors or 
recombinant factors should be considered in specific situations although their 
effectiveness remains to be established.(class 11a, level C) 
7. In patients with renal failure or on hemodialysis , desmopressin(DDAVP) may be 
considered, although its use is necessary in patients on stable dialysis regimen(class 11a, 
level B) 
8. Patients on chronic haemodialysis should be well dialysed prior to liver biopsy and 
heparin should be avoided if at all possible(class 1, level C) 
5. Conclusion 
The indications for liver biopsy are evolving. While liver biopsy may play a major role in 
management of some of the hepatic disorders, it is not without risk. Mild pain following the 
procedure is not uncommon however persistent and severe pain should warrant further 
investigation to rule out significant intraperitoneal bleed. Liver biopsy performed under 
ultrasound guidance and premedication is reported to significantly reduce complications 
including pain. The risk of major bleeding post liver biopsy is low but is of serious 
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consequence as it is the main cause of a rare event of death. Among the various factors that 
may influence complication risk, patients coagulation status and operator experience are of 
outmost importance. The coagulation status should be optimized to the extent possible with 
platelet and coagulation factor infusion and the use of DDAVP and haemodialysis in 
patients with renal failure. The most critical aspect of management of these complications is 
to be acutely aware of it and to promptly treat it. 
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Suspicion of a potential complication should be high when the patient complains of pain 
that is out of proportion to the clinical events that surrounded the biopsy and is 
associated with drop in blood pressure and tachycardia and is then confirmed by 
radiological investigation. All complications are supported by initial resuscitation. 
Bleeding is most often managed expectantly with placement of wide bore intravenous 
cannula, volume resuscitation and blood transfusion as necessary. Angiographic 
embolisation and surgery may be required in some of these patients with persistent 
bleeding. Pneumothorax may be self limiting but may require more aggressive 
intervention depending on the severity of symptoms. Visceral perforation is usually 
managed expectantly in most situations. Observation is all that may be required although 
occasionally surgical intervention may be needed in the case of gall bladder puncture 
with persistent bile leak or in case of secondary peritonitis 
4. Recommendations 
1. The person who performs the LB should be acutely aware of the multiple potential 
complications (including death) that may occur after liver biopsy and it is of outmost 
importance to discuss these appropriately with the patient’s beforehand (class 1. Level 
C evidence) 
2. Percutaneous liver biopsy with or without image guidance is appropriate only in 
cooperative patients and this technique should not be utilized in uncooperative 
patients(claas 1 level C) 
3. Uncooperative patients who require liver biopsy should undergo the procedure under 
general anaesthesia or via transvenous route(class 1 level C) 
4. In patients with clinically evident ascites requiring a liver biopsy a transvenous 
approach is generally recommended although percutaneous biopsy (after removal of 
ascites) or laparoscopic biopsy are acceptable alternatives(class 1 level C) 
5. Haematological abnormalities particularly low platelet count (levels less than 50,000-
60,000/ml) should be dealt with platelet transfusion prior to the procedure. This applies 
for both percutaneous and transvenous approach 
6. The use of prophylactic or rescue strategies such as plasma, fibrinolytic inhibitors or 
recombinant factors should be considered in specific situations although their 
effectiveness remains to be established.(class 11a, level C) 
7. In patients with renal failure or on hemodialysis , desmopressin(DDAVP) may be 
considered, although its use is necessary in patients on stable dialysis regimen(class 11a, 
level B) 
8. Patients on chronic haemodialysis should be well dialysed prior to liver biopsy and 
heparin should be avoided if at all possible(class 1, level C) 
5. Conclusion 
The indications for liver biopsy are evolving. While liver biopsy may play a major role in 
management of some of the hepatic disorders, it is not without risk. Mild pain following the 
procedure is not uncommon however persistent and severe pain should warrant further 
investigation to rule out significant intraperitoneal bleed. Liver biopsy performed under 
ultrasound guidance and premedication is reported to significantly reduce complications 
including pain. The risk of major bleeding post liver biopsy is low but is of serious 
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consequence as it is the main cause of a rare event of death. Among the various factors that 
may influence complication risk, patients coagulation status and operator experience are of 
outmost importance. The coagulation status should be optimized to the extent possible with 
platelet and coagulation factor infusion and the use of DDAVP and haemodialysis in 
patients with renal failure. The most critical aspect of management of these complications is 
to be acutely aware of it and to promptly treat it. 
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